PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Deng, GR; Lu, Y; Zlotnikov, G; Thor, AD; Smith, HS				Deng, GR; Lu, Y; Zlotnikov, G; Thor, AD; Smith, HS			Loss of heterozygosity in normal tissue adjacent to breast carcinomas	SCIENCE			English	Article							CHAIN-REACTION PCR; GENETIC ALTERATIONS; CANCER; POLYMORPHISM; CHROMOSOME-17; 17P	Loss of heterozygosity (LOH) was detected in morphologically normal lobules adjacent to breast cancers. The most frequent aberration was at chromosome 3p22-25; of ten cases with this LOH in the carcinoma, six displayed the same LOH in adjacent normal lobules. This suggests that in a subset of sporadic breast cancers, a tumor suppresser gene at 3p22-25 may be important in initiation or early progression of tumorigenesis. Among sixteen breast cancers with LOH at 17p13.1 and five breast cancers with LOH at 11p15.5, one case each displayed the same LOH in adjacent normal lobules. Thus the molecular heterogeneity that characterizes invasive breast cancers may occur at the earliest detectable stages of progression.	CALIF PACIFIC MED CTR,GERALDINE BRUSH CANC RES INST,SAN FRANCISCO,CA 94619; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; NORTHWESTERN UNIV,EVANSTON HOSP,SCH MED,DEPT PATHOL,EVANSTON,IL 60201	California Pacific Medical Center; University of California System; University of California San Francisco; NorthShore University Health System; Northwestern University					NATIONAL CANCER INSTITUTE [P50CA058207] Funding Source: NIH RePORTER; NCI NIH HHS [2P50CA58207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; BLOUNT PL, 1994, CANCER RES, V54, P2292; Dairkee SH, 1996, J MAMMARY GLAND BIOL, V1, P139, DOI 10.1007/BF02013638; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3761, DOI 10.1093/nar/19.13.3761; GANLY PS, 1991, NUCLEIC ACIDS RES, V19, P3760; GAZDAR AF, 1956, 86 ANN M AM ASS CANC; HARADA Y, 1994, CANCER, V74, P2281, DOI 10.1002/1097-0142(19941015)74:8<2281::AID-CNCR2820740812>3.0.CO;2-I; HILDRETH NG, 1989, NEW ENGL J MED, V321, P1281, DOI 10.1056/NEJM198911093211901; JENSEN RA, 1994, P NATL ACAD SCI USA, V91, P9257, DOI 10.1073/pnas.91.20.9257; LI H, 1992, HUM MOL GENET, V1, P425; MCDANIEL T, 1991, NUCLEIC ACIDS RES, V19, P6969; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; OCONNELL P, 1994, BREAST CANCER RES TR, V32, P5, DOI 10.1007/BF00666201; OLSCHWANG S, 1991, HUM GENET, V86, P369; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P3753, DOI 10.1093/nar/19.13.3753; RADFORD DM, 1993, CANCER RES, V53, P2947; SAITO H, 1991, CYTOGENET CELL GENET, V58, P1806; TAKITA K, 1992, CANCER RES, V52, P3914; TOKUNAGA M, 1984, BREAST CANC ATOMIC B, P45; Tsai YC, 1996, CANCER RES, V56, P402; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WELLINGS SR, 1980, PATHOL RES PRACT, V166, P515, DOI 10.1016/S0344-0338(80)80248-2; Zhuang ZP, 1996, CANCER RES, V56, P1961	26	466	489	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2057	2059		10.1126/science.274.5295.2057	http://dx.doi.org/10.1126/science.274.5295.2057			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953032				2022-12-28	WOS:A1996VY97400042
J	Doerfler, ME; Naidich, DP				Doerfler, ME; Naidich, DP			Midtracheal stricture	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Doerfler, ME (corresponding author), NYU,SCH MED,NEW YORK,NY 10016, USA.			naidich, david/0000-0003-3751-5836					0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1879	1879		10.1056/NEJM199612193352504	http://dx.doi.org/10.1056/NEJM199612193352504			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948563				2022-12-28	WOS:A1996VX87400004
J	DeRubertis, F; Kadosh, D; Henchoz, S; Pauli, D; Reuter, G; Struhl, K; Spierer, P				DeRubertis, F; Kadosh, D; Henchoz, S; Pauli, D; Reuter, G; Struhl, K; Spierer, P			The histone deacetylase RPD3 counteracts genomic silencing in Drosophila and yeast	NATURE			English	Article							POSITION-EFFECT VARIEGATION; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL STATES; X-CHROMOSOME; ACETYLATION; EXPRESSION; GENE; REPRESSION; TELOMERE; DOMAINS	BOTH position-effect variegation (PEV)(1,2) in Drosophila and telomeric position-effect in yeast (TPE)(3-5) result from the mosaic inactivation of genes relocated next to a block of centromeric heterochromatin or next to telomeres. In many aspects, these phenomena are analogous to other epigenetic silencing mechanisms, such as the control of homeotic gene clusters(6), X-chromosome inactivation(7) and imprinting in mammals(8), and mating-type control in yeast(5), Dominant mutations that suppress or enhance PEV are thought to encode either chromatin proteins or factors that directly affect chromatin structure(1), We have identified an insertional mutation in Drosophila that enhances PEV and reduces transcription of the gene in the eye-antenna imaginal disc, The gene corresponds to that encoding the transcriptional regulator RPD3 in yeast(9,10), and to a human histone deacetylase(11). In yeast, RRD3-deletion strains show enhanced TPE, suggesting a conserved role of the histone deacetylase RPD3 in counteracting genomic silencing, This function of RPD3, which is in contrast to the general correlation between histone acetylation and increased transcription, might be due to a specialized chromatin structure at silenced loci.	UNIV GENEVA,DEPT ZOOL & ANIM BIOL,CH-1211 GENEVA 4,SWITZERLAND; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; UNIV HALLE WITTENBERG,INST GENET,D-06108 HALLE,GERMANY	University of Geneva; Harvard University; Harvard Medical School; Martin Luther University Halle Wittenberg								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; RUNDLETT SE, 1996, P NATL ACAD SCI USA, V93, P13723; Seum C, 1996, DEVELOPMENT, V122, P1949; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SOLTER D, 1988, ANNU REV GENET, V22, P127; SUSSEL L, 1995, GENETICS, V141, P873; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1991, J CELL SCI, V99, P13; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4	26	191	194	1	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					589	591						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955276				2022-12-28	WOS:A1996VX76900066
J	Nelson, KD; Zhao, WJ; Brown, LD; Kuo, J; Che, JK; Liu, XW; Klemperer, SL; Makovsky, Y; Meissner, R; Mechie, J; Kind, R; Wenzel, F; Ni, J; Nabelek, J; Chen, LS; Tan, HD; Wei, WB; Jones, AG; Booker, J; Unsworth, M; Kidd, WSF; Hauck, M; Alsdorf, D; Ross, A; Cogan, M; Wu, CD; Sandvol, E; Edwards, M				Nelson, KD; Zhao, WJ; Brown, LD; Kuo, J; Che, JK; Liu, XW; Klemperer, SL; Makovsky, Y; Meissner, R; Mechie, J; Kind, R; Wenzel, F; Ni, J; Nabelek, J; Chen, LS; Tan, HD; Wei, WB; Jones, AG; Booker, J; Unsworth, M; Kidd, WSF; Hauck, M; Alsdorf, D; Ross, A; Cogan, M; Wu, CD; Sandvol, E; Edwards, M			Partially molten middle crust beneath southern Tibet: Synthesis of project INDEPTH results	SCIENCE			English	Article							EASTERN NEPAL HIMALAYA; CONTINENTAL COLLISION; OROGENIC BELTS; SHEAR ZONE; PLATEAU; EVOLUTION; TECTONICS; UPLIFT; METAMORPHISM; GEOTRAVERSE	INDEPTH geophysical and geological observations imply that a partially molten mid-crustal layer exists beneath southern Tibet, This partially molten layer has been produced by crustal thickening and behaves as a fluid on the time scale of Himalayan deformation; it is confined on the south by the structurally imbricated Indian crust underlying the Tethyan and High Himalaya and is underlain, apparently, by a stiff Indian mantle lid. The results suggest that during Neogene time the underthrusting Indian crust has acted as a plunger, displacing the molten middle crust to the north while at the same time contributing to this layer by melting and ductile flow. Viewed broadly, the Neogene evolution of the Himalaya is essentially a record of the southward extrusion of the partially molten middle crust underlying southern Tibet.	CHINESE ACAD GEOL SCI,BEIJING 100037,PEOPLES R CHINA; CORNELL UNIV,INST STUDY CONTINENTS,ITHACA,NY 14853; LAMONT DOHERTY EARTH OBSERV,PALISADES,NY 10964; STANFORD UNIV,DEPT GEOPHYS,STANFORD,CA 94305; CHRISTIAN ALBRECHTS UNIV KIEL,INST GEOPHYS,D-24098 KIEL,GERMANY; GEOFORSCHUNGSZENTRUM POTSDAM,D-14473 POTSDAM,GERMANY; UNIV KARLSRUHE,INST GEOPHYS,D-76187 KARLSRUHE,GERMANY; NEW MEXICO STATE UNIV,DEPT PHYS,LAS CRUCES,NM 88003; OREGON STATE UNIV,COLL OCEANOG,CORVALLIS,OR 97331; CHINA UNIV GEOSCI,BEIJING,PEOPLES R CHINA; GEOL SURVEY CANADA,OTTAWA,ON,CANADA; UNIV WASHINGTON,GEOPHYS PROGRAM,SEATTLE,WA 98195; SUNY ALBANY,DEPT GEOSCI,ALBANY,NY 12222	Chinese Academy of Geological Sciences; Cornell University; Columbia University; Stanford University; University of Kiel; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Helmholtz Association; Karlsruhe Institute of Technology; New Mexico State University; Oregon State University; China University of Geosciences; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Nelson, KD (corresponding author), SYRACUSE UNIV,DEPT EARTH SCI,SYRACUSE,NY 13244, USA.		Wenzel, Friedemann/A-7332-2013; Klemperer, Simon L/A-5919-2012; Makovsky, Yizhaq/L-1168-2017; Unsworth, Martyn J/A-6395-2012; Jones, Alan G/A-3241-2009; Makovsky, Yizhaq/ABH-7281-2020	Makovsky, Yizhaq/0000-0001-6762-9549; Unsworth, Martyn J/0000-0001-8282-4174; Jones, Alan G/0000-0002-3482-2518; Makovsky, Yizhaq/0000-0001-6762-9549; Klemperer, Simon/0000-0001-7050-1829				ALLEGRE CJ, 1984, NATURE, V307, P17, DOI 10.1038/307017a0; [Anonymous], 1990, EXPOSED CROSS SECTIO, DOI DOI 10.1007/978-94-009-0675-4_21; ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; BANDON C, 1986, J GEOPHYS RES, V91, P6547; BEGHOUL N, 1993, J GEOPHYS RES-SOL EA, V98, P1997, DOI 10.1029/92JB02274; Brown LD, 1996, SCIENCE, V274, P1688, DOI 10.1126/science.274.5293.1688; Burchfiel B.C., 1992, GEOL SOC AM SPEC PAP, V269, DOI [10.1130/SPE269, DOI 10.1130/SPE269]; BURG JP, 1984, NATURE, V311, P219, DOI 10.1038/311219a0; BURG JP, 1994, TECTONICS, V13, P474; Chen LH, 1996, SCIENCE, V274, P1694, DOI 10.1126/science.274.5293.1694; CHUN KY, 1986, J GEOPHYS RES-SOLID, V91, P405, DOI 10.1029/JB091iB10p10405; DEWEY JF, 1988, PHILOS T R SOC A, V327, P379, DOI 10.1098/rsta.1988.0135; DEWEY JF, 1973, J GEOL, V81, P683, DOI 10.1086/627920; ENGLAND PC, 1984, J PETROL, V25, P894, DOI 10.1093/petrology/25.4.894; ENGLAND PC, 1986, GEOL SOC LOND SPEC P, V19, P83, DOI DOI 10.1144/GSL.SP.1986.019.01.05; FIELDING E, 1994, GEOLOGY, V22, P163, DOI 10.1130/0091-7613(1994)022<0163:HFIT>2.3.CO;2; FRANCHETEAU J, 1984, NATURE, V307, P32, DOI 10.1038/307032a0; Gansser A., 1983, GEOLOGY BHUTAN HIMAL, P181; HARRISON TM, 1995, TECTONICS, V14, P658, DOI 10.1029/95TC00608; HIRN A, 1984, NATURE, V307, P23, DOI 10.1038/307023a0; HODGES KV, 1992, SCIENCE, V258, P1466, DOI 10.1126/science.258.5087.1466; HOLLISTER LS, 1993, CHEM GEOL, V108, P31, DOI 10.1016/0009-2541(93)90316-B; HUBBARD MS, 1989, TECTONICS, V8, P865, DOI 10.1029/TC008i004p00865; JIN Y, 1994, NATURE, V371, P669, DOI 10.1038/371669a0; JIN Y, 1995, J GEOPHYS RES, V101, P11275; KIDD WSF, 1988, PHILOS T R SOC A, V327, P287, DOI 10.1098/rsta.1988.0130; Kind R, 1996, SCIENCE, V274, P1692, DOI 10.1126/science.274.5293.1692; KRUSE S, 1991, J GEOPHYS RES-SOLID, V96, P4435, DOI 10.1029/90JB02621; LEFORT P, 1988, PHILOS T R SOC A, V326, P281; LEFORT P, 1975, AM J SCI, VA275, P1; Makovsky Y, 1996, SCIENCE, V274, P1690, DOI 10.1126/science.274.5293.1690; Makovsky Y, 1996, TECTONICS, V15, P997, DOI 10.1029/96TC00310; MCNAMARA DE, 1995, J GEOPHYS RES-SOL EA, V100, P22215, DOI 10.1029/95JB01863; MOLNAR P, 1978, J GEOPHYS RES, V83, P5361, DOI 10.1029/JB083iB11p05361; MOLNAR P, 1988, T R SOC LONDON A, V327, P33; NABELEK J, 1994, EOS S, V75, P628; NI J, 1983, GEOPHYS J ROY ASTR S, V72, P665, DOI 10.1111/j.1365-246X.1983.tb02826.x; OWENS RJ, 1993, B SEISMOL SOC AM, V6, P305; OWENS TJ, 1993, B SEISMOL SOC AM, V83, P1959; PAN Y, 1992, GEOLOGY, V20, P775, DOI 10.1130/0091-7613(1992)020<0775:NSZALM>2.3.CO;2; PARRISH RR, 1993, GEOL SOC AM ABSTR, V25, pA174; PHAM VN, 1990, GEOLOGY HIMALAYAS, V1, P115; PINET C, 1987, EARTH PLANET SC LETT, V84, P87, DOI 10.1016/0012-821X(87)90179-8; RATSCHBACHER L, 1994, J GEOPHYS RES-SOL EA, V99, P19917, DOI 10.1029/94JB00932; ROMANOWICZ BA, 1982, J GEOPHYS RES, V87, P6865, DOI 10.1029/JB087iB08p06865; ROYDEN LH, 1993, J GEOPHYS RES-SOL EA, V98, P4487, DOI 10.1029/92JB01954; SCHELLING D, 1991, TECTONICS, V10, P851, DOI 10.1029/91TC01011; SEARLE MP, 1987, GEOL SOC AM BULL, V98, P678, DOI 10.1130/0016-7606(1987)98<678:TCOTAT>2.0.CO;2; SHACKLETON R, 1988, PHILOS T R SOC A, V327, P3, DOI 10.1098/rsta.1988.0120; TONG JW, 1981, GEOLOGICAL ECOLOGICA, P841; TURNER S, 1993, NATURE, V364, P50, DOI 10.1038/364050a0; WILLETT SD, 1994, NATURE, V369, P642, DOI 10.1038/369642a0; YIN A, 1994, J GEOPHYS RES-SOL EA, V99, P18175, DOI 10.1029/94JB00504; YIN A, 1995, GEOL SOC AM ABSTR, V27, pA335; YUAN X, 1990, GEOLOGY HIMALAYAS, V1, P105; Zhao LS, 1996, GEOPHYS J INT, V125, P355, DOI 10.1111/j.1365-246X.1996.tb00004.x; ZHAO WJ, 1993, NATURE, V366, P557, DOI 10.1038/366557a0; ZHAO WL, 1987, TECTONICS, V6, P489, DOI 10.1029/TC006i004p00489; ZHU L, 1993, ACTA SEISMOL SIN, V6, P305	59	1013	1157	16	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1684	1688		10.1126/science.274.5293.1684	http://dx.doi.org/10.1126/science.274.5293.1684			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939851				2022-12-28	WOS:A1996VW71200050
J	Sherr, CJ				Sherr, CJ			Cancer cell cycles	SCIENCE			English	Review							WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; DEPENDENT KINASE INHIBITOR; D-TYPE CYCLINS; TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; RETINOBLASTOMA-PROTEIN; DNA-DAMAGE; IN-VIVO; MAMMALIAN FIBROBLASTS	Uncontrolled cell proliferation is the hallmark of cancer, and tumor cells have typically acquired damage to genes that directly regulate their cell cycles. Genetic alterations affecting p16(INK4a) and cyclin D1, proteins that govern phosphorylation of the retinoblastoma protein (RE) and control exit from the G(1) phase of the cell cycle, are so frequent in human cancers that inactivation of this pathway may well be necessary for tumor development. Like the tumor suppressor protein p53, components of this ''RB pathway,'' although not essential for the cell cycle per se, may participate in checkpoint functions that regulate homeostatic tissue renewal throughout life.			Sherr, CJ (corresponding author), ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURO D, 1995, ONCOGENE, V11, P21; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Fraumeni J.F., 1989, CANC PRINCIPLES PRAC, P196; FRIEND SJ, 1986, NATURE, V323, P653; FUKUSAWA K, 1996, SCIENCE, V271, P1744; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Geng Y, 1996, ONCOGENE, V12, P1173; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1993, ONCOGENE, V8, P2457; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG W, 1993, ONCOGENE, V8, P3447; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kang JS, 1996, MOL CELL BIOL, V16, P3370; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li SF, 1996, CANCER, V77, P321, DOI 10.1002/(SICI)1097-0142(19960115)77:2<321::AID-CNCR15>3.0.CO;2-3; LIN J, 1994, COLD SPRING HARB SYM, V59, P215, DOI 10.1101/SQB.1994.059.01.026; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LODA M, COMMUNICATION; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MAO L, 1995, CANCER RES, V55, P2995; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROBERTS JD, COMMUNICATION; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Scuderi R, 1996, BLOOD, V87, P3360, DOI 10.1182/blood.V87.8.3360.bloodjournal8783360; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P267; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERR CJ, 1993, CELL, V73, P1069; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STONE S, 1995, CANCER RES, V55, P1988; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAHARA E, 1995, CANCER, V75, P1410, DOI 10.1002/1097-0142(19950315)75:6+<1410::AID-CNCR2820751504>3.0.CO;2-O; TAM SW, 1994, ONCOGENE, V9, P2663; THOMAS DB, 1991, COMPREHENSIVE TXB ON, P153; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P699; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; ZINDY F, UNPUB	195	4789	5032	15	935	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1672	1677		10.1126/science.274.5293.1672	http://dx.doi.org/10.1126/science.274.5293.1672			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939849				2022-12-28	WOS:A1996VW71200048
J	Morrison, RS; Meier, DE; Cassel, CK				Morrison, RS; Meier, DE; Cassel, CK			When too much is too little	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MECHANICAL RESTRAINTS; PHYSICAL RESTRAINTS; ELDERLY PATIENTS; MEDICAL-SCHOOLS; TERMINALLY ILL; DEATH; EDUCATION; NUTRITION; HYDRATION; CARE				Morrison, RS (corresponding author), CUNY MT SINAI SCH MED,HENRY L SCHWARTZ DEPT GERIATR & ADULT DEV,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.							Ahronheim JC, 1996, CLIN GERIATR MED, V12, P379; AHRONHEIM JC, 1994, ETHICS CLIN PRACTICE; AHRONHEIM JC, 1996, ARCH INTERN MED, V154, P2094; APPELBAUM PS, 1988, NEW ENGL J MED, V319, P1635, DOI 10.1056/NEJM198812223192504; Appelbaum PS, 1989, NEW ENGL J MED, V320, P748; BERRY ZS, 1993, JAMA-J AM MED ASSOC, V270, P221, DOI 10.1001/jama.270.2.221; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; DICKINSON GE, 1985, J MED EDUC, V60, P942; DUPONT EM, 1988, LOSS GRIEF CARE, V2, P33; Hansot E, 1996, ANN INTERN MED, V125, P149, DOI 10.7326/0003-4819-125-2-199607150-00016; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; *JOINT COMM ACCR H, 1996, STAND RESTR SECL JOI, P1; LOFGREN RP, 1989, AM J PUBLIC HEALTH, V79, P735, DOI 10.2105/AJPH.79.6.735; MACPHERSON DS, 1990, J AM GERIATR SOC, V38, P516, DOI 10.1111/j.1532-5415.1990.tb02400.x; MAHLER J, 1988, HOSP COMMUNITY PSYCH, V39, P856; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; McMillan A, 1990, Health Care Financ Rev, V12, P1; MEISEL A, 1989, RIGHT DIE; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; MION LC, 1989, J AM GERIATR SOC, V37, P949, DOI 10.1111/j.1532-5415.1989.tb07280.x; MION LC, 1990, J AM GERIATR SOC, V38, P181; MOSS RJ, 1991, HASTINGS CENT REP, V21, P22, DOI 10.2307/3563342; *NAT HOSP ORG, 1995, HOSP AM STAT PROF; National Center for Health Statistics, 1991, DHHS PUBL PHS, V2, P380; PRUITT JO, 1995, CRIT CARE NURS CLIN, V7, P363; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; RAPPAPORT W, 1993, SURGERY, V113, P163; SCOTT J, 1993, OXFORD TXB PALLIATIV, P761; SOUTHWICK F, 1993, ANN INTERN MED, V118, P146, DOI 10.7326/0003-4819-118-2-199301150-00011; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591; Taggart J A, 1994, Dimens Crit Care Nurs, V13, P114, DOI 10.1097/00003465-199405000-00001; TAMLER MS, 1992, AM J PHYS MED REHAB, V71, P236, DOI 10.1097/00002060-199208000-00007; TINETTI ME, 1992, ANN INTERN MED, V116, P369, DOI 10.7326/0003-4819-116-5-369; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389	41	17	17	2	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1755	1759		10.1056/NEJM199612053352308	http://dx.doi.org/10.1056/NEJM199612053352308			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VW795	8929269				2022-12-28	WOS:A1996VW79500008
J	Patel, L; David, TJ				Patel, L; David, TJ			Everybody has won, and all must have prizes	LANCET			English	Editorial Material									UNIV MANCHESTER,DEPT CHILD HLTH,MANCHESTER,LANCS,ENGLAND	University of Manchester			Patel, Leena/AAL-7366-2020	Patel, Leena/0000-0002-1134-4074				DAVID TJ, 1995, ARCH DIS CHILD, V73, P357, DOI 10.1136/adc.73.4.357; Dweck C.S., 1989, FDNS PSYCHOL ED, P87; Pressley M., 1995, ADV ED PSYCHOL ED RE	3	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1497	1497		10.1016/S0140-6736(96)06346-5	http://dx.doi.org/10.1016/S0140-6736(96)06346-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942783				2022-12-28	WOS:A1996VV46300016
J	Beverley, SM				Beverley, SM			Hijacking the cell: Parasites in the driver's seat	CELL			English	Review							INTRACELLULAR INFECTION; TOXOPLASMA-GONDII; MAMMALIAN-CELLS; ERYTHROCYTES; INVASION; MARKER				Beverley, SM (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, 240 LONGWOOD AVE, BOSTON, MA 02115 USA.			Beverley, Stephen/0000-0001-5319-0811				BURLEIGH BA, 1995, ANNU REV MICROBIOL, V49, P175, DOI 10.1146/annurev.mi.49.100195.001135; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; FALKOW S, 1988, REV INFECT DIS, V10, pS274; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Haldar Kasturi, 1993, Seminars in Cell Biology, V4, P345, DOI 10.1006/scel.1993.1041; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; LAUER SA, 1995, P NATL ACAD SCI USA, V92, P9181, DOI 10.1073/pnas.92.20.9181; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; MOORE KJ, 1994, J IMMUNOL, V152, P2930; REINER NE, 1994, IMMUNOL TODAY, V15, P374, DOI 10.1016/0167-5699(94)90176-7; SCHWAB JC, 1994, P NATL ACAD SCI USA, V91, P509, DOI 10.1073/pnas.91.2.509; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Williams R O, 1993, Semin Cell Biol, V4, P363, DOI 10.1006/scel.1993.1043	18	30	32	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					787	789		10.1016/S0092-8674(00)81984-4	http://dx.doi.org/10.1016/S0092-8674(00)81984-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945504	Bronze			2022-12-28	WOS:A1996VV77400003
J	Lesch, KP; Bengel, D; Heils, A; Sabol, SZ; Greenberg, BD; Petri, S; Benjamin, J; Muller, CR; Hamer, DH; Murphy, DL				Lesch, KP; Bengel, D; Heils, A; Sabol, SZ; Greenberg, BD; Petri, S; Benjamin, J; Muller, CR; Hamer, DH; Murphy, DL			Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region	SCIENCE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; UNIFIED BIOSOCIAL THEORY; H-3 PAROXETINE BINDING; MYOCARDIAL-INFARCTION; QUANTITATIVE TRAITS; PERSONALITY-DISORDERS; SEXUAL ORIENTATION; MAJOR DEPRESSION; MARKERS; LINKAGE	Transporter-facilitated uptake of serotonin (5-hydroxytryptamine or 5-HT) has been implicated in anxiety in humans and animal models and is the site of action of widely used uptake-inhibiting antidepressant and antianxiety drugs. Human 5-HT transporter (5-HTT) gene transcription is modulated by a common polymorphism in its upstream regulatory region. The short variant of the polymorphism reduces the transcriptional efficiency of the 5-HTT gene promoter, resulting in decreased 5-HTT expression and 5-HT uptake in lymphoblasts. Association studies in two independent samples totaling 505 individuals revealed that the 5-HTT polymorphism accounts for 3 to 4 percent of total variation and 7 to 9 percent of inherited variance in anxiety-related personality traits in individuals as well as sibships.	NIMH,CLIN SCI LAB,NIH,BETHESDA,MD 20892; NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892; UNIV WURZBURG,INST HUMAN GENET,D-97074 WURZBURG,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wurzburg	Lesch, KP (corresponding author), UNIV WURZBURG,DEPT PSYCHIAT,FUCHSLEINSTR 15,D-97080 WURZBURG,GERMANY.		Petri, Susanne/AID-7665-2022; Hamer, Dean H/L-1248-2015; Lesch, Klaus-Peter/J-4906-2013	Hamer, Dean H/0000-0002-6211-5781; Lesch, Klaus-Peter/0000-0001-8348-153X; Lagrange, hugues/0000-0002-2180-5284				Altemus M, 1996, AM J MED GENET, V67, P409, DOI 10.1002/(SICI)1096-8628(19960726)67:4<409::AID-AJMG16>3.0.CO;2-N; ANDREWS G, 1990, J AFFECT DISORDERS, V19, P23, DOI 10.1016/0165-0327(90)90005-S; [Anonymous], 1990, PERSONALITY ADULTHOO; ARBUSTINI E, 1995, BRIT HEART J, V74, P584; BEASLEY CM, 1992, PSYCHOPHARMACOLOGY, V107, P1, DOI 10.1007/BF02244958; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BENKERT O, 1993, INT CLIN PSYCHOPHARM, V8, P3, DOI 10.1097/00004850-199309001-00001; BERGEMAN CS, 1988, PSYCHOL AGING, V3, P399, DOI 10.1037/0882-7974.3.4.399; BLIER P, 1994, TRENDS PHARMACOL SCI, V15, P220, DOI 10.1016/0165-6147(94)90315-8; BOJA JW, 1994, DOPAMINE RECEPTORS T, P611; CAMBIEN F, 1994, CLIN GENET, V46, P94; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cattell R. B., 1946, DESCRIPTION MEASUREM; Cattell RB, 1943, J ABNORM SOC PSYCH, V38, P476, DOI 10.1037/h0054116; CHEEK J, IN PRESS; CHEN HT, 1992, J PHARMACOL TOXICOL, V27, P209, DOI 10.1016/1056-8719(92)90043-Z; Cloninger C.R., 1986, PSYCHIATRIC DEV, V3, P167; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; CLONINGER CR, 1988, PSYCHIAT DEV, V6, P83; COLLIER D, IN PRESS MOL PSYCHIA; Collier DA, 1996, NEUROREPORT, V7, P1675, DOI 10.1097/00001756-199607080-00030; COOK EH, 1994, NEUROREPORT, V5, P1745, DOI 10.1097/00001756-199409080-00014; COSTA PTJ, HDB PERSONALITY INVE; DENBOER JA, 1995, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199501004-00007; DIBELLA D, 1995, PSYCHIAT GENET, V5, pS100; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; ELSTON RC, 1994, SAGE USERS GUIDE REL; EYSENCK HJ, 1957, HDB ABNORMAL PSYCHOL, P131; FALUDI G, 1994, J PSYCHIATR NEUROSCI, V19, P109; FARAJ BA, 1994, INT J IMMUNOPHARMACO, V16, P561, DOI 10.1016/0192-0561(94)90107-4; FLINT J, 1995, SCIENCE, V269, P1432, DOI 10.1126/science.7660127; FUXE K, 1983, NEUROPHARMACOLOGY, V22, P389, DOI 10.1016/0028-3908(83)90188-0; GARDEMANN A, 1995, CIRCULATION, V92, P2796, DOI 10.1161/01.CIR.92.10.2796; GELERNTER J, 1995, HUM GENET, V95, P677; GEORGE VT, 1987, GENET EPIDEMIOL, V4, P193, DOI 10.1002/gepi.1370040304; Gray JA, 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; GRIEBEL G, 1995, PHARMACOL THERAPEUT, V65, P319, DOI 10.1016/0163-7258(95)98597-J; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HANDLEY SL, 1995, PHARMACOL THERAPEUT, V66, P103, DOI 10.1016/0163-7258(95)00004-Z; HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762; Heils A, 1996, J NEUROCHEM, V66, P2621; Heils A, 1995, J NEURAL TRANSM-GEN, V102, P247, DOI 10.1007/BF01281159; Heninger George R., 1995, P471; HENSLER JG, 1994, SYNAPSE, V17, P1, DOI 10.1002/syn.890170102; HU S, 1995, NAT GENET, V11, P248, DOI 10.1038/ng1195-248; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; INY LJ, 1994, BIOL PSYCHIAT, V36, P281; KENDLER KS, 1987, ARCH GEN PSYCHIAT, V44, P451; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P863; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; LESCH KP, 1995, BIOL PSYCHIAT, V37, P215, DOI 10.1016/0006-3223(94)00147-U; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; LOEHLIN JC, 1989, AM PSYCHOL, V44, P1285, DOI 10.1037/0003-066X.44.10.1285; MACKINNON A, 1994, HDB DEPRESSION ANXIE, P71; MAJ J, 1992, J NEURAL TRANSM-GEN, V88, P143, DOI 10.1007/BF01244819; MULDER RT, 1994, COMPR PSYCHIAT, V35, P225, DOI 10.1016/0010-440X(94)90195-3; MURPHY DL, 1993, SEROTONIN CELL BIOL, V2, P223; NICK TG, 1995, GENET EPIDEMIOL, V12, P145, DOI 10.1002/gepi.1370120204; Ogilvie AD, 1996, LANCET, V347, P731, DOI 10.1016/S0140-6736(96)90079-3; Ohno T, 1996, METABOLISM, V45, P218, DOI 10.1016/S0026-0495(96)90057-8; OWENS MJ, 1994, CLIN CHEM, V40, P288; PATERSON AH, 1991, GENETICS, V127, P181; PEDERSEN NL, 1988, J PERS SOC PSYCHOL, V55, P950, DOI 10.1037/0022-3514.55.6.950; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; RAMAMOORTHY JD, 1995, J BIOL CHEM, V270, P17189, DOI 10.1074/jbc.270.29.17189; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; SHUEY DL, 1992, TERATOLOGY, V46, P367, DOI 10.1002/tera.1420460407; STUBER CW, 1992, GENETICS, V132, P823; SVRAKIC DM, 1993, ARCH GEN PSYCHIAT, V50, P991; WESTENBERG HG, 1996, ADV NEUROBIOLOGY ANX; WHITAKERAZMITIA P, 1990, ANN NY ACAD SCI, V600, P4; WIGGINS JS, 1992, ANNU REV PSYCHOL, V43, P473, DOI 10.1146/annurev.ps.43.020192.002353	73	3978	4123	6	435	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1527	1531		10.1126/science.274.5292.1527	http://dx.doi.org/10.1126/science.274.5292.1527			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VV775	8929413				2022-12-28	WOS:A1996VV77500048
J	Liu, CC; Young, LHY; Young, JDE				Liu, CC; Young, LHY; Young, JDE			Lymphocyte-mediated cytolysis and disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; TUMOR-INFILTRATING LYMPHOCYTES; CYTOTOXIC T-LYMPHOCYTES; ACTIVATED KILLER-CELLS; TARGET-CELLS; GRANZYME-A; CD8+ LYMPHOCYTES; PERFORIN GENE; HIV-INFECTION; MICE LACKING		HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Liu, CC (corresponding author), ROCKEFELLER UNIV, LAB MOL IMMUNOL & CELL BIOL, 1230 YORK AVE, NEW YORK, NY 10021 USA.			Young, Lucy/0000-0001-8634-7512	NCI NIH HHS [CA47307] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047307] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; CLEMENT MV, 1994, TRANSPLANTATION, V57, P322, DOI 10.1097/00007890-199402150-00002; CURIEL TJ, 1993, J IMMUNOL, V151, P2024; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DOHERTY PC, 1990, IMMUNOL TODAY, V11, P55; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERRARI C, 1990, J IMMUNOL, V145, P3442; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; Golstein P, 1995, Curr Top Microbiol Immunol, V198, P25; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; GRIFFITHS GM, 1991, EUR J IMMUNOL, V21, P687, DOI 10.1002/eji.1830210322; HAHN S, 1995, IMMUNOL REV, V146, P57, DOI 10.1111/j.1600-065X.1995.tb00684.x; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; Herberman R B, 1974, Adv Cancer Res, V19, P207, DOI 10.1016/S0065-230X(08)60055-X; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOLLANDER GA, 1995, IMMUNITY, V3, P27, DOI 10.1016/1074-7613(95)90156-6; HOU S, 1992, J IMMUNOL, V149, P1319; HUDIG D, 1991, J IMMUNOL, V147, P1360; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, EUR J IMMUNOL, V24, P3068, DOI 10.1002/eji.1830241223; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KOLB H, 1995, IMMUNOL TODAY, V16, P170, DOI 10.1016/0167-5699(95)80115-4; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KRADIN RL, 1989, LANCET, V1, P577; LAFRENIERE R, 1985, CANCER RES, V45, P3735; LARSEN HS, 1984, J VIROL, V50, P56, DOI 10.1128/JVI.50.1.56-59.1984; LEGERRAVET MB, 1994, AM J PATHOL, V144, P492; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIPMAN ML, 1992, TRANSPLANTATION, V53, P73, DOI 10.1097/00007890-199201000-00014; LIU CC, 1995, J IMMUNOL, V155, P602; LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9; LOWIN B, 1994, P NATL ACAD SCI USA, V91, P11571, DOI 10.1073/pnas.91.24.11571; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LOWRY RP, 1985, TRANSPLANTATION, V40, P545, DOI 10.1097/00007890-198511000-00014; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; OWENS T, 1995, NEUROL CLIN, V13, P51, DOI 10.1016/S0733-8619(18)30061-6; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; QUINNAN GV, 1982, NEW ENGL J MED, V307, P7, DOI 10.1056/NEJM198207013070102; REDDEHASE MJ, 1987, J VIROL, V61, P3102, DOI 10.1128/JVI.61.10.3102-3108.1987; REHERMANN B, 1995, J EXP MED, V181, P1047, DOI 10.1084/jem.181.3.1047; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL SR, 1993, CURR OPIN IMMUNOL, V5, P484, DOI 10.1016/0952-7915(93)90027-P; RIDDELL SR, 1992, SCIENCE, V257, P238; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SEKO Y, 1994, J CLIN INVEST, V93, P750, DOI 10.1172/JCI117029; SEKO Y, 1993, J PATHOL, V170, P53, DOI 10.1002/path.1711700109; SEKO Y, 1991, CIRCULATION, V84, P788, DOI 10.1161/01.CIR.84.2.788; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SHIVER JW, 1991, CELL, V64, P1175, DOI 10.1016/0092-8674(91)90272-Z; SHULZ M, 1995, EUR J IMMUNOL, V25, P474, DOI 10.1002/eji.1830250225; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUN D, 1986, NATURE, V320, P70, DOI 10.1038/320070a0; TALENTO A, 1992, J IMMUNOL, V149, P4009; TARLETON RL, 1994, INFECT IMMUN, V62, P1820, DOI 10.1128/IAI.62.5.1820-1829.1994; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854; Welsh R M, 1981, Curr Top Microbiol Immunol, V92, P83; WU Z, 1994, CLIN EXP IMMUNOL, V98, P470; YAGITA H, 1995, IMMUNOL REV, V146, P223, DOI 10.1111/j.1600-065X.1995.tb00691.x; YANNELLI JR, 1986, J IMMUNOL, V136, P377; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG JDE, 1986, CELL, V44, P849, DOI 10.1016/0092-8674(86)90007-3; YOUNG LHY, 1990, LANCET, V336, P1019, DOI 10.1016/0140-6736(90)92486-2; YOUNG LHY, 1989, J EXP MED, V169, P2159, DOI 10.1084/jem.169.6.2159; YOUNG LHY, 1989, J IMMUNOL, V143, P3994; YOUNG LHY, 1989, J EXP MED, V170, P2191; YOUNG LHY, 1992, AM J PATHOL, V140, P1261; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1; ZYCHLINSKY A, 1991, J IMMUNOL, V146, P393	102	84	90	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1651	1659		10.1056/NEJM199611283352206	http://dx.doi.org/10.1056/NEJM199611283352206			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929363				2022-12-28	WOS:A1996VV93600006
J	Hotamisligil, GS; Johnson, RS; Distel, RJ; Ellis, R; Papaioannou, VE; Spiegelman, BM				Hotamisligil, GS; Johnson, RS; Distel, RJ; Ellis, R; Papaioannou, VE; Spiegelman, BM			Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; ADIPOSE-TISSUE; EXPRESSION; RECEPTOR; MICE; GENE	Fatty acid binding proteins (FABPs) are small cytoplasmic proteins that are expressed in a highly tissue-specific manner and bind to fatty acids such as oleic and retinoic acid. Mice with a null mutation in aP2, the gene encoding the adipocyte FABP, were developmentally and metabolically normal. The aP2-deficient mice developed dietary obesity but, unlike control mice, they did not develop insulin resistance or diabetes. Also unlike their obese wild-type counterparts, obese aP2(-/-) animals failed to express in adipose tissue tumor necrosis factor-alpha (TNF-alpha), a molecule implicated in obesity-related insulin resistance. These results indicate that aP2 is central to the pathway that links obesity to insulin resistance, possibly by linking fatty acid metabolism to expression of TNF-alpha.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA	University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Columbia University	Hotamisligil, GS (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601	NICHD NIH HHS [HD27295] Funding Source: Medline; NIDDK NIH HHS [DK31405] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405, R01DK031405] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNLOHR DA, UNPUB; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HOTAMISLIGIL GS, UNPUB; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRIEG P, 1993, J BIOL CHEM, V268, P17362; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LEMONNIER D, 1975, DIABETES METAB, V1, P77; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; Moller DE, 1993, INSULIN RESISTANCE; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RANDLE PJ, 1963, LANCET, V1, P785; SALMON DMW, 1985, INT J OBESITY, V9, P443; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STORCH J, UNPUB; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570	30	621	676	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 22	1996	274	5291					1377	1379		10.1126/science.274.5291.1377	http://dx.doi.org/10.1126/science.274.5291.1377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910278				2022-12-28	WOS:A1996VU95400054
J	Livermore, C; Crouch, CH; Westervelt, RM; Campman, KL; Gossard, AC				Livermore, C; Crouch, CH; Westervelt, RM; Campman, KL; Gossard, AC			The Coulomb blockade in coupled quantum dots	SCIENCE			English	Article							ENERGY	Individual quantum dots are often referred to as ''artificial atoms.'' Two tunnel-coupled quantum dots can be considered an ''artificial molecule.'' Low-temperature measurements were made on a series double quantum dot with adjustable interdot tunnel conductance that was fabricated in a gallium arsenide-aluminum gallium arsenide heterostructure, The Coulomb blockade was used to determine the ground-state charge configuration within the ''molecule'' as a function of the total charge on the double dot and the interdot polarization induced by electrostatic gates. As the tunnel conductance between the two dots is increased from near zero to 2e (2)/h (where e is the electron charge and h is Planck's constant), the measured conductance peaks of the double dot exhibit pronounced changes in agreement with many-body theory.	HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; UNIV CALIF SANTA BARBARA,DEPT MAT,SANTA BARBARA,CA 93106	Harvard University; University of California System; University of California Santa Barbara	Livermore, C (corresponding author), HARVARD UNIV,DIV APPL SCI,CAMBRIDGE,MA 02138, USA.							Adourian AS, 1996, SUPERLATTICE MICROST, V20, P411, DOI 10.1006/spmi.1996.0097; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; Blick RH, 1996, PHYS REV B, V53, P7899, DOI 10.1103/PhysRevB.53.7899; Crouch CH, 1996, SURF SCI, V361, P631, DOI 10.1016/0039-6028(96)00487-6; Dixon D, 1996, PHYS REV B, V53, P12625, DOI 10.1103/PhysRevB.53.12625; FALCI G, 1995, PHYS REV LETT, V74, P3257, DOI 10.1103/PhysRevLett.74.3257; Glazman L. I., 1990, Soviet Physics - JETP, V71, P1031; Golden JM, 1996, PHYS REV B, V53, P3893, DOI 10.1103/PhysRevB.53.3893; GOLDEN JM, IN PRESS PHYS REV B; Grabert H., 1992, NATO ASI SERIES B, V294; KASTNER MA, 1992, REV MOD PHYS, V64, P849, DOI 10.1103/RevModPhys.64.849; KEMERINK M, 1994, APPL PHYS LETT, V65, P1012, DOI 10.1063/1.112209; KLIMECK G, 1994, PHYS REV B, V50, P2316, DOI 10.1103/PhysRevB.50.2316; LIVERMORE C, IN PRESS SUPERLATTIC; Matveev K. A., 1991, Soviet Physics - JETP, V72, P892; Matveev KA, 1996, PHYS REV B, V54, P5637, DOI 10.1103/PhysRevB.54.5637; Matveev KA, 1996, PHYS REV B, V53, P1034, DOI 10.1103/PhysRevB.53.1034; MATVEEV KA, 1995, PHYS REV B, V51, P1743, DOI 10.1103/PhysRevB.51.1743; MOLENKAMP LW, 1995, PHYS REV LETT, V75, P4282, DOI 10.1103/PhysRevLett.75.4282; RUZIN IM, 1992, PHYS REV B, V45, P13469, DOI 10.1103/PhysRevB.45.13469; STAFFORD CA, 1994, PHYS REV LETT, V72, P3590, DOI 10.1103/PhysRevLett.72.3590; STOPA M, COMMUNICATION; VANDERVAART NC, 1995, PHYS REV LETT, V74, P4702, DOI 10.1103/PhysRevLett.74.4702; VANDERVAART NC, 1995, THESIS DELFT TU; Waugh FR, 1996, PHYS REV B, V53, P1413, DOI 10.1103/PhysRevB.53.1413; WAUGH FR, 1995, PHYS REV LETT, V75, P705, DOI 10.1103/PhysRevLett.75.705	27	242	246	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1332	1335		10.1126/science.274.5291.1332	http://dx.doi.org/10.1126/science.274.5291.1332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910263				2022-12-28	WOS:A1996VU95400039
J	Wang, Q; Stacy, T; Miller, JD; Lewis, AF; Gu, TL; Huang, XM; Bushweller, JH; Bories, JC; Alt, FW; Ryan, G; Liu, PP; WynshawBoris, A; Binder, M; MarinPadilla, M; Sharpe, AH; Speck, NA				Wang, Q; Stacy, T; Miller, JD; Lewis, AF; Gu, TL; Huang, XM; Bushweller, JH; Bories, JC; Alt, FW; Ryan, G; Liu, PP; WynshawBoris, A; Binder, M; MarinPadilla, M; Sharpe, AH; Speck, NA			The CBF beta subunit is essential for CBF alpha 2 (AML1) function in vivo	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MOUSE EMBRYO; RUNT DOMAIN; TRANSCRIPTION FACTORS; TARGETED MUTATION; CEREBRAL-CORTEX; CHIMERIC MICE; PROTEIN RBTN2; YOLK-SAC	The CBF beta subunit is the non-DNA-binding subunit of the heterodimeric core-binding factor (CBF). CBF beta associates with DNA-binding CBF alpha subunits and increases their affinity for DNA. Genes encoding the CBF beta subunit (CBFB) and one of the CBF alpha subunits (CBFA2, otherwise known as AML1) are the most frequent targets of chromosomal translocations in acute leukemias in humans. We and others previously demonstrated that homozygous disruption of the mouse Cbfa2 (AML1) gene results in embryonic lethality at midgestation due to hemorrhaging in the central nervous system and blocks fetal liver hematopoiesis. Here we demonstrate that homozygous mutation of the Cbfb gene results in the same phenotype. Our results demonstrate that the CBF beta subunit is required for CBF alpha 2 function in vivo.	DARTMOUTH COLL,DEPT CHEM,HANOVER,NH 03755; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02215; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; DARTMOUTH COLL SCH MED,DEPT ANAT,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT PATHOL,HANOVER,NH 03755; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Dartmouth College; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Dartmouth College; Dartmouth College; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wang, Q (corresponding author), DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755, USA.		Liu, Paul/A-7976-2012; Bories, Jean-Christophe/L-6952-2017	Liu, Paul/0000-0002-6779-025X; Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [CA58343] Funding Source: Medline; NIAID NIH HHS [AI39536-01] Funding Source: Medline; NINDS NIH HHS [NS22897] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039536, R01AI039536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022897] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES KH, 1967, Z ZELLFORSCH MIK ANA, V79, P272, DOI 10.1007/BF00369291; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; BOWIE JU, 1989, J BIOL CHEM, V264, P7596; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harlow E., 1988, ANTIBODIES LAB MANUA; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KRISCH B, 1984, CELL TISSUE RES, V238, P459; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARINPADILLA M, 1985, J COMP NEUROL, V241, P237, DOI 10.1002/cne.902410210; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHURTLEFF SA, 1995, BLOOD, V85, P3695, DOI 10.1182/blood.V85.12.3695.bloodjournal85123695; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; SOLFER SJ, 1994, AM J PATHOL, V144, P60; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TSAL JY, 1994, NATURE, V371, P221; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	46	533	540	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					697	708		10.1016/S0092-8674(00)81389-6	http://dx.doi.org/10.1016/S0092-8674(00)81389-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929538	hybrid			2022-12-28	WOS:A1996VU03500012
J	Libby, P				Libby, P			Atheroma: More than mush	LANCET			English	Article							CORONARY						Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X				BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; GENG YJ, 1995, AM J PATHOL, V147, P251; GERHARD M, 1995, CIRCULATION, V92, P5, DOI 10.1161/01.CIR.92.1.5; HANSSON GK, 1996, ATHEROSCLEROSIS CORO, P557; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIBBY P, 1996, ATHEROSCLEROSIS CORO, P5985; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; METCHNIKOFF E, 1893, COMP PATHOLOGY INFLA; METCHNIKOFF E, 1893, J CLIN INVEST; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; POOLE JCF, 1958, J PATHOL BACTERIOL, V75, P245, DOI 10.1002/path.1700750202; RAINES EW, 1996, ATHEROSCLEROSIS CORO, P539; *SCAND SIMV SURV S, 1994, LANCET, V344, P1383; SHAW GB, 1911, DOCTORS DILEMMA; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	18	42	44	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV	1996	348			1			S4	S7		10.1016/S0140-6736(96)98002-2	http://dx.doi.org/10.1016/S0140-6736(96)98002-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918519				2022-12-28	WOS:A1996VU00800003
J	McClain, JB; Betts, DE; Canelas, DA; Samulski, ET; DeSimone, JM; Londono, JD; Cochran, HD; Wignall, GD; ChilluraMartino, D; Triolo, R				McClain, JB; Betts, DE; Canelas, DA; Samulski, ET; DeSimone, JM; Londono, JD; Cochran, HD; Wignall, GD; ChilluraMartino, D; Triolo, R			Design of nonionic surfactants for supercritical carbon dioxide	SCIENCE			English	Article							ANGLE NEUTRON-SCATTERING; MICROEMULSIONS; MICELLAR; FLUIDS; POLYMERIZATIONS	Interfacially active block copolymer amphiphiles have been synthesized and their self-assembly into micelles in supercritical carbon dioxide (CO2) has been demonstrated with small-angle neutron scattering (SANS). These materials establish the design criteria for molecularly engineered surfactants that can stabilize and disperse otherwise insoluble matter into a CO2 continuous phase. Polystyrene-b-poly(1,1-dihydroperfluorooctyl acrylate) copolymers self-assembled into polydisperse core-shell-type micelles as a result of the disparate solubility characteristics of the different block segments in CO2. These nonionic surfactants for CO2 were shown by SANS to be capable of emulsifying up to 20 percent by weight of a CO2-insoluble hydrocarbon into CO2. This result demonstrates the efficacy of surfactant-modified CO2 in reducing the large volumes of organic and halogenated solvent waste streams released into our environment by solvent-intensive manufacturing and process industries.	OAK RIDGE NATL LAB,OAK RIDGE,TN 37831; UNIV N CAROLINA,DEPT CHEM,VENABLE & KENAN LABS,CHAPEL HILL,NC 27599; UNIV PALERMO,DIPARTIMENTO CHIM FIS,I-90123 PALERMO,ITALY	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of North Carolina; University of North Carolina Chapel Hill; University of Palermo			Chillura Martino, Delia/E-5730-2012	Chillura Martino, Delia/0000-0001-5141-7285				BARTSCHERER KA, 1995, FLUID PHASE EQUILIBR, V107, P93, DOI 10.1016/0378-3812(95)02726-U; Beckman EJ, 1996, SCIENCE, V271, P613, DOI 10.1126/science.271.5249.613; BIRSHTEIN TM, 1989, POLYMER, V30, P171; BRIOLO R, 1992, IND TECHNICAL APPL N, P402; CAPONETTI E, 1990, ADV COLLOID INTERFAC, V32, P235, DOI 10.1016/0001-8686(90)80020-Z; CHILLURAMARTIN D, IN PRESS J MOL STRUC; CHU B, 1995, LANGMUIR, V11, P414, DOI 10.1021/la00002a009; COGAN KA, 1990, MACROMOLECULES, V23, P745, DOI 10.1021/ma00205a009; DESIMONE JM, 1992, SCIENCE, V257, P945, DOI 10.1126/science.257.5072.945; Eastoe J, 1996, LANGMUIR, V12, P1423, DOI 10.1021/la950546c; ELY JF, 1986, CO2PAC COMPUTER PROG; FULTON JL, 1995, LANGMUIR, V11, P4241, DOI 10.1021/la00011a014; GUAN ZB, 1994, MACROMOLECULES, V27, P5527, DOI 10.1021/ma00098a002; HALPERIN A, 1992, ADV POLYM SCI, V100, P31; HOEFLING TA, 1991, J PHYS CHEM-US, V95, P7127, DOI 10.1021/j100172a006; HSIAO YL, 1995, MACROMOLECULES, V28, P8159, DOI 10.1021/ma00128a028; HYATT JA, 1984, J ORG CHEM, V49, P5097, DOI 10.1021/jo00200a016; JANSSEN S, 1993, MACROMOLECULES, V26, P5587, DOI 10.1021/ma00073a009; Johnston KP, 1996, SCIENCE, V271, P624, DOI 10.1126/science.271.5249.624; KOEHLER WC, 1986, PHYSICA B & C, V137, P320, DOI 10.1016/0378-4363(86)90337-2; MAGID LJ, 1986, COLLOID SURFACE, V19, P129, DOI 10.1016/0166-6622(86)80332-8; McClain JB, 1996, J AM CHEM SOC, V118, P917, DOI 10.1021/ja952750s; MCHUGH M, 1993, SUPERCRITICAL FLUIDS; NELMES RJ, 1993, ACTA CRYSTALLOGR A, V49, P427; OTSU T, 1982, MAKROMOL CHEM-RAPID, V3, P127; RAVEY JC, 1984, J COLLOID INTERF SCI, V97, P9, DOI 10.1016/0021-9797(84)90269-8; SHAFFER KA, 1995, TRENDS POLYM SCI, V3, P146; SMITH VS, 1996, INT J THERMOPHYS, V1, P23; TUZAR Z, 1993, SURF COLLOID SCI, V15, P1; Walsh KA, 1996, CHEM WEEK, V158, P38; WIGNALL GD, 1993, PHYSICAL PROPERTIES, P313; [No title captured]	32	253	275	2	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2049	2052		10.1126/science.274.5295.2049	http://dx.doi.org/10.1126/science.274.5295.2049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953029				2022-12-28	WOS:A1996VY97400039
J	Mitch, WE; Goldberg, AL				Mitch, WE; Goldberg, AL			Mechanisms of disease - Mechanisms of muscle wasting - The role of the ubiquitin-proteasome pathway	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RAT SKELETAL-MUSCLE; DEPENDENT PROTEOLYTIC SYSTEM; TOTAL PARENTERAL-NUTRITION; ACUTE-RENAL-FAILURE; TUMOR-BEARING RATS; PROTEIN BREAKDOWN; METABOLIC-ACIDOSIS; DENERVATION ATROPHY; MESSENGER-RNA; KAPPA-B		HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA USA	Harvard University; Harvard Medical School	Mitch, WE (corresponding author), EMORY UNIV, SCH MED, DIV RENAL, 1364 CLIFTON RD, ATLANTA, GA 30322 USA.				NIDDK NIH HHS [R01 DK37175, P50 DK42515] Funding Source: Medline; NIGMS NIH HHS [R01 GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagatell CJ, 1996, NEW ENGL J MED, V334, P707, DOI 10.1056/NEJM199603143341107; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; BREUILLE D, 1993, AM J PHYSIOL, V265, pE660, DOI 10.1152/ajpendo.1993.265.4.E660; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CLARK AS, 1984, J CLIN INVEST, V74, P888, DOI 10.1172/JCI111506; CLARK AS, 1983, J CLIN INVEST, V72, P836, DOI 10.1172/JCI111054; CLOWES GHA, 1983, NEW ENGL J MED, V308, P545, DOI 10.1056/NEJM198303103081001; CLOWES GHA, 1976, SURG CLIN N AM, V56, P1169; COHN SH, 1983, AM J PHYSIOL, V244, pE305, DOI 10.1152/ajpendo.1983.244.3.E305; COSTELLI P, 1993, J CLIN INVEST, V92, P2783, DOI 10.1172/JCI116897; COSTELLI P, 1995, J CLIN INVEST, V95, P2367, DOI 10.1172/JCI117929; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DING H, 1993, J CLIN INVEST, V91, P2281, DOI 10.1172/JCI116456; ENGLAND BK, 1995, AM J PHYSIOL-CELL PH, V268, pC1395, DOI 10.1152/ajpcell.1995.268.6.C1395; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FANG CH, 1995, J AM COLL SURGEONS, V180, P161; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Goldberg AL, 1995, COLD SPRING HARB SYM, V60, P479, DOI 10.1101/SQB.1995.060.01.052; GOLDBERG AL, 1988, J CLIN INVEST, V81, P1378, DOI 10.1172/JCI113466; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GOODMAN MN, 1994, P SOC EXP BIOL MED, V205, P182; HASSELGREN PO, 1986, ARCH SURG-CHICAGO, V121, P918; HASSELGREN PO, 1989, METABOLISM, V38, P634, DOI 10.1016/0026-0495(89)90100-5; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Isozaki Y, 1996, P NATL ACAD SCI USA, V93, P1967, DOI 10.1073/pnas.93.5.1967; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAYSEN GA, 1984, KIDNEY INT, V25, P107, DOI 10.1038/ki.1984.15; LAWSON DH, 1982, ANNU REV NUTR, V2, P277, DOI 10.1146/annurev.nu.02.070182.001425; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LOWELL BB, 1986, BIOCHEM J, V234, P237, DOI 10.1042/bj2340237; MA CP, 1994, J BIOL CHEM, V269, P3539; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; MAY RC, 1991, J NUTR, V121, P293, DOI 10.1093/jn/121.3.293; MAY RC, 1987, J CLIN INVEST, V79, P1099, DOI 10.1172/JCI112924; MAY RC, 1986, J CLIN INVEST, V77, P614, DOI 10.1172/JCI112344; May RC, 1996, KIDNEY INT, V49, P679, DOI 10.1038/ki.1996.96; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MILLER SB, 1994, KIDNEY INT, V46, P201, DOI 10.1038/ki.1994.260; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; REAICH D, 1994, J AM SOC NEPHROL, V5, P953; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHAW JHF, 1987, ANN SURG, V205, P288, DOI 10.1097/00000658-198703000-00012; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; TAWA NE, 1992, AM J PHYSIOL, V263, pE317, DOI 10.1152/ajpendo.1992.263.2.E317; TAWA NE, 1994, MYOLOGY, P683; Tawa Nicholas T. Jr., 1995, Surgical Forum, V46, P12; TEMPARIS S, 1994, CANCER RES, V54, P5568; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; Todorov P, 1996, NATURE, V379, P739, DOI 10.1038/379739a0; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WALDMANN TA, 1970, PLASMA PROTEIN METAB, P269; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARNOLD I, 1988, ANN SURG, V208, P143, DOI 10.1097/00000658-198808000-00003; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639; YOUNG VR, 1986, PROGR NATURE RENAL D, V14, P263; ZAMIR O, 1992, ARCH SURG-CHICAGO, V127, P170; ZAMIR O, 1994, INT J BIOCHEM, V26, P943, DOI 10.1016/0020-711X(94)90088-4; ZIEGLER TR, 1994, ANNU REV MED, V45, P459	70	866	906	3	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1897	1905		10.1056/NEJM199612193352507	http://dx.doi.org/10.1056/NEJM199612193352507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948566				2022-12-28	WOS:A1996VX87400007
J	Tokatlidis, K; Junne, T; Moes, S; Schatz, G; Glick, BS; Kronidou, N				Tokatlidis, K; Junne, T; Moes, S; Schatz, G; Glick, BS; Kronidou, N			Translocation arrest of an intramitochondrial sorting signal next to Tim11 at the inner-membrane import site	NATURE			English	Article							MITOCHONDRIAL INTERMEMBRANE SPACE; PROTEIN IMPORT; PRECURSOR PROTEIN; MATRIX; ATP; BINDING	THE import of proteins from the cytosol into the mitochondrial matrix involves the concerted action of two separate import systems: the TOM system in the outer membrane, and the TIM system in the inner membrane(1,2), Here we report that the inner-membrane system also sorts proteins to the intermembrane space. Some intermembrane-space proteins, such as cytochromes b(2) and c(1), are synthesized with a complex pre-sequence consisting of a positively charged matrix targeting signal followed by an uncharged sequence that acts as sorting signal for the intermembrane space(3). We show that this sorting signal can be efficiently crosslinked to an inner-membrane protein of relative molecular mass 11K after the mature part of the precursor has been sorted to the intermembrane space. The 11K protein, which we term Tim11, is a component of the protein import system in the inner membrane.	UNIV CHICAGO,CUMMINGS LIFE SCI CTR,CHICAGO,IL 60637	University of Chicago	Tokatlidis, K (corresponding author), UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND.			Tokatlidis, Kostas/0000-0001-6295-8183				BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GARTNER F, 1995, EMBO J, V14, P1349; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1992, TRENDS BIOCHEM SCI, V17, P453, DOI 10.1016/0968-0004(92)90487-T; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HUANG ST, 1991, J BIOL CHEM, V266, P21083; JASCUR T, 1992, J BIOL CHEM, V267, P13636; KAUFMANN SH, 1984, EXP CELL RES, V155, P477, DOI 10.1016/0014-4827(84)90208-8; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PHIL A, 1962, J BIOL CHEM, V237, P1356; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; TOKATLIDIS K, 1991, FEBS LETT, V282, P205, DOI 10.1016/0014-5793(91)80478-L; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; WACH A, 1994, YEAST, V10, P1791; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	27	55	55	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					585	588		10.1038/384585a0	http://dx.doi.org/10.1038/384585a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955275				2022-12-28	WOS:A1996VX76900065
J	Kantor, DB; Lanzrein, M; Stary, SJ; Sandoval, GM; Smith, WB; Sullivan, BM; Davidson, N; Schuman, EM				Kantor, DB; Lanzrein, M; Stary, SJ; Sandoval, GM; Smith, WB; Sullivan, BM; Davidson, N; Schuman, EM			A role for endothelial NO synthase in LTP revealed by adenovirus-mediated inhibition and rescue	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; LONG-TERM POTENTIATION; SYNAPTIC POTENTIATION; RAT HIPPOCAMPUS; PROTEIN; GENE; ACID; MYRISTOYLATION; INVOLVEMENT; MESSENGER	Pharmacological studies support the idea that nitric oxide (NO) serves as a retrograde messenger during long-term potentiation (LTP) in area CAI of the hippocampus. Mice with a defective form of the gene for neuronal NO synthase (nNOS), however, exhibit normal LTP. The myristoyl protein endothelial NOS (eNOS) is present in the dendrites of CA1 neurons. Recombinant adenovirus vectors containing either a truncated eNOS (a putative dominant negative) or an eNOS fused to a transmembrane protein were used to demonstrate that membrane-targeted eNOS is required for LTP. The membrane localization of eNOS may optimally position the enzyme both to respond to Ca2+ influx and to release NO into the extracellular space during LTP induction.	CALTECH, DIV BIOL 216 76, PASADENA, CA 91125 USA	California Institute of Technology			Schuman, Erin M/D-6204-2011	Kantor, David/0000-0002-0466-1012	NINDS NIH HHS [NS37292] Funding Source: Medline; PHS HHS [49176] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS037292] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CUMMINGS JA, 1994, NEUROSCI LETT, V176, P110, DOI 10.1016/0304-3940(94)90883-4; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HALEY JE, IN PRESS LEARN MEM; HELM R, 1995, NATURE, V373, P663; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; KANTOR DB, UNPUB; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; LIU JW, 1994, J BIOL CHEM, V269, P11691; MCILHINNEY RAJ, 1990, J NEUROCHEM, V54, P110, DOI 10.1111/j.1471-4159.1990.tb13289.x; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; SUKHATME VP, 1985, CELL, V40, P591, DOI 10.1016/0092-8674(85)90207-7; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A	33	161	166	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1744	1748		10.1126/science.274.5293.1744	http://dx.doi.org/10.1126/science.274.5293.1744			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939872				2022-12-28	WOS:A1996VW71200071
J	Kirkpatrick, AF				Kirkpatrick, AF			Role of the USA in shortage of food and medicine in Cuba	LANCET			English	Article							EPIDEMIC	For over 30 years an embargo by the USA has restricted Cuba's ability to purchase foods and medicines. In 1992, the USA enacted the Cuban Democracy Act (CDA), which ''exempted'' the sale of medicines from the embargo. However, the implementation of the CDA's requirements and the intensification of the embargo as a result of the passage of the Helms-Burton Act in March, 1996, have undermined the purpose of the medicine exemption. The resultant lack of food and medicine to Cuba contributed to the worst epidemic of neurological disease this century. The Inter-American Commission on Human Rights of the Organization of American States has informed the US Government that such activities violate international law and has requested that the US take immediate steps to exempt food and medicine from the embargo.			Kirkpatrick, AF (corresponding author), UNIV S FLORIDA,COLL MED,12901 BRUCE B DOWNS BLVD,BOX 59,TAMPA,FL 33612, USA.							*AM PUBL HLTH ASS, 1993, POL SUFF IMP US EMB; *AMN INT, 1995, US HUM RIGHTS VIOL S; BARRAL PE, 1990, 15 YEARS RESULTS PHA; CARTER T, 1995, WASHINGTON TIME 0730; *CUBA NEUR FIELD I, 1995, NEW ENGL J MED, V333, P1176; *HUM RIGHTS WATCH, 1995, CUB IMPR REF; Kirkpatrick AF, 1996, JAMA-J AM MED ASSOC, V275, P1633, DOI 10.1001/jama.1996.03530450023014; MONMANEY T, 1995, LOS ANGELES TIM 1120; *PHARM RES MAN AM, 1994, WORLD CLASS DRUGS OR; REDWOOD H, 1994, PRICE REGULATION PHA; ROMAN GC, 1995, ANN INTERN MED, V122, P530, DOI 10.7326/0003-4819-122-7-199504010-00009; ROMAN GC, 1994, NEUROLOGY, V44, P1784, DOI 10.1212/WNL.44.10.1784; WALTE J, 1995, USA TODAY       0307; 1995, USA TODAY       1025, pA3	14	27	31	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1489	1491		10.1016/S0140-6736(96)07376-X	http://dx.doi.org/10.1016/S0140-6736(96)07376-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942780				2022-12-28	WOS:A1996VV46300013
J	Foote, M				Foote, M			Ecological controls on the evolutionary recovery of post-Paleozoic crinoids	SCIENCE			English	Article							FUNCTIONAL-MORPHOLOGY; TAXONOMIC DIVERSITY; DISPARITY; DIVERSIFICATION; ARTICULATIONS; ECHINODERMS; RECORD; TAXA	Analysis of morphological characters of a global sample of post-Paleozoic crinoid echinoderms shows that this group underwent a rapid diversification after the extinction at the end of the Permian to reach maximal morphological disparity by the Late Triassic, which is essentially the same evolutionary pattern seen during the group's early Paleazoic radiation. The accelerated morphological diversification of a single class implies that, even if clades surviving from the Paleozoic represented ecological incumbents that hindered the origin of new higher taxa, species within individual higher taxa rapidly exploited available ecological opportunities in the Mesozoic.			Foote, M (corresponding author), UNIV CHICAGO,DEPT GEOPHYS SCI,5734 S ELLIS AVE,CHICAGO,IL 60637, USA.							[Anonymous], 1995, DISKURS, P15; Arendt Y. A., 1974, T PALEONTOLOGICHESKE, V144, P1, DOI 10.1017/S037689290000429X; AUSICH WI, 1983, J PALEONTOL, V57, P31; AUSICH WI, 1988, J PALEONTOL, V62, P906, DOI 10.1017/S0022336000030171; AUSICH WI, 1980, J PALEONTOL, V54, P273; AUSICH WI, 1996, 6 N AM PAL CONV ABST, P16; Bambach R.K., 1985, P191; BAMBACH RK, 1983, BIOTIC INTERACTIONS, P719; BREIMER A, 1975, P K NED AKAD B PHYS, V78, P149; BREIMER A, 1969, KONINKLIJKE NEDERL B, V72, P139; BREIMER A, 1978, TREATISE INVERTEBR T, V2, P316; BRETT CE, 1981, LETHAIA, V14, P343, DOI 10.1111/j.1502-3931.1981.tb01110.x; BRIGGS DEG, 1992, SCIENCE, V256, P1670, DOI 10.1126/science.256.5064.1670; BROWER JAMES C., 1966, J PALEONTOL, V40, P613; BROWER JC, 1987, J PALEONTOL, V61, P999, DOI 10.1017/S002233600002936X; CONWAYMORRIS S, 1993, NATURE, V361, P219; DELORIOL P, 1982, PALEONTOLOGIE FRAN 1; DONOVAN SK, 1988, LETHAIA, V21, P169, DOI 10.1111/j.1502-3931.1988.tb00807.x; DONOVAN SK, 1990, LETHAIA, V23, P291, DOI 10.1111/j.1502-3931.1990.tb01454.x; ERWIN DH, 1987, EVOLUTION, V41, P1177, DOI 10.1111/j.1558-5646.1987.tb02459.x; FOOTE M, 1992, P NATL ACAD SCI USA, V89, P7325, DOI 10.1073/pnas.89.16.7325; FOOTE M, 1992, SCIENCE, V258, P1816, DOI 10.1126/science.258.5089.1816; FOOTE M, 1993, PALEOBIOLOGY, V19, P185, DOI 10.1017/S0094837300015864; FOOTE M, 1994, PALEOBIOLOGY, V20, P320, DOI 10.1017/S009483730001280X; FOOTE M, 1995, PALEOBIOLOGY, V21, P273, DOI 10.1017/S0094837300013300; FOOTE M, 1992, PALEOBIOLOGY, V18, P1, DOI 10.1017/S0094837300012185; FOOTE M, 1993, PALEOBIOLOGY, V19, P403, DOI 10.1017/S0094837300014056; Foote Mike, 1994, Contributions from the Museum of Paleontology University of Michigan, V29, P1; Foote Mike, 1995, Contributions from the Museum of Paleontology University of Michigan, V29, P135; GOULD SJ, 1991, PALEOBIOLOGY, V17, P411, DOI 10.1017/S0094837300010745; GOULD SJ, 1980, PALEOBIOLOGY, V6, P383, DOI 10.1017/S0094837300003572; GOWER JC, 1966, BIOMETRIKA, V53, P325, DOI 10.1093/biomet/53.3-4.325; Harland W.B., 1990, GEOLOGIC TIME SCALE; HOLTERHOFF PF, 1996, 6 N AM PAL CONV ABST, P176; JABLONSKI D, 1991, SCIENCE, V253, P754, DOI 10.1126/science.253.5021.754; Jablonski D., 1990, P21; JABLONSKI D, 1991, SCIENCE, V252, P1831, DOI 10.1126/science.252.5014.1831; JANGOUX M, 1983, ECHINODERM NUTR, P25; KAMMER TW, 1985, J PALEONTOL, V59, P551; KAMMER TW, 1987, PALEOBIOLOGY, V13, P379; LANE NG, 1963, J PALEONTOL, V37, P917; MEYER D L, 1977, Paleobiology, V3, P74; MEYER DL, 1973, MAR BIOL, V22, P105, DOI 10.1007/BF00391776; Pearson ES, 1926, BIOMETRIKA, V18, P173, DOI 10.2307/2332501; RAUP DM, 1979, SCIENCE, V206, P217, DOI 10.1126/science.206.4415.217; ROUX M, 1978, Geobios (Villeurbanne), V11, P213, DOI 10.1016/S0016-6995(78)80089-8; Sepkoski J.J. Jr, 1986, P3; SEPKOSKI JJ, COMMUNICATION; Sepkoski Jr J.J., 1992, MILWAUKEE PUBLIC MUS, V83, P1; Simms M.J., 1988, Historical Biology, V1, P17; Simms M. J., 1990, MAJOR EVOLUTIONARY R, P287; SIMMS MJ, 1986, PALAEONTOLOGY, V29, P475; Simms MJ, 1988, ECHINODERM PHYLOGENY, P269; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; SLATKIN M, 1981, PALEOBIOLOGY, V7, P421, DOI 10.1017/S0094837300025471; SMITH AB, 1994, SYSTEMATICS FOSSIL R; Sprinkle J., 1973, MORPHOLOGY EVOLUTION; UBAGHS G, 1978, TREATISE INVERTEBR T, V2, P58; Valentine J. W., 1969, Palaeontology, V12, P684; VALENTINE JW, 1994, PALEOBIOLOGY, V20, P131, DOI 10.1017/S0094837300012641; VANVALEN L, 1971, EVOLUTION, V25, P420, DOI 10.1111/j.1558-5646.1971.tb01898.x; WAGNER PJ, 1995, PALEOBIOLOGY, V21, P248, DOI 10.1017/S0094837300013294; WILLS MA, 1994, PALEOBIOLOGY, V20, P93, DOI 10.1017/S009483730001263X; [No title captured]; [No title captured]	65	57	60	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1492	1495		10.1126/science.274.5292.1492	http://dx.doi.org/10.1126/science.274.5292.1492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929402				2022-12-28	WOS:A1996VV77500037
J	Keigwin, LD				Keigwin, LD			The Little Ice Age and Medieval warm period in the Sargasso Sea	SCIENCE			English	Article							ATLANTIC DEEP-WATER; NORTH-ATLANTIC; OCEAN CIRCULATION; SURFACE-TEMPERATURE; BERMUDA RISE; SEDIMENT; CLIMATE; VARIABILITY; RECORD; TH-230	Sea surface temperature (SST), salinity, and flux of terrigenous material oscillated on millennial time scales in the Pleistocene North Atlantic, but there are few records of Holocene variability. Because of high rates of sediment accumulation, Holocene oscillations are well documented in the northern Sargasso Sea. Results from a radiocarbondated box core show that SST was similar to 1 degrees C cooler than today similar to 400 years ago (the Little Ice Age) and 1700 years ago, and similar to 1 degrees C warmer than today 1000 years ago (the Medieval Warm Period). Thus, at least some of the warming since the Little Ice Age appears to be part of a natural oscillation.			Keigwin, LD (corresponding author), WOODS HOLE OCEANOG INST,WOODS HOLE,MA 02543, USA.							[Anonymous], 1991, HOLOCENE; BACON MP, 1982, GEOCHIM COSMOCHIM AC, V46, P651, DOI 10.1016/0016-7037(82)90166-1; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; BOYLE EA, 1990, GLOBAL PLANET CHANGE, V89, P113, DOI 10.1016/0921-8181(90)90058-K; Bradley R. S., 1995, CLIMATE AD 1500; Bradley RS., 1993, HOLOCENE, V3, P367, DOI [10.1177/095968369300300409, DOI 10.1177/095968369300300409]; BRIFFA KR, 1992, CLIM DYNAM, V7, P111, DOI 10.1007/BF00211153; BRIFFA KR, 1990, NATURE, V346, P434, DOI 10.1038/346434a0; CAYAN DR, 1992, J CLIMATE, V5, P354, DOI 10.1175/1520-0442(1992)005<0354:LASHFA>2.0.CO;2; CRAIG H, 1965, OCCAS PUBL NARRAGANS, V3; DEUSER WG, 1987, J FORAMIN RES, V17, P14, DOI 10.2113/gsjfr.17.1.14; DICKSON R, IN PRESS PROG OCEANO; DICKSON RR, 1976, MON WEATHER REV, V104, P1255, DOI 10.1175/1520-0493(1976)104<1255:NAIOTC>2.0.CO;2; DRUFFEL EM, 1982, SCIENCE, V218, P13, DOI 10.1126/science.218.4567.13; Dunbar R. B., 1993, CORAL RECORDS OCEAN; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; GROVE JM, 1994, CLIMATIC CHANGE, V26, P143, DOI 10.1007/BF01092411; HASS HC, 1993, MAR GEOL, V111, P361, DOI 10.1016/0025-3227(93)90141-H; HOLLISTER CD, 1984, NATURE, V309, P220, DOI 10.1038/309220a0; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; HUGHES MK, 1994, CLIMATIC CHANGE, V26, P109, DOI 10.1007/BF01092410; Jenkins WJ, 1982, J MAR RES, V40, P265; JONES PD, 1986, NATURE, V322, P430, DOI 10.1038/322430a0; JOYCE TM, IN PRESS J CLIM; JUILLETLECLERC A, 1987, NATURE, V329, P146, DOI 10.1038/329146a0; KEIGWIN LD, 1994, J GEOPHYS RES-OCEANS, V99, P12397, DOI 10.1029/94JC00525; KEIGWIN LD, 1989, DEEP-SEA RES, V36, P845, DOI 10.1016/0198-0149(89)90032-0; KENNETT JP, 1995, NATURE, V377, P510, DOI 10.1038/377510a0; KUSHNIR Y, 1994, J CLIMATE, V7, P141, DOI 10.1175/1520-0442(1994)007<0141:IVINAS>2.0.CO;2; KUTZBACH JE, 1974, J ATMOS SCI, V31, P1958, DOI 10.1175/1520-0469(1974)031<1958:VSOHCF>2.0.CO;2; LAINE EP, 1994, MAR GEOL, V119, P159, DOI 10.1016/0025-3227(94)90146-5; LAINE EP, 1981, MAR GEOL, V39, P277, DOI 10.1016/0025-3227(81)90076-1; LAMB HH, 1979, QUATERNARY RES, V11, P1, DOI 10.1016/0033-5894(79)90067-X; LEHMAN SJ, 1992, NATURE, V358, P198; MCCARTNEY WJ, 1993, REV GEOPHYS, V31, P29; MITCHELL JM, 1976, QUATERNARY RES, V6, P481, DOI 10.1016/0033-5894(76)90021-1; OPPO DW, 1993, SCIENCE, V259, P1148, DOI 10.1126/science.259.5098.1148; OPPO DW, 1995, PALEOCEANOGRAPHY, V10, P901, DOI 10.1029/95PA02089; PATZOLD J, 1992, 4 INT C PAL KIEL, P224; PIPER DJW, 1995, 5 INT C PAL HAL NOV, P58; PISIAS NG, 1978, QUATERNARY RES, V10, P66; PORTER SC, 1967, AM J SCI, V265, P177, DOI 10.2475/ajs.265.3.177; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; Santer BD, 1995, CLIM DYNAM, V12, P77, DOI 10.1007/BF00223722; Shackleton N.J., 1974, Colloques int Cent natn Res Scient, VNo. 219,1974, P203; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; SUMAN DO, 1989, DEEP-SEA RES, V36, P869, DOI 10.1016/0198-0149(89)90033-2; TALBOT MR, 1977, NATURE, V268, P722, DOI 10.1038/268722a0; TALBOT MR, 1980, EARTH PLANET SC LETT, V47, P336, DOI 10.1016/0012-821X(80)90020-5; Talley LD, 1982, J MAR RES, V40, P757; TALLEY LD, IN PRESS PHYSICA D; Worthington L.V., 1976, J HOPKINS OCEANOGRAP, V6	52	345	375	4	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1504	1508		10.1126/science.274.5292.1504	http://dx.doi.org/10.1126/science.274.5292.1504			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929406				2022-12-28	WOS:A1996VV77500041
J	Takagaki, Y; Seipelt, RL; Peterson, ML; Manley, JL				Takagaki, Y; Seipelt, RL; Peterson, ML; Manley, JL			The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation	CELL			English	Article							SACCHAROMYCES-CEREVISIAE RNA14; SPLICE SITE SELECTION; 2 MESSENGER-RNAS; SPECIFICITY FACTOR; 3' ENDS; IN-VIVO; BINDING DOMAIN; SR PROTEINS; CLEAVAGE; SUBUNIT	The switch from membrane-bound to secreted-form IgM that occurs during differentiation of B lymphocytes has long been known to involve regulated processing of the heavy chain pre-mRNA. Here, we show that accumulation of one subunit of an essential polyadenylation factor (CstF-64) is specifically repressed in mouse primary B cells and that overexpression of CstF-64 is sufficient to switch heavy chain expression from membrane-bound (mu m) to secreted form (mu s). We further show that CstF-64 is limiting for formation of intact CstF, that CstF has a higher affinity for the pm poly(A) site than for the mu s site, and that the mu m site is stronger in a reconstituted in vitro processing reaction. Our results indicate that CstF-64 plays a key role in regulating IgM heavy chain expression during B cell differentiation.	UNIV KENTUCKY,MED CTR,DEPT MICROBIOL & IMMUNOL,DEPT PATHOL & LAB MED,LEXINGTON,KY 40536	University of Kentucky	Takagaki, Y (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Seipelt-Thiemann, Rebecca/0000-0001-5265-7897; Manley, James/0000-0002-8341-1459; Peterson, Martha/0000-0002-7214-421X	NIGMS NIH HHS [GM28983] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BLATTNER FR, 1984, NATURE, V307, P417, DOI 10.1038/307417a0; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; Guise J. W., 1989, Immunoglobulin genes., P275; GUISE JW, 1988, J IMMUNOL, V140, P3988; Harlow E., 1988, ANTIBODIES LAB MANUA; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MANDART E, 1995, MOL CELL BIOL, V15, P6979; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MANLEY JL, 1982, J MOL BIOL, V159, P581, DOI 10.1016/0022-2836(82)90102-4; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MITCHELSON A, 1993, GENE DEV, V7, P241, DOI 10.1101/gad.7.2.241; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; OHARE K, 1995, TRENDS GENET, V11, P255, DOI 10.1016/S0168-9525(00)89067-8; PETERSON ML, 1994, MOL CELL BIOL, V14, P7891, DOI 10.1128/MCB.14.12.7891; PETERSON ML, 1986, P NATL ACAD SCI USA, V83, P8883, DOI 10.1073/pnas.83.23.8883; PETERSON ML, 1991, MOL CELL BIOL, V11, P2324, DOI 10.1128/MCB.11.4.2324; PETERSON ML, 1994, HDB B T LYMPHOCYTES, P321; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WANG J, 1995, RNA, V1, P335; YAN DH, 1995, MOL CELL BIOL, V15, P1901; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	48	321	323	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					941	952		10.1016/S0092-8674(00)82000-0	http://dx.doi.org/10.1016/S0092-8674(00)82000-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945520	hybrid			2022-12-28	WOS:A1996VV77400019
J	Bowyer, S; Lampton, M; Lieu, R				Bowyer, S; Lampton, M; Lieu, R			Extreme-ultraviolet flux from the Virgo cluster: Further evidence for a 500,000-kelvin component	SCIENCE			English	Article							INTERSTELLAR-MEDIUM; SPECTROSCOPY; ABSORPTION; CONTINUUM; EMISSION; HYDROGEN; HELIUM; LINE	A surprising discovery in x-ray astronomy was that clusters of galaxies often contain vast quantities of hot (20 million kelvin) diffuse gas. Substantial diffuse extreme-ultraviolet (EUV) emission has recently been detected in the Virgo cluster of galaxies. Depending on the character of the interstellar medium in our galaxy, this emission could be either an aspect of the hot cluster gas or a previously undetected 500,000-kelvin component. Analysis of the observational data in combination with our current knowledge of the interstellar medium revealed that the EUV flux cannot be an effect of the interstellar medium. Hence, a warm cluster component appears likely.	UNIV ALABAMA,DEPT PHYS,HUNTSVILLE,AL 35899	University of Alabama System; University of Alabama Huntsville	Bowyer, S (corresponding author), UNIV CALIF BERKELEY,CTR EXTREME ULTRAVIOLET ASTROPHYS,BERKELEY,CA 94720, USA.							Bowyer S., 1991, EXTREME ULTRAVIOLET, P397; DANLY L, 1992, ASTROPHYS J SUPPL S, V81, P125, DOI 10.1086/191689; Dixon WV, 1996, ASTROPHYS J, V469, pL77, DOI 10.1086/310271; DUPUIS J, 1995, ASTROPHYS J, V455, P574, DOI 10.1086/176605; EDELSTEIN J, 1995, ASTROPHYS J, V454, P442, DOI 10.1086/176495; Fabian AC, 1996, SCIENCE, V271, P1244, DOI 10.1126/science.271.5253.1244; FABIAN AC, 1994, ANNU REV ASTRON ASTR, V32, P277, DOI 10.1146/annurev.aa.32.090194.001425; Heiles C, 1996, ASTROPHYS J, V462, P326, DOI 10.1086/177154; HUCHTMEIER W, COMMUNICATION; JELINSKY P, COMMUNICATION; LAOR A, 1994, ASTROPHYS J, V435, P611, DOI 10.1086/174841; Lieu R, 1996, ASTROPHYS J, V458, pL5, DOI 10.1086/309908; MEWE R, 1986, ASTRON ASTROPHYS SUP, V65, P511; Mewe R., 1985, Astronomy & Astrophysics Supplement Series, V62, P197; MORRISON R, 1983, ASTROPHYS J, V270, P119, DOI 10.1086/161102; Reynolds R. J., 1990, IAU S, V139, P157; REYNOLDS RJ, 1995, ASTROPHYS J, V439, pL17, DOI 10.1086/187734; RUMPH T, 1994, ASTRON J, V107, P2108, DOI 10.1086/117021; SNOWDEN S, 1995, CALROS95003 OGIP NAS; Truemper J., 1982, ADV SPACE RES, V2, P241; VENNES S, 1993, ASTROPHYS J, V410, pL119, DOI 10.1086/186894; WILLACY K, 1993, MON NOT R ASTRON SOC, V261, P165, DOI 10.1093/mnras/261.1.165	23	31	31	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1338	1340		10.1126/science.274.5291.1338	http://dx.doi.org/10.1126/science.274.5291.1338			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910265				2022-12-28	WOS:A1996VU95400041
J	Cressman, DE; Greenbaum, LE; DeAngelis, RA; Ciliberto, G; Furth, EE; Poli, V; Taub, R				Cressman, DE; Greenbaum, LE; DeAngelis, RA; Ciliberto, G; Furth, EE; Poli, V; Taub, R			Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; NECROSIS-FACTOR RECEPTOR; FACTOR KAPPA-B; MOUSE-LIVER; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; PARTIAL-HEPATECTOMY; RAPID ACTIVATION; SERUM LEVELS	Liver regeneration stimulated by a loss of liver mass leads to hepatocyte and nonparenchymal cell proliferation and rapid restoration of liver parenchyma. Mice with targeted disruption of the interleukin-6 (IL-6) gene had impaired liver regeneration characterized by liver necrosis and failure. There was a blunted DNA synthetic response in hepatocytes of these mice but not in nonparenchymal liver cells. Furthermore; there were discrete G(1) phase (prereplicative stage in the cell cycle) abnormalities including absence of STAT3 (signal transducer and activator of transcription protein 3) activation and depressed AP-1, Myc, and cyclin D1 expression. Treatment of IL-6-deficient mice with a single preoperative dose of IL-6 returned STAT3 binding, gene expression, and hepatocyte proliferation to near normal and prevented liver damage, establishing that IL-6 is a critical component of the regenerative response.	UNIV PENN,SCH MED,DEPT GENET & MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; IRBM PIETRO ANGELETTI,INST RIC BIOL MOL,POMEZIA,ROMA,ITALY	University of Pennsylvania; University of Pennsylvania			Ciliberto, Gennaro/J-4131-2017; Poli, Valeria/A-9215-2012	Ciliberto, Gennaro/0000-0003-2851-8605; Poli, Valeria/0000-0002-3739-3966	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049629, P01DK049210, R01DK044237] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44237, DK49629, DK49210] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BAUER J, 1988, BLOOD, V72, P1134; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BLUETHMANN H, 1994, J LEUKOCYTE BIOL, V56, P565, DOI 10.1002/jlb.56.5.565; COFFER P, 1995, ONCOGENE, V10, P985; CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; CRESSMAN DE, 1994, J BIOL CHEM, V269, P26594; CRESSMAN DE, UNPUB; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; DABEVA MD, 1993, AM J PATHOL, V143, P1606; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVIERE J, 1989, CLIN EXP IMMUNOL, V77, P221; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Fausto Nelson, 1994, P1059; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; GREENBAUM LE, 1995, J CLIN INVEST, V96; GREENWEL P, 1993, LAB INVEST, V69, P210; Gressner AM, 1996, KIDNEY INT, V49, pS39; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Higgins GM, 1931, ARCH PATHOL, V12, P186; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; KUMA S, 1990, IMMUNOBIOLOGY, V180, P235, DOI 10.1016/S0171-2985(11)80331-1; LEE JY, 1994, HEPATOLOGY, V19, P656, DOI 10.1002/hep.1840190317; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PHUCHAREON J, 1995, CANCER LETT, V92, P203, DOI 10.1016/0304-3835(95)03780-Z; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; RABES HM, 1977, CANCER RES, V37, P1105; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROKICKI M, 1993, RES EXP MED, V193, P305, DOI 10.1007/BF02576238; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHUTTE B, 1987, J HISTOCHEM CYTOCHEM, V35, P1343, DOI 10.1177/35.11.3116075; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; TAUB R, 1995, LIVER REGENERATION C, P71; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9679; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YAMADA Y, UNPUB; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	62	1278	1339	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1379	1383		10.1126/science.274.5291.1379	http://dx.doi.org/10.1126/science.274.5291.1379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910279				2022-12-28	WOS:A1996VU95400055
J	Saxena, SK; Dubrovinsky, LS; Lazor, P; Cerenius, Y; Haggkvist, P; Hanfland, M; Hu, JZ				Saxena, SK; Dubrovinsky, LS; Lazor, P; Cerenius, Y; Haggkvist, P; Hanfland, M; Hu, JZ			Stability of perovskite (MgSiO3) in the Earth's mantle	SCIENCE			English	Article							STISHOVITE; PHASE	Available thermodynamic data and seismic models favor perovskite (MgSiO3) as the stable phase in the mantle. MgSiO3 was heated at temperatures from 1900 to 3200 kelvin with a Nd-YAG laser in diamond-anvil cells to study the phase relations at pressures from 45 to 100 gigapascals. The quenched products were studied with synchrotron x-ray radiation. The results show that MgSiO3 broke down to a mixture of MgO (periclase) and SiO2 (stishovite or an unquenchable polymorph) at pressures from 58 to 85 gigapascals. These results imply that perovskite may not be stable in the lower mantle and that it might be necessary to reconsider the compositional and density models of the mantle.	EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; CARNEGIE INST WASHINGTON,GEOPHYS LAB,CTR HIGH PRESSURE RES,WASHINGTON,DC 20015	European Synchrotron Radiation Facility (ESRF); Carnegie Institution for Science	Saxena, SK (corresponding author), UPPSALA UNIV,INST EARTH SCI,S-75236 UPPSALA,SWEDEN.			Dubrovinsky, Leonid/0000-0002-3717-7585; Cerenius, Yngve/0000-0001-5805-0113				Anderson D.L., 1989, THEORY EARTH, P366; Anderson OL., 1995, EQUATIONS STATE SOLI, P405; Belonoshko AB, 1996, AM MINERAL, V81, P785; Boehler R, 1996, PHYS EARTH PLANET IN, V96, P181, DOI 10.1016/0031-9201(96)03150-0; Funamori N, 1996, J GEOPHYS RES-SOL EA, V101, P8257, DOI 10.1029/95JB03732; ITO E, 1984, EARTH PLANET SC LETT, V67, P238, DOI 10.1016/0012-821X(84)90119-5; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; LAZOR P, 1966, PHILOS T ROY SOC LON, V354, P1307; MEADE C, 1995, SCIENCE, V268, P1745; Saxena SK, 1996, GEOCHIM COSMOCHIM AC, V60, P2379, DOI 10.1016/0016-7037(96)00096-8; SHEN GY, 1995, J GEOPHYS RES-SOL EA, V100, P17699, DOI 10.1029/95JB01864; TSUCHIDA Y, 1989, NATURE, V340, P217, DOI 10.1038/340217a0	12	86	94	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1357	1359		10.1126/science.274.5291.1357	http://dx.doi.org/10.1126/science.274.5291.1357			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910272				2022-12-28	WOS:A1996VU95400048
J	Marcus, R				Marcus, R			Skeletal ''impact'' of exercise	LANCET			English	Editorial Material											Marcus, R (corresponding author), STANFORD UNIV, DIV ENDOCRINOL GERONTOL & METAB, PALO ALTO, CA 94304 USA.							Marcus Robert, 1996, P1135; ROBINSON TL, 1995, J BONE MINER RES, V10, P26; Snow-Harter C, 1991, Exerc Sport Sci Rev, V19, P351	3	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1996	348	9038					1326	1327		10.1016/S0140-6736(05)65404-9	http://dx.doi.org/10.1016/S0140-6736(05)65404-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918272				2022-12-28	WOS:A1996VT33200005
J	Shepherd, J; Cobbe, SM; Lorimer, AR; McKillop, JH; Ford, I; Packard, CJ; Macfarlane, PW; Isles, C; Oliver, MF; Lever, AF; Brown, BW; Ledingham, JGG; Pocock, SJ; Rifkind, BM; Vallance, BD; Ballantyne, D; Anderson, L; Duncan, D; Kean, S; Lawrence, A; McGrath, J; Montgomery, V; Norrie, J; Percy, M; Pomphrey, E; Whitehouse, A; Cameron, P; Parker, P; Porteous, F; Fletcher, L; Kilday, C; Shoat, D; Latif, S; Kennedy, J; Bell, MA; Birrell, R; Mellies, M; Meyer, J; Campbell, W				Shepherd, J; Cobbe, SM; Lorimer, AR; McKillop, JH; Ford, I; Packard, CJ; Macfarlane, PW; Isles, C; Oliver, MF; Lever, AF; Brown, BW; Ledingham, JGG; Pocock, SJ; Rifkind, BM; Vallance, BD; Ballantyne, D; Anderson, L; Duncan, D; Kean, S; Lawrence, A; McGrath, J; Montgomery, V; Norrie, J; Percy, M; Pomphrey, E; Whitehouse, A; Cameron, P; Parker, P; Porteous, F; Fletcher, L; Kilday, C; Shoat, D; Latif, S; Kennedy, J; Bell, MA; Birrell, R; Mellies, M; Meyer, J; Campbell, W			West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials	LANCET			English	Article							HEART-DISEASE; HYPERTENSION; SOCIETY	Background We assessed the potential benefit of treatment for low-risk and high-risk groups in the West of Scotland Coronary Prevention Study (WOSCOPS) population, and compared the benefits of primary and secondary prevention of coronary heart disease (CHD) by lipid lowering with the benefits of blood pressure reduction in the primary prevention of stroke. Methods We did a subgroup analysis of placebo-treated men in the WOSCOPS population by age, vascular disease at trial entry, and other established risk factors. We also compared WOSCOPS findings with those of the Scandinavian Simvastatin Survival Study (4S) and the Medical Research Council (MRC) trial of treatment for mild to moderate hypertension in middle-aged men. The WOSCOPS population comprised 6595 men aged 45-64 years with no history of myocardial infarction (MI) and plasma total cholesterol concentrations of 6 . 5-8 . 0 mmol/L at initial screening. Participants were randomly allocated pravastatin (40 mg daily) or placebo, and followed up for an average of 4 . 9 years. Findings Coronary event rates at 5 years in the WOSCOPS placebo group were higher than 10% (the recommended treatment threshold) in men with pre-existing vascular disease and in those 55 years or older without symptoms least one other low in men with hypercholesterolaemia but no other risk factor: 3 . 5% (95% CI 1 . 3-5 . 7) for men aged 45-54 years and 5 . 3% (2 . 7-8 . 0) for men aged 55-64 years. Three times more men had to be treated for 5 years to prevent one endpoint in WOSCOPS than in 4S, By contrast, two to four times fewer men with hyperlipidaemia were treated to save one coronary event in WOSCOPS than hypertensives to save one stroke in the MRC trial. These differences persisted after adjustment for the low-risk status of many of the patients with hypertension who took part in the MRC trial. Interpretation There were a substantial number of men whose risk of a coronary event was more than 10% at 5 years in the WOSCOPS cohort, The absolute benefit of pravastatin treatment of hyperlipidaemia is less in the primary prevention of CHD than in secondary prevention, but is similar to that for primary prevention of stroke by treatment of mild to moderate hypertension in middle-aged men.	DUMFRIES & GALLOWAY ROYAL INFIRM, DEPT MED, DUMFRIES DG1 4AP, SCOTLAND				Ford, Ian/ABE-6145-2020					[Anonymous], 1995, Am J Cardiol, V76, P485; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Haq IU, 1996, CLIN SCI, V91, P773; LEVER AF, 1995, J HYPERTENS, V13, P571, DOI 10.1097/00004872-199506000-00001; LEVER AF, 1987, CURR OPIN CARDIOL S1, V2, pS6; MIALL WE, 1987, MILD HYPERTENSION IS, P103; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; WHINCUP PH, 1996, J CARDIOVASC RISK, V2, P533	13	212	213	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1996	348	9038					1339	1342						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918276				2022-12-28	WOS:A1996VT33200009
J	Marko, IE; Giles, PR; Tsukazaki, M; Brown, SM; Urch, CJ				Marko, IE; Giles, PR; Tsukazaki, M; Brown, SM; Urch, CJ			Copper-catalyzed oxidation of alcohols to aldehydes and ketones: An efficient, aerobic alternative	SCIENCE			English	Article							MOLECULAR-OXYGEN; COMPLEX	An efficient, copper-based catalyst has been discovered that oxidizes a wide range of alcohols into aldehydes and ketones under mild conditions. This catalytic system utilizes oxygen or air as the ultimate, stoichiometric oxidant, producing water as the only by-product.	ZENECA PROC TECHNOL DEPT,HUDDERSFIELD WORKS,HUDDERSFIELD HD2 1FF,W YORKSHIRE,ENGLAND; ZENECA AGROCHEM,JEALOTTS HILL RES STN,BRACKNELL RG42 6ET,BERKS,ENGLAND		Marko, IE (corresponding author), UNIV CATHOLIQUE LOUVAIN,DEPT CHIM,CHIM ORGAN LAB,BATIMENT LAVOISIER,PL LOUIS PASTEUR 1,B-1348 LOUVAIN,BELGIUM.							BHADURI S, 1981, J CHEM SOC DALTON, P2585, DOI 10.1039/dt9810002585; CAPDEVIELLE P, 1984, TETRAHEDRON LETT, V25, P4397, DOI 10.1016/S0040-4039(01)81448-9; CAPDEVIELLE P, 1993, J CHEM RES S, V10; ERLENMEYER H, 1969, J AM CHEM SOC, V91, P1065, DOI 10.1021/ja01033a005; FELDBERG L, 1994, J CHEM SOC CHEM COMM, P1807, DOI 10.1039/c39940001807; GRIFFITH WP, 1991, DIOXYGEN ACTIVATION; INOKUCHI T, 1995, TETRAHEDRON LETT, V36, P3223, DOI 10.1016/0040-4039(95)00519-I; IWAHAMA T, 1995, TETRAHEDRON LETT, V36, P6923, DOI 10.1016/0040-4039(95)01431-G; JALLABERT C, 1980, TETRAHEDRON, V36, P1191, DOI 10.1016/0040-4020(80)87017-7; JALLABERT C, 1982, J MOL CATAL, V14, P75, DOI 10.1016/0304-5102(82)80050-3; KARLIN KD, 1987, PROG INORG CHEM, V35, P219, DOI 10.1002/9780470166369.ch3; Krohn K, 1996, J ORG CHEM, V61, P1467, DOI 10.1021/jo9518720; Larock R. C., 1989, COMPREHENSIVE ORGANI, P604; LEY SV, 1994, SYNTHESIS-STUTTGART, P639; MUNAKATA M, 1980, J CHEM SOC CHEM COMM, P219, DOI 10.1039/c39800000219; MURAHASHI SI, 1995, SYNLETT, P733; MURAHASHI SI, 1993, J ORG CHEM, V58, P7318, DOI 10.1021/jo00078a002; NARASAKA K, 1977, B CHEM SOC JPN, V50, P2773, DOI 10.1246/bcsj.50.2773; PROCTER G, 1991, COMPREHENSIVE ORGANI, V7; SAKHAROV AM, 1988, J MOL CATAL, V48, P157, DOI 10.1016/0304-5102(88)85002-8; SEMMELHACK MF, 1984, J AM CHEM SOC, V106, P3374, DOI 10.1021/ja00323a064; Sheldon R A., 1981, METAL CATALYZED OXID; TETYAKOV VP, 1982, REACT KINET CATAL LE, V19, P263; ZHONG YP, 1989, J AM CHEM SOC, V111, P8398, DOI 10.1021/ja00204a011; Zuberbu hler A. D, 1983, COPPER COORDINATION, P237	25	617	633	3	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2044	2046		10.1126/science.274.5295.2044	http://dx.doi.org/10.1126/science.274.5295.2044			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953027				2022-12-28	WOS:A1996VY97400037
J	Roach, GW; Kanchuger, M; Mangano, CM; Newman, M; Nussmeier, N; Wolman, R; Aggarwal, A; Marschall, K; Graham, SH; Ley, C; Ozanne, G; Mangano, DT				Roach, GW; Kanchuger, M; Mangano, CM; Newman, M; Nussmeier, N; Wolman, R; Aggarwal, A; Marschall, K; Graham, SH; Ley, C; Ozanne, G; Mangano, DT			Adverse cerebral outcomes after coronary bypass surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATHEROSCLEROTIC ASCENDING AORTA; ARTERY BYPASS; CARDIOPULMONARY BYPASS; RISK-FACTORS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ELDERLY PATIENTS; CARDIAC-SURGERY; BLOOD-FLOW; STROKE; OPERATIONS	Background Acute changes in cerebral function after elective coronary bypass surgery are a difficult clinical problem. We carried out a multicenter study to determine the incidence and predictors of - and the use of resources associated with - perioperative adverse neurologic events, including cerebral injury. Methods In a prospective study, we evaluated 2108 patients from 24 U.S. institutions for two general categories of neurologic outcome: type I (focal injury, or stupor or coma at discharge) and type II (deterioration in intellectual function, memory deficit, or seizures). Results Adverse cerebral outcomes occurred in 129 patients (6.1 percent). A total of 3.1 percent had type I neurologic outcomes (8 died of cerebral injury, 55 had nonfatal strokes, 2 had transient ischemic attacks, and 1 had stupor), and 3.0 percent had type II outcomes (55 had deterioration of intellectual function and 8 had seizures). Patients with adverse cerebral outcomes had higher in-hospital mortality (21 percent of patients with type I outcomes died, vs. 10 percent of those with type II and 2 percent of those with no adverse cerebral outcome; P<0.001 for all comparisons), longer hospitalization (25 days with type I outcomes, 21 days with type II, and 10 days with no adverse outcome; P<0.001), and a higher rate of discharge to facilities for intermediate- or long-term care (47 percent, 30 percent, and 8 percent; P<0.001). Predictors of type I outcomes were proximal aortic atherosclerosis, a history of neurologic disease, and older age; predictors of type II outcomes were older age, systolic hypertension on admission, pulmonary disease, and excessive consumption of alcohol. Conclusions Adverse cerebral outcomes after coronary bypass surgery are relatively common and serious; they are associated with substantial increases in mortality, length of hospitalization, and use of intermediate- or Iong-term care facilities. New diagnostic and therapeutic strategies must be developed to lessen such injury.	ISCHEMIA RES & EDUC FDN,SAN FRANCISCO,CA 94143; KAISER PERMANENTE MED CTR,SAN FRANCISCO,CA; NYU,NEW YORK,NY; STANFORD UNIV,STANFORD,CA; DUKE UNIV,DURHAM,NC; MERCY MED CTR,REDDING,CA; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298; VET AFFAIRS MED CTR,MILWAUKEE,WI; UNIV PITTSBURGH,PITTSBURGH,PA; VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94121	Kaiser Permanente; New York University; Stanford University; Duke University; Virginia Commonwealth University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ACINAPURA AJ, 1988, CIRCULATION, V78, P179; ALTER M, 1994, STROKE, V25, P1605, DOI 10.1161/01.STR.25.8.1605; ARANKI SF, 1994, ANN THORAC SURG, V58, P296, DOI 10.1016/0003-4975(94)92196-2; BAREL Y, 1992, J THORAC CARDIOV SUR, V104, P469; BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361; BREUER AC, 1983, STROKE, V14, P682, DOI 10.1161/01.STR.14.5.682; Bull D A, 1993, Cardiovasc Surg, V1, P182; Clark RE, 1996, ANN THORAC SURG, V62, pS2, DOI 10.1016/0003-4975(96)00818-1; CLARK RE, 1995, J THORAC CARDIOV SUR, V109, P249, DOI 10.1016/S0022-5223(95)70386-1; DAVILAROMAN VG, 1991, CIRCULATION, V84, P47; DAVIS SM, 1983, NEUROLOGY, V33, P391, DOI 10.1212/WNL.33.4.391; FUSE K, 1988, JPN CIRC J, V52, P460, DOI 10.1253/jcj.52.460; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GOLD JP, 1995, J THORAC CARDIOV SUR, V110, P1302, DOI 10.1016/S0022-5223(95)70053-6; HELLER SS, 1970, NEW ENGL J MED, V283, P1015, DOI 10.1056/NEJM197011052831903; HERSOKOWITZ A, 1996, ANESTHESIOLOGY, V85, P454; HOSMER DW, 1989, APPL LOGISTIC REGRES; JUDE B, 1994, CIRCULATION, V90, P1662, DOI 10.1161/01.CIR.90.4.1662; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; LAVY S, 1978, ANN NEUROL, V4, P445, DOI 10.1002/ana.410040510; LYNN GM, 1992, J THORAC CARDIOV SUR, V104, P1518, DOI 10.1016/S0022-5223(19)33878-4; MANGANO CTM, IN PRESS J INTENSIVE; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1995, J CARDIAC SURG, V10, P366, DOI 10.1111/j.1540-8191.1995.tb00663.x; MANGANO DT, IN PRESS JAMA; Marschall K, 1994, J Cardiothorac Vasc Anesth, V8, P5, DOI 10.1016/1053-0770(94)90004-3; Mathew JP, 1996, JAMA-J AM MED ASSOC, V276, P300, DOI 10.1001/jama.276.4.300; MILLS NL, 1991, J THORAC CARDIOV SUR, V102, P546; Mora CT, 1996, J THORAC CARDIOV SUR, V112, P514, DOI 10.1016/S0022-5223(96)70280-5; Mora CT, 1995, CENTRAL NERVOUS SYST, P114, DOI [10.1007/978-1-4612-2484-6_6, DOI 10.1007/978-1-4612-2484-6_6]; *MULT STUD PER ISC, 1995, ANESTHESIOLOGY, V83, P658; NAUNHEIM KS, 1988, J AM COLL CARDIOL, V11, P494, DOI 10.1016/0735-1097(88)91522-7; Newman MF, 1996, CIRCULATION, V94, P74; NEWMAN MF, 1994, CIRCULATION, V90, P243; OKA Y, 1986, J THORAC CARDIOV SUR, V91, P329; PUGSLEY W, 1994, STROKE, V25, P1393, DOI 10.1161/01.STR.25.7.1393; RIBAKOVE GH, 1992, ANN THORAC SURG, V53, P758, DOI 10.1016/0003-4975(92)91431-8; RICOTTA JJ, 1995, J VASC SURG, V21, P359, DOI 10.1016/S0741-5214(95)70276-8; SAKAKIBARA Y, 1991, JPN J SURG, V21, P25, DOI 10.1007/BF02470862; SALOMON NW, 1991, J THORAC CARDIOV SUR, V101, P209; SHAW PJ, 1985, BRIT MED J, V291, P1384, DOI 10.1136/bmj.291.6506.1384; SLOGOFF S, 1982, ANESTH ANALG, V61, P903; SOTANIEMI KA, 1981, ARCH NEUROL-CHICAGO, V38, P2, DOI 10.1001/archneur.1981.00510010028003; SOTANIEMI KA, 1983, ARCH NEUROL-CHICAGO, V40, P75, DOI 10.1001/archneur.1983.04050020037006; TUMAN KJ, 1992, J THORAC CARDIOV SUR, V104, P1510, DOI 10.1016/S0022-5223(19)33877-2; WAREING TH, 1992, J THORAC CARDIOV SUR, V103, P453; WEINTRAUB WS, 1989, CIRCULATION, V80, P276, DOI 10.1161/01.CIR.80.2.276; YAMAMOTO M, 1980, ARCH NEUROL-CHICAGO, V37, P489, DOI 10.1001/archneur.1980.00500570037005; ZWART HHJ, 1975, ANN THORAC SURG, V20, P418, DOI 10.1016/S0003-4975(10)64239-7	49	1386	1459	1	36	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1857	1863		10.1056/NEJM199612193352501	http://dx.doi.org/10.1056/NEJM199612193352501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948560	Green Published			2022-12-28	WOS:A1996VX87400001
J	Chew, SJ; Vicario, DS; Nottebohm, F				Chew, SJ; Vicario, DS; Nottebohm, F			Quantal duration of auditory memories	SCIENCE			English	Article							ZEBRA FINCHES; ANISOMYCIN; PERIODS; SONG	Neuronal responses in the caudomedial neostriatum (NCM) of adult zebra finches (Taeniopygia guttata) decreased upon repeated, unreinforced presentations of conspecific song, calls, or other complex sounds. This ''stimulus-specific habituation'' is a form of learning, and its spontaneous loss, a form of ''forgetting,'' Spontaneous forgetting occurred only at narrowly defined times (2 to 3, 6 to 7, 14 to 15, 17 to 18.5, 46 to 48, or 85 to 89 hours after first exposure to a stimulus), determined by stimulus class, number of presentations, and interval between presentations. The first five forgetting times coincided with periods when gene expression and protein; synthesis in NCM were required for maintenance of the longer lasting (85 to 89 hours) habituation. The number of successive episodes of gene expression induced by a stimulus, but occurring long after stimulus presentation, appears to determine the quantal duration of auditory memories.	ROCKEFELLER UNIV,LAB ANIM BEHAV,NEW YORK,NY 10021	Rockefeller University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040900, R37MH018343, R01MH018343] Funding Source: NIH RePORTER; NIMH NIH HHS [MH40900, MH18343] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CHEW SJ, 1995, P NATL ACAD SCI USA, V92, P3406, DOI 10.1073/pnas.92.8.3406; Chew SJ, 1996, P NATL ACAD SCI USA, V93, P1950, DOI 10.1073/pnas.93.5.1950; FREEMAN FM, 1995, NEUROBIOL LEARN MEM, V63, P291, DOI 10.1006/nlme.1995.1034; GRECKSCH G, 1980, PHARMACOL BIOCHEM BE, V12, P663, DOI 10.1016/0091-3057(80)90145-8; Kroodsma DE., 1982, ACOUSTIC COMMUNICATI; MATTHIES H, 1994, LONG TERM POTENTIATI, P233; SIMPSON HB, 1990, J NEUROSCI, V10, P1541; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Vates GE, 1996, J COMP NEUROL, V366, P613, DOI 10.1002/(SICI)1096-9861(19960318)366:4<613::AID-CNE5>3.0.CO;2-7; ZANN R, 1990, ANIM BEHAV, V40, P811, DOI 10.1016/S0003-3472(05)80982-0	10	57	58	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1909	1914		10.1126/science.274.5294.1909	http://dx.doi.org/10.1126/science.274.5294.1909			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943204				2022-12-28	WOS:A1996VY20000044
J	Reymond, JM; Sztajzel, J				Reymond, JM; Sztajzel, J			Severe chest pain, diagnostic electrocardiogram, and ileus	LANCET			English	Article							MYOCARDIAL-INFARCTION		UNIV HOSP GENEVA,CARDIOL CLIN,CH-1211 GENEVA 4,SWITZERLAND; UNIV HOSP GENEVA,DEPT INTERNAL MED,MED CLIN,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva								CHAPMAN GD, 1993, AM J CARDIOL, V71, P783, DOI 10.1016/0002-9149(93)90824-V; LIEBERMAN ME, 1989, AM J EMERG MED, V7, P28, DOI 10.1016/0735-6757(89)90079-X; MOSSERI M, 1986, ISRAEL J MED SCI, V22, P451; RYAN ET, 1992, ANN INTERN MED, V116, P218, DOI 10.7326/0003-4819-116-3-218; SHAMMAA MH, 1962, AM J MED, V32, P827, DOI 10.1016/0002-9343(62)90174-2	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1560	1560		10.1016/S0140-6736(96)09166-0	http://dx.doi.org/10.1016/S0140-6736(96)09166-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950884				2022-12-28	WOS:A1996VX02300012
J	Srajer, V; Teng, TY; Ursby, T; Pradervand, C; Ren, Z; Adachi, S; Schildkamp, W; Bourgeois, D; Wulff, M; Moffat, K				Srajer, V; Teng, TY; Ursby, T; Pradervand, C; Ren, Z; Adachi, S; Schildkamp, W; Bourgeois, D; Wulff, M; Moffat, K			Photolysis of the carbon monoxide complex of myoglobin: Nanosecond time-resolved crystallography	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATION; LIGAND-BINDING; LAUE DIFFRACTION; PROTEIN CRYSTALS; SINGLE-CRYSTALS; MACROMOLECULAR CRYSTALLOGRAPHY; CONFORMATIONAL RELAXATION; RESONANCE RAMAN; HEME-PROTEINS; DOCKING SITE	The biological activity of macromolecules is accompanied by rapid structural changes. The photosensitivity of the carbon monoxide complex of myoglobin was used al the European Synchrotron Radiation Facility to obtain pulsed, Laue x-ray diffraction data with nanosecond time resolution during the process of heme and protein relaxation after carbon monoxide photodissociation and during rebinding. These time-resolved experiments reveal the structures of myoglobin photoproducts, provide a structural foundation to spectroscopic results and molecular dynamics calculations, and demonstrate that time-resolved macromolecular crystallography can elucidate the structural bases of biochemical mechanisms on the nanosecond time scale.	UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,CONSORTIUM ADV RADIAT SOURCES,CHICAGO,IL 60637; EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; INST PHYS & CHEM RES,BIOPHYS CHEM LAB,WAKO,SAITAMA 35101,JAPAN; IBS,UPR 9015,F-38027 GRENOBLE,FRANCE	University of Chicago; University of Chicago; European Synchrotron Radiation Facility (ESRF); RIKEN; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Pradervand, Claude/GPF-4155-2022; , Bourgeois/AAI-2337-2020; Pradervand, Claude P/I-8114-2013	Pradervand, Claude/0000-0001-5251-3930; Adachi, Shin-ichi/0000-0002-3676-1165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036452, R37GM036452] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 07707] Funding Source: Medline; NIGMS NIH HHS [GM 36452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; ANSARI A, 1992, SCIENCE, V256, P1796, DOI 10.1126/science.1615323; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; CHEN Y, 1994, REV SCI INSTRUM, V65, P1506, DOI 10.1063/1.1144883; Cruickshank D. W. J., 1992, TIME RESOLVED MACROM; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; GENBERG L, 1991, SCIENCE, V251, P1051, DOI 10.1126/science.1998121; GENICK U, UNPUB; GIBSON QH, 1986, J BIOL CHEM, V261, P228; HAGEN SJ, 1995, SCIENCE, V269, P959, DOI 10.1126/science.7638618; HARTMANN, 1996, P NATL ACAD SCI USA, V93, P7013; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; IBEN IET, 1989, BIOPHYS J, V56, P459, DOI 10.1016/S0006-3495(89)82693-1; JANES SM, 1988, BIOPHYS J, V54, P545, DOI 10.1016/S0006-3495(88)82987-4; KENDREW JC, 1956, P ROY SOC          A, V238, P305; KUCZERA K, 1993, P NATL ACAD SCI USA, V90, P5805, DOI 10.1073/pnas.90.12.5805; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LI HY, 1993, J BIOL CHEM, V268, P17908; LI P, 1992, J CHEM PHYS, V97, P3214, DOI 10.1063/1.463008; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LINGLE R, 1991, J AM CHEM SOC, V113, P3992, DOI 10.1021/ja00010a052; MARTIN JL, 1992, ANNU REV BIOPH BIOM, V21, P199, DOI 10.1146/annurev.bb.21.060192.001215; MOFFAT K, 1984, SCIENCE, V223, P1423, DOI 10.1126/science.223.4643.1423; MOFFAT K, 1995, CURR OPIN STRUC BIOL, V5, P656, DOI 10.1016/0959-440X(95)80059-X; MOFFAT K, 1989, ANNU REV BIOPHYS BIO, V18, P309, DOI 10.1146/annurev.biophys.18.1.309; MORIKIS D, 1988, J AM CHEM SOC, V110, P6341, DOI 10.1021/ja00227a011; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; PHILLIPS SEV, 1981, BROOKHAVEN PROTEIN D; REN Z, 1995, J APPL CRYSTALLOGR, V28, P461, DOI 10.1107/S0021889895003207; REN Z, 1995, J APPL CRYSTALLOGR, V28, P482, DOI 10.1107/S0021889895003219; SCHAAD O, 1993, P NATL ACAD SCI USA, V90, P9547, DOI 10.1073/pnas.90.20.9547; SCHLICHTING, 1994, NATURE, V317, P808; SIKORA S, 1994, BIOCHEMISTRY-US, V33, P4454, DOI 10.1021/bi00181a004; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013; ZHU L, 1992, J MOL BIOL, V224, P207, DOI 10.1016/0022-2836(92)90584-7	42	448	455	3	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1726	1729		10.1126/science.274.5293.1726	http://dx.doi.org/10.1126/science.274.5293.1726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939867				2022-12-28	WOS:A1996VW71200066
J	Hanzlick, R				Hanzlick, R			Coroner training needs - A numeric and geographic analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH; REQUIREMENTS; SYSTEMS	Objective.-To define geographically and numerically the need for coroner training programs. Design.-Survey and literature review. Setting.-States in the United States that have coroners. Main Outcome Measures.-Which states have coroners; which states require coroners to be physicians or have mandated training requirements; and the number of coroners potentially requiring training on an annual basis. Results.-Twenty-nine states have coroners in some or all counties with coroner states being located throughout most of the United States except for New England and the Mid-Atlantic states. Four states (Louisiana, Kansas, North Dakota, and Ohio) require coroners to be physicians. Seven states (Georgia, Illinois, Kentucky, Mississippi, Montana, Pennsylvania, and Wyoming) have mandated training requirements. At any given time, there are approximately 2759 individuals serving as coroners. Nationwide, the annual number of newly elected or appointed coroners ranges from 159 to 1546. Conclusions.-It is feasible to provide training to all newly elected or appointed coroners annually. The use of existing training programs, development of state-specific training programs, and the development of a standard national training curriculum may be useful strategies. Funding sources for coroner training need to be explored.	EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322	Emory University								CLARK SC, 1996, MEDICOLEGAL DEATH IN; COMBS DL, 1995, DEATH INVESTIGATION; HANZLICK R, 1993, J FORENSIC SCI, V38, P628; Hanzlick R, 1996, ARCH PATHOL LAB MED, V120, P329; Jentzen JM, 1996, AM J FOREN MED PATH, V17, P112, DOI 10.1097/00000433-199606000-00006; PRAHLOW JA, 1995, J FORENSIC SCI, V40, P55; SMITH SR, 1995, AM J FOREN MED PATH, V16, P181, DOI 10.1097/00000433-199506000-00023; VOELKER R, 1995, JAMA-J AM MED ASSOC, V273, P1164, DOI 10.1001/jama.273.15.1164	8	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1775	1778		10.1001/jama.276.21.1775	http://dx.doi.org/10.1001/jama.276.21.1775			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940332				2022-12-28	WOS:A1996VV56600038
J	Robb, DL; Heasman, J; Raats, J; Wylie, C				Robb, DL; Heasman, J; Raats, J; Wylie, C			A kinesin-like protein is required for germ plasm aggregation in Xenopus	CELL			English	Article							MATERNAL MESSENGER-RNA; VEGETAL CORTEX; MESODERM INDUCTION; OOCYTES; EMBRYOS; EGGS; LOCALIZATION; DROSOPHILA; TRANSLOCATION; MICROTUBULES	In embryos of X. laevis, and many other species, early development requires targeted movements of molecules and molecular aggregates within the oocyte or egg cytoplasm. One well-known example in Xenopus is the aggregation of germ plasm, a group of cytoplasmic islands that become distributed during the first few cell cycles to cells that will give rise to the germ line. Nothing is known about the cytoskeletal motor proteins that may drive these movements. We show here that a recently identified Xenopus kinesin-like protein, Xklp1, is required for the aggregation of germ plasm in early Xenopus embryos, thus assigning this protein a role in a developmentally important cytoplasmic localization.	UNIV MINNESOTA, SCH MED, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA; KATHOLIEKE UNIV, DEPT BIOCHEM, NIJMEGEN, NETHERLANDS	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Radboud University Nijmegen	Robb, DL (corresponding author), UNIV MINNESOTA, SCH MED, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA.							AKITA Y, 1985, J EMBRYOL EXP MORPH, V90, P251; BLACKLER AW, 1958, J EMBRYOL EXP MORPH, V6, P491; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; BOUNOURE LOUIS, 1934, ANN SCI NAT ZOOL, V17, P67; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; COLE DG, 1995, TRENDS CELL BIOL, V5, P259, DOI 10.1016/S0962-8924(00)89028-5; Conklin E, 1905, BIOL BULL-US, V8, P205, DOI 10.2307/1535879; Conklin E.G., 1905, J ACAD NAT SCI PHILA, V12, P1, DOI DOI 10.5962/BHL.TITLE.4801; CZOLOWSKA R, 1969, J EMBRYOL EXP MORPH, V22, P229; CZOLOWSKA R, 1972, ROUX ARCH DEV BIOL, V169, P335, DOI 10.1007/BF00580253; DIXON KE, 1981, NETH J ZOOL, V31, P5; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GARD DL, 1994, DEV BIOL, V161, P131, DOI 10.1006/dbio.1994.1015; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; Harlow E., 1988, ANTIBODIES LAB MANUA; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HOLWILL S, 1987, DEVELOPMENT, V100, P735; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HOULISTON E, 1994, DEVELOPMENT, V120, P1213; IKENISHI K, 1982, DEV GROWTH DIFFER, V24, P205; IKENISHI K, 1986, DEV BIOL, V113, P259, DOI 10.1016/0012-1606(86)90128-4; ILLMENSEE K, 1976, DEV BIOL, V49, P40, DOI 10.1016/0012-1606(76)90257-8; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; LEHMANN R, 1995, CELL, V83, P353, DOI 10.1016/0092-8674(95)90111-6; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; Micklem DR, 1995, DEV BIOL, V172, P377, DOI 10.1006/dbio.1995.8048; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RESSOM RE, 1988, DEVELOPMENT, V103, P507; Reverberi G., 1946, Pubblicazioni della Stazione Zoologica di Napoli, V20, P199; SAVAGE RM, 1993, DEV BIOL, V157, P371, DOI 10.1006/dbio.1993.1142; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; SMITH LD, 1966, DEV BIOL, V14, P330, DOI 10.1016/0012-1606(66)90019-4; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; TORPEY NP, 1992, J CELL SCI, V101, P151; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; WAKAHARA M, 1977, J EMBRYOL EXP MORPH, V39, P221; WEEKS DL, 1987, P NATL ACAD SCI USA, V84, P2798, DOI 10.1073/pnas.84.9.2798; WHITINGTON PM, 1975, J EMBRYOL EXP MORPH, V33, P57; Wilson EB, 1904, J EXP ZOOL, V1, P1, DOI 10.1002/jez.1400010102; WYLIE CC, 1986, J CELL SCI, P329; YISRAELI JK, 1989, DEVELOPMENT, V107, P31; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	58	65	65	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					823	831		10.1016/S0092-8674(00)81990-X	http://dx.doi.org/10.1016/S0092-8674(00)81990-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945510	Bronze			2022-12-28	WOS:A1996VV77400009
J	Wolthers, KC; Wisman, GBA; Otto, SA; Husman, AMD; Schaft, N; deWolf, F; Goudsmit, J; Coutinho, RA; vanderZee, AGJ; Meyaard, L; Miedema, F				Wolthers, KC; Wisman, GBA; Otto, SA; Husman, AMD; Schaft, N; deWolf, F; Goudsmit, J; Coutinho, RA; vanderZee, AGJ; Meyaard, L; Miedema, F			T cell telomere length in HIV-1 infection: No evidence for increased CD4(+) T cell turnover	SCIENCE			English	Article							HUMAN FIBROBLASTS; TERMINAL TRANSFERASE; HUMAN-LYMPHOCYTES; IMMORTAL CELLS; MITOTIC CLOCK; IN-VITRO; AIDS; INDIVIDUALS; PROGRESSION; MEMORY	Progression to acquired immunodeficiency syndrome (AIDS) has been related to exhaustion of the regenerative capacity of the immune system resulting from high T cell turnover. Analysis of telomeric terminal restriction fragment (TRF) length, a marker for cellular replicative history, showed that CD8(+) T cell TRF length decreased but CD4(+) T cell TRF length was stable during the course of human immunodeficiency Virus type-1 (HIV-1) infection, which was not explained by differential telomerase activity. This observation provides evidence that turnover in the course of HIV-1 infection can be increased considerably in CD8(+) T cells, but not in CD4(+) T cells. These results are compatible with CD4(+) T cell decline in HIV-1 infection caused by interference with cell renewal.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT CLIN VIROIMMUNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPT & CLIN IMMUNOL LAB, AMSTERDAM, NETHERLANDS; UNIV GRONINGEN, ACAD HOSP GRONINGEN, DEPT OBSTET & GYNAECOL, GRONINGEN, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN RETROVIROL, NL-1105 AZ AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT PUBL HLTH, AMSTERDAM, NETHERLANDS	University of Amsterdam; University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam			Wolthers, Katja C./E-5140-2018; Schaft, Niels/H-3713-2011	Wolthers, Katja C./0000-0003-1617-7049; Schaft, Niels/0000-0001-8236-9298; Meyaard, Linde/0000-0003-0707-4793				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bofill M, 1996, AIDS, V10, P827, DOI 10.1097/00002030-199607000-00005; Boudet F, 1996, J IMMUNOL, V156, P2282; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; GIORGI JV, 1987, J IMMUNOL, V138, P3725; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GRUTERS RA, 1991, AIDS, V5, P837, DOI 10.1097/00002030-199107000-00007; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO HN, 1993, J IMMUNOL, V150, P3070; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Ohyashiki JH, 1996, JPN J CANCER RES, V87, P329, DOI 10.1111/j.1349-7006.1996.tb00225.x; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PHILLIPS AN, 1995, NATURE, V375, P195, DOI 10.1038/375195a0; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SLAGBOOM PE, 1994, AM J HUM GENET, V55, P876; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091	54	245	259	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1543	1547		10.1126/science.274.5292.1543	http://dx.doi.org/10.1126/science.274.5292.1543			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929418				2022-12-28	WOS:A1996VV77500053
J	Ezekowitz, A				Ezekowitz, A			Mannose-binding protein and susceptibility to chronic hepatitis B infection	LANCET			English	Editorial Material							VIRUS-INFECTION				Ezekowitz, A (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SERV PEDIAT,BOSTON,MA 02114, USA.							EZEKOWITZ RAB, 1996, COLLECTINS INNATE IM, pCH1; MORADPOUR D, 1995, NEW ENGL J MED, V332, P1092, DOI 10.1056/NEJM199504203321610; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WANDS JR, 1992, SEMIN LIVER DIS, V12, P252, DOI 10.1055/s-2007-1007397; WEISS WI, 1992, NATURE, V360, P1437	5	5	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1396	1397		10.1016/S0140-6736(05)67498-3	http://dx.doi.org/10.1016/S0140-6736(05)67498-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937276				2022-12-28	WOS:A1996VU98600006
J	Ren, PF; Lim, CS; Johnsen, R; Albert, PS; Pilgrim, D; Riddle, DL				Ren, PF; Lim, CS; Johnsen, R; Albert, PS; Pilgrim, D; Riddle, DL			Control of C-elegans larval development by neuronal expression of a TGF-beta homolog	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GREEN FLUORESCENT PROTEIN; DAUER LARVA; PHEROMONE; TEMPERATURE; SUPERFAMILY; ENCODES	The Caenorhabditis elegans dauer larva is specialized for dispersal without growth and is formed under conditions of overcrowding and limited food. The daf-7 gene, required for transducing environmental cues that support continuous development with plentiful food, encodes a transforming growth factor-beta (TGF-beta) superfamily member. A daf-7 reporter construct is expressed in the ASI chemosensory neurons. Dauer-inducing pheromone inhibits daf-7 expression and promotes dauer formation, whereas food reactivates daf-7 expression and promotes recovery from the dauer state. When the food/pheromone ratio is high, the level of daf-7 mRNA peaks during the L1 larval stage, when commitment to non-dauer development is made.	UNIV MISSOURI,PROGRAM MOL BIOL,COLUMBIA,MO 65211; UNIV MISSOURI,DIV BIOL SCI,COLUMBIA,MO 65211; UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2E9,CANADA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Alberta			Pilgrim, David/A-2676-2014	Pilgrim, David/0000-0001-7820-7915	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011239] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11239] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; EPSTEIN HF, 1995, MODERN BIOL ANAL ORG; ESTEVEZ A, UNPUB; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; Evans A. A. F., 1976, The organization of nematodes., P383; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1985, MOL GEN GENET, V198, P534, DOI 10.1007/BF00332953; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; PILGRIM D, 1993, GENOME, V36, P712, DOI 10.1139/g93-096; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; Rushforth AM, 1996, MOL CELL BIOL, V16, P422; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SCHACKWITZ WS, IN PRESS NEURON; SWANSON MM, 1981, DEV BIOL, V84, P27, DOI 10.1016/0012-1606(81)90367-5; THOMAS JH, 1993, GENETICS, V134, P1105; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	27	414	426	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1389	1391		10.1126/science.274.5291.1389	http://dx.doi.org/10.1126/science.274.5291.1389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910282				2022-12-28	WOS:A1996VU95400058
J	Carey, TS; Garrett, J; Curtis, P; Darter, J; DeFriese, G; Fryer, J; Hadler, N; Hunter, G; Joines, J; Jackman, A; Kalsbeek, W; McLaughlin, C; Konrad, T; Ricketts, T; Taylor, D; McNutt, R; Smucker, D				Carey, TS; Garrett, J; Curtis, P; Darter, J; DeFriese, G; Fryer, J; Hadler, N; Hunter, G; Joines, J; Jackman, A; Kalsbeek, W; McLaughlin, C; Konrad, T; Ricketts, T; Taylor, D; McNutt, R; Smucker, D			Patterns of ordering diagnostic tests for patients with acute low back pain	ANNALS OF INTERNAL MEDICINE			English	Article						low back pain; magnetic resonance; imaging; tomography, computed; lumbosacral region; radiography	PHYSICIANS; BEHAVIOR; COSTS; CARE	Background: Low back pain is a common reason for visiting a physician. Authors of guidelines and insurance payers are currently scrutinizing use of radiography and computed tomography (CT) or magnetic resonance imaging (MRI). Objective: To study the determinants of the use of lumbar spine radiography and either CT or MRI in patients with acute low back pain. Design: Prospective cohort study. Setting: Community-based practices in North Carolina in six strata: urban primary care physicians, rural primary care physicians, urban chiropractors, rural chiropractors, orthopedic surgeons, and practitioners at a group-model health maintenance organization. Patients: 1580 patients with acute low back pain. Measurements: Telephone interviews done after the index office visit and at 2, 4, 8, 12, and 24 weeks or until complete recovery; survey of practitioners; and chart abstraction. Results: During the acute back pain episode, 46% of patients had radiography and 9% had CT or MRI. Patient variables related to use of radiography included pain that began more than 2 weeks before the index visit and no previous episodes of low back pain. Practitioner variables associated with use of radiography were being a chiropractor or orthopedic surgeon and having a solo practice. Use of CT or MRI was associated with white race, neurologic deficit at baseline, sciatica, poor functional status at baseline, and small group-practice size. Practitioners' responses to clinical vignettes were associated with aggregate practitioner behavior: In the vignettes and in real life, practitioners were more likely to order CT for patients with sciatica. However, a practitioner's response to a vignette did not predict that practitioner's use of CT or MRI for similar patients in his or her own practice. Conclusion: Radiography is commonly used as a diagnostic test for patients with acute back pain. Clinical factors and provider specialty are major correlates of the use of imaging studies.			Carey, TS (corresponding author), UNIV N CAROLINA, SHEPS CTR HLTH SERV RES, CB 7590, CHAPEL HILL, NC 27599 USA.				AHRQ HHS [HSO 6664] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006664] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bigos S, 1994, AHCPR PUBLICATION; BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; Carey TS, 1996, SPINE, V21, P339, DOI 10.1097/00007632-199602010-00018; CHERKIN DC, 1994, ARTHRITIS RHEUM, V37, P15, DOI 10.1002/art.1780370104; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1989, ARCH INTERN MED, V149, P27, DOI 10.1001/archinte.149.1.27; FRAZIER LM, 1989, ARCH INTERN MED, V149, P47, DOI 10.1001/archinte.149.1.47; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HILLMAN BJ, 1992, JAMA-J AM MED ASSOC, V268, P2050, DOI 10.1001/jama.268.15.2050; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; LIANG M, 1982, ARCH INTERN MED, V142, P1108, DOI 10.1001/archinte.142.6.1108; MORRELL DC, 1990, BRIT J GEN PRACT, V40, P182; NORMAN GR, 1981, MED EDUC, V15, P26, DOI 10.1111/j.1365-2923.1981.tb02311.x; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; SURIES KB, 1993, CHES STUDIES, V72; SWEDLOW A, 1992, NEW ENGL J MED, V327, P1502, DOI 10.1056/NEJM199211193272107; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003	21	93	94	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					807	+		10.7326/0003-4819-125-10-199611150-00004	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928987				2022-12-28	WOS:A1996VU52400007
J	Pyorala, K				Pyorala, K			CHD prevention in clinical practice	LANCET			English	Article							CORONARY HEART-DISEASE											ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1996, J Am Coll Cardiol, V27, P957; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; PYORALA K, 1994, EUR HEART J, V15, P1300; *SCAND SIMV SURV S, 1994, LANCET, V344, P1383; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *WHO, 1982, WHO TECH REP SER, V678	7	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV	1996	348			1			S26	S28		10.1016/S0140-6736(96)98009-5	http://dx.doi.org/10.1016/S0140-6736(96)98009-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918526	Bronze			2022-12-28	WOS:A1996VU00800010
J	Siegler, EL				Siegler, EL			April may be cruel, but November's pretty lousy, too	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Siegler, EL (corresponding author), BROOKLYN HOSP CTR, 121 DEKALB AVE, BROOKLYN, NY 11201 USA.			Siegler, Eugenia/0000-0001-9449-5873					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					774	775		10.7326/0003-4819-125-9-199611010-00014	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929014				2022-12-28	WOS:A1996VQ07200012
J	Adams, MD; Venter, JC				Adams, MD; Venter, JC			Should non-peer-reviewed raw DNA sequence data release be forced on the scientific community?	SCIENCE			English	Editorial Material							GENOME				Adams, MD (corresponding author), INST GENOM RES,MED CTR DR,ROCKVILLE,MD 20850, USA.							ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P151; ANDERSON C, 1993, SCIENCE, V259, P1685, DOI 10.1126/science.259.5102.1685; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; LIPMAN D, COMMUNICATION; Marshall E, 1996, SCIENCE, V272, P477; WHITE O, 1993, NUCLEIC ACIDS RES, V21, P3829, DOI 10.1093/nar/21.16.3829	9	18	29	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					534	536		10.1126/science.274.5287.534	http://dx.doi.org/10.1126/science.274.5287.534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VN919	8928007				2022-12-28	WOS:A1996VN91900035
J	Fytas, G; Anastasiadis, SH; Seghrouchni, R; Vlassopoulos, D; Li, JB; Factor, BJ; Theobald, W; Toprakcioglu, C				Fytas, G; Anastasiadis, SH; Seghrouchni, R; Vlassopoulos, D; Li, JB; Factor, BJ; Theobald, W; Toprakcioglu, C			Probing collective motions of terminally anchored polymers	SCIENCE			English	Article							ADSORBED POLYMER; TETHERED CHAINS; DYNAMICS; BRUSHES; SIMULATION; LAYERS; MODES	Polymer chains attached by one end to an impenetrable surface at high coverage exemplify a tethered layer of mesoscopic dimensions. At equilibrium, thermal fluctuations of the segment density profile of the brushlike layer reflect the tethered chain dynamics; the probing of these fluctuations by evanescent-wave dynamic light scattering is reported. By utilizing a set of terminally attached layers with thicknesses (L(0)) from 45 to 130 nanometers, it was found that there is a preferred wavelength of order L(0) of these fluctuations with a concurrent slowing down of their thermal decay rate. This technique could open the route for the investigation of the largely unexplored area of polymer surface dynamics.	UNIV CRETE,DEPT PHYS,IRAKLION 71103,GREECE; UNIV PATRAS,DEPT PHYS,PATRAS 26500,GREECE	University of Crete; University of Patras	Fytas, G (corresponding author), FDN RES & TECHNOL HELLAS,INST ELECT STRUCT & LASER,POB 1527,IRAKLION 71110,GREECE.		Vlassopoulos, Dimitris/A-7341-2014; Anastasiadis, Spiros H/D-2778-2009; Li, Junbai/M-4351-2016; Vlassopoulos, Dimitris/AAO-4067-2021; Theobald, Wolfgang/E-8121-2013	Anastasiadis, Spiros H/0000-0003-0936-1614; Li, Junbai/0000-0001-9575-3125; Vlassopoulos, Dimitris/0000-0003-0866-1930; 				Boudenne N, 1996, PHYS REV LETT, V77, P506, DOI 10.1103/PhysRevLett.77.506; DEGENNES PG, 1987, ADV COLLOID INTERFAC, V27, P189, DOI 10.1016/0001-8686(87)85003-0; DEGENNES PG, 1986, CR ACAD SCI II, V302, P765; FARAGO B, 1993, PHYS REV LETT, V71, P1015, DOI 10.1103/PhysRevLett.71.1015; FIELD JB, 1992, MACROMOLECULES, V25, P434, DOI 10.1021/ma00027a067; FREDRICKSON GH, 1992, MACROMOLECULES, V25, P2882, DOI 10.1021/ma00037a015; FYTAS G, 1993, DYNAMIC LIGHT SCATTE, P407; HALPERIN A, 1992, ADV POLYM SCI, V100, P31; HALPERIN A, 1988, EUROPHYS LETT, V6, P329, DOI 10.1209/0295-5075/6/4/009; JIAN T, 1994, MACROMOLECULES, V27, P4762, DOI 10.1021/ma00095a017; JOHNSON HE, 1992, SCIENCE, V255, P966, DOI 10.1126/science.255.5047.966; KLUSHIN LI, 1991, MACROMOLECULES, V24, P1549, DOI 10.1021/ma00007a016; Koberstein JT, 1996, MRS BULL, V21, P16, DOI 10.1557/S0883769400035089; KUBO R, STAT PHYSICS, V2; LAI PY, 1991, J CHEM PHYS, V95, P9288, DOI 10.1063/1.461158; LAN KH, 1986, PHYS REV LETT, V57, P17, DOI 10.1103/PhysRevLett.57.17; Long D, 1996, LANGMUIR, V12, P1675, DOI 10.1021/la950701n; MARCUS AH, 1996, PHYS REV E, V53, P1965; MARKO JF, 1993, PHYS REV E, V48, P2739, DOI 10.1103/PhysRevE.48.2739; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; MOTSCHMANN H, 1991, MACROMOLECULES, V24, P3691; MURAT M, 1989, MACROMOLECULES, V22, P4054, DOI 10.1021/ma00200a041; PARK CS, 1995, LIQ CRYST, V16, P135; SOLIS FJ, 1995, MACROMOLECULES, V28, P4307, DOI 10.1021/ma00116a037; TAUNTON HJ, 1990, MACROMOLECULES, V23, P571, DOI 10.1021/ma00204a033; Xi HW, 1996, MACROMOLECULES, V29, P4772, DOI 10.1021/ma951325g; YERUSHALMIROZEN R, 1995, PHYS WORLD, V8, P30	27	106	106	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2041	2044		10.1126/science.274.5295.2041	http://dx.doi.org/10.1126/science.274.5295.2041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953026				2022-12-28	WOS:A1996VY97400036
J	Hodge, MR; Chun, HJ; Rengarajan, J; Alt, A; Lieberson, R; Glimcher, LH				Hodge, MR; Chun, HJ; Rengarajan, J; Alt, A; Lieberson, R; Glimcher, LH			NF-AT-driven interleukin-4 transcription potentiated by NIP45	SCIENCE			English	Article							CYCLOSPORINE-A; T-CELLS; GENE; IDENTIFICATION; ROLES; AP-1	The induction of cytokine gene transcription is mediated in part by the nuclear factor of activated T cells (NF-AT). Factors involved in the mechanisms of NF-AT-mediated transcription are not well understood. A nuclear factor that interacted with the Rel homology domain (RHD) of NF-ATp was identified with the use of a two-hybrid interaction trap. Designated NIP45 (NF-AT interacting protein), it has minimal similarity to any known genes. Transcripts encoding this factor were enriched in lymphoid tissues and testes. NIP45 synergized with NF-ATp and the proto-oncogene c-Maf to activate the interleukin-4 (IL-4) cytokine promoter; transient overexpression of NIP45 with NF-ATp and c-maf in B lymphoma cells induced measurable endogenous IL-4 protein production. The identification of NIP45 advances our understanding of gene activation of cytokines, critical mediators of the immune response.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			chun, hyung/AAE-1463-2020; Chun, Hyung/K-1859-2013	Chun, Hyung/0000-0003-3508-2678	NIAID NIH HHS [AI37833] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037833] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HODGE M, UNPUB; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; LIEBERSON R, UNPUB; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3	17	124	131	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1903	1905		10.1126/science.274.5294.1903	http://dx.doi.org/10.1126/science.274.5294.1903			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943202				2022-12-28	WOS:A1996VY20000042
J	Ropper, AH; Caliendo, AM; Young, VB; Moreno, L; Dooling, EC				Ropper, AH; Caliendo, AM; Young, VB; Moreno, L; Dooling, EC			An 18-year-old man with severe headache, pleocytosis, and ataxia - Q fever, acute (with cerebellar and meningeal involvement).	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; MYCOPLASMA-PNEUMONIAE; MENINGITIS; INFECTION; ENCEPHALITIS; HIV		TUFTS UNIV,SCH MED,MEDFORD,MA 02155	Tufts University	Ropper, AH (corresponding author), ST ELIZABETH HOSP,DEPT NEUROL,WASHINGTON,DC 20032, USA.		Young, Vincent B/B-3179-2009; Young, Vincent Bensan/M-9916-2019	Young, Vincent B/0000-0003-3687-2364; Young, Vincent Bensan/0000-0003-3687-2364				AITKEN ID, 1989, EUR J EPIDEMIOL, V5, P420, DOI 10.1007/BF00140132; Batten FE, 1905, BRAIN, V28, P484; BATTEN FE, 1905, T CLIN SOC LONDON, V38, P193; CLEARY TG, 1980, JAMA-J AM MED ASSOC, V243, P148, DOI 10.1001/jama.243.2.148; CONNOLLY AM, 1994, ANN NEUROL, V35, P673, DOI 10.1002/ana.410350607; DUPUIS G, 1985, J CLIN MICROBIOL, V22, P484, DOI 10.1128/JCM.22.4.484-487.1985; ENDTZ LJ, 1970, REV NEUROL, V122, P52; FARRAR WE, 1995, MANDELL DOUGLAS BENN, V2, P2137; FELDMAN W, 1972, CAN MED ASSOC J, V106, P1104; FERRANTE MA, 1993, CLIN INFECT DIS, V16, P489, DOI 10.1093/clind/16.4.489; GIERONKORTHALS MA, 1994, J CHILD NEUROL, V9, P381, DOI 10.1177/088307389400900408; HACKSTADT T, 1985, INFECT IMMUN, V48, P359, DOI 10.1128/IAI.48.2.359-365.1985; HOLTOM PD, 1992, INFECT DIS, P1657; KLOCKGETHER T, 1993, J NEUROL, V240, P17, DOI 10.1007/BF00838440; KOHLER J, 1992, FORTSCHR NEUROL PSYC, V60, P110, DOI 10.1055/s-2007-999129; LEEDOM JM, 1980, CURRENT CLIN TOPICS, V1, P304; MARRIE TJ, 1992, SEMIN NEUROL, V12, P213, DOI 10.1055/s-2008-1041178; MCALLISTER RM, 1959, NEW ENGL J MED, V261, P1159, DOI 10.1056/NEJM195912032612304; NARITA M, 1992, PEDIATRICS, V90, P250; PETERS ACB, 1978, ARCH NEUROL-CHICAGO, V35, P769, DOI 10.1001/archneur.1978.00500350073016; PULIK M, 1995, PRESSE MED, V24, P417; SAWYER LA, 1987, REV INFECT DIS, V9, P935; SCARPINI E, 1991, J NEUROL, V238, P356, DOI 10.1007/BF00315340; SCHATTNER A, 1993, POSTGRAD MED J, V69, P636, DOI 10.1136/pgmj.69.814.636; SCHWARTZ JF, 1972, NEUROLOGY, V22, P1071, DOI 10.1212/WNL.22.10.1071; SILPAPOJAKUL K, 1991, ARCH INTERN MED, V151, P1753, DOI 10.1001/archinte.151.9.1753; STEELE JC, 1972, J PEDIATR-US, V80, P467, DOI 10.1016/S0022-3476(72)80507-9; TELLEZ A, 1988, REV INFECT DIS, V10, P198; WEISS S, 1978, HDB CLIN NEUROLOGY, V34, P619; WESTPHAL C, 1872, ARCH PSYCHIAT, V3, P376	30	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1829	1834		10.1056/NEJM199612123352408	http://dx.doi.org/10.1056/NEJM199612123352408			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943166				2022-12-28	WOS:A1996VW68300008
J	Anker, SD; Coats, AJS				Anker, SD; Coats, AJS			Metabolic, functional, and haemodynamic staging for CHF?	LANCET			English	Editorial Material							HEART-FAILURE; EXERCISE CAPACITY; TRANSPLANTATION				Anker, SD (corresponding author), NATL HEART & LUNG INST,IMPERIAL COLL,LONDON SW3 6LY,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				Coats Andrew J. S., 1994, British Heart Journal, V72, pS36; Haywood GA, 1996, HEART, V75, P455, DOI 10.1136/hrt.75.5.455; MANDAK JS, 1995, J HEART LUNG TRANSPL, V14, P468; MAXWELL AE, 1977, MONOGRAPHS APPL PROB; MUDGE GH, 1993, J AM COLL CARDIOL, V22, P21, DOI 10.1016/0735-1097(93)90812-F; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; STEVENSON LW, 1990, CIRCULATION, V81, P78, DOI 10.1161/01.CIR.81.1.78; STEVENSON WG, 1995, J AM COLL CARDIOL, V26, P1417, DOI 10.1016/0735-1097(95)00341-X; SURVIVAL MJ, 1992, CHEST, V101, pS340; TSUTAMOTO T, 1995, AM J CARDIOL, V76, P803, DOI 10.1016/S0002-9149(99)80231-8	10	36	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1530	1531		10.1016/S0140-6736(05)66163-6	http://dx.doi.org/10.1016/S0140-6736(05)66163-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950874				2022-12-28	WOS:A1996VX02300002
J	Li, WZ; Xie, SS; Qian, LX; Chang, BH; Zou, BS; Zhou, WY; Zhao, RA; Wang, G				Li, WZ; Xie, SS; Qian, LX; Chang, BH; Zou, BS; Zhou, WY; Zhao, RA; Wang, G			Large-scale synthesis of aligned carbon nanotubes	SCIENCE			English	Article							FIELD-EMISSION; GROWTH; TUBULES; MICROTUBULES	Large-scale synthesis of aligned carbon nanotubes was achieved by using a method based on chemical vapor deposition catalyzed by iron nanoparticles embedded in mesoporous silica. Scanning electron microscope images show that the nanotubes are approximately perpendicular to the surface of the silica and form an aligned array of isolated tubes with spacings between the tubes of about 100 nanometers. The tubes are up to about 50 micrometers long and well graphitized. The growth direction of the nanotubes may be controlled by the pores from which the nanotubes grow.	CHINESE ACAD SCI,INST PHYS,BEIJING 100080,PEOPLES R CHINA; CENT UNIV NATIONALITIES,DEPT PHYS,BEIJING 100081,PEOPLES R CHINA	Chinese Academy of Sciences; Institute of Physics, CAS; Minzu University of China			zou, bingsuo/AAP-3083-2020; Li, Wenzhi/J-6797-2016	zou, bingsuo/0000-0003-4561-4711; Li, Wenzhi/0000-0001-8442-2232				AJAYAN PM, 1994, SCIENCE, V265, P1212, DOI 10.1126/science.265.5176.1212; AMELINCKX S, 1994, SCIENCE, V265, P635, DOI 10.1126/science.265.5172.635; BAKER RTK, 1989, CARBON, V27, P315, DOI 10.1016/0008-6223(89)90062-6; BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0; COLBERT DT, 1994, SCIENCE, V266, P1218, DOI 10.1126/science.266.5188.1218; Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523; DAI HJ, 1995, NATURE, V375, P769, DOI 10.1038/375769a0; DEHEER WA, 1995, SCIENCE, V268, P845, DOI 10.1126/science.268.5212.845; DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179; DRAVID VP, 1993, SCIENCE, V259, P1601, DOI 10.1126/science.259.5101.1601; DRESSELHAUS MS, 1992, NATURE, V358, P195, DOI 10.1038/358195a0; Ebbesen TW, 1996, NATURE, V382, P54, DOI 10.1038/382054a0; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; ENDO M, 1993, J PHYS CHEM SOLIDS, V54, P1841, DOI 10.1016/0022-3697(93)90297-5; HAMADA N, 1992, PHYS REV LETT, V68, P1579, DOI 10.1103/PhysRevLett.68.1579; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; ILIJIMA S, 1980, J CRYST GROWTH, V50, P675; IVANOV V, 1994, CHEM PHYS LETT, V223, P329, DOI 10.1016/0009-2614(94)00467-6; MINTMIRE JW, 1992, PHYS REV LETT, V68, P631, DOI 10.1103/PhysRevLett.68.631; NOVAK BM, 1993, ADV MATER, V5, P422, DOI 10.1002/adma.19930050603; PARTHASARATHY RV, 1995, ADV MATER, V7, P896, DOI 10.1002/adma.19950071103; RINZLER AG, 1995, SCIENCE, V269, P1550, DOI 10.1126/science.269.5230.1550; ROBERTSON DH, 1992, PHYS REV B, V45, P12592, DOI 10.1103/PhysRevB.45.12592; SAITO R, 1992, APPL PHYS LETT, V60, P2204, DOI 10.1063/1.107080; SAITO Y, 1993, CHEM PHYS LETT, V204, P277, DOI 10.1016/0009-2614(93)90009-P; SERAPHIN S, 1993, APPL PHYS LETT, V63, P2073, DOI 10.1063/1.110596; SNYDER CE, 1989, Patent No. 07163; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; UGARTE D, 1993, CHEM PHYS LETT, V209, P99, DOI 10.1016/0009-2614(93)87208-K; Wong EW, 1996, CHEM MATER, V8, P2041, DOI 10.1021/cm960083b; YACAMAN MJ, 1993, APPL PHYS LETT, V62, P657; ZHANG XF, 1993, J CRYST GROWTH, V130, P368, DOI 10.1016/0022-0248(93)90522-X	33	1642	1903	16	754	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1701	1703		10.1126/science.274.5293.1701	http://dx.doi.org/10.1126/science.274.5293.1701			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939858				2022-12-28	WOS:A1996VW71200057
J	Moore, PS; Boshoff, C; Weiss, RA; Chang, Y				Moore, PS; Boshoff, C; Weiss, RA; Chang, Y			Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV	SCIENCE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; KAPOSIS-SARCOMA; DNA-SEQUENCES; CELL-LINES; GROWTH-FACTOR; SEARCH TOOL; B-CELLS; INTERLEUKIN-6; EXPRESSION	Four virus proteins similar to two human macrophage inflammatory protein (MIP) chemokines, interleukin-6 (IL-6), and interferon regulatory factor (IRF) are encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV) genome. vIL-6 was functional in B9 proliferation assays and primarily expressed in KSHV-infected hematopoietic cells rather than KS lesions. HIV-1 transmission studies showed that vMIP-I is similar to human MIP chemokines in its ability to inhibit replication of HIV-1 strains dependent on the CCR5 co-receptor. These viral genes may form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-1 interactions.	COLUMBIA UNIV, DEPT PATHOL, NEW YORK, NY 10032 USA; INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	Columbia University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Li, Chia Cheng/D-9906-2015; Moore, Patrick/GVR-8294-2022; Chang, Yuan/F-4146-2011; Moore, Patrick S./F-3960-2011	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X	NCI NIH HHS [CA67391] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; APPLEMAN LJ, 1995, INT J CANCER, V63, P576, DOI 10.1002/ijc.2910630419; BERAL V, 1991, CANCER SURV, V10, P5; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Corbellino M, 1996, CLIN INFECT DIS, V22, P1120, DOI 10.1093/clinids/22.6.1120; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dictor M, 1996, AM J PATHOL, V148, P2009; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FLAMAND L, 1996, J AIDS HUM RETROVIRO, V15, P194; FLORE O, UNPUB; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Gessain A, 1996, BLOOD, V87, P414; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARDY AM, 1991, J ACQ IMMUN DEF SYND, V4, P386; HOLZINGER C, 1993, IMMUNOL LETT, V35, P109, DOI 10.1016/0165-2478(93)90078-G; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Lafeuillade A, 1996, J ACQ IMMUN DEF SYND, V12, P95, DOI 10.1097/00042560-199605010-00015; LARCHER C, 1995, EUR J IMMUNOL, V25, P1713, DOI 10.1002/eji.1830250634; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LUNDGREN JD, 1995, AM J EPIDEMIOL, V141, P652, DOI 10.1093/oxfordjournals.aje.a117481; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; Miles S A, 1992, Cancer Treat Res, V63, P129; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MOORE PS, 1996, VIROLOGY, V70, P549; MURPHY PM, 1994, INFECT AGENT DIS, V3, P137; OLeary JJ, 1996, NAT MED, V2, P862, DOI 10.1038/nm0896-862; PALMERO I, 1993, ONCOGENE, V8, P1049; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SARID R, UNPUB; SARID R, 1996, J VIROL, V70, P8218; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Strauchen JA, 1996, ANN INTERN MED, V125, P822, DOI 10.7326/0003-4819-125-10-199611150-00006; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOSATO G, 1990, J VIROL, V64, P3033, DOI 10.1128/JVI.64.6.3033-3041.1990; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	71	769	805	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1739	1744		10.1126/science.274.5293.1739	http://dx.doi.org/10.1126/science.274.5293.1739			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939871				2022-12-28	WOS:A1996VW71200070
J	Stern, RJ; Abdelsalam, MG				Stern, RJ; Abdelsalam, MG			The origin of the great bend of the Nile from SIR-C/X-SAR imagery	SCIENCE			English	Article							NORTHEAST AFRICA; DELGO SUTURE; SUDAN; HISTORY; RADAR; ZONE	The course of the Nile in northern Sudan follows a contorted path through Precambrian bedrock, Radar imagery shows that basement structures control the river's course in this region. Northward-flowing segments follow Precambrian fabrics, whereas east-west segments follow faults of much younger age. These faults may reflect recent uplift of the Nubian Swell and deflection of the river to the southwest to form the great bend of the Nile.			Stern, RJ (corresponding author), UNIV TEXAS,CTR LITHOSPHER STUDIES,POB 830688,RICHARDSON,TX 75083, USA.		Stern, Robert/N-8344-2019; BLUMBERG, DAN G/F-1285-2012	Stern, Robert/0000-0002-8083-4632; BLUMBERG, DAN G/0000-0001-9337-1617				ABDELSALAM MG, 1995, J GEOL, V103, P475, DOI 10.1086/629771; Abdelsalam MG, 1996, J GEOPHYS RES-PLANET, V101, P23063, DOI 10.1029/96JE01391; Adamson D., 1980, SAHARA NILE, P225; ADAMSON DA, 1980, NATURE, V288, P50, DOI 10.1038/288050a0; AHMED F, 1983, ADV SPACE RES, V3, P71; Almond D. C., 1969, B VOLCANOL, V33, P549, DOI DOI 10.1007/BF02596524; BARAZI N, 1987, GEOL RUNDSCH, V76, P529, DOI 10.1007/BF01821090; BERRY L, 1968, GEOGR J, V134, P1, DOI 10.2307/1792135; BOSWORTH W, 1992, TECTONOPHYSICS, V209, P115, DOI 10.1016/0040-1951(92)90014-W; Butzer K.W., 1968, DESERT RIVER NUBIA; Cahen L., 1984, GEOCHRONOLOGY EVOLUT; Franz G., 1993, GEOSCIENTIFIC RES NE, P227; HARMS U, 1994, GEOL RUNDSCH, V83, P591, DOI 10.1007/BF01083230; HSU KJ, 1973, NATURE, V242, P240, DOI 10.1038/242240a0; Hume WF, 1934, GEOLOGY EGYPT 1; ISSAWI B, 1973, ANN GEOL SURV EGYPT, V3, P25; JORDAN RL, 1995, IEEE T GEOSCI REMOTE, V33, P829, DOI 10.1109/36.406669; Klitzsch E., 1984, BERLINER GEOWISS A A, V50, P23; KLITZSCH EH, 1990, AAPG BULL, V74, P1203; MULLERSOHNIUS D, 1994, GEOL RUNDSCH, V83, P604, DOI 10.1007/BF01083231; Said R., 1981, GEOLOGICAL EVOLUTION, DOI [10.1007/978-1-4612-5841-4, DOI 10.1007/978-1-4612-5841-4]; Said R., 1994, NILE SHARING SCARCE, P17; SCHANDELMEIER H, 1994, GEOLOGY, V22, P563, DOI 10.1130/0091-7613(1994)022<0563:ADSANO>2.3.CO;2; STERN RJ, 1994, ANNU REV EARTH PL SC, V22, P319, DOI 10.1146/annurev.ea.22.050194.001535; SULTAN M, 1994, GEOL RUNDSCH, V83, P514, DOI 10.1007/BF01083224; [No title captured]	26	32	33	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1696	1698		10.1126/science.274.5293.1696	http://dx.doi.org/10.1126/science.274.5293.1696			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939856				2022-12-28	WOS:A1996VW71200055
J	Nightingale, SL				Nightingale, SL			Breath test for Helicobacter pylori collection kit approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-28	WOS:A1996VV56600009
J	Pierie, JPEN; Walvoort, HC; Overbeke, AJPM				Pierie, JPEN; Walvoort, HC; Overbeke, AJPM			Readers' evaluation of effect of peer review and editing on quality of articles in the Nederlands Tijdschrift voor Geneeskunde	LANCET			English	Article							INTERNAL-MEDICINE; ANNALS	Background Academic biomedical journals use peer review and editing to help to select and improve the quality of articles. We have investigated whether articles accepted by the Nederlands Tijdschrift voor Geneeskunde, the Dutch Journal of Medicine, were improved after peer review and editing (post-acceptance scientific and copy editing). Methods 400 readers of the journal (100 each of medical students, recent medical graduates, general practitioners, and specialists) were invited to participate in a questionnaire survey. The first 25 from each group who agreed to participate were included. We posted a pack containing a set of identically appearing typescripts (ie, blinding) of the submitted, accepted, and published versions of 50 articles that had been published in Ned Tijdschr Geneeskd. Each evaluator received two of the sets of versions, and each set was evaluated by one person from each group. The package also included two questionnaires: the first was used to compare the submitted with the accepted version (25 questions), the second compared the accepted with the published version (17 questions). The questions were answered on five-point scales, and were about the quality of the articles or were general/overall scores. We analysed the data as scores of 3-5 (ie, improvement) versus 1-2. Findings After peer review, the quality in 14 of 23 questions (61%) was significantly improved (p=0.03 or smaller). In particular, the overall score and general medical value were significantly improved (p=0.00001 for each). Editing led to significant improvement in 11 of 16 questions (69%, p=0.017 or smaller), and especially in style and readability (p=0.001 and p=0.004). Generally, we found no differences between the scores of the four categories of evaluators, 72% of the evaluators correctly identified which version was which. Interpretation Evaluations by readers of the Ned Tijdschr Geneeskd indicated significant improvement of published articles after both peer review and editing. We think that peer review and editing are worthwhile tasks. We also think that possible biases would have had a negligible effect on our results (including the fact that we selected the first 25 evaluators who responded, that some evaluators may have read the published version, and that one questionnaire may have looked more scientific than the other, more editorial one).	NEDERLANDS TIJDSCHRIFT GENEESKUNDE,AMSTERDAM,NETHERLANDS									BOWER B, 1991, SCI NEWS, V22, P394; Comans M L, 1990, Ned Tijdschr Geneeskd, V134, P2338; GOLD JA, 1993, JAMA-J AM MED ASSOC, V270, P2964, DOI 10.1001/jama.270.24.2964; GOODMAN SN, 1994, ANN INTERN MED, V121, P11, DOI 10.7326/0003-4819-121-1-199407010-00003; Hanzlick R, 1990, J Med Assoc Ga, V79, P319; Hobma S O, 1992, Ned Tijdschr Geneeskd, V136, P637; Kan C C, 1991, Ned Tijdschr Geneeskd, V135, P840; Lagerwij E W, 1993, Ned Tijdschr Geneeskd, V137, P402; PETERS DP, 1982, BEHAV BRAIN SCI, V5, P187, DOI 10.1017/S0140525X00011183; ROBERTS JC, 1994, JAMA-J AM MED ASSOC, V272, P119, DOI 10.1001/jama.272.2.119; ROLAND CG, 1975, NEW ENGL J MED, V292, P1273, DOI 10.1056/NEJM197506122922405	11	61	62	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1480	1483		10.1016/S0140-6736(96)05016-7	http://dx.doi.org/10.1016/S0140-6736(96)05016-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942777				2022-12-28	WOS:A1996VV46300010
J	Jernvall, J; Hunter, JP; Fortelius, M				Jernvall, J; Hunter, JP; Fortelius, M			Molar tooth diversity, disparity, and ecology in cenozoic ungulate radiations	SCIENCE			English	Article							MAMMALS; EVOLUTION; CLIMATES; HISTORY; EOCENE	A classic example of adaptive radiation is the diversification of Cenozoic ungulates into herbivore adaptive zones. Their taxonomic diversification has been associated with changes in molar tooth morphology. Analysis of molar crown types of the Artiodactyla, Perissodactyla, and archaic ungulates (''Condylarthra'') shows that the diversity of genera and crown types was high in the Eocene. Post-Eocene molars of intermediate crown types are rare, and thus the ungulate fauna contained more taxa having fewer but more disparate crown types. Taxonomic diversity trends' alone give incomplete descriptions pf adaptive radiations.	SUNY STONY BROOK,DEPT ANTHROPOL,STONY BROOK,NY 11794; UNIV HELSINKI,DEPT SYSTEMAT & ECOL,HELSINKI 00014,FINLAND; SUNY STONY BROOK,DEPT ANAT SCI,STONY BROOK,NY 11794; UNIV HELSINKI,FINNISH MUSEUM NAT HIST,DIV PALAEONTOL,FIN-00014 HELSINKI,FINLAND	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Helsinki; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Helsinki	Jernvall, J (corresponding author), UNIV HELSINKI,INST BIOTECHNOL,POB 56,HELSINKI 00014,FINLAND.		Hunter, John/A-2573-2013					Archibald JD, 1996, SCIENCE, V272, P1150, DOI 10.1126/science.272.5265.1150; Damuth John D., 1992, P183; Diamond JA, COMMUNITY ECOL, P126; Foote M, 1996, EVOLUTION, V50, P1, DOI 10.1111/j.1558-5646.1996.tb04467.x; FOOTE M, 1993, PALEOBIOLOGY, V19, P185, DOI 10.1017/S0094837300015864; Fortelius M., 1985, ACTA ZOOL FENN, V180, P1; Gould S. J., 1989, WONDERFUL LIFE; GOULD SJ, 1991, PALEOBIOLOGY, V17, P41; GREENWOOD DR, 1995, GEOLOGY, V23, P1044, DOI 10.1130/0091-7613(1995)023<1044:ECCALT>2.3.CO;2; Hooker J.J., 1992, P494; HUNTER JP, 1995, P NATL ACAD SCI USA, V92, P10718, DOI 10.1073/pnas.92.23.10718; JANIS CM, 1993, ANNU REV ECOL SYST, V24, P467, DOI 10.1146/annurev.es.24.110193.002343; JANIS CM, 1988, BIOL REV, V63, P197, DOI 10.1111/j.1469-185X.1988.tb00630.x; JANIS CM, 1989, PALAEONTOLOGY, V32, P463; Jernvall Jukka, 1995, Acta Zoologica Fennica, V198, P1; KNOBLOCH E, 1993, REV PALAEOBOT PALYNO, V78, P41, DOI 10.1016/0034-6667(93)90016-N; LABANDEIRA CC, 1993, SCIENCE, V261, P310, DOI 10.1126/science.11536548; Prothero D.R., 1994, EOCENE OLIGOCENE TRA; PROTHERO DR, 1995, GEOCHRONOLOGY TIME S, P305; RAYMO ME, 1992, NATURE, V359, P117, DOI 10.1038/359117a0; RENSBERGER JM, 1988, TEETH REVISITED, P351; Rosenzweig Michael L., 1993, P52; Savage DE, 1983, MAMMALIAN PALEOFAUNA; STUCKY RK, 1990, CURRENT MAMMALOGY, P375; STUCKY RK, 1993, FOSS REC, V2, P739; Upchurch GR, 1987, ORIGINS ANGIOSPERMS, P75; Van Valkenburgh Blaire, 1993, P330; VANVALEN L, 1974, J THEOR BIOL, V45, P235, DOI 10.1016/0022-5193(74)90053-8; VANVALEN LM, 1985, EVOL THEOR, V7, P127; WEBB SD, 1977, ANNU REV ECOL SYST, V8, P355, DOI 10.1146/annurev.es.08.110177.002035; WING SL, 1993, PHILOS T ROY SOC B, V341, P243, DOI 10.1098/rstb.1993.0109; WOODBOURNE MO, 1987, CENOZOIC MAMMALS N A; Wright David H., 1993, P66; WRIGHT DH, 1983, OIKOS, V41, P496, DOI 10.2307/3544109	34	117	121	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1489	1492		10.1126/science.274.5292.1489	http://dx.doi.org/10.1126/science.274.5292.1489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929401				2022-12-28	WOS:A1996VV77500036
J	Fox, PW; Hershberger, SL; Bouchard, TJ				Fox, PW; Hershberger, SL; Bouchard, TJ			Genetic and environmental contributions to the acquisition of a motor skill	NATURE			English	Article								PRACTICE, with feedback, is a fundamental variable that influences the aquisition of motor skills(1): with it, everyone improves, but some improve more than others, This simple fact has led to frequent debate over the relative importance of genetic and environmental influences on motor learning, In principle these factors could influence subjects' initial level of proficiency, their rate of improvement or their final level of attainment, The problem has been investigated using the rotary pursuit (RP) task, in which subjects learn to track a rotating target with a stylus(2); this is a factorially pure task which is relatively unaffected by cognitive or verbal factors(3,4). Earlier studies of twins reared together(2,5) indicated that heredity was the primary factor responsible for individual differences in motor skill, Here we have studied learning in a sample of monozygotic (MZA) and dizygotic (DZA) twins who had been reared apart, Heritability of performance mas high even in the initial phase, and increased with practice, The rate of learning was also significantly heritable, We propose that the effect of practice is to decrease the effect of environmental variation (previous learning) and increase the relative strength of genetic influences on motor performance.	UNIV KANSAS,DEPT PSYCHOL,LAWRENCE,KS 66045; UNIV MINNESOTA,DEPT PSYCHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	University of Kansas; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities								BILODEAU EA, 1961, ANNU REV PSYCHOL, V12, P243, DOI 10.1146/annurev.ps.12.020161.001331; BOUCHARD TJ, 1990, SCIENCE, V250, P223, DOI 10.1126/science.2218526; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Eaves L, 1989, GENES CULTURE PERSON; FLEISHMAN EA, 1960, J EXP PSYCHOL, V60, P162, DOI 10.1037/h0044953; LYKKEN DT, 1992, AM PSYCHOL, V47, P1565, DOI 10.1037/0003-066X.47.12.1565; MARISI DQ, 1977, ACTA GENET MED GEMEL, V26, P197, DOI 10.1017/S0001566000009685; MCGUE M, 1984, BEHAV GENET, V14, P325, DOI 10.1007/BF01080045; McNemar Q, 1933, PEDAGOG SEMIN J GEN, V42, P70; Neale MC, 1992, METHODOLOGY GENETIC; NEALE MC, 1994, MX STAT MODELLING; NOBLE CE, 1970, J EXP PSYCHOL, V86, P360, DOI 10.1037/h0030162	12	66	67	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					356	358		10.1038/384356a0	http://dx.doi.org/10.1038/384356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VV271	8934520				2022-12-28	WOS:A1996VV27100048
J	Ekwanzala, M; Pepin, J; Khonde, N; Molisho, S; Bruneel, H; DeWals, P				Ekwanzala, M; Pepin, J; Khonde, N; Molisho, S; Bruneel, H; DeWals, P			In the heart of darkness: Sleeping sickness in Zaire	LANCET			English	Editorial Material									BUR CENT TRYPANOSOMLASE, KINSHASA, DEM REP CONGO; UNIV SHERBROOKE, SHERBROOKE, PQ J1K 2R1, CANADA; FONDS MED TROP, BRUSSELS, BELGIUM	University of Sherbrooke								BRUNEEL H, 1994, ANN SOC BELG MED TR, V74, P203; BURKE J, 1971, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V51, P465; BURKE J, 1992, MED HYGIENE AFRIQUE; *CTR DIS CONTR PRE, 1995, MMWR-MORBID MORTAL W, V44, P468; Kabeya N.M., 1988, Medecine Tropicale, V48, P277; Khonde N, 1995, T ROY SOC TROP MED H, V89, P607, DOI 10.1016/0035-9203(95)90408-5; NEUJEAN G, 1963, B WORLD HEALTH ORGAN, V28, P797; SCOTT D, 1970, AFRICAN TRYPANOSOMIA; VANHOOF LMJJ, 1947, T ROY SOC TROP MED H, V40, P728	9	67	68	2	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1996	348	9039					1427	1430		10.1016/S0140-6736(96)06088-6	http://dx.doi.org/10.1016/S0140-6736(96)06088-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937285				2022-12-28	WOS:A1996VU98600017
J	Finucane, TE; Bynum, JPW				Finucane, TE; Bynum, JPW			Use of tube feeding to prevent aspiration pneumonia	LANCET			English	Review							SALIVA; INFECTION				Finucane, TE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BAYVIEW MED CTR,DEPT MED,DIV GERIATR MED & GERONTOL,BALTIMORE,MD 21224, USA.							*AM GASTR ASS, 1993, AGA HLTH CAR REF UPD, P1; BOSCOE MJ, 1984, BRIT MED J, V289, P1421, DOI 10.1136/bmj.289.6456.1421; CANEL D, 1987, J PEDIATR SURG, V22, P54; CIOCON JO, 1993, JPEN-PARENTER ENTER, V17, P230; COLE MJ, 1987, J CLIN GASTROENTEROL, V9, P90, DOI 10.1097/00004836-198702000-00023; CRAIG TJ, 1980, AM J PSYCHIAT, V137, P1366; DEPASO WJ, 1991, CLIN CHEST MED, V12, P269; EISELE DW, 1989, AM J SURG, V157, P230, DOI 10.1016/0002-9610(89)90534-5; EKBERG O, 1991, AM J ROENTGENOL, V156, P1181, DOI 10.2214/ajr.156.6.2028863; HORNER J, 1988, NEUROLOGY, V38, P1359; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; KOUFMAN JA, 1986, LARYNGOSCOPE, V96, P726; LAZARUS BA, 1990, ARCH PHYS MED REHAB, V71, P46; LEVY J, 1989, JPEN-PARENTER ENTER, V13, P228, DOI 10.1177/0148607189013003228; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; OLIVARES L, 1974, STROKE, V5, P654, DOI 10.1161/01.STR.5.5.654; OSTERBERG T, 1992, SCAND J DENT RES, V100, P340; SHIP JA, 1991, J AM DENT ASSOC, V122, P63, DOI 10.14219/jada.archive.1991.0098; SILVER KH, 1991, ARCH PHYS MED REHAB, V72, P902, DOI 10.1016/0003-9993(91)90009-8; Stoschus B., 1993, Dysphagia, V8, P154, DOI 10.1007/BF02266997; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; TERPENNING M, 1993, CLIN INFECT DIS, V16, pS314, DOI 10.1093/clinids/16.Supplement_4.S314; THURN J, 1990, J HOSP INFECT, V15, P203, DOI 10.1016/0195-6701(90)90028-M; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; WADE DT, 1987, ACTA NEUROL SCAND, V76, P50, DOI 10.1111/j.1600-0404.1987.tb03543.x; WYNNE JW, 1977, ANN INTERN MED, V87, P466, DOI 10.7326/0003-4819-87-4-466	27	172	178	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1421	1424		10.1016/S0140-6736(96)03369-7	http://dx.doi.org/10.1016/S0140-6736(96)03369-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937283	hybrid			2022-12-28	WOS:A1996VU98600015
J	Sarmiento, JL; LeQuere, C				Sarmiento, JL; LeQuere, C			Oceanic carbon dioxide uptake in a model of century-scale global warming	SCIENCE			English	Article							ATMOSPHERIC CO2	In a model of ocean-atmosphere interaction that excluded biological processes, the oceanic uptake of atmospheric carbon dioxide (CO2) was substantially reduced in scenarios involving global warming relative to control scenarios. The primary reason for the reduced uptake was the weakening or collapse of the ocean thermohaline circulation. Such a large reduction in this ocean uptake would have a major impact on the future growth rate of atmospheric CO2. Model simulations that include a simple representation of biological processes show a potentially large offsetting effect resulting from the downward flux of biogenic carbon. However, the magnitude of the offset is difficult to quantify with present knowledge.			Sarmiento, JL (corresponding author), PRINCETON UNIV,PROGRAM ATMOSPHER & OCEAN SCI,PRINCETON,NJ 08544, USA.		Le Quere, Corinne/C-2631-2017	Le Quere, Corinne/0000-0003-2319-0452				BERNER RA, 1994, AM J SCI, V294, P56, DOI 10.2475/ajs.294.1.56; CHISHOLM SW, 1991, LIMNOL OCEANOGR, V36, pU1507; ENTING IG, 1994, ASSESSMENT IPCC CO2; HARVEY LDD, 1994, J GEOPHYS RES-OCEANS, V99, P18447, DOI 10.1029/94JC00970; Houghton J.T., 1990, CLIMATE CHANGE IPCC; MaierReimer E, 1996, CLIM DYNAM, V12, P711, DOI 10.1007/s003820050138; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; MANABE S, 1993, NATURE, V364, P215, DOI 10.1038/364215a0; MANABE S, 1994, J CLIMATE, V7, P5, DOI 10.1175/1520-0442(1994)007<0005:MCROAC>2.0.CO;2; MANABE S, COMMUNICATION; MARTIN JH, 1987, DEEP-SEA RES, V34, P267, DOI 10.1016/0198-0149(87)90086-0; NEFTEL A, 1982, NATURE, V295, P220, DOI 10.1038/295220a0; RAYNAUD D, 1993, SCIENCE, V259, P926, DOI 10.1126/science.259.5097.926; SARMIENTO JL, 1991, LIMNOL OCEANOGR, V36, P1928, DOI 10.4319/lo.1991.36.8.1928; SARMIENTO JL, 1995, PHILOS T R SOC B, V348, P211, DOI 10.1098/rstb.1995.0063; SARMIENTO JL, 1995, GLOBAL BIOGEOCHEM CY, V9, P121, DOI 10.1029/94GB01779; SARMIENTO JL, 1984, NATURE, V308, P621, DOI 10.1038/308621a0; Schimel D., 1995, CLIMATE CHANGE 1994, P39; SHINE KP, 1995, CLIMATE CHANGE 1994, P161; WANNINKHOF R, 1992, J GEOPHYS RES-OCEANS, V97, P7373, DOI 10.1029/92JC00188	20	249	260	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1346	1350		10.1126/science.274.5291.1346	http://dx.doi.org/10.1126/science.274.5291.1346			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910268				2022-12-28	WOS:A1996VU95400044
J	Clegg, CH; Rulffes, JT; Wallace, PM; Haugen, HS				Clegg, CH; Rulffes, JT; Wallace, PM; Haugen, HS			Regulation of an extrathymic T-cell development pathway by oncostatin M	NATURE			English	Article							STEM-CELLS; EXPRESSION; CD4+	MOST Of the T lymphocytes that populate the immune system develop in the thymus before its involution during late adolescence, Therefore, subsequent losses in T cells caused by HIV infection(1), chemotherapy(2) or age related factors(3) can greatly diminish immune responses to new antigenic challenge, Here we report the discovery of a thymus-independent pathway of T-cell development that may provide help for T cell immunodeficiency, We show that expression of an oncostatin M transgene(4) in the early T lineage stimulates a dramatic accumulation of immature and mature T cells in lymph nodes, A functional thymus is not required for this effect as reconstitution of nu/nu mice with transgenic bone marrow stimulated a 500-fold increase in Thy-1(+) lymph node cells and restored immune responsiveness to allogeneic mouse melanoma cells, This lymphopoietic pathway is not unique to transgenic mice because administration of oncostatin M protein produced a similar response in non-transgenic mice, These results identify a new pathway of T-cell development and a potential treatment for T-cell immunodeficiency with oncostatin M.			Clegg, CH (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.							BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FRANCESCHI C, 1995, IMMUNOL TODAY, V16, P12, DOI 10.1016/0167-5699(95)80064-6; GEANING DP, 1992, SCIENCE, V255, P1434; KSIELOW P, 1995, ADV IMMUNOL, V58, P87; LI YW, 1994, J IMMUNOL, V153, P421; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MALIK N, 1995, MOL CELL BIOL, V15, P2349; ROCHA B, 1995, CURR OPIN IMMUNOL, V7, P235, DOI 10.1016/0952-7915(95)80008-5; ROEDERER M, 1995, NAT MED, V1, P621, DOI 10.1038/nm0795-621; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SHEN MM, 1994, EMBO J, V13, P1375, DOI 10.1002/j.1460-2075.1994.tb06391.x; Wallace PM, 1995, ANN NY ACAD SCI, V762, P42; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	16	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					261	263		10.1038/384261a0	http://dx.doi.org/10.1038/384261a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918875				2022-12-28	WOS:A1996VU38100050
J	Bowles, KM; Muller, AF; Ilesley, IC				Bowles, KM; Muller, AF; Ilesley, IC			A 35-year-old with swollen knees who had recurrent fever and pericarditis, then diarrhoea before getting better	LANCET			English	Article									KENT & CANTERBURY HOSP,DEPT MED,CANTERBURY CT1 3NG,KENT,ENGLAND; KENT & CANTERBURY HOSP,DEPT PATHOL,CANTERBURY CT1 3NG,KENT,ENGLAND	University of Kent; University of Kent				Bowles, Kristian/0000-0003-1334-4526				GROSS JB, 1959, GASTROENTEROLOGY, V36, P65; KELLY JJ, 1963, ARTHRITIS RHEUM-US, V6, P615, DOI 10.1002/art.1780060505; LIE JT, 1976, AM J CLIN PATHOL, V66, P22, DOI 10.1093/ajcp/66.1.22; PUITE RH, 1955, AM J MED, V19, P383, DOI 10.1016/0002-9343(55)90127-3; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382	5	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1356	1356		10.1016/S0140-6736(96)08101-9	http://dx.doi.org/10.1016/S0140-6736(96)08101-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918280				2022-12-28	WOS:A1996VT33200013
J	Jarvis, LM; Davidson, F; Hanley, JP; Yap, PL; Ludlam, CA; Simmonds, P				Jarvis, LM; Davidson, F; Hanley, JP; Yap, PL; Ludlam, CA; Simmonds, P			Infection with hepatitis G virus among recipients of plasma products	LANCET			English	Article							C VIRUS; BLOOD-DONORS; FACTOR-VIII; HEMOPHILIACS; PREVALENCE; ORGANIZATION; GENOTYPES	Background Hepatitis G virus (HGV or GBV-C) is a newly discovered human flavivirus distantly related to hepatitis C Virus (HCV). Little information is available on its natural history or routes of transmission, although it can be transmitted parenterally. We investigated the prevalence of persistent infection of HGV and HCV in patients exposed to non-virus-inactivated pooled blood products associated with transmission of HCV. Methods RNA was extracted from the plasma of 112 patients with haemophilia and 57 with hypogammaglobulinaemia, as well as from 64 different batches of archived coagulation-factor concentrates and immunoglobulins. RNA was reverse transcribed and amplified with primers from the 5' non-coding region of HCV and HGV by a nested polymerase chain reaction (PCR): Viral RNA was quantified by titration of complementary DNA before amplification. Findings Among non-remunerated UK blood donors HGV infection (detected by PCR) was more common than HCV infection (four [3 . 2%] of 125 compared with 137 [0 . 076%] of 180 658 in southeast Scotland]. Testing of batches of factor VIII and factor IX concentrates prepared without viral inactivation procedures showed high frequencies of contamination with HGV (16 of 17 factor VIII batches positive; six of six factor IX batches positive), with no difference between remunerated and non-renumerated donors. However, among 95 haemophiliacs who had received non-virus-inactivated concentrates, 13 (14%) were positive for HGV compared with 79 (83%) who were positive for HCV. Two of 37 recipients of long-term immunoglobulin replacement therapy were positive for HGV. Virus inactivation of blood products substantially reduced or eliminated contamination by HGV RNA sequences. Interpretation Despite the extremely high level of HGV contamination of non-virus-inactivated blood products, their use was not associated with high rates of persistent infection in recipients. The infectivity of HGV in blood products may be lower than that of HCV, or the virus may be less able to establish persistent infection in humans. Whatever the case, the high prevalence of active HGV infection in the general population remains difficult to explain.	UNIV EDINBURGH, DEPT HAEMATOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; EDINBURGH & SE SCOTLAND BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Jarvis, LM (corresponding author), UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.			Simmonds, Peter/0000-0002-7964-4700				CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CRAWFORD RJ, 1994, TRANSFUSION MED, V4, P121, DOI 10.1111/j.1365-3148.1994.tb00252.x; DAVIDSON F, 1995, J GEN VIROL, V76, P1197, DOI 10.1099/0022-1317-76-5-1197; Feucht HH, 1996, LANCET, V347, P615, DOI 10.1016/S0140-6736(96)91309-4; FLETCHER ML, 1983, BRIT MED J, V287, P1754, DOI 10.1136/bmj.287.6407.1754; FOLLETT EAC, 1992, LANCET, V339, P928, DOI 10.1016/0140-6736(92)90964-5; JARVIS LM, 1994, J INFECT DIS, V170, P1018, DOI 10.1093/infdis/170.4.1018; Kao JH, 1996, LANCET, V347, P120, DOI 10.1016/S0140-6736(96)90244-5; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Moaven LD, 1996, MED J AUSTRALIA, V165, P84, DOI 10.5694/j.1326-5377.1996.tb124854.x; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; TEDDER RS, 1991, BRIT J HAEMATOL, V79, P512, DOI 10.1111/j.1365-2141.1991.tb08064.x; WATSON HG, 1992, BRIT J HAEMATOL, V80, P514, DOI 10.1111/j.1365-2141.1992.tb04566.x; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7	18	227	229	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1996	348	9038					1352	1355		10.1016/S0140-6736(96)04041-X	http://dx.doi.org/10.1016/S0140-6736(96)04041-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918279				2022-12-28	WOS:A1996VT33200012
J	Modigh, C; Axelsson, G; Alavanja, M; Andersson, L; Rylander, R				Modigh, C; Axelsson, G; Alavanja, M; Andersson, L; Rylander, R			Pet birds and risk of lung cancer in Sweden: A case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSMOKING WOMEN	Objective-To investigate the association between keeping birds and the risk of lung cancer in Sweden. Design-Case-control study based on cases of lung cancer and community controls. Interviews were performed by two nurses specially trained for this project. Setting-Three major referral hospitals located in southwest Sweden. Subjects-All patients aged 75 and under with newly diagnosed lung cancer and of Scandinavian birth who lived in one of 26 municipalities in Gothenburg and Bohus county or Alvsborg county. Potential control subjects matched on county of residence, sex, and closest date of birth were selected from population registries. In the context of a larger case-control study, information on pet birds was obtained from 380 patients with lung cancer (252 men) and 696 controls (433 men). Main outcome measures-Odds ratios for lung cancer in relation to whether or not pet birds were kept and the duration of keeping pet birds. Results-The adjusted odds ratio for ever versus never exposed to pet birds at home was 0.94 (95% confidence interval 0.64 to 1.39) for men and 1.10 (0.64 to 1.90) for women. There was no evidence of a trend for increased risk of lung cancer with duration of bird ownership. Conclusion-Bird keeping does not seem to confer any excess risk of lung cancer to Swedish men or women.	NCI, DIV CANC EPIDEMIOL & GENET, ROCKVILLE, MD 20852 USA; N ALVSBORG GEN HOSP, LUNG CLIN, TROLLHATTAN, SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Modigh, C (corresponding author), GOTHENBURG UNIV, DEPT ENVIRONM MED, MEDICINAREGATAN 16, S-41390 GOTHENBURG, SWEDEN.							Alavanja MCR, 1996, BMJ-BRIT MED J, V313, P1233, DOI 10.1136/bmj.313.7067.1233; ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623, DOI 10.1093/oxfordjournals.aje.a116542; ALAVANJA MCR, 1993, J NATL CANCER I, V85, P1906, DOI 10.1093/jnci/85.23.1906; Axelsson G, 1996, INT J EPIDEMIOL, V25, P32, DOI 10.1093/ije/25.1.32; BRITTON J, 1992, BRIT MED J, V305, P970, DOI 10.1136/bmj.305.6860.970; CULTAS DB, 1994, EPIDEMIOLOGY LUNG CA, P299; GARDINER A, 1993, BRIT MED J, V306, P60, DOI 10.1136/bmj.306.6869.60-a; GARDINER AJS, 1992, BRIT MED J, V305, P989, DOI 10.1136/bmj.305.6860.989; General U.S. Surgeon, 1986, HLTH CONS INV SMOK; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; KOHLMEIER L, 1992, BMJ-BRIT MED J, V305, P986, DOI 10.1136/bmj.305.6860.986; KOHLMEIER L, 1993, BRIT MED J, V306, P60, DOI 10.1136/bmj.306.6869.60; MORABIA A, 1993, BRIT MED J, V306, P60, DOI 10.1136/bmj.306.6869.60-b; PERSHAGEN G, 1990, COMPLEX MIXTURES CAN, P240; RAMPEN FHJ, 1993, BRIT MED J, V306, P61, DOI 10.1136/bmj.306.6869.61-a; Speizer FE, 1994, EPIDEMIOLOGY LUNG CA, P131; *STAT EP RES, 1991, EGRET REV 2; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672	18	18	18	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1996	313	7067					1236	1238		10.1136/bmj.313.7067.1236	http://dx.doi.org/10.1136/bmj.313.7067.1236			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939112	Green Published			2022-12-28	WOS:A1996VU20800021
J	Starr, SE				Starr, SE			Novel mechanism of immunosuppression after measles	LANCET			English	Editorial Material							INTERLEUKIN-12				Starr, SE (corresponding author), UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104, USA.							AABY P, 1993, INT J EPIDEMIOL, V20, P156; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; GRIFFIN DE, 1994, J INFECT DIS S1, V170, P24; Hussey GD, 1996, J INFECT DIS, V173, P1320, DOI 10.1093/infdis/173.6.1320; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; STARR S, 1964, NEW ENGL J MED, V270, P386, DOI 10.1056/NEJM196402202700802; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1257	1258		10.1016/S0140-6736(05)65753-4	http://dx.doi.org/10.1016/S0140-6736(05)65753-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909375	hybrid			2022-12-28	WOS:A1996VR55500005
J	Pfeifer, A; Aszodi, A; Seidler, U; Ruth, P; Hofmann, F; Fassler, R				Pfeifer, A; Aszodi, A; Seidler, U; Ruth, P; Hofmann, F; Fassler, R			Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II	SCIENCE			English	Article							HEAT-STABLE ENTEROTOXIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; MOUSE MODEL; ACTIVATION; EXPRESSION; CLONING; RAT; RECEPTOR; GUANYLIN; SEQUENCE	Cyclic guanosine 3',5'-monophosphate (cGMP)-dependent protein kinases (cGKs) mediate cellular signaling induced by nitric oxide and cGMP. Mice deficient in the type II cGK were resistant to Escherichia coli STa, an enterotoxin that stimulates cGMP accumulation and intestinal fluid secretion. The cGKII-deficient mice also developed dwarfism that was caused by a severe defect in endochondral ossification at the growth plates. These results indicate that cGKII plays a central role in diverse physiological processes.	UNIV TUBINGEN,MED KLIN 1,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen	Pfeifer, A (corresponding author), TECH UNIV MUNICH,INST PHARMACOL & TOXICOL,BIEDERSTEINER STR 29,D-80802 MUNICH,GERMANY.		Seidler, Ursula/HII-8049-2022	Seidler, Ursula/0000-0002-9600-2769				CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; FELTS WJL, 1957, TRANSPLAN B, V4, P5; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GIANNELLA RA, 1976, INFECT IMMUN, V14, P95, DOI 10.1128/IAI.14.1.95-99.1976; GIANNELLA RA, 1981, ANNU REV MED, V32, P341, DOI 10.1146/annurev.me.32.020181.002013; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HUNZIKER EB, 1987, J BONE JOINT SURG AM, V69A, P162, DOI 10.2106/00004623-198769020-00002; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCIAKY D, 1994, GENOMICS, V24, P583, DOI 10.1006/geno.1994.1670; SHABB JB, 1992, J BIOL CHEM, V267, P5723; UHLER MD, 1993, J BIOL CHEM, V268, P13586; USSING HH, 1951, ACTA PHYSIOL SCAND, V23, P110, DOI 10.1111/j.1748-1716.1951.tb00800.x; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X	27	316	343	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2082	2086		10.1126/science.274.5295.2082	http://dx.doi.org/10.1126/science.274.5295.2082			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953039				2022-12-28	WOS:A1996VY97400049
J	Bikah, G; Carey, J; Ciallella, JR; Tarakhovsky, A; Bondada, S				Bikah, G; Carey, J; Ciallella, JR; Tarakhovsky, A; Bondada, S			CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells	SCIENCE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; NF-KAPPA-B; LYMPHOCYTES-B; CROSS-LINKING; SH2 DOMAIN; T-CELLS; ACTIVATION; MICE; CD5; STIMULATION	A subset of B lymphocytes present primarily in the peritoneal and pleural cavities is defined by the expression of GD5 and is elevated in autoimmune diseases. Upon signaling through membrane immunoglobulin M (mIgM), splenic B lymphocytes (B-2) proliferate, whereas peritoneal B cells (B-1) undergo apoptosis, However, in CD5-deficient mice, B-1 cells responded to mlgM crosslinking by developing a resistance to apoptosis and entering the cell cycle, In wild-type B-1 cells, prevention of association between CD5 and mlgM rescued their growth response to mlgM crosslinking, Thus the B cell receptor-mediated signaling is negatively regulated by CD5 in normal B-1 cells.	UNIV KENTUCKY, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, CTR AGING, LEXINGTON, KY 40536 USA; UNIV COLOGNE, INST GENET, D-50937 COLOGNE, GERMANY	University of Kentucky; University of Kentucky; University of Cologne					NIAID NIH HHS [AI21490] Funding Source: Medline; NIA NIH HHS [AG05731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELLOC F, 1988, CYTOMETRY, V9, P19, DOI 10.1002/cyto.990090104; BIKAH G, UNPUB; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; DALE LM, 1993, J EXP MED, V177, P857; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HAYAKAWA K, 1983, J EXP MED, V157, P202, DOI 10.1084/jem.157.1.202; HEATH AW, 1994, EUR J IMMUNOL, V24, P1828, DOI 10.1002/eji.1830240816; HERZENBERG LA, 1992, ANN NY ACAD SCI, V651, P1; ILLERA VA, 1993, J IMMUNOL, V151, P2965; JAKWAY JP, 1986, J IMMUNOL, V137, P2225; Jamin C, 1996, SCAND J IMMUNOL, V43, P73, DOI 10.1046/j.1365-3083.1996.d01-8.x; KEARNEY JF, 1986, IMMUNOL REV, V94, P39, DOI 10.1111/j.1600-065X.1986.tb01163.x; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LIOU LB, 1992, INT IMMUNOL, V4, P15, DOI 10.1093/intimm/4.1.15; LIU JL, 1991, J IMMUNOL, V146, P1685; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCEVOY L, 1988, J LEUKOCYTE BIOL, V44, P337, DOI 10.1002/jlb.44.5.337; MORRIS DL, 1993, J EXP MED, V177, P857, DOI 10.1084/jem.177.3.857; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; MUTHUKKUMAR S, 1995, INT IMMUNOL, V7, P305, DOI 10.1093/intimm/7.2.305; MUTHUSAMY N, 1991, J IMMUNOL, V147, P2483; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; O'Garra A, 1992, Int Rev Immunol, V8, P219, DOI 10.3109/08830189209055575; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; PENNELL CA, 1985, P NATL ACAD SCI USA, V82, P3799, DOI 10.1073/pnas.82.11.3799; PLAS DR, 1996, SCIENCE, V272, P117; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; ROONEY JW, 1991, EUR J IMMUNOL, V21, P2993, DOI 10.1002/eji.1830211214; ROTHSTEIN TL, 1988, J IMMUNOL, V141, P4089; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TARAKHOVSKY A, 1994, EUR J IMMUNOL, V24, P1678, DOI 10.1002/eji.1830240733; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8; UDHAYAKUMAR V, 1991, J IMMUNOL, V146, P4120; VAN DE VELDE H, 1991, NATURE, V351, P662; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	43	248	250	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1906	1909		10.1126/science.274.5294.1906	http://dx.doi.org/10.1126/science.274.5294.1906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943203				2022-12-28	WOS:A1996VY20000043
J	Ugarte, D; Chatelain, A; deHeer, WA				Ugarte, D; Chatelain, A; deHeer, WA			Nanocapillarity and chemistry in carbon nanotubes	SCIENCE			English	Article							METAL; CAPILLARITY; TUBULES; GROWTH	Open carbon nanotubes were filled with molten silver nitrate by capillary forces. Only those tubes with inner diameters of 4 nanometers or more were filled, suggesting a capillarity size dependence as a result of the lowering of the nanotube-salt interface energy with increasing curvature of the nanotube walls. Nanotube cavities should also be less chemically reactive than graphite and may serve as nanosize test tubes. This property has been illustrated by monitoring the decomposition of silver nitrate within nanotubes in situ in an electron microscope, which produced chains of silver nanobeads separated by high-pressure gas pockets.	ECOLE POLYTECH FED LAUSANNE,DEPT PHYS,INST PHYS EXPT,CH-1015 LAUSANNE,SWITZERLAND; GEORGIA INST TECHNOL,SCH PHYS,ATLANTA,GA 30332	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University System of Georgia; Georgia Institute of Technology	Ugarte, D (corresponding author), CNPQ,MCT,LAB NACL LUZ SINCROTRON,CAIXA POSTAL 6192,BR-13083970 CAMPINAS,SP,BRAZIL.		Ugarte, Daniel/C-2326-2012	Ugarte, Daniel Mario/0000-0003-3332-9139				AJAYAN PM, 1993, NATURE, V361, P333, DOI 10.1038/361333a0; AJAYAN PM, 1993, NATURE, V362, P522, DOI 10.1038/362522a0; AJAYAN PM, 1994, PHYS REV LETT, V72, P1722, DOI 10.1103/PhysRevLett.72.1722; AJAYAN PM, 1995, NATURE, V375, P564, DOI 10.1038/375564a0; BETHUNE DS, 1993, NATURE, V363, P605, DOI 10.1038/363605a0; BLASE X, 1994, PHYS REV LETT, V72, P1878, DOI 10.1103/PhysRevLett.72.1878; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; DEHEER WA, 1993, CHEM PHYS LETT, V207, P480, DOI 10.1016/0009-2614(93)89033-E; DEHEER WA, 1993, REV MOD PHYS, V65, P611, DOI 10.1103/RevModPhys.65.611; DUJARDIN E, 1994, SCIENCE, V265, P1850, DOI 10.1126/science.265.5180.1850; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; GUERRET-PIECOURT C, 1994, NATURE, V372, P761, DOI 10.1038/372761a0; HADDON RC, 1993, SCIENCE, V261, P1545, DOI 10.1126/science.261.5128.1545; HENKE K, 1976, ANGEW CHEM INT EDIT, V15, P165; IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; JACKSON JD, 1967, CLASSICAL ELECTRODYN; KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0; LAASONEN K, 1992, SCIENCE, V258, P1916, DOI 10.1126/science.258.5090.1916; LAGO RM, 1995, J CHEM SOC CHEM COMM, P1355, DOI 10.1039/c39950001355; MIYAMOTO Y, 1995, PHYS REV LETT, V74, P2993, DOI 10.1103/PhysRevLett.74.2993; PEDERSON MR, 1992, PHYS REV LETT, V69, P2689, DOI 10.1103/PhysRevLett.69.2689; Rubio A, 1996, PHYS REV B, V53, P4023, DOI 10.1103/PhysRevB.53.4023; RUOFF RS, 1993, SCIENCE, V259, P346, DOI 10.1126/science.259.5093.346; SERAPHIN S, 1993, NATURE, V362, P503, DOI 10.1038/362503a0; Stephan O, 1996, PHYS REV B, V53, P13824, DOI 10.1103/PhysRevB.53.13824; TOMITA M, 1993, JPN J APPL PHYS 2, V32, pL280, DOI 10.1143/JJAP.32.L280; TSANG SC, 1994, NATURE, V372, P159, DOI 10.1038/372159a0; UGARTE D, 1993, CHEM PHYS LETT, V209, P99, DOI 10.1016/0009-2614(93)87208-K	29	498	522	6	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1897	1899		10.1126/science.274.5294.1897	http://dx.doi.org/10.1126/science.274.5294.1897			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943200				2022-12-28	WOS:A1996VY20000040
J	Fauci, AS				Fauci, AS			Host factors and the pathogenesis of HIV-induced disease	NATURE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TYPE-1 INFECTION; IMMUNE-RESPONSE; FACTOR-ALPHA; PERIPHERAL-BLOOD; HOMOSEXUAL MEN; CELL-LINE; IN-VIVO	The level of human immunodeficiency virus (HIV) replication in patients reflects a balance between stimulatory and inhibitory host factors (particularly endogenous cytokines). New information concerning the cellular co-receptors for HIV and the cellular tropism of different strains of virus will advance our understanding of HIV-induced pathogenesis and suggests new therapeutic and preventive strategies.			Fauci, AS (corresponding author), NIAID,NIH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ASCHER MS, 1995, ADV EXP MED BIOL, V374, P203; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Barker TD, 1996, J IMMUNOL, V156, P4476; Bates P, 1996, CELL, V86, P1, DOI 10.1016/S0092-8674(00)80070-7; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BROWN CC, 1994, J INFECT DIS, V169, P975, DOI 10.1093/infdis/169.5.975; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHENG-MAYER C, 1990, AIDS (London), V4, pS49; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COLEBUNDERS RL, 1991, AIDS, V5, pS103; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CORNELISSEN M, 1995, J VIROL, V69, P1810, DOI 10.1128/JVI.69.3.1810-1818.1995; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DENIS M, 1994, CLIN EXP IMMUNOL, V97, P76; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOLKS T, 1986, J IMMUNOL, V136, P4049; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FULTZ PN, 1993, CLIN INFECT DIS, V17, pS230, DOI 10.1093/clinids/17.Supplement_1.S230; Goletti D, 1996, J IMMUNOL, V157, P1271; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HENG MCY, 1994, LANCET, V343, P255, DOI 10.1016/S0140-6736(94)91110-X; Hill CM, 1996, NATURE, V382, P668, DOI 10.1038/382668a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; ISRAELBIET D, 1993, AM REV RESPIR DIS, V148, P1308, DOI 10.1164/ajrccm/148.5.1308; Kinter AL, 1996, P NATL ACAD SCI USA, V93, P14076, DOI 10.1073/pnas.93.24.14076; KINTER AL, 1995, J IMMUNOL, V154, P2448; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; Moore JP, 1996, J EXP MED, V184, P311, DOI 10.1084/jem.184.2.311; MORIUCHI H, IN PRESS P NATL ACAD; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NAGELKERKE NJD, 1990, AIDS, V4, P743, DOI 10.1097/00002030-199008000-00005; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBRIEN WA, 1995, BLOOD, V86, P1082; Oravecz T, 1996, J IMMUNOL, V157, P1329; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; Poli G, 1995, HUMAN CYTOKINES THEI, P421; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHIBATA R, 1995, J VIROL, V69, P4453, DOI 10.1128/JVI.69.7.4453-4462.1995; SPIJKERMAN IJB, 1995, AIDS, V9, P1085, DOI 10.1097/00002030-199509000-00016; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TERSMETTE M, 1989, LANCET, V1, P983; Thea DM, 1996, ANN INTERN MED, V124, P757, DOI 10.7326/0003-4819-124-8-199604150-00009; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VALENTIN A, 1994, J VIROL, V68, P6684, DOI 10.1128/JVI.68.10.6684-6689.1994; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; WACHTER H, 1986, LANCET, V2, P1216; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weiss RA, 1996, NATURE, V381, P647, DOI 10.1038/381647a0; WEISSMAN D, 1994, AIDS RES HUM RETROV, V10, P1199, DOI 10.1089/aid.1994.10.1199; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; WOLFS TFW, 1993, CHEM IMMUNOL, V56, P1; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	113	730	765	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					529	534		10.1038/384529a0	http://dx.doi.org/10.1038/384529a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955267	Green Published			2022-12-28	WOS:A1996VX76900048
J	Garcia, KC; Scott, CA; Brunmark, A; Carbone, FR; Peterson, PA; Wilson, IA; Teyton, L				Garcia, KC; Scott, CA; Brunmark, A; Carbone, FR; Peterson, PA; Wilson, IA; Teyton, L			CD8 enhances formation of stable T-cell receptor MHC class I molecule complexes	NATURE			English	Article							TOXIC LYMPHOCYTES-T; ANTIGEN RECEPTOR; PEPTIDE; AFFINITY; BINDING; KINETICS; ANTIBODY; PROTEIN; RECOGNITION; ASSOCIATION	T-CELL antigen receptors (TCR) generally interact with moderate affinity with the complex formed by major histocompatibility complex (MHC) molecules and foreign peptides(1-7), MHC/TCR recognition is followed by the generation of a signal to the T cell through a monomorphic multicomponent system that includes the CD3 complex and accessory molecules such as CD4 and CD8, The interaction between the extracellular domains of MHC and TCR molecules(1-7), and the interaction of MHC and CD4/CD8 molecules(8-10), have been considered to occur independently of one another. We report here that the affinity of CD8 dimers for MHC class I molecules is independent of haplotype and peptide content, and that the affinity of the TCR for its specific ligand is enhanced through a reduced 'off' rate in the presence of either CD8 alpha alpha homo- or CD8 alpha beta heterodimers. Moreover, CD8 seems to help recognition of the specific MHC-peptide complex either by guiding an energetically favourable docking of TCR onto MHC, or by inducing conformational changes in the MHC complex that can augment the TCR/MHC-peptide interaction. CD8 should therefore be considered as an active participant in the T-cell recognition complex, rather than simply as an accessory molecule.	RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA; SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; MONASH UNIV, ALFRED HOSP, MELBOURNE, VIC 3181, AUSTRALIA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; Scripps Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University			Carbone, Francis/ABF-2141-2020					AJITKUMAR P, 1989, CELL, V58, P911; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; HOO WS, 1993, J IMMUNOL, V150, P4331; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; Scott CA, 1996, J EXP MED, V183, P2087, DOI 10.1084/jem.183.5.2087; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; SYKULEV Y, 1994, P NATL ACAD SCI USA, V91, P11487, DOI 10.1073/pnas.91.24.11487; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UDAKA K, 1993, P NATL ACAD SCI USA, V90, P11271; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; Vignali DAA, 1996, J EXP MED, V183, P2097, DOI 10.1084/jem.183.5.2097; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	26	268	275	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					577	581		10.1038/384577a0	http://dx.doi.org/10.1038/384577a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955273				2022-12-28	WOS:A1996VX76900063
J	Bose, S; Weikl, T; Bugl, H; Buchner, J				Bose, S; Weikl, T; Bugl, H; Buchner, J			Chaperone function of Hsp90-associated proteins	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; HSP90; RECEPTOR	The Hsp90 heat shock protein of eukaryotic cells regulates the activity of proteins involved in signal transduction pathways and may direct intracellular protein folding in general. Hsp90 performs at least part of its function in a complex with a specific set of partner proteins that include members of the prolyl isomerase family. The properties of the major components of the Hsp90 complex were examined through the use of in vitro protein folding assays. Two of the components, FKBP52 and p23, functioned as mechanistically distinct molecular chaperones. These results suggest the existence of a super-chaperone complex in the cytosol of eukaryotic cells.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93040 REGENSBURG, GERMANY	University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BOSE S, 1994, BIOCHEM J, V300, P865, DOI 10.1042/bj3000865; BOSE S, UNPUB; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; EHRNSPERGER M, IN PRESS EMBO J; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEBEAU MC, 1993, STEROID HORMONE RECE, P261; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; SCHEIBEL T, UNPUB; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1995, SCI MED, V2, P38; SMITH DF, 1993, STEROID HORMONE RECE, P247; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0	28	311	324	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1715	1717		10.1126/science.274.5293.1715	http://dx.doi.org/10.1126/science.274.5293.1715			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939863				2022-12-28	WOS:A1996VW71200062
J	Kallunki, T; Deng, TL; Hibi, M; Karin, M				Kallunki, T; Deng, TL; Hibi, M; Karin, M			c-jun Can recruit JNK to phosphorylate dimerization partners via specific docking interactions	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED PROTEIN-KINASES; NEGATIVE REGULATOR; AP-1 ACTIVITY; HA-RAS; FOS; TYROSINE; BINDING; TRANSFORMATION; COMPLEXES	Structurally related serine/threonine kinases recognize similar phosphoacceptor peptides in vitro yet in vivo, they phosphorylate distinct substrates. To understand the basis for this specificity, we stud led the interaction between the Jun kinases (JNKs) and Jun proteins. JNKs phosphorylate c-Jun very efficiently, JunD less efficiently, but they do not phosphorylate JunB. Effective JNK substrates require a separate docking site and specificity-conferring residues flanking the phosphoacceptor. The docking site increases the efficiency and specificity of the phosphorylation reaction. JunB has a functional JNK docking site but lacks specificity-conferring residues. Insertion of such residues brings JunB under JNK control. JunD, by contrast, lacks a JNK docking site, but its phosphoacceptor peptide is identical to that of c-Jun. Substrates such as JunD can be phosphorylated by JNK through heterodimerization with docking competent partners. Therefore, heterodimerization can affect the recognition of transcription factors by signal-regulated protein kinases.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, SCH MED, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; UNIV FLORIDA, DEPT BIOCHEM & MOL BIOL, GAINESVILLE, FL 32610 USA	University of California System; University of California San Diego; State University System of Florida; University of Florida			Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444; Kallunki, Tuula/0000-0002-8571-383X	NCI NIH HHS [CA-50528] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	42	399	406	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					929	939		10.1016/S0092-8674(00)81999-6	http://dx.doi.org/10.1016/S0092-8674(00)81999-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945519	Bronze			2022-12-28	WOS:A1996VV77400018
J	Wiegers, TA; Keirse, MJNC; vanderZee, J; Berghs, GAH				Wiegers, TA; Keirse, MJNC; vanderZee, J; Berghs, GAH			Outcome of planned home and planned hospital births in low risk pregnancies: Prospective study in midwifery practices in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article							OPTIMALITY CONCEPT	Objective-To investigate the relation between the intended place of birth (home or hospital) and perinatal outcome in women with low risk pregnancies after controlling for parity and social, medical, and obstetric background. Design-Analysis of prospective data from midwives and their clients. Setting-54 midwifery practices in the province of Gelderland, Netherlands. Subjects-97 midwives and 1836 women with low risk pregnancies who had planned to give birth at home or in hospital. Main outcome measure-Perinatal outcome index based on ''maximal result with minimal intervention'' and incorporating 22 items on childbirth, 9 on the condition of the newborn, and 5 on the mother after the birth. Results-There was no relation between the planned place of birth and perinatal outcome in primiparous women when controlling for a favourable or less favourable background. In multiparous women, perinatal outcome was significantly better for planned home births than for planned hospital births, with or without control for background variables. Conclusions-The outcome of planned home births is at least as good as that of planned hospital births in women at low risk receiving midwifery care in the Netherlands.	FLINDERS UNIV S AUSTRALIA,DEPT OBSTET & GYNAECOL,FLINDERS MED CTR,ADELAIDE,SA 5001,AUSTRALIA	Flinders Medical Centre; Flinders University South Australia	Wiegers, TA (corresponding author), NETHERLANDS INST PRIMARY HLTH CARE,POB 1568,NL-3500 BN UTRECHT,NETHERLANDS.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				Carmines E. G., 1979, RELIABILITY VALIDITY, DOI DOI 10.4135/9781412985642; *CENTR BUR STAT, 1993, MAANDBER GEZONDHEID, V12, P19; CRANDON AJ, 1979, J PSYCHOSOM RES, V23, P109, DOI 10.1016/0022-3999(79)90014-X; DAMSTRAWIJMENGA SMI, 1984, J ROY COLL GEN PRACT, V34, P425; ENKIN M, 1995, GUIDE EFFECTIVE CARE, P389; KEIRSE MJN, 1982, EFFECTIVENESS SATISF, P222; KEIRSE MJNC, 1984, LANCET, V1, P1166; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; PRECHTL HFR, 1980, EARLY HUM DEV, V4, P201; TOUWEN BCL, 1980, EARLY HUM DEV, V4, P207, DOI 10.1016/0378-3782(80)90027-4; TREFFERS PE, 1990, JAMA-J AM MED ASSOC, V264, P2203, DOI 10.1001/jama.264.17.2203; van Teijlingen E, 1987, Midwifery, V3, P178, DOI 10.1016/S0266-6138(87)80038-4; Wiegers TA, 1996, J CLIN EPIDEMIOL, V49, P319, DOI 10.1016/0895-4356(95)00549-8; *ZIEK, 1987, VERL IND 1987 FIN RE	14	118	119	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1309	1313						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942693				2022-12-28	WOS:A1996VV15300027
J	Lipsky, JJ				Lipsky, JJ			Mycophenolate mofetil	LANCET			English	Article							IMP DEHYDROGENASE INHIBITORS; IN-VIVO; ACID; RS-61443; TRANSPLANTATION; EXPERIENCE; REJECTION		MAYO CLIN & MAYO FDN, DEPT PHARMACOL, CLIN PHARMACOL UNIT, ROCHESTER, MN 55905 USA	Mayo Clinic	Lipsky, JJ (corresponding author), MAYO CLIN & MAYO FDN, DEPT MED, CLIN PHARMACOL UNIT, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; Allison AC, 1996, CLIN TRANSPLANT, V10, P77; Bullingham R, 1996, J CLIN PHARMACOL, V36, P315, DOI 10.1002/j.1552-4604.1996.tb04207.x; Bullingham RES, 1996, TRANSPLANT P, V28, P925; CARR SF, 1993, J BIOL CHEM, V268, P27286; CATAPANO CV, 1995, MOL PHARMACOL, V47, P948; Danovitch G, 1996, TRANSPLANTATION, V61, P722; DEIERHOI MH, 1993, ANN SURG, V217, P476, DOI 10.1097/00000658-199305010-00007; EPINETTE WW, 1987, J AM ACAD DERMATOL, V17, P962, DOI 10.1016/S0190-9622(87)70285-0; FLOREY HW, 1946, LANCET, V250, P46; FRANKLIN TJ, 1994, ADV ENZYME REGUL, V34, P107, DOI 10.1016/0065-2571(94)90011-6; GOLDBLUM R, 1993, CLIN EXP RHEUMATOL, V11, pS117; GRAY DWR, 1995, LANCET, V346, P390, DOI 10.1016/S0140-6736(95)92775-1; GRINYO J, 1995, LANCET, V345, P1321; Keown P, 1996, TRANSPLANTATION, V61, P1029; KIRKLIN JK, 1994, J HEART LUNG TRANSPL, V13, P444; LANGMAN LJ, 1995, CLIN CHEM, V41, P295; Langman LJ, 1996, TRANSPLANTATION, V61, P87, DOI 10.1097/00007890-199601150-00018; MITCHELL BS, 1993, ANN NY ACAD SCI, V685, P217, DOI 10.1111/j.1749-6632.1993.tb35869.x; MORRIS RE, 1995, THER DRUG MONIT, V17, P564, DOI 10.1097/00007691-199512000-00003; MULKINS MA, 1992, CELL IMMUNOL, V141, P508, DOI 10.1016/0008-8749(92)90167-N; NAGY SE, 1993, IMMUNOPHARMACOLOGY, V26, P11, DOI 10.1016/0162-3109(93)90062-U; SHAW LM, 1995, THER DRUG MONIT, V17, P690, DOI 10.1097/00007691-199512000-00025; SHAW LM, 1995, THER DRUG MONIT, V17, P685, DOI 10.1097/00007691-199512000-00024; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SOLLINGER HW, 1992, TRANSPLANTATION, V53, P428, DOI 10.1097/00007890-199202010-00031; TAYLOR DO, 1994, J HEART LUNG TRANSPL, V13, P571; TRESSLER RJ, 1994, INT J CANCER, V57, P568, DOI 10.1002/ijc.2910570421	28	253	266	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1996	348	9038					1357	1359		10.1016/S0140-6736(96)10310-X	http://dx.doi.org/10.1016/S0140-6736(96)10310-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918281				2022-12-28	WOS:A1996VT33200014
J	Frisch, M; Hjalgrim, H; Olsen, JH; Melbye, M				Frisch, M; Hjalgrim, H; Olsen, JH; Melbye, M			Risk for subsequent cancer after diagnosis of basal-cell carcinoma - A population-based, epidemiologic study	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, basal-cell; melanoma; lymphoma, non-Hodgkin; testicular neoplasms; breast neoplasms	SALIVARY-GLAND CARCINOMA; NON-HODGKINS-LYMPHOMA; SKIN-CANCER; MALIGNANCIES	Background: Considerable debate is taking place over whether patients with basal-cell carcinoma and other skin neoplasms are at increased risk for internal cancer. Objective: To investigate risk for subsequent cancer in patients with basal-cell carcinoma. Design: Population-based cohort study. Setting: Denmark, from 1978 to 1991. Patients: 37 674 patients followed for a maximum of 14 years after a first diagnosis of basal-cell carcinoma. Measurements: The occurrence of subsequent cancer was compared with the expected cancer pattern (which was determined on the basis of national incidence data). Standardized incidence ratios (SIRs), ratios of actual to expected number of cases of cancer, yielded estimates of the relative risk. Results: During 190 945 patient-years of follow-up, 3663 new cases of cancer occurred where only 3245 were expected. As anticipated, malignant melanoma occurred frequently (SIR, 2.64 [95% CI, 2.21 to 3.13]), but patients were also at increased risk for noncutaneous cancer (SIR, 1.19 [CI, 1.13 to 1.24] for men and 1.09 [CI, 1.03 to 1.16] for women). The excess risk for noncutaneous cancer pertained to cancer of the lip (SIR, 2.07), salivary glands (SIR, 2.45), larynx (SIR, 1.41), lung (SIR, 1.40), breast (SIR, 1.13), and kidney (SIR, 1.30) and non-Hodgkin lymphoma (SIR, 1.36). Patients receiving a diagnosis of basal-cell carcinoma before 60 years of age (SIR, 1.26) had a statistically higher risk for developing new cancer (P < 0.01) than did those receiving the diagnosis at 60 years of age or older (SIR, 1.11). This applied to breast cancer (SIR, 1.37 in patients <60 years of age compared with 1.05 in those greater than or equal to 60 years of age), testicular cancer (SIR, 3.52 in patients <60 years of age compared with 0 seen and 1.96 expected in those greater than or equal to 60 years of age), and non-Hodgkin lymphoma (SIR, 2.50 in patients <60 years of age compared with 1.16 in those greater than or equal to 60 years of age). Conclusion: In addition to having an increased risk for new skin cancer, patients with basal-cell carcinoma have an increased risk for noncutaneous cancer at various sites. Increased risks for testicular cancer, breast cancer, and non-Hodgkin lymphoma should be kept in mind, particularly for patients in whom basal-cell carcinoma is diagnosed when they are at a young age.	DANISH CANC SOC, DIV CANC EPIDEMIOL, DK-2100 COPENHAGEN O, DENMARK	Danish Cancer Society	Frisch, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016; Hjalgrim, Henrik/AAG-4973-2021	Frisch, Morten/0000-0002-3864-8860; Olsen, Jorgen Helge/0000-0001-9633-5662; melbye, mads/0000-0001-8264-6785				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; BATSAKIS JG, 1981, CLIN OTOLARYNGOL, V6, P129, DOI 10.1111/j.1365-2273.1981.tb01799.x; Breslow N. E., 1987, STAT METHODS CANC RE, VII, P65; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CHUTE CG, 1991, JAMA-J AM MED ASSOC, V266, P816, DOI 10.1001/jama.266.6.816; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Hartge P, 1996, J NATL CANCER I, V88, P298, DOI 10.1093/jnci/88.5.298; Hunter David J., 1990, Annals of Epidemiology, V1, P13; KARAGAS MR, 1992, JAMA-J AM MED ASSOC, V267, P3305, DOI 10.1001/jama.267.24.3305; LINDELOF B, 1991, J AM ACAD DERMATOL, V25, P245, DOI 10.1016/0190-9622(91)70189-9; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; SANDSTROM A, 1984, ACTA RADIOL ONCOL, V23, P227, DOI 10.3109/02841868409136016; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SPITZ MR, 1985, ANN OTO RHINOL LARYN, V94, P129, DOI 10.1177/000348948509400206; SPITZ MR, 1984, CANCER, V54, P1854, DOI 10.1002/1097-0142(19841101)54:9<1854::AID-CNCR2820540915>3.0.CO;2-1; Storm H H, 1985, Natl Cancer Inst Monogr, V68, P411; STORM HH, 1994, CANC INCIDENCE DENMA; STORM HH, 1991, CANC REGISTRATION PR, P220; TEPPO L, 1985, J NATL CANCER I, V75, P207; World Health Organization, 1976, INT CLASS DIS	22	106	107	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					815	+		10.7326/0003-4819-125-10-199611150-00005	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928988				2022-12-28	WOS:A1996VU52400008
J	MAndelboim, O; Davis, DM; Reyburn, HT; ValesGomez, M; Sheu, EG; Pazmany, L; Strominger, JL				MAndelboim, O; Davis, DM; Reyburn, HT; ValesGomez, M; Sheu, EG; Pazmany, L; Strominger, JL			Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins	SCIENCE			English	Article							NATURAL-KILLER-CELLS; HLA-C MOLECULES; HISTOCOMPATIBILITY COMPLEX; ANTIGEN RECOGNITION; CLONES; P58; RESISTANCE; LYSIS; HETEROGENEITY; LYMPHOCYTES	An important feature of the human immune system is the ability of T cells to respond to small quantities of antigen. Class II major histocompatibility complex (MHC)-restricted T cells that expressed a costimulatory natural killer (NK) cell receptor for class I MHC proteins were cloned. In the presence of low doses of superantigen, the proliferative response of these T cell clones was three- to ninefold greater when the T cells were costimulated by way of the NK receptor. Thus, the action of costimulatory NK receptors on T cells may play a significant role in initiating and sustaining immune responses.			MAndelboim, O (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Reyburn, Hugh T/B-4338-2009; Valés-Gómez, Mar/F-5351-2012; Vales-Gomez, Mar/ABG-7808-2020; Sheu, Eric/U-2188-2019	Reyburn, Hugh T/0000-0003-2855-1595; Valés-Gómez, Mar/0000-0001-7424-3206; Vales-Gomez, Mar/0000-0001-7424-3206; Sheu, Eric/0000-0003-2707-1768; Mandelboim, Ofer/0000-0002-9354-1855; Davis, Daniel/0000-0002-9182-291X	NATIONAL CANCER INSTITUTE [R35CA047554] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DANDREA A, 1995, J IMMUNOL, V155, P2306; DANDREA A, 1996, J EXP MED, V194, P784; FALK CS, 1995, J EXP MED, V182, P1005, DOI 10.1084/jem.182.4.1005; FERRINI S, 1994, EUR J IMMUNOL, V24, P2294, DOI 10.1002/eji.1830241005; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; Mandelboim O, 1996, J EXP MED, V184, P913, DOI 10.1084/jem.184.3.913; MANDELBOIM O, UNPUB; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; NAKAJIMA H, 1995, J IMMUNOL, V155, P4139; Olcese L, 1996, J IMMUNOL, V156, P4531; Pazmany L, 1996, SCIENCE, V274, P792, DOI 10.1126/science.274.5288.792; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; REYBURN HT, UNPUB; SHIMIZU Y, 1989, J IMMUNOL, V142, P3320; SPITS H, 1995, BLOOD, V85, P10; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X	32	88	88	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2097	2100		10.1126/science.274.5295.2097	http://dx.doi.org/10.1126/science.274.5295.2097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953044				2022-12-28	WOS:A1996VY97400054
J	Jollis, JG; DeLong, ER; Peterson, ED; Muhlbaier, LH; Fortin, DF; Califf, RM; Mark, DB				Jollis, JG; DeLong, ER; Peterson, ED; Muhlbaier, LH; Fortin, DF; Califf, RM; Mark, DB			Outcome of acute myocardial, infarction according to the specialty of the admitting physician	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICARE BENEFICIARIES; CARE; MORTALITY; MORBIDITY; PATTERNS; SURVIVAL; TRIALS	Background In order to limit costs, health care organizations in the United States are shifting medical care from specialists to primary care physicians. Although primary care physicians provide less resource-intensive care, there is little information concerning the effects of this strategy on outcomes. Methods We examined mortality according to the specialty of the admitting physician among 8241 Medicare patients who were hospitalized for acute myocardial infarction in four states during a seven-month period in 1992. proportional-hazards regression models were used to examine survival up to one year after the myocardial infarction. To determine the generalizability of our findings, we also examined insurance claims and survival data for all 220,535 patients for whom there were Medicare claims for hospital care for acute myocardial infarction in 1992. Results After adjustment for characteristics of the patients and hospitals, patients who were admitted to the hospital by a cardiologist were 12 percent less likely to die within one year than those admitted by a primary care physician (P<0.001). Cardiologists also had the highest rate of use of cardiac procedures and medications, including medications (such as thrombolytic agents and beta-blockers) that are associated with improved survival. Conclusions Health care strategies that shift the care of elderly patients with myocardial infarction from cardiologists to primary care physicians lower rates of use of resources (and potentially lower costs), but they may also cause decreased survival. Additional information is needed to elucidate how primary care physicians and specialists should interact in the care of severely ill patients.	DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA	Duke University	Jollis, JG (corresponding author), DUKE UNIV, MED CTR, DEPT MED, BOX 3254, DURHAM, NC 27710 USA.		Peterson, Eric David/ABF-5033-2021	Mark, Daniel/0000-0001-6340-8087	AHRQ HHS [HS-08805, HS-06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM MED ASS, 1994, PHYS CURR PROC TERM; [Anonymous], 1987, LANCET, V2, P871; [Anonymous], 1988, LANCET, V2, P349; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V272, P276; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; COX DR, 1972, J R STAT SOC B, V34, P187; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P122; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; May D S, 1991, MMWR CDC Surveill Summ, V40, P7; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; *US BUR CENS, 1991, STAT METR AR DAT BOO; YUSUF, 1994, LANCET, V344, P1446; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	22	326	328	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1880	1887		10.1056/NEJM199612193352505	http://dx.doi.org/10.1056/NEJM199612193352505			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948564	Bronze			2022-12-28	WOS:A1996VX87400005
J	Hannun, YA				Hannun, YA			Functions of ceramide in coordinating cellular responses to stress	SCIENCE			English	Review							TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; SPHINGOLIPID BREAKDOWN PRODUCTS; FACTOR RECEPTOR PHOSPHORYLATION; EPIDERMOID CARCINOMA-CELLS; PHOSPHOLIPASE-D ACTIVITY; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; HL-60 CELLS	Sphingolipid metabolites. participate in key events of signal transduction and cell regulation. In the sphingomyelin cycle, a number of extracellular agents and insults (such as tumor necrosis factor, Fas ligands, and chemotherapeutic agents) cause the activation of sphingomyelinases, which act on membrane sphingomyelin and release ceramide. Multiple experimental approaches suggest an important role for ceramide in regulating such diverse responses as cell cycle arrest, apoptosis, and cell senescence. In vitro, ceramide activates a serine-threonine protein phosphatase, and in cells it regulates protein phosphorylation as well as multiple downstream targets [such as interleukin converting enzyme (ICE)-like proteases, stress-activated protein kinases, and the retinoblastoma gene product] that mediate its distinct cellular effects. This spectrum of inducers of ceramide accumulation and the nature of ceramide-mediated responses suggest that ceramide is a key component of intracellular stress response pathways.			Hannun, YA (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brady R. O., 1983, METABOLIC BASIS INHE, P831; Brugg B, 1996, J NEUROCHEM, V66, P733; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; CHEN M, 1995, CANCER RES, V55, P991; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DBAIBO GS, UNPUB; DeSimone C, 1996, IMMUNOL TODAY, V17, P48, DOI 10.1016/0167-5699(96)80570-6; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOBROWSKY RT, 1993, ADV LIPID RES, V25, P91; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HENSENS OD, 1995, J ORG CHEM, V60, P1772, DOI 10.1021/jo00111a040; Higuchi M, 1996, J IMMUNOL, V157, P297; ITO A, 1995, J NEUROCHEM, V65, P463; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 1995, BBA-MOL CELL RES, V1266, P1, DOI 10.1016/0167-4889(94)00219-5; JARVIS WD, 1994, CANCER RES, V54, P1707; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KIM MY, 1991, J BIOL CHEM, V266, P484; KISS Z, 1995, FEBS LETT, V365, P146, DOI 10.1016/0014-5793(95)00445-F; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LINARDIC CM, 1992, J BIOL CHEM, V267, P14909; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LISCOVITCH M, 1991, BIOCHEM PHARMACOL, V42, P2071, DOI 10.1016/0006-2952(91)90340-B; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; Nakamura Y, 1996, J IMMUNOL, V156, P256; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ODA T, 1995, J BIOL CHEM, V270, P4088, DOI 10.1074/jbc.270.8.4088; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P39, DOI 10.1016/0005-2760(95)00009-2; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; Saba JD, 1996, PHILOS T ROY SOC B, V351, P233, DOI 10.1098/rstb.1996.0021; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; STRUM JC, 1995, J BIOL CHEM, V270, P13541, DOI 10.1074/jbc.270.22.13541; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TOMITA M, 1991, J TOXICOL-TOXIN REV, V10, P169, DOI 10.3109/15569549109077272; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG E, 1991, J BIOL CHEM, V266, P14486; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; YANAGA F, 1994, BIOCHEM J, V298, P733, DOI 10.1042/bj2980733; YANG ZH, 1993, J BIOL CHEM, V268, P20520; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; ZWEERINK MM, 1992, J BIOL CHEM, V267, P25032	126	1456	1500	2	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1855	1859		10.1126/science.274.5294.1855	http://dx.doi.org/10.1126/science.274.5294.1855			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943189				2022-12-28	WOS:A1996VY20000029
J	Schendel, DE; Berg, CJ; YearginAllsopp, M; Boyle, CA; Decoufle, P				Schendel, DE; Berg, CJ; YearginAllsopp, M; Boyle, CA; Decoufle, P			Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIVENTRICULAR-INTRAVENTRICULAR HEMORRHAGE; GERMINAL MATRIX HEMORRHAGE; PRETERM INFANTS; POPULATION; PREDICTION; BRAIN; TRENDS; REDUCE; TRIAL	Objective.-To examine the relationship between prenatal magnesium sulfate exposure and the risk for cerebral palsy (CP) or mental retardation (MR) among very low-birth-weight (VLBW; <1500 g) children. Secondarily, to investigate the effect of prenatal magnesium sulfate exposure on VLBW infant mortality. Design.-Cohort study with follow-up to 1 year of age; a subset followed up to 3 to 5 years. Setting.-Twenty-nine Georgia counties, including the Ei-county Atlanta metropolitan area. Participants.-All VLBW births (N=1097) occurring during 2 years (1986-1988); all metropolitan Atlanta VLBW neonates who survived infancy (N=519). Main Outcome Measures.-lnfant mortality as determined from vital statistics records, Development of CP or MR by 3 to 5 years of age among metropolitan Atlanta VLBW survivors as determined from the Metropolitan Atlanta Developmental Disabilities Surveillance Program. Results.-For the entire cohort, there was no association between prenatal magnesium sulfate exposure and infant mortality (adjusted rate ratio, 1.02; 95% confidence interval [CI], 0.83-1.25). Among Atlanta-born survivors, those exposed to magnesium sulfate had a lower prevalence of GP or MR than those not exposed (CP: magnesium sulfate, 0.9%, no magnesium sulfate, 7.7%, crude odds ratio [OR], 0.11, 95% CI, 0.02-0.81; MR: magnesium sulfate, 1.8%, no magnesium sulfate, 5.8%, crude OR, 0.30, 95% CI, 0.07-1.29). Multivariable adjustment had no appreciable effect on the ORs for CP or MR, but the Cls included 1.0. Conclusions.-A reduced risk for CP, and possibly MR, among VLBW children is associated with prenatal magnesium sulfate exposure. The reduced risk for childhood CP or MR does not appear to be due to selective mortality of magnesium sulfate-exposed infants.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV BIRTH DEFECTS & DEV DISABIL,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,DIV REPROD HLTH,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								*AM COLL OBST GYN, 1986, TECHN B AM COLL OBST, V91; [Anonymous], 1992, Arch Dis Child, V67, P675; AZIZ K, 1995, PEDIATRICS, V95, P837; BERG CJ, 1994, PAEDIATR PERINAT EP, V8, P53, DOI 10.1111/j.1365-3016.1994.tb00435.x; BHUSHAN V, 1993, PEDIATRICS, V91, P1094; Blair E, 1996, PEDIATRICS, V97, P780; Boyle C A, 1996, MMWR CDC Surveill Summ, V45, P1; COOKE RWI, 1990, ARCH DIS CHILD, V65, P201, DOI 10.1136/adc.65.2.201; COSTELLO AMD, 1988, DEV MED CHILD NEUROL, V30, P711; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; ENSDOKKUM MH, 1994, ARCH DIS CHILD-FETAL, V70, pF96, DOI 10.1136/fn.70.2.F96; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; GRAZIANI LJ, 1986, PEDIATRICS, V78, P88; GROOME LJ, 1992, AM J OBSTET GYNECOL, V167, P873, DOI 10.1016/S0002-9378(12)80004-4; Hauth J. C., 1995, American Journal of Obstetrics and Gynecology, V172, P419; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; JOHNSON M A, 1987, Canadian Medical Association Journal, V136, P1157; JOHNSTON MM, 1990, AM J OBSTET GYNECOL, V163, P743, DOI 10.1016/0002-9378(90)91060-P; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KUBAN KCK, 1992, J CHILD NEUROL, V7, P70, DOI 10.1177/088307389200700113; LEVITON A, 1993, PEDIATRICS, V91, P1083; MARRET S, 1995, DEV MED CHILD NEUROL, V37, P473; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; MERVIS CA, 1995, PAEDIATR PERINAT EP, V9, P455, DOI 10.1111/j.1365-3016.1995.tb00168.x; MUTCH L, 1992, DEV MED CHILD NEUROL, V34, P547; NELSON KB, 1995, PEDIATRICS, V95, P263; O'Shea M, 1992, Paediatr Perinat Epidemiol, V6, P352, DOI 10.1111/j.1365-3016.1992.tb00775.x; PICKLES CJ, 1989, BRIT J OBSTET GYNAEC, V96, P38, DOI 10.1111/j.1471-0528.1989.tb01574.x; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; RANTAKALLIO P, 1985, DEV MED CHILD NEUROL, V27, P655; *SCOTT LOW BIRTHW, 1992, ARCH DIS CHILD, V67, P682; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; VANDEBOR M, 1987, J PERINAT MED, V15, P333, DOI 10.1515/jpme.1987.15.4.333; Volpe J., 1995, NEUROLOGY NEWBORN; WEISGLASKUPERUS N, 1993, PEDIATRICS, V92, P658; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2	36	193	194	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1805	1810		10.1001/jama.276.22.1805	http://dx.doi.org/10.1001/jama.276.22.1805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946900				2022-12-28	WOS:A1996VV99700029
J	Wolozin, B; Iwasaki, K; Vito, P; Ganjei, JK; Lacana, E; Sunderland, T; Zhao, BY; Kusiak, JW; Wasco, V; DAdamio, L				Wolozin, B; Iwasaki, K; Vito, P; Ganjei, JK; Lacana, E; Sunderland, T; Zhao, BY; Kusiak, JW; Wasco, V; DAdamio, L			Participation of Presenilin 2 in apoptosis: Enhanced basal activity conferred by an Alzheimer mutation	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; PROGRAMMED CELL-DEATH; MISSENSE MUTATIONS; ENDOTHELIAL-CELLS; DISEASE; GENE; ACTIVATION	Overexpression of the familial Alzheimer's disease gene Presenilin 2 (PS2) in nerve growth factor-differentiated PC12 cells increased apoptosis induced by trophic factor withdrawal or beta-amyloid. Transfection of antisense PS2 conferred protection against apoptosis induced by trophic withdrawal in nerve growth factor-differentiated or amyloid precursor protein-expressing PC12 cells, The apoptotic cell death induced by PS2 protein was sensitive to pertussis toxin, suggesting that heterotrimeric GTP-binding proteins are involved, A PS2 mutation associated with familial Alzheimer's disease was found to generate a molecule with enhanced basal apoptotic activity, This gain of function might accelerate the process of neurodegeneration that occurs in Alzheimer's disease, leading to the earlier age of onset characteristic a familial Alzheimer's disease.	NIMH,UNIT ALZHEIMER BIOL,CLIN SCI LAB,BETHESDA,MD 20892; NIAID,T CELL MOL BIOL UNIT,CELLULAR & MOL IMMUNOL LAB,BETHESDA,MD 20892; NIA,MOL NEUROBIOL UNIT,BALTIMORE,MD 21224; NINCDS,CELLULAR NEUROBIOL BRANCH,GERONTOL RES CTR,BALTIMORE,MD 21224; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP E,DEPT NEUROL,GENET & AGING UNIT,CHARLESTOWN,MA 02139; NIH,T CELL MOL BIOL UNIT,CELLULAR & MOL IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Harvard University; National Institutes of Health (NIH) - USA			vito, pasquale/ABF-5505-2020	D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441; vito, pasquale/0000-0002-5721-7716				BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CIALLELLA JR, 1994, J NEUROSCI RES, V37, P769, DOI 10.1002/jnr.490370611; Dewji NN, 1996, SCIENCE, V271, P159, DOI 10.1126/science.271.5246.159; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GESCHWIND M, 1995, J NEUROCHEM, V65, P292; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MESNER PW, 1995, J NEUROSCI, V15, P7357; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHAO B, 1995, J NEUROSCI RES, V40, P261, DOI 10.1002/jnr.490400215	28	398	412	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1710	1713		10.1126/science.274.5293.1710	http://dx.doi.org/10.1126/science.274.5293.1710			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939861				2022-12-28	WOS:A1996VW71200060
J	Chin, G; Senesac, LR; Blass, WE; Hillman, JJ				Chin, G; Senesac, LR; Blass, WE; Hillman, JJ			Stabilizing lead-salt diode lasers: Understanding and controlling chaotic frequency emission	SCIENCE			English	Article							MULTIMODE LASER; TIME-SERIES; SYSTEM	lead-salt tunable diode lasers (TDLs) are the only devices currently available that can generate tunable monochromatic radiation at arbitrary wavelengths between 3 and 30 micrometers and are particularly useful for high-resolution spectroscopy over a wide range of spectral regimes. Detailed observations oi TDLs show that the observed instrumental linewidth is actually a temporal average of many narrow (less than 0.5 megahertz) emission ''modes.'' The lime scale characteristic of these ''modes,'' which appear to be of relatively constant intensity, is of the order of a microsecond. The laser's behavior is highly suggestive of a chaotic process, that is, seemingly random excursions of a dynamic variable (frequency) within a bounded range. This report shows experimentally that TDL emissions are indeed chaotic. Furthermore, in a simple and robust fashion, this chaotic behavior has been successfully controlled with the use of recent techniques that take advantage of chaos to produce a narrow band laser output.	UNIV TENNESSEE,DEPT PHYS & ASTRON,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville	Chin, G (corresponding author), NASA,GODDARD SPACE FLIGHT CTR,EXTRATERR PHYS LAB,GREENBELT,MD 20771, USA.		Chin, Gordon/E-1520-2012; Blass, William/A-2792-2008					BROOMHEAD DS, 1986, PHYSICA D, V20, P217, DOI 10.1016/0167-2789(86)90031-X; CARR TW, 1995, PHYS REV E, V51, P5109, DOI 10.1103/PhysRevE.51.5109; CARR TW, IN PRESS PHYSICA D; DING MZ, 1993, PHYS REV LETT, V70, P3872, DOI 10.1103/PhysRevLett.70.3872; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; DRESSLER U, 1992, PHYS REV LETT, V68, P1, DOI 10.1103/PhysRevLett.68.1; ECKMANN JP, 1986, PHYS REV A, V34, P4971, DOI 10.1103/PhysRevA.34.4971; ECKMANN JP, 1985, REV MOD PHYS, V57, P617, DOI 10.1103/RevModPhys.57.617; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; GILLS Z, 1992, PHYS REV LETT, V69, P3169, DOI 10.1103/PhysRevLett.69.3169; HUNT ER, 1991, PHYS REV LETT, V67, P1953, DOI 10.1103/PhysRevLett.67.1953; JENNINGS DE, 1984, APPL OPTICS, V23, P1299, DOI 10.1364/AO.23.001299; JENNINGS DE, 1988, J QUANT SPECTROSC RA, V40, P221, DOI 10.1016/0022-4073(88)90116-1; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; PACKARD NH, 1980, PHYS REV LETT, V45, P712, DOI 10.1103/PhysRevLett.45.712; ROMEIRAS FJ, 1992, PHYSICA D, V58, P165, DOI 10.1016/0167-2789(92)90107-X; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; SINGER J, 1991, PHYS REV LETT, V66, P1123, DOI 10.1103/PhysRevLett.66.1123; TAKIZAWA T, 1994, IEEE J QUANTUM ELECT, V30, P334, DOI 10.1109/3.283778; WANG H, 1992, P IFAC NONL CONTR SY; 1993, P SPIE, V2038	21	8	8	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1498	1501		10.1126/science.274.5292.1498	http://dx.doi.org/10.1126/science.274.5292.1498			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929404				2022-12-28	WOS:A1996VV77500039
J	Groisman, EA; Ochman, H				Groisman, EA; Ochman, H			Pathogenicity islands: Bacterial evolution in quantum leaps	CELL			English	Review							NECROTIZING FACTOR TYPE-1; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; GENE; CHROMOSOME; DETERMINANTS; FIMBRIAE; INVASION		UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA	University of Rochester	Groisman, EA (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA.							BLUM G, 1995, FEMS MICROBIOL LETT, V126, P189, DOI 10.1016/0378-1097(95)00009-T; BLUM G, 1994, INFECT IMMUN, V62, P606, DOI 10.1128/IAI.62.2.606-614.1994; CHEETHAM BF, 1995, MOL MICROBIOL, V18, P201, DOI 10.1111/j.1365-2958.1995.mmi_18020201.x; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FETHERSTON JD, 1992, MOL MICROBIOL, V6, P2693, DOI 10.1111/j.1365-2958.1992.tb01446.x; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GOUIN E, 1994, INFECT IMMUN, V62, P3550, DOI 10.1128/IAI.62.8.3550-3553.1994; GROISMAN EA, 1993, P NATL ACAD SCI USA, V90, P1033, DOI 10.1073/pnas.90.3.1033; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; Groisman Eduardo A., 1994, Trends in Microbiology, V2, P444, DOI 10.1016/0966-842X(94)90802-8; HACKER J, 1990, MICROB PATHOGENESIS, V8, P213, DOI 10.1016/0882-4010(90)90048-U; INOUYE S, 1991, SCIENCE, V252, P969, DOI 10.1126/science.1709758; Lee CA, 1996, INFECT AGENT DIS, V5, P1; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; MILLS DM, 1995, MOL MICROBIOL, V15, P749, DOI 10.1111/j.1365-2958.1995.tb02382.x; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; ZAGAGLIA C, 1991, INFECT IMMUN, V59, P792, DOI 10.1128/IAI.59.3.792-799.1991	20	400	419	2	135	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					791	794		10.1016/S0092-8674(00)81985-6	http://dx.doi.org/10.1016/S0092-8674(00)81985-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945505	hybrid			2022-12-28	WOS:A1996VV77400004
J	Picaut, J; Ioualalen, M; Menkes, C; Delcroix, T; McPhaden, MJ				Picaut, J; Ioualalen, M; Menkes, C; Delcroix, T; McPhaden, MJ			Mechanism of the zonal displacements of the Pacific warm pool: Implications for ENSO	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; EQUATORIAL PACIFIC; EL-NINO; SOUTHERN OSCILLATION; OCEAN; DYNAMICS; MODEL; ANOMALIES; SALINITY; CLIMATE	The western equatorial Pacific warm pool is subject to strong east-west migrations on interannual time scales in phase with the Southern Oscillation Index. The dominance of surface zonal advection in this migration is demonstrated with four different current data sets and three ocean models. The eastward advection of warm and less saline water from the western Pacific together with the westward advection of cold and more saline water from the central-eastern Pacific induces a convergence of water masses at the eastern edge of the warm pool and a well-defined salinity front. The location of this convergence is zonally displaced in association with El Nino-La Nina wind-driven surface current variations. These advective processes and water-mass convergences have significant implications for understanding and simulating coupled ocean-atmosphere interactions associated with El Nino-Southern Oscillation (ENSO).	ORSTOM,CTR RECH OCEANOG,ABIDJAN,COTE IVOIRE; NOAA,PACIFIC MARINE ENVIRONM LAB,SEATTLE,WA 98115	Institut de Recherche pour le Developpement (IRD); National Oceanic Atmospheric Admin (NOAA) - USA	Picaut, J (corresponding author), ORSTOM,INST FRANCAIS RECH SCI DEV COOPERAT,GRP SURTROPAC,BP A5,NOUMEA 98848,NEW CALEDONIA.		menkes, christophe/H-9085-2016; McPhaden, Michael J/D-9799-2016; menkes, christophe/X-6073-2019; Delcroix, Thierry/I-6103-2016	menkes, christophe/0000-0002-1457-9696; McPhaden, Michael J/0000-0002-8423-5805; menkes, christophe/0000-0002-1457-9696; Delcroix, Thierry/0000-0002-8850-4865				BATTISTI DS, 1988, J ATMOS SCI, V45, P2889, DOI 10.1175/1520-0469(1988)045<2889:DATOAW>2.0.CO;2; Boulanger JP, 1996, J GEOPHYS RES-OCEANS, V101, P16361, DOI 10.1029/96JC01282; CANE MA, 1984, J PHYS OCEANOGR, V14, P1853, DOI 10.1175/1520-0485(1984)014<1853:ANMFLF>2.0.CO;2; CHEN D, 1995, P INT C TOGA PROG, P675; DELCROIX T, 1994, J GEOPHYS RES-OCEANS, V99, P25093, DOI 10.1029/94JC02138; DELCROIX T, 1991, J GEOPHYS RES-OCEANS, V96, P22135, DOI 10.1029/91JC02124; DELCROIX T, 1992, J GEOPHYS RES-OCEANS, V97, P5423, DOI 10.1029/92JC00127; DELECLUSE P, 1993, 9305 LODYC U PAR 6; DONGUY JR, 1994, PROG OCEANOGR, V34, P45, DOI 10.1016/0079-6611(94)90026-4; ESBENSEN SK, 1981, 21 OR STAT U; Frankignoul C, 1996, J GEOPHYS RES-OCEANS, V101, P3629, DOI 10.1029/95JC03439; FU CB, 1986, MON WEATHER REV, V114, P1716, DOI 10.1175/1520-0493(1986)114<1716:COTROS>2.0.CO;2; GILL AE, 1983, J PHYS OCEANOGR, V13, P586, DOI 10.1175/1520-0485(1983)013<0586:AEOSLA>2.0.CO;2; GRAHAM NE, 1995, J CLIMATE, V8, P544, DOI 10.1175/1520-0442(1995)008<0544:EAERPP>2.0.CO;2; KURODA Y, 1993, J GEOPHYS RES-OCEANS, V98, P4747, DOI 10.1029/92JC02684; LEMASSON L, 1968, CAH ORSTOM OCEANOGR, V6, P39; LINDZEN RS, 1987, J ATMOS SCI, V44, P2418, DOI 10.1175/1520-0469(1987)044<2418:OTROSS>2.0.CO;2; LUKAS R, 1991, J GEOPHYS RES-OCEANS, V96, P3343, DOI 10.1029/90JC01951; MAES C, 1996, THESIS U PARIS 6 PAR; MANGUM L, 1992, J GEOPHYS RES, V95, P7279; Mantua NJ, 1995, J CLIMATE, V8, P2897, DOI 10.1175/1520-0442(1995)008<2897:AVITZC>2.0.CO;2; McPhaden M. J., 1993, OCEANOGRAPHY, V6, P36; MCPHADEN MJ, 1990, SCIENCE, V250, P1385, DOI 10.1126/science.250.4986.1385; Menkes C, 1995, J GEOPHYS RES-OCEANS, V100, P25087, DOI 10.1029/95JC03026; Murtugudde R, 1996, J CLIMATE, V9, P1795, DOI 10.1175/1520-0442(1996)009<1795:SOTTOW>2.0.CO;2; PALMER TN, 1984, NATURE, V310, P483, DOI 10.1038/310483a0; PHILANDER SGH, 1980, J GEOPHYS RES-OCEANS, V85, P1123, DOI 10.1029/JC085iC02p01123; PICAUT J, 1995, J GEOPHYS RES-OCEANS, V100, P18393, DOI 10.1029/95JC01358; POULAIN PM, 1993, J PHYS OCEANOGR, V23, P601, DOI 10.1175/1520-0485(1993)023<0601:EOHDAV>2.0.CO;2; REYNOLDS RW, 1995, J CLIMATE, V8, P1571, DOI 10.1175/1520-0442(1995)008<1571:AHRGSS>2.0.CO;2; SCHOPF PS, 1990, J PHYS OCEANOGR, V20, P629, DOI 10.1175/1520-0485(1990)020<0629:OWDATT>2.0.CO;2; VIALARD J, UNPUB; *WORLD CLIM RES PR, 1990, WMO PUBL SER, V3; WYRTKI K, 1975, J PHYS OCEANOGR, V5, P572, DOI 10.1175/1520-0485(1975)005<0572:ENTDRO>2.0.CO;2	34	316	338	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1486	1489		10.1126/science.274.5292.1486	http://dx.doi.org/10.1126/science.274.5292.1486			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929400				2022-12-28	WOS:A1996VV77500035
J	Stumpf, G; Domdey, H				Stumpf, G; Domdey, H			Dependence of yeast pre-mRNA 3'-end processing on CFT1: A sequence homolog of the mammalian AAUAAA binding factor	SCIENCE			English	Article							POLYADENYLATION SPECIFICITY FACTOR; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; POLY(A) POLYMERASE; CLEAVAGE; GENE; SITE; SUBUNIT; PROTEIN; IDENTIFICATION	3'-End formation of pre-mRNA in yeast and mammals follows a similar but distinct pathway. In Saccharomyces cerevisiae, the cleavage reaction can be reconstituted by two activities called cleavage factor I and II (CFI and CFII). A CFII component, designated CFT1 (cleavage factor two) was identified by its sequence similarity to the AAUAAA-binding subunit of the mammalian cleavage and polyadenylation specificity factor (CPSF), even though the AAUAAA signal sequence appears to play no rote in yeast pre-mRNA 3' processing. Depletion of a yeast whole-cell extract with antibodies to CFT1 protein abolished cleavage and polyadenylation of pre-mRNAs, Addition of CFII restored cleavage activity, but not polyadenylation. Polyadenylation required the further addition of poly(A) polymerase and polyadenylation factor I, suggesting a close but not necessarily direct association of these two factors with the CFT1 protein.	UNIV MUNICH,GENZENTRUM,INST BIOCHEM,D-81377 MUNICH,GERMANY	University of Munich								BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; BUTLER JS, 1988, SCIENCE, V242, P1270, DOI 10.1126/science.2848317; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HEIDMANN S, 1994, MOL CELL BIOL, V14, P4633, DOI 10.1128/MCB.14.7.4633; HEIDMANN S, 1992, MOL CELL BIOL, V12, P4215, DOI 10.1128/MCB.12.9.4215; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KESSLER MM, 1995, BIOCHEMISTRY-US, V34, P1750, DOI 10.1021/bi00005a032; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MOREIRA A, 1995, EMBO J, V14, P3809, DOI 10.1002/j.1460-2075.1995.tb00050.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Stumpf G, 1996, MOL CELL BIOL, V16, P2204; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; ZHELKOVSKY AM, 1995, J BIOL CHEM, V270, P26715, DOI 10.1074/jbc.270.44.26715	29	42	43	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1517	1520		10.1126/science.274.5292.1517	http://dx.doi.org/10.1126/science.274.5292.1517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929410				2022-12-28	WOS:A1996VV77500045
J	Walker, PL				Walker, PL			Facing creationist challenges	LANCET			English	Editorial Material											Walker, PL (corresponding author), UNIV CALIF SANTA BARBARA,DEPT ANTHROPOL,SANTA BARBARA,CA 93106, USA.							Lord T, 1993, J COLL SCI TEACH, V22, P353; Newport F., 1993, GALLUP POLL MONTHLY, V336, P24; NUMBERS R, 1995, CHRISTIAN CENTURY, V112, P574; Schmidt K, 1996, SCIENCE, V273, P420, DOI 10.1126/science.273.5274.420	4	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1397	1398		10.1016/S0140-6736(05)67499-5	http://dx.doi.org/10.1016/S0140-6736(05)67499-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937277				2022-12-28	WOS:A1996VU98600007
J	Jia, ZC; DeLuca, CI; Chao, HM; Davies, PL				Jia, ZC; DeLuca, CI; Chao, HM; Davies, PL			Structural basis for the binding of a globular antifreeze protein to ice	NATURE			English	Article							ADSORPTION; MECHANISM; PROGRAM	ANTIFREEZE proteins (AFPs) have the unique ability to adsorb to ice and inhibit its growth(1). Many organisms ranging from fish to bacteria use AFPs to retard freezing or lessen the damage incurred upon freezing and thawing(2-6). The ice-binding mechanism of the long linear alpha-helical type I AFPs has been attributed to their regularly spaced polar residues matching the ice lattice along a pyramidal plane(7,8). In contrast, it is not known how globular antifreeze proteins such as type III AFP that lack repeating ice-binding residues bind to ice. Here we report the 1.25 Angstrom crystal structure of recombinant type III AFP (QAE isoform(9)) from eel pout (Macrozoarces americanus), which reveals a remarkably hat amphipathic ice-binding site where five hydrogen-bonding atoms match two ranks of oxygens on the {10 (1) over bar 0} ice prism plane in the [0001] direction, giving high ice binding affinity and specificity. This binding site, substantiated by the structures and properties of several ice-binding site mutants, suggests that the AFP occupies a niche in the ice surface in which it covers the basal plane while binding to the prism face.			Jia, ZC (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAO H, 1993, PROTEIN SCI, V2, P1411, DOI 10.1002/pro.5560020906; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; CHAO H, 1994, THESIS QUEENS U; Cheng C.C., 1991, P1; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; Duman J.G., 1991, P94; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; GRIFFITH M, 1992, PLANT PHYSIOL, V100, P593, DOI 10.1104/pp.100.2.593; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JIA ZC, 1995, PROTEIN SCI, V4, P1236, DOI 10.1002/pro.5560040621; KALLUNGAL JP, 1975, THESIS SYRACUSE U; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sheldrick G.M., 1986, SHELXS86 PROGRAM SOL; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; SUN XY, 1995, CAN J MICROBIOL, V41, P776, DOI 10.1139/m95-107; UMUTLA ME, 1992, BIOCHIM BIOPHYS ACTA, V1121, P199; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2	26	197	213	4	75	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					285	288		10.1038/384285a0	http://dx.doi.org/10.1038/384285a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918883				2022-12-28	WOS:A1996VU38100058
J	Fieschi, C; Toni, D; Pantano, P				Fieschi, C; Toni, D; Pantano, P			Are studies of early reperfusion after a stroke worthwhile?	LANCET			English	Editorial Material							ACUTE ISCHEMIC STROKE; EMISSION-COMPUTED-TOMOGRAPHY				Fieschi, C (corresponding author), UNIV ROMA LA SAPIENZA,DEPT NEUROL SCI,I-00185 ROME,ITALY.		Patrizia, Pantano/C-8214-2009; Toni, Danilo/K-3151-2016	Patrizia, Pantano/0000-0001-9659-8294; Toni, Danilo/0000-0003-2735-8427				BARID AE, 1996, J NEUROL NEUROSUR PS, V61, P26; GIUBILEI F, 1990, STROKE, V21, P895, DOI 10.1161/01.STR.21.6.895; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HANSON SK, 1993, STROKE, V24, P1322, DOI 10.1161/01.STR.24.9.1322; OVERGAARD K, 1993, STROKE, V24, P1439, DOI 10.1161/01.STR.24.10.1439; TONI D, 1995, ARCH NEUROL-CHICAGO, V52, P670, DOI 10.1001/archneur.1995.00540310040014; Toni D, 1996, NEUROLOGY, V46, P341, DOI 10.1212/WNL.46.2.341; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1327	1328		10.1016/S0140-6736(05)65405-0	http://dx.doi.org/10.1016/S0140-6736(05)65405-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918273				2022-12-28	WOS:A1996VT33200006
J	Sun, LS; Steinberg, SF				Sun, LS; Steinberg, SF			Examining vulnerability of broken young hearts to injury	LANCET			English	Editorial Material							ISCHEMIA		COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University	Sun, LS (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT ANESTHESIOL,NEW YORK,NY 10032, USA.							BAKER EJ, 1995, AM J PHYSIOL-HEART C, V268, pH1165, DOI 10.1152/ajpheart.1995.268.3.H1165; KIRKLIN JK, 1981, AM J CARDIOL, V48, P500, DOI 10.1016/0002-9149(81)90079-5; MATTFELDT T, 1987, J MOL CELL CARDIOL, V19, P1237, DOI 10.1016/S0022-2828(87)80533-3; MURASHITA T, 1992, J MOL CELL CARDIOL, V24, P1143, DOI 10.1016/0022-2828(92)93178-M; QUANTZ M, 1992, J THORAC CARDIOV SUR, V103, P927; SASSE S, 1993, CIRC RES, V72, P932, DOI 10.1161/01.RES.72.5.932; Taggart DP, 1996, HEART, V76, P214, DOI 10.1136/hrt.76.3.214	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1325	1326		10.1016/S0140-6736(05)65403-7	http://dx.doi.org/10.1016/S0140-6736(05)65403-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918271				2022-12-28	WOS:A1996VT33200004
J	Kobayashi, H; Nakagawa, T; Sekizawa, K; Arai, H; Sasaki, H				Kobayashi, H; Nakagawa, T; Sekizawa, K; Arai, H; Sasaki, H			Levodopa and swallowing reflex	LANCET			English	Letter									TOHOKU UNIV,SCH MED,DEPT GERIATR MED,SENDAI,MIYAGI 980,JAPAN	Tohoku University								Itoh M, 1994, Ann Nucl Med, V8, P245; PINTO A, 1994, LANCET, V344, P820, DOI 10.1016/S0140-6736(94)92377-9; WALLIN A, 1989, ACTA NEUROL SCAND, V79, P397, DOI 10.1111/j.1600-0404.1989.tb03807.x	3	50	51	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1320	1321		10.1016/S0140-6736(05)65809-6	http://dx.doi.org/10.1016/S0140-6736(05)65809-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909412				2022-12-28	WOS:A1996VR55500068
J	Shoffner, JM				Shoffner, JM			Maternal inheritance and the evaluation of oxidative phosphorylation diseases	LANCET			English	Review							MUSCLE MITOCHONDRIAL-DNA; POINT MUTATION; LACTIC-ACIDOSIS; MTDNA MUTATION; EPISODES MELAS; MYOCLONIC EPILEPSY; LEIGH-SYNDROME; RNALYS GENE; DELETIONS; MYOPATHY	Mitochondrial DNA is more susceptible than nuclear DNA to mutations. Mitochondrial mutations have been associated with a range of disorders, some of which can be inherited maternally as well as by mendelian patterns. The oxidative phosphorylation diseases are a group of such disorders characterised by a complex phenotype; the Kearns-Sayre syndrome, for example, can include cardiac abnormalities, diabetes mellitus, cerebellar ataxia, and deafness. An understanding of the genetic and biochemical basis of these disorders wilt help in the adoption of a systematic approach to their diagnosis and to patient management.	EMORY UNIV,SCH MED,DEPT NEUROL,ATLANTA,GA 30322	Emory University	Shoffner, JM (corresponding author), EMORY UNIV,SCH MED,DEPT GENET & MOL MED,1462 CLIFTON RD,SUITE 276,ATLANTA,GA 30322, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000039, M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033999] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR-00039, M01RR-00827] Funding Source: Medline; NINDS NIH HHS [NS33999] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HOLT IJ, 1990, AM J HUM GENET, V46, P428; KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016; LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081; OTABE S, 1994, J CLIN ENDOCR METAB, V79, P768, DOI 10.1210/jc.79.3.768; POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23; POULTON J, 1989, NUCLEIC ACIDS RES, V17, P10223, DOI 10.1093/nar/17.24.10223; SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612; SANTORELLI FM, 1994, NEUROLOGY, V44, P972, DOI 10.1212/WNL.44.5.972; SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055; SHOFFNER JM, 1992, NEUROLOGY, V42, P2168, DOI 10.1212/WNL.42.11.2168; SHOFFNER JM, 1995, KIDNEY INT, V47, P1101, DOI 10.1038/ki.1995.157; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, 1995, NEUROLOGY, V45, P286, DOI 10.1212/WNL.45.2.286; SHOFFNER JM, 1995, METABOLIC MOL BASES, P1535; SILVESTRI G, 1992, AM J HUM GENET, V51, P1213; STADHOUDERS A, 1990, J NEUROL SCI, V98, P304; SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Tatuch Yuriy, 1994, European Journal of Human Genetics, V2, P35; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1995, REPORT COMMITTEE HUM; Wallace DC, 1994, HUMAN GENE MAPPING 1, P813; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; Zeviani Massimo, 1993, European Journal of Human Genetics, V1, P80; ZHENG XX, 1990, BIOCHIM BIOPHYS ACTA, V1019, P1, DOI 10.1016/0005-2728(90)90118-N	35	61	61	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1283	1288		10.1016/S0140-6736(96)09138-6	http://dx.doi.org/10.1016/S0140-6736(96)09138-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909383				2022-12-28	WOS:A1996VR55500013
J	Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P				Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P			Twenty-year dynamics of serum cholesterol levels in the middle-aged population of eastern Finland	ANNALS OF INTERNAL MEDICINE			English	Article						cholesterol; Finland; middle age; dietary fats; cardiovascular diseases	CORONARY HEART-DISEASE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; NORTH KARELIA; LIPOPROTEINS; FRAMINGHAM; MORTALITY; PROJECT; ADULTS	Background: In cross-sectional analyses, serum cholesterol levels differ among different age groups. However, secular time trends in cholesterol levels can be seen across age groups in a population. A birth cohort analysis provides useful information on the combined effect of age and time on changes in serum cholesterol levels. Objective: To analyze the 20-year dynamics of serum total cholesterol levels in relation to age, sex, birth cohort, time period, mortality rate, and changes in the intake of saturated fats. Design: Cross-sectional measurements of serum total cholesterol levels in five independent population surveys done in 1972, 1977, 1982, 1987, and 1992. Setting: Kuopio and North Karelia provinces in eastern Finland. Patients: Random sample of 16 711 men and 17 542 women 25 to 64 years of age. Persons in the oldest birth cohort were born in 1913; persons in the youngest birth cohort were born in 1967. Measurements: Total serum cholesterol levels and daily intake of dietary fat. Results: Between 1972 and 1992, mean cholesterol levels decreased with time in each age group and for both sexes. According to the cross-sectional data, cholesterol levels increased with age and increased more steeply in women than in men. Contrary to these data, cholesterol levels in birth cohorts did not increase with age. Cholesterol levels did not change at all within birth cohorts of women and started to decrease after 45 years of age in birth cohorts of men. Cholesterol levels in the youngest birth cohorts (persons 25 to 29 years of age) entering the study each study year were markedly lower than levels in the same age group in the previous survey of risk factors. Daily intake of saturated fat decreased markedly between 1972 and 1992. Most of this decrease could be explained by change in intake of liquid dairy products and spreadable fats. In both sexes, changes in saturated fat intake were correlated with the time period, whereas the association with age was weak. Conclusions: In this Finnish population, total serum cholesterol levels are more closely associated with birth cohort than with age. Changes in dietary intake of saturated fat over time may account for changes in cholesterol levels. This finding suggests that community-based strategies for preventing cardiovascular disease can affect most of the population.			Jousilahti, P (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIIOL & HLTH PROMOT, MANNERHEIMINTIE 166, FIN-00300 HELSINKI, FINLAND.							[Anonymous], 1990, SAS STAT US GUID VER; [Anonymous], COMMUNITY CONTROL CA; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FULWOOD R, 1986, DHHS PUBLICATION; GUTZWILLER F, 1985, PREV MED, V14, P482, DOI 10.1016/0091-7435(85)90008-8; HJORTLAND MC, 1976, AM J EPIDEMIOL, V103, P304, DOI 10.1093/oxfordjournals.aje.a112228; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1970, CIRCULATION, V41, pI1; Kleemola P, 1994, 1992 DIETARY SURVEY; KOSKINEN EH, 1975, REPORT SOCIAL INSURA; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MENOTTI A, 1993, EUR J EPIDEMIOL, V9, P527, DOI 10.1007/BF00209531; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; NEWSCHAFFER CJ, 1992, AM J EPIDEMIOL, V136, P23, DOI 10.1093/oxfordjournals.aje.a116417; Nissinen A, 1988, Scand J Prim Health Care Suppl, V1, P49; OKAYAMA A, 1993, INT J EPIDEMIOL, V22, P1038, DOI 10.1093/ije/22.6.1038; Pietinen P, 1996, INT J OBESITY, V20, P114; PUSKA P, 1983, BRIT MED J, V287, P1840, DOI 10.1136/bmj.287.6408.1840; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROSSOUW JE, 1986, ATHEROSCLEROSIS, V7; STAMLER J, 1979, CIRCULATION, V60, P1575, DOI 10.1161/01.CIR.60.7.1575; Thelle Dag S., 1995, Current Opinion in Lipidology, V6, P25, DOI 10.1097/00041433-199502000-00006; Thom TJ, 1992, NIH PUBLICATION; UUSITALO U, 1990, FOOD NUTRIENT INTAKE; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; VIIKARI J, 1991, ANN MED, V23, P53, DOI 10.3109/07853899109147931; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1991, WORLD HLTH STAT Q, V44, P48	34	32	32	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					713	+		10.7326/0003-4819-125-9-199611010-00002	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929004				2022-12-28	WOS:A1996VQ07200002
J	Quill, TE; Brody, H				Quill, TE; Brody, H			Physician recommendations and patient autonomy: Finding a balance between physician power and patient choice	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							LIFE-SUSTAINING TREATMENT; MEDICAL-CARE; UNCERTAINTY; PATERNALISM; LIMITATIONS; FUTILITY; KIND	Medical care in the United States has rapidly moved away from a paternalistic approach to patients and toward an emphasis on patient autonomy. At one extreme end of this spectrum is the ''independent choice'' model of decision making, in which physicians objectively present patients with options and odds but withhold their own experience and recommendations to avoid overly influencing patients. This model confuses the concepts of independence and autonomy and assumes that the physician's exercise of power and influence inevitably diminishes the patient's ability to choose freely. It sacrifices competence for control, and it discourages active persuasion when differences of opinion exist between physician and patient. This paper proposes an ''enhanced autonomy'' model, which encourages patients and physicians to actively exchange ideas, explicitly negotiate differences, and share power and influence to serve the patient's best interests. Recommendations are offered that promote an intense collaboration between patient and physician so that patients can autonomously make choices that are informed by both the medical facts and the physician's experience.	MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, CLIN CTR B100, E LANSING, MI 48824 USA; UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY USA	Michigan State University; University of Rochester	Quill, TE (corresponding author), GENESEE HOSP, DEPT MED, 224 ALEXANDER ST, ROCHESTER, NY 14607 USA.		Brody, Howard/GQA-6310-2022					ANGELL M, 1991, NEW ENGL J MED, V325, P511, DOI 10.1056/NEJM199108153250712; BARSKY AJ, 1988, WORRIED SICK OUR TRO; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; BRODY H, 1994, J AM GERIATR SOC, V42, P875, DOI 10.1111/j.1532-5415.1994.tb06562.x; BRODY H, 1985, J ROY SOC MED, V78, P380, DOI 10.1177/014107688507800507; BRODY H, 1992, HEALERS POWER, P12; BRODY H, 1987, STORIES SICKNESS, P161; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Fisher R., 2011, GETTING YES NEGOTIAT; Fox Renee C., 1959, EXPERIMENT PERILOUS; GORDON GH, 1991, ARCH INTERN MED, V151, P567, DOI 10.1001/archinte.151.3.567; GREEN JA, 1988, ANN INTERN MED, V109, P234, DOI 10.7326/0003-4819-109-3-234; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; Illich I., 1976, MED NEMESIS; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KATZ J, 1984, HASTINGS CENT REP, V14, P35, DOI 10.2307/3560848; Kleinman A., 1988, ILLNESS NARRATIVES; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LAZARE A, 1975, ARCH GEN PSYCHIAT, V32, P553; LAZARE A, 1989, OUTPATIENT PSYCHIAT; LIGHT D, 1979, J HEALTH SOC BEHAV, V20, P310, DOI 10.2307/2955407; MARZUK PM, 1985, NEW ENGL J MED, V313, P1474, DOI 10.1056/NEJM198512053132310; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; PERRY CB, 1985, J AM GERIATR SOC, V33, P353, DOI 10.1111/j.1532-5415.1985.tb07136.x; *PEWF TASK FORC AD, 1994, HLTH PROF ED REL CTR; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; QUILL TE, 1993, HUM MED, V9, P109; Ryan R. M., 1993, NEBRASKA S MOTIVATIO, P1; Ryan R. M., 1995, DEV PSYCHOPATHOL, P618; RYAN RM, 1995, ADDICT BEHAV, V20, P279, DOI 10.1016/0306-4603(94)00072-7; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; SENGLE PM, 1990, 5 DISCIPLINE ART PRA, P238; SIEGLER M, 1982, ARCH INTERN MED, V142, P1899, DOI 10.1001/archinte.142.10.1899; SMITH RC, 1991, ANN INTERN MED, V115, P470, DOI 10.7326/0003-4819-115-6-470; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; TRUOG RD, 1992, NEW ENGL J MED, V326, P1560, DOI 10.1056/NEJM199206043262310; United States President's Commission for the Study of Ethical Problems in Medicine Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; Williams GC, 1996, J PERS SOC PSYCHOL, V70, P115, DOI 10.1037/0022-3514.70.1.115	46	451	455	0	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					763	769		10.7326/0003-4819-125-9-199611010-00010	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ072	8929011	Green Published			2022-12-28	WOS:A1996VQ07200009
J	Zeiher, AM				Zeiher, AM			Endothelial vasodilator dysfunction: Pathogenetic link to myocardial ischaemia or epiphenomenon	LANCET			English	Article							NITRIC-OXIDE; DEPENDENT VASODILATION; ANGINA-PECTORIS; CORONARY; ATHEROSCLEROSIS; CELLS; HYPERCHOLESTEROLEMIA; VASOREACTIVITY; MECHANISMS; DISEASE											ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; BASSENGE E, 1988, PROG CARDIOVASC DIS, V30, P349, DOI 10.1016/0033-0620(88)90003-5; BENZULY KH, 1994, CIRCULATION, V89, P1810, DOI 10.1161/01.CIR.89.4.1810; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; EGASHIRA K, 1993, NEW ENGL J MED, V328, P1659, DOI 10.1056/NEJM199306103282302; EPSTEIN SE, 1981, AM J CARDIOL, V48, P797, DOI 10.1016/0002-9149(81)90160-0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; LEVINE GN, 1995, NEW ENGL J MED, V332, P512, DOI 10.1056/NEJM199502233320807; MEREDITH IT, 1993, CIRCULATION, V87, P56; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; QUYYUMI AA, 1995, CIRCULATION, V92, P320, DOI 10.1161/01.CIR.92.3.320; SCHACHINGER V, 1995, CIRCULATION, V92, P2087, DOI 10.1161/01.CIR.92.8.2087; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634; ZEIHER AM, 1995, CIRCULATION, V91, P941, DOI 10.1161/01.CIR.91.4.941; ZEIHER AM, 1995, CIRCULATION, V91, P2345, DOI 10.1161/01.CIR.91.9.2345; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980	19	72	73	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV	1996	348			1			S10	S12		10.1016/S0140-6736(96)98004-6	http://dx.doi.org/10.1016/S0140-6736(96)98004-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918521	Bronze			2022-12-28	WOS:A1996VU00800005
J	Bentley, DR				Bentley, DR			Genomic sequence information should be released immediately and freely in the public domain	SCIENCE			English	Editorial Material											Bentley, DR (corresponding author), SANGER CTR,WELLCOME TRUST GENOME CAMPUS,HINXTON HALL,CAMBRIDGE CB10 1SA,ENGLAND.							*BAT CTR HUM GEN R, 1996, POL AV PAT HUM GEN D; *BIOIND ASS, 1995, PENT HUM GEN; Marshall E, 1996, SCIENCE, V272, P188, DOI 10.1126/science.272.5259.188; MARSHALL E, 1995, SCIENCE, V267, P783, DOI 10.1126/science.7846520; *NAT SCI COUNC, 1988, MAPP SEQ HUM GEN; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; *WELLC TRUST, 1996, 1 INT STRAT M HUM GE; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; 1996, HUMAN GENOME NEWS, V7	9	42	47	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					533	534		10.1126/science.274.5287.533	http://dx.doi.org/10.1126/science.274.5287.533			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928006				2022-12-28	WOS:A1996VN91900034
J	Smith, V; Chou, KN; Lashkari, D; Botstein, D; Brown, PO				Smith, V; Chou, KN; Lashkari, D; Botstein, D; Brown, PO			Functional analysis of the genes of yeast chromosome V by genetic footprinting	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SECRETORY PATHWAY; PROTEIN; ENCODES; MUTANTS; EXPRESSION; SYNTHETASE; SUBFAMILY; COMPLEX	Genetic footprinting was used to assess the phenotypic effects of Ty1 transposon insertions in 268 predicted genes of chromosome V of Saccharomyces cerevisiae. When seven selection protocols were used, Ty1 insertions in more than half the genes tested (157 of 268) were found to result in a detectable reduction in fitness. Results could not be obtained for fewer than 3 percent of the genes tested (7 of 268). Previously known mutant phenotypes were confirmed, and, for about 30 percent of the genes, new mutant phenotypes were identified.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000205] Funding Source: NIH RePORTER; NHGRI NIH HHS [1PO1 HG00205-05] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BOONCHIRD C, 1991, MOL GEN GENET, V226, P154, DOI 10.1007/BF00273599; BRANDRISS MC, 1979, J BACTERIOL, V138, P816, DOI 10.1128/JB.138.3.816-822.1979; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; DIETRICH F, IN PRESS NATURE; ELLEDGE J, 1990, GENE DEV, V4, P4740; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HARRINGTON A, 1993, MOL MICROBIOL, V9, P545; IRIE K, 1994, MOL CELL BIOL, V14, P3150, DOI 10.1128/MCB.14.5.3150; KIM YJ, 1994, J CELL BIOL, V127, P1381, DOI 10.1083/jcb.127.5.1381; MASSELOT M, 1975, MOL GEN GENET, V139, P121, DOI 10.1007/BF00264692; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2767, DOI 10.1128/MCB.4.12.2767; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2758, DOI 10.1128/MCB.4.12.2758; MOEHLE CM, 1987, GENETICS, V115, P255; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NASS G, 1976, MOL GEN GENET, V147, P39, DOI 10.1007/BF00337933; OHMEN JD, 1988, NUCLEIC ACIDS RES, V16, P10783, DOI 10.1093/nar/16.22.10783; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PRAKASH S, 1977, GENETICS, V87, P229; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568	31	194	215	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2069	2074		10.1126/science.274.5295.2069	http://dx.doi.org/10.1126/science.274.5295.2069			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953036				2022-12-28	WOS:A1996VY97400046
J	Sirrenberg, C; Bauer, MF; Guiard, B; Neupert, W; Brunner, M				Sirrenberg, C; Bauer, MF; Guiard, B; Neupert, W; Brunner, M			Import of carrier proteins into the mitochondrial Inner membrane mediated by Tim22	NATURE			English	Article							ADP-ATP CARRIER; TRANSLOCATION; COMPLEX; HSP70; BIOGENESIS; ENCODES; SYSTEM; MATRIX	TRANSLOCATION of mitochondrial preproteins across the inner membrane is facilitated by the TIM machinery(1-8). Tim34 binds to matrix targeting signals and initiates membrane potential-dependent import(8). Tim23 and Tim17 are constituents of a translocation channel across the inner membrane(6). Tim44 is associated with this channel at the matrix side(6), and Tim44 recruits mitochondrial Hsp70 and its co-chaperone Mge1, which drive protein translocation into the matrix using ATP as an energy source(9-14). Tim22 is a new component of the import machinery of mitochondria, which shares sequence similarity with both Tim23 and Tim17. Here we report that Tim22 is required for the import of proteins of the mitochondrial ADP/ATP carrier (AAC) family into the inner membrane. Members of the yeast AAC family are synthesized without matrix targeting signals(15,16). Tim22 is in an assembly of high relative molecular mass that is distinct from the Tim23-Tim17 complex(6). Import of proteins of the AAC family is independent of Tim23, and import of matrix targeting signals containing preproteins is independent of Tim22.	UNIV MUNICH,INST PHYSIOL CHEM,D-80336 MUNICH,GERMANY; UNIV PARIS 06,CNRS,CTR MOL GENET,F-91190 GIF SUR YVETTE,FRANCE	University of Munich; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay				Brunner, Michael/0000-0001-9798-3047				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1996, EUR J BIOCHEM, V232, P309; DAYHOFF MO, ATLAS PROTEIN SEQUEN, V5, P342; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; EMTAGE JLT, 1993, J CELL BIOL, V122, P1003, DOI 10.1083/jcb.122.5.1003; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KLINGENBERG M, 1978, BIOCHIM BIOPHYS ACTA, V503, P193, DOI 10.1016/0005-2728(78)90182-2; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; ZARA V, 1991, EUR J BIOCHEM, V198, P405, DOI 10.1111/j.1432-1033.1991.tb16029.x; ZIMMERMAN R, 1979, EUR J BIOCHEM, V99, P247, DOI 10.1111/j.1432-1033.1979.tb13251.x	26	257	261	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					582	585		10.1038/384582a0	http://dx.doi.org/10.1038/384582a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955274				2022-12-28	WOS:A1996VX76900064
J	Trivier, E; DeCesare, D; Jacquot, S; Pannetier, S; Zackai, E; Young, I; Mandel, JL; SassoneCorsi, P; Hanauer, A				Trivier, E; DeCesare, D; Jacquot, S; Pannetier, S; Zackai, E; Young, I; Mandel, JL; SassoneCorsi, P; Hanauer, A			Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome	NATURE			English	Article							RIBOSOMAL S6 KINASE; PROTEIN-KINASES; C-FOS; EXPRESSION; SEQUENCE; DOMAINS; GENE; LOCALIZATION; CLONING; FAMILY	THE Coffin-Lowry syndrome (CLS), an X-linked disorder, is characterized by severe psychomotor retardation, facial and digital dysmorphisms, and progressive skeletal deformations(1). Genetic linkage analysis mapped the CLS locus to an interval of 2-3 megabases at Xp22.2. The gene coding for Rsk-2, a member of the growth-factor-regulated protein kinases, maps within the candidate interval, and was tested as a candidate gene for CLS. Initial screening for mutations in the gene for Rsk-2 in 76 unrelated CLS patients revealed one intragenic deletion, a nonsense, two splice site, and two missense mutations. The two missenses affect sites critical for the function of Rsk-2. The mutated Rsk-2 proteins were found to be inactive in a S6 kinase assay. These findings provide direct evidence that abnormalities in the MAPK/RSK signalling pathway cause Coffin-Lowry syndrome.	ULP,CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,CLIN GENET CTR,PHILADELPHIA,PA 19104; CITY HOSP NOTTINGHAM,CTR MED GENET,NOTTINGHAM NG5 1PB,ENGLAND	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Nottingham University Hospital NHS Trust; Nottingham City Hospital								ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BIANCALANA V, 1994, GENOMICS, V22, P617, DOI 10.1006/geno.1994.1435; BIRD H, 1995, AM J MED GENET, V59, P512, DOI 10.1002/ajmg.1320590420; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHONCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HANAUER A, 1988, AM J MED GENET, V30, P523, DOI 10.1002/ajmg.1320300154; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Trump D, 1996, HUM GENET, V97, P60; WASSARMAN DA, 1994, GENE, V144, P309, DOI 10.1016/0378-1119(94)90396-4; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	22	320	328	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					567	570		10.1038/384567a0	http://dx.doi.org/10.1038/384567a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955270				2022-12-28	WOS:A1996VX76900060
J	Modan, B; Gak, E; SadeBruchim, RB; HirshYechezkel, G; Theodor, L; Lubin, F; BenBaruch, G; Beller, U; Fishman, A; Dgani, R; Menczer, J; Papa, M; Friedman, E				Modan, B; Gak, E; SadeBruchim, RB; HirshYechezkel, G; Theodor, L; Lubin, F; BenBaruch, G; Beller, U; Fishman, A; Dgani, R; Menczer, J; Papa, M; Friedman, E			High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST; FAMILIES; GENE	Objective.-To determine the role of BRCA1 185delAG mutation in ovarian carcinogenesis. Design.-Genetic testing of a subset of cases from an ongoing study of ovarian cancer and of controls. Setting.-A community-based case-control incidence study. Subjects.-Seventy-nine patients with ovarian cancer, 62 hospitalized women without cancer (controls), and 120 healthy women participating in a fragile X screening program (also controls), examined for the presence of germline BRCA1 185delAG mutation. Main Outcome Measures.-Polymerase chain reaction-amplified BRCA1 exon 2 fragments generated from patients' and controls' blood samples, analyzed by heteroduplex gel shift assay and direct sequence analyses. Results.-The 185delAG mutation was detected in 38.9% (7/18) of ovarian cancer patients with familial history, and 13.1% (8/61) of family history-negative ovarian cancer cases. Only 1 carrier was detected among the 120 healthy controls, and none in the hospital controls. A significant difference in mutation carrier rates between family history-negative cases and control groups of 120 and 62 subjects was identified (Fisher exact test, P=.001 and P=.003, respectively). The median age (+/-SE) at disease diagnosis was tower among both familial and family history-negative mutation carriers, as compared with mutation-negative, family history-negative cases-50 (+/-1.4) vs 60.5 (+/-3.5) years old, respectively (hazard ratio, 1.68; 95% confidence interval, 0.94-3.01). Conclusions.-Our data are preliminary but suggest that BRCA1 185delAG germline mutation is frequent in Israeli ovarian cancer patients, irrespective of family history, and may confer an early-onset phenotype of ovarian cancer.	CHAIM SHEBA MED CTR,ONCOGENET UNIT,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,DEPT SURG,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,GYNECOL ONCOL UNIT,IL-52621 TEL HASHOMER,ISRAEL; TEL AVIV UNIV,STANLEY STEYER INST CANC EPIDEMIOL & RES,IL-69978 TEL AVIV,ISRAEL; SHAARE ZEDEK MED CTR,JERUSALEM,ISRAEL; KAPLAN MED CTR,KEFAR SAVA,ISRAEL; EDITH WOLFSON MED CTR,HOLON,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center	Modan, B (corresponding author), CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,IL-52621 TEL HASHOMER,ISRAEL.				NCI NIH HHS [CA 61126-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Muto MG, 1996, CANCER RES, V56, P1250; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; STRUEWING JP, 1993, AM J HUM GENET, V67, P1; SYVANEN AC, 1989, FEBS LETT, V258, P71, DOI 10.1016/0014-5793(89)81618-7; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TONIN P, 1995, AM J HUM GENET, V57, P189	14	57	57	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1823	1825		10.1001/jama.276.22.1823	http://dx.doi.org/10.1001/jama.276.22.1823			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946903				2022-12-28	WOS:A1996VV99700032
J	Chuang, PT; Lieb, JD; Meyer, BJ				Chuang, PT; Lieb, JD; Meyer, BJ			Sex-specific assembly of a dosage compensation complex on the nematode X chromosome	SCIENCE			English	Article							UBIQUITOUS PROTEIN FAMILY; CAENORHABDITIS-ELEGANS; C-ELEGANS; SMC FAMILY; GENE; CONDENSATION; SEGREGATION; EXPRESSION; DEFINES; DPY-30	In nematodes, flies, and mammals, dosage compensation equalizes X-chromosome gene expression between the sexes through chromosome-wide regulatory mechanisms that function in one sex to adjust the levels of X-linked transcripts. Here, a dosage compensation complex was identified in the nematode Caenorhabditis elegans that reduces transcript levels from the two X chromosomes in hermaphrodites, This complex contains at least four proteins, including products of the dosage compensation genes dpy-26 and dpy-27. Specific localization of the complex to the hermaphrodite X chromosomes is conferred by XX-specific regulatory genes that coordinately control both sex determination and dosage compensation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Lieb, Jason/0000-0001-7601-8061; Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [T32 GM07127, GM30702, R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007127, R37GM030702, R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CHUANG PT, UNPUB; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAWES HM, UNPUB; DELONG L, 1993, GENETICS, V133, P875; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; HSU DR, 1995, DEVELOPMENT, V121, P3323; HSU DR, 1994, GENETICS, V137, P999; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; VILLENEUVE AM, 1990, GENETICS, V124, P91	27	81	94	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1736	1739		10.1126/science.274.5293.1736	http://dx.doi.org/10.1126/science.274.5293.1736			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939870				2022-12-28	WOS:A1996VW71200069
J	Makovsky, Y; Klemperer, SL; Ratschbacher, L; Brown, LD; Li, M; Zhao, WJ; Meng, FL				Makovsky, Y; Klemperer, SL; Ratschbacher, L; Brown, LD; Li, M; Zhao, WJ; Meng, FL			INDEPTH wide-angle reflection observation of P-wave-to-S-wave conversion from crustal bright spots in Tibet	SCIENCE			English	Article								Three-component wide-angle seismic data acquired in southern Tibet during Project INDEPTH show strong P-to-S converted reflections from reflectors that area aligned at a depth of similar to 15 kilometers beneath the northern Yadong-Gulu rift, These converted reflections are locally higher in amplitude than the corresponding P-wave reflections; Modeling of reflection mode conversion as-a function of incidence angle indicates that this condition obtains for a reflector that is a solid over fluid interface; it is not typical of a solid-solid interface, The likely candidates for a fluid trapped within the crystalline crust of southern Tibet are granitic magma and water (brine).	CORNELL UNIV,DEPT GEOL SCI,ITHACA,NY 14853; CHINESE ACAD GEOL SCI,BEIJING 100037,PEOPLES R CHINA	Cornell University; Chinese Academy of Geological Sciences	Makovsky, Y (corresponding author), STANFORD UNIV,DEPT GEOPHYS,STANFORD,CA 94305, USA.		Makovsky, Yizhaq/ABH-7281-2020; Klemperer, Simon L/A-5919-2012; Makovsky, Yizhaq/L-1168-2017	Makovsky, Yizhaq/0000-0001-6762-9549; Makovsky, Yizhaq/0000-0001-6762-9549; Klemperer, Simon/0000-0001-7050-1829; Ratschbacher, Lothar/0000-0001-9960-2084				Brown LD, 1996, SCIENCE, V274, P1688, DOI 10.1126/science.274.5293.1688; FRANCHETEAU J, 1984, NATURE, V307, P32, DOI 10.1038/307032a0; GOUGH DI, 1986, NATURE, V323, P143, DOI 10.1038/323143a0; JARCHOW CM, 1993, J GEOPHYS RES-SOL EA, V98, P22095, DOI 10.1029/93JB02021; JONES AG, 1987, GEOPHYS J INT, V89, P7, DOI 10.1111/j.1365-246X.1987.tb04380.x; MAKOVSKY Y, 1996, 11 HIM KAR TIB WORKS, P91; MAVKO GM, 1980, J GEOPHYS RES, V85, P5173, DOI 10.1029/JB085iB10p05173; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; OCONNELL RJ, 1974, J GEOPHYS RES, V79, P5412, DOI 10.1029/JB079i035p05412; Sanford A. R., 1977, EARTHS CRUST ITS NAT, P385; SHERIFF RE, 1982, EXPLORATION SEISMOLO, P73; WANG JY, 1981, J VOLCANOL GEOTH RES, V9, P57; WYLLIE PJ, 1977, TECTONOPHYSICS, V43, P41, DOI 10.1016/0040-1951(77)90005-1	13	101	117	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1690	1691		10.1126/science.274.5293.1690	http://dx.doi.org/10.1126/science.274.5293.1690			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939853				2022-12-28	WOS:A1996VW71200052
J	Liang, R; Yan, L; Loebach, J; Ge, M; Uozumi, Y; Sekanina, K; Horan, N; Gildersleeve, J; Thompson, C; Smith, A; Biswas, K; Still, WC; Kahne, D				Liang, R; Yan, L; Loebach, J; Ge, M; Uozumi, Y; Sekanina, K; Horan, N; Gildersleeve, J; Thompson, C; Smith, A; Biswas, K; Still, WC; Kahne, D			Parallel synthesis and screening of a solid phase carbohydrate library	SCIENCE			English	Article							SUPPORTED SOLUTION SYNTHESIS; INFLUENZA-VIRUS; CHEMICAL LIBRARIES; DRUG DISCOVERY; GENERAL-METHOD; OLIGOSACCHARIDES; GLYCOSYLATION; AGGLUTINATION; ERYTHROCYTES; RECOGNITION	A solid phase carbohydrate library was synthesized and screened against Bauhinia purpurea lectin. The library, which contains approximately 1300 di- and trisaccharides, was synthesized with chemical encoding on TentaGel resin so that each bead contained a single carbohydrate. Two ligands that bind more tightly to the lectin than Gal-beta-1,3-GalNAc (the known ligand) have been identified. The strategy outlined can be used to identify carbohydrate-based ligands for any receptor; however, because the derivatized beads mimic the polyvalent presentation of cell surface carbohydrates, the screen may prove especially valuable for discovering new compounds that bind to proteins participating in cell adhesion.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Princeton University; Columbia University			Gildersleeve, Jeffrey/N-3392-2014; Uozumi, Yasuhiro/A-7841-2016	Gildersleeve, Jeffrey/0000-0002-3744-6423; Uozumi, Yasuhiro/0000-0001-6805-3422				BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; DANISHEFSKY SJ, 1993, SCIENCE, V260, P1307, DOI 10.1126/science.8493573; DOUGLAS SP, 1995, J AM CHEM SOC, V117, P2116, DOI 10.1021/ja00112a035; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Frechet J. M., 1980, POLYM SUPPORTED REAC, P407; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GLICK GD, 1991, J AM CHEM SOC, V113, P4701, DOI 10.1021/ja00012a060; GORDON EM, 1994, J MED CHEM, V37, P1385, DOI 10.1021/jm00036a001; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; Hunt JA, 1996, J AM CHEM SOC, V118, P9998, DOI 10.1021/ja962128f; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P10779, DOI 10.1073/pnas.91.23.10779; Kanie O, 1995, ANGEW CHEM INT EDIT, V34, P2720; Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X; KINGERYWOOD JE, 1992, J AM CHEM SOC, V114, P7303, DOI 10.1021/ja00044a057; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; Mortell KH, 1996, J AM CHEM SOC, V118, P2297, DOI 10.1021/ja953574q; NESTLER HP, 1994, J ORG CHEM, V59, P4723, DOI 10.1021/jo00096a008; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Osawa T, 1978, Methods Enzymol, V50, P367; Rademann J, 1996, TETRAHEDRON LETT, V37, P3989, DOI 10.1016/0040-4039(96)00763-0; ROY R, 1995, TETRAHEDRON LETT, V36, P4377, DOI 10.1016/0040-4039(95)00817-V; ROY R, 1988, CARBOHYD RES, V177, pC1, DOI 10.1016/0008-6215(88)85068-7; SCHNAAR RL, 1978, J BIOL CHEM, V253, P7940; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; SHARON N, 1993, SCI AM, V268, P82, DOI 10.1038/scientificamerican0193-82; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047; Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081; TOSHIMA K, 1993, CHEM REV, V93, P1503, DOI 10.1021/cr00020a006; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VERDUYN R, 1993, RECL TRAV CHIM PAY B, V112, P464; WU AM, 1980, ARCH BIOCHEM BIOPHYS, V204, P622, DOI 10.1016/0003-9861(80)90074-0; YAN L, 1994, J AM CHEM SOC, V116, P6953, DOI 10.1021/ja00094a067	35	266	456	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1520	1522		10.1126/science.274.5292.1520	http://dx.doi.org/10.1126/science.274.5292.1520			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929411				2022-12-28	WOS:A1996VV77500046
J	Ogryzko, VV; Schiltz, RL; Russanova, V; Howard, BH; Nakatani, Y				Ogryzko, VV; Schiltz, RL; Russanova, V; Howard, BH; Nakatani, Y			The transcriptional coactivators p300 and CBP are histone acetyltransferases	CELL			English	Article							NUCLEAR-PROTEIN CBP; E1A; SEQUENCE; CREB; DNA; NUCLEOSOME; ALIGNMENT; ADAPTER; FAMILY	p300/CBP is a transcriptional adaptor that integrates signals from many sequence-specific activators via direct interactions. Various cellular and viral factors target p300/CBP to modulate transcription and/or cell cycle progression. One such factor, the cellular p300/CBP associated factor (PCAF), possesses intrinsic histone acetyltransferase activity. Here, we demonstrate that p300/CBP is not only a transcriptional adaptor but also a histone acetyltransferase. p300/CBP represents a novel class of acetyltransferases in that it does not have the conserved motif found among various other acetyltransferases. p300/CBP acetylates all four core histones in nucleosomes. These observations suggest that p300/CBP acetylates nucleosomes in concert with PCAF.			Ogryzko, VV (corresponding author), NICHHD,LAB MOL GROWTH REPROD,NIH,BETHESDA,MD 20892, USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LU L, 1996, RGFGIGS IS AMINO ACI, V271, P18920; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ONATE SA, 1995, SCIENCE, V270, P1354; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1994, CURR OPIN STRUC BIOL, V4, P44, DOI 10.1016/S0959-440X(94)90058-2; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; SHIMAMURA A, 1989, J BIOL CHEM, V264, P14524; SONG CZ, 1995, J BIOL CHEM, V270, P23263, DOI 10.1074/jbc.270.40.23263; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	42	2332	2383	6	106	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					953	959		10.1016/S0092-8674(00)82001-2	http://dx.doi.org/10.1016/S0092-8674(00)82001-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945521	Bronze			2022-12-28	WOS:A1996VV77400020
J	Wilhelmi, LK; Preuss, D				Wilhelmi, LK; Preuss, D			Self-sterility in Arabidopsis due to defective pollen tube guidance	SCIENCE			English	Article							MOLECULAR MECHANISMS; GROWTH; INCOMPATIBILITY; GLYCOPROTEIN; PLANTS; GENE	In flowering plants, a series of cell-cell interactions govern the delivery of sperm to the ovules through precise guidance of pollen tubes. Two Arabidopsis genes, POP2 and POP3, were found that mediate pollen tube guidance and are critical for self-fertility in diploid reproductive cells. The pop2 and pop3 mutations exhibited genetic redundancy: Self-sterility occurred only when male and female tissues were defective in both genes. This phenotype resembles that found in many self-incompatible species.	UNIV CHICAGO, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA	University of Chicago								BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CHEUNG AY, 1995, CELL, V82, P383, DOI 10.1016/0092-8674(95)90427-1; Dodds PN, 1996, CELL, V85, P141, DOI 10.1016/S0092-8674(00)81090-9; FOOTE HCC, 1994, P NATL ACAD SCI USA, V91, P2265, DOI 10.1073/pnas.91.6.2265; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; HILL JP, 1987, AM J BOT, V74, P988, DOI 10.2307/2443938; HISCOCK SJ, 1995, PLANTA, V196, P367, DOI 10.1007/BF00201397; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; KANDASAMY MK, 1994, DEVELOPMENT, V120, P3405; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; LORD EM, 1992, DEV BIOL, V153, P16, DOI 10.1016/0012-1606(92)90088-X; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; MO YY, 1992, P NATL ACAD SCI USA, V89, P7213, DOI 10.1073/pnas.89.15.7213; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NIYOGI KK, 1993, PLANT CELL, V5, P1011, DOI 10.1105/tpc.5.9.1011; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; PRUITT RE, 1994, ARABIDOPSIS, P467; SEAVEY SR, 1986, BOT REV, V52, P195, DOI 10.1007/BF02861001; TAYLOR LP, 1992, J HERED, V83, P11, DOI 10.1093/oxfordjournals.jhered.a111149	20	74	79	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1535	1537		10.1126/science.274.5292.1535	http://dx.doi.org/10.1126/science.274.5292.1535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929415				2022-12-28	WOS:A1996VV77500050
J	Kelly, JP; Kaufman, DW; Jurgelon, JM; Sheehan, J; Koff, RS; Shapiro, S				Kelly, JP; Kaufman, DW; Jurgelon, JM; Sheehan, J; Koff, RS; Shapiro, S			Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; PEPTIC-ULCER; THERAPY; COMPLICATIONS; ANALGESICS; DISEASE; MUCOSA	Background Aspirin products are known to cause irritation and injury to the gastric mucosa. The belief that enteric-coated and buffered varieties are less likely to occasion major upper-gastrointestinal bleeding (UGIB) than plain aspirin was tested in data from a multicentre case-control study. Methods 550 incident cases of UGIB admitted to hospital with melaena or haematemesis and confirmed by endoscopy, and 1202 controls identified from population census lists, were interviewed about use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) during the 7 days before the onset of bleeding (cases) or interview (controls), Relative risks of UGIB for each type of aspirin used regularly (at least every other day) were calculated overall, and according to dose, by multiple logistic regression, with control for age, sex, marital status, date, education, cigarette smoking, alcohol use, and use of NSAIDs. Findings The relative risks of UGIB for plain, enteric-coated, and buffered aspirin at average daily doses of 325 mg or less were 2.6, 2.7, and 3.1, respectively. At doses greater than 325 mg, the relative risk was 5.8 for plain and 7.0 for buffered aspirin; there were insufficient data to evaluate enteric-coated aspirin at this dose level. There were no important differences in risk attributable to the three aspirin forms according to bleeding site (gastric vs duodenal), or when users of NSAIDs were excluded. Interpretation Use of low doses of enteric-coated or buffered aspirin carries a three-fold increase in the risk of major UGIB. The assumption that these formulations less harmful than plain aspirin may be mistaken.	METROWEST MED CTR,DEPT MED,FRAMINGHAM,MA		Kelly, JP (corresponding author), BOSTON UNIV,SCH MED,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,BROOKLINE,MA 02146, USA.			Kaufman, David/0000-0002-2150-5070	NIDDK NIH HHS [2 R01 DK36997-0502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036997] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLE WR, 1986, ARCH INTERN MED, V146, P2365, DOI 10.1001/archinte.146.12.2365; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; FRIES JF, 1993, ARCH INTERN MED, V153, P2465, DOI 10.1001/archinte.153.21.2465; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P644; GRAHAM DY, 1986, ANN INTERN MED, V104, P390, DOI 10.7326/0003-4819-104-3-390; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GROSSMAN CM, 1994, LANCET, V344, P57; HAWTHORNE AB, 1991, BRIT J CLIN PHARMACO, V32, P77, DOI 10.1111/j.1365-2125.1991.tb05616.x; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; HOFTIEZER JW, 1980, LANCET, V2, P609; HOLVOET J, 1991, GUT, V32, P730, DOI 10.1136/gut.32.7.730; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LANZA FL, 1980, NEW ENGL J MED, V303, P136, DOI 10.1056/NEJM198007173030305; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; *MED EC DAT PROD C, 1995, PHYS DESK REF; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; SAVAGE RL, 1993, ARTHRITIS RHEUM, V36, P84, DOI 10.1002/art.1780360114; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SILVOSO GR, 1979, ANN INTERN MED, V91, P517, DOI 10.7326/0003-4819-91-4-517; SOMERVILLE K, 1986, LANCET, V1, P462; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827	23	333	356	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1413	1416		10.1016/S0140-6736(96)01254-8	http://dx.doi.org/10.1016/S0140-6736(96)01254-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937281	hybrid			2022-12-28	WOS:A1996VU98600012
J	Skinner, JA; Cohen, AT				Skinner, JA; Cohen, AT			Amputation for premature peripheral atherosclerosis: Do young patients do better	LANCET			English	Editorial Material							ADULTS; LIMB		UNIV LONDON KINGS COLL HOSP,DEPT MED,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Skinner, JA (corresponding author), WHIPPS CROSS HOSP & CHEST CLIN,DEPT ORTHOPAED,LONDON E11 1NR,ENGLAND.			Skinner, John/0000-0002-1901-9057				*ANT TRIAL COLL, 1994, BMJ-BRIT MED J, V308, P159; BODILY KC, 1983, AM J SURG, V146, P280, DOI 10.1016/0002-9610(83)90391-4; DASILVA E, 1980, OCCLUSIVE PERIPHERAL; EDMONDSON RA, 1994, LANCET, V344, P914, DOI 10.1016/S0140-6736(94)92269-1; Greant P, 1990, Ann Vasc Surg, V4, P288; HANSEN ME, 1995, SURGERY, V118, P834, DOI 10.1016/S0039-6060(05)80273-9; Olsen P S, 1988, Eur J Vasc Surg, V2, P15, DOI 10.1016/S0950-821X(88)80101-4; PAIROLERO PC, 1984, J VASC SURG, V1, P459, DOI 10.1067/mva.1984.avs0010459; VALENTINE RJ, 1995, J VASC SURG, V21, P296, DOI 10.1016/S0741-5214(95)70270-9; Valentine RJ, 1996, SURGERY, V119, P487, DOI 10.1016/S0039-6060(96)80255-8	10	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1396	1396		10.1016/S0140-6736(05)67497-1	http://dx.doi.org/10.1016/S0140-6736(05)67497-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937275				2022-12-28	WOS:A1996VU98600005
J	Slaper, H; Velders, GJM; Daniel, JS; deGruijl, FR; vanderLeun, JC				Slaper, H; Velders, GJM; Daniel, JS; deGruijl, FR; vanderLeun, JC			Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements	NATURE			English	Article							ULTRAVIOLET; UV; RADIATION; RISK; INDUCTION; SUNLIGHT; CLOUDS	DEPLETION of the ozone layer has been observed on a global scale(1), and is probably related to halocarbon emissions, Ozone depletion increases the biologically harmful solar ultraviolet radiation reaching the surface of the Earth, which leads to a variety of adverse effects, including an increase in the incidence of skin cancer. The 1985 Vienna Convention provided the framework for international restrictions on the production of ozone-depleting substances, The consequences of such restrictions have not yet been assessed in terms of effects avoided. Here we present a new method of estimating future excess skin cancer risks which is used to compare effects of a 'no restrictions' scenario with two restrictive scenarios specified under the Vienna Convention: the Montreal Protocol, and the much stricter Copenhagen Amendments, The no-restrictions and Montreal Protocol scenarios produce a runaway increase in skin cancer incidence, up to a quadrupling and doubling, respectively, by the year 2100. The Copenhagen Amendments scenario leads to an ozone minimum around the year 2000, and a peak relative increase in incidence of skin cancer of almost 10% occurring 60 years later. These results demonstrate the importance of the international measures agreed upon under the Vienna Convention.	NATL INST PUBL HLTH & ENVIRONM,AIR RES LAB,NL-3720 BA BILTHOVEN,NETHERLANDS; NOAA,AERON LAB,BOULDER,CO 80303; UNIV UTRECHT,INST DERMATOL,NL-3508 GA UTRECHT,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; National Oceanic Atmospheric Admin (NOAA) - USA; Utrecht University	Slaper, H (corresponding author), NATL INST PUBL HLTH & ENVIRONM,RADIAT RES LAB,POB 1,NL-3720 BA BILTHOVEN,NETHERLANDS.		Daniel, John S/D-9324-2011; Velders, Guus/H-1204-2013	Velders, Guus/0000-0002-6597-7088				*ALT FLUOR ENV ACC, 1993, PROD SAL ATM REL FLU; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; BORDEWIJK JA, 1995, GEOPHYS RES LETT, V22, P2151, DOI 10.1029/95GL01506; DANIEL JS, 1995, J GEOPHYS RES-ATMOS, V100, P1271, DOI 10.1029/94JD02516; DEGRUIJL FR, 1994, HEALTH PHYS, V67, P319, DOI 10.1097/00004032-199410000-00001; DEGRUIJL FR, 1993, CANCER RES, V53, P53; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DEWINTER R, 1995, 722201005 RIVM; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; *HLTH COUNC NETH, 1994, UV RAD SUNL; HOLMAN CD, 1984, JNCI-J NATL CANCER I, V73, P75; KERR RA, 1995, SCIENCE, V270, P376; KRICKER A, 1994, NATURE, V368, P594, DOI 10.1038/368594b0; LONGSTRETH JD, 1987, UAEPA400187001D; LUBIN D, 1995, NATURE, V377, P710, DOI 10.1038/377710a0; MADRONICH S, 1993, NATURE, V366, P23, DOI 10.1038/366023a0; MCKENZIE RL, 1995, WMO REP, V37, pCH9; SCOTTO J, 1981, NIH PUBLICATION; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SLAPER H, 1995, GEOPHYS RES LETT, V22, P2721, DOI 10.1029/95GL02824; SLAPER H, 1986, PHOTODERMATOLOGY, V3, P271; SLAPER H, 1987, THESIS UTRECHT U; SLAPER H, 1992, 749202001 RIVM; VELDERS GJM, 1995, 722201006 RIVM; VITASA BC, 1990, CANCER, V65, P2611; World Meteorological Organization, 1992, 25 WMO; World Meteorological Organization, 1995, 37 WMO; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	28	178	182	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					256	258		10.1038/384256a0	http://dx.doi.org/10.1038/384256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918873				2022-12-28	WOS:A1996VU38100048
J	Bree, RL; Kazerooni, EA; Katz, SJ				Bree, RL; Kazerooni, EA; Katz, SJ			Effect of mandatory radiology consultation on inpatient imaging use - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; EXPECTATIONS; PHYSICIANS; GUIDELINES; SERVICE; MODEL; COST	Objective.-To determine if a mandatory radiology consultation service can decrease radiology resource use on inpatient internal medicine services. Design and Setting.-Randomized controlled trial on 4 internal medicine services at a university hospital. Patients and Other Participants.-Six radiologists performed the intervention on 2 internal medicine services over a 12-month period. A total of 1022 patients were admitted to the 2 intervention services and 1178 patients were admitted to the 2 control services, Each was staffed by an attending internist and 3 house officers. Intervention.-Each radiology examination required approval by the attending radiologist before it was performed. Main Outcome Measure.-Relative resource costs (relative value units [RVUs]), number of examinations per patient, proportion of patients with 1 or more tests, and mean length of stay (LOS). Results.-Mean RVUs for the intervention group were 356.1, and for the control group, 336.0 (P=.5), Mean examinations per patient for both groups was 4.4. Mean LOS for the intervention group was 6.0 days, and for the control group, 6.1 days (P=.8). Conclusions.-An inpatient radiology consultation service, with a goal to reduce resource use, did not achieve its goal. A more appropriate use of time and expense for radiology utilization management may be in the outpatient setting.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT HLTH POLICY & MANAGEMENT,ANN ARBOR,MI; UNIV MICHIGAN,MED CTR,CHOICES,ANN ARBOR,MI	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bree, RL (corresponding author), UNIV MICHIGAN,MED CTR,DEPT RADIOL,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.		KATZ, STEVEN/ABH-8886-2020					BAKER SR, 1984, RADIOLOGY, V152, P331, DOI 10.1148/radiology.152.2.6739794; BAKER SR, 1982, JAMA-J AM MED ASSOC, V248, P2152, DOI 10.1001/jama.248.17.2152; BERNARD AM, 1995, MED CARE, V33, P663, DOI 10.1097/00005650-199507000-00003; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CASCADE PN, 1994, RADIOLOGY, V192, pA50; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; COOK PS, 1995, SEMIN INTERVENT RAD, V12, P260, DOI 10.1055/s-2008-1061335; HAYWARD RA, 1994, MED CARE, V32, P788, DOI 10.1097/00005650-199408000-00003; HEILMAN RS, 1982, NEW ENGL J MED, V306, P477, DOI 10.1056/NEJM198202253060809; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KELLER RB, 1990, J BONE JOINT SURG AM, V72A, P1286, DOI 10.2106/00004623-199072090-00002; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; KESSLER HB, 1994, AM J ROENTGENOL, V163, P1; KHORASANI R, 1994, AM J ROENTGENOL, V163, P457, DOI 10.2214/ajr.163.2.8037049; LEVIN DC, 1994, AM J ROENTGENOL, V162, P513, DOI 10.2214/ajr.162.3.8109487; MCMAHON LF, 1989, ANN INTERN MED, V111, P318, DOI 10.7326/0003-4819-111-4-318; ROSENBERG SN, 1995, NEW ENGL J MED, V333, P1326, DOI 10.1056/NEJM199511163332006; SHAPIRO MF, 1995, NEW ENGL J MED, V333, P1353, DOI 10.1056/NEJM199511163332012; SHUMAN WP, 1979, JAMA-J AM MED ASSOC, V242, P1519, DOI 10.1001/jama.242.14.1519; THRALL JH, 1994, AM J ROENTGENOL, V163, P11, DOI 10.2214/ajr.163.1.8010194; UBEL PA, 1995, ARCH INTERN MED, V155, P1837, DOI 10.1001/archinte.155.17.1837; Woodside J R, 1991, Qual Assur Util Rev, V6, P47	23	30	30	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1595	1598		10.1001/jama.276.19.1595	http://dx.doi.org/10.1001/jama.276.19.1595			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918858				2022-12-28	WOS:A1996VT02500033
J	Heinonen, A; Kannus, P; Sievanen, H; Oja, P; Pasanen, M; Rinne, M; UusiRasi, K; Vuori, I				Heinonen, A; Kannus, P; Sievanen, H; Oja, P; Pasanen, M; Rinne, M; UusiRasi, K; Vuori, I			Randomised controlled trial of effect of high-impact exercise on selected risk factors for osteoporotic fractures	LANCET			English	Article							BONE-MINERAL DENSITY; WEIGHT-BEARING EXERCISE; POSTMENOPAUSAL WOMEN; HIGH-INTENSITY; HIP-FRACTURES; OLDER WOMEN; YOUNG-WOMEN; STRENGTH; ESTROGEN; INCREASE	Background Osteoporotic fractures among the elderly are common, and without preventive measures the burden of these fractures on health-care systems will increase further. The purpose of this randomised controlled study was to evaluate, in premenopausal women, the effects of high-impact loading on several determinants of osteoporotic fractures. Methods 98 healthy, sedentary female volunteers aged 35-45 years were randomly assigned to either a training (n=49) or a control group (n=49). Progressive high-impact exercises were done three times per week for 18 months. We measured bone mineral density (BMD) in specific axial and lower-limb sites, by dual-energy X-ray absorptiometry, at baseline and after 12 and 18 months. Maximum isometric strength, muscular and cardiovascular performance, and dynamic balance were also assessed. Findings BMD at the femoral neck, a weightbearing site, increased significantly more in the training group (mean 1 . 6% [95% CI 0 . 8-2 . 4]) than in the control group (0 . 6% [-0 . 2 to 1 . 4], p=0 . 006). By contrast, at non-weightbearing sites, such as the distal radius, there was no significant difference between the training and control groups (-1 . 5% [-2 . 7 to -0 . 3] vs -0 . 7% [-1 . 9 to -0 . 5], p=0 . 60). In the training group there was a significant improvement in vertical jump and predicted oxygen consumption per min at maximum exercise compared with controls. Interpretation High-impact exercises that load bones with a rapidly rising force profile in versatile movements improve integrity, muscular performance, and dynamic in premenopausal women. If done on a regular basis, this type of exercise may help decrease the risk of osteoporotic fractures in later life. Long-term studies are required to show whether these 18-month results can be translated into long-term benefit.			Heinonen, A (corresponding author), UKK INST HLTH PROMOT RES, POB 30, FIN-33501 TAMPERE, FINLAND.		Heinonen, Ari/I-5292-2019; Heinonen, Ari/A-9199-2014	Heinonen, Ari/0000-0002-3681-9953; Heinonen, Ari/0000-0002-3681-9953				BASSEY EJ, 1994, OSTEOPOROSIS INT, V4, P72, DOI 10.1007/BF01623226; BLUMENTHAL JA, 1991, J AM GERIATR SOC, V39, P1065, DOI 10.1111/j.1532-5415.1991.tb02870.x; COURTNEY AC, 1994, CALCIFIED TISSUE INT, V55, P53, DOI 10.1007/BF00310169; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DRINKWATER BL, 1995, MED SCI SPORT EXER, V27, pR1; FRIEDLANDER AL, 1995, J BONE MINER RES, V10, P574, DOI 10.1002/jbmr.5650100410; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; GROVE KA, 1992, MED SCI SPORT EXER, V24, P1190; Hayes WC, 1996, BONE, V18, pS77, DOI 10.1016/8756-3282(95)00383-5; HEINONEN A, 1995, BONE, V17, P197, DOI 10.1016/8756-3282(95)00151-3; HEINONEN A, 1994, EUR J APPL PHYSIOL, V68, P310, DOI 10.1007/BF00571449; KANNUS P, 1995, ANN INTERN MED, V123, P27, DOI 10.7326/0003-4819-123-1-199507010-00003; Kannus P, 1996, BONE, V18, pS57, DOI 10.1016/8756-3282(95)00381-9; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; KOHRT WM, 1995, J BONE MINER RES, V10, P1303, DOI 10.1002/jbmr.5650100906; Lanyon LE, 1996, BONE, V18, pS37, DOI 10.1016/8756-3282(95)00378-9; Lauritzen JB, 1996, BONE, V18, pS65, DOI 10.1016/8756-3282(95)00382-7; MORITANI T, 1993, J BIOMECH, V26, P95, DOI 10.1016/0021-9290(93)90082-P; Myers AH, 1996, BONE, V18, pS87, DOI 10.1016/8756-3282(95)00384-3; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; NOTELOVITZ M, 1991, J BONE MINER RES, V6, P583, DOI 10.1002/jbmr.5650060609; OJA P, 1991, INT J SPORTS MED, V12, P356, DOI 10.1055/s-2007-1024694; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; PRUITT LA, 1995, J BONE MINER RES, V10, P1788; SIEVANEN H, 1994, MED PHYS, V21, P1795, DOI 10.1118/1.597278; Sillanpaa J, 1995, 15 C INT SOC BIOM JY, P850; SMITH R, 1994, J BONE JOINT SURG BR, V76B, P345, DOI 10.1302/0301-620X.76B3.8175830; Snow CM, 1996, BONE, V18, pS51, DOI 10.1016/8756-3282(95)00380-0; TAAFFE DR, 1995, J BONE MINER RES, V10, P586; TEGNER Y, 1986, AM J SPORT MED, V14, P156, DOI 10.1177/036354658601400212	33	323	330	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1996	348	9038					1343	1347		10.1016/S0140-6736(96)04214-6	http://dx.doi.org/10.1016/S0140-6736(96)04214-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918277				2022-12-28	WOS:A1996VT33200010
J	Nashef, L; Brown, S				Nashef, L; Brown, S			Epilepsy and sudden death	LANCET			English	Editorial Material							UNEXPLAINED DEATH; UNEXPECTED DEATH; COHORT		NORWICH COMMUNITY HLTH PARTNERSHIP,NORWICH,NORFOLK,ENGLAND		Nashef, L (corresponding author), KENT & CANTERBURY HOSP,CANTERBURY,KENT,ENGLAND.							Coyle H P, 1994, Seizure, V3, P247, DOI 10.1016/S1059-1311(05)80171-2; JOHNSTON SC, 1995, ANN NEUROL, V37, P531, DOI 10.1002/ana.410370416; Lathers CM, 1990, EPILEPSY SUDDEN DEAT, V7; LEESTMA JE, 1989, ANN NEUROL, V26, P195, DOI 10.1002/ana.410260203; LIP GYH, 1992, J ROY SOC MED, V85, P609; Nashef L, 1996, J NEUROL NEUROSUR PS, V60, P297, DOI 10.1136/jnnp.60.3.297; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; NASHEF L, 1995, EPILEPSIA, V36, P1187, DOI 10.1111/j.1528-1157.1995.tb01061.x; *OFF NAT STAT MON, 1996, DHW962, P6; TENNIS P, 1995, EPILEPSIA, V36, P29, DOI 10.1111/j.1528-1157.1995.tb01661.x	10	57	57	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1324	1325		10.1016/S0140-6736(05)65402-5	http://dx.doi.org/10.1016/S0140-6736(05)65402-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918270				2022-12-28	WOS:A1996VT33200003
J	Starr, JM; Inch, S; Cross, S; Deary, IJ; MacLennan, WJ				Starr, JM; Inch, S; Cross, S; Deary, IJ; MacLennan, WJ			Blood pressure and mortality in healthy old people: The r shaped curve	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; MANAGEMENT; HYPERTENSION		UNIV EDINBURGH,DEPT GERIATR MED,EDINBURGH EH4 2DN,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH EH4 2DN,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Starr, John/C-8951-2011; Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; FOTHERBY MD, 1992, BMJ-BRIT MED J, V305, P750, DOI 10.1136/bmj.305.6856.750; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Starr J.M., 1996, EPIDEMIOLOGY OLD AGE; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1243	1244		10.1136/bmj.313.7067.1243	http://dx.doi.org/10.1136/bmj.313.7067.1243			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU208	8939116	Green Published, Green Submitted			2022-12-28	WOS:A1996VU20800025
J	Castilla, LH; Wijmenga, C; Wang, Q; Stacy, T; Speck, NA; Eckhaus, M; MarinPadilla, M; Collins, FS; WynshawBoris, A; Liu, PP				Castilla, LH; Wijmenga, C; Wang, Q; Stacy, T; Speck, NA; Eckhaus, M; MarinPadilla, M; Collins, FS; WynshawBoris, A; Liu, PP			Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11	CELL			English	Article							ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR-DELTA-ENHANCER; TRANSCRIPTION FACTOR; ERYTHROID DEVELOPMENT; MICE LACKING; AML1 GENE; C-MYB	The fusion oncogene CBFB-MYH11 is generated by a chromosome 16 inversion in human acute myeloid leukemia subtype M4Eo. Mouse embryonic stem (ES) cells heterozygous for this oncogene were generated by inserting part of the human MYH11 cDNA into the mouse Cbfb gene through homologous recombination (knock-in). Chimeric mice were leukemia free, but the ES cells with the knocked-in Cbfb-MYH11 gene did not contribute to their hematopoietic tissues. Mouse embryos heterozygous for Cbfb-MYH11 lacked definitive hematopoiesis and developed multiple fatal hemorrhages around embryonic day 12.5. This phenotype is very similar to that resulting from homozygous deletions of either Cbfb or Cbfa2 (AML1), consistent with a dominant negative function of the Cbfb-MYH11 fusion oncogene. An impairment of primitive hematopoiesis was also observed, however, suggesting a possible additional function of Cbfb-MYH11.	NIH,NATL CTR HUMAN GENOME RES,LAB GENET DIS RES,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT PATHOL,HANOVER,NH 03755	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; Dartmouth College; Dartmouth College	Castilla, LH (corresponding author), NIH,NATL CTR HUMAN GENOME RES,LAB GENE TRANSFER,BETHESDA,MD 20892, USA.		Liu, Paul/A-7976-2012; Wijmenga, Cisca/AAE-7719-2019; Wijmenga, Cisca/D-2173-2009	Liu, Paul/0000-0002-6779-025X; Wijmenga, Cisca/0000-0002-5635-1614; 	NATIONAL CANCER INSTITUTE [R01CA058343] Funding Source: NIH RePORTER; NCI NIH HHS [CA58343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DIGGS LW, 1954, MORPHOLOGY BLOOD CEL; Eaves C, 1995, ATLAS HUMAN HEMATOPO; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MARLTON P, 1995, BLOOD, V85, P772, DOI 10.1182/blood.V85.3.772.bloodjournal853772; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	41	242	249	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					687	696		10.1016/S0092-8674(00)81388-4	http://dx.doi.org/10.1016/S0092-8674(00)81388-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929537	hybrid			2022-12-28	WOS:A1996VU03500011
J	Hardison, WGM				Hardison, WGM			I've been where it's gone, so I know what I got ... An American Fulbright Lecturer in Albania, 1994-1995	ANNALS OF INTERNAL MEDICINE			English	Article								Spending 10 months as a Fulbright Lecturer in Medical Sciences at the University Medical Center, University of Tirana, Albania, gave me a first-hand view of academic medicine in a country emerging from more than 45 years of Communist rule that impoverished the country and isolated it from the rest of the world. Even after the fall of Communism, every aspect of medicine in Albania continues to be government controlled, Early specialization is still the rule for academic physicians. Division chiefs exert absolute authority over their domain and seldom delegate this authority. Learning and teaching resources are scant, and access to current western medical literature is extremely limited because of both poverty and priority. Despite these obstacles, the medical students and postgraduate trainees I encountered were bright and receptive, which strongly reinforces the tremendous urge to help them. Fellowships abroad, however, are limited and available only to selected junior faculty; students and clinical trainees do not qualify. If we are to help, we must take the training to them. It takes time to become an effective clinical teacher in Albania: time to understand the system; time to devise the best teaching vehicles; and time to gain the trust of the students, trainees, and faculty. Given the time, the effort can be successful. The problem is, where do we find physicians with the time and interest? Might this be a role for still-energetic retired physicians? My experience in Albania permitted me only to formulate these questions; the answers must now come from this side of the Atlantic.	UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego								HRDISON WG, 1996, ACP OBSERVER, V15, P7	1	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					835	838		10.7326/0003-4819-125-10-199611150-00008	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928991				2022-12-28	WOS:A1996VU52400011
J	Hill, LN				Hill, LN			My not-so-near-death experience	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Hill, LN (corresponding author), AMER EMBASSY, APO, AP 96440 USA.								0	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					855	857		10.7326/0003-4819-125-10-199611150-00012	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928995				2022-12-28	WOS:A1996VU52400015
J	Mombaerts, P; Wang, F; Dulac, C; Chao, SK; Nemes, A; Mendelsohn, M; Edmondson, J; Axel, R				Mombaerts, P; Wang, F; Dulac, C; Chao, SK; Nemes, A; Mendelsohn, M; Edmondson, J; Axel, R			Visualizing an olfactory sensory map	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; MITRAL TUFTED CELLS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BULB; MOUSE; NEURONS; ORGANIZATION; EPITHELIUM; MOLECULES	We have developed a genetic approach to visualize axons from olfactory sensory neurons expressing a given odorant receptor, as they project to the olfactory bulb. Neurons expressing a specific receptor project to only two topographically fixed loci among the 1800 glomeruli in the mouse olfactory bulb. Our data provide direct support for a model in which a topographic map of receptor activation encodes odor quality in the olfactory bulb. Receptor swap experiments suggest that the olfactory receptor plays an instructive role in the guidance process but cannot be the sole determinant in the establishment of this map. This genetic approach may be more broadly applied to visualize the development and plasticity of projections in the mammalian nervous system.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute; Columbia University				Axel, Richard/0000-0002-3141-4076; Dulac, Catherine/0000-0001-5024-5418	NCI NIH HHS [5 PO1 CA23767] Funding Source: Medline; NIMH NIH HHS [5 P50 MH 50733] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUIAKOVA OI, 1994, GENOMICS, V20, P452, DOI 10.1006/geno.1994.1200; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; SAUER B, 1990, New Biologist, V2, P441; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1995, EUR J NEUROSCI, V7, P492, DOI 10.1111/j.1460-9568.1995.tb00345.x; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Woolsey T.A., 1990, P461	41	1538	1560	9	133	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					675	686		10.1016/S0092-8674(00)81387-2	http://dx.doi.org/10.1016/S0092-8674(00)81387-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929536	hybrid			2022-12-28	WOS:A1996VU03500010
J	Rikkert, MGMO; tenHave, HAMJ; Hoefnagels, WHL				Rikkert, MGMO; tenHave, HAMJ; Hoefnagels, WHL			Informed consent in biomedical studies on aging: Survey of four journals	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV NIJMEGEN, SCH MED SCI, DEPT ETH PHILOSOPHY & HIST MED, NIJMEGEN, NETHERLANDS	Radboud University Nijmegen	Rikkert, MGMO (corresponding author), UNIV NIJMEGEN HOSP, DEPT GERIATR MED, POB 9101, NL-6500 HB NIJMEGEN, NETHERLANDS.		Rikkert, Marcel Olde/D-9773-2012; Have, Henk ten/AAF-5188-2020					GARFIELD E, 1994, SCI J CITATION REPOR; HIGH DM, 1992, J AM GERIATR SOC, V40, P950, DOI 10.1111/j.1532-5415.1992.tb01995.x; LOCK S, 1991, BRIT MED J, V302, P338; TYMCHUK AJ, 1990, EDUC GERONTOL, V16, P245, DOI 10.1080/0380127900160302	4	39	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1117	1117		10.1136/bmj.313.7065.1117	http://dx.doi.org/10.1136/bmj.313.7065.1117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VR217	8916698	Green Published			2022-12-28	WOS:A1996VR21700023
J	Kravitz, RL; Callahan, EJ; Paterniti, D; Antonius, D; Dunham, M; Lewis, CE				Kravitz, RL; Callahan, EJ; Paterniti, D; Antonius, D; Dunham, M; Lewis, CE			Prevalence and sources of patients' unmet expectations for care	ANNALS OF INTERNAL MEDICINE			English	Article						patient satisfaction; patient-centered care; physician-patient relations; quality of health care; patient care characteristics	SATISFACTION; DOCTOR	Background: Patients' expectations and the role they play in medical care are increasingly considered to be important, but the factors that influence these expectations have not been well studied. Objective: To examine the factors that influence patients' expectations for care in office practice. Design: Qualitative inquiry nested within a large clinical survey. Setting: Three general internal medicine practices in one mid-sized city in northern California. Patients: 688 patients visiting their internists' offices were surveyed (response rate, 86%); 88 patients who reported one or more omissions of care on a post-visit questionnaire and were available for a telephone interview 1 to 7 days after the visit were included in the qualitative inquiry. Measurements: Proportion of surveyed patients who reported one or more omissions of care, and qualitative analysis of the sources of patients' expectations, as determined from the telephone interviews. Interviews focused on the sources of expectations and perceptions of omission. Using an iterative process and working by consensus, investigators developed coding categories on a randomly selected 50% of the transcripts. The other 50% of the sample was used for validation. Results: The 125 patients who had unmet expectations perceived omissions that were related to physician preparation for the visit (23%), history taking (26%), physical examination (30%), diagnostic testing (28%), prescription of medication (19%), referral to specialists (26%), and physician-patient communication (15%). Unmet expectations were shaped by patients' current somatic symptoms (intensity of symptoms, functional impairment, duration of symptoms, and perceived seriousness of symptoms) (74%); perceived vulnerability to illness (related to age, family history, personal lifestyle, or previously diagnosed conditions) (50%); past experiences (personal or familial) with similar illnesses (42%); and knowledge acquired from physicians, friends, family, or the media (54%). Conclusions: Patients' expectations for care are derived from multiple sources; their complexity should discourage simple schemes for ''demand management.'' Nevertheless, the results of this study may help physicians to take a more empathetic stance toward their patients' requests and to devise more successful strategies for clinical negotiation.	KAISER PERMANENTE MED CTR, SACRAMENTO, CA USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA	Kaiser Permanente; University of California System; University of California Los Angeles	Kravitz, RL (corresponding author), UNIV CALIF DAVIS, PRIMARY CARE CTR, DIV GEN MED, ROOM 3017, 2221 STOCKTON BLVD, SACRAMENTO, CA 95817 USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				BARSKY AJ, 1995, JAMA-J AM MED ASSOC, V274, P1931, DOI 10.1001/jama.274.24.1931; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRODY DS, 1989, MED CARE, V27, P1027, DOI 10.1097/00005650-198911000-00004; CLEARY PD, 1988, INQUIRY-J HEALTH CAR, V25, P25; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Glaser B.G., 1965, AWARENESS DYING; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kravitz RL, 1996, MED CARE RES REV, V53, P3, DOI 10.1177/107755879605300101; KRAVITZ RL, 1994, J GEN INTERN MED, V9, P75, DOI 10.1007/BF02600205; LAZARE A, 1975, ARCH GEN PSYCHIAT, V32, P553; Partridge P, 1996, Health Care Strateg Manage, V14, P14; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; SEIDEL J, 1995, ETHNOGRAPH V 4 0 USE; SOX HC, 1993, J GEN INTERN MED, V8, P580, DOI 10.1007/BF02599645; SPEEDLING EJ, 1985, SOC SCI MED, V21, P115, DOI 10.1016/0277-9536(85)90079-6; Strauss A., 1990, BASIS QUALITATIVE RE; VICKERY DM, 1995, J OCCUP ENVIRON MED, V37, P551, DOI 10.1097/00043764-199505000-00001; WOOLF SH, 1990, ARCH INTERN MED, V150, P2451, DOI 10.1001/archinte.150.12.2451	19	144	149	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					730	+		10.7326/0003-4819-125-9-199611010-00004	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VQ072	8929006				2022-12-28	WOS:A1996VQ07200004
J	Roche, PA				Roche, PA			Out, damned CLIP! Out, I say!	SCIENCE			English	Editorial Material							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; HLA-DR MOLECULES; MHC; DM; DISSOCIATION				Roche, PA (corresponding author), NCI,EXPT IMMUNOL BRANCH,NIH,BETHESDA,MD 20892, USA.			Roche, Paul/0000-0002-8949-9172				DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618	10	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					526	527		10.1126/science.274.5287.526	http://dx.doi.org/10.1126/science.274.5287.526			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928005				2022-12-28	WOS:A1996VN91900032
J	Orrell, RW; Shakir, R; Lane, RJM; Kennard, C; Wade, JPH; Poser, CM				Orrell, RW; Shakir, R; Lane, RJM; Kennard, C; Wade, JPH; Poser, CM			Grand rounds - Hammersmith Hospitals - Distinguishing acute disseminated encephalomyelitis from multiple sclerosis - Genetic predisposition may differ	BRITISH MEDICAL JOURNAL			English	Editorial Material											Orrell, RW (corresponding author), CHARING CROSS HOSP,HAMMERSMITH HOSP NHS TRUST,DEPT NEUROL,LONDON W6 8RF,ENGLAND.		Orrell, Richard/L-2123-2013					ALDIN ASN, 1990, J NEUROL SCI, V100, P137, DOI 10.1016/0022-510X(90)90024-H; ALVORD EC, 1985, HDB CLIN NEUROLOGY, V3, P467; KAHN S, 1995, J NEUROL NEUROSUR PS, V58, P467; KESSELRING J, 1990, BRAIN, V113, P291, DOI 10.1093/brain/113.2.291; KUROIWA Y, 1985, HDB CLIN NEUROLOGY, V3, P397; McAlpine D, 1931, LANCET, V1, P846; ORiordan JI, 1996, J NEUROL NEUROSUR PS, V60, P382, DOI 10.1136/jnnp.60.4.382; POSER CM, 1989, J NEUROL SCI, V94, P69, DOI 10.1016/0022-510X(89)90218-9; POSER CM, 1989, ARCH NEUROL-CHICAGO, V46, P946, DOI 10.1001/archneur.1989.00520450016008	9	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					802	804						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8924845				2022-12-28	WOS:A1996VK56600033
J	Connolly, JB; Roberts, IJH; Armstrong, JD; Kaiser, K; Forte, M; Tully, T; OKane, CJ				Connolly, JB; Roberts, IJH; Armstrong, JD; Kaiser, K; Forte, M; Tully, T; OKane, CJ			Associative learning disrupted by impaired G(s) signaling in Drosophila mushroom bodies	SCIENCE			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; STIMULATORY G-PROTEIN; ADENYLYL-CYCLASE; PREFERENTIAL EXPRESSION; GENE-EXPRESSION; ALPHA-SUBUNIT; MEMORY; MELANOGASTER; RUTABAGA; MUTANT	Disruptions in mushroom body (MB) or central complex (CC) brain structures impair Drosophila associative olfactory learning. Perturbations in adenosine 3',5' monophosphate signaling also disrupt learning. To integrate these observations, expression of a constitutively activated stimulatory heterotrimeric guanosine triphosphate-binding protein alpha subunit (G alpha(s)(star)) was targeted to these brain structures. The ability to associate odors with electroshock was abolished when G alpha(s)(star) was targeted to MB, but not CC, structures, whereas sensorimotor responses to these stimuli remained normal, Expression of G alpha(s)(star) did not affect gross MB morphology, and wild-type G alpha(s) expression did not affect learning, Thus, olfactory learning depends on regulated G(s) signaling in Drosophila MBs.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV MOL GENET,GLASGOW G11 6NU,LANARK,SCOTLAND; OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	University of Cambridge; University of Glasgow; Oregon Health & Science University	Connolly, JB (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		O'Kane, Cahir/Q-6681-2019	O'Kane, Cahir/0000-0002-3488-2078; Armstrong, Douglas/0000-0002-5397-3864; Connolly, John B./0000-0002-7033-3463	NICHD NIH HHS [HD 32245] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMSTRONG JD, 1995, THESIS U GLASGOW SCO; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYNTON S, 1992, GENETICS, V131, P655; BRAND AH, 1993, DEVELOPMENT, V118, P401; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; deBelle JS, 1996, P NATL ACAD SCI USA, V93, P9875, DOI 10.1073/pnas.93.18.9875; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; HAMMER M, 1995, J NEUROSCI, V15, P1617, DOI 10.1523/JNEUROSCI.15-03-01617.1995; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; KANDEL E, 1995, SCIENCE, V268, P825, DOI 10.1126/science.7754367; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; KKAISER K, UNPUB; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; Li W, 1996, LEARN MEMORY, V2, P320, DOI 10.1101/lm.2.6.320; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; NEER E, 1995, CELL, V60, P249; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; QUAN F, 1989, P NATL ACAD SCI USA, V86, P4321, DOI 10.1073/pnas.86.11.4321; QUAN F, 1991, P NATL ACAD SCI USA, V88, P1898, DOI 10.1073/pnas.88.5.1898; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; SOKAL RR, 1981, BIOMETRY PRINCIPLES, P229; SPRADLING A, 1986, DROSOPHILA PRACTICAL, P75; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; TANG W, 1994, PROTEINS, P19; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; URBAN J, 1994, GENE DEV, V8, P1787; WOLFGANG WJ, 1990, J NEUROSCI, V10, P1014; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; YANG MY, 1995, NEURON, V15, P45; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036	41	409	413	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2104	2107		10.1126/science.274.5295.2104	http://dx.doi.org/10.1126/science.274.5295.2104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953046				2022-12-28	WOS:A1996VY97400056
J	Saffran, JR; Aslin, RN; Newport, EL				Saffran, JR; Aslin, RN; Newport, EL			Statistical learning by 8-month-old infants	SCIENCE			English	Article							ACQUISITION; EXPERIENCE; PATTERNS; SPEECH; WORDS	Learners rely on a combination of experience-independent and experience-dependent mechanisms to extract information from the environment, Language acquisition involves both types of mechanisms, but most theorists emphasize the relative importance of experience-independent mechanisms. The present study shows that a fundamental task of language acquisition, segmentation of words from fluent speech, can be accomplished by 8-month-old infants based solely on the statistical relationships between neighboring speech sounds. Moreover, this word segmentation was based on statistical learning from only 2 minutes of exposure, suggesting that infants have access to a powerful mechanism for the computation of statistical properties of the language input.			Saffran, JR (corresponding author), UNIV ROCHESTER,DEPT BRAIN & COGNIT SCI,601 ELMWOOD AVE,ROCHESTER,NY 14627, USA.		Galantucci, Bruno/E-5770-2010		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000167] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC000167-26, R01 DC000167, DC00167] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		[Anonymous], 1980, PERCEPTION PRODUCTIO; BICKERTON D, 1984, BEHAV BRAIN SCI, V7, P173, DOI 10.1017/S0140525X00044149; Brent MR, 1996, COGNITION, V61, P93, DOI 10.1016/S0010-0277(96)00719-6; Brown R., 1973, 1 LANGUAGE; Chomsky Noam, 1980, RULES REPRESENTATION; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; CHRISTOPHE A, 1994, J ACOUST SOC AM, V95, P1570, DOI 10.1121/1.408544; CRAIN S, 1991, BEHAV BRAIN SCI, V14, P597, DOI 10.1017/S0140525X00071491; Cutler A., 1987, Computer Speech and Language, V2, P133, DOI 10.1016/0885-2308(87)90004-0; DECASPER AJ, 1994, INFANT BEHAV DEV, V17, P159, DOI 10.1016/0163-6383(94)90051-5; Erbaugh MS., 1992, CROSSLINGUISTIC STUD, P373, DOI [10.4324/9781315808208, DOI 10.4324/9781315808208]; Fodor J. A, 1983, MODULARITY MIND; Gleitman LR, 1995, LANGUAGE INVITATION, P1; GOULD E, 1975, DEV PSYCHOBIOL, V8, P33; Harris ZS, 1955, LANGUAGE, V31, P190, DOI 10.2307/411036; Hayes J. R., 1970, COGNITION DEV LANGUA; Hess Eric H., 1973, IMPRINTING; HOY RR, 1974, AM ZOOL, V14, P1067; JUSCZYK P, 1993, J MEM LANG, V32, P401; JUSCZYK PW, 1993, CHILD DEV, V64, P675, DOI 10.2307/1131210; JUSCZYK PW, 1995, COGNITIVE PSYCHOL, V29, P1, DOI 10.1006/cogp.1995.1010; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; LENNEBERG EH, 1967, BIOL F LANGUAGE; LEON M, 1975, PHYSIOL BEHAV, V14, P311, DOI 10.1016/0031-9384(75)90039-6; MEHLER J, 1988, COGNITION, V29, P149; SAFFRAN J, IN PRESS PSYCHOL SCI; Saffran JR, 1996, J MEM LANG, V35, P606, DOI 10.1006/jmla.1996.0032; SLOBIN D, 1987, CROSSLINGUISTIC STUD, V2; Slobin D I, 1985, CROSSLINGUISTIC STUD, V1; TEICHER MH, 1977, SCIENCE, V198, P635, DOI 10.1126/science.918660	30	2972	3000	21	405	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1926	1928		10.1126/science.274.5294.1926	http://dx.doi.org/10.1126/science.274.5294.1926			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VY200	8943209				2022-12-28	WOS:A1996VY20000049
J	Daley; Resnick, NM				Daley; Resnick, NM			An 89-year-old woman with urinary incontinence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMMUNITY-DWELLING WOMEN; BLADDER NECK SUSPENSION; NURSING-HOME RESIDENTS; PELVIC MUSCLE EXERCISE; ELDERLY WOMEN; STRESS-INCONTINENCE; ELECTRICAL-STIMULATION; OLDER; BIOFEEDBACK; PATIENT		BRIGHAM & WOMENS HOSP, GERONTOL DIV, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, GRECC DIV, BOSTON, MA USA; HEBREW REHABIL CTR AGED, BOSTON, MA 02131 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School					NIA NIH HHS [AG-08812, AG-04390] Funding Source: Medline; NIDDK NIH HHS [R01-DK49482] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG008812, P01AG004390, P30AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMS P, 1988, NEUROUROL URODYNAM, V7, P403, DOI 10.1002/nau.1930070502; ASPLUND R, 1993, SCAND J UROL NEPHROL, V27, P77, DOI 10.3109/00365599309180419; BAIGISSMITH J, 1989, GERONTOLOGIST, V29, P229, DOI 10.1093/geront/29.2.229; BECK RA, 1992, ARCH INTERN MED, V152, P1242, DOI 10.1001/archinte.152.6.1242; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BRANCH LG, 1994, J AM GERIATR SOC, V42, P1257, DOI 10.1111/j.1532-5415.1994.tb06507.x; BRANDEIS G H, 1990, Journal of Urology, V143, p223A; BRINK CA, 1990, J AM GERIATR SOC, V38, P368, DOI 10.1111/j.1532-5415.1990.tb03524.x; BURGIO KL, 1990, J AM GERIATR SOC, V38, P338, DOI 10.1111/j.1532-5415.1990.tb03516.x; BURNS PA, 1993, J GERONTOL, V48, pM167; DEQUEKER J, 1965, GERONTOL CLIN, V7, P311, DOI 10.1159/000244914; DIOKNO AC, 1991, UROLOGY, V38, P39, DOI 10.1016/0090-4295(91)80010-5; DIOKNO AC, 1988, J UROLOGY, V140, P567, DOI 10.1016/S0022-5347(17)41720-4; DIOKNO AC, 1987, J AM GERIATR SOC, V35, P940, DOI 10.1111/j.1532-5415.1987.tb02296.x; DIOKNO AC, 1990, J AM GERIATR SOC, V38, P300, DOI 10.1111/j.1532-5415.1990.tb03509.x; DUBEAU CE, 1991, UROL CLIN N AM, V18, P243; DUBEAU CE, 1995, J AM GERIATR SOC, V43, P310, DOI 10.1111/j.1532-5415.1995.tb07345.x; ELBADAWI A, 1993, J UROLOGY, V150, P1668, DOI 10.1016/S0022-5347(17)35868-8; ELBADAWI A, IN PRESS J UROL; ERIKSEN BC, 1990, ACTA OBSTET GYN SCAN, V69, P45, DOI 10.3109/00016349009021038; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; FANTL JA, 1990, NEUROUROL URODYNAM, V9, P25, DOI 10.1002/nau.1930090104; FANTL JA, 1996, AHCPR PUBLICATION; Ferguson D, 1996, TRENDS PHARMACOL SCI, V17, P161, DOI 10.1016/0165-6147(96)81593-8; GORMLEY EA, 1993, NEUROUROL URODYNAM, V12, P445, DOI 10.1002/nau.1930120502; GRIFFITHJONES MD, 1990, BRIT J UROL, V65, P170, DOI 10.1111/j.1464-410X.1990.tb14692.x; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; HILTON P, 1981, BRIT MED J, V282, P940, DOI 10.1136/bmj.282.6268.940; HU TW, 1989, JAMA-J AM MED ASSOC, V261, P2656, DOI 10.1001/jama.261.18.2656; JENSEN JK, 1994, OBSTET GYNECOL, V83, P904; KIRKLAND JL, 1983, BRIT MED J, V287, P1665, DOI 10.1136/bmj.287.6406.1665; KONG TK, 1990, AGE AGEING, V19, P257, DOI 10.1093/ageing/19.4.257; MCDOWELL BJ, 1994, J AM GERIATR SOC, V42, P501, DOI 10.1111/j.1532-5415.1994.tb04971.x; *NAT ASS CONT, 1996, RES GUID; NITTI VW, 1993, J UROLOGY, V149, P802, DOI 10.1016/S0022-5347(17)36212-2; NORTON PA, 1994, OBSTET GYNECOL, V84, P770; OUSLANDER JG, 1995, ANN INTERN MED, V122, P749, DOI 10.7326/0003-4819-122-10-199505150-00003; OUSLANDER JG, 1995, ANN INTERN MED, V122, P438, DOI 10.7326/0003-4819-122-6-199503150-00007; OUSLANDER JG, 1992, NEUROUROL URODYNAM, V11, P159; Ouslander Joseph G., 1995, JAMA (Journal of the American Medical Association), V273, P1366, DOI 10.1001/jama.273.17.1366; Resnick NM, 1996, NEUROUROL URODYNAM, V15, P583, DOI 10.1002/(SICI)1520-6777(1996)15:6<583::AID-NAU1>3.0.CO;2-B; Resnick NM, 1996, NEUROUROL URODYNAM, V15, P599, DOI 10.1002/(SICI)1520-6777(1996)15:6<599::AID-NAU2>3.0.CO;2-A; RESNICK NM, 1990, GERONTOLOGY, V36, P8, DOI 10.1159/000213236; Resnick NM, 1996, UROL CLIN N AM, V23, P55, DOI 10.1016/S0094-0143(05)70293-7; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; RESNICK NM, 1995, LANCET, V346, P94, DOI 10.1016/S0140-6736(95)92117-6; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; Resnick NM., 1994, HARRISONS PRINCIPLES, P30; Resnick NM, 1984, MED GRAND ROUNDS, V3, P281; RESNICK NM, 1988, NEUROUROL URODYNAM, V7, P274; RESNICK NM, 1991, MINIMUM DATA SET TRA, pF24; Resnick NM, 1995, NEUROUROL URODYNAM, V14, P577; RESNICK NM, 1996, QUALITY CARE NURSING, P377; Resnik NM, 1988, NEUROUROL URODYNAM, P303; SAND PK, 1995, AM J OBSTET GYNECOL, V173, P72, DOI 10.1016/0002-9378(95)90172-8; SEILER WO, 1992, CLIN INVESTIGATOR, V70, P619; SUAREZ GM, 1991, UROLOGY, V37, P119, DOI 10.1016/0090-4295(91)80205-L; SUSSET J, 1995, J UROLOGY, V153, P1461, DOI 10.1016/S0022-5347(01)67433-0; WELLS TJ, 1990, J AM GERIATR SOC, V38, P333, DOI 10.1111/j.1532-5415.1990.tb03515.x; WELLS TJ, 1991, J AM GERIATR SOC, V39, P785, DOI 10.1111/j.1532-5415.1991.tb02701.x; WETLE T, 1995, J AM GERIATR SOC, V43, P349, DOI 10.1111/j.1532-5415.1995.tb05806.x; ZEITLIN MP, 1992, J AM GERIATR SOC, V40, P635, DOI 10.1111/j.1532-5415.1992.tb02118.x	62	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1832	1840						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946905				2022-12-28	WOS:A1996VV99700034
J	King, RW; Deshaies, RJ; Peters, JM; Kirschner, MW				King, RW; Deshaies, RJ; Peters, JM; Kirschner, MW			How proteolysis drives the cell cycle	SCIENCE			English	Review							UBIQUITIN-CONJUGATING ENZYME; MATURATION-PROMOTING FACTOR; PROTEIN LIGASE SYSTEM; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; BUDDING YEAST; GENE ENCODES; S-PHASE; PHYSARUM-POLYCEPHALUM; REGULATED DEGRADATION	Oscillations in the activity of cyclin-dependent kinases (CDKs) promote progression through the eukaryotic cell cycle. This review examines how proteolysis regulates CDK activity-by degrading CDK activators or inhibitors-and also how proteolysis may directly trigger the transition from metaphase to anaphase; Proteolysis during the cell cycle is mediated by two distinct ubiquitin-conjugation pathways. One pathway, requiring CDC34, initiates DNA replication by degrading a CaK inhibitor, The second pathway, involving a large protein complex called the anaphase-promoting complex or cyclosome, initiates chromosome segregation and exit from mitosis by degrading anaphase inhibitors and mitotic cyclins, Proteolysis therefore drives cell cycle progression not only by regulating CDK activity, but by directly influencing chromosome and spindle dynamics.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CALTECH,DIV BIOL 15629,PASADENA,CA 91125	Harvard University; Harvard Medical School; California Institute of Technology			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; CHAU V, COMMUNICATION; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COHENFIX O, IN PRESS GENES DEV; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DANDREA AD, 1996, P NATL ACAD SCI USA, V93, P3275; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELDMAN RD, UNPUB; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOCHSTRASSER M, COMMUNICATION; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; JAMES SW, 1995, J CELL SCI, V108, P3485; JUANG YD, UNPUB; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KAUFFMAN S, 1975, J THEOR BIOL, V55, P47, DOI 10.1016/S0022-5193(75)80108-1; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LI JK, 1995, MOL BIOL CELL, V9, P1111; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LYAPINA S, UNPUB; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MATHOG D, COMMUNICATION; MCGARRY T, UNPUB; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL M, COMMUNICATION; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; ODONNELL KL, 1991, J CELL SCI, V99, P711; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIMMINGTON G, 1994, J CELL SCI, V107, P2729; SACHSENMAIER W, 1972, EXP CELL RES, V73, P41, DOI 10.1016/0014-4827(72)90099-7; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Schwob E, 1996, CELL, V84, pU13; SCHWOB E, COMMUNICATION; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Singer JD, 1996, MOL CELL BIOL, V16, P1356; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STARBORG M, 1994, J BIOL CHEM, V269, P24133; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VANDERVELDEN HMW, 1993, MOL CELL BIOL, V13, P1480, DOI 10.1128/MCB.13.3.1480; VANDERVELDEN HMW, 1994, MOL BIOL CELL, V5, P713, DOI 10.1091/mbc.5.7.713; Verma R. P., UNPUB; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YEW R, UNPUB; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zhang DH, 1996, NATURE, V382, P466, DOI 10.1038/382466a0; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	145	1098	1164	1	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1652	1659		10.1126/science.274.5293.1652	http://dx.doi.org/10.1126/science.274.5293.1652			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939846				2022-12-28	WOS:A1996VW71200045
J	Yamagata, K; Furuta, H; Oda, N; Kaisaki, PJ; Menzel, S; Cox, NJ; Fajans, SS; Signorini, S; Stoffel, M; Bell, GI				Yamagata, K; Furuta, H; Oda, N; Kaisaki, PJ; Menzel, S; Cox, NJ; Fajans, SS; Signorini, S; Stoffel, M; Bell, GI			Mutations In the hepatocyte nuclear factor-4 alpha gene in maturity-onset diabetes of the young (MODY1)	NATURE			English	Article							LIGAND-BINDING DOMAIN; RECEPTOR SUPERFAMILY; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; HORMONE RECEPTOR; LIVER; HNF-4; MELLITUS; SUBTYPE	THE disease maturity-onset diabetes of the young (MODY) is a genetically heterogeneous monogenic form of non-insulin-dependent (type 2) diabetes mellitus (NIDDM), characterized by early onset, usually before 25 years of age and often in adolescence or childhood, and by autosomal dominant inheritance(1). It has been estimated that 2-5% of patients with NIDDM may have this form of diabetes mellitus(2,3). Clinical studies have shown that prediabetic MODY subjects have normal insulin sensitivity but suffer from a defect in glucose-stimulated insulin secretion, suggesting that pancreatic beta-cell dysfunction rather than insulin resistance is the primary defect in this disorder(4,5). Linkage studies have localized the genes that are mutated in MODY on human chromosomes 20 (MODY1)(6), 7 (MODY2)(2) and 12 (MODY3)(7), with MODY2 and MODY3 being allelic with the genes encoding glucokinase(2), a key regulator of insulin secretion, and hepatocyte nuclear factor-1 alpha (HNF-1 alpha)(8), a transcription factor involved in tissue-specific regulation of liver genes but also expressed in pancreatic islets, insulinoma cells and other tissues. Here we show that MODY1 is the gene encoding HNF-4 alpha (gene symbol, TCF14), a member of the steroid/thyroid hormone receptor superfamily and an upstream regulator of HNF-1 alpha expressiong-(9,11).	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; ROCKEFELLER UNIV,LAB METAB DIS,NEW YORK,NY 10021	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Michigan System; University of Michigan; Rockefeller University			Menzel, Stephan/U-6906-2019	Menzel, Stephan/0000-0002-1590-9108; Stoffel, Markus/0000-0003-1304-5817				BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BYME MM, 1995, DIABETES, V44, P699; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Drewes T, 1996, MOL CELL BIOL, V16, P925; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FAJANS SS, 1994, LIFE SCI, V55, P413, DOI 10.1016/0024-3205(94)90052-3; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HERMAN WH, 1994, DIABETES, V43, P40, DOI 10.2337/diabetes.43.1.40; HERMAN WH, 1994, DIABETES, V43, P1171; IRWIN M, 1994, P NATL ACAD SCI USA, V91, P11684, DOI 10.1073/pnas.91.24.11684; Iwasaki Naoki, 1996, Journal of the Japan Diabetes Society, V39, P409; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LEDERMANN HM, 1995, LANCET, V345, P648, DOI 10.1016/S0140-6736(95)90548-0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STOFFEL M, 1996, P NATL ACAD SCI USA, V93, P3939; TAVAVIRAS S, 1994, MECH DEVELOP, V48, P67; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	30	922	955	1	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					458	460		10.1038/384458a0	http://dx.doi.org/10.1038/384458a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945471	Green Submitted			2022-12-28	WOS:A1996VW68700061
J	Kuida, K; Zheng, TS; Na, SQ; Kuan, CY; Yang, D; Karasuyama, H; Rakic, P; Flavell, RA				Kuida, K; Zheng, TS; Na, SQ; Kuan, CY; Yang, D; Karasuyama, H; Rakic, P; Flavell, RA			Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice	NATURE			English	Article							PROGRAMMED CELL-DEATH; CHICK-EMBRYO; SPINAL-CORD; PHOSPHATIDYLSERINE; INHIBITION; MIGRATION; PROTEASE; ELEGANS	PROGRAMMED cell death (apoptosis) is a prominent feature of the development of the immune and nervous systems(1,2). The identification of the Caenorhabditis elegans cell death gene, ced-3, as a prototype of the interleukin-1 beta converting enzyme (ICE) protease family has led to extensive evidence implicating these enzymes in apoptosis(3,4). Among the ten or more members of the ICE protease family, CPP32/yama/apopain(5-7) exhibits the highest similarity to CED-3 in both sequence homolog and substrate specificity(8). To analyse its function in vivo, we generated CPP32-deficient mice by homologous recombination, These mice, horn at a frequency lower than expected by mendelian genetics, mere smaller than their Littermates and died at 1-3 weeks of age, Although their thymocytes retained normal susceptibility to various apoptotic stimuli, brain development in CPP32-deficient mice was profoundly affected, and discernible by embryonic day 12, resulting in a variety of hyperplasias and disorganized cell deployment, These supernumerary cells were postmitotic and terminally differentiated by the postnatal stage, Pyknotic clusters at sites of major morphogenetic change during normal brain development(9) were not observed in the mutant embryos, indicating decreased apoptosis in the absence of CPP32. Thus CPP32 is shown to play a critical role during morphogenetic cell death(9,10) in the mammalian brain.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510; TOKYO METROPOLITAN INST MED SCI,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Howard Hughes Medical Institute; Yale University; Yale University; Tokyo Metropolitan Institute of Medical Science			Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836				Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HAMBURGER V, 1958, AM J ANAT, V102, P265; HOMMA S, 1994, J COMP NEUROL, V345, P377, DOI 10.1002/cne.903450305; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; KALLEN B, 1955, J ANAT, V89, P153; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Osborne BA, 1996, CURR OPIN IMMUNOL, V8, P245, DOI 10.1016/S0952-7915(96)80063-X; PITTMAN R, 1979, J COMP NEUROL, V187, P425, DOI 10.1002/cne.901870210; RAKIC P, 1968, J COMP NEUROL, V132, P45, DOI 10.1002/cne.901320103; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; SILVER J, 1973, J MORPHOL, V140, P159, DOI 10.1002/jmor.1051400204; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	30	1656	1687	2	66	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					368	372		10.1038/384368a0	http://dx.doi.org/10.1038/384368a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934524				2022-12-28	WOS:A1996VV27100052
J	Petrov, DA; Lozovskaya, ER; Hartl, DL				Petrov, DA; Lozovskaya, ER; Hartl, DL			High intrinsic: Rate of DNA loss in Drosophila	NATURE			English	Article							TRANSPOSABLE ELEMENTS; PROCESSED PSEUDOGENES; SEQUENCE EVOLUTION; GENES; MECHANISM	PSEUDOGENES are common in mammals but virtually absent in Drosophila(1). All putative Drosophila pseudogenes show patterns of molecular evolution that are inconsistent with the lack of functional constraints(2-5). The absence of bona fide pseudogenes is not only puzzling it also hampers attempts to estimate rates and patterns of neutral DNA change. The estimation problem is especially acute in the case of deletions and insertions, which are likely to have large effects when they occur in functional genes and are therefore subject to strong purifying selection. We propose a solution to this problem by taking advantage of the propensity of retrotransposable elements, without long terminal repeats (non-LTR) to: create non-functional, 'dead-on-arrival' copies of themselves as a common by-product of their transpositional cycle(6-8). Phylogenetic analysis of a non-LTR element, Helena, demonstrates that copies lose DNA at an unusually high rate, suggesting that lack of pseudogenes in Drosophila is the product of rampant deletion of DNA in unconstrained regions, This finding has important implications for the study of genome evolution in general and the 'C-value paradox'(9) in particular.			Petrov, DA (corresponding author), HARVARD UNIV, DEPT ORGANISM & EVOLUTIONARY BIOL, 16 DIVINITY AVE, CAMBRIDGE, MA 02138 USA.			Petrov, Dmitri/0000-0002-3664-9130				BEBENEK K, 1993, REVERSE TRANSCRIPTAS; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; CURRIE PD, 1994, GENETICS, V138, P353; deSouza SJ, 1996, GENES CELLS, V1, P493, DOI 10.1046/j.1365-2443.1996.d01-264.x; EICKBUSH DG, 1995, GENETICS, V139, P685; FINNEGAN DJ, 1989, MOBILE DNA, P503; GRAUR D, 1989, J MOL EVOL, V28, P279, DOI 10.1007/BF02103423; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JONES CW, 1982, J MOL EVOL, V19, P87, DOI 10.1007/BF02100227; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MADDISON WP, 1992, VERSION 3; MCCLURE M, 1993, REVERSE TRANSCRIPTAS; PETROV DA, 1995, P NATL ACAD SCI USA, V92, P8050, DOI 10.1073/pnas.92.17.8050; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; SPRINGER MS, 1995, MOL BIOL EVOL, V12, P219; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SULLIVAN DT, 1994, MOL BIOL EVOL, V11, P443; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; [No title captured]	23	295	300	2	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					346	349		10.1038/384346a0	http://dx.doi.org/10.1038/384346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934517				2022-12-28	WOS:A1996VV27100045
J	Bresee, JS; Mast, EE; Coleman, FJ; Baron, MJ; Schonberger, LB; Alter, MJ; Jonas, MM; Yu, MYW; Renzi, PM; Schneider, LC				Bresee, JS; Mast, EE; Coleman, FJ; Baron, MJ; Schonberger, LB; Alter, MJ; Jonas, MM; Yu, MYW; Renzi, PM; Schneider, LC			Hepatitis C virus infection associated with administration of intravenous immune globulin - A cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-B-HEPATITIS; NON-A-HEPATITIS; POSTTRANSFUSION HEPATITIS; IMMUNOGLOBULIN; PLASMA; FRACTIONATION; TRANSMISSION; ANTIBODY; ASSAY	Objective.-To determine the risk of and risk factors for hepatitis C virus (HCV) infection among persons with immune deficiencies who had received intravenous immune globulin (IGIV) between March 1993 and February 1994. Design.-Retrospective cohort study. Setting.-An immunology program in a tertiary care hospital. Patients.-Of 341 persons who had received IGIV between March 1, 1993, and February 22, 1994, 278 (82%) were enrolled. The mean age for the enrolled persons was 9 years, and 99% had primary immune deficiencies. Main Outcome Measures.-Evidence of HCV infection by detection in sera of antibody to HCV and/or HCV RNA by reverse transcriptase polymerase chain reaction. Results.-Twenty-three (11%) of 210 persons who received the IGIV Gammagard (Baxter Healthcare Corporation, Deerfield, Ill) became infected compared with none of 52 persons who received exclusively other IGIV products (P=.01). In a multivariate analysis, HCV infection was associated only with Gammagard produced from plasma screened by second-generation (multiantigen) anti-HCV tests (P=.03). Hepatitis C virus RNA was detected in Gammagard, and the risk of transmission to recipients increased with increasing quantity of HCV RNA infused, from 0 for those who received no HCV RNA-positive lots to 29% for the quartile of patients receiving the greatest amount (P<.001). At least 9 different lots of Gammagard were required to account for all cases. Conclusion.-Gammagard was the only IGIV product implicated in the transmission of HCV. Infection was associated with higher quantities of HCV RNA in Gammagard produced from second-generation anti-HCV-screened plasma. Further studies are needed to determine reasons for the infectivity of Gammagard, and viral inactivation and removal steps are needed to ensure the safety of IGIV products.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV GASTROENTEROL, BOSTON, MA USA; US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL, BETHESDA, MD 20892 USA; CHILDRENS HOSP, DIV IMMUNOL, BOSTON, MA USA	Centers for Disease Control & Prevention - USA; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; US Food & Drug Administration (FDA); Harvard University; Boston Children's Hospital					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 2172] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; BISWAS RM, 1994, TRANSFUSION, V34, P100, DOI 10.1046/j.1537-2995.1994.34294143934.x; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P505; Davis G L, 1993, Recent Results Cancer Res, V132, P213; FINLAYSON JS, 1990, LANCET, V335, P1274, DOI 10.1016/0140-6736(90)91335-8; LAI ME, 1993, J PEDIATR GASTR NUTR, V16, P458, DOI 10.1097/00005176-199305000-00020; LANE RS, 1983, LANCET, V2, P974; LEVER AML, 1984, LANCET, V2, P1062; LOK ASF, 1993, HEPATOLOGY, V18, P497, DOI 10.1002/hep.1840180305; MARCELLIN P, 1994, J INFECT DIS, V170, P433, DOI 10.1093/infdis/170.2.433; MARTIN P, 1989, GASTROENTEROLOGY, V97, P1559, DOI 10.1016/0016-5085(89)90405-8; OCHS HD, 1985, LANCET, V1, P404; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992; WEILAND O, 1986, LANCET, V1, P976; WILLIAMS PE, 1988, LANCET, V2, P501; YAP PL, 1994, J HEPATOL, V21, P455, DOI 10.1016/S0168-8278(05)80328-9; YEI S, 1992, TRANSFUSION, V32, P824, DOI 10.1046/j.1537-2995.1992.32993110753.x; YU MW, 1995, LANCET, V345, P1173, DOI 10.1016/S0140-6736(95)91002-6; YU MYW, 1994, TRANSFUSION, V34, P596, DOI 10.1046/j.1537-2995.1994.34794330014.x	20	80	81	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1563	1567		10.1001/jama.276.19.1563	http://dx.doi.org/10.1001/jama.276.19.1563			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918853				2022-12-28	WOS:A1996VT02500028
J	Fowke, KR; Nagelkerke, NJD; Kimani, J; Simonsen, JN; Anzala, AO; Bwayo, JJ; MacDonald, KS; Ngugi, EN; Plummer, FA				Fowke, KR; Nagelkerke, NJD; Kimani, J; Simonsen, JN; Anzala, AO; Bwayo, JJ; MacDonald, KS; Ngugi, EN; Plummer, FA			Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; POLYMERASE CHAIN-REACTION; BLOOD MONONUCLEAR-CELLS; HOMOSEXUAL MEN; PERIPHERAL-BLOOD; TYPE-1 INFECTION; TRANSMISSION; AMPLIFICATION; RESPONSES	Background There is indirect evidence that HIV-1 exposure does not inevitably lead to persistent infection. Heterogeneity in susceptibility to infection could be due to protective immunity. The objective of this study was to find out whether in highly HIV-1-exposed populations some individuals are resistant to infection. Methods We did an observational cohort study of incident HIV-1 infection among 424 initially HIV-1-seronegative prostitutes in Nairobi, Kenya, between 1985 and 1994. 239 women seroconverted to HIV-1 during the study period. Exponential, Weibull, and mixture survival models were used to examine the effect of the duration of follow-up on incidence of HIV-1 infection. The influence of the duration of exposure to HIV-1 through prostitution on seroconversion risk was examined by Cox proportional hazards modelling, with control for other known or suspected risk factors for incident HIV-1 infection. HIV-1 PCR with env, nef, and vif gene primers was done on 43 persistently seronegative prostitutes who remained seronegative after 3 or more years of follow-up. Findings Modelling of the time to HIV-1 seroconversion showed that the incidence of HIV-1 seroconversion decreased with increasing duration of exposure, which indicates that there is heterogeneity in HIV-1. susceptibility or acquired immunity to HIV-1. Each weighted year of exposure through prostitution resulted in a 1.2-fold reduction in HIV-1 seroconversion risk (hazard ratio 0 . 83 [95% CI 0 . 79-0 . 88], p<0 . 0001). Analyses of epidemiological and laboratory data, show that persistent seronegativity is not explained by seronegative HIV-1 infection or by differences in risk factors for HIV-1 infection such as safer sexual behaviours or the incidence of other sexually transmitted infections. Interpretation We conclude that a small proportion of highly exposed individuals, who may have natural protective immunity to HIV-1, are resistant to HIV-1.	UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT MED,WINNIPEG,MB R3E 0W3,CANADA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; UNIV NAIROBI,DEPT COMMUNITY HLTH,NAIROBI,KENYA	University of Manitoba; University of Manitoba; University of Nairobi; University of Nairobi			MacDonald, Kelly S/L-3315-2019	Fowke, Keith/0000-0001-8227-6649				ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BARCELLINI W, 1995, AIDS, V9, P691, DOI 10.1097/00002030-199507000-00004; BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BRUISTEN SM, 1992, J INFECT DIS, V166, P620, DOI 10.1093/infdis/166.3.620; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; DAWOOD MR, 1992, J CLIN MICROBIOL, V30, P2279, DOI 10.1128/JCM.30.9.2279-2283.1992; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; FISCHL MA, 1987, 2 INT C AIDS WASH DC; FOWKE K, 1990, 5 INT C AIDS AFR KIN; FOWKE KR, 1995, CAN J INFECT DIS, V6, pB8; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PAN LZ, 1991, J INFECT DIS, V164, P962, DOI 10.1093/infdis/164.5.962; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; SIMONSEN JN, 1990, AIDS, V4, P139, DOI 10.1097/00002030-199002000-00007; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414	31	357	363	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1347	1351		10.1016/S0140-6736(95)12269-2	http://dx.doi.org/10.1016/S0140-6736(95)12269-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918278				2022-12-28	WOS:A1996VT33200011
J	Newburn, M; Gready, M				Newburn, M; Gready, M			Informed choice for users of health services: Views on ultrasonography leaflets of women in early pregnancy, midwives, and ultrasonographers - Evidence based information for women is important - Commentary	BRITISH MEDICAL JOURNAL			English	Article											Newburn, M (corresponding author), NATL CHILDBIRTH TRUST,ALEXANDRA HOUSE,LONDON W3 6NH,ENGLAND.							DODDS R, IN PRESS WOMENS EXPE; GRADY M, 1995, BIRTH COICES WOMENS; GREADY M, IN PRESS REPORT 2 PH; HENDERSON C, 1996, BRIT J MIDWIFERY, V4, P117; MARTEAU TM, 1992, PUBLIC HEALTH, V106, P131, DOI 10.1016/S0033-3506(05)80390-7	5	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1253	1254		10.1136/bmj.313.7067.1253	http://dx.doi.org/10.1136/bmj.313.7067.1253			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU208	8939121	Green Published			2022-12-28	WOS:A1996VU20800033
J	Bugge, TH; Kombrinck, KW; Flick, MJ; Daugherty, CC; Danton, MJS; Degen, JL				Bugge, TH; Kombrinck, KW; Flick, MJ; Daugherty, CC; Danton, MJS; Degen, JL			Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency	CELL			English	Article							TUMOR-CELL INVASION; UROKINASE RECEPTOR; DEGRADATION PRODUCTS; ACTIVATOR; MOUSE; GROWTH; INHIBITION; EMBRYOGENESIS; DISSEMINATION; LOCALIZATION	Plasmin(ogen) is an extracellular serine protease implicated in the activation of latent growth factors and procollagenase, degradation of extracellular matrix components, and fibrin clearance. Plasminogen (Plg) deficiency in mice results in high mortality, wasting, spontaneous gastrointestinal ulceration, rectal prolapse, and severe thrombosis. Furthermore, Plg-deficient mice display delayed wound healing following skin injury, a defect partly related to impaired keratinocyte migration. We generated mice deficient in Pig and fibrinogen (Fib) and show that removal of fibrin(ogen) from the extracellular environment alleviates the diverse spontaneous pathologies previously associated with Pig deficiency and corrects healing times. Mice deficient in Pig and Fib are phenotypically indistinguishable from Fib-deficient mice. These data suggest that the fundamental and possibly only essential physiological role of Pig is fibronolysis.	RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN 0,DENMARK; CHILDRENS HOSP RES FDN,DIV PATHOL,CINCINNATI,OH 45229	Rigshospitalet; University of Copenhagen; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Bugge, TH (corresponding author), CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BODE VC, 1979, DEV BIOL, V73, P272, DOI 10.1016/0012-1606(79)90067-8; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; Clark R. A. F., 1988, MOL CELLULAR BIOL WO; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Leonardsson G, 1995, P NATL ACAD SCI USA, V92, P12446, DOI 10.1073/pnas.92.26.12446; MAROTTI KR, 1982, DEV BIOL, V90, P154, DOI 10.1016/0012-1606(82)90220-2; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PEPPER MS, 1987, J CELL BIOL, V105, P2435; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PLOW EF, 1986, J IMMUNOL, V137, P1910; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; ROBSON SC, 1993, BLOOD, V81, P3006; ROBSON SC, 1994, BRIT J HAEMATOL, V86, P322, DOI 10.1111/j.1365-2141.1994.tb04733.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SKOGEN WF, 1988, BLOOD, V71, P1475; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; THOMPSON WD, 1993, BLOOD COAGUL FIBRIN, V4, P113, DOI 10.1097/00001721-199304010-00019; TRUDEL M, 1994, BLOOD, V84, P3189; VALINSKY JE, 1981, CELL, V25, P471, DOI 10.1016/0092-8674(81)90065-9; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801	54	321	333	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					709	719		10.1016/S0092-8674(00)81390-2	http://dx.doi.org/10.1016/S0092-8674(00)81390-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929539	Bronze			2022-12-28	WOS:A1996VU03500013
J	Chinery, R; Coffey, RJ				Chinery, R; Coffey, RJ			Trefoil peptides: Less clandestine in the intestine	SCIENCE			English	Editorial Material							PANCREATIC SPASMOLYTIC POLYPEPTIDE; HUMAN-BREAST-CANCER; PS2; MIGRATION; FAMILY				Chinery, R (corresponding author), VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232, USA.							Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; CARR MD, 1992, BIOCHEMISTRY-US, V31, P1998, DOI 10.1021/bi00122a015; CHINERY R, 1995, FEBS LETT, V357, P50, DOI 10.1016/0014-5793(94)01297-E; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; LEFEBVRE O, 1996, SCIENCE, V274, P252; MASHIMO H, 1996, SCIENCE, V274, P249; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; PLAYFORD RJ, 1995, GASTROENTEROLOGY, V108, P108, DOI 10.1016/0016-5085(95)90014-4; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; RIO MC, 1990, CANCER CELL-MON REV, V2, P269; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	12	9	9	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					204	204		10.1126/science.274.5285.204	http://dx.doi.org/10.1126/science.274.5285.204			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8927980				2022-12-28	WOS:A1996VM67100030
J	Zhao, DP; Kanamori, H; Negishi, H; Wiens, D				Zhao, DP; Kanamori, H; Negishi, H; Wiens, D			Tomography of the source area of the 1995 Kobe earthquake: Evidence for fluids at the hypocenter?	SCIENCE			English	Article							RUPTURE; CALIFORNIA; VELOCITY; JAPAN; ZONE; SEISMICITY; SEQUENCE; REGION; FAULTS; ROCKS	Seismic tomography revealed a low seismic velocity (-5%) and high Poisson's ratio (+6%) anomaly covering about 300 square kilometers at the hypocenter bf the 17 January 1995, magnitude 7.2, Kobe earthquake in Japan. This anomaly may be due to an overpressurized, fluid-filled, fractured rock matrix that contributed to the initiation of the Kobe earthquake.	CALTECH,SEISMOL LAB 25221,PASADENA,CA 91125; KYOTO UNIV,DISASTER PREVENT RES INST,UJI,KYOTO 611,JAPAN	California Institute of Technology; Kyoto University	Zhao, DP (corresponding author), WASHINGTON UNIV,DEPT EARTH & PLANETARY SCI,ST LOUIS,MO 63130, USA.		Wiens, Douglas A/J-9259-2016	Wiens, Douglas A/0000-0002-5169-4386; Zhao, Dapeng/0000-0003-2096-5195				CHATTERJEE SN, 1985, J VOLCANOL GEOTH RES, V26, P213, DOI 10.1016/0377-0273(85)90057-5; COX SJD, 1988, J STRUCT GEOL, V10, P413, DOI 10.1016/0191-8141(88)90019-3; EBERHARTPHILLIPS D, 1993, J GEOPHYS RES-SOL EA, V98, P15737, DOI 10.1029/93JB01029; FORSTER CB, 1991, GEOPHYS RES LETT, V18, P979, DOI 10.1029/91GL00950; FOXALL W, 1993, J GEOPHYS RES-SOL EA, V98, P17691, DOI 10.1029/93JB01424; Fuis G S., 1996, EOS T AM GEOPHYS UN, V77, P173; FUKUYAMA E, 1995, FALL M SEISM SOC JAP, pA87; Gupta HK, 1996, GEOPHYS RES LETT, V23, P1569, DOI 10.1029/96GL01032; HAGIWARA T, 1990, EARTHQUAKES JAPAN IS; Hasegawa A., 1994, MAGMATIC SYSTEMS, P179; HICKMAN S, 1995, J GEOPHYS RES-SOL EA, V100, P12831, DOI 10.1029/95JB01121; HIRAHARA K, 1981, TECTONOPHYSICS, V79, P1, DOI 10.1016/0040-1951(81)90231-6; HIRATA N, 1996, P 1996 JAP EARTH PLA, P38; HIRATA N, IN PRESS J PHYS EART; ITO K, 1995, FALL M SEISM SOC JAP, pA79; JOHNSON PA, 1995, J GEOPHYS RES-SOL EA, V100, P12937, DOI 10.1029/95JB00474; Kanamori H., 1995, SEISMOL RES LETT, V66, P6, DOI [10.1785/gssrl.66.2.6, DOI 10.1785/GSSRL.66.2.6]; KATAO H, 1995, FALL M SEISM SOC JAP, pA74; KERRICH R, 1984, J GEOPHYS RES, V89, P4331, DOI 10.1029/JB089iB06p04331; LEES JM, 1993, GEOLOGY, V21, P387, DOI 10.1130/0091-7613(1993)021<0387:TDTOTS>2.3.CO;2; LEES JM, 1990, GEOPHYS RES LETT, V17, P1433, DOI 10.1029/GL017i009p01433; MAMADA Y, 1995, FALL M SEISM SOC JAP, pP37; MATSUMOTO S, 1996, P 1996 JAP EARTH PLA, P46; MOOS D, 1983, J GEOPHYS RES, V88, P2345, DOI 10.1029/JB088iB03p02345; OBARA K, 1996, P 1996 JAP EARTH PLA, P46; OCONNELL RJ, 1974, J GEOPHYS RES, V79, P5412, DOI 10.1029/JB079i035p05412; OHMI S, 1995, FALL M SEISM SOC JAP, pA39; OKUBO Y, 1989, TECTONOPHYSICS, V159, P279, DOI 10.1016/0040-1951(89)90134-0; SCHOLZ CH, 1987, GEOLOGY, V15, P493, DOI 10.1130/0091-7613(1987)15<493:WAGFIB>2.0.CO;2; Sibson R.H., 1981, EARTHQUAKE PRED RES, V4, P593, DOI DOI 10.1029/ME004P0593; SIBSON RH, 1992, TECTONOPHYSICS, V211, P283, DOI 10.1016/0040-1951(92)90065-E; Somerville P., 1995, EOS T AM GEOPHYS UNI, V76, P49; TADOKORO K, 1996, P 1996 JAP EARTH PLA, P44; TOKSOZ MN, 1976, GEOPHYSICS, V41, P621, DOI 10.1190/1.1440639; TSUBOI S, 1989, J SEISMOL SOC JPN, V42, P277; TSUMURA N, 1996, P 1996 JAP EARTH PLA, P39; UMEDA Y, 1995, FALL M SEISM SOC JAP, pA78; UMEDA Y, 1996, P 1996 JAP EARTH PLA, P36; WALCK MC, 1988, J GEOPHYS RES-SOLID, V93, P2047, DOI 10.1029/JB093iB03p02047; YOKOYAMA I, 1987, VOLCANOES; ZHAO D, 1995, EOS S, V76, P378; ZHAO DP, 1993, GEOPHYS RES LETT, V20, P1083, DOI 10.1029/93GL01239; ZHAO DP, 1995, GEOPHYS RES LETT, V22, P763, DOI 10.1029/94GL03222; ZHAO DP, 1994, J GEOPHYS RES-SOL EA, V99, P22313, DOI 10.1029/94JB01149	44	293	334	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1891	1894		10.1126/science.274.5294.1891	http://dx.doi.org/10.1126/science.274.5294.1891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943198				2022-12-28	WOS:A1996VY20000038
J	Scheffzek, K; Lautwein, A; Kabsch, W; Ahmadian, MR; Wittinghofer, A				Scheffzek, K; Lautwein, A; Kabsch, W; Ahmadian, MR; Wittinghofer, A			Crystal structure of the GTPase-activating domain of human p120GAP and implications for the interaction with Ras	NATURE			English	Article							TYPE-1 NF1 GENE; PROTEIN; MECHANISM; GAP; HYDROLYSIS; NEUROFIBROMIN; P21; DIFFERENTIATION; MUTAGENESIS; STIMULATION	RAS-RELATED GTP-binding proteins function as molecular switches which cycle between GTP-bound 'on'- and GDP-bound 'off'-states(1), GTP hydrolysis is the common timing mechanism that mediates the return from the 'on' to the 'off'-state, It is usually slow but can be accelerated by orders of magnitude upon interaction with GTPase-activating proteins (GAPs). In the case of Ras, a major regulator of cellular growth, point mutations are found in approximately 30% of human tumours which render the protein unable to hydrolyse GTP, even in the presence of Ras-GAPs, The first structure determination of a GTPase-activating protein reveals the catalytically active fragment of the Ras-specific p120GAP (ref. 2), GAP-334, as an elongated, exclusively helical protein which appears to represent a novel protein fold, The molecule consists of two domains, one of which contains all the residues conserved among different GAPs for Ras. From the location of conserved residues around a shallow groove in the central domain we can identify the site of interaction with Ras-GTP. This leads to a model for the interaction between Ras and GAP that satisfies numerous biochemical and genetic data on this important regulatory process.	MAX PLANCK INST MOL PHYSIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BRUNGER TA, 1992, XPLOR VERSION 3 1; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GUTMANN DH, 1993, ONCOGENE, V8, P761; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HETTICH L, 1994, CANCER RES, V54, P5438; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MON S, 1995, J BIOL CHEM, V270, P28834; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Morcos P, 1996, MOL CELL BIOL, V16, P2496; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISHI T, 1991, ONCOGENE, V6, P1555; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; REY I, 1994, ONCOGENE, V9, P685; RUBINFELD B, 1991, INT J PEPT PROT RES, V38, P47; SCHEFFZEK K, IN PRESS PROTEINS ST; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YODERHILL J, 1995, J BIOL CHEM, V270, P27615, DOI 10.1074/jbc.270.46.27615	35	139	143	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1996	384	6609					591	596		10.1038/384591a0	http://dx.doi.org/10.1038/384591a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955277				2022-12-28	WOS:A1996VX76900067
J	Edgar, BA; Lehner, CF				Edgar, BA; Lehner, CF			Developmental control of cell cycle regulators: A fly's perspective	SCIENCE			English	Review							TUMOR-SUPPRESSOR GENE; DROSOPHILA WING DISC; IMAGINAL LEG DISKS; S-PHASE; LIMB DEVELOPMENT; PROTEIN-KINASE; MOUSE GENOME; PATTERN REGULATION; METAPHASE ARREST; DNA-REPLICATION	During early development in many species, maternally supplied gene products permit the cell cycle to run at maximum velocity, subdividing the fertilized egg into smaller and smaller cells. As development proceeds, zygotic controls are activated that first limit divisions to defined spatial and temporal domains, coordinating them with morphogenesis, and then halt proliferation altogether, to allow cell differentiation. Analysis of the regulation of cyclin-dependent kinases (Cdks) in Drosophila has provided insights into how this embryonic program of cell proliferation is controlled at the molecular level and how it is linked to developmental cues. Recent studies have also begun to reveal how cell proliferation is controlled during the second phase of Drosophila development, which occurs in imaginal tissues. In contrast to their embryonic progenitors, imaginal cells proliferate with a cycle that requires cell growth and is linked to patterning processes controlled by secreted cell signaling molecules. The functions of these signaling molecules appear to be nearly as conserved between vertebrates and invertebrates as the cell cycle control apparatus itself, suggesting that the mechanisms that coordinate growth, patterning, and cell proliferation in developing tissues have ancient origins.	UNIV BAYREUTH,DEPT GENET,D-95440 BAYREUTH,GERMANY	University of Bayreuth	Edgar, BA (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98109, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051186] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM51186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER PN, 1984, DEV BIOL, V103, P28, DOI 10.1016/0012-1606(84)90004-6; ADLER PN, 1981, EXP CELL RES, V133, P452, DOI 10.1016/0014-4827(81)90340-2; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; BAIJERSBERGEN RL, 1996, BIOCHIM BIOPHYS ACTA, V1287, P103; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BISSEN ST, 1995, DEVELOPMENT, V121, P3035; BRANDON EP, 1995, CURR BIOL, V5, P873, DOI 10.1016/S0960-9822(95)00177-1; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; Brook A, 1996, EMBO J, V15, P3676, DOI 10.1002/j.1460-2075.1996.tb00737.x; Brook WJ, 1996, SCIENCE, V273, P1373, DOI 10.1126/science.273.5280.1373; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Bryant PJ, 1996, BIOESSAYS, V18, P781, DOI 10.1002/bies.950181003; Bryant PJ, 1978, GENETICS BIOL DROS C, V2c, P229; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; Burke R, 1996, DEVELOPMENT, V122, P2261; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHIANG C, 1996, NATURE, V383, P365; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; DONG X, IN PRESS GENES DEV; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; DURONIO RJ, IN PRESS GENES DEV; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; Edgar BA, 1996, GENE DEV, V10, P1966, DOI 10.1101/gad.10.15.1966; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; EDGAR BA, UNPUB; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; FOLETTE P, COMMUNICATION; FREDERICK DL, 1994, J EXP ZOOL, V270, P410, DOI 10.1002/jez.1402700411; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GATEFF E, 1994, INT J DEV BIOL, V38, P565; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; GONZALEZ MA, 1994, EUR J PHARM BIOPHARM, V40, P183; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; HAO XF, 1995, J CELL SCI, V108, P2945; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; Hartley RS, 1996, DEV BIOL, V173, P408, DOI 10.1006/dbio.1996.0036; Hayashi S, 1996, DEVELOPMENT, V122, P1051; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Howe JA, 1996, P NATL ACAD SCI USA, V93, P2060, DOI 10.1073/pnas.93.5.2060; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JAMES AA, 1981, DEV BIOL, V85, P39, DOI 10.1016/0012-1606(81)90234-7; JANG JK, 1995, SCIENCE, V268, P1917, DOI 10.1126/science.7604267; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnston LA, 1996, DEVELOPMENT, V122, P3519; JOHNSTON LJ, UNPUB; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KIEHLE CP, 1985, DEV BIOL, V109, P336, DOI 10.1016/0012-1606(85)90460-9; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KIPREOS ET, 1996, GENE DEV, V85, P829; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; LANE ME, COMMUNICATION; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEHNER CF, UNPUB; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; MATHIAS, IN PRESS CELL; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; MEINHARDT H, 1994, BIOESSAYS, V16, P627, DOI 10.1002/bies.950160906; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; MILAN M, 1996, P NATL ACAD SCI USA, V96, P11687; NAGL W, 1982, CELL GROWTH; NAKAYAMA K, 1995, CELL, V82, P707; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; ORRWEAVER TL, 1995, P NATL ACAD SCI USA, V92, P10443, DOI 10.1073/pnas.92.23.10443; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PATTERSON BD, COMMUNICATION; PEDERSON RA, 1994, PHYSL REPROD; Penton A, 1996, NATURE, V382, P162, DOI 10.1038/382162a0; PENTON A, IN PRESS SCIENCE; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; Pritchard DK, 1996, GENE DEV, V10, P1131, DOI 10.1101/gad.10.9.1131; RAVNIK SE, 1995, DEV GENET, V16, P171, DOI 10.1002/dvg.1020160209; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROTHE M, 1992, NATURE, V359, P156, DOI 10.1038/359156a0; Sagata N, 1996, TRENDS CELL BIOL, V6, P22, DOI 10.1016/0962-8924(96)81034-8; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SHERMOEN AW, 1991, CELL, V67, P1; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIBON O, COMMUNICATION; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SICINSKI P, IN PRESS NATURE; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SMITH AV, 1991, DEVELOPMENT, V112, P997; SONENBERG N, 1996, TRANSLATIONAL CONTRO; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; SPRENGER F, COMMUNICATION; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1995, DEVELOPMENT, V121, P3359; THOMAS BB, UNPUB; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOROK T, 1993, GENETICS, V135, P71; Twitty VC, 1930, J EXP ZOOL, V55, P43, DOI 10.1002/jez.1400550105; Verlhac MH, 1996, DEVELOPMENT, V122, P815; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; WATSON KL, 1994, J CELL SCI S, V18, P19; WEIGMANN K, UNPUB; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WICKRAMASINGHE D, 1995, DEVELOPMENT, V121, P1283; WIERSDORFF V, 1995, DEVELOPMENT, V121, P2153; WILLEMS AR, 1996, GENE DEV, V86, P453; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207; XU TA, 1995, DEVELOPMENT, V121, P1053; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YASUDA GK, 1992, TRENDS GENET, V8, P124; ZECCA M, 1995, DEVELOPMENT, V121, P2265; ZINZAR SN, 1971, TRANSPLANTATION, V11, P499, DOI 10.1097/00007890-197105000-00015; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	154	218	222	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1646	1652		10.1126/science.274.5293.1646	http://dx.doi.org/10.1126/science.274.5293.1646			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939845				2022-12-28	WOS:A1996VW71200044
J	Erickson, JC; Hollopeter, G; Palmiter, RD				Erickson, JC; Hollopeter, G; Palmiter, RD			Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y	SCIENCE			English	Article							GENE-PRODUCT; MOUSE; RATS; HYPOTHALAMUS; PROTEIN; RNA	The obesity syndrome of ob/ob mice results from lack of leptin, a hormone released by fat cells that acts in the brain to suppress feeding and stimulate metabolism. Neuropeptide Y (NPY) is a neuromodulator implicated in the control of energy balance and is overproduced in the hypothalamus of ob/ob mice. To determine the role of NPY in the response to leptin deficiency, ob/ob mice deficient for NPY were generated. In the absence of NPY, ob/ob mice are less obese because of reduced food intake and increased energy expenditure, and are less severely affected by diabetes, sterility, and somatotropic defects, These results suggest that NPY is a central effector of leptin deficiency.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Barash IA, 1996, ENDOCRINOLOGY, V137, P3144, DOI 10.1210/en.137.7.3144; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; LANE PW, 1954, J HERED, V45, P56, DOI 10.1093/oxfordjournals.jhered.a106439; LARSON BA, 1976, ENDOCRINOLOGY, V98, P139, DOI 10.1210/endo-98-1-139; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pierroz DD, 1996, ENDOCRINOLOGY, V137, P3, DOI 10.1210/en.137.1.3; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; SHEHAB FF, 1996, NAT GENET, V12, P318; Smith FJ, 1996, NATURE, V382, P307, DOI 10.1038/382307a0; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEIN DT, 1995, INT J OBESITY, V19, P804; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	35	707	727	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1704	1707		10.1126/science.274.5293.1704	http://dx.doi.org/10.1126/science.274.5293.1704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939859				2022-12-28	WOS:A1996VW71200058
J	Wengler, GS; Lanfranchi, A; Frusca, T; Verardi, R; Neva, A; Brugnoni, D; Giliani, S; Fiorini, M; Mella, P; Guandalini, F; Mazzolari, E; Pecorelli, S; Notarangelo, LD; Porta, F; Ugazio, AG				Wengler, GS; Lanfranchi, A; Frusca, T; Verardi, R; Neva, A; Brugnoni, D; Giliani, S; Fiorini, M; Mella, P; Guandalini, F; Mazzolari, E; Pecorelli, S; Notarangelo, LD; Porta, F; Ugazio, AG			In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDXI)	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; STEM-CELLS; RECIPIENTS; GENE	Background X-linked severe combined immunodeficiency (SCIDXI) is an inherited immune defect which leads to death in infancy from severe infections. The defect is caused by mutations of the IL-2RG gene that encodes for the common gamma chain shared by several cytokine receptors. The disease is characterised by lack of T and NK cells with normal numbers of B cells. SCIDXI can be cured by bone marrow transplantation (BMT) or prevented by abortion after prenatal diagnosis. Methods A male fetus was diagnosed as having SCIDXI by molecular, immunophenotypic, and functional analyses. The fetus was injected intraperitoneally under ultrasound guidance with CD34 haematopoietic progenitor cells purified from paternal bone marrow and T-cell depleted by E resetting. Chimerism analysis was by HLA-DQ alpha typing and gamma-chain staining on cord blood. Findings A healthy 3.6 kg boy was delivered by caesarean section at 38 weeks of gestation with no clinical or laboratory signs of graft-versus-host disease. Engraftment of donor-derived CD2 cells was found at birth, At 3.5 months of age the infant is well and his T-cell counts and function are normal. Interpretation In-utero transplantation of haematopoietic progenitor cells allowed immune reconstitution of a fetus with SCIDXI and may be an alternative to elective abortion. Our report should encourage applications of this method to other inherited disorders curable by BMT.	UNIV BRESCIA,DEPT GYNAECOL,I-25124 BRESCIA,ITALY; UNIV BRESCIA,INST CLIN IMMUNOL,I-25124 BRESCIA,ITALY; UNIV BRESCIA,INST CHEM,I-25124 BRESCIA,ITALY	University of Brescia; University of Brescia; University of Brescia	Wengler, GS (corresponding author), UNIV BRESCIA,DEPT PAEDIAT,I-25124 BRESCIA,ITALY.		Brugnoni, Duilio/AAG-9425-2019; Giliani, Silvia/AAX-8843-2020; Ugazio, Alberto/AAA-6092-2020	Brugnoni, Duilio/0000-0001-9420-9961; Giliani, Silvia/0000-0001-8137-4642; 	Telethon [A.042] Funding Source: Medline	Telethon(Fondazione Telethon)		Blau CA, 1996, NAT MED, V2, P161, DOI 10.1038/nm0296-161; BLAZAR BR, 1995, BLOOD, V86, P4353, DOI 10.1182/blood.V86.11.4353.bloodjournal86114353; BLAZAR BR, 1995, BLOOD, V85, P833, DOI 10.1182/blood.V85.3.833.bloodjournal853833; BORDIGNON C, 1995, NATURE, V270, P470; CLARK PA, 1995, HUM GENET, V96, P427; Cowan MJ, 1996, BONE MARROW TRANSPL, V17, P1157; DURANDY A, 1985, ARCH FR PEDIATR, V42, P163; Flake A. W., 1995, Blood, V86, p125A; Friedrich W, 1993, Immunodeficiency, V4, P315; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; HARRISON MR, 1989, LANCET, V2, P425; MCKINNON S, 1995, BLOOD, V86, P1261; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOTARANGELO LD, 1993, DEV PHYSIOPATH CLIN, V4, P109; REISNER Y, 1983, P NATL ACAD SCI USA, V79, P6047; SLAVIN S, 1992, BONE MARROW TRANSPL, V9, P189; SROUR EF, 1993, BLOOD, V82, P3333; Sutherland DR, 1996, EXP HEMATOL, V24, P795; TOURAINE JL, 1987, THYMUS, V10, P75; Vossen J M, 1993, Immunodeficiency, V4, P311; WENGLER GS, 1993, J IMMUNOL, V150, P700; WENGLER GS, 1995, SCIENCE, V86, P3648	22	190	192	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1484	1487		10.1016/S0140-6736(96)09392-0	http://dx.doi.org/10.1016/S0140-6736(96)09392-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942778				2022-12-28	WOS:A1996VV46300011
J	Grunewald, A; Lankheet, MJM				Grunewald, A; Lankheet, MJM			Orthogonal motion after-effect illusion predicted by a model of cortical motion processing	NATURE			English	Article							TRANSPARENT MOTION; AREA MT; PERCEPTION; DIRECTION; INTEGRATION; MOVEMENT; PATTERNS; ADAPTATION; COHERENCE; NEURONS	THE motion after-effect occurs after prolonged viewing of motion; a subsequent stationary scene is perceived as moving in the opposite direction(1,2). This illusion Is thought to arise because motion is represented by the differential activities of populations of cortical neurons toned to opposite directions; fatigue in one population leads to an imbalance that favours the opposite direction once the stimulus ceases(3). Following adaptation to multiple directions of motion, the after-effect is unidirectional(4-6), indicating that motion signals are integrated across all directions. Yet humans can perceive several directions of motion simultaneously(7-10). The question therefore arises as to how the visual system can perform both sharp segregation and global integration of motion signals, Here me show in computer simulations that this can occur if excitatory interactions between different directions are sharply tuned while inhibitory interactions are broadly tuned, Our model predicts that adaptation to simultaneous motion in opposite directions will lead to an orthogonal motion after-effect. This prediction was confirmed in psychophysical experiments, Thus, broadly tuned inhibitory interactions are likely to be important in the integration and segregation of motion signals. These interactions may occur in the cortical area MT, which contains motion-sensitive neurons with properties similar to those required by our model(11-14).	MAX PLANCK INST BIOL CYBERNET,D-72076 TUBINGEN,GERMANY; UNIV UTRECHT,DEPT COMPARAT PHYSIOL,NL-3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,HELMHOLTZ INST,NL-3584 CH UTRECHT,NETHERLANDS	Max Planck Society; Utrecht University; Utrecht University	Grunewald, A (corresponding author), CALTECH,DIV BIOL,MAIL CODE 216-76,PASADENA,CA 91125, USA.							Addams J, 1834, LONDON EDINBURGH PHI, V5, P373, DOI [DOI 10.1080/14786443408648481, 10.1080/14786443408648481]; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRADLEY DC, 1995, NATURE, V373, P609, DOI 10.1038/373609a0; CLARKE PGH, 1977, VISION RES, V17, P1243, DOI 10.1016/0042-6989(77)90164-X; GIASCHI D, 1993, J NEUROPHYSIOL, V70, P2024, DOI 10.1152/jn.1993.70.5.2024; GROSSBERG S, 1972, Mathematical Biosciences, V15, P253, DOI 10.1016/0025-5564(72)90038-7; GROSSBERG S, 1976, BIOL CYBERN, V23, P121, DOI 10.1007/BF00344744; Grunewald A, 1996, ADV NEUR IN, V8, P837; Heeger DJ, 1996, P NATL ACAD SCI USA, V93, P623, DOI 10.1073/pnas.93.2.623; HINS E, 1992, P NATL ACAD SCI USA, V89, P9025; Hiris E, 1996, VISUAL NEUROSCI, V13, P187, DOI 10.1017/S0952523800007227; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MATHER G, 1980, PERCEPTION, V9, P379, DOI 10.1068/p090379; MINGOLLA E, 1992, VISION RES, V32, P1015, DOI 10.1016/0042-6989(92)90003-2; MULLIGAN JB, 1993, VISION RES, V33, P2021, DOI 10.1016/0042-6989(93)90025-R; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; QIAN N, 1994, J NEUROSCI, V14, P7357; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; STONER GR, 1990, NATURE, V344, P153, DOI 10.1038/344153a0; SUTHERLAND NS, 1961, Q J EXP PSYCHOL, V13, P222, DOI 10.1080/17470216108416498; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; VANDOORN AJ, 1985, PERCEPTION, V14, P209, DOI 10.1068/p140209; VERSTRATEN FAJ, 1994, VISION RES, V34, P349, DOI 10.1016/0042-6989(94)90093-0; VERSTRATEN FAJ, 1994, VISION RES, V34, P1149, DOI 10.1016/0042-6989(94)90297-6; WATAMANIUK SNJ, 1989, VISION RES, V29, P47, DOI 10.1016/0042-6989(89)90173-9; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1	29	62	62	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					358	360		10.1038/384358a0	http://dx.doi.org/10.1038/384358a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934521				2022-12-28	WOS:A1996VV27100049
J	Nelson, RG; Bennett, PH; Beck, GJ; Tan, M; Knowler, WC; Mitch, WE; Hirschman, GH; Myers, BD				Nelson, RG; Bennett, PH; Beck, GJ; Tan, M; Knowler, WC; Mitch, WE; Hirschman, GH; Myers, BD			Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVERT NEPHROPATHY; ALBUMIN EXCRETION; NEPHROTIC HUMANS; PROTEINURIA; SELECTIVITY; PREVALENCE; DIET	Background Non-insulin-dependent diabetes mellitus (NIDDM) is a major cause of end-stage renal disease. However, the course and determinants of renal failure in this type of diabetes have not been clearly defined. Methods We studied glomerular function at intervals of 6 to 12 months for 4 years in 194 Pima Indians selected to represent different stages in the development and progression of diabetic renal disease. Initially, 31 subjects had normal glucose tolerance, 29 had impaired glucose tolerance, 30 had newly diagnosed diabetes, and 104 had had diabetes for five years or more; of these 104, 20 had normal albumin excretion, 50 had microalbuminuria, and 34 had macroalbuminuria. The glomerular filtration rate, renal plasma flow, urinary albumin excretion, and blood pressure were measured at each examination. Results Initially, the mean (+/-SE) glomerular filtration rate was 143+/-7 ml per minute in subjects with newly diagnosed diabetes, 155+/-7 ml per minute in those with microalbuminuria, and 124+/-7 ml per minute in those with macroalbuminuria; these values were 16 percent, 26 percent, and 1 percent higher, respectively, than in the subjects with normal glucose tolerance (123+/-4 ml per minute). During four years of follow-up, the glomerular filtration rate increased by 18 percent in the subjects who initially had newly diagnosed diabetes (P=0.008); the rate declined by 3 percent in those with microalbuminuria at base line (P=0.29) and by 35 percent in those with macroalbuminuria (P<0.001). Higher base-line blood pressure predicted increasing urinary albumin excretion (P=0.006), and higher base-line urinary albumin excretion predicted a decline in the glomerular filtration rate (P<0.001). The initial glomerular filtration rate did not predict worsening albuminuria. Conclusions The glomerular filtration rate is elevated at the onset of NIDDM and remains so while normal albumin excretion or microalbuminuria persists. it declines progressively after the development of macroalbuminuria. (C)1996, Massachusetts Medical Society.	CLEVELAND CLIN FDN,DEPT BIOSTAT & EPIDEMIOL,DIABET RENAL DIS STUDY DATA COORDINATING CTR,CLEVELAND,OH 44195; EMORY UNIV,SCH MED,DIV RENAL,ATLANTA,GA 30322; NIDDKD,DIV KIDNEY UROL & HEMATOL DIS,CHRON RENAL DIS PROGRAM,BETHESDA,MD; NIDDKD,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ; STANFORD UNIV,SCH MED,DIV NEPHROL,STANFORD,CA 94305	Cleveland Clinic Foundation; Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University			Bennett, Peter/AAH-9605-2021; Nelson, Robert G/B-1470-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK062285, N01DK072291] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01-DK-6-2285, N01-DK-7-2291] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG RLS, 1975, BIOPHYS J, V15, P861, DOI 10.1016/S0006-3495(75)85862-0; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; DEEN WM, 1985, AM J PHYSIOL, V249, pF374, DOI 10.1152/ajprenal.1985.249.3.F374; DRUMOND MC, 1994, J CLIN INVEST, V94, P1187, DOI 10.1172/JCI117435; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; HOSTETTER TH, 1981, KIDNEY INT, V19, P410, DOI 10.1038/ki.1981.33; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MENARD L, 1980, CLIN CHEM, V26, P1598; MYERS BD, 1995, KIDNEY INT, V47, P1781, DOI 10.1038/ki.1995.246; NAKAMURA Y, 1988, DIABETES, V37, P1202, DOI 10.2337/diabetes.37.9.1202; NELSON RG, 1991, ARCH INTERN MED, V151, P1761, DOI 10.1001/archinte.151.9.1761; NELSON RG, 1995, DIABETES CARE, V18, P182, DOI 10.2337/diacare.18.2.182; NELSON RG, 1989, DIABETOLOGIA, V32, P870, DOI 10.1007/BF00297452; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; NELSON RG, 1991, ACTA DIABETOL, V28, P143, DOI 10.1007/BF00579717; PAGTALUNAN ME, 1994, J AM SOC NEPHROL, V5, P381; PARVING HH, 1992, KIDNEY INT, V41, P758, DOI 10.1038/ki.1992.118; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; VASQUEZ B, 1984, DIABETOLOGIA, V26, P127, DOI 10.1007/BF00281119; World Health Organization, 1985, WHO TECH REP SER, V727, P7; [No title captured]	25	369	377	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1636	1642		10.1056/NEJM199611283352203	http://dx.doi.org/10.1056/NEJM199611283352203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929360	Bronze			2022-12-28	WOS:A1996VV93600003
J	Joneson, T; McDonough, M; BarSagi, D; VanAelst, L				Joneson, T; McDonough, M; BarSagi, D; VanAelst, L			RAC regulation of actin polymerization and proliferation by a pathway distinct from Jun kinase	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASES; BINDING; GTPASES; TRANSFORMATION; CDC42; RHOA; PHOSPHORYLATION; IDENTIFICATION; DOMAIN	The RAC guanine nucleotide binding proteins regulate multiple biological activities, including actin polymerization, activation of the Jun kinase (JNK) cascade, and cell proliferation. RAC effector loop mutants were identified that separate the ability of RAC to interact with different downstream effecters. One mutant of activated human RAC protein, RAC(V12H40) (with valine and histidine substituted at position 12 and 40, respectively), was defective in binding to PAK3, a Ste20-related p21-activated kinase (PAK), but bound to PORI, a RAG-binding protein. This mutant failed to stimulate PAK and JNK activity but still induced membrane ruffling and mediated transformation. A second mutant, RAC(V12L37) (with leucine substituted at position 37), which bound PAK but not PORI, induced JNK activation but was defective in inducing membrane ruffling and transformation, These results indicate that the effects of RAC on the JNK cascade and on actin polymerization and cell proliferation are mediated by distinct effector pathways that diverge at the level of RAC itself.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,DEPT MOL GENET & MICROBIOL,STONY BROOK,NY 11794	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				McDonough, Michele/0000-0002-3718-6465; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055360, R37CA055360, R56CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P1; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JONESON T, UNPUB; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	32	234	238	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1374	1376		10.1126/science.274.5291.1374	http://dx.doi.org/10.1126/science.274.5291.1374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910277				2022-12-28	WOS:A1996VU95400053
J	Paytan, A; Kastner, M; Chavez, FP				Paytan, A; Kastner, M; Chavez, FP			Glacial to interglacial fluctuations in productivity in the equatorial Pacific as indicated by marine barite	SCIENCE			English	Article							ATMOSPHERIC CO2; EXPORT PRODUCTION; OCEAN; SEDIMENTS; FLUX; ACCUMULATION; STRONTIUM; SEAWATER; CARBON; RATES	An empirical correlation between marine barite (BaSO4) accumulation rate in core-top sediment samples from two equatorial Pacific transects (at 140 degrees W and 110 degrees W) and the estimated primary productivity of the overlying water column were used to evaluate glacial to interglacial changes in productivity. Fluctuations in barite-accumulation rates down-core indicate that during glacial periods of the past 450,000 years, the productivity in the central and eastern equatorial Pacific was about two times that during intervening interglacial periods. This result is consistent with other evidence that productivity was high in the eastern and central equatorial Pacific during the last glacial.	MBARI,MOSS LANDING,CA 95039	Monterey Bay Aquarium Research Institute	Paytan, A (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.							ANDERSON RF, 1994, OC SCI M ASLO SAN DI, P71; Anderson Roy, COMMUNICATION; ARRHENIUS G, 1963, SEA, V3, P655; BARBER RT, 1994, AMBIO, V23, P62; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; BERGER WH, 1991, LIMNOL OCEANOGR, V36, P1899, DOI 10.4319/lo.1991.36.8.1899; BERGER WH, 1982, MAR GEOL, V45, P93, DOI 10.1016/0025-3227(82)90182-7; Berger WH, 1989, OCEAN PRODUCTIVITY P; BERGER WH, 1994, CARBON CYCLING GLACI, P385; BERNSTEIN RE, 1992, GEOCHIM COSMOCHIM AC, V56, P3273, DOI 10.1016/0016-7037(92)90304-2; BISHOP JKB, 1988, NATURE, V331, P341; Bostrom K., 1973, LITHOS, V6, P159; BROECKER WS, 1982, GEOCHIM COSMOCHIM AC, V46, P689; CHAVEZ FP, 1990, DEEP-SEA RES, V37, P1733, DOI 10.1016/0198-0149(90)90074-6; CHAVEZ FP, 1987, DEEP-SEA RES, V34, P1229, DOI 10.1016/0198-0149(87)90073-2; CHAVEZ FP, IN PRESS DEEP SEA RE; CHURCH TM, 1979, MINERALOGICAL SOC AM, V6, P175; DEHAIRS F, 1992, SCIENCE, V258, P1332, DOI 10.1126/science.258.5086.1332; DEHAIRS F, 1980, EARTH PLANET SC LETT, V49, P529; DEMASTER DJ, 1996, OC SCI M ASLO SAN DI, P187; DYMOND J, 1985, LIMNOL OCEANOGR, V30, P699, DOI 10.4319/lo.1985.30.4.0699; DYMOND J, IN PRESS DEEP SEA RE; Dymond J, 1992, PALEOCEANOGRAPHY, V7, P163, DOI 10.1029/92PA00181; Elderfield H, 1990, PALEOCEANOGRAPHY, V5, P711, DOI 10.1029/PA005i005p00711; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; GINGELE F, 1994, PALEOCEANOGRAPHY, V9, P151, DOI 10.1029/93PA02559; GOLDBERG ED, 1958, GEOCHIM COSMOCHIM AC, V13, P153, DOI 10.1016/0016-7037(58)90046-2; KNOWLTON CW, 1995, INT C PAL HAL CAN 10, P136; MARCANTONIO F, 1995, EARTH PLANET SC LETT, V133, P549, DOI 10.1016/0012-821X(95)00079-R; MARCANTONIO F, IN PRESS NATURE; MIX A, COMMUNICATION; MURRAY JW, 1989, DEEP-SEA RES, V36, P1471, DOI 10.1016/0198-0149(89)90052-6; MURRAY JW, 1994, SCIENCE, V266, P58, DOI 10.1126/science.266.5182.58; MURRAY RW, 1993, PALEOCEANOGRAPHY, V8, P651, DOI 10.1029/93PA02195; MURRAY RW, 1995, GLOBAL BIOGEOCHEM CY, V9, P667, DOI 10.1029/95GB02833; MURRAY RW, IN PRESS GEOCHIM COS; NEFTEL A, 1982, NATURE, V295, P220, DOI 10.1038/295220a0; PAYTAN A, 1993, NATURE, V366, P445, DOI 10.1038/366445a0; PEDERSEN TF, 1983, GEOLOGY, V11, P16, DOI 10.1130/0091-7613(1983)11<16:IPITEE>2.0.CO;2; PLATT T, 1985, NATURE, V318, P55, DOI 10.1038/318055a0; Rea DK, 1991, PALEOCEANOGRAPHY, V6, P227, DOI 10.1029/90PA02542; Schmitz B, 1987, PALEOCEANOGRAPHY, V2, P63, DOI 10.1029/PA002i001p00063; SHIMMIELD GB, 1988, CHEM GEOL, V70, P112, DOI 10.1016/0009-2541(88)90520-7; SNOECKX H, 1994, MAR GEOL, V120, P327, DOI 10.1016/0025-3227(94)90065-5; SNOECKX H, 1995, THESIS U MICHIGAN AN	45	255	276	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1355	1357		10.1126/science.274.5291.1355	http://dx.doi.org/10.1126/science.274.5291.1355			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910271				2022-12-28	WOS:A1996VU95400047
J	Carley, S; MackwayJones, K				Carley, S; MackwayJones, K			Are British hospitals ready for the next major incident? Analysis of hospital major incident plans	BRITISH MEDICAL JOURNAL			English	Article											Carley, S (corresponding author), MANCHESTER ROYAL INFIRM,DEPT EMERGENCY MED,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND.		carley, simon/W-7944-2019	carley, simon/0000-0003-1561-5553				HIDDEN A, 1989, INVESTIGATION CLAPHA; MALONE WD, 1989, INJURY, V21, P49; NACEKIEVILL DG, 1992, BRIT MED J, V305, P721; NEW B, 1992, TOO MANY COOKS; *NHS MAN EX, 1990, HC9025	5	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1242	1243		10.1136/bmj.313.7067.1242	http://dx.doi.org/10.1136/bmj.313.7067.1242			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939115	Green Published			2022-12-28	WOS:A1996VU20800024
J	Gent, M; Beaumont, D; Blanchard, J; Bousser, MG; Coffman, J; Easton, JD; Hampton, JR; Harker, LA; Janzon, L; Kusmierek, JJE; Panak, E; Roberts, RS; Shannon, JS; Sicurella, J; Tognoni, G; Topol, EJ; Verstraete, M; Warlow, C				Gent, M; Beaumont, D; Blanchard, J; Bousser, MG; Coffman, J; Easton, JD; Hampton, JR; Harker, LA; Janzon, L; Kusmierek, JJE; Panak, E; Roberts, RS; Shannon, JS; Sicurella, J; Tognoni, G; Topol, EJ; Verstraete, M; Warlow, C			A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)	LANCET			English	Article							ACUTE CORONARY SYNDROMES; ARTERY DISEASE; PATHOGENESIS; MECHANISMS	Background Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine have been shown to be effective, but both have potentially serious adverse effects. Clopidogrel, a new thienopyridine derivative similar to ticlopidine, is an inhibitor of platelet aggregation induced by adenosine diphosphate. Methods CAPRIE was a randomised, blinded, international trial designed to assess the relative efficacy of clopidogrel (75 mg once daily) and aspirin (325 mg once daily) in reducing the risk of a composite outcome cluster of ischaemic stroke, myocardial infarction, or vascular death; their relative safety was also assessed. The population studied comprised subgroups of patients with atherosclerotic Vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease. Patients were followed for 1 to 3 years. Findings 19 185 patients, with more than 6300 in each of the clinical subgroups, were recruited over 3 years, with a mean follow-up of 1 . 91 years. There were 1960 first events included in the outcome cluster on which an intention-to-treat analysis showed that patients treated with clopidogrel had an annual 5 . 32% risk of ischaemic stroke, myocardial infarction, or vascular death compared with 5 . 83% with aspirin. These rates reflect a statisticaly significant (p=0 . 043) relative-risk reduction of 8 . 7% in favour of clopidogrel (95% CI 0 . 3-16 . 5). Corresponding on-treatment analysis yielded a relative-risk reduction of 9 . 4%. There were no major differences in terms of safety. Reported adverse experiences in the clopidogrel and aspirin groups judged to be severe included rash (0 . 26% vs 0 . 10%), diarrhoea (0 . 23% vs 0 . 11%), upper gastrointestinal discomfort (0 . 97% vs 1 . 22%), intracranial haemorrhage (0 . 33% vs 0 . 47%), and gastrointestinal haemorrhage (0 . 52% vs 0 . 72%), respectively. There were ten (0 . 10%) patients in the clopidogrel group with significant reductions in neutrophils (<1 . 2 X 10(9)/L) and 16 (0 . 17%) in the aspirin group. Interpretation Long-term administration of clopidogrel to patients with atherosclerotic vascular disease is more effective than aspirin in reducing the combined risk of ischaemic stroke, myocardial infarction, or vascular death. The overall safety profile of clopidogrel is at least as good as that of medium-dose aspirin.	MCMASTER UNIV, HAMILTON, ON, CANADA	McMaster University	Gent, M (corresponding author), HAMILTON CIV HOSP, RES CTR, CLIN TRIALS METHODOL GRP, COORDINATING & METHODS CTR, 711 CONCESS ST, HAMILTON, ON L8V 1C3, CANADA.		McQuillan, Brendan/B-8271-2013; Sieunarine, Kishore/AAI-5548-2020; Davis, Stephen M/L-5260-2013; gresele, paolo/AAG-8019-2019; Gresele, Paolo/F-6775-2013; Thompson, Peter L/P-1071-2014; Hankey, Graeme J/H-4968-2014; LEYS, Didier/G-2955-2016; Buchan, Alastair M/B-9095-2009; CATALANO, MARIA/F-2708-2017	McQuillan, Brendan/0000-0002-2130-8114; Sieunarine, Kishore/0000-0003-4151-5505; Davis, Stephen M/0000-0003-0962-2300; Gresele, Paolo/0000-0001-5365-8445; Hankey, Graeme J/0000-0002-6044-7328; LEYS, Didier/0000-0003-4408-4392; Buchan, Alastair M/0000-0002-2918-5200; Jessup, Mariell/0000-0002-3010-0112; Cunha, Luis/0000-0002-0828-3485; Schultz, David/0000-0001-6319-7574; Moulin, thierry/0000-0002-6639-8117; Hershey, Linda/0000-0001-5090-6634; CATALANO, MARIA/0000-0002-8355-0344; Weder, Bruno/0000-0002-8106-9899; Dippel, Diederik/0000-0002-9234-3515; McDougall, Alan/0000-0002-7358-3548				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, BRIT MED J, V296, P320; COX DR, 1972, J R STAT SOC B, V34, P187; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Gent M, 1993, TICLOPIDINE PLATELET, P99; HERBERT JM, 1993, CARDIOVASC DRUG REV, V11, P180, DOI 10.1111/j.1527-3466.1993.tb00275.x; HERBERT JM, 1993, ARTERIOSCLER THROMB, V13, P1171, DOI 10.1161/01.ATV.13.8.1171; HIRSH J, 1995, CHEST, V108, pS247, DOI 10.1378/chest.108.4_Supplement.247S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Moloney BA, 1993, TICLOPIDINE PLATELET, P117; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Savi P, 1996, CLIN APPL THROMB-HEM, V2, P35, DOI 10.1177/107602969600200108; SAVI P, 1994, J PHARMACOL EXP THER, V269, P772	15	4748	4964	6	193	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 16	1996	348	9038					1329	1339		10.1016/s0140-6736(96)09457-3	http://dx.doi.org/10.1016/s0140-6736(96)09457-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918275				2022-12-28	WOS:A1996VT33200008
J	Schekman, R				Schekman, R			Polypeptide translocation: A pretty picture is worth a thousand words	CELL			English	Review							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN-CONDUCTING CHANNEL; ESCHERICHIA-COLI; SECRETORY PROTEINS; SECY; RIBOSOMES; EXPORT; SEC61P				Schekman, R (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA.							AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G., 1971, BIOMEMBRANE, P193; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; KIM YJ, 1994, CELL, V78, P845; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	23	9	10	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					593	595		10.1016/S0092-8674(00)81378-1	http://dx.doi.org/10.1016/S0092-8674(00)81378-1			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929528	Bronze			2022-12-28	WOS:A1996VU03500002
J	Winter, GB				Winter, GB			What about the ethics?	BRITISH MEDICAL JOURNAL			English	Editorial Material							CARIES											DODDSSMITH I, 1992, DOCTORS PATIENTS LAW, P157; ISOKANGAS P, 1991, CARIES RES, V25, P444, DOI 10.1159/000261408; KANDELMAN D, 1988, CARIES RES, V22, P55, DOI 10.1159/000261084; Makinen KK, 1995, J DENT RES, V74, P1904, DOI 10.1177/00220345950740121501; RUGGGUNN AJ, 1993, DENT CARIES NONSUGAR, P272; Scheinin A., 1975, ACTA ODONTOL SCAND, V33, P1	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1183	1184		10.1136/bmj.313.7066.1183	http://dx.doi.org/10.1136/bmj.313.7066.1183			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916750	Green Published			2022-12-28	WOS:A1996VR90700023
J	Nicholson, KG; Kent, J; Hammersley, V; Cancio, E				Nicholson, KG; Kent, J; Hammersley, V; Cancio, E			Risk factors for lower respiratory complications of rhinovirus infections in elderly people living in the community: Prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFLUENZA IMMUNIZATION; ILLNESS; SUSCEPTIBILITY; FREQUENCY; TECUMSEH; ASTHMA; ADULTS; NASAL; COLDS	Objective-To assess the role of rhinoviruses in elderly people living in the community. Design-Prospective community based surveillance of elderly people, without intervention. Subjects were telephoned weekly to identify symptomatic upper respiratory tract infections. Symptoms and impact of illnesses were monitored, and specimens were collected for diagnostic serology and human rhinovirus polymerase chain reaction. Setting-Leicestershire, England. Subjects-533 subjects aged 60 to 90. Main outcome measures-Symptoms, restriction of activity, medical consultations, and antibiotic use during 96 rhinovirus infections. Adjusted odds ratios for lower respiratory syndromes with respect to smoking and health status. Results-A viral cause was established in 211 (43%) of 497 respiratory illnesses; rhinoviruses were identified in 121 (24%) and as single pathogens in 107. The median duration of the first or only rhinovirus infection in the 96 people with 107 rhinovirus infections was 16 days; 18 of the 96 patients were confined to bed and 25 were unable to cope with routine household activities. Overall, 60 patients with rhinovirus infections had lower respiratory tract syndromes; 41 patients consulted their doctor, 31 of them (76%) receiving antibiotics. One patient died. Logistic regression analysis showed that chronic medical conditions increased the estimated probability of lower respiratory rhinovirus illness by 40% (95% confidence interval 17% to 68%) and smoking by 47% (14% to 90%). There were almost six times as many symptomatic rhinovirus infections as influenza A and B infections. Conclusions-Rhinoviruses are an important cause of debility and lower respiratory illness among elderly people in the community. Chronic ill health and smoking increase the likelihood of lower respiratory complications from such infections. The overall burden of rhinovirus infections in elderly people may approach that of influenza.			Nicholson, KG (corresponding author), UNIV LEICESTER, SCH MED, DEPT MICROBIOL & IMMUNOL, LEICESTER LE1 9HN, LEICS, ENGLAND.							[Anonymous], IMM INF DIS; AROLA M, 1988, J PEDIATR-US, V113, P693, DOI 10.1016/S0022-3476(88)80380-9; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; CATE TR, 1973, AM REV RESPIR DIS, V108, P858; COHEN S, 1993, AM J PUBLIC HEALTH, V83, P1277, DOI 10.2105/AJPH.83.9.1277; CRAIGHEAD JE, 1969, NEW ENGL J MED, V281, P1403, DOI 10.1056/NEJM196912182812506; DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; DOUGLAS RG, 1966, AM REV RESPIR DIS, V94, P159; EADIE MB, 1966, BMJ-BRIT MED J, V2, P671, DOI 10.1136/bmj.2.5515.671; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FLEMING DM, 1993, EUR J EPIDEMIOL, V9, P571, DOI 10.1007/BF00211429; FORSYTH BR, 1963, NEW ENGL J MED, V269, P602, DOI 10.1056/NEJM196309192691203; FRIDY WW, 1974, ANN INTERN MED, V80, P150, DOI 10.7326/0003-4819-80-2-150; GEORGE RB, 1969, ANN INTERN MED, V71, P1073, DOI 10.7326/0003-4819-71-6-1073; GOINGS SAJ, 1989, AM REV RESPIR DIS, V139, P1075, DOI 10.1164/ajrccm/139.5.1075; GWALTNEY JM, 1967, J AMER MED ASSOC, V202, P494, DOI 10.1001/jama.202.6.494; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; HAMRE D, 1961, BRIT MED J, V2, P1382, DOI 10.1136/bmj.2.5264.1382; HOBSON D, 1960, BRIT MED J, V2, P1414, DOI 10.1136/bmj.2.5210.1414; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; MONTO AS, 1993, EPIDEMIOL INFECT, V110, P145, DOI 10.1017/S0950268800050779; MONTO AS, 1971, AM J EPIDEMIOL, V94, P280, DOI 10.1093/oxfordjournals.aje.a121321; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957; NICHOLSON KG, 1990, EPIDEMIOL INFECT, V105, P609, DOI 10.1017/S0950268800048251; NICHOLSON KG, 1995, VACCINE, V13, P365, DOI 10.1016/0264-410X(95)98258-C; Office of Health Economics, 1989, COMP HLTH STAT; REILLY CM, 1962, ANN INTERN MED, V57, P515, DOI 10.7326/0003-4819-57-4-515; STENHOUSE AC, 1967, BMJ-BRIT MED J, V3, P461, DOI 10.1136/bmj.3.5563.461; STOTT EJ, 1968, J MED MICROBIOL, V1, P109, DOI 10.1099/00222615-1-1-109; WALD TG, 1995, ANN INTERN MED, V123, P588, DOI 10.7326/0003-4819-123-8-199510150-00004; WINTHER B, 1984, ACTA OTO-LARYNGOL, V98, P315, DOI 10.3109/00016488409107569	36	108	113	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1119	1123		10.1136/bmj.313.7065.1119	http://dx.doi.org/10.1136/bmj.313.7065.1119			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916700	Green Published			2022-12-28	WOS:A1996VR21700025
J	Sheth, BR; Sharma, J; Rao, SC; Sur, M				Sheth, BR; Sharma, J; Rao, SC; Sur, M			Orientation maps of subjective contours in visual cortex	SCIENCE			English	Article							ILLUSORY CONTOURS; RETINOTOPIC ORGANIZATION; CYTOCHROME-OXIDASE; STRIATE CORTEX; CAT; AREA-17; NEURONS; RESPONSES; PATTERNS; KITTENS	Responses to subjective contours in visual cortical areas V1 and V2 in adult cats were investigated by optical imaging of intrinsic signals and single-unit recording. Both V1 and V2 contain maps of the orientation of subjective gratings that have their basis in specific kinds of neuronal responses to subjective orientations. A greater proportion of neurons in V2 than in V1 show a robust response to subjective edges. Through the use of subjective stimuli in which the orientation of the luminance component is invariant, an unmasked V1 response to subjective edges alone can be demonstrated. The data indicate that the processing of subjective contours begins as early as V1 and continues progressively in higher cortical areas.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NEI NIH HHS [EY07023] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBUS K, 1975, EXP BRAIN RES, V24, P159, DOI 10.1007/BF00234061; BONHOEFFER T, 1995, EUR J NEUROSCI, V7, P1973, DOI 10.1111/j.1460-9568.1995.tb00720.x; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BRAVO M, 1988, VISION RES, V28, P861, DOI 10.1016/0042-6989(88)90095-8; DEWEERD P, 1990, BEHAV BRAIN RES, V39, P1, DOI 10.1016/0166-4328(90)90117-W; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GREGORY RL, 1963, NATURE, V199, P678, DOI 10.1038/199678a0; GRINVALD A, 1986, NATURE, V324, P351; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUMPHREY AL, 1985, J COMP NEUROL, V233, P190, DOI 10.1002/cne.902330204; KAGEYAMA GH, 1986, J COMP NEUROL, V243, P182, DOI 10.1002/cne.902430204; Kanizsa G., 1979, ORG VISION ESSAYS GE, P192; Kanizsa G., 1955, RIV PSICOL, V49, P7; KOENDERINK JJ, 1984, PERCEPTION, V13, P321, DOI 10.1068/p130321; LAMME VAF, 1995, J NEUROSCI, V15, P1605; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P101, DOI 10.1113/jphysiol.1978.sp012490; NELSON S, 1994, SCIENCE, V265, P774, DOI 10.1126/science.8047882; OTSUKA R, 1962, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V203, P212, DOI 10.1007/BF00352744; PAYNE BR, 1990, VISUAL NEUROSCI, V4, P445, DOI 10.1017/S0952523800005204; PRICE DJ, 1985, EXP BRAIN RES, V58, P125; Rao S. C., 1994, Society for Neuroscience Abstracts, V20, P836; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; REDIES C, 1986, EXP BRAIN RES, V61, P469; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; Rossi AF, 1996, SCIENCE, V273, P1104, DOI 10.1126/science.273.5278.1104; Schumann F, 1900, Z PSYCHOL PHYSIOL SI, V23, P1; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; Toth LJ, 1996, P NATL ACAD SCI USA, V93, P9869, DOI 10.1073/pnas.93.18.9869; TUSA RJ, 1979, J COMP NEUROL, V185, P657, DOI 10.1002/cne.901850405; TUSA RJ, 1978, J COMP NEUROL, V177, P213, DOI 10.1002/cne.901770204; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731	35	143	146	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2110	2115		10.1126/science.274.5295.2110	http://dx.doi.org/10.1126/science.274.5295.2110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953048				2022-12-28	WOS:A1996VY97400058
J	McIntyre, A; Molfino, B				McIntyre, A; Molfino, B			Forcing of Atlantic equatorial and subpolar millennial cycles by precession	SCIENCE			English	Article							HEINRICH EVENTS; NORTH-ATLANTIC; CLIMATE VARIABILITY; LAST GLACIATION; OCEAN; OSCILLATIONS; RECORD; SEA	Abundance cycles of the marine alga Florisphaera profunda centered on a period of 7600 carbon-14 years (8400 calendar years) are present in high-resolution records from the equatorial Atlantic spanning 0 to 45,000 years ago. These cycles correlate with Heinrich events 1 through 5, which document rapid changes in continental ice melting around the subpolar North Atlantic. These variations in F. profunda are a direct response to modulation in zonal wind-driven divergence produced by a precessional component of orbital variation during a time of reduced eccentricity modulation.			McIntyre, A (corresponding author), COLUMBIA UNIV, LAMONT DOHERTY EARTH OBSERV, PALISADES, NY 10964 USA.							BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; BERGER A, 1988, SCI REP I ASTRON GEO, V13, P1; Berger A., 1989, QUATERN INT, V2, P1, DOI DOI 10.1016/1040-6182(89)90016-5; BICKEL PJ, 1977, MATH STATISTICS; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Broecker W, 1992, CLIM DYNAM, V6, P265, DOI 10.1007/BF00193540; DAHL SO, 1993, HOLOCENE, V3, P269; FONTAINE B, 1993, INT J CLIMATOL, V13, P271, DOI 10.1002/joc.3370130304; FRONVAL T, 1995, NATURE, V374, P443, DOI 10.1038/374443a0; GASSE F, 1994, EARTH PLANET SC LETT, V126, P435, DOI 10.1016/0012-821X(94)90123-6; GRIMM EC, 1993, SCIENCE, V261, P198, DOI 10.1126/science.261.5118.198; HAFLIDASON H, 1995, GEOLOGY, V23, P1059, DOI 10.1130/0091-7613(1995)023<1059:CROTLG>2.3.CO;2; HAGELBERG TK, 1994, PALEOCEANOGRAPHY, V9, P545, DOI 10.1029/94PA00443; Harrison SP, 1996, QUATERNARY RES, V45, P138, DOI 10.1006/qres.1996.0016; Heinrich H., 1988, QUATERNARY RES, V29, P143, DOI DOI 10.1016/0033-5894(88)90057-9); HODELL DA, 1995, NATURE, V375, P391, DOI 10.1038/375391a0; Jenkins G., 1968, SPECTRAL ANAL ITS AP; JONES GA, IN PRESS DEEP SEA RE; KEIGWIN LD, 1995, PALEOCEANOGRAPHY, V10, P973, DOI 10.1029/95PA02643; KOTILAINEN AT, 1995, NATURE, V377, P323, DOI 10.1038/377323a0; Lorenz E.N., 1968, METEOROL MONOGR, P1, DOI [10.1007/978-1-935704-38-6_1, DOI 10.1007/978-1-935704-38-6_1]; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775, DOI 10.1029/93PA02200; MAYEWSKI PA, 1994, SCIENCE, V263, P1747, DOI 10.1126/science.263.5154.1747; MCINTYRE A, 1995, 5 INT C PAL HAL NOV, P54; McIntyre A, 1989, PALEOCEANOGRAPHY, V4, P19, DOI 10.1029/PA004i001p00019; MOLFINO B, 1990, SCIENCE, V249, P766, DOI 10.1126/science.249.4970.766; PESTIAUX P, 1988, CLIMATIC CHANGE, V12, P9, DOI 10.1007/BF00140262; PORTER SC, 1995, NATURE, V375, P305, DOI 10.1038/375305a0; Reverdin G, 1995, DAHL WS ENV, V18, P125; SHORT DA, 1991, QUATERNARY RES, V35, P157, DOI 10.1016/0033-5894(91)90064-C; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; VERARDO DJ, 1994, PALEOCEANOGRAPHY, V9, P63, DOI 10.1029/93PA02901; WEISBERG RH, 1987, J GEOPHYS RES-OCEANS, V92, P3709, DOI 10.1029/JC092iC04p03709; YIOU P, 1995, GEOPHYS RES LETT, V22, P2175	34	176	182	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1867	1870		10.1126/science.274.5294.1867	http://dx.doi.org/10.1126/science.274.5294.1867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943191				2022-12-28	WOS:A1996VY20000031
J	Thomson, KT; Wentzcovitch, RM; Bukowinski, MST				Thomson, KT; Wentzcovitch, RM; Bukowinski, MST			Polymorphs of alumina predicted by first principles: Putting pressure on the ruby pressure scale	SCIENCE			English	Article							INDUCED BREATHING MODEL; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; PHASE-TRANSITION; SINGLE-CRYSTAL; FLUORESCENCE; CORUNDUM; MGSIO3	Fully optimized quantum mechanical calculations indicate that Al2O3 transforms from the corundum structure to the as yet unobserved Rh2O3 (II) structure at about 78 gigapascals, and it further transforms to Pbnm-perovskite structure at 223 gigapascals, The predicted x-ray spectrum of the Rh2O3 (II) structure is similar to that of the corundum structure, suggesting that the Rh2O3 (II) structure could go undetected in high-pressure x-ray measurements. It is therefore possible that the ruby (Cr3+-doped corundum) fluorescence pressure scale is sensitive to the thermal history of the ruby chips in a given experiment.	UNIV MINNESOTA,MINNESOTA SUPERCOMP INST,MINNEAPOLIS,MN 55455; UNIV SAO PAULO,INST FIS,BR-05389970 SAO PAULO,BRAZIL; UNIV CALIF BERKELEY,DEPT GEOL & GEOPHYS,BERKELEY,CA 94720	University of Minnesota System; University of Minnesota Twin Cities; Universidade de Sao Paulo; University of California System; University of California Berkeley	Thomson, KT (corresponding author), UNIV MINNESOTA,DEPT CHEM ENGN & MAT SCI,MINNEAPOLIS,MN 55455, USA.		Wentzcovitch, Renata M/J-8768-2015					BELL PM, 1984, SCIENCE, V226, P542, DOI 10.1126/science.226.4674.542; BIRCH F, 1978, J GEOPHYS RES, V83, P1257, DOI 10.1029/JB083iB03p01257; Bukowinski M., 1996, MOL ENG, V6, P81; BURBANK RD, 1970, J APPL CRYSTALLOGR, V3, P112; CEPERLEY DM, 1980, PHYS REV LETT, V45, P566, DOI 10.1103/PhysRevLett.45.566; COHEN RE, 1987, GEOPHYS RES LETT, V14, P37, DOI 10.1029/GL014i001p00037; CYNN H, 1990, AM MINERAL, V75, P439; DAMOUR H, 1978, J APPL PHYS, V49, P4411, DOI 10.1063/1.325494; DERIGHET.B, 1965, ACTA CRYSTALLOGR, V18, P557, DOI 10.1107/S0365110X65001184; FINGER LW, 1978, J APPL PHYS, V49, P5823, DOI 10.1063/1.324598; GASPARIK T, 1988, EOS T AGU, V69, P1451; GLAZER AM, 1972, ACTA CRYSTALLOGR B, VB 28, P3384, DOI 10.1107/S0567740872007976; HEMLEY RJ, 1992, ANNU REV EARTH PL SC, V20, P553; HEMLEY RJ, 1989, PHYS REV B, V39, P11827; Insley R. H., 1990, ALUMINA CHEM SCI TEC, P293; JEPHCOAT AP, 1988, PHYSICA B, V150, P116; LUNDQVIST S, 1987, THEORY INHOMOGENEOUS; Mao H. K., 1985, Solid State Physics under Pressure: Recent Advance with Anvil Devices, P11; MAO HK, 1986, J GEOPHYS RES, V91, P4637; MAREZIO M, 1972, J SOLID STATE CHEM, V4, P11, DOI 10.1016/0022-4596(72)90126-0; MARTON FC, 1994, AM MINERAL, V79, P789; NELLIS WJ, 1990, J GEOPHYS RES-SOLID, V95, P21749, DOI 10.1029/JB095iB13p21749; PERDEW JP, 1981, PHYS REV B, V23, P5048, DOI 10.1103/PhysRevB.23.5048; PISTORIUS CWF, 1976, PROGR SOLID STATE CH, V11, P1; RICHET P, 1988, PHYS CHEM MINER, V16, P207; Shannon R. D., 1970, J SOLID STATE CHEM, V2, P134; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; WEAST RC, 1985, CRC HDB CHEM PHYSICS, P66; Wentzcovitch R. M., 1996, Quantum theory of real materials, P113; WENTZCOVITCH RM, 1993, PHYS REV LETT, V70, P3947, DOI 10.1103/PhysRevLett.70.3947; WENTZCOVITCH RM, 1995, PHYS EARTH PLANET IN, V90, P101, DOI 10.1016/0031-9201(94)03001-Y; WENTZCOVITCH RM, 1991, PHYS REV B, V44, P2358, DOI 10.1103/PhysRevB.44.2358; XU JA, 1986, SCIENCE, V232, P1404, DOI 10.1126/science.232.4756.1404; YIN MT, 1980, PHYS REV LETT, V45, P1004, DOI 10.1103/PhysRevLett.45.1004; Yoo C. S., 1992, Shock Compression of Condensed Matter - 1991. Proceedings of the American Physical Society Topical Conference, P733; YU JS, 1968, APPL SCI RES, V19, P220, DOI 10.1007/BF00383924	36	84	84	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1880	1882		10.1126/science.274.5294.1880	http://dx.doi.org/10.1126/science.274.5294.1880			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943195				2022-12-28	WOS:A1996VY20000035
J	Michels, KB; Trichopoulos, D; Robins, JM; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE; Willett, WC				Michels, KB; Trichopoulos, D; Robins, JM; Rosner, BA; Manson, JE; Hunter, DJ; Colditz, GA; Hankinson, SE; Speizer, FE; Willett, WC			Birthweight as a risk factor for breast cancer	LANCET			English	Article							BIRTH-WEIGHT; GESTATIONAL-AGE; MAMMARY-GLAND; CARCINOGENESIS; DIFFERENTIATION; SUSCEPTIBILITY; HYPOTHESIS; PATTERNS	Background The mammary gland is largely undifferentiated before birth and may be particularly susceptible to intrauterine influences that could increase the risk of cancer through acceleration of cell proliferation or other pregnancy-related processes. Studies of migrant populations, animal data, and limited epidemiological evidence suggest that breast cancer may originate in utero. In a nested case-control study we assessed whether birthweight and other perinatal factors are associated with risk of breast cancer. Methods This case-control study was nested within the cohorts of the two Nurses' Health Studies. We used self-administered questionnaires to obtain information from the mothers of 582 nurses with. invasive breast cancer and the mothers of 1569 nurses who did not have breast cancer (controls). Information on risk factors for breast cancer during adulthood were obtained from the nurses; multiple logistic regression analysis adjusted for these risk factors. Findings Birthweight was a significant predictor of breast-cancer risk. With women who weighed 4000 g or more at birth as the reference category, the adjusted odds ratios for breast cancer were 0.86 (95% CI 0.59-1.25) for birthweights of 3500-3999 g, 0.68 (0.48-0.97) for birthweights of 3000-3499 g, 0.66 (0.45-0.98) for birthweights of 2500-2999 g, and 0.55 (0.33-0.93) for birthweights below 2500 g (p for trend 0.004). Prematurity was not significantly associated with risk of breast cancer. Interpretation Birthweight is significantly associated with breast-cancer risk, which suggests that intrauterine factors or processes affect the risk of breast cancer in the offspring, High concentrations of pregnancy oestrogens may have an important role in breast carcinogenesis, but other pregnancy hormones or intrauterine factors may also be involved.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; CHANNING LABS,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT MED,DIV PREVENT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Michels, KB (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 50385, CA 55075, CA 40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050385, R01CA040356, R37CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adami HO, 1995, MUTAT RES-FUND MOL M, V333, P29, DOI 10.1016/0027-5107(95)00128-X; ANBAZHAGAN R, 1994, EUR J CANCER, V30A, P1, DOI 10.1016/S0959-8049(05)80006-1; BERNSTEIN L, 1993, EPIDEMIOL REV, V15, P48, DOI 10.1093/oxfordjournals.epirev.a036116; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COLE P, 1969, LANCET, V1, P604; DALING JR, 1984, J NATL CANCER I, V72, P1039; EKBOM A, 1995, INT J CANCER, V61, P177, DOI 10.1002/ijc.2910610206; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; GERHARD I, 1987, EUR J OBSTET GYN R B, V26, P313, DOI 10.1016/0028-2243(87)90129-8; GERHARD I, 1986, J PERINAT MED, V14, P279, DOI 10.1515/jpme.1986.14.5.279; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; Hanai A, 1982, Natl Cancer Inst Monogr, V62, P3; JANERICH DT, 1994, MED HYPOTHESES, V43, P105, DOI 10.1016/0306-9877(94)90059-0; LEMARCHAND L, 1988, BRIT J CANCER, V57, P437, DOI 10.1038/bjc.1988.99; MACMAHON B, 1962, J NATL CANCER I, V28, P231; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; RUSSO J, 1980, CANCER RES, V40, P2677; RUSSO J, 1979, AM J PATHOL, V96, P721; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SEIDMAN DS, 1987, BRIT J OBSTET GYNAEC, V94, P731, DOI 10.1111/j.1471-0528.1987.tb03717.x; TIBBLIN G, 1995, EPIDEMIOLOGY, V6, P423, DOI 10.1097/00001648-199507000-00017; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; WANG XB, 1994, INT J EPIDEMIOL, V23, P119, DOI 10.1093/ije/23.1.119; ZIEGLER RG, 1993, JNCI-J NATL CANCER I, V85, P1819, DOI 10.1093/jnci/85.22.1819	32	310	314	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1542	1546		10.1016/S0140-6736(96)03102-9	http://dx.doi.org/10.1016/S0140-6736(96)03102-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950880				2022-12-28	WOS:A1996VX02300008
J	Chen, LH; Booker, JR; Jones, AG; Wu, N; Unsworth, MJ; Wei, WB; Tan, HD				Chen, LH; Booker, JR; Jones, AG; Wu, N; Unsworth, MJ; Wei, WB; Tan, HD			Electrically conductive crust in southern Tibet from INDEPTH magnetotelluric surveying	SCIENCE			English	Article							INVERSION	The crust north of the Himalaya is generally electrically conductive below depths of 10 to 20 km, This conductive zone approaches the surface beneath the Kangmar dome (dipping north) and extends beneath the Zangbo suture, A profile crossing the northern Yadong-Gulu rift shows that the high conductivity region extends outside the rift, and its top within the rift coincides with a bright spot horizon imaged on the INDEPTH CMP (common midpoint) profiles. The high conductivity of the middle crust is atypical of stable continental regions and suggests that there is a regionally interconnected fluid phase in the crust of the region.	GEOL SURVEY CANADA,OTTAWA,ON K1A 0Y3,CANADA; CHINA UNIV GEOSCI,BEIJING,PEOPLES R CHINA; UNIV WASHINGTON,SCH GEOPHYS,SEATTLE,WA 98195	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; China University of Geosciences; University of Washington; University of Washington Seattle			Jones, Alan G/A-3241-2009; Unsworth, Martyn J/A-6395-2012	Jones, Alan G/0000-0002-3482-2518; Unsworth, Martyn J/0000-0001-8282-4174				Brown LD, 1996, SCIENCE, V274, P1688, DOI 10.1126/science.274.5293.1688; DEGROOTHEDLIN C, 1990, GEOPHYSICS, V55, P1613, DOI 10.1190/1.1442813; FRANCHETEAU J, 1984, NATURE, V307, P32, DOI 10.1038/307032a0; GROOM RW, 1993, GEOPHYS J INT, V115, P1095, DOI 10.1111/j.1365-246X.1993.tb01512.x; GROOM RW, 1989, J GEOPHYS RES-SOLID, V94, P1913, DOI 10.1029/JB094iB02p01913; GUO XF, 1990, B CHINESE ACAD GEOLO, V21, P191; JONES AG, 1993, PHYS EARTH PLANET IN, V81, P289, DOI 10.1016/0031-9201(93)90137-X; JONES AG, 1988, GEOPHYSICS, V53, P967, DOI 10.1190/1.1442533; JONES AG, 1982, CONTINENTAL LOWER CR, P81; MARQUIS G, 1995, GEOPHYS J INT, V120, P111, DOI 10.1111/j.1365-246X.1995.tb05915.x; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; SMITH JT, 1991, J GEOPHYS RES-SOLID, V96, P3905, DOI 10.1029/90JB02416; VANNGOC P, 1986, NATURE, V311, P615; WANNAMAKER PE, 1989, J GEOPHYS RES-SOLID, V94, P14127, DOI 10.1029/JB094iB10p14127; WU GJ, 1992, CHIN J GEOPHYS, V35, P195	15	180	223	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1694	1696		10.1126/science.274.5293.1694	http://dx.doi.org/10.1126/science.274.5293.1694			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939855				2022-12-28	WOS:A1996VW71200054
J	Elledge, SJ				Elledge, SJ			Cell cycle checkpoints: Preventing an identity crisis	SCIENCE			English	Review							ATAXIA-TELANGIECTASIA GENE; YEAST SACCHAROMYCES-CEREVISIAE; SPINDLE ASSEMBLY CHECKPOINT; XENOPUS EGG EXTRACTS; WILD-TYPE P53; FISSION YEAST; DNA-DAMAGE; S-PHASE; BUDDING YEAST; ESCHERICHIA-COLI	Cell cycle checkpoints are regulatory pathways that control the order and timing of cell cycle transitions and ensure that critical events such as DNA replication and chromosome segregation are completed with high fidelity. in addition, checkpoints respond to damage by arresting the cell cycle to provide time for repair and by inducing transcription or genes that facilitate repair, Checkpoint loss results In genomic instability and has been implicated in the evolution oi normal cells into cancer cells. Recent advances have revealed signal transduction pathways that transmit checkpoint signals in response to DNA damage, replication blocks, and spindle damage. Checkpoint pathways have components shared among ail eukaryotes, underscoring the conservation of cell cycle regulatory machinery.	BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute	Elledge, SJ (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboussekhra A, 1996, EMBO J, V15, P3912, DOI 10.1002/j.1460-2075.1996.tb00765.x; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; BENTLY N, IN PRESS EMBO J; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CASTELLAZZI M, 1972, MOL GEN GENET, V119, P153, DOI 10.1007/BF00269134; CASTELLAZZI M, 1972, MOL GEN GENET, V119, P139, DOI 10.1007/BF00269133; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; COHENFIX O, IN PRESS GENES DEV; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG C, 1995, CELL, V82, P67; DURSO G, 1995, J CELL SCI, V108, P3109; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUISMAN O, 1984, P NATL ACAD SCI-BIOL, V81, P4490, DOI 10.1073/pnas.81.14.4490; HUISMAN O, 1981, NATURE, V290, P797, DOI 10.1038/290797a0; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KEEGAN, IN PRESS GENES DEV; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kiser GL, 1996, MOL BIOL CELL, V7, P703, DOI 10.1091/mbc.7.5.703; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; LEIBMAN H, IN PRESS P NATL ACAD; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; LYDALL D, IN PRESS NATURE; MIHSULL J, IN PRESS CURR BIOL; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1989, CHROMOSOMA, V92, P313; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; PAULOVITCH A, IN PRESS GENETICS; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; REIDER CL, 1995, J CELL BIOL, V130, P941; RHIND N, UNPUB; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSCH HP, 1964, J CELL BIOL, V31, P204; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAKA Y, 1994, J CELL SCI S, V18, P57; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SANCHEZ Y, UNPUB; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Siede W, 1996, NUCLEIC ACIDS RES, V24, P1669, DOI 10.1093/nar/24.9.1669; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; WALDMAN T, 1995, CANCER RES, V55, P5187; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WEINERT TA, 1994, GENE DEV, V8, P653; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WITKIN EM, 1967, P NATL ACAD SCI USA, V57, P1275, DOI 10.1073/pnas.57.5.1275; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; YE XS, IN PRESS EMBO J; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhang DH, 1996, NATURE, V382, P466, DOI 10.1038/382466a0; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	106	1704	1757	2	186	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1664	1672		10.1126/science.274.5293.1664	http://dx.doi.org/10.1126/science.274.5293.1664			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939848				2022-12-28	WOS:A1996VW71200047
J	VanderZee, CEEM; Ross, GM; Riopelle, RJ; Hagg, T				VanderZee, CEEM; Ross, GM; Riopelle, RJ; Hagg, T			Survival of cholinergic forebrain neurons in developing p75(NGFR)-deficient mice	SCIENCE			English	Article							NERVE GROWTH-FACTOR; AFFINITY NEUROTROPHIN RECEPTOR; PROGRAMMED CELL-DEATH; NGF RECEPTOR; P75; SYSTEM; TRK; ACETYLTRANSFERASE; LOCALIZATION; APOPTOSIS	The functions of the low-affinity p75 nerve growth factor receptor (p75(NGFR)) in the central nervous system were explored in vivo. In normal mice, approximately 25 percent of the cholinergic basal forebrain neurons did not express TrkA and died between postnatal day 6 and 15. This loss did not occur in p75(NGFR)-deficient mice or in normal mice systemically injected with a p75(NGFR)-inhibiting peptide. Control, but not p75(NGFR)-deficient, mice also had fewer cholinergic striatal interneurons. Apparently, p75(NGFR) mediates apoptosis of these developing neurons in the absence of TrkA, and modulation of p75(NGFR) can promote neuronal survival. Cholinergic basal forebrain neurons are involved in learning and memory.	DALHOUSIE UNIV,DEPT NEUROBIOL & ANAT,HALIFAX,NS B3H 4H7,CANADA; QUEENS UNIV,DEPT MED NEUROL,KINGSTON,ON K7L 2V7,CANADA	Dalhousie University; Queens University - Canada			Van der Zee, Catharina E.E.M./L-4773-2015					Barker P., COMMUNICATION; Barrett GL, 1996, J NEUROSCI RES, V45, P117, DOI 10.1002/(SICI)1097-4547(19960715)45:2<117::AID-JNR4>3.0.CO;2-D; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHAO MV, 1995, MOL CELL NEUROSCI, V6, P91, DOI 10.1006/mcne.1995.1009; CURTIS R, 1995, NEURON, V14, P1201, DOI 10.1016/0896-6273(95)90267-8; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Dostaler SM, 1996, EUR J NEUROSCI, V8, P870, DOI 10.1111/j.1460-9568.1996.tb01574.x; FIGUEIREDO BC, 1993, DEV BRAIN RES, V72, P237, DOI 10.1016/0165-3806(93)90188-G; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOULD E, 1991, BRAIN RES BULL, V27, P767, DOI 10.1016/0361-9230(91)90209-3; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HAGG T, 1989, BRAIN RES, V505, P29, DOI 10.1016/0006-8993(89)90112-1; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; KOH S, 1989, EXP NEUROL, V106, P209, DOI 10.1016/0014-4886(89)90154-4; KOH SY, 1989, J NEUROSCI, V9, P2999; Kril Y., 1995, Society for Neuroscience Abstracts, V21, P1539; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KK, 1991, HPLC PEPTIDES PROTEI, P389; LI YW, 1995, J NEUROSCI, V15, P2888; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RISEAU W, 1990, TRENDS NEUROSCI, V13, P174; SOBREVIELA T, 1994, J COMP NEUROL, V350, P587, DOI 10.1002/cne.903500407; Taglialatela G, 1996, J NEUROCHEM, V66, P1826; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	33	178	181	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1729	1732		10.1126/science.274.5293.1729	http://dx.doi.org/10.1126/science.274.5293.1729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939868				2022-12-28	WOS:A1996VW71200067
J	Shibata, D; Reale, MA; Lavin, P; Silverman, M; Fearon, ER; Steele, G; Jessup, JM; Loda, M; Summerhayes, IC				Shibata, D; Reale, MA; Lavin, P; Silverman, M; Fearon, ER; Steele, G; Jessup, JM; Loda, M; Summerhayes, IC			The DCC protein and prognosis in colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPRESSOR GENE DCC; FLUOROURACIL PLUS LEVAMISOLE; FREQUENT LOSS; ADJUVANT THERAPY; COLON-CANCER; CHROMOSOME 18Q; CARCINOMA GENE; ALLELIC LOSS; EXPRESSION; HETEROZYGOSITY	Background Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in colorectal carcinoma. Methods The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II or III colorectal carcinomas. The Cox proportional-hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy. Results The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P = 0.03). Conclusions DCC is a prognostic marker in patients with stage II or stage III colorectal cancer. In stage II colorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of (C) 1996, Massachusetts Medical Society.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG, LAB CANC BIOL, BOSTON, MA 02215 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA; YALE UNIV, SCH MED, SECT MED ONCOL, NEW HAVEN, CT USA; BOSTON BIOSTAT RES FDN, FRAMINGHAM, MA USA; LAHEY HITCHCOCK MED CTR, DEPT PATHOL, BURLINGTON, MA USA; UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV MED & MOL GENET, ANN ARBOR, MI 48109 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Lahey Hospital & Medical Center; University of Michigan System; University of Michigan					NCI NIH HHS [CA-44704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1984, NEW ENGL J MED, V310, P737; BRABANT G, 1993, CANCER RES, V53, P4987; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; BREWSTER SF, 1994, BRIT J CANCER, V70, P697, DOI 10.1038/bjc.1994.376; BROWN RW, 1995, MODERN PATHOL, V8, P515; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; Cordon-Cardo C, 1994, Important Adv Oncol, P71; COX DR, 1972, J R STAT SOC B, V34, P187; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; FROGGATT NJ, 1995, J CANCER RES CLIN, V121, P7, DOI 10.1007/BF01202723; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; IACOPETTA B, 1994, EUR J CANCER, V30A, P664, DOI 10.1016/0959-8049(94)90541-X; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASHIWABA M, 1995, VIRCHOWS ARCH, V426, P441; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KODNER IJ, 1994, PRINCIPLES SURG, P1191; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LUMADUE JA, 1995, SURG CLIN N AM, V75, P845, DOI 10.1016/S0039-6109(16)46731-9; MIYAKE K, 1994, LEUKEMIA LYMPHOMA, V16, P13, DOI 10.3109/10428199409114135; MIYAKE K, 1993, BLOOD, V82, P927; MIYAKE S, 1994, CANCER RES, V54, P3007; MOERTEL CG, 1995, J CLIN ONCOL, V13, P2936, DOI 10.1200/JCO.1995.13.12.2936; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; MURTY VVVS, 1994, ONCOGENE, V9, P3227; NARAYANAN R, 1992, ONCOGENE, V7, P553; OCONNELL MJ, 1992, CANCER-AM CANCER SOC, V70, P1732, DOI 10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; REALE MA, 1994, CANCER RES, V54, P4493; SCHECK AC, 1993, CANCER RES, V53, P5605; Shibata David, 1995, Surgical Forum, V46, P526; TURLEY H, 1995, CANCER RES, V55, P5628; UCHINO S, 1992, CANCER RES, V52, P3099; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879	46	238	247	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1727	1732		10.1056/NEJM199612053352303	http://dx.doi.org/10.1056/NEJM199612053352303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929264				2022-12-28	WOS:A1996VW79500003
J	Nightingale, SL				Nightingale, SL			Warning on severe renal impairment with use of cidofovir injection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-28	WOS:A1996VV56600010
J	Hudson, MM; Morton, RS				Hudson, MM; Morton, RS			Fracastoro and syphilis: 500 years on	LANCET			English	Item About an Individual									UNIV SHEFFIELD,SHEFFIELD,S YORKSHIRE,ENGLAND	University of Sheffield	Hudson, MM (corresponding author), ROYAL HALLAMSHIRE HOSP,DEPT GENITOURINARY MED,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							ANDOUZE J, 1994, CAMBRIDGE ATLAS ASTR, P111; [Anonymous], 1990, CONCISE OXFORD ENGLI, P1238; BOAS M, 1970, SCI RENAISSANCE 1450, V1, P69; COPLESTON F, 1953, HIST PHILOS, V3, P249; DIVUS AUGUSTUS, 1928, LOEB CLASSICAL LIB, V1, P242; ELTON GR, 1975, NEW CAMBRIDGE MODERN, V2, P289; GAIRDNER J, 1898, STORY PERKIN WARBECK; Morton R. S., 1985, European Journal of Sexually Transmitted Diseases, V2, P133; MORTON RS, 1961, BRIT J VENER DIS, V37, P285; NUTTON V, 1983, MED HIST, V27, P1; Singer Charles, 1917, Ann Med Hist, V1, P1; SPARROW J, 1960, ITALIAN RENAISSANCE, P356; *W R CHAMB, 1993, CHAMB CONC DICT, P1084; WYNNEFINCH H, 1935, FRACASTOR SYPHILIS F, P2; 1989, OXFORD ENGLISH DICT, V17; 1921, BRIT MED J, P216	16	9	9	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1495	1496		10.1016/S0140-6736(96)08170-6	http://dx.doi.org/10.1016/S0140-6736(96)08170-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942782				2022-12-28	WOS:A1996VV46300015
J	Mena, M; Ambrose, BA; Meeley, RB; Briggs, SP; Yanofsky, MF; Schmidt, RJ				Mena, M; Ambrose, BA; Meeley, RB; Briggs, SP; Yanofsky, MF; Schmidt, RJ			Diversification of C-function activity in maize flower development	SCIENCE			English	Article							FLORAL HOMEOTIC GENES; ZEA-MAYS; ARABIDOPSIS; SEPARATION	The Arabidopsis gene AGAMOUS is required for male and female reproductive organ development and for floral determinacy. Reverse genetics allowed the isolation of a transposon-induced mutation in ZAG1, the maize homolog of AGAMOUS. ZAG1 mutants exhibited a loss of determinacy, but the identity of reproductive organs was largely unaffected. This suggested a redundancy in maize sex organ specification that led to the identification and cloning of a second AGAMOUS homolog, ZMM2, that has a pattern of expression distinct from that of ZAG1. C-function organ identity in maize (as defined by the A, B, C model of floral organ development) may therefore be orchestrated by two closely related genes, ZAG1 and ZMM2, with overlapping but nonidentical activities.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA; PIONEER HI BRED INT INC, DEPT BIOTECHNOL RES, JOHNSTON, IA 50131 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; DuPont; Pioneer Hi-Bred International, Inc.			Mena, Montaña/AAB-1153-2019	Mena, Montaña/0000-0001-7521-1644				BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CHENG PC, 1983, AM J BOT, V70, P450, DOI 10.2307/2443252; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; Davies B, 1994, Results Probl Cell Differ, V20, P235; GOODMAN MM, 1980, GENETICS, V96, P697; HELENTJARIS T, 1989, GENETICS, V118, P6442; KIESSELBACH TA, 1949, U NEBR AGR EXP STN R, V161; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; MANDEL A, UNPUB; Mena M, 1995, PLANT J, V8, P845, DOI 10.1046/j.1365-313X.1995.8060845.x; MIZUKAMI Y, 1995, PLANT MOL BIOL, V28, P767, DOI 10.1007/BF00042064; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; SCHMIDT RJ, 1993, PLANT CELL, V5, P729, DOI 10.1105/tpc.5.7.729; SIEBURTH LE, 1995, PLANT CELL, V7, P1249, DOI 10.1105/tpc.7.8.1249; THEISSEN G, 1995, GENE, V156, P155, DOI 10.1016/0378-1119(95)00020-7; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WENDEL JF, 1986, THEOR APPL GENET, V72, P178, DOI 10.1007/BF00266990; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	22	240	258	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1537	1540		10.1126/science.274.5292.1537	http://dx.doi.org/10.1126/science.274.5292.1537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929416				2022-12-28	WOS:A1996VV77500051
J	Nozette, S; Lichtenberg, CL; Spudis, P; Bonner, R; Ort, W; Malaret, E; Robinson, M; Shoemaker, EM				Nozette, S; Lichtenberg, CL; Spudis, P; Bonner, R; Ort, W; Malaret, E; Robinson, M; Shoemaker, EM			The Clementine bistatic radar experiment	SCIENCE			English	Article							OUTER PLANET SATELLITES; GREENLAND ICE-SHEET; COHERENT-BACKSCATTER; MOON; MERCURY; STABILITY; MODEL; POLARIZATION; GANYMEDE; CRATERS	During the Clementine 1 mission, a bistatic radar experiment measured the magnitude and polarization of the radar echo versus bistatic angle, beta, for selected lunar areas. Observations of the lunar south pole yield a same-sense polarization enhancement around beta = 0. Analysis shows that the observed enhancement is localized to the permanently shadowed regions of the lunar south pole. Radar observations of periodically solar-illuminated lunar surfaces, including the north pole, yielded no such enhancement. A probable explanation for these differences is the presence of low-loss volume scatterers, such as water ice, in the permanently shadowed region at the south pole.	USN,RES LAB,WASHINGTON,DC 20375; LUNAR & PLANETARY INST,HOUSTON,TX 77058; PROTASIS INC,ALEXANDRIA,VA 22314; APPL COHERENT TECHNOL,HERNDON,VA 22070; US GEOL SURVEY,FLAGSTAFF,AZ 86001	United States Department of Defense; United States Navy; Naval Research Laboratory; United States Department of the Interior; United States Geological Survey	Nozette, S (corresponding author), USAF,PHILLIPS LAB,SPACE EXPT DIRECTORATE,711 N FAYETTE ST,ALEXANDRIA,VA 22314, USA.							ARNOLD JR, 1979, J GEOPHYS RES, V84, P5659, DOI 10.1029/JB084iB10p05659; BUTLER BJ, 1993, J GEOPHYS RES-PLANET, V98, P15003, DOI 10.1029/93JE01581; CAMPBELL DB, 1978, ICARUS, V34, P254, DOI 10.1016/0019-1035(78)90166-5; ESCHLEMAN VR, 1986, SCIENCE, V234, P587, DOI 10.1126/science.234.4776.587; Eternad S., 1987, PHYS REV LETT, V59, P1420; Evans J.V., 1968, RADAR ASTRONOMY; GOLDSTEIN RM, 1980, SCIENCE, V207, P179, DOI 10.1126/science.207.4427.179; GORODNICHEV EE, 1990, PHYS LETT A, V144, P48, DOI 10.1016/0375-9601(90)90047-R; HAPKE B, 1990, ICARUS, V88, P407, DOI 10.1016/0019-1035(90)90091-M; HAPKE B, 1991, NATURE, V352, P46, DOI 10.1038/352046a0; HARMON JK, 1994, NATURE, V369, P213, DOI 10.1038/369213a0; INGERSOLL AP, 1992, ICARUS, V100, P40, DOI 10.1016/0019-1035(92)90016-Z; MISHCHENKO MI, 1992, ASTROPHYS SPACE SCI, V194, P327, DOI 10.1007/BF00644001; MISHCHENKO MI, 1992, J OPT SOC AM A, V9, P978, DOI 10.1364/JOSAA.9.000978; MISHCHENKO MI, 1992, EARTH MOON PLANETS, V58, P127, DOI 10.1007/BF00054650; MUHLEMAN DO, 1991, SCIENCE, V253, P1508, DOI 10.1126/science.253.5027.1508; NOZETTE S, 1994, SCIENCE, V266, P1835, DOI 10.1126/science.266.5192.1835; OSTRO SJ, 1990, ICARUS, V85, P335, DOI 10.1016/0019-1035(90)90121-O; OSTRO SJ, 1982, SATELLITES JUPITER; PAIGE DA, 1992, SCIENCE, V258, P643, DOI 10.1126/science.258.5082.643; PETERS KJ, 1992, PHYS REV B, V46, P801, DOI 10.1103/PhysRevB.46.801; RIGNOT E, 1995, J GEOPHYS RES-PLANET, V100, P9389, DOI 10.1029/95JE00485; RIGNOT EJ, 1993, SCIENCE, V261, P1710, DOI 10.1126/science.261.5129.1710; SALVAIL JR, 1994, ICARUS, V111, P441, DOI 10.1006/icar.1994.1155; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; SIMPSON RA, 1993, IEEE T GEOSCI REMOTE, V31, P465, DOI 10.1109/36.214923; SLADE MA, 1992, SCIENCE, V258, P635, DOI 10.1126/science.258.5082.635; Spudis P.D., 1993, GEOLOGY MULTIRING IM; SPUDIS PD, 1994, SCIENCE, V266, P1848, DOI 10.1126/science.266.5192.1848; SPUDIS PD, 1995, LUNAR PLANET SCI, V26, P1339; STACY NJS, 1993, THESIS CORNELL U; Tsang L., 1985, THEORY MICROWAVE REM; WATSON K, 1961, J GEOPHYS RES, V66, P3033, DOI 10.1029/JZ066i009p03033; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839	34	254	275	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1495	1498		10.1126/science.274.5292.1495	http://dx.doi.org/10.1126/science.274.5292.1495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929403	Green Submitted			2022-12-28	WOS:A1996VV77500038
J	Davies, J; Hey, E; Reid, W; Young, G				Davies, J; Hey, E; Reid, W; Young, G			Prospective regional study of planned home births	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTITIONER; OBSTETRICS; DELIVERY; AUDIT; CARE; UNIT	Objective-To collect data from a cohort of women requesting a home birth and examine the experience and outcome of pregnancy, the indications for hospital transfer, and the attitudes of mothers, midwives, and general practitioners. Design-Follow up study with anonymised postal questionnaires. Setting-Northern Regional Health Authority area. Subjects-The 256 women resident in the Northern region who expected to deliver in 1993 and whose request for a home birth became known to one of the local supervisors of midwives. Limited cross validating information was also collected retrospectively on all other women delivering a baby outside hospital in 1993. Main outcome measures-Rate of and reason for transferred care; maternal, midwifery, and general practitioner views; perinatal outcome. Results-Five women miscarried, leaving 251 in the study. Of these, 142 (57%) delivered at home. There were 17 (7%) caesarean sections but no perinatal deaths. General practitioners had reservations about half of the booking requests. Two thirds of the women thought they had not been offered any option about place of birth, 74 (29%) were referred to hospital for delivery before the onset of labour, and 35 (14%) were referred to hospital during labour. Intrapartum transfers were uneventful, and half the mothers commented spontaneously that they valued having spent even part of their labour at home. Conclusions-Home birth is valued for its family setting. General practitioners' support is sought and influential but uncommon, possibly because of a lack of understanding of the of the midwife and general practitioner.	MED SCH NEWCASTLE UPON TYNE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; CUMBERLAND INFIRM,CARLISLE CA2 7HY,CUMBERLAND,ENGLAND; TEMPLE SOWERBY,CUMBRIA CA10 1RZ,ENGLAND	Newcastle University - UK	Davies, J (corresponding author), MATERN SURVEY OFF,25 CLAREMONT PL,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND.							Baird AG, 1996, BRIT MED J, V312, P223; BROWN DJ, 1994, BRIT MED J, V309, P777, DOI 10.1136/bmj.309.6957.777; CAMPBELL R, 1990, BRIT MED J, V301, P1103, DOI 10.1136/bmj.301.6760.1103-c; CAMPBELL R, 1994, TO BE BORN DEBATE EV; CHAMBERLAIN G, 1991, BRIT J OBSTET GYNAEC, V98, P1067, DOI 10.1111/j.1471-0528.1991.tb15355.x; CHAMBERLAIN G, 1994, FUTURE MATERNITY SER, P298; CHAPMAN MG, 1986, BRIT J OBSTET GYNAEC, V93, P182, DOI 10.1111/j.1471-0528.1986.tb07884.x; CUNNINGHAM JD, 1993, SOC SCI MED, V36, P475, DOI 10.1016/0277-9536(93)90409-W; Department of Health, 1993, CHANGING CHILDBIRTH; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; HUNDLEY VA, 1994, BRIT MED J, V309, P1400, DOI 10.1136/bmj.309.6966.1400; KITZINGER S, 1978, PLACE BIRTH STUDY EN; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; MARSH BT, 1989, BRIT MED J, V298, P1313, DOI 10.1136/bmj.298.6683.1313; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; MARSH GN, 1989, BRIT MED J, V298, P1077, DOI 10.1136/bmj.298.6680.1077; MARSH GN, 1989, BRIT MED J, V298, P1579, DOI 10.1136/bmj.298.6687.1579; MATTHEWS AEB, 1975, HLTH TRENDS, V7, P69; *NO REG PER MORT S, 1996, BRIT MED J, V313, P1306; O'Brien M, 1978, J R Coll Gen Pract, V28, P460; *OFF NAT STAT, BIRTH STAT; *PER MORT SURV COO, 1991, COLL SURV PER LAT NE; PRENTICE A, 1989, BRIT MED J, V299, P1090, DOI 10.1136/bmj.299.6707.1090; PRENTICE A, 1989, BRIT MED J, V299, P1402; SCHNEIDER D, 1986, SOC SCI MED, V23, P1011, DOI 10.1016/0277-9536(86)90258-3; SHEARER JML, 1985, BRIT MED J, V291, P1478, DOI 10.1136/bmj.291.6507.1478; SODERSTROM B, 1990, CAN MED ASSOC J, V142, P963; Strauss AL., 1987, QUALITATIVE ANAL SOC, Vxv, P319; YOUNG G, 1987, BRIT MED J, V294, P744, DOI 10.1136/bmj.294.6574.744	29	60	60	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1302	1306						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942691				2022-12-28	WOS:A1996VV15300025
J	Hahne, M; Rimoldi, D; Schroter, M; Romero, P; Schreier, M; French, LE; Schneider, P; Bornand, T; Fontana, A; Lienard, D; Cerottini, JC; Tschopp, J				Hahne, M; Rimoldi, D; Schroter, M; Romero, P; Schreier, M; French, LE; Schneider, P; Bornand, T; Fontana, A; Lienard, D; Cerottini, JC; Tschopp, J			Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape	SCIENCE			English	Article							HUMAN FAS LIGAND; T-LYMPHOCYTES; CD95 LIGAND; ANTIGENS; MICE; IDENTIFICATION; CYTOTOXICITY; MECHANISMS; INHIBITOR; PERFORIN	Malignant melanoma accounts for most of the increasing mortality from skin cancer. Melanoma cells were found to express Fas (also called Apo-1 or CD95) ligand (Fast). In metastatic lesions, Fas-expressing T cell infiltrates were proximal to FasL(+) tumor cells. In vitro, apoptosis of Fas-sensitive target cells occurred upon incubation with melanoma tumor cells; and in vivo, injection of FasL(+) mouse melanoma cells in mice led to rapid tumor formation. In contrast, tumorigenesis was delayed in Fas-deficient lpr mutant mice in which immune effector Cells cannot be killed by Fast. Thus, Fast may contribute to the immune privilege of tumors.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; UNIV LAUSANNE,LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND; UNIV ZURICH HOSP,DEPT INTERNAL MED,CH-8044 ZURICH,SWITZERLAND; CHU VAUDOIS,CTR PLURIDISCIPLINAIRE ONCOL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; University of Geneva; University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			French, Lars/AAL-5977-2020; Romero, Pedro/S-6015-2017	French, Lars/0000-0002-4629-1486; Romero, Pedro/0000-0002-9688-2882; Schneider, Pascal/0000-0003-0677-9409				BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; Carrel S, 1996, INT J CANCER, V67, P417, DOI 10.1002/(SICI)1097-0215(19960729)67:3<417::AID-IJC17>3.0.CO;2-4; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRENCH LE, 1996, J CELL BIOL, P335; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HAHN S, 1995, EUR J IMMUNOL, V25, P2679, DOI 10.1002/eji.1830250942; HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381; HAHNE M, UNPUB; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; HUBER D, 1992, J IMMUNOL, V148, P277; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KLEIN G, 1993, CURR OPIN IMMUNOL, V5, P687, DOI 10.1016/0952-7915(93)90122-9; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; Lowin B, 1996, INT IMMUNOL, V8, P57, DOI 10.1093/intimm/8.1.57; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Mukherji Bijay, 1995, Current Opinion in Oncology, V7, P175, DOI 10.1097/00001622-199503000-00014; MUUL LM, 1987, J IMMUNOL, V138, P989; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; Zier K, 1996, IMMUNOL TODAY, V17, P39, DOI 10.1016/0167-5699(96)80567-6	34	1136	1226	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1363	1366		10.1126/science.274.5291.1363	http://dx.doi.org/10.1126/science.274.5291.1363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910274				2022-12-28	WOS:A1996VU95400050
J	Chamberlain, P; Boyd, PA				Chamberlain, P; Boyd, PA			Informed choice for users of health services: Views on ultrasonography leaflets of women in early pregnancy, midwives, and ultrasonographers - Evidence based practice and antenatal ultrasonography - The need for more studies - Commentary	BRITISH MEDICAL JOURNAL			English	Article							ULTRASOUND				Chamberlain, P (corresponding author), JOHN RADCLIFFE HOSP,OXFORD PRENATAL DIAG SERV,OXFORD OX3 9DU,ENGLAND.							BRAND IR, 1994, BRIT J OBSTET GYNAEC, V101, P392, DOI 10.1111/j.1471-0528.1994.tb11910.x; Chitty LS, 1996, BRIT MED J, V313, P478; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SNIJDERS RJM, 1996, FRONTIERS FETAL MED; Villar J, 1982, Obstet Gynecol Surv, V37, P499, DOI 10.1097/00006254-198208000-00001	7	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1254	1255		10.1136/bmj.313.7067.1254	http://dx.doi.org/10.1136/bmj.313.7067.1254			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939122	Green Published			2022-12-28	WOS:A1996VU20800034
J	Zanetta, G; Lissoni, A; Torri, V; DallaValle, C; Trio, D; Rangoni, G; Mangioni, C				Zanetta, G; Lissoni, A; Torri, V; DallaValle, C; Trio, D; Rangoni, G; Mangioni, C			Role of puncture and aspiration in expectant management of simple ovarian cysts: A randomised study	BRITISH MEDICAL JOURNAL			English	Article							ULTRASOUND; CANCER; DIAGNOSIS; WOMEN; LESIONS; TUMORS	Objectives-To assess the potential of expectant management for simple ovarian cysts diagnosed by transabdominal or transvaginal ultrasonography. To compare the results of needle aspiration with those achieved with simple observation. Design-Randomised trial. Setting-Hospital department of obstetrics and gynaecology. Subjects-278 women with simple cysts randomly allocated to simple observation (143) or ultrasound guided fine needle aspiration (135) between 1990 and 1944. Main outcome measures-Resolution of cyst or development of malignancy. Results-After six months 269 were available for follow up. The rate of resolution was 46% (59/128) with aspiration and 44.6% (63/141) with observation. Only the diameter of the cyst (P<0.0001) was a significant independent prognostic factor for resolution in a multivariate analysis. Age and treatment had no significant effect. One woman was subsequently found to have borderline malignant changes on histopathological examination. Her cyst was detected by transabdominal ultrasonography. Conclusions-Expectant management for up to six months does not cause risks for the patients and allows spontaneous resolution in over a third of cases, avoiding the costs and risks of unnecessary surgery. Aspiration does not provide better results than simple observation.	UNIV MILAN,OSPED SAN GERARDO MONZA,DEPT OBSTET & GYNAECOL,BRANCH 3,MILAN,ITALY; IST RIC FARMACOL MARIO NEGRI,DEPT ONCOL,MILAN,ITALY	University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Torri, Valter/H-7550-2015	Torri, Valter/0000-0001-9541-9354				ANDOLF E, 1989, BRIT J OBSTET GYNAEC, V96, P1076, DOI 10.1111/j.1471-0528.1989.tb03384.x; BELINSON JL, 1981, AM J OBSTET GYNECOL, V139, P148, DOI 10.1016/0002-9378(81)90437-3; BHAN V, 1989, BRIT J OBSTET GYNAEC, V96, P384; BOURNE TH, 1994, GYNECOL ONCOL, V51, P4; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; CHRISTOPHERSON WM, 1983, CANCER, V51, P1201, DOI 10.1002/1097-0142(19830401)51:7<1201::AID-CNCR2820510706>3.0.CO;2-9; Cox DR., 1989, ANAL BINARY DATA; DECRESPIGNY LC, 1989, BRIT J OBSTET GYNAEC, V96, P1035; DEWILDE RL, 1994, AM J OBSTET GYNECOL, V170, P253, DOI 10.1016/S0002-9378(13)70311-9; DIERNAES E, 1987, LANCET, V1, P1084; DORDONI D, 1993, J ULTRAS MED, V12, P27; ERIKSSON L, 1985, GYNECOL OBSTET INVES, V19, P155, DOI 10.1159/000299027; FOX H, 1990, OVARIAN CANC BIOL TH, P185; GOLDSTEIN SR, 1989, OBSTET GYNECOL, V73, P8; GRANBERG S, 1990, GYNECOL ONCOL, V37, P224, DOI 10.1016/0090-8258(90)90337-K; GRANBERG S, 1989, GYNECOL ONCOL, V35, P139, DOI 10.1016/0090-8258(89)90031-0; GRIMES DA, 1989, OBSTET GYNECOL, V73, P1037; Machin D., 1987, STAT TABLES DESIGN C; MEIRE HB, 1978, BRIT J OBSTET GYNAEC, V85, P893, DOI 10.1111/j.1471-0528.1978.tb15850.x; Reading Carl C., 1994, Ultrasound Quarterly, V12, P67, DOI 10.1097/00013644-199412020-00001; *SAS I INC, 1989, SAS STAT US GUID, V2, P997; SCHWARTZ PE, 1993, CLIN OBSTET GYNECOL, V36, P384, DOI 10.1097/00003081-199306000-00017; TRIO D, 1992, ULTRASONICA, V7, P45; WOLF SI, 1991, RADIOLOGY, V180, P65, DOI 10.1148/radiology.180.1.2052725; ZANETTA G, 1993, RADIOLOGY, V189, P161, DOI 10.1148/radiology.189.1.8372188	25	53	53	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1110	1113		10.1136/bmj.313.7065.1110	http://dx.doi.org/10.1136/bmj.313.7065.1110			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916695	Green Published			2022-12-28	WOS:A1996VR21700020
J	Martin, G				Martin, G			Pass the butter ...	SCIENCE			English	Editorial Material							TERMINAL CLEAVAGE PRODUCT; MOTOR-NEURON INDUCTION; SONIC-HEDGEHOG; FLOOR PLATE; SCLEROTOME INDUCTION; POLARIZING ACTIVITY; DROSOPHILA; AUTOPROTEOLYSIS; NOTOCHORD; HOMOLOG				Martin, G (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.							Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; Fitz C R, 1994, Neuroimaging Clin N Am, V4, P263; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; MARIGO V, 1995, GENOMICS, V28, P44, DOI 10.1006/geno.1995.1104; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROUX C, 1966, CR SOC BIOL, V160, P1353; ROUX CHARLES, 1964, ARCH FRANC PEDIAT, V21, P451; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8	23	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1996	274	5285					203	204		10.1126/science.274.5285.203	http://dx.doi.org/10.1126/science.274.5285.203			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8927979				2022-12-28	WOS:A1996VM67100029
J	Su, WJ; Dziewonski, AM; Jeanloz, R				Su, WJ; Dziewonski, AM; Jeanloz, R			Planet within a planet: Rotation of the inner core of earth	SCIENCE			English	Article							DIFFERENTIAL TRAVEL-TIMES; FREE OSCILLATIONS; GEOMAGNETIC JERK; MAGNETIC-FIELD; SPIN-UP; ANISOTROPY; PKIKP; IRON	The time dependence of the orientation of Earth's inner core relative to the mantle was determined using a recently discovered 10-degree tilt in the axis of symmetry of the inner core's seismic-velocity anisotropy. Two methods of analyzing travel-time variations for rays traversing the inner core, on the basis of 29 years of data from the International Seismological Centre (1964-1992), reveal that the inner core appears to rotate about 3 degrees per year faster than the mantle. An anomalous variation in inner-core orientation from 1969 to 1973 coincides in time with a sudden change (''jerk'') in the geomagnetic field.	HARVARD UNIV,DEPT EARTH & PLANETARY SCI,CAMBRIDGE,MA 02138; UNIV CALIF BERKELEY,DEPT GEOL & GEOPHYS,BERKELEY,CA 94720	Harvard University; University of California System; University of California Berkeley								BENTON ER, 1974, ANNU REV FLUID MECH, V6, P257, DOI 10.1146/annurev.fl.06.010174.001353; BONDI H, 1948, P CAMB PHILOS SOC, V44, P345; BOOK DL, IN PRESS J PLASMA PH; COURTILLOT V, 1978, CR ACAD SCI D NAT, V287, P1095; CREAGER KC, 1992, NATURE, V356, P309, DOI 10.1038/356309a0; DAVIS RG, 1994, GEOPHYS RES LETT, V21, P1815, DOI 10.1029/94GL01369; GLATZMAIER GA, 1995, NATURE, V377, P203, DOI 10.1038/377203a0; GLATZMAIER GA, 1995, PHYS EARTH PLANET IN, V91, P63, DOI 10.1016/0031-9201(95)03049-3; GLATZMAIER GA, COMMUNICATION; Greenspan H. P., 1968, THEORY ROTATING FLUI; GUBBINS D, 1981, J GEOPHYS RES, V86, P1695, DOI 10.1029/JB086iB12p11695; Gubbins D., 1987, GEOMAGN AERONOMY+, V2, P1; GWINN CR, 1986, J GEOPHYS RES-SOLID, V91, P4755, DOI 10.1029/JB091iB05p04755; HOLLERBACH R, 1993, NATURE, V365, P541, DOI 10.1038/365541a0; *INT SEISM CTR, 1967, B INT SEISM CTR, V1; JEANLOZ R, 1988, GEOPHYS RES LETT, V15, P72, DOI 10.1029/GL015i001p00072; JEANLOZ R, 1990, ANNU REV EARTH PL SC, V18, P357; KARATO S, 1993, SCIENCE, V262, P1708, DOI 10.1126/science.262.5140.1708; Lambeck K., 1980, EARTHS VARIABLE ROTA; Lambeck K., 1988, GEOPHYSICAL GEODESY; Lehmann I., 1936, BUR CENT SEISMOL INT, V14, P3; LOPER DE, 1970, PHYS FLUIDS, V13, P2995, DOI 10.1063/1.1692891; MALIN SRC, 1982, NATURE, V296, P726, DOI 10.1038/296726a0; MCLEOD MG, 1985, J GEOPHYS RES-SOLID, V90, P4597, DOI 10.1029/JB090iB06p04597; Merrill R.T., 1983, EARTHS MAGNETIC FIEL; MORELLI A, 1986, GEOPHYS RES LETT, V13, P1545, DOI 10.1029/GL013i013p01545; POUPINET G, 1983, NATURE, V305, P204, DOI 10.1038/305204a0; Romanowicz B, 1996, SCIENCE, V274, P963, DOI 10.1126/science.274.5289.963; SHEARER PM, 1994, J GEOPHYS RES-SOL EA, V99, P19647, DOI 10.1029/94JB01470; SHEARER PM, 1988, NATURE, V333, P228, DOI 10.1038/333228a0; SHEARER PM, 1991, J GEOPHYS RES-SOLID, V96, P2233, DOI 10.1029/90JB02370; SONG XD, 1995, J GEOPHYS RES-SOL EA, V100, P9805, DOI 10.1029/95JB00244; SONG XD, 1993, GEOPHYS RES LETT, V20, P2591, DOI 10.1029/93GL02812; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; SU WJ, 1995, J GEOPHYS RES-SOL EA, V100, P9831, DOI 10.1029/95JB00746; TROMP J, 1993, NATURE, V366, P678, DOI 10.1038/366678a0; VINNIK L, 1994, GEOPHYS RES LETT, V21, P1671, DOI 10.1029/94GL01600; WASSERMAN E, 1996, EOS, V77, pS268; WOODHOUSE JH, 1986, GEOPHYS RES LETT, V13, P1549, DOI 10.1029/GL013i013p01549	40	133	150	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1883	1887		10.1126/science.274.5294.1883	http://dx.doi.org/10.1126/science.274.5294.1883			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943196				2022-12-28	WOS:A1996VY20000036
J	Blanas, E; Carbone, FR; Allison, J; Miller, JFAP; Heath, WR				Blanas, E; Carbone, FR; Allison, J; Miller, JFAP; Heath, WR			Induction of autoimmune diabetes by oral administration of autoantigen	SCIENCE			English	Article							COLLAGEN-INDUCED ARTHRITIS; MYELIN BASIC-PROTEIN; CD8(+) T-CELLS; II COLLAGEN; VIRUS-INFECTION; NOD MICE; TOLERANCE; INSULIN; SUPPRESSION; ANTIGEN	An antigen administered orally can induce immunological tolerance to a subsequent challenge with the same antigen. Evidence has been provided for the efficacy of this approach in the treatment of human autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. However, oral administration of autoantigen in mice was found to induce a cytotoxic T lymphocyte response that could lead to the onset of autoimmune diabetes. Thus, feeding autoantigen can cause autoimmunity, which suggests that caution should be used when applying this approach to the treatment of human autoimmune diseases.	WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA; ALFRED HOSP, MONASH MED SCH, PRAHRAN, VIC 3181, AUSTRALIA	Walter & Eliza Hall Institute; Florey Institute of Neuroscience & Mental Health; Monash University			Carbone, Francis/ABF-2141-2020	Heath, William/0000-0001-9670-259X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029385] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29385] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT SP, 1995, EUR J IMMUNOL, V25, P2686, DOI 10.1002/eji.1830250943; Bennett S. N. L., UNPUB; BERGEROT I, 1994, J AUTOIMMUN, V7, P655, DOI 10.1006/jaut.1994.1050; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BLANAS E, UNPUB; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; GARSIDE P, 1995, INT IMMUNOL, V7, P501, DOI 10.1093/intimm/7.3.501; HANCOCK WW, 1995, AM J PATHOL, V147, P1193; HARRISON LC, 1995, MOL MED, V1, P722, DOI 10.1007/BF03401887; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HEATH WR, 1995, J IMMUNOL, V155, P2339; HEHMKE B, 1995, DIABETES, V44, P1414, DOI 10.2337/diabetes.44.12.1414; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; HOGAN B, 1986, MANIPULATING MOUSE E; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; ITOH N, 1993, J CLIN INVEST, V92, P2313, DOI 10.1172/JCI116835; Ke Y, 1996, J IMMUNOL, V156, P916; KHARE SD, 1995, J IMMUNOL, V155, P3653; LAMONT AG, 1989, IMMUNOLOGY, V66, P595; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; THOMPSON HSG, 1990, IMMUNOL TODAY, V11, P396; TITUS RG, 1981, INT ARCH ALLER A IMM, V65, P323, DOI 10.1159/000232772; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VAZ NM, 1977, J ALLERGY CLIN IMMUN, V60, P110, DOI 10.1016/0091-6749(77)90035-5; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; ZHANG ZJ, 1992, FASEB J, V6, pA1693; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	35	220	246	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1707	1709		10.1126/science.274.5293.1707	http://dx.doi.org/10.1126/science.274.5293.1707			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939860				2022-12-28	WOS:A1996VW71200059
J	vanVreeswijk, C; Sompolinsky, H				vanVreeswijk, C; Sompolinsky, H			Chaos in neuronal networks with balanced excitatory and inhibitory activity	SCIENCE			English	Article							NEURAL NETWORK; NOISE	Neurons in the cortex of behaving animals show temporally irregular spiking patterns. The origin of this irregularity and its implications for neural processing are unknown. The hypothesis that the temporal variability in the firing of a neuron results from an approximate balance between its excitatory and inhibitory inputs was investigated theoretically, Such a balance emerges naturally in large networks of excitatory and inhibitory neuronal populations that are sparsely connected by relatively strong synapses. The resulting state is characterized by strongly chaotic dynamics, even when the external inputs to the network are constant in time. Such a network exhibits a linear response, despite the highly nonlinear dynamics of single neurons, and reacts to changing external stimuli on time scales much smaller than the integration time constant of a single neuron.	HEBREW UNIV JERUSALEM,CTR NEURAL COMPUTAT,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	vanVreeswijk, C (corresponding author), HEBREW UNIV JERUSALEM,RACAH INST PHYS,IL-91904 JERUSALEM,ISRAEL.		Sompolinsky, Haim/ABB-8398-2021					ABELES M, UNPUB; AMIT DJ, IN PRESS CEREB CORTE; BELL A, 1994, SOC NEUR ABSTR, V20, P1527; BURNS BD, 1976, PROC R SOC SER B-BIO, V194, P211, DOI 10.1098/rspb.1976.0074; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; DERRIDA B, 1987, EUROPHYS LETT, V4, P167, DOI 10.1209/0295-5075/4/2/007; DOUGLAS RJ, 1991, TRENDS NEUROSCI, V14, P286, DOI 10.1016/0166-2236(91)90139-L; HANSEL D, 1992, PHYS REV LETT, V68, P718, DOI 10.1103/PhysRevLett.68.718; HANSEL D, 1996, J COMPUT NEUROSCI, V3, P5; Holt GR, 1996, J NEUROPHYSIOL, V75, P1806, DOI 10.1152/jn.1996.75.5.1806; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Shadlen M N, 1995, Curr Opin Neurobiol, V5, P248, DOI 10.1016/0959-4388(95)80033-6; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8; SOFTKY WR, 1993, J NEUROSCI, V13, P334; SOMPOLINSKY H, 1988, PHYS REV LETT, V61, P259, DOI 10.1103/PhysRevLett.61.259; TSODYKS MV, 1995, NETWORK-COMP NEURAL, V6, P111, DOI 10.1088/0954-898X/6/2/001	17	1066	1072	6	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1724	1726						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939866				2022-12-28	WOS:A1996VW71200065
J	Berkowitz, RS; Goldstein, DP				Berkowitz, RS; Goldstein, DP			Medical progress - Chorionic tumors	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GESTATIONAL TROPHOBLASTIC DISEASE; PARTIAL HYDATIDIFORM MOLE; CENTRAL NERVOUS-SYSTEM; SINGLE-AGENT CHEMOTHERAPY; RISK-FACTORS; PROPHYLACTIC CHEMOTHERAPY; ACTINOMYCIN-D; PROGNOSTIC-SIGNIFICANCE; RESPIRATORY-FAILURE; NATURAL-HISTORY		DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Berkowitz, RS (corresponding author), BRIGHAM & WOMENS HOSP,DIV GYNECOL ONCOL,NEW ENGLAND TROPHOBLAST DIS CTR,75 FRANCIS ST,BOSTON,MA 02115, USA.							ACAIA B, 1988, GYNECOL ONCOL, V31, P310, DOI 10.1016/S0090-8258(88)80009-X; ATHANASSIOU A, 1983, CANCER, V52, P1728, DOI 10.1002/1097-0142(19831101)52:9<1728::AID-CNCR2820520929>3.0.CO;2-U; AYHAN A, 1992, J REPROD MED, V37, P461; AZAB M, 1989, CANCER-AM CANCER SOC, V64, P1829, DOI 10.1002/1097-0142(19891101)64:9<1829::AID-CNCR2820640912>3.0.CO;2-G; AZUMA C, 1991, GYNECOL ONCOL, V40, P29, DOI 10.1016/0090-8258(91)90080-O; BAGSHAWE KD, 1990, LANCET, V335, P1074, DOI 10.1016/0140-6736(90)92641-T; BAGSHAWE KD, 1976, CANCER, V38, P1373, DOI 10.1002/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E; BAGSHAWE KD, 1976, CANCER, V38, P112, DOI 10.1002/1097-0142(197607)38:1<112::AID-CNCR2820380120>3.0.CO;2-P; BAKRI Y, 1994, J REPROD MED, V39, P179; BAKRI YN, 1994, J REPROD MED, V39, P175; Berkowitz R S, 1981, Pathobiol Annu, V11, P391; Berkowitz R. S., 1993, GYNECOL ONCOL, P328; BERKOWITZ RS, 1995, AM J OBSTET GYNECOL, V173, P788, DOI 10.1016/0002-9378(95)90342-9; BERKOWITZ RS, 1981, OBSTET GYNECOL, V58, P474; BERKOWITZ RS, 1985, OBSTET GYNECOL, V66, P677; BERKOWITZ RS, 1994, J REPROD MED, V39, P228; BERKOWITZ RS, 1981, SURG GYNECOL OBSTET, V153, P687; BERKOWITZ RS, 1987, J REPROD MED, V32, P634; BERKOWITZ RS, 1985, AM J OBSTET GYNECOL, V152, P1016, DOI 10.1016/0002-9378(85)90550-2; BERKOWITZ RS, 1986, GYNECOL ONCOL, V23, P111, DOI 10.1016/0090-8258(86)90123-X; BOLIS G, 1988, GYNECOL ONCOL, V31, P439, DOI 10.1016/S0090-8258(88)80029-5; BOLIS G, 1988, TUMORI J, V74, P93, DOI 10.1177/030089168807400116; BRACKEN MB, 1987, BRIT J OBSTET GYNAEC, V94, P1123, DOI 10.1111/j.1471-0528.1987.tb02311.x; CURRY SL, 1989, AM J OBSTET GYNECOL, V160, P805, DOI 10.1016/0002-9378(89)90295-0; CURRY SL, 1975, OBSTET GYNECOL, V45, P1; CURRY SL, 1989, OBSTET GYNECOL, V73, P357; CZERNOBILSKY B, 1982, OBSTET GYNECOL, V59, P75; DOBKIN GR, 1991, J REPROD MED, V36, P14; DOSHI N, 1983, HUM PATHOL, V14, P716, DOI 10.1016/S0046-8177(83)80145-2; DUBESHTER B, 1989, J REPROD MED, V34, P189; DUBESHTER B, 1987, OBSTET GYNECOL, V69, P390; DUBUCLISSOIR J, 1992, GYNECOL ONCOL, V45, P40, DOI 10.1016/0090-8258(92)90488-5; FASOLI M, 1982, OBSTET GYNECOL, V60, P205; FINE C, 1989, OBSTET GYNECOL, V73, P414; FINKLER NJ, 1988, OBSTET GYNECOL, V71, P854; GENEST DR, 1991, OBSTET GYNECOL, V78, P402; GOLDSTEIN DP, 1995, SEMIN ONCOL, V22, P157; GOLDSTEIN DP, 1971, OBSTET GYNECOL, V38, P817; GOLDSTEIN DP, 1994, J REPROD MED, V39, P139; Goldstein DP, 1982, MAJOR PROBLEMS OBSTE, V14, P143; GORDON AN, 1989, GYNECOL ONCOL, V34, P54, DOI 10.1016/0090-8258(89)90106-6; GOTO S, 1993, GYNECOL ONCOL, V48, P165, DOI 10.1006/gyno.1993.1028; HOMESLEY HD, 1994, J REPROD MED, V39, P185; JEFFERS MD, 1993, INT J GYNECOL PATHOL, V12, P315, DOI 10.1097/00004347-199310000-00006; JONES WB, 1990, AM J OBSTET GYNECOL, V162, P1286, DOI 10.1016/0002-9378(90)90039-A; KAJII T, 1977, NATURE, V268, P633, DOI 10.1038/268633a0; KASHIMURA Y, 1986, CANCER, V58, P624, DOI 10.1002/1097-0142(19860801)58:3<624::AID-CNCR2820580305>3.0.CO;2-6; KELLY MP, 1990, GYNECOL ONCOL, V38, P149, DOI 10.1016/0090-8258(90)90031-F; KIM DS, 1986, OBSTET GYNECOL, V67, P690, DOI 10.1097/00006250-198605000-00017; KOHORN EI, 1984, CLIN OBSTET GYNECOL, V27, P181, DOI 10.1097/00003081-198403000-00025; KOHORN EI, 1982, OBSTET GYNECOL, V59, P78; KOHORN EI, 1991, J REPROD MED, V36, P49; LAGE JM, 1992, OBSTET GYNECOL, V79, P403, DOI 10.1097/00006250-199203000-00016; LAWLER SD, 1991, AM J OBSTET GYNECOL, V164, P1270, DOI 10.1016/0002-9378(91)90698-Q; LURAIN J R, 1991, European Journal of Gynaecological Oncology, V12, P425; LURAIN JR, 1983, AM J OBSTET GYNECOL, V145, P591, DOI 10.1016/0002-9378(83)91202-4; MCLAREN DS, 1966, T ROY SOC TROP MED H, V60, P436, DOI 10.1016/0035-9203(66)90266-5; Montes M, 1996, AM J CLIN PATHOL, V105, P411; MORROW CP, 1984, CLIN OBSTET GYNECOL, V27, P211, DOI 10.1097/00003081-198403000-00028; MORROW CP, 1977, AM J OBSTET GYNECOL, V128, P424, DOI 10.1016/0002-9378(77)90562-2; MORTAKIS AE, 1990, OBSTET GYNECOL, V76, P272; MUNYER TP, 1981, J CLIN ULTRASOUND, V9, P349, DOI 10.1002/jcu.1870090702; MUTCH DG, 1986, OBSTET GYNECOL, V68, P348, DOI 10.1097/00006250-198609000-00011; NEWLANDS ES, 1991, BRIT J OBSTET GYNAEC, V98, P550, DOI 10.1111/j.1471-0528.1991.tb10369.x; OSATHANONDH R, 1986, J REPROD MED, V31, P179; OTOOLE BA, 1974, J NUTR, V104, P1513, DOI 10.1093/jn/104.11.1513; PALMER JR, 1994, J REPROD MED, V39, P155; Paradinas FJ, 1996, HISTOPATHOLOGY, V28, P101, DOI 10.1046/j.1365-2559.1996.247295.x; PARAZZINI F, 1988, GYNECOL ONCOL, V30, P57, DOI 10.1016/0090-8258(88)90046-7; PARAZZINI F, 1991, OBSTET GYNECOL, V78, P1039; PARAZZINI F, 1988, AM J OBSTET GYNECOL, V158, P93, DOI 10.1016/0002-9378(88)90785-5; PARAZZINI F, 1986, BRIT J OBSTET GYNAEC, V93, P582, DOI 10.1111/j.1471-0528.1986.tb07957.x; PATTILLO RA, 1981, AM J OBSTET GYNECOL, V141, P104; RICE LW, 1990, GYNECOL ONCOL, V36, P358, DOI 10.1016/0090-8258(90)90142-8; ROMERO R, 1985, OBSTET GYNECOL, V66, P553; Rustin GJS, 1996, J CLIN ONCOL, V14, P2769, DOI 10.1200/JCO.1996.14.10.2769; RUSTIN GJS, 1983, NEW ENGL J MED, V308, P473, DOI 10.1056/NEJM198303033080901; RUSTIN GJS, 1989, J CLIN ONCOL, V7, P900, DOI 10.1200/JCO.1989.7.7.900; SANTOSRAMOS R, 1980, OBSTET GYNECOL, V56, P186; SCHINK JC, 1992, OBSTET GYNECOL, V80, P817; SCHLAERTH JB, 1984, GYNECOL ONCOL, V19, P53, DOI 10.1016/0090-8258(84)90157-4; SCULLY RE, 1981, AM J SURG PATHOL, V5, P75, DOI 10.1097/00000478-198101000-00010; SOPER JT, 1994, OBSTET GYNECOL, V83, P113; SOPER JT, 1994, GYNECOL ONCOL, V54, P76, DOI 10.1006/gyno.1994.1169; SOPER JT, 1994, J REPROD MED, V39, P168; SOTOWRIGHT V, 1995, OBSTET GYNECOL, V86, P775, DOI 10.1016/0029-7844(95)00268-V; STONE M, 1976, BRIT J OBSTET GYNAEC, V83, P913, DOI 10.1111/j.1471-0528.1976.tb00774.x; SZULMAN AE, 1978, AM J OBSTET GYNECOL, V132, P20, DOI 10.1016/0002-9378(78)90792-5; SZULMAN AE, 1982, OBSTET GYNECOL, V59, P597; SZULMAN AE, 1978, AM J OBSTET GYNECOL, V131, P665, DOI 10.1016/0002-9378(78)90829-3; Tow W S, 1966, J Obstet Gynaecol Br Commonw, V73, P544; TSUKAMOTO N, 1985, GYNECOL ONCOL, V20, P53, DOI 10.1016/0090-8258(85)90124-6; VASSILAKOS P, 1977, AM J OBSTET GYNECOL, V127, P167, DOI 10.1016/S0002-9378(16)33244-6; WEED JC, 1980, OBSTET GYNECOL, V55, P89; *WHO, 1983, WHO TECH REP SER, V692, P51; WONG LC, 1984, ARCH GYNECOL, V234, P161, DOI 10.1007/BF00570751; WONG LC, 1986, CANCER, V58, P14, DOI 10.1002/1097-0142(19860701)58:1<14::AID-CNCR2820580104>3.0.CO;2-R; XIA ZG, 1980, CHINESE MED J-PEKING, V93, P605; YAMASHITA K, 1979, AM J OBSTET GYNECOL, V135, P597, DOI 10.1016/S0002-9378(16)32983-0; YORDAN EL, 1987, OBSTET GYNECOL, V69, P627	100	217	225	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1740	1748		10.1056/NEJM199612053352306	http://dx.doi.org/10.1056/NEJM199612053352306			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929267				2022-12-28	WOS:A1996VW79500006
J	Wiertz, EJHJ; Tortorella, D; Bogyo, M; Yu, J; Mothes, W; Jones, TR; Rapoport, TA; Ploegh, HL				Wiertz, EJHJ; Tortorella, D; Bogyo, M; Yu, J; Mothes, W; Jones, TR; Rapoport, TA; Ploegh, HL			Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction	NATURE			English	Article							CLASS-I MOLECULES; LIGHT-CHAINS; DEGRADATION; TRANSLOCATION; COMPLEX; EXPRESSION; COMPARTMENT; INHIBITORS; PATHWAY; PEPTIDE	The human cytomegalovirus genome encodes proteins that trigger destruction of newly synthesized major histocompatibility complex (MHC) class I molecules. The human cytomegalovirus gene US2 specifies a product capable of dislocating MHC class I molecules from the endoplasmic reticulum to the cytosol and delivering them to the proteasome. This process involves the Sec61 complex, in what appears to be a reversal of the reaction by which it translocates nascent chains into the endoplasmic reticulum.	MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; WYETH AYERST RES, INFECT DIS SECT, DEPT MOL BIOL, PEARL RIVER, NY 10965 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Pfizer				Tortorella, Domenico/0000-0003-0961-3535; Bogyo, Matthew/0000-0003-3753-4412				BACALLAO R, 1994, J CELL SCI, V107, P3301; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; BONIFACINO JS, 1994, MODERN CELL BIOL CEL, V15, P137; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CIECHANOVER AJ, 1994, CELLULAR PROTEOLYTIC, P3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JONES TR, 1995, J VIROL, V69, P4830, DOI 10.1128/JVI.69.8.4830-4841.1995; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PARHAM P, 1979, J IMMUNOL, V123, P342; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753	50	920	942	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					432	438		10.1038/384432a0	http://dx.doi.org/10.1038/384432a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945469				2022-12-28	WOS:A1996VW68700053
J	Nightingale, SL				Nightingale, SL			New spinal fusion devices approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-28	WOS:A1996VV56600007
J	Zook, HA; Grun, E; Baguhl, M; Hamilton, DP; Linkert, G; Liou, JC; Forsyth, R; Phillips, JL				Zook, HA; Grun, E; Baguhl, M; Hamilton, DP; Linkert, G; Liou, JC; Forsyth, R; Phillips, JL			Solar wind magnetic field bending of Jovian dust trajectories	SCIENCE			English	Article							JUPITER; EJECTION; GALILEO	From September 1991 to October 1992, the cosmic dust detector on the Ulysses spacecraft recorded 11 short bursts, or streams, of dust. These dust grains emanated from the jovian system, and their trajectories were strongly affected by solar wind magnetic field forces. Analyses of the on-board measurements of these fields, and of stream approach directions, show that stream-associated dust grain masses are of the order of 10(-18) gram and dust grain velocities exceed 200 kilometers per second. These masses and velocities are, respectively, about 10(3) times less massive and 5 to 10 times faster than earlier reported.	MAX PLANCK INST KERNPHYS,D-69029 HEIDELBERG,GERMANY; UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,BLACKETT LAB,LONDON SW7 2BZ,ENGLAND; LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545	Max Planck Society; University System of Maryland; University of Maryland College Park; Imperial College London; United States Department of Energy (DOE); Los Alamos National Laboratory	Zook, HA (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,HOUSTON,TX 77058, USA.							BAGUHI M, 1994, PLANET SPACE SCI, V41, P1085; BALOGH A, 1993, GEOPHYS RES LETT, V20, P2331, DOI 10.1029/93GL02621; BARNE SJ, 1993, GEOPHYS RES LETT, V20, P2323; GOLLER JR, 1989, PLANET SPACE SCI, V37, P1197, DOI 10.1016/0032-0633(89)90014-7; GRUN E, 1995, PLANET SPACE SCI, V43, P971, DOI 10.1016/0032-0633(94)00233-H; GRUN E, 1993, NATURE, V362, P428, DOI 10.1038/362428a0; GRUN E, 1995, PLANET SPACE SCI, V43, P941, DOI 10.1016/0032-0633(94)00232-G; GRUN E, 1992, SCIENCE, V257, P1550, DOI 10.1126/science.11538054; Grun E, 1996, SCIENCE, V274, P399, DOI 10.1126/science.274.5286.399; Grun E, 1996, NATURE, V381, P395, DOI 10.1038/381395a0; HAMILTON DP, 1993, NATURE, V364, P695, DOI 10.1038/364695a0; HORANYI M, 1993, NATURE, V363, P144, DOI 10.1038/363144a0; MARIANI F, 1990, PHYSICS INNER HELIOS, P99; ZOOK HA, 1996, P 150 C INT ASTR UN, V104, P23	14	75	75	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1501	1503		10.1126/science.274.5292.1501	http://dx.doi.org/10.1126/science.274.5292.1501			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929405				2022-12-28	WOS:A1996VV77500040
J	Seidelman, WE				Seidelman, WE			The path to Nuremberg in the pages of JAMA, 1933-1939	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NAZI		YORK UNIV,DEPT HIST,N YORK,ON M3J 1P3,CANADA; UNIV TORONTO,DEPT FAMILY & COMMUNITY MED,TORONTO,ON M5S 1A1,CANADA	York University - Canada; University of Toronto	Seidelman, WE (corresponding author), WELLESLEY HLTH CTR,HIV AMBULATORY PROGRAM,410 SHERBOURNE ST,TORONTO,ON M4X 1K2,CANADA.							Bloch H, 1973, Bull Hist Med, V47, P297; BURLEIGH M, 1994, DEATH DELIVANCE EUTH; FISHBEIN M, 1969, M FISHBEIN MD AUTOBI; Friedlander Henry, 1995, ORIGINS NAZI GENOCID; KATER M., 1983, NAZI PARTY; KATER MH, 1987, GER STUD REV, V10, P31, DOI 10.2307/1430442; Kater MH, 1989, DOCTORS HITLER; Lifton R. J., 1986, NAZI DOCTORS MED KIL; Muller-Hill B., 1988, MURDEROUS SCI; Posner G. L., 1986, MENGELE COMPLETE STO; Proctor R. N., 1988, RACIAL HYGIENE; Seidelman W E, 1995, Med Glob Surviv, V2, P148; SEIDELMAN WE, 1989, NATURE, V337, P300, DOI 10.1038/337300a0; SEIDELMAN WE, 1988, MILBANK Q, V66, P221, DOI 10.2307/3350031; Weindling P, 1989, HLTH RACE GERMAN POL; WISTRICH RS, 1982, WHOS WHO NAZI GERMAN; 1933, JAMA-J AM MED ASSOC, V101, P1491; 1933, JAMA-J AM MED ASSOC, V101, P295; 1938, JAMA-J AM MED ASSOC, V110, P2020; 1933, JAMA-J AM MED ASSOC, V100, P1616; 1933, JAMA-J AM MED ASSOC, V101, P1893; 1933, JAMA-J AM MED ASSOC, V101, P1327; 1933, JAMA-J AM MED ASSOC, V101, P722; 1935, JAMA-J AM MED ASSOC, V105, P1051; 1933, JAMA-J AM MED ASSOC, V101, P866; 1936, JAMA-J AM MED ASSOC, V106, P1214; 1993, SCI CITATION INDE 11; 1993, JAMA-J AM MED ASSOC, V101, P294; 1993, JAMA-J AM MED ASSOC, V100, P1550; 1938, JAMA-J AM MED ASSOC, V110, P221; 1933, JAMA-J AM MED ASSOC, V101, P1165; 1994, SCI CITATION INDE 10; 1933, JAMA-J AM MED ASSOC, V100, P1706; 1933, JAMA-J AM MED ASSOC, V100, P1707; 1933, JAMA-J AM MED ASSOC, V101, P939; 1933, JAMA-J AM MED ASSOC, V101, P459; 1938, JAMA-J AM MED ASSOC, V101, P722; 1939, JAMA-J AM MED ASSOC, V113, P434; 1933, JAMA-J AM MED ASSOC, V101, P943; 1938, JAMA-J AM MED ASSOC, V111, P1778	40	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1693	1696		10.1001/jama.276.20.1693	http://dx.doi.org/10.1001/jama.276.20.1693			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU209	8922459				2022-12-28	WOS:A1996VU20900041
J	Schnipper, HH				Schnipper, HH			Through the looking glass	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1535	1536						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918836				2022-12-28	WOS:A1996VT02500001
J	Sandham, JD; Hull, RD; Brant, RF				Sandham, JD; Hull, RD; Brant, RF			Pulmonary artery flow directed catheter: The evidence	LANCET			English	Editorial Material											Sandham, JD (corresponding author), UNIV CALGARY,DEPT MED,3330 HOSP DR NW,CALGARY,AB T2N 2T9,CANADA.			Brant, Rollin/0000-0002-8026-2451				Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; GORE JM, 1987, CHEST, V92, P721, DOI 10.1378/chest.92.4.721; ROBIN ED, 1987, CHEST, V92, P727, DOI 10.1378/chest.92.4.727; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; SANDHAM JD, 1996, AM J RESP CRIT CARE, V153, pA601; SANDHAM JD, 1996, AM J RESP CRIT CARE, V153, pA422; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591	8	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1324	1324		10.1016/S0140-6736(05)65401-3	http://dx.doi.org/10.1016/S0140-6736(05)65401-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918269				2022-12-28	WOS:A1996VT33200002
J	Wary, KK; Mainiero, F; Isakoff, SJ; Marcantonio, EE; Giancotti, FG				Wary, KK; Mainiero, F; Isakoff, SJ; Marcantonio, EE; Giancotti, FG			The adaptor protein Shc couples a class of integrins to the control of cell cycle progression	CELL			English	Article							HUMAN-ENDOTHELIAL CELLS; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; MEMBRANE DOMAINS; DIFFERENTIATION; FIBRONECTIN; EXPRESSION; RECEPTOR; CAVEOLIN	We provide evidence that a class of integrins combines with the adaptor She and thereby with Grb2. Coimmunoprecipitation and mutagenesis experiments indicate that the recruitment of She is specified by the extracellular or transmembrane domain of integrin cu subunit and suggest that this process is mediated by caveolin. Mutagenesis and dominant-negative inhibition studies reveal that She is necessary and sufficient for activation of the MAP kinase pathway in response to integrin ligation. Mitogens and She-activating integrins cooperate to promote transcription from the Fos serum response element and transit through G1. In contrast, adhesion mediated by integrins not linked to She results in cell cycle arrest and apoptosis even in presence of mitogens. These findings indicate that the association of specific integrins with She regulates cell survival and cell cycle progression.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; NYU,SCH MED,SACKLER INST GRAD BIOMED SCI,NEW YORK,NY 10016; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	New York University; New York University; New York University; Columbia University			Isakoff, Steven/ABE-3566-2020	Wary, Kishore/0000-0001-8851-8565; Mainiero, Fabrizio/0000-0002-7136-9839	NATIONAL CANCER INSTITUTE [R01CA058976, P30CA016087, R37CA058976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044585] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16087, CA-58976] Funding Source: Medline; NIGMS NIH HHS [GM-44585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONFORTI G, 1989, BLOOD, V73, P1576; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIANCOTTI FG, 1994, METHOD ENZYMOL, V245, P297; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1996, IN PRESS DEV BIOL; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KEM A, 1994, J BIOL CHEM, V269, P22811; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pullan S, 1996, J CELL SCI, V109, P631; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	48	633	642	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					733	743		10.1016/S0092-8674(00)81392-6	http://dx.doi.org/10.1016/S0092-8674(00)81392-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929541	hybrid			2022-12-28	WOS:A1996VU03500015
J	Stein, CE; Fall, CHD; Kumaran, K; Osmond, C; Cox, V; Barker, DJP				Stein, CE; Fall, CHD; Kumaran, K; Osmond, C; Cox, V; Barker, DJP			Fetal growth and coronary heart disease in South India	LANCET			English	Article							CARDIOVASCULAR-DISEASE; RURAL-POPULATION; ADULT LIFE; PREVALENCE; THINNESS; BIRTH; DEATH	Background Coronary heart disease is predicted to become the commonest cause of death in India within 15 years, People from India living overseas already have high rates of the disease that are not explained by known coronary risk factors. Small size at birth is a newly described risk factor for coronary heart disease, but associations between size at birth and the disease have not been examined in India. Methods We studied 517 men and women who were born between 1934 and 1954 in a mission hospital in Mysore, South India, and who still lived near to the hospital. We related the prevalence of coronary heart disease, defined by standard criteria, to their birth size. Findings 25 (9%) men and 27 (11%) women had coronary heart disease. Low birthweight, short birth length, and small head circumference at birth were associated with a raised prevalence of the disease. Prevalence fell from 11% in people whose birthweights were 55 lb (2.5 kg) or less to 3% in those whose birthweights were more than 7 lb (3.1 kg), p for trend = 0.09. The trends were stronger and statistically significant among people aged 45 years and over (p = 0.03 for birthweight, 0.04 for length, and 0.02 for head circumference), High rates of disease were also found in those whose mothers had a low body weight during pregnancy. The highest prevalence of the disease (20%) was in people who weighed 5.5 lb (2.5 kg) or less at birth and whose mothers weighed less than 100 lb (45 kg) in pregnancy. These associations were largely independent of known coronary risk factors. Interpretation In India, as in the UK, coronary heart disease is associated with small size al birth, suggesting that its pathogenesis is influenced by events in utero, The association with low maternal bodyweight is further evidence that the disease originates through fetal undernutrition, Prevention of the rising epidemic of the disease in India may require improvements in the nutrition and health of young women.	SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; HOLDSWORTH MEM HOSP,MYSORE,KARNATAKA,INDIA	University of Southampton				Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; EDWARDS JR, 1995, AM J EPIDEMIOL, V141, pS78; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAIRDNER D, 1971, ARCH DIS CHILD, V46, P783, DOI 10.1136/adc.46.250.783; GUPTA R, 1994, BRIT MED J, V309, P1332, DOI 10.1136/bmj.309.6965.1332; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Kuppuswamy B., 1962, MANUAL SOCIOECONOMIC; KUTTY VR, 1993, INT J CARDIOL, V39, P59; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1993, J EPIDEMIOL COMMUN H, V47, P255, DOI 10.1136/jech.47.4.255; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MANN M, 1990, INDIAN PEDIATR, V27, P43; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; *OFF POP CENS SURV, 1990, DIST NUTR SURV BRIT; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Prineas R., 1982, MINNESOTA CODE MANUA; REID DD, 1974, LANCET, V1, P469; Rose G, 1968, CARDIOVASCULAR SURVE; SARVOTHAM SG, 1968, CIRCULATION, V37, P939, DOI 10.1161/01.CIR.37.6.939; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170	25	401	410	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1269	1273		10.1016/S0140-6736(96)04547-3	http://dx.doi.org/10.1016/S0140-6736(96)04547-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909379				2022-12-28	WOS:A1996VR55500009
J	McDonald, SJ; Lefebvre, C; Clarke, MJ				McDonald, SJ; Lefebvre, C; Clarke, MJ			Identifying reports of controlled trials in the BMJ and the Lancet	BMJ-BRITISH MEDICAL JOURNAL			English	Article									RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	McDonald, SJ (corresponding author), UK COCHRANE CTR, OXFORD OX2 7LG, ENGLAND.		McDonald, Steve/AAE-1613-2020	McDonald, Steve/0000-0003-2832-5205				CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; *COCHR COLL, 1996, COCHR LIB DAT CD ROM; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Lefebvre C, 1994, Health Libr Rev, V11, P235, DOI 10.1046/j.1365-2532.1994.1140235.x	4	18	18	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1116	1117		10.1136/bmj.313.7065.1116	http://dx.doi.org/10.1136/bmj.313.7065.1116			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916697	Green Published			2022-12-28	WOS:A1996VR21700022
J	Epstein, SE; Speir, E; Zhou, YF; Guetta, E; Leon, M; Finkel, T				Epstein, SE; Speir, E; Zhou, YF; Guetta, E; Leon, M; Finkel, T			The role of infection in restenosis and atherosclerosis: Focus on cytomegalovirus	LANCET			English	Article							ENDOTHELIAL-CELLS; VIRUS-INFECTION; POTENTIAL ROLE; GROWTH-FACTOR; ANTIGEN; ARTERIOSCLEROSIS; HERPESVIRUS; FIBROBLASTS; EXPRESSION; PROTEINS											ALBRECHT T, 1976, J GEN VIROL, V30, P167, DOI 10.1099/0022-1317-30-2-167; ALCAMI J, 1991, J GEN VIROL, V72, P2765, DOI 10.1099/0022-1317-72-11-2765; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; FABRICANT CG, 1983, FED PROC, V42, P2476; GAO JL, 1994, J BIOL CHEM, V269, P28539; GONCZOL E, 1984, J GEN VIROL, V65, P1833, DOI 10.1099/0022-1317-65-10-1833; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; GRUNDY JE, 1993, IMMUNOLOGY, V78, P405; GUETTA E, 1995, CIRCULATION S, V92, P161; HAJJAR DP, 1987, J CLIN INVEST, V80, P1317, DOI 10.1172/JCI113208; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; LEMSTROM KB, 1994, ARTERIOSCLER THROMB, V14, P2043, DOI 10.1161/01.ATV.14.12.2043; MELNICK JL, 1990, JAMA-J AM MED ASSOC, V263, P2204, DOI 10.1001/jama.263.16.2204; MELNICK JL, 1983, LANCET, V2, P644; MINICK CR, 1979, AM J PATHOL, V96, P673; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SPAN AHM, 1991, IMMUNOLOGY, V72, P355; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; SPEIR E, 1995, CIRCULATION, V92, P231; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VANDAMMIERAS MCE, 1992, THROMB HAEMOSTASIS, V68, P364; VERCELLOTTI GM, 1995, TRENDS CARDIOVAS MED, V5, P128, DOI 10.1016/1050-1738(95)00052-B; VISSER MR, 1988, P NATL ACAD SCI USA, V85, P8227, DOI 10.1073/pnas.85.21.8227; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZHOU Y, IN PRESS J CLIN INVE; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; ZHOU YF, 1995, J AM COLL CARDIOL, V25, pA242; ZHU H, 1995, J VIROL, V69, P7960, DOI 10.1128/JVI.69.12.7960-7970.1995	31	87	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV	1996	348			1			S13	S17		10.1016/S0140-6736(96)98005-8	http://dx.doi.org/10.1016/S0140-6736(96)98005-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918522				2022-12-28	WOS:A1996VU00800006
J	Burgess, R; Rawls, A; Brown, D; Bradley, A; Olson, EN				Burgess, R; Rawls, A; Brown, D; Bradley, A; Olson, EN			Requirement of the paraxis gene for somite formation and musculoskeletal patterning	NATURE			English	Article							LOOP-HELIX PROTEIN; MOUSE EMBRYOGENESIS; BOX GENE; MESODERM; EXPRESSION; TRANSCRIPTION; SEGMENTATION; LINEAGES; MEMBER; FAMILY	THE segmental organization of the vertebrate embryo is first apparent when somites form in a rostrocaudal progression from the paraxial mesoderm adjacent to the neural tube. Newly formed somites appear as paired epithelial spheres that become patterned to form vertebrae, ribs, skeletal muscle and derms(1-3). Paraxis is a basic helix-loop-helix transcription factor expressed in paraxial mesoderm and somites(4). Here we show that in mice homozygous for a paraxis null mutation, cells from the paraxial mesoderm are unable to form epithelia and so somite formation is disrupted. In the absence of normal somites, the axial skeleton and skeletal muscle form but are improperly patterned. Unexpectedly, however, we found that formation of epithelial somites was not required for segmentation of the embryo or for the establishment of somitic cell lineages. These results demonstrate that paraxis regulates somite morphogenesis, and that the function of somites is to pattern the axial skeleton and skeletal muscles.	UNIV TEXAS,SW MED CTR,HAMON CTR BASIC CANC RES,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235; LEXICON GENET INC,THE WOODLANDS,TX 77381; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Lexicon Pharmaceuticals; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839				BLANAR MA, 1995, P NATL ACAD SCI USA, V92, P5870, DOI 10.1073/pnas.92.13.5870; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; COULY GF, 1993, DEVELOPMENT, V117, P409; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; JACOBSON AG, 1988, DEVELOPMENT, V104, P209; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Muller M, 1996, DEVELOPMENT, V122, P2071; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; TAM PPL, 1982, AM J ANAT, V164, P209, DOI 10.1002/aja.1001640303; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; YAMAGUCHI TP, 1992, DEV BIOL, V152, P75, DOI 10.1016/0012-1606(92)90157-C	26	192	196	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					570	573		10.1038/384570a0	http://dx.doi.org/10.1038/384570a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955271				2022-12-28	WOS:A1996VX76900061
J	McEvilly, RJ; Erkman, L; Luo, L; Sawchenko, PE; Ryan, AF; Rosenfeld, MG				McEvilly, RJ; Erkman, L; Luo, L; Sawchenko, PE; Ryan, AF; Rosenfeld, MG			Requirement for Brn-3.0 In differentiation and survival of sensory and motor neurons	NATURE			English	Article							NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; CNS NEURONS; POU FAMILY; CELLS; EXPRESSION; RAT; HOMEODOMAIN; PROTEIN	SPECIFIC families of transcription factors mediate events in the sequential maturation of distinct neuronal phenotypes. Members of one such family, the class IV POU domain transcription factor Brn-3.0, and two highly related factors Brn-3.1 and Brn-3.2, are differentially expressed in the developing and mature mammalian nervous system(1-11). The expression pattern of Brn-3.0 suggested that it has an important role in the development of sensory ganglia, as well as red nucleus, inferior olive, and nucleus ambiguus. Analysis of mice null for the Brn-3.0 locus shows that Brn-3.0 is required for the survival of subpopulations of proprioceptive, mechanoreceptive and nociceptive sensory neurons, where deletion of the gene affects neurotrophin and neurotrophin-receptor gene expression. Deletion of Brn-3.0 also alters either differentiation, migration or survival of specific central neuronal populations.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT SURG, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT OTOLARYNGOL & NEUROSCI, LA JOLLA, CA 92093 USA; VET AFFAIRS MED CTR, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, NEURONAL STRUCT & FUNCT LAB, SAN DIEGO, CA 92186 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Salk Institute					BLRD VA [I01 BX001205] Funding Source: Medline; Veterans Affairs [I01BX001205] Funding Source: NIH RePORTER	BLRD VA; Veterans Affairs(US Department of Veterans Affairs)		ALTMAN J, 1982, ADV ANAT EMBRYOL CEL, V74, P1; ALTMAN J, 1987, J COMP NEUROL, V257, P490, DOI 10.1002/cne.902570403; BHARGAVA AK, 1993, P NATL ACAD SCI USA, V90, P10260, DOI 10.1073/pnas.90.21.10260; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CUNNINGHAM ET, 1989, J NEUROSCI, V9, P1668; DIENER PS, 1994, NEUROREPORT, V5, P1913, DOI 10.1097/00001756-199410000-00018; EMFORS P, 1994, NATURE, V368, P147; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHWARTZ IR, 1990, J ELECTRON MICR TECH, V15, P225, DOI 10.1002/jemt.1060150304; SHER AE, 1971, ACTA OTO-LARYNGOL, P1; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; XIANG MQ, 1995, J NEUROSCI, V15, P4762	30	216	217	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 12	1996	384	6609					574	577		10.1038/384574a0	http://dx.doi.org/10.1038/384574a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955272				2022-12-28	WOS:A1996VX76900062
J	Wedin, DA; Tilman, D				Wedin, DA; Tilman, D			Influence of nitrogen loading and species composition on the carbon balance of grasslands	SCIENCE			English	Article							FOREST ECOSYSTEMS; SECONDARY SUCCESSION; USE EFFICIENCY; PLANT; DEPOSITION; BIOSPHERE; GRADIENTS; RESPONSES; ADDITIONS; STORAGE	In a 12-year experimental study oi nitrogen (N) deposition on Minnesota grasslands, plots dominated by native warm-season grasses shifted to low-diversity mixtures dominated by cool-season grasses at all but the lowest N addition rates. This shift was associated with decreased biomass carbon (C):N ratios, increased N mineralization, increased soil nitrate, high N losses, and low C storage, In addition, plots originally dominated by nonnative cool-season grasses retained little added N and stored little C, even allow N input rates. Thus, grasslands with high N retention and C storage rates were the most vulnerable to species losses and major shifts in C and N cycling.	UNIV MINNESOTA, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Wedin, DA (corresponding author), UNIV TORONTO, DEPT BOT, 25 WILLCOCKS ST, TORONTO, ON M5S 3B2, CANADA.		Tilman, David/ABD-5309-2021; Wedin, David A/K-4093-2012					ABER JD, 1993, ECOL APPL, V3, P156, DOI 10.2307/1941798; ABER JD, 1992, TRENDS ECOL EVOL, V7, P220, DOI 10.1016/0169-5347(92)90048-G; Aerts R., 1993, HEATHLANDS PATTERNS; AGREN GI, 1988, ENVIRON POLLUT, V54, P185, DOI 10.1016/0269-7491(88)90111-X; BERENDSE F, 1990, J ECOL, V78, P413, DOI 10.2307/2261121; BOBBINK R, 1991, J APPL ECOL, V28, P28, DOI 10.2307/2404111; BROWN RH, 1978, CROP SCI, V18, P93, DOI 10.2135/cropsci1978.0011183X001800010025x; DeAngelis D. L., 1992, DYNAMICS NUTR CYCLIN; DISE NB, 1995, FOREST ECOL MANAG, V71, P153, DOI 10.1016/0378-1127(94)06092-W; GALLOWAY JN, 1995, GLOBAL BIOGEOCHEM CY, V9, P235, DOI 10.1029/95GB00158; GORHAM E, 1979, ANNU REV ECOL SYST, V10, P53, DOI 10.1146/annurev.es.10.110179.000413; HEDIN LO, 1995, ECOLOGY, V76, P493, DOI 10.2307/1941208; HUDSON RJM, 1994, GLOBAL BIOGEOCHEM CY, V8, P307, DOI 10.1029/94GB01044; INOUYE RS, 1988, ECOLOGY, V69, P995, DOI 10.2307/1941254; Johnson KH, 1996, TRENDS ECOL EVOL, V11, P372, DOI 10.1016/0169-5347(96)10040-9; MATTHEWS E, 1994, GLOBAL BIOGEOCHEM CY, V8, P411, DOI 10.1029/94GB01906; OLFF H, 1991, J APPL ECOL, V28, P1040, DOI 10.2307/2404224; PARTON WJ, 1995, GLOBAL CHANGE BIOL, V1, P13, DOI 10.1111/j.1365-2486.1995.tb00002.x; PARTON WJ, 1987, SOIL SCI SOC AM J, V51, P1173, DOI 10.2136/sssaj1987.03615995005100050015x; PETERSON BJ, 1985, TELLUS B, V37, P117, DOI 10.1111/j.1600-0889.1985.tb00060.x; RYDEN JC, 1984, NATURE, V311, P50, DOI 10.1038/311050a0; SCHIMEL DS, 1995, GLOBAL CHANGE BIOL, V1, P77, DOI 10.1111/j.1365-2486.1995.tb00008.x; SCHIMEL DS, 1994, GLOBAL BIOGEOCHEM CY, V8, P279, DOI 10.1029/94GB00993; SCHINDLER DW, 1993, GLOBAL BIOGEOCHEM CY, V7, P717, DOI 10.1029/93GB02562; SCHULZE ED, 1989, SCIENCE, V244, P776, DOI 10.1126/science.244.4906.776; SEASTEDT TR, 1991, OECOLOGIA, V87, P72, DOI 10.1007/BF00323782; TILMAN D, 1987, ECOL MONOGR, V57, P189, DOI 10.2307/2937080; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; TILMAN D, 1991, ECOLOGY, V72, P685, DOI 10.2307/2937208; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; TILMAN D, 1988; Townsend AR, 1996, ECOL APPL, V6, P806, DOI 10.2307/2269486; VITOUSEK P, 1982, AM NAT, V119, P553, DOI 10.1086/283931; VITOUSEK PM, 1994, ECOLOGY, V75, P1861, DOI 10.2307/1941591; VITOUSEK PM, 1984, SCIENCE, V225, P51, DOI 10.1126/science.225.4657.51; VITOUSEK PM, 1979, SCIENCE, V204, P469, DOI 10.1126/science.204.4392.469; WEDIN DA, 1990, OECOLOGIA, V84, P433, DOI 10.1007/BF00328157; WOODMANSEE RG, 1978, BIOSCIENCE, V28, P448, DOI 10.2307/1307227; WRIGHT RF, 1995, FOREST ECOL MANAG, V71, P163, DOI 10.1016/0378-1127(94)06093-X	39	424	504	12	308	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1720	1723		10.1126/science.274.5293.1720	http://dx.doi.org/10.1126/science.274.5293.1720			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939865				2022-12-28	WOS:A1996VW71200064
J	Mangano, DT; Layug, EL; Wallace, A; Tateo, I				Mangano, DT; Layug, EL; Wallace, A; Tateo, I			Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIOPERATIVE MYOCARDIAL-ISCHEMIA; HYPERTENSIVE PATIENTS; CARDIAC MORBIDITY; VASCULAR-SURGERY; SILENT ISCHEMIA; INFARCTION; TRIALS; NITROGLYCERIN; ANESTHESIA; PREVENTION	Background Perioperative myocardial ischemia is the single most important potentially reversible risk factor for mortality and cardiovascular complications after noncardiac surgery. Although more than 1 million patients have such complications annually, there is no effective preventive therapy. Methods We performed a randomized, double-blind, placebo-controlled trial to compare the effect of atenolol with that of a placebo on overall survival and cardiovascular morbidity in patients with or at risk for coronary artery disease who were undergoing noncardiac surgery. Atenolol was given intravenously before and immediately after surgery and orally thereafter for the duration of hospitalization. Patients were followed over the subsequent two years. Results A total of 200 patients were enrolled. Ninety-nine were assigned to the atenolol group, and 101 to the placebo group. One hundred ninety-four patients survived to be discharged from the hospital, and 192 of these were followed for two years. Overall mortality after discharge from the hospital was significantly lower among the atenolol-treated patients than among those who were given placebo over the six months following hospital discharge (0 vs. 8 percent, P<0.001), over the first year (3 percent vs. 14 percent, P = 0.005), and over two years (10 percent vs. 21 percent, P = 0.019). The principal effect was a reduction in deaths from cardiac causes during the first six to eight months. Combined cardiovascular outcomes were similarly reduced among the atenolol-treated patients; event-free survival throughout the two-year study period was 68 percent in the placebo group and 83 percent in the atenolol group (P = 0.008). Conclusions In patients who have or are at risk for coronary artery disease who must undergo noncardiac surgery, treatment with atenolol during hospitalization can reduce mortality and the incidence of cardiovascular complications for as long as two years after surgery. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; ISCHEMIA RES & EDUC FDN, SAN FRANCISCO, CA USA	University of California System; University of California San Francisco	Mangano, DT (corresponding author), VET AFFAIRS MED CTR, 4150 CLEMENT ST, 129, SAN FRANCISCO, CA 94121 USA.							[Anonymous], 1986, LANCET, V2, P57; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; CHUNG F, 1988, ANESTHESIOLOGY, V69, P343, DOI 10.1097/00000542-198809000-00010; Collett D, 1994, MODELLING SURVIVAL D, P53; CORIAT P, 1984, ANESTHESIOLOGY, V61, P193, DOI 10.1097/00000542-198408000-00013; CUCCHIARA RF, 1986, ANESTHESIOLOGY, V65, P528, DOI 10.1097/00000542-198611000-00016; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; EISENBERG MJ, 1992, JAMA-J AM MED ASSOC, V268, P210, DOI 10.1001/jama.268.2.210; GALLAGHER JD, 1986, ANESTHESIOLOGY, V64, P785, DOI 10.1097/00000542-198606000-00018; GHIGNONE M, 1987, ANESTHESIOLOGY, V67, P3, DOI 10.1097/00000542-198707000-00002; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P756, DOI 10.1016/S0735-1097(87)80267-X; HJALMARSON A, 1985, AM J CARDIOL, V56, pG3; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MAGNUSSON J, 1986, BRIT J ANAESTH, V58, P251, DOI 10.1093/bja/58.3.251; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MANGANO DT, 1992, JAMA-J AM MED ASSOC, V268, P233, DOI 10.1001/jama.268.2.233; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; MERIN RG, 1987, ANESTHESIOLOGY, V66, P111; PEPINE CJ, 1994, CIRCULATION, V90, P762, DOI 10.1161/01.CIR.90.2.762; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; SILICIANO D, 1991, OPIOIDS ANESTHESIA, V2, P164; SLOGOFF S, 1985, ANESTHESIOLOGY, V62, P107, DOI 10.1097/00000542-198502000-00002; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; TALKE P, 1995, ANESTHESIOLOGY, V82, P620, DOI 10.1097/00000542-199503000-00003; WALLACE A, 1994, ANESTHESIOLOGY, V81, pA99; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	34	1155	1213	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1713	1720		10.1056/NEJM199612053352301	http://dx.doi.org/10.1056/NEJM199612053352301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929262	Bronze			2022-12-28	WOS:A1996VW79500001
J	Chertow, GM; Milford, EL; Mackenzie, HS; Brenner, BM				Chertow, GM; Milford, EL; Mackenzie, HS; Brenner, BM			Antigen-independent determinants of cadaveric kidney transplant failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-TRANSPLANTATION; AGE; GLOMERULI; SURVIVAL; MASS; RECIPIENTS; REJECTION; RATS; SIZE	Objective.-To determine the association of various antigen-independent factors with long-term cadaveric kidney transplant failure. Design.-Cohort analytic study. Setting.-Kidney transplant centers (N=131) in the United States. Patients.-A total of 31 515 patients who received cadaveric kidney transplants between October 1987 and December 1991. Patients with unknown or uninterpretable vital status or graft survival time (n=264 [0.8%]) were excluded. Main Outcome Measure.-Graft failure, estimated at 2 extremes, depending on whether the death of a patient with a functioning graft was censored ("censored graft failure") or not ("uncensored graft failure"). Results.-During the 62-month study period, 5883 patients required the reinstitution of dialysis because of graft failure, 2404 patients died with graft failure, and 2041 patients died with a functioning graft. The relative risks of censored and uncensored graft failure were significantly associated with donor age, sex, and race and recipient body surface area, after adjusting for recipient age, sex, race, diabetes, cold ischemia time, panel cross-reactivity, pretransplant blood transfusions, previous renal transplantation, functional status, and HLA antigen mismatch. Conclusions.-In cadaveric kidney transplantation, selected demographic and anthropometric factors are significantly related to long-term graft outcomes, even after adjusting for well-known antigen-dependent risk factors. These results support the hypothesis that the supply of viable donor nephrons and the physiologic demands of the transplant recipient are important determinants of long-term graft failure. Antigen-independent factors such as donor age should be incorporated into organ allocation algorithms to optimize equity and efficiency.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,RENAL DIV,DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School				Chertow, Glenn/0000-0002-7599-0534				[Anonymous], 1990, SAS STAT US GUID VER; BRENNER BM, 1988, AM J HYPERTENS, V1, P335, DOI 10.1093/ajh/1.4.335; BRENNER BM, 1992, J AM SOC NEPHROL, V3, P162; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; Cecka J M, 1994, Clin Transpl, P1; Collett D, 1994, MODELLING SURVIVAL D; COX DR, 1972, J R STAT SOC B, V34, P187; Gaston RS, 1996, TRANSPLANTATION, V61, P383, DOI 10.1097/00007890-199602150-00010; HEEMANN UW, 1995, TRANSPLANT P, V27, P549; HEEMANN UW, 1994, TRANSPLANT P, V26, P2047; HOWARD RJ, 1990, CLIN TRANSPLANT, V4, P181; KAPLAN C, 1975, AM J PATHOL, V80, P227; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPPEL B, 1980, VIRCHOWS ARCH A, V387, P271, DOI 10.1007/BF00454830; KUPIN W, 1994, J AM SOC NEPHROL, V5, P1019; Kupin Warren L., 1993, Journal of the American Society of Nephrology, V4, P945; Mackay EM, 1932, ARCH INTERN MED, V50, P590, DOI 10.1001/archinte.1932.00150170082008; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NYENGAARD JR, 1992, ANAT REC, V232, P194, DOI 10.1002/ar.1092320205; OPELZ G, 1991, TRANSPLANT P, V23, P373; RENNKE HG, 1986, PROGR NATURE RENAL D, P111; ROTH D, 1994, J AM SOC NEPHROL, V5, P1035; TAUCHI H, 1971, GERONTOLOGY, V17, P87, DOI 10.1159/000211811; TERASAKI PI, 1994, TRANSPLANTATION, V57, P1450, DOI 10.1097/00007890-199405270-00008; TESI RJ, 1994, LANCET, V343, P461, DOI 10.1016/S0140-6736(94)92698-0; THERNEAU TM, 1990, BIOMETRIKA, V77, P147, DOI 10.2307/2336057; *UNOS, 1994, 1994 REP CTR SPEC GR; Walter F, 1939, J EXP MED, V69, P467, DOI 10.1084/jem.69.3.467	28	119	119	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1732	1736		10.1001/jama.276.21.1732	http://dx.doi.org/10.1001/jama.276.21.1732			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940321				2022-12-28	WOS:A1996VV56600030
J	Tamura, T; Tamura, N; Cejka, Z; Hegerl, R; Lottspeich, F; Baumeister, W				Tamura, T; Tamura, N; Cejka, Z; Hegerl, R; Lottspeich, F; Baumeister, W			Tricorn protease - The core of a modular proteolytic system	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; PROJECTION DIRECTIONS; CRYSTAL-STRUCTURE; 20S PROTEASOME; RNA-POLYMERASE; EXPRESSION; GENES; ARCHAEBACTERIA; COMPLEX	Large macromolecular assemblies have evolved as a means of compartmentalizing reactions in organisms lacking membrane-bounded compartments. A tricorn-shaped protease was isolated from the archaeon Thermoplasma and was shown to form a multisubunit proteolytic complex. The 120-kilodalton monomer assembled to form a hexameric toroid that could assemble further into a capsid structure. Tricorn protease appeared to act as the core of a proteolytic system; when it interacted with several smaller proteins, it displayed multicatalytic activities.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society			Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				ALFANDARI D, 1994, PCR METH APPL, V4, P46; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; CHRISTIANSEN C, 1975, INT J SYST BACTERIOL, V25, P99, DOI 10.1099/00207713-25-2-99; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; FARROW NA, 1992, J OPT SOC AM A, V9, P1749, DOI 10.1364/JOSAA.9.001749; Jentsch S, 1996, SCIENCE, V271, P955, DOI 10.1126/science.271.5251.955; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KEILER KC, 1995, J BIOL CHEM, V270, P28864, DOI 10.1074/jbc.270.48.28864; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; LIOU GIH, 1991, PROG CLIN BIOL RES, V362, P115; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TAMURA T, IN PRESS FEBS LETT; TAMURA T, UNPUB; TANAKA K, 1992, NEW BIOL, V4, P173; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; ZILLIG W, 1988, EUR J BIOCHEM, V173, P473, DOI 10.1111/j.1432-1033.1988.tb14023.x	31	92	94	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1385	1389		10.1126/science.274.5291.1385	http://dx.doi.org/10.1126/science.274.5291.1385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910281				2022-12-28	WOS:A1996VU95400057
J	Gajewski, TF; Thompson, CB				Gajewski, TF; Thompson, CB			Apoptosis meets signal transduction: Elimination of a BAD influence	CELL			English	Review							BCL-2; SUPPRESSION		UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MED GENET & CELL BIOL,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago	Gajewski, TF (corresponding author), UNIV CHICAGO,DEPT MED,HEMATOL ONCOL SECT,COMM IMMUNOL,CHICAGO,IL 60637, USA.							CHANG BS, 1996, IN PRESS EMBO; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cortazzo M, 1996, CANCER RES, V56, P1199; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; MAY WS, 1994, J BIOL CHEM, V269, P26865; Middleton G, 1996, DEVELOPMENT, V122, P695; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TOMEL LD, 1995, NATURE, V374, P736; WANG HG, 1994, ONCOGENE, V9, P2751; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	19	296	307	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					589	592		10.1016/S0092-8674(00)81377-X	http://dx.doi.org/10.1016/S0092-8674(00)81377-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929527	Bronze			2022-12-28	WOS:A1996VU03500001
J	Lorber, B				Lorber, B			Are all diseases infectious?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEPATITIS-C VIRUS; GUILLAIN-BARRE-SYNDROME; ESCHERICHIA-COLI O157-H7; DNA-SEQUENCES; MIXED CRYOGLOBULINEMIA; CAMPYLOBACTER-JEJUNI; CHLAMYDIA-PNEUMONIAE; WHIPPLES-DISEASE; KAPOSIS-SARCOMA; WEGENERS GRANULOMATOSIS	The complex interactions between microorganisms and human hosts include the well-known, traditional infectious diseases and the symbiotic relation we have with our normal flora. The media have brought to the public's attention many newly described infectious diseases, such as Ebola virus hemorrhagic fever, that were not part of common medical parlance a decade ago. While flooding us with interesting and often dramatic reports of so-called emerging infectious diseases, the media have largely ignored a more fundamental change in our appreciation of human-microorganism interactions: the discovery that transmissible agents may play important roles in diseases not suspected of being infectious in origin. A well-known example is ulcer disease; other examples include neurodegenerative disease, inflammatory disease, and cancer. These fascinating instances of host-pathogen interaction open new prospects for the prevention of disease through immunization.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	Lorber, B (corresponding author), TEMPLE UNIV HOSP & MED SCH, INFECT DIS SECT, BROAD & ONTARIO ST, PHILADELPHIA, PA 19140 USA.							ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ARRIBAS JR, 1995, J CLIN MICROBIOL, V33, P1580, DOI 10.1128/JCM.33.6.1580-1583.1995; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; Bartlett J G, 1977, Adv Intern Med, V22, P455; BOYCE TG, 1995, NEW ENGL J MED, V333, P364, DOI 10.1056/NEJM199508103330608; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; CACOUB P, 1994, AM J MED, V96, P124, DOI 10.1016/0002-9343(94)90132-5; *CDCP, 1995, EM INF DIS; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CLARK HW, 1995, ANN INTERN MED, V123, P393, DOI 10.7326/0003-4819-123-5-199509010-00022; COVER TL, 1995, ASM NEWS, V61, P21; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DOBBINS WO, 1995, NEW ENGL J MED, V332, P390, DOI 10.1056/NEJM199502093320611; FOHLMAN J, 1993, ANN MED, V25, P569; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GESSAIN A, 1985, LANCET, V2, P407; HELFAND RF, 1995, J INFECT DIS, V172, P1206, DOI 10.1093/infdis/172.5.1206; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; JOHNSON RT, 1992, NEW ENGL J MED, V326, P486, DOI 10.1056/NEJM199202133260711; KARCHER DS, 1995, NEW ENGL J MED, V333, P797; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KOSKINEN PK, 1993, J HEART LUNG TRANSPL, V12, P724; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; LEVEY JM, 1994, MEDICINE, V73, P53, DOI 10.1097/00005792-199401000-00005; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LORBER B, 1988, AM J MED, V84, P569, DOI 10.1016/0002-9343(88)90138-6; MISHU B, 1993, CLIN INFECT DIS, V17, P104, DOI 10.1093/clinids/17.1.104; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MULLER C, 1993, LANCET, V341, P701, DOI 10.1016/0140-6736(93)90475-V; Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PRUSINER SB, 1987, NEW ENGL J MED, V317, P1571, DOI 10.1056/NEJM198712173172505; PRUSINER SB, 1995, SCI AM, V272, P48, DOI 10.1038/scientificamerican0195-48; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RICKMAN LS, 1995, NEW ENGL J MED, V332, P363, DOI 10.1056/NEJM199502093320604; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SALVARANI C, 1995, ANN INTERN MED, V123, P192, DOI 10.7326/0003-4819-123-3-199508010-00006; Sartor R. Balfour, 1995, P435; SCHOFIELD JK, 1993, BRIT J DERMATOL, V128, P542, DOI 10.1111/j.1365-2133.1993.tb00232.x; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; SOMER T, 1995, CLIN INFECT DIS, V20, P1010, DOI 10.1093/clinids/20.4.1010; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; STANIER RY, 1963, MICROBIAL WORLD, P3; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; SU CY, 1995, ANN INTERN MED, V123, P698, DOI 10.7326/0003-4819-123-9-199511010-00009; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; TAUROG JD, 1993, PRIMER RHEUMATIC DIS, P53; Taylor David N., 1995, P551; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; TILLEY BC, 1995, ANN INTERN MED, V122, P81, DOI 10.7326/0003-4819-122-2-199501150-00001; UNGER ER, 1995, J INFECT DIS, V172, P1184, DOI 10.1093/infdis/172.5.1184; VONWULFFEN H, 1994, J INFECT DIS, V170, P828, DOI 10.1093/infdis/170.4.828; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILSON KH, 1993, NEW ENGL J MED, V328, P62, DOI 10.1056/NEJM199301073280113; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	65	66	68	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					844	851		10.7326/0003-4819-125-10-199611150-00010	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928993				2022-12-28	WOS:A1996VU52400013
J	Reeder, TC; Hawley, DK				Reeder, TC; Hawley, DK			Promoter proximal sequences modulate RNA polymerase II elongation by a novel mechanism	CELL			English	Article							INDUCED TRANSCRIPT CLEAVAGE; LATE ATTENUATION SITE; ESCHERICHIA-COLI; TERNARY COMPLEXES; PREMATURE TERMINATION; MONKEY CELLS; FACTOR-SII; DNA; INVITRO; GENE	The adenovirus major late arrest site blocks transcription by mammalian RNA polymerase II in vitro downstream of the major late promoter but not the mouse beta-globin promoter. We localized the sequences responsible for anti-arrest to the 5' end of the beta-globin transcript and demonstrated that anti-arrest required that this region of RNA form base pairs with the nascent transcript upstream of the arrest site. Small antisense RNA or DNA oligonucleotides hybridizing upstream of the arrest site also prevented arrest when added in trans. Our results suggest that arrest is accompanied by retraction of the nascent transcript into the interior of the polymerase and that hybridization of the transcript prevents this movement, thereby allowing the polymerase to continue elongation.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	Reeder, TC (corresponding author), UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403, USA.							ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; Blau J, 1996, MOL CELL BIOL, V16, P2044; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FENG GH, 1994, J BIOL CHEM, V269, P22282; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; HAWLEY DK, 1993, CELL MOL BIOL RES, V39, P339; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; JOHNSTON JM, 1985, J VIROL, V56, P378, DOI 10.1128/JVI.56.2.378-385.1985; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LEE DN, 1994, J BIOL CHEM, V269, P22295; MADERIOUS A, 1984, P NATL ACAD SCI-BIOL, V81, P5931, DOI 10.1073/pnas.81.19.5931; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MOK M, 1984, MOL CELL BIOL, V4, P2031, DOI 10.1128/MCB.4.10.2031; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SEIBERG M, 1989, J VIROL, V63, P4093, DOI 10.1128/JVI.63.9.4093-4096.1989; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	44	121	121	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					767	777		10.1016/S0092-8674(00)81395-1	http://dx.doi.org/10.1016/S0092-8674(00)81395-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929544	Bronze			2022-12-28	WOS:A1996VU03500018
J	Zha, JP; Harada, H; Yang, E; Jockel, J; Korsmeyer, SJ				Zha, JP; Harada, H; Yang, E; Jockel, J; Korsmeyer, SJ			Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BGL-X(L)	CELL			English	Article							PROTEIN-KINASE; CELL-SURVIVAL; HEMATOPOIETIC-CELLS; C-MYC; APOPTOSIS; BCL-2; 14-3-3-PROTEINS; ACTIVATION; ASSOCIATION; RAF-1	Extracellular survival factors alter a cell's susceptibility to apoptosis, often through posttranslational mechanisms. However, no consistent relationship has been established between such survival signals and the BCL-2 family, where the balance of death agonists versus antagonists determines susceptibility. One distant member, BAD, heterodimerizes with BCL-X(L) or BCL-2, neutralizing their protective effect and promoting cell death. In the presence of survival factor IL-3, cells phosphorylated BAD on two serine residues embedded in 14-3-3 consensus binding sites. Only the nonphosphorylated BAD heterodimerized with BCL-X(L) at membrane sites to promote cell death. Phosphorylated BAD was sequestered in the cytosol bound to 14-3-3. Substitution of serine phosphorylation sites further enhanced BAD's death-promoting activity. The rapid phosphorylation of BAD following IL-3 connects a proximal survival signal with the BCL-5 family, modulating this checkpoint for apoptosis.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT PATHOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	Zha, JP (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, DIV MOL ONCOL, ST LOUIS, MO 63110 USA.				NCI NIH HHS [R01 CA50239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LIN EY, 1993, J IMMUNOL, V151, P1979; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG HG, 1994, ONCOGENE, V9, P2751; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	51	2198	2271	0	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					619	628		10.1016/S0092-8674(00)81382-3	http://dx.doi.org/10.1016/S0092-8674(00)81382-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929531	Bronze			2022-12-28	WOS:A1996VU03500005
J	Rowe, PM				Rowe, PM			Ribozymes enter clinical trials for HIV-1 treatment	LANCET			English	News Item																			0	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1302	1302		10.1016/S0140-6736(05)65767-4	http://dx.doi.org/10.1016/S0140-6736(05)65767-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909386				2022-12-28	WOS:A1996VR55500025
J	Glatzmaier, GA; Roberts, PH				Glatzmaier, GA; Roberts, PH			Rotation and magnetism of earth's inner core	SCIENCE			English	Article								Three-dimensional numerical simulations of the geodynamo suggest that a super-rotation of Earth's solid inner core relative to the mantle is maintained by magnetic coupling between the inner core and an eastward thermal wind in the fluid outer core. This mechanism, which is analogous to a synchronous motor, also plays a fundamental role in the generation oi Earth's magnetic field.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Glatzmaier, GA (corresponding author), LOS ALAMOS NATL LAB,INST GEOPHYS & PLANETARY PHYS,POB 1663,LOS ALAMOS,NM 87545, USA.							Braginsky S. I., 1964, GEOMAGN AERON, V4, P572; BRAGINSKY SI, 1995, GEOPHYS ASTRO FLUID, V79, P1, DOI 10.1080/03091929508228992; Buffett BA, 1996, GEOPHYS RES LETT, V23, P2279, DOI 10.1029/96GL02083; BUFFETT BA, COMMUNICATION; BUSSE FH, 1970, J FLUID MECH, V44, P441, DOI 10.1017/S0022112070001921; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Glatzmaier GA, 1996, PHYSICA D, V97, P81, DOI 10.1016/0167-2789(96)00100-5; GLATZMAIER GA, 1995, PHYS EARTH PLANET IN, V91, P63, DOI 10.1016/0031-9201(95)03049-3; HOLLERBACH R, 1995, PHYS EARTH PLANET IN, V87, P171, DOI 10.1016/0031-9201(94)02965-E; HOLLERBACH R, 1993, NATURE, V365, P541, DOI 10.1038/365541a0; JACOBS JA, 1953, NATURE, V172, P297, DOI 10.1038/172297a0; OLSON P, 1995, PHYS EARTH PLANET IN, V92, P109, DOI 10.1016/0031-9201(95)03065-5; ROBERTS PH, 1968, PHILOS TR R SOC S-A, V263, P93, DOI 10.1098/rsta.1968.0007; ROBERTS PH, 1995, NATURE, V377, P203; Song XD, 1996, NATURE, V382, P221, DOI 10.1038/382221a0; STACEY FD, 1992, PHYSICS EARTH; Su WJ, 1996, SCIENCE, V274, P1883, DOI 10.1126/science.274.5294.1883; TACKLEY PJ, 1994, J GEOPHYS RES-SOL EA, V99, P15877, DOI 10.1029/94JB00853	18	198	202	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1887	1891		10.1126/science.274.5294.1887	http://dx.doi.org/10.1126/science.274.5294.1887			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943197				2022-12-28	WOS:A1996VY20000037
J	Goodfriend, GA; Gould, SJ				Goodfriend, GA; Gould, SJ			Paleontology and chronology of two evolutionary transitions by hybridization in the Bahamian land snail Cerion	SCIENCE			English	Article							SHELL CARBONATE; CALIBRATION; CONSTRAINT; FAUNA	The late Quaternary fossil record of the Bahamian land snail Cerion on Great Inagua documents two transitions apparently resulting from hybridization. In the first, a localized modern population represents the hybrid descendants of a 13,000-year-old fossil form from the same area, introgressed with the modern form now characteristic of the adjacent regions. In the second case, a chronocline spanning 15,000 to 20,000 years and expressing the transition of an extinct fossil form to the modern form found on the south coast was documented by morphometry of fossils dated by amino acid racemization and radiocarbon. Hybrid intermediates persisted for many thousands of years.	HARVARD UNIV,MUSEUM COMPARAT ZOOL,CAMBRIDGE,MA 02138	Harvard University								BARTON NH, 1985, ANNU REV ECOL SYST, V16, P113, DOI 10.1146/annurev.es.16.110185.000553; BARTSCH P, 1922, CARNEGIE I WASHINGTO, V20, P198; Bartsch P, 1931, CARNEGIE I WASHINGTO, V30, P373; BURCHULADZE AA, 1989, RADIOCARBON, V31, P771; CAIN AJ, 1963, PHILOS T ROY SOC B, V246, P1, DOI 10.1098/rstb.1963.0001; GOODFRIEND GA, 1989, RADIOCARBON, V31, P1041; GOODFRIEND GA, 1983, GEOLOGY, V11, P575, DOI 10.1130/0091-7613(1983)11<575:LATPOR>2.0.CO;2; GOODFRIEND GA, 1987, RADIOCARBON, V29, P159; GOODFRIEND GA, 1994, J BIOGEOGR, V21, P309, DOI 10.2307/2845532; GOODFRIEND GA, 1993, GEOL SOC AM BULL, V105, P18, DOI 10.1130/0016-7606(1993)105<0018:AYROAT>2.3.CO;2; Goodfriend GA, 1996, MAR GEOL, V129, P271, DOI 10.1016/0025-3227(96)83348-2; GOULD S J, 1986, Bulletin of the American Museum of Natural History, V182, P389; GOULD SJ, 1990, BIOL J LINN SOC, V40, P67, DOI 10.1111/j.1095-8312.1990.tb00535.x; GOULD SJ, 1989, EVOLUTION, V43, P516, DOI 10.1111/j.1558-5646.1989.tb04249.x; GOULD SJ, 1984, PALEOBIOLOGY, V10, P172, DOI 10.1017/S0094837300008150; HARE PE, 1985, CHEM BIOCH AMINO ACI, P415; HEWITT GM, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P140; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; STUIVER M, 1986, RADIOCARBON, V28, P805, DOI 10.1017/S0033822200060161; SZYMURA JM, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P261; WOODRUFF DS, 1987, EVOLUTION, V41, P1022, DOI 10.1111/j.1558-5646.1987.tb05874.x	21	48	49	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1894	1897		10.1126/science.274.5294.1894	http://dx.doi.org/10.1126/science.274.5294.1894			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943199				2022-12-28	WOS:A1996VY20000039
J	Flake, AW; Roncarolo, MG; Puck, JM; AlmeidaPorada, G; Evans, MI; Johnson, MP; Abella, EM; Harrison, DD; Zanjani, ED				Flake, AW; Roncarolo, MG; Puck, JM; AlmeidaPorada, G; Evans, MI; Johnson, MP; Abella, EM; Harrison, DD; Zanjani, ED			Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; CHROMOSOME INACTIVATION; INUTERO TRANSPLANTATION; CD34(+) CELLS; LYMPHOCYTES-T; SHEEP; ENGRAFTMENT; CARRIERS; ONTOGENY; LINKAGE		WAYNE STATE UNIV, DEPT PEDIAT SURG, DETROIT, MI USA; WAYNE STATE UNIV, DEPT OBSTET & GYNECOL, CTR MOL MED & GENET, DETROIT, MI USA; WAYNE STATE UNIV, DEPT PEDIAT, DETROIT, MI 48202 USA; DNAX RES INST MOL & CELLULAR BIOL INC, DEPT HUMAN IMMUNOL, PALO ALTO, CA 94304 USA; NIH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA; UNIV NEVADA, VET AFFAIRS MED CTR, DEPT MED, RENO, NV 89557 USA	Wayne State University; Wayne State University; Wayne State University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Nevada System of Higher Education (NSHE); University of Nevada Reno; US Department of Veterans Affairs; Veterans Health Administration (VHA)				RONCAROLO, Maria Grazia/0000-0002-2193-9186; Almeida-Porada, Maria da Graca/0000-0002-6715-865X	NHLBI NIH HHS [HL 52954, HL48378, HL49042-04] Funding Source: Medline; Telethon [TGT06S01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048378, R01HL049042, R37HL049042] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BUCKLEY RH, 1993, SEMIN HEMATOL, V30, P92; CIVIN CI, 1993, BLOOD, V82, pA180; CONLEY ME, 1988, P NATL ACAD SCI USA, V85, P3090, DOI 10.1073/pnas.85.9.3090; CROMBLEHOLME TM, 1990, J PEDIATR SURG, V25, P885, DOI 10.1016/0022-3468(90)90197-H; DEWYNTER EA, 1995, STEM CELLS, V13, P524, DOI 10.1002/stem.5530130510; FISCHER A, 1992, Immunodeficiency Reviews, V3, P83; FISCHER A, 1994, BLOOD, V83, P1149; FISCHER A, 1992, BONE MARROW TRANSPL, V9, P39; FLAKE AW, 1993, CRIT REV ONCOL HEMAT, V15, P35, DOI 10.1016/1040-8428(93)90019-Z; FLAKE AW, 1986, SCIENCE, V233, P776, DOI 10.1126/science.2874611; FLEISCHMAN RA, 1979, P NATL ACAD SCI USA, V76, P5736, DOI 10.1073/pnas.76.11.5736; GEPPERT TD, 1988, J CLIN INVEST, V81, P1497, DOI 10.1172/JCI113481; HAYNES BF, 1988, J EXP MED, V168, P1061, DOI 10.1084/jem.168.3.1061; HAYNES BF, 1989, J EXP MED, V169, P603; Hendriks R W, 1993, Immunodeficiency, V4, P209; Hinds H, 1993, Immunodeficiency, V4, P213; KOZAK RW, 1982, J IMMUNOL, V128, P1723; METCALF D, 1971, HAEMOPOIETIC CELLS, V24, P172; MOISE KJ, 1993, WESTERN J MED, V159, P318; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OREILLY RJ, 1987, TRANSPLANT P, V19, P55; PALLAVICINI MG, 1992, TRANSPLANT P, V24, P542; PUCK JM, 1992, AM J HUM GENET, V50, P742; PUCK JM, 1995, J CLIN INVEST, V95, P895, DOI 10.1172/JCI117740; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; PUCK JM, 1993, AM J HUM GENET, V53, P176; PUCK JM, 1990, NEW ENGL J MED, V322, P1063, DOI 10.1056/NEJM199004123221508; RILEY RJ, 1995, CLIN EXP IMMUNOL, V99, P1; ROYO C, 1987, THYMUS, V10, P57; SHULMAN LP, 1993, WESTERN J MED, V159, P260; SROUR EF, 1992, BLOOD, V79, P1404; SROUR EF, 1993, BLOOD, V82, P3333; TAVASSOLI M, 1991, BLOOD CELLS, V17, P269; TJONNFJORD GE, 1994, BLOOD, V84, P3584; Touraine J L, 1991, Allergol Immunopathol (Madr), V19, P49; TOURAINE JL, 1990, NOUV REV FR HEMATOL, V32, P441; TOURAINE JL, 1993, BONE MARROW TRANSPL, V11, P119; TOURAINE JL, 1989, LANCET, V1, P1382; ZANJANI ED, 1993, BLOOD, V82, pA655; ZANJANI ED, 1992, J CLIN INVEST, V89, P1178, DOI 10.1172/JCI115701; ZANJANI ED, 1982, NATURE, V295, P244, DOI 10.1038/295244a0	42	253	261	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1806	1810		10.1056/NEJM199612123352404	http://dx.doi.org/10.1056/NEJM199612123352404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943162				2022-12-28	WOS:A1996VW68300004
J	Strassman, AM; Raymond, SA; Burstein, R				Strassman, AM; Raymond, SA; Burstein, R			Sensitization of meningeal sensory neurons and the origin of headaches	NATURE			English	Article							SAGITTAL SINUS; TRIGEMINOVASCULAR SYSTEM; THALAMIC NEURONS; STIMULATION; MIGRAINE; CAT; ARTERY; RAT; BRADYKININ; MECHANISMS	THE headaches that accompany certain intracranial pathologies (such as meningitis, subarachnoid haemorrhage and tumour) have been considered to result from mechanical or chemical stimulation of pain-sensitive structures of the intracranial meninges(1,2). Although the recurrent headache of migraine is of unknown origin and is not accompanied by an identifiable pathology, it shares with intracranial headaches features that suggest an exaggerated intracranial mechanosensititivity (worsening of the pain by coughing, breath-holding or sudden head movement(1,3)). One possible basis for such symptoms would be a sensitization of meningeal afferents to mechanical stimuli. Previous studies of neuronal responses to meningeal stimulation have focused primarily on cells in the central portion of the trigeminal pathway, and have not investigated the possible occurrence of sensitization(4-12). We have recorded the activity of primary afferent neurons in the rat trigeminal ganglion that innervate the dural venous sinuses. Chemical stimulation of their dural receptive fields with inflammatory mediators both directly excited the neurons and enhanced their mechanical sensitivity, such that they were strongly activated by mechanical stimuli that initially had evoked little or no response, These properties of meningeal afferents (chemosensitivity and sensitization) may contribute to the intracranial mechanical hypersensitivity that is characteristic of some types of clinically occurring headaches, and may also contribute to the throbbing pain of migraine.	HARVARD UNIV,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115; HARVARD UNIV,INST MED,DEPT NEUROBIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT ANESTHESIA,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard University; Brigham & Women's Hospital	Strassman, AM (corresponding author), BETH ISRAEL DEACONESS MED CTR,DEPT ANESTHESIA & CRIT CARE,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							ANDRES KH, 1987, ANAT EMBRYOL, V175, P289, DOI 10.1007/BF00309843; BAKER DG, 1980, J PHYSIOL-LONDON, V306, P519, DOI 10.1113/jphysiol.1980.sp013412; BLAU JN, 1981, CEPHALALGIA, V1, P143, DOI 10.1046/j.1468-2982.1981.0103143.x; Burstein R., 1996, Society for Neuroscience Abstracts, V22, P864; DALEY ML, 1995, IEEE T BIO-MED ENG, V42, P420, DOI 10.1109/10.376137; DAVIS KD, 1988, J NEUROPHYSIOL, V59, P648, DOI 10.1152/jn.1988.59.2.648; DAVIS KD, 1993, J NEUROPHYSIOL, V69, P1071, DOI 10.1152/jn.1993.69.4.1071; DAVIS KD, 1988, BRAIN RES, V446, P401, DOI 10.1016/0006-8993(88)90902-X; DAVIS KD, 1988, BRAIN RES, V454, P89, DOI 10.1016/0006-8993(88)90806-2; DOSTROVSKY JO, 1991, CAN J PHYSIOL PHARM, V69, P652, DOI 10.1139/y91-097; FRIBERG L, 1991, LANCET, V338, P13, DOI 10.1016/0140-6736(91)90005-A; GOADSBY PJ, 1993, ANN NEUROL, V33, P48, DOI 10.1002/ana.410330109; Graham JR, 1938, ARCH NEURO PSYCHIATR, V39, P737, DOI 10.1001/archneurpsyc.1938.02270040093005; IVERSEN HK, 1990, LANCET, V336, P837, DOI 10.1016/0140-6736(90)92339-J; KAUBE H, 1992, CEPHALALGIA, V12, P133, DOI 10.1046/j.1468-2982.1992.1203133.x; LAMBERT GA, 1991, CEPHALALGIA, V11, P75, DOI 10.1046/j.1468-2982.1991.1102075.x; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; MARTIN JB, 1991, HARRISONS PRINCIPLES, P108; MOSKOWITZ MA, 1993, CEREBROVAS BRAIN MET, V5, P159; Orr Edward L., 1995, Society for Neuroscience Abstracts, V21, P1858; Penfield W, 1940, ARCH NEURO PSYCHIATR, V44, P43, DOI 10.1001/archneurpsyc.1940.02280070051003; SCHAIBLE HG, 1988, J PHYSIOL-LONDON, V403, P91, DOI 10.1113/jphysiol.1988.sp017240; STEEN KH, 1992, J NEUROSCI, V12, P86; STRASSMAN A, 1986, BRAIN RES, V379, P242, DOI 10.1016/0006-8993(86)90777-8; STRASSMAN AM, 1994, J NEUROSCI, V14, P3725; THOMSEN LL, 1995, CEPHALALGIA, V15, P109, DOI 10.1046/j.1468-2982.1995.015002109.x; Wolff H. G., 1963, HEADACHE OTHER HEAD; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; ZAGAMI AS, 1991, NEUROSCI LETT, V121, P187, DOI 10.1016/0304-3940(91)90681-I; ZAGAMI AS, 1990, EXP BRAIN RES, V81, P552, DOI 10.1007/BF02423504	30	493	515	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 12	1996	384	6609					560	564		10.1038/384560a0	http://dx.doi.org/10.1038/384560a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955268				2022-12-28	WOS:A1996VX76900058
J	Albertini, JJ; Lyman, GH; Cox, C; Yeatman, T; Balducci, L; Ku, NN; Shivers, S; Berman, C; Wells, K; Rapaport, D; Shons, A; Horton, J; Greenberg, H; Nicosia, S; Clark, R; Cantor, A; Reintgen, DS				Albertini, JJ; Lyman, GH; Cox, C; Yeatman, T; Balducci, L; Ku, NN; Shivers, S; Berman, C; Wells, K; Rapaport, D; Shons, A; Horton, J; Greenberg, H; Nicosia, S; Clark, R; Cantor, A; Reintgen, DS			Lymphatic mapping and sentinel node biopsy in the patient with breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; EARLY-STAGE MELANOMA; MALIGNANT-MELANOMA; DISSECTION; METASTASES; MANAGEMENT; CARCINOMA; LYMPHADENECTOMY; MICROMETASTASES	Objectives.-To identify the sentinel lymph node(s) (SLN[s]) (the first node[s] draining the primary tumor in the regional lymphatic basin) in patients with invasive breast cancer and to test the hypothesis that the histologic characteristics of the SLN predict the histologic characteristics of the remaining lymph nodes in the axilla. Design.-A prospective trial. Participants.-Sixty-two patients with newly diagnosed invasive breast cancers. Intervention.-Patients underwent intraoperative lymphatic mapping using a combination of a vital blue dye and filtered technetium-labeled sulfur colloid. The SLN was identified and removed, followed by a definitive cancer operation, including a complete axillary node dissection. Main Outcome Measure The metastatic distribution in the axilla was determined in patients with occult nodal disease. Results.-The SLN was successfully identified in 57 (92%) of 62 patients using the 2 lymphatic mapping procedures. After focalization, 18 patients (32%) were found to have metastatic disease, and the SLN tested positive in all 18 patients. There were no ''skip'' metastases, defined as an SLN that tested negative with higher nodes that tested positive. In 12 (67%) of 18 patients with metastatic disease, the SLN was the only site of disease. The metastatic distribution significantly favored SLN involvement. Among subjects with discordant nodal involvement, the probability of observing the distribution of SLN involvement by chance is very small (P<.001). Conclusions.-This study confirms that lymphatic mapping is technically possible in the patient with breast cancer and that the histologic characteristics of the SLN probably reflect the histologic characteristics of the rest of the axillary lymph nodes. The procedure also allows the pathologist to focus the histologic examination on 1 or 2 nodes, potentially increasing the yield of positive dissections and the accuracy of staging.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,COMPREHENS BREAST CANC PROGRAM,TAMPA,FL 33612	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida			Shivers, Steven/AAE-9288-2022; Lyman, Gary H/K-5227-2019; Shivers, Steve/E-6438-2013	Lyman, Gary H/0000-0002-0823-8086; Shivers, Steve/0000-0001-9538-4016	NCI NIH HHS [R21 CA66553-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA066553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BALCH CM, 1993, ANN SURG, V217, P207; Baxter N, 1996, ANN SURG ONCOL, V3, P235, DOI 10.1007/BF02306277; BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; CADY B, 1994, CANCER, V73, P505, DOI 10.1002/1097-0142(19940201)73:3<505::AID-CNCR2820730302>3.0.CO;2-B; DEWAR JA, 1987, INT J RADIAT ONCOL, V13, P475, DOI 10.1016/0360-3016(87)90060-5; FIELDS KK, 1996, J CLIN ONCOL, V6, P1868; FRAZIER TG, 1977, AM J SURG, V133, P697, DOI 10.1016/0002-9610(77)90156-8; GARDNER B, 1993, ANN SURG, V218, P270, DOI 10.1097/00000658-199309000-00006; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; HAAGENSEN CD, 1977, INT J RADIAT ONCOL, V2, P975, DOI 10.1016/0360-3016(77)90198-5; HAINSWORTH PJ, 1993, BRIT J SURG, V80, P459, DOI 10.1002/bjs.1800800417; HOLLANDER M, 1973, NONPARAMETRIC STATIS; *INT LUDW BREAST C, 1990, LANCET, V335, P1565; IVENS D, 1992, BRIT J CANCER, V66, P136, DOI 10.1038/bjc.1992.230; KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; LIN PP, 1993, J CLIN ONCOL, V11, P1536, DOI 10.1200/JCO.1993.11.8.1536; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; MORENO JG, 1992, CANCER RES, V52, P6110; Morrow M, 1996, ANN SURG ONCOL, V3, P233, DOI 10.1007/BF02306276; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; Nathanson SD, 1996, ANN SURG ONCOL, V3, P329, DOI 10.1007/BF02305661; NICASTRI GR, 1991, SURG GYNECOL OBSTET, V172, P457; NICOSIA S V, 1991, Acta Cytologica, V35, P609; Noguchi S, 1996, AM J PATHOL, V148, P649; RECHT A, 1995, CANCER, V76, P1491, DOI 10.1002/1097-0142(19951101)76:9<1491::AID-CNCR2820760902>3.0.CO;2-8; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; ROSS MI, 1993, SEMIN SURG ONCOL, V9, P219; SCHOENFELD A, 1994, CANCER RES, V54, P2986; SILVERSTEIN MJ, 1994, CANCER-AM CANCER SOC, V73, P664, DOI 10.1002/1097-0142(19940201)73:3<664::AID-CNCR2820730326>3.0.CO;2-S; SILVERSTEIN MJ, 1987, CANCER, V59, P1819, DOI 10.1002/1097-0142(19870515)59:10<1819::AID-CNCR2820591023>3.0.CO;2-V; SPRINGALL RJ, 1990, J PATHOL, V160, P174; THOMPSON JF, 1995, MELANOMA RES, V5, P255, DOI 10.1097/00008390-199508000-00008; TROJANI M, 1987, BRIT J CANCER, V55, P303, DOI 10.1038/bjc.1987.59; VERONESI U, 1987, CANCER, V59, P682, DOI 10.1002/1097-0142(19870215)59:4<682::AID-CNCR2820590403>3.0.CO;2-Z; WANEBO HJ, 1984, ANN SURG, V199, P569, DOI 10.1097/00000658-198405000-00012; WANG XN, 1994, ANN SURG, V220, P768, DOI 10.1097/00000658-199412000-00010	41	1029	1066	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1818	1822		10.1001/jama.276.22.1818	http://dx.doi.org/10.1001/jama.276.22.1818			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946902				2022-12-28	WOS:A1996VV99700031
J	Saenger, P				Saenger, P			Current concepts - Turner's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DYSGENETIC GONAD; AORTIC DILATION; GROWTH-HORMONE; ABNORMALITIES; CHROMOSOMES; MANAGEMENT; DIAGNOSIS; MOSAICISM; CHILDREN				Saenger, P (corresponding author), ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DIV PEDIAT ENDOCRINOL, BRONX, NY 10467 USA.							ALLEN DB, 1986, J PEDIATR-US, V109, P302, DOI 10.1016/S0022-3476(86)80001-4; *AM FERT SOC, 1993, FERTIL STERIL S1, V59, pS5; BECKER B, 1995, MED GENET, V2, P233; BENDER B, 1984, PEDIATRICS, V73, P175; BINDER G, 1995, J CLIN ENDOCR METAB, V80, P3532, DOI 10.1210/jc.80.12.3532; Boyd PA, 1996, ARCH DIS CHILD-FETAL, V74, pF38, DOI 10.1136/fn.74.1.F38; BROOK CGD, 1974, ARCH DIS CHILD, V49, P789, DOI 10.1136/adc.49.10.789; Caprio S, 1995, INT CONGR SER, V1089, P275; COCKWELL AE, 1991, J MED GENET, V28, P152; FERGUSON-SMITH M A, 1965, J Med Genet, V2, P142, DOI 10.1136/jmg.2.2.142; HALL JG, 1990, TURNER SYNDROME, P495; HELD KR, 1992, HUM GENET, V88, P288; HOLL RW, 1994, EUR J PEDIATR, V153, P11, DOI 10.1007/BF02000780; HULTCRANTZ M, 1994, HEARING RES, V76, P127, DOI 10.1016/0378-5955(94)90094-9; KANEKO N, 1990, GYNECOL OBSTET INVES, V29, P81, DOI 10.1159/000293307; LIN AE, 1986, J PEDIATR-US, V109, P820, DOI 10.1016/S0022-3476(86)80700-4; LIPPE B, 1991, ENDOCRIN METAB CLIN, V20, P121, DOI 10.1016/S0889-8529(18)30284-6; LIPPE BM, 1996, PEDIAT ENDOCRINOLOGY, P387; MATHUR A, 1991, AM J HUM GENET, V48, P682; MIGEON BR, 1993, P NATL ACAD SCI USA, V90, P12025, DOI 10.1073/pnas.90.24.12025; Naeraa RW, 1995, INT CONGR SER, V1089, P323; NAVOT D, 1986, NEW ENGL J MED, V314, P806, DOI 10.1056/NEJM198603273141302; NEELY EK, 1993, J CLIN ENDOCR METAB, V76, P861, DOI 10.1210/jcem.76.4.8473397; Nilsson KO, 1996, J CLIN ENDOCR METAB, V81, P635, DOI 10.1210/jc.81.2.635; Page DC, 1995, INT CONGR SER, V1089, P11; PAI GS, 1977, J PEDIATR-US, V91, P267, DOI 10.1016/S0022-3476(77)80827-5; RANKE MB, 1983, EUR J PEDIATR, V141, P81, DOI 10.1007/BF00496795; RANKE MB, 1989, INTRO TURNERS SYNDRO; ROSENFELD RG, 1994, ENDOCRINOLOGIST, V4, P351, DOI 10.1097/00019616-199409000-00006; ROSENFELD RG, IN PRESS J PEDIAT; ROSS JL, 1995, J PEDIATR-US, V126, P242, DOI 10.1016/S0022-3476(95)70551-1; ROSS JL, 1993, INT CONGR SER, V1014, P215; Rovet JF, 1995, INT CONGR SER, V1089, P285; SAENGER P, 1993, J CLIN ENDOCR METAB, V77, P297, DOI 10.1210/jcem.77.2.8345029; Saenger P, 1995, INT CONGR SER, V1089, P259; Saenger Paul, 1996, Pediatric Research, V39, p98A; SCHELLHAS HF, 1974, OBSTET GYNECOL, V44, P298; SCHELLHAS HF, 1974, OBSTET GYNECOL, V44, P455; SIMPSON J L, 1975, Birth Defects Original Article Series, V11, P23; STRATAKIS CA, 1994, ENDOCRINOLOGIST, V4, P442, DOI 10.1097/00019616-199411000-00007; Sybert VP, 1995, INT CONGR SER, V1089, P205; Taback SP, 1996, LANCET, V348, P25, DOI 10.1016/S0140-6736(96)01267-6; TSUCHIYA K, 1995, AM J HUM GENET, V57, P1400; Turner HH, 1938, ENDOCRINOLOGY, V23, P566, DOI 10.1210/endo-23-5-566; VANDENBROECK J, 1995, J PEDIATR-US, V127, P729, DOI 10.1016/S0022-3476(95)70161-3	45	193	202	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1749	1754		10.1056/NEJM199612053352307	http://dx.doi.org/10.1056/NEJM199612053352307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929268				2022-12-28	WOS:A1996VW79500007
J	Nightingale, SL				Nightingale, SL			Protease inhibitor charts available	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1710	1710						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940307				2022-12-28	WOS:A1996VV56600008
J	King, RA; BanikMaiti, S; Jin, DJ; Weisberg, RA				King, RA; BanikMaiti, S; Jin, DJ; Weisberg, RA			Transcripts that increase the processivity and elongation rate of RNA polymerase	CELL			English	Article							ESCHERICHIA-COLI RNA; TERMINATION EFFICIENCY; PHAGE-LAMBDA; PAUSE SITE; ANTITERMINATION; PROTEIN; RHO; PHAGE-HK022; PROMOTERS; HAIRPIN	Transcripts encoded by the cis-acting antitermination sites (put sites) of lambdoid phage HK022 promote readthrough of downstream transcription terminators. Proper conformation of the transcripts is essential for activity, since put mutations that prevent the formation of predicted RNA stems prevented antitermination, and suppressor mutations that restore the stems restored antitermination. Antitermination does not appear to require proteins other than RNA polymerase, since put-dependent readthrough of multiple sequential terminators was observed in a purified transcription system consisting of template, polymerase, substrates, and buffer. Transcription of put also increased the elongation rate of polymerase, very likely by suppressing pausing. A mutation that alters the zinc-finger region of the beta' subunit of polymerase specifically prevented the put-dependent increases in terminator readthrough and elongation rate. The simplicity of HK022 antitermination contrasts with that of other known antitermination pathways. We propose that the central effector is a transcript that directly alters the elongation properties of RNA polymerase.	NICHHD,SECT MICROBIAL GENET,GENET MOL LAB,NIH,BETHESDA,MD 20892; NCI,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BUROVA E, 1995, J BACTERIOL, V177, P1388, DOI 10.1128/jb.177.5.1388-1392.1995; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; CLERGET M, 1995, J MOL BIOL, V248, P768, DOI 10.1006/jmbi.1995.0259; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GRUNDY FJ, 1993, CELL, V74, P475, DOI 10.1016/0092-8674(93)80049-K; GUSTIN KE, 1993, BIOTECHNIQUES, V14, P22; INNIS MA, 1990, PCR PROTOCOLS; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; MENZEL R, 1989, ANAL BIOCHEM, V181, P40, DOI 10.1016/0003-2697(89)90391-6; Miller J.H., 1972, EXPT MOL GENETICS; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; NURDLER E, 1996, SCIENCE, V273, P211; OBERTO J, 1989, J MOL BIOL, V207, P675, DOI 10.1016/0022-2836(89)90237-4; OBERTO J, 1993, J MOL BIOL, V229, P368, DOI 10.1006/jmbi.1993.1040; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; POWELL BS, 1994, NUCLEIC ACIDS RES, V23, P1278; Rees WA, 1996, P NATL ACAD SCI USA, V93, P342, DOI 10.1073/pnas.93.1.342; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; ROBERTS JW, 1995, REGULATION GENE EXPR, P27; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Silhavy T. J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; STUEBER D, 1982, EMBO J, V1, P1399, DOI 10.1002/j.1460-2075.1982.tb01329.x; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	36	47	47	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					893	903		10.1016/S0092-8674(00)81996-0	http://dx.doi.org/10.1016/S0092-8674(00)81996-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945516	Bronze			2022-12-28	WOS:A1996VV77400015
J	Mel, SF; Mekalanos, JJ				Mel, SF; Mekalanos, JJ			Modulation of horizontal gene transfer in pathogenic bacteria by in vivo signals	CELL			English	Review									HARVARD UNIV,SCH MED,SHIPLEY INST MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Mel, SF (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115, USA.							BETLEY MJ, 1986, ANNU REV MICROBIOL, V40, P577, DOI 10.1146/annurev.mi.40.100186.003045; DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x; DOUCETPOPULAIRE F, 1991, ANTIMICROB AGENTS CH, V35, P185, DOI 10.1128/AAC.35.1.185; Farrand S. K., 1993, BACTERIAL CONJUGATIO, P255; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; FUQUA C, 1996, IN PRESS ANN REV MIC; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; GYLES C, 1978, AM J VET RES, V39, P1438; KOVACH ME, 1996, IN PRESS MICROBIOLOG; MEKALANOS JJ, 1995, HARVEY LECT SERIES, V89, P1; PAPPENHEIMER AM, 1983, LANCET, V2, P923; SALMOND GPC, 1995, MOL MICROBIOL, V16, P615, DOI 10.1111/j.1365-2958.1995.tb02424.x; SCHNEIDER H, 1961, J EXP MED, V114, P141, DOI 10.1084/jem.114.1.141; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992	18	36	40	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					795	798		10.1016/S0092-8674(00)81986-8	http://dx.doi.org/10.1016/S0092-8674(00)81986-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945506	Bronze			2022-12-28	WOS:A1996VV77400005
J	Oldstone, MBA				Oldstone, MBA			Principles of viral pathogenesis	CELL			English	Review							INFECTION; CELLS; HOST				Oldstone, MBA (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							AHMED R, 1988, J EXP MED, V167, P1719, DOI 10.1084/jem.167.5.1719; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; BORROW P, 1996, IN PRESS VIRAL PATHO; DELATORRE JC, 1992, P NATL ACAD SCI USA, V89, P9939, DOI 10.1073/pnas.89.20.9939; Dockter J, 1996, J VIROL, V70, P1799, DOI 10.1128/JVI.70.3.1799-1803.1996; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P6947, DOI 10.1073/pnas.92.15.6947; FURTH K, 1996, IN PRESS J MOL MED; HAYES BF, 1996, SCIENCE, V271, P324; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KING CC, 1992, J VIROL, V66, P3155, DOI 10.1128/JVI.66.5.3155-3160.1992; NIBERT ML, 1991, J CLIN INVEST, V88, P727, DOI 10.1172/JCI115369; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	15	15	15	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					799	801		10.1016/S0092-8674(00)81987-X	http://dx.doi.org/10.1016/S0092-8674(00)81987-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945507	Bronze			2022-12-28	WOS:A1996VV77400006
J	Buntinx, F; Brouwers, M				Buntinx, F; Brouwers, M			Relation between sampling device and detection of abnormality in cervical smears: A meta-analysis of randomised and quasi-randomised studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CELLULAR COMPOSITION; PAPANICOLAOU SMEARS; INTEROBSERVER VARIABILITY; UTERINE CERVIX; COTTON SWAB; CYTOBRUSH; SPATULA; TRIAL; BRUSH; QUALITY	Objective-In assess the diagnostic yield of different sampling devices used in cervical screening. Design-Meta-analysis of randomised and quasi-randomised studies. Setting-All randomised and quasi-randomised studies comparing the yield of cytological or histological abnormalities when two or more different sampling devices were used. Subjects-85 000 patients included in 29 studies reported in 28 papers. Main outcome measures-Pooled relative risk and 95% confidence interval of the yield of mild dysplasia or worse in smears recovered by each sampling method versus each other method with which it was compared; sensitivity or positive predictive value, or both, of cytological versus histological results in six studies from which sufficient data were available. Results-There were no substantial differences in the yield of cytological abnormalities between the Ayre spatula, the Cytobrush, and the cotton swab used alone. There were also no substantial differences in the yield of cytological abnormalities between the extended tip spatula, the Ayre spatula combined with the Cytobrush or cotton swab, or the Cervex brush. The Ayre spatula, Cytobrush, or cotton swab used alone generally performed significantly worse than the combinations, the extended tip spatula, or the Cervex brush. There were no substantial differences in sensitivity or positive predictive value between the sampling methods. Conclusions-These results support the use of either the extended tip spatula, a combination of any spatula plus the Cytobrush or cotton swab, or the Cervex brush for cervical screening.	UNIV LOUVAIN, DEPT GEN PRACTICE, B-3001 LOUVAIN, BELGIUM		Buntinx, F (corresponding author), UNIV MAASTRICHT, DEPT GEN PRACTICE, POB 616, NL-6200 MD MAASTRICHT, NETHERLANDS.		Buntinx, Frank/E-4950-2011					AYRE JE, 1948, JAMA-J AM MED ASSOC, V136, P513, DOI 10.1001/jama.1948.02890250001001; BEIBY JO, 1982, OBSTET GYNECOL, V60, P46; BLENKINSOPP WK, 1986, LANCET, V2, P986; BOON ME, 1989, ACTA CYTOL, V33, P843; BOON ME, 1986, ACTA CYTOL, V30, P264; BOON ME, 1985, HUISARS WET, V28, P322; BOUNDS W, 1976, BRIT J OBSTET GYNAEC, V83, P981, DOI 10.1111/j.1471-0528.1976.tb00785.x; BROCK CD, 1986, J FAM PRACTICE, V22, P498; BUNTINX F, 1991, ACTA CYTOL, V35, P64; BUNTINX F, 1994, EUR J CANCER PREV, V4, P325; CAUTHEN DB, 1991, J AM BOARD FAM PRACT, V5, P365; Dean A.G., 1994, EPI INFO VERSION 6 W; DEVET HCW, 1990, J CLIN EPIDEMIOL, V43, P1395, DOI 10.1016/0895-4356(90)90107-Z; DOORNEWAARD H, 1990, J CLIN PATHOL, V43, P393, DOI 10.1136/jcp.43.5.393; EDDY DM, 1992, FASTPRO VERSION 1 7; ELIAS A, 1983, ACTA CYTOL, V27, P225; FOKKE HE, 1993, EUR J OBSTET GYN R B, V48, P103, DOI 10.1016/0028-2243(93)90248-B; GARITE TJ, 1978, ACTA CYTOL, V22, P83; GLENTHOJ A, 1988, NEW FRONTIERS CYTOLO, P421; GOORNEY BP, 1989, GENITOURIN MED, V65, P161; HICKLIN MD, 1984, ACTA CYTOL, V28, P58; HOFFMAN MS, 1991, J REPROD MED, V36, P267; HUTCHINSON M, 1991, J REPROD MED, V36, P581; JOHANSEN P, 1979, ACTA OBSTET GYN SCAN, V58, P265, DOI 10.3109/00016347909154046; KLINKHAMER PJJM, 1989, ACTA CYTOL, V33, P215; KOONINGS PP, 1992, OBSTET GYNECOL, V80, P241; KORDELLAR JJM, 1988, ACTA CYTOL, V3, P801; KUO AF, 1990, ACTA CYTOL, V34, P740; LAIGOLDMAN M, 1990, J REPROD MED, V35, P959; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LONGFIELD JC, 1993, ACTA CYTOL, V37, P472; LUNDVALL L, 1990, ACTA OBSTET GYN SCAN, V69, P147, DOI 10.3109/00016349009006161; LUTHY DA, 1978, OBSTET GYNECOL, V51, P713; METCALF KS, 1994, CYTOPATHOLOGY, V5, P219, DOI 10.1111/j.1365-2303.1994.tb00423.x; MURATA PJ, 1990, OBSTET GYNECOL, V75, P690; NAUJOKS H, 1990, PATHOL RES PRACT, V186, P150, DOI 10.1016/S0344-0338(11)81023-X; ORR JW, 1992, GYNECOL ONCOL, V44, P260, DOI 10.1016/0090-8258(92)90053-L; Papanicolaou GN, 1941, AM J OBSTET GYNECOL, V42, P193; PISTORIUS RG, 1988, OBSTET GYNECOL, V67, P153; RAMMOUKINIA R, 1991, ACTA CYTOL, V35, P69; RICHART RM, 1965, CANCER, V18, P1474, DOI 10.1002/1097-0142(196511)18:11<1474::AID-CNCR2820181117>3.0.CO;2-V; RIVLIN ME, 1993, J REPROD MED, V38, P147; SEDLIS A, 1974, ACTA CYTOL, V18, P291; SELVAGGI SM, 1991, DIAGN CYTOPATHOL, V7, P318, DOI 10.1002/dc.2840070322; SHCETTINO F, 1993, EUR J GYNAECOL ONCOL, V14, P234; SPURRETT B, 1989, AUST NZ J OBSTET GYN, V29, P44, DOI 10.1111/j.1479-828X.1989.tb02875.x; SZAREWSKI A, 1990, GENITOURIN MED, V66, P439; SZAREWSKI A, 1993, ACTA CYTOL, V37, P457; SZAREWSKI A, 1991, ACTA CYTOL, V35, P76; VANERP EJM, 1989, INT J GYNECOL OBSTET, V30, P139, DOI 10.1016/0020-7292(89)90308-1; VANERP EJM, 1988, EUR J GYNAECOL ONCOL, V6, P456; VOOIJS GP, 1987, ACTA CYTOL, V31, P417; VOOIJS GP, 1986, ACTA CYTOL, V30, P251; VOOIJS GP, 1988, NEW FRONTIERS CYTOLO, P412; Waddell C A, 1990, Cytopathology, V1, P171, DOI 10.1111/j.1365-2303.1990.tb00343.x; WOLFENDALE M, 1991, BMJ-BRIT MED J, V302, P1554, DOI 10.1136/bmj.302.6792.1554; WOLFENDALE MR, 1987, BRIT MED J, V294, P33, DOI 10.1136/bmj.294.6563.33; WOODMAN CJB, 1991, BRIT J OBSTET GYNAEC, V98, P21, DOI 10.1111/j.1471-0528.1991.tb10305.x	59	46	46	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	1996	313	7068					1285	1290						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942687				2022-12-28	WOS:A1996VV15300021
J	Craig, AD; Reiman, EM; Evans, A; Bushnell, MC				Craig, AD; Reiman, EM; Evans, A; Bushnell, MC			Functional imaging of an illusion of pain	NATURE			English	Article							COLD; VIBRATION; PRIMATE; NEURONS; CORTEX; BLOCK; INPUT	TOUCHING warm and cool bars that are spatially interlaced produces a painful burning sensation resembling that caused by intense, noxious cold. We demonstrated previously that this thermal grill illusion can be explained as an unmasking phenomenon that reveals the central inhibition of pain by thermosensory integration(1). In order to localize this unmasking in the human brain, we have used positron emission tomography (PET) to compare the cortical activation patterns evoked by the thermal grill and by cool, warm, noxious cold and noxious heat stimuli. The thermal grill illusion produces activation in the anterior cingulate cortex, whereas its component warm and cool stimuli do not. This area is also activated bq noxious heat or cold. Thus, increased activity in the anterior cingulate cortex appears to be selectively associated with the perception of thermal pain. Disruption of thermosensory and pain integration may account for the central pain syndrome that can occur after stroke damage.	GOOD SAMARITAN REG MED CTR, POSITRON EMISS TOMOG CTR, PHOENIX, AZ 85006 USA; UNIV ARIZONA, DEPT PSYCHIAT, TUCSON, AZ 85721 USA; MCGILL UNIV, MONTREAL NEUROL INST, MCCONNELL BRAIN IMAGING CTR, POSITRON IMAGING LABS, MONTREAL, PQ H3A 2B4, CANADA; UNIV MONTREAL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, FAC MED DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA	University of Arizona; McGill University; Universite de Montreal; Universite de Montreal	Craig, AD (corresponding author), BARROW NEUROL INST, DIV NEUROBIOL, 350 W THOMAS RD, PHOENIX, AZ 85013 USA.							BINI G, 1984, PAIN, V18, P239, DOI 10.1016/0304-3959(84)90819-4; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BOIVIE J, 1991, SYMP PAIN R, P65; Bushnell M. C., 1995, Society for Neuroscience Abstracts, V21, P1637; Casey KL, 1996, J NEUROPHYSIOL, V76, P571, DOI 10.1152/jn.1996.76.1.571; COGHILL RC, 1994, J NEUROSCI, V14, P4095; Craig A. D., 1995, Society for Neuroscience Abstracts, V21, P1165; Craig A. D, 1996, SOMESTHESIS NEUROBIO, P27; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; CRAIG AD, 1994, SCIENCE, V265, P252, DOI 10.1126/science.8023144; CRAIG AD, 1991, EXP BRAIN RES, V85, P470; CRAIG AD, 1996, SOC NEUR ABSTR, V22, P11; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; FRUHSTORFER H, 1984, PAIN, V20, P355, DOI 10.1016/0304-3959(84)90112-X; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KENSHALO DR, 1982, PAIN, V12, P141, DOI 10.1016/0304-3959(82)90190-7; LAMOTTE RH, 1982, BRAIN RES, V244, P279, DOI 10.1016/0006-8993(82)90086-5; OCHOA JL, 1994, BRAIN, V117, P185, DOI 10.1093/brain/117.1.185; OSGOOD PF, 1990, BRAIN RES, V507, P11, DOI 10.1016/0006-8993(90)90514-C; RELMAN EM, 1996, NEW ENGL J MED, V334, P752; SCHMAHMANN JD, 1992, ARCH NEUROL-CHICAGO, V49, P1032, DOI 10.1001/archneur.1992.00530340048017; SIKES RW, 1992, J NEUROPHYSIOL, V68, P1720, DOI 10.1152/jn.1992.68.5.1720; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; VANHOESEN GW, 1996, NEUROBIOLOGY CINGULA, P249; WAHREN LK, 1989, PAIN, V38, P313, DOI 10.1016/0304-3959(89)90218-2; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; YARNITSKY D, 1990, BRAIN, V113, P893, DOI 10.1093/brain/113.4.893	30	410	422	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					258	260		10.1038/384258a0	http://dx.doi.org/10.1038/384258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918874				2022-12-28	WOS:A1996VU38100049
J	Yamashita, YM; Nakaseko, Y; Samejima, I; Kumada, K; Yamada, H; Michaelson, D; Yanagida, M				Yamashita, YM; Nakaseko, Y; Samejima, I; Kumada, K; Yamada, H; Michaelson, D; Yanagida, M			20S cyclosome complex formation and proteolytic activity inhibited by the cAMP/PKA pathway	NATURE			English	Article							FISSION YEAST; GENE; UBIQUITIN; PROTEIN; MITOSIS; SPINDLE; ASPERGILLUS; REGULATOR; ANAPHASE; MUTATION	THE 20S cyclosome complex (also known as the anaphase-promoting complex) has ubiquitin ligase activity and is required for mitotic cyclin destruction(1-3) and sister chromatid separation(4,5). The formation and activation of the 20S cyclosome complex is regulated by an unknown mechanism. Here we show that Cut4 (ref. 6) is an essential component of the cyclosome in fission yeast. Cut4 shares sequence similarity with BimE, a protein that regulates mitosis in Aspergillus nidulans(7-9). Mutations in cut4 result In hypersensitivity to cyclic AMP and to stress-inducing heavy metals, inhibition of the onset of anaphase, disruption of the 20S complex, and inhibition of mitotic cyclin ubiquitination, These phenotypes are fully suppressed by cAMP phosphodiesterase and the protein kinase A (PKA) regulatory subunit and weakly suppressed by Sti1 (an activator of the Hsp70 and Hsp90 chaperones(10,11)), Suppression correlates with the amount of 20S complex, indicating that cyclosome formation and activation is inhibited by the cAMP/PKA pathway.	KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Yamada, Hiroshi/0000-0002-0536-5581; Yamashita, Yukiko/0000-0001-5541-0216				CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; DEVOTI J, 1991, EMBO J, V10, P3759, DOI 10.1002/j.1460-2075.1991.tb04945.x; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; ISHII T, IN PRESS EMBO J; JAMES SW, 1995, J CELL SCI, V108, P3495; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; MACNEIL SA, 1993, CELL CYCLE PRACTICAL, P93; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMEJIMA I, 1994, J CELL BIOL, V127, P1665; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; STARBORG M, 1994, J BIOL CHEM, V269, P24133; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4	26	140	144	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					276	279		10.1038/384276a0	http://dx.doi.org/10.1038/384276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918880				2022-12-28	WOS:A1996VU38100055
J	Orth, B; Frei, R; Itin, PH; Rinaldi, MG; Speck, B; Gratwohl, A; Widmer, AF				Orth, B; Frei, R; Itin, PH; Rinaldi, MG; Speck, B; Gratwohl, A; Widmer, AF			Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion	ANNALS OF INTERNAL MEDICINE			English	Article						Paecilomyces lilacinus; mycoses; immunocompromised host; opportunistic infections	BONE-MARROW TRANSPLANTATION; SOLID-ORGAN TRANSPLANTATION; SPECIES INFECTIONS; FUNGAL INFECTION; PATIENT; NEUTROPENIA; CELLULITIS; CANCER	Background: Invasive mycoses are an important cause of illness and death in immunocompromised patients. Infections with molds other than aspergilli have been increasingly seen in patients with hematologic cancers, but epidemics of these infections have not yet been reported. Objective: To describe an outbreak of invasive mycoses with Paecilomyces lilacinus in severely neutropenic patients. Design: An outbreak investigation. Setting: The hematology-oncology isolation and bone marrow transplantation unit of the University Hospital, Basel, Switzerland. Patients: 25 consecutive patients admitted between 17 August 1993 (the date of the first manifestation of P. lilacinus infection) and 31 October 1993 (when the unit was closed). Measurements: Clinical and microbiological data, including histologic findings; cultures from several patient sites; and environmental examinations of potential airborne, parenteral, enteric, and horizontal routes of transmission. Infections were defined by the isolation of P. lilacinus from clinically evident skin eruptions. Results: 12 of the 25 patients (48%) were infected or colonized. Nine patients (36%), including all bone marrow transplant recipients, had documented invasive P. lilacinus infections. All 9 infected patients had papular, pustular, or necrotic skin eruptions. Two patients with severe graft-versus-host disease died with refractory fungal disease; 1 also had microbiologically documented endophthalmitis and kidney infiltrates. Seven affected patients no longer had P. lilacinus after recovery of bone marrow function. The organism was resistant in vitro to amphotericin B, itraconazole, and fluconazole. Patients did not respond clinically to these agents. The outbreak was ultimately traced to a contaminated, commercially available, pharmaceutically prepared skin lotion. The outbreak ended after the skin lotion was recalled and has not recurred after a follow-up period of 2 years. Conclusion: Contaminated skin lotion is a potential cause of opportunistic fungal infections in immunocompromised hosts. Paecilomyces lilacinus is a common saprophytic mold that can cause, by direct cutaneous inoculation, invasive infections associated with illness and death.	UNIV BASEL HOSP, DIV CLIN EPIDEMIOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT LAB MED, BACTERIOL LAB, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DEPT DERMATOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DIV HEMATOL, CH-4031 BASEL, SWITZERLAND; UNIV BASEL HOSP, DIV CLIN EPIDEMIOL, CH-4031 BASEL, SWITZERLAND; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; University of Texas System; University of Texas Health San Antonio								ABDELHAFEZ AII, 1990, J BASIC MICROB, V30, P3; ANAISSIE E, 1992, CLIN INFECT DIS, V14, pS43, DOI 10.1093/clinids/14.Supplement_1.S43; BENEDICT LM, 1992, CLIN INFECT DIS, V15, P17, DOI 10.1093/clinids/15.1.17; Bernacer M., 1992, Medical Microbiology Letters, V1, P207; BODEY GP, 1993, CLIN INFECT DIS, V17, P705, DOI 10.1093/clinids/17.4.705; CASTRO LGM, 1990, J MED VET MYCOL, V28, P15; DOEBBELING BN, 1988, ANN INTERN MED, V109, P394, DOI 10.7326/0003-4819-109-5-394; ESPINELINGROFF A, 1995, ANTIMICROB AGENTS CH, V39, P314, DOI 10.1128/AAC.39.2.314; GORDON MA, 1984, SABOURAUDIA, V22, P109; JADE KB, 1986, ARCH DERMATOL, V122, P1169, DOI 10.1001/archderm.122.10.1169; Merz William G., 1995, P709; MORSE LJ, 1967, NEW ENGL J MED, V277, P472, DOI 10.1056/NEJM196708312770906; NELSON PE, 1994, CLIN MICROBIOL REV, V7, P479, DOI 10.1128/CMR.7.4.479-504.1994; OPAL SM, 1986, J INFECT DIS, V153, P634, DOI 10.1093/infdis/153.3.634; PANDEY A, 1990, MYCOSES, V33, P116, DOI 10.1111/myc.1990.33.3.116; PASSWEG J, 1994, SCHWEIZ MED WSCHR, V124, P62; PAYA CV, 1993, CLIN INFECT DIS, V16, P677, DOI 10.1093/clind/16.5.677; PETERSEN FB, 1992, BONE MARROW TRANSPL, V10, P83; PETTIT TH, 1980, ARCH OPHTHALMOL-CHIC, V98, P1025, DOI 10.1001/archopht.1980.01020031015002; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; RAPER KB, 1949, MANUAL PENICILLIA, P284; RILEY DK, 1994, AM J MED, V97, P509, DOI 10.1016/0002-9343(94)90345-X; SACHS MK, 1990, ARCH INTERN MED, V150, P1907, DOI 10.1001/archinte.150.9.1907; SHTAYEH MSA, 1996, MYCOPATHOLOGIA, V106, P95; SPECK B, 1992, TRANSPLANT P, V24, P88; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; TAKAYASU S, 1977, ARCH DERMATOL, V113, P1687, DOI 10.1001/archderm.113.12.1687; TAN TQ, 1992, J CLIN MICROBIOL, V30, P2479, DOI 10.1128/JCM.30.9.2479-2483.1992; VARTIVARIAN SE, 1993, CLIN INFECT DIS, V17, pS487, DOI 10.1093/clinids/17.Supplement_2.S487; VOLNA F, 1990, Ceskoslovenska Epidemiologie Mikrobiologie Imunologie, V39, P315; WILLIAMSON PR, 1992, CLIN INFECT DIS, V14, P1023, DOI 10.1093/clinids/14.5.1023; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; ZIMMERLI W, 1991, BLOOD, V77, P393	33	83	90	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					799	+		10.7326/0003-4819-125-10-199611150-00003	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928986				2022-12-28	WOS:A1996VU52400006
J	Marmot, MG; Shipley, MJ				Marmot, MG; Shipley, MJ			Do socioeconomic differences in mortality persist after retirement? 25 year follow up of civil servants from the first Whitehall study	BRITISH MEDICAL JOURNAL			English	Article							INEQUALITIES; HEALTH; LIFE	Objective-To assess the risk of death associated with work based and non-work based measures of socioeconomic status before and after retirement age. Design-Follow up study of mortality in relation to employment grade and car ownership over 25 years. Setting-The first Whitehall study. Subjects-18 133 male civil servants aged 40-69 years who attended a screening examination between 1967 and 1970. Main outcome measure-Death. Results-Grade of employment was a strong predictor of mortality before retirement. For men dying at ages 40-64 the lowest employment grade had 3.12 times the mortality of the highest grade (95% confidence interval 2.4 to 4.1). After retirement the ability of grade to predict mortality declined (rate ratio 1.86; 1.6 to 2.2). A non-work based measure of socioeconomic status (car ownership) predicted mortality less well than employment grade before retirement but its ability to predict mortality declined less after retirement. Using a relative index of inequality that was sensitive to the distribution among socioeconomic groups showed employment grade and car ownership to have independent associations with mortality that were of equal magnitude after retirement. The absolute difference in death rates between the lowest and highest employment grades increased with age from 12.9 per 1000 person years at ages 40-64 to 38.3 per 1000 at ages 70-89. Conclusions-Socioeconomic differences in mortality persist beyond retirement age and in magnitude increase with age. Social differentials in mortality based on an occupational status measure seem to decrease to a greater degree after retirement than those based on a non-work measure. This suggests that alongside other socioeconomic factors work itself may play an important part in generating social inequalities in health in men of working age.			Marmot, MG (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		FOX AJ, 1978, J EPIDEMIOL COMMUN H, V32, P73, DOI 10.1136/jech.32.2.73; FOX J, 1990, LONGITUDINAL STUDY M, P99; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P163; GOLDBLATT P, 1990, 1971 1981 LONGITUDIN; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; *NUM ALG GROUP, 1987, GLIM SYST REL 3 77 M; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265	12	264	270	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1177	1180		10.1136/bmj.313.7066.1177	http://dx.doi.org/10.1136/bmj.313.7066.1177			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VR907	8916748	Green Published			2022-12-28	WOS:A1996VR90700021
J	Schiano, TD; Bellary, SV; Cassidy, MJ; Thomas, RM; Black, M				Schiano, TD; Bellary, SV; Cassidy, MJ; Thomas, RM; Black, M			Subfulminant liver failure and severe hepatotoxicity caused by loratadine use	ANNALS OF INTERNAL MEDICINE			English	Article							EFFICACY		TEMPLE UNIV HOSP & MED SCH, GASTROENTEROL SECT, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV HOSP & MED SCH, DEPT PATHOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; ROMAN IJ, 1993, CLIN REV ALLERG, V11, P89; ULRICH PP, 1990, J CLIN INVEST, V86, P1609, DOI 10.1172/JCI114882; 1993, MED LETT DRUGS THER, V35, P71; 1995, PHYSICIANS DESK REFE, P2246	5	14	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					738	740		10.7326/0003-4819-125-9-199611010-00006	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929007				2022-12-28	WOS:A1996VQ07200005
J	Hu, ED; Kim, JB; Sarraf, P; Spiegelman, BM				Hu, ED; Kim, JB; Sarraf, P; Spiegelman, BM			Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR gamma	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; ADIPOSE-TISSUE DEVELOPMENT; TUMOR NECROSIS FACTOR; MYELIN BASIC-PROTEIN; ADIPOCYTE DIFFERENTIATION; SUBSTRATE RECOGNITION; 3T3-L1 ADIPOCYTES; INSULIN-RECEPTORS; ESTROGEN-RECEPTOR	Adipocyte differentiation is an important component of obesity and other metabolic diseases. This process is strongly inhibited by many mitogens and oncogenes. Several growth factors that inhibit fat cell differentiation caused mitogen-activated protein (MAP) kinase-mediated phosphorylation of the dominant adipogenic transcription factor peroxisome proliferator-activated receptor gamma (PPAR gamma) and reduction of its transcriptional activity. Expression of PPAR gamma with a nonphosphorylatable mutation at this site (serine-112) yielded cells with increased sensitivity to ligand-induced adipogenesis and resistance to inhibition of differentiation by mitogens. These results indicate that covalent modification of PPAR gamma by serum and growth factors is a major regulator of the balance between cell growth and differentiation in the adipose cell lineage.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Song, Minsun/I-5701-2015	KIM, Jae Bum/0000-0003-2337-6935	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37DK31405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDO A, 1992, J BIOL CHEM, V267, P12788; BERG M, 1994, CYTOKINE, V6, P425, DOI 10.1016/1043-4666(94)90067-1; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EXTON JH, 1972, J BIOL CHEM, V247, P3579; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORMAN BM, 1995, CELL, V83, P813; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; HORIEIN A, 1995, NATURE, V377, P451; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HU EX, UNPUB; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Maniatis T, 1989, DECONTAMINATION DILU; Moore DD, 1995, GLOB MOB SURV; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; ONATE SA, 1995, SCIENCE, V270, P1354; RODBELL M, 1964, J BIOL CHEM, V239, P375; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPLEGLEMAN BM, 1996, CELL, V87, P377; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	52	903	928	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2100	2103		10.1126/science.274.5295.2100	http://dx.doi.org/10.1126/science.274.5295.2100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953045				2022-12-28	WOS:A1996VY97400055
J	Scofield, SR; Tobias, CM; Rathjen, JP; Chang, JH; Lavelle, DT; Michelmore, RW; Staskawicz, BJ				Scofield, SR; Tobias, CM; Rathjen, JP; Chang, JH; Lavelle, DT; Michelmore, RW; Staskawicz, BJ			Molecular basis of gene-for-gene specificity in bacterial speck disease of tomato	SCIENCE			English	Article							2-HYBRID SYSTEM; RESISTANCE; SENSITIVITY; IDENTIFY; FAMILY; P53	Transient expression of the Pseudomonas syringae avirulence gene avrPto in plant cells resulted in a Pto-dependent necrosis. The AvrPto avirulence protein was observed to interact directly with the Pto resistance protein in the yeast two-hybrid system. Mutations in the Pto and avrPto genes which reduce in vivo activity had parallel effects on association in the two-hybrid assay. These data suggest that during infection the pathogen delivers AvrPto into the plant host cell and that resistance is specified by direct interaction of Pto with AvrPto.	UNIV CALIF DAVIS,NSF CTR ENGN PLANTS RESISTANCE AGAINST PATHOGENS,DAVIS,CA 94720; UNIV CALIF DAVIS,DEPT PLANT & MICROBIAL BIOL,DAVIS,CA 94720; UNIV CALIF DAVIS,DEPT VEGETABLE CROPS,DAVIS,CA 94720	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis			Scofield, Steven/C-3868-2016; Tobias, Christian/B-6602-2009; rathjen, john p/C-9327-2009	Tobias, Christian/0000-0002-7881-750X; rathjen, john p/0000-0003-4073-8088; Chang, Jeff/0000-0002-1833-0695				Bonas U, 1994, Curr Top Microbiol Immunol, V192, P79; CRUTE IR, 1986, PLANT PATHOL, V35, P15, DOI 10.1111/j.1365-3059.1986.tb01975.x; Ellingboe A.H., 1976, PHYSL PLANT PATHOLOG, V4, P761, DOI DOI 10.1007/978-3-642-66279-9_29; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HANKS S, 1995, FASEB J, V9, P577; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Keen N. T., 1982, Advances in plant pathology Vol.1., P35; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; LINDGREN PB, 1986, J BACTERIOL, V168, P512, DOI 10.1128/jb.168.2.512-522.1986; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; Miller J.H., 1972, EXPT MOL GENETICS; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SALMERON JM, 1993, MOL GEN GENET, V239, P6, DOI 10.1007/BF00281595; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374	18	424	451	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2063	2065		10.1126/science.274.5295.2063	http://dx.doi.org/10.1126/science.274.5295.2063			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953034				2022-12-28	WOS:A1996VY97400044
J	Ginsberg, JS				Ginsberg, JS			Drug therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; RANDOMIZED CONTROLLED TRIAL; ORAL ANTICOAGULANT-THERAPY; SERIAL IMPEDANCE PLETHYSMOGRAPHY; TISSUE PLASMINOGEN-ACTIVATOR; ACUTE PULMONARY-EMBOLISM; ACUTE VENOUS THROMBOSIS; LONG-TERM SEQUELAE; UNFRACTIONATED HEPARIN				Ginsberg, JS (corresponding author), MCMASTER UNIV, MED CTR,DEPT MED,THROMBOEMBOLISM SERV, 1200 MAIN ST W, HSC-3W11, HAMILTON, ON L8N 3Z5, CANADA.		ginsberg, jeffrey s/ABC-1065-2020					Anand S., 1995, JGIM, V10, P38; BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; BARRITT DW, 1960, LANCET, V1, P1309; BASU D, 1972, NEW ENGL J MED, V287, P324, DOI 10.1056/NEJM197208172870703; BECKER DM, 1992, ARCH INTERN MED, V152, P1985, DOI 10.1001/archinte.152.10.1985; BENDETOWICZ AV, 1994, THROMB HAEMOSTASIS, V71, P305; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; BRILLEDWARDS P, 1993, ANN INTERN MED, V119, P104, DOI 10.7326/0003-4819-119-2-199307150-00002; BROEKMANS AW, 1983, THROMB HAEMOSTASIS, V49, P2; CARTER CJ, 1982, BLOOD, V59, P1239; CHIU HM, 1977, BLOOD, V49, P171; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; DEMERS C, 1992, ANN INTERN MED, V116, P754, DOI 10.7326/0003-4819-116-9-754; DEMERS C, 1991, BLOOD, V78, P2194; DENHEIJER M, 1995, LANCET, V345, P882, DOI 10.1016/S0140-6736(95)90008-X; DEVALK HW, 1995, ANN INTERN MED, V123, P1; FLESSA HC, 1965, AM J OBSTET GYNECOL, V93, P570, DOI 10.1016/0002-9378(65)90518-1; GALLUS A, 1986, LANCET, V2, P1293; GANDHI BD, 1984, POSTGRAD MED J, V60, P349; GINSBERG JS, 1990, THROMB HAEMOSTASIS, V64, P286; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; GINSBERG JS, 1994, THROMB HAEMOSTASIS, V72, P523; GINSBERG JS, 1989, ARCH INTERN MED, V149, P1651, DOI 10.1001/archinte.149.7.1651; GLOVER JJ, 1995, CHEST, V108, P987, DOI 10.1378/chest.108.4.987; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; GOLDHABER SZ, 1990, AM J MED, V88, P235, DOI 10.1016/0002-9343(90)90148-7; GOLDHABER SZ, 1986, LANCET, V2, P886; GOLDHABER SZ, 1984, AM J MED, V76, P393, DOI 10.1016/0002-9343(84)90656-9; GOLDHABER SZ, 1994, CHEST, V106, P718, DOI 10.1378/chest.106.3.718; GREINACHER A, 1995, THROMB HAEMOSTASIS, V73, P1456; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HELLEMANS J, 1963, BRIT J HAEMATOL, V9, P506, DOI 10.1111/j.1365-2141.1963.tb05475.x; HIRSH J, 1992, ARCH INTERN MED, V152, P257, DOI 10.1001/archinte.152.2.257; HIRSH J, 1994, HEMOSTASIS THROMBOSI, P1567; HIRSH J, 1994, HEMOSTASIS THROMBOSI, P1543; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1994, ARCH INTERN MED, V154, P289, DOI 10.1001/archinte.154.3.289; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, ARCH INTERN MED, V152, P1589, DOI 10.1001/archinte.152.8.1589; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; JACOBS P, 1983, ANNU REV MED, V34, P91, DOI 10.1146/annurev.me.34.020183.000515; JAMIESON SW, 1993, J THORAC CARDIOV SUR, V106, P116, DOI 10.1016/S0022-5223(19)33748-1; JONES NAG, 1980, BRIT J SURG, V67, P569, DOI 10.1002/bjs.1800670814; KAKKAR VV, 1985, AM J SURG, V150, P54; KAKKAR VV, 1969, BRIT MED J, V1, P806, DOI 10.1136/bmj.1.5647.806; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KILLEWICH LA, 1985, ARCH SURG-CHICAGO, V120, P424; KING DJ, 1984, ANN INTERN MED, V100, P535, DOI 10.7326/0003-4819-100-4-535; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; LAGERSTEDT CI, 1985, LANCET, V2, P515; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, AM J MED, V87, P153; LEIZOROVICZ A, 1994, BMJ-BRIT MED J, V309, P299, DOI 10.1136/bmj.309.6950.299; LENSING AWA, 1995, ARCH INTERN MED, V155, P601, DOI 10.1001/archinte.155.6.601; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE MN, 1994, ARCH INTERN MED, V154, P49, DOI 10.1001/archinte.154.1.49; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P1072; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P554; MARKEL A, 1992, ARCH INTERN MED, V152, P1265, DOI 10.1001/archinte.152.6.1265; MELISSARI E, 1992, THROMB HAEMOSTASIS, V68, P652; MOIA M, 1995, THROMB HAEMOSTASIS, V73, P1456; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; NOYES LD, 1987, SURGERY, V102, P813; ODONNELL TF, 1979, JAMA-J AM MED ASSOC, V242, P2766, DOI 10.1001/jama.242.25.2766; OKAJIMA K, 1990, THROMB HAEMOSTASIS, V63, P48; OMEARA JJ, 1994, NEW ENGL J MED, V330, P1864, DOI 10.1056/NEJM199406303302605; ORME ML, 1977, BRIT MED J, V1, P1564, DOI 10.1136/bmj.1.6076.1564; PARENT F, 1993, THROMB HAEMOSTASIS, V70, P386; PIERSON S, 1983, JAMA-J AM MED ASSOC, V249, P242, DOI 10.1001/jama.249.2.242; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; ROBERTS HR, 1965, THROMB DIATH HAEMOST, V13, P305, DOI 10.1055/s-0038-1656232; SCHULMAN S, 1986, ACTA MED SCAND, V219, P349; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SHETTY HGM, 1992, THROMB HAEMOSTASIS, V67, P13; Siragusa S, 1996, AM J MED, V100, P269, DOI 10.1016/S0002-9343(97)89484-3; SORS H, 1994, CHEST, V106, P712, DOI 10.1378/chest.106.3.712; STRANDNESS DE, 1983, JAMA-J AM MED ASSOC, V250, P1289, DOI 10.1001/jama.250.10.1289; SUDLOW MF, 1992, LANCET, V340, P873; TURPIE AGG, 1990, CHEST, V97, pS172, DOI 10.1378/chest.97.4_Supplement.172S; VITOUX JF, 1986, THROMB HAEMOSTASIS, V55, P37; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1994, ANN INTERN MED, V121, P676, DOI 10.7326/0003-4819-121-9-199411010-00009; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; WELLS PS, 1995, LANCET, V346, P516; WESSLER S, 1984, NEW ENGL J MED, V311, P345; WOLZT M, 1995, THROMB HAEMOSTASIS, V73, P439; YOUNG E, 1994, THROMB HAEMOSTASIS, V71, P300; YOUNG E, 1993, THROMB HAEMOSTASIS, V70, P625; YOUNG E, 1992, THROMB HAEMOSTASIS, V67, P639; ZIVELIN A, 1993, J CLIN INVEST, V92, P2131, DOI 10.1172/JCI116814	108	270	273	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1816	1828		10.1056/NEJM199612123352407	http://dx.doi.org/10.1056/NEJM199612123352407			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943165				2022-12-28	WOS:A1996VW68300007
J	Lieb, JD; Capowski, EE; Meneely, P; Meyer, BJ				Lieb, JD; Capowski, EE; Meneely, P; Meyer, BJ			DPY-26, a link between dosage compensation and meiotic chromosome segregation in the nematode	SCIENCE			English	Article							UBIQUITOUS PROTEIN FAMILY; CAENORHABDITIS-ELEGANS; SEX DETERMINATION; C-ELEGANS; FISSION YEAST; X-CHROMOSOME; GENE; CONDENSATION; DROSOPHILA; MUTATIONS	The DPY-26 protein is required in the nematode Caenorhabditis elegans for X-chromosome dosage compensation as well as for proper meiotic chromosome segregation. DPY-26 was shown to mediate both processes through its association with chromosomes. in somatic cells, DPY-26 associates specifically with hermaphrodite X chromosomes to reduce their transcript levels, in germ cells, DPY-26 associates with all meiotic chromosomes to mediate its role in chromosome segregation. The X-specific localization of DPY-26 requires two dosage compensation proteins (DPY-27 and DPY-30) and two proteins that coordinately control both sex determination and dosage compensation (SDC-2 and SDC-3).	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of California System; University of California Berkeley; Fred Hutchinson Cancer Center				Lieb, Jason/0000-0001-7601-8061; Meyer, Barbara/0000-0002-6530-4588	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702, T32GM007127, R37GM030702] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24324] Funding Source: Medline; NIGMS NIH HHS [T32 GM07127, R01 GM030702, GM30702] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; CAPOWSKI EE, UNPUB; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; DAWES HM, UNPUB; DELONG L, 1993, GENETICS, V133, P875; EISSENBERG JC, 1990, EUR J CELL BIOL, V50, P170; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HIRAOKA Y, 1990, BIOPHYS J, V57, P321; HODGKIN J, 1993, MOL GEN GENET, V192, P452; HSU DR, 1995, DEVELOPMENT, V121, P3323; HSU DR, 1994, GENETICS, V137, P999; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KELLUM R, 1995, J CELL SCI, V108, P1419; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; LIEB JD, UNPUB; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; VILLENEUVE AM, 1990, GENETICS, V124, P91	34	100	114	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1732	1736		10.1126/science.274.5293.1732	http://dx.doi.org/10.1126/science.274.5293.1732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939869				2022-12-28	WOS:A1996VW71200068
J	Ting, CN; Olson, MC; Barton, KP; Leiden, JM				Ting, CN; Olson, MC; Barton, KP; Leiden, JM			Transcription factor GATA-3 is required for development of the T-cell lineage	NATURE			English	Article							THYMOCYTE DIFFERENTIATION; RECEPTOR GENES; MICE LACKING; EXPRESSION; ENHANCER; EMBRYOGENESIS; HEMATOPOIESIS; REARRANGEMENT; PROTOONCOGENE; DISRUPTION	THE zinc-finger transcription factor GATA-3 is expressed in haematopoietic cells and in the developing kidney and nervous system(1-7). Within the haematopoietic lineages, expression of GATA-3 is restricted to thymocytes and T cells. Functionally important GATA-3 binding sites have been identified in multiple T-cell-specific genes(1,6-8). Mice containing homozygous null mutations of the GATA-3 gene die on embryonic day 12, precluding a detailed assessment of the role of GATA-3 in haematopoietic development(9). Here we have used murine embryonic stem (ES) cells containing homozygous mutations in the GATA-3 gene (GATA-3(-/-)) in conjunction with the RAG-2(-/-) (ref. 10) and C57BL/6 complementation systems to study the role of GATA-3 in mammalian haematopoiesis. Our results show that GATA-3(-/-) ES cells can contribute to the development of the mature erythroid, myelomonocytic and B-cell lineages, but fail to give rise to thymocytes or mature peripheral T cells. The differentiation of GATA-3(-/-) T cells is blocked at or before the earliest double-negative (CD4(-)/CD8(-)) stage of thymocyte development, such that the GATA-3(-/-) ES cells are unable to contribute measurably to the double-negative thymocyte population. These findings suggest that GATA-3 is an essential and specific regulator of early thymocyte development.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	University of Chicago; University of Chicago								ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODFREY DI, 1994, J IMMUNOL, V152, P4783; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LABASTIE MC, 1995, KIDNEY INT, V47, P1597, DOI 10.1038/ki.1995.223; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MARINE J, 1991, P NATL ACAD SCI USA, V88, P7284, DOI 10.1073/pnas.88.16.7284; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; OOSTERWEGEL M, 1992, DEV IMMUNOL, V3, P1, DOI 10.1155/1992/27903; PADUA RA, 1978, BIOCHEM GENET, V16, P127, DOI 10.1007/BF00484389; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0	30	518	530	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					474	478		10.1038/384474a0	http://dx.doi.org/10.1038/384474a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945476				2022-12-28	WOS:A1996VW68700066
J	Drappa, J; Vaishnaw, AK; Sullivan, KE; Chu, JL; Elkon, KB				Drappa, J; Vaishnaw, AK; Sullivan, KE; Chu, JL; Elkon, KB			Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; TUMOR-NECROSIS-FACTOR; MEDIATED CYTOTOXICITY; MONOCLONAL-ANTIBODY; APOPTOSIS; EXPRESSION; INDUCTION; ANTIGEN; CELLS; MICE	Background The Canale-Smith syndrome is a childhood disorder characterized by lymphadenopathy and autoimmunity. The similarity between this syndrome and that in mice with the lymphoproliferation (lpr) phenotype or the generalized-lymphoproliferative-disease (gld) phenotype led us to investigate whether it too is caused by mutations of the Fas gene (lpr mice) or the Fas ligand (gld mice), which regulate apoptosis in lymphocytes. Methods We studied four patients with the syndrome and their families. T-lymphocyte phenotypes were analyzed, and the susceptibility of activated T cells to Fas-mediated apoptosis in vitro was determined. Mutations of Fas were sought by nucleotide-sequence analysis. Results Patients with the Canale-Smith syndrome had increased numbers of circulating double-negative T cells (>20 percent) and profoundly impaired apoptosis of activated T cells incubated with an anti-Fas antibody. Three novel Fas mutations were identified, all of which were heterozygous and predicted to impair signal transduction by Fas. Autoimmune manifestations of the disease, such as hemolytic anemia and thrombocytopenia, persisted into adolescence. Two patients followed into adulthood had intermittent lymphadenopathy, which diminished over time. Neoplasms developed in both, and one died of hepatocellular carcinoma at the age of 43. Conclusions Patients with the Canale-Smith syndrome have mutations in Fas - a fact that implicates this gene in the accumulation of lymphocytes and the autoimmunity characteristic of the syndrome. (C)1996, Massachusetts Medical Society.	CORNELL UNIV,HOSP SPECIAL SURG,MED CTR,DIV RHEUMATOL,NEW YORK,NY 10021; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,DIV PEDIAT,PHILADELPHIA,PA 19104	Cornell University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia				Sullivan, Kathleen/0000-0003-4018-1646	NIAMS NIH HHS [SLE P50-AR42588] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR042588] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; ASHANY D, 1992, CLIN EXP IMMUNOL, V88, P84; ASHANY D, 1995, P NATL ACAD SCI USA, V92, P11225, DOI 10.1073/pnas.92.24.11225; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; CANALE VC, 1967, J PEDIATR-US, V70, P891, DOI 10.1016/S0022-3476(67)80262-2; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHU JL, 1993, J EXP MED, V178, P723, DOI 10.1084/jem.178.2.723; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DHEIN J, 1992, J IMMUNOL, V149, P3166; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FIUCCI G, 1994, IMMUNOGENETICS, V39, P437; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GHARAVI AE, 1992, J CLIN INVEST, V90, P1105, DOI 10.1172/JCI115927; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; ITOH N, 1993, J BIOL CHEM, V268, P10932; IZUI S, 1984, J IMMUNOL, V133, P227; KAELL AT, 1993, ANN INTERN MED, V119, P1079, DOI 10.7326/0003-4819-119-11-199312010-00004; KELLERER K, 1976, EUR J PEDIATR, V121, P203, DOI 10.1007/BF00445483; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Lin A., 1995, Blood, V86, p271A; MALZBERG MS, 1991, J CLIN ULTRASOUND, V19, P172, DOI 10.1002/jcu.1870190309; MONTEL AH, 1995, CELL IMMUNOL, V166, P236, DOI 10.1006/cimm.1995.9974; MYSLER E, 1994, J CLIN INVEST, V93, P1029, DOI 10.1172/JCI117051; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OGASAWARA J, 1993, NATURE, V365, P568, DOI 10.1038/365568a0; OGATA Y, 1993, CELL IMMUNOL, V148, P91, DOI 10.1006/cimm.1993.1093; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RENSINGEHL A, 1995, EUR J IMMUNOL, V25, P2253, DOI 10.1002/eji.1830250821; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; ROSAL J, 1972, Cancer, V30, P1174, DOI 10.1002/1097-0142(197211)30:5<1174::AID-CNCR2820300507>3.0.CO;2-S; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sambrook J., 2002, MOL CLONING LAB MANU; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALSH CM, 1994, J IMMUNOL, V153, P2506; WARREN RW, 1984, CLIN IMMUNOL IMMUNOP, V31, P65, DOI 10.1016/0090-1229(84)90190-9; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zhou T, 1996, J IMMUNOL, V156, P2661	45	400	404	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1643	1649		10.1056/NEJM199611283352204	http://dx.doi.org/10.1056/NEJM199611283352204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929361				2022-12-28	WOS:A1996VV93600004
J	Grouard, G; Durand, I; Filgueira, L; Banchereau, J; Liu, YJ				Grouard, G; Durand, I; Filgueira, L; Banchereau, J; Liu, YJ			Dendritic cells capable of stimulating T cells in germinal centres	NATURE			English	Article							AIDS-RELATED LYMPHADENOPATHY; VIRUS-LIKE PARTICLES; RETICULUM CELLS; LYMPHOID-TISSUE; HUMAN BLOOD; B-CELLS; CENTERS; ANTIGEN; INFECTION; LYMPHOCYTES	THE B cells within the germinal centres of lymphoid organs undergo affinity maturation of their antigen receptors, a critical event for antibody memory(1-3). Follicular dendritic cells within the germinal centres retain immune complexes(4-6) that select the developing B cells for which they have a higher affinity(7). We have now identified a subset of CD4(+)CD11c(+)CD3(-) dendritic cells in the germinal centres. These are strong antigen-presenting cells for T cells, but do not co-stimulate CD40-activated B cells, These dendritic cells probably stimulate germinal centre T cells and aid the complicated processes that are required for the generation of memory B cells.	SCHERING PLOUGH CORP,LAB IMMUNOL RES,F-69571 DARDILLY,FRANCE; UNIV ZURICH IRCHEL,DIV CELL BIOL,INST ANAT,CH-8057 ZURICH,SWITZERLAND	Merck & Company; Schering Plough Corporation; University of Zurich			Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650				ARMSTRONG JA, 1984, LANCET, V2, P370; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHEN LL, 1978, J CELL BIOL, V77, P148, DOI 10.1083/jcb.77.1.148; CLARK EA, 1994, J IMMUNOL, V153, P2951; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; FULLER KA, 1993, J IMMUNOL, V151, P4505; GORCZYCA W, 1993, LEUKEMIA, V7, P659; GROUARD G, 1995, J IMMUNOL, V155, P3345; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KIM HS, 1994, J IMMUNOL, V153, P2951; KNAPP W, 1989, LEUCOCYTE TYPING, V4, P183; KOSCO MH, 1988, J IMMUNOL, V140, P354; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LAUSE DB, 1981, CELL TISSUE RES, V218, P557; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, IN PRESS J EXP MED; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; NAIEM M, 1983, J CLIN PATHOL, V36, P167, DOI 10.1136/jcp.36.2.167; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PARWARESCH MR, 1983, J IMMUNOL, V131, P2719; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHIEVER F, 1989, J EXP MED, V169, P2043; TENNERRACZ K, 1985, LANCET, V1, P105; TEW JG, 1989, IMMUNOL TODAY, V10, P229, DOI 10.1016/0167-5699(89)90258-2	32	233	240	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					364	367		10.1038/384364a0	http://dx.doi.org/10.1038/384364a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934523				2022-12-28	WOS:A1996VV27100051
J	Corr, LA				Corr, LA			The future of interventional cardiology	LANCET			English	Article							CORONARY-ARTERY DISEASE; BALLOON ANGIOPLASTY; DIRECTIONAL ATHERECTOMY; RANDOMIZED TRIALS; METAANALYSIS; THERAPY											ADELMAN AG, 1993, NEW ENGL J MED, V329, P228, DOI 10.1056/NEJM199307223290402; Alderman EL, 1996, NEW ENGL J MED, V335, P217; Appelman YEA, 1996, LANCET, V347, P79, DOI 10.1016/S0140-6736(96)90209-3; BENTIVOGLIO LG, 1994, J AM COLL CARDIOL, V24, P1195, DOI 10.1016/0735-1097(94)90098-1; Calafiore AM, 1996, LANCET, V347, P263; Casscells W, 1996, LANCET, V347, P1447, DOI 10.1016/S0140-6736(96)91684-0; Corr L, 1996, EUR HEART J, V17, P1296; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; ONEILL WW, 1993, CIRCULATION, V88, P106; PARISI AF, 1992, NEW ENGL J MED, V326, P10, DOI 10.1056/NEJM199201023260102; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; Serruys PW, 1996, CIRCULATION, V93, P412, DOI 10.1161/01.CIR.93.3.412; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIEVERS B, 1993, CIRCULATION, V88, P297; TIERSTEIN PS, 1996, J AM COLL CARDIOL, V27, pA15; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; vandeWerf F, 1996, EUR HEART J, V17, P325; WEINTRAUB WS, 1995, CIRCULATION, V92, P2831, DOI 10.1161/01.CIR.92.10.2831	21	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV	1996	348			1			S23	S26		10.1016/S0140-6736(96)98008-3	http://dx.doi.org/10.1016/S0140-6736(96)98008-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918525				2022-12-28	WOS:A1996VU00800009
J	Kromhout, D				Kromhout, D			Diet heart issues in a pharmacological era	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; TRANS-FATTY-ACIDS; SECONDARY PREVENTION; 7 COUNTRIES; DISEASE; CHOLESTEROL; MORTALITY; RISK						Kromhout, Daan/A-8566-2014					[Anonymous], 1996, EUR HEART J, V17, P163; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Greenberg ER, 1996, NEW ENGL J MED, V334, P1189, DOI 10.1056/NEJM199605023341810; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KROMHOUT D, 1995, PREV MED, V24, P308, DOI 10.1006/pmed.1995.1049; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Muldoon MF, 1996, BRIT MED J, V312, P458, DOI 10.1136/bmj.312.7029.458; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1329; National Research Council, 1989, DIET HLTH IMPL RED C; OLIVER M, 1995, BMJ-BRIT MED J, V310, P1280, DOI 10.1136/bmj.310.6990.1280; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Serafini M, 1996, EUR J CLIN NUTR, V50, P28; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; TRUSWELL AS, 1994, AUST NZ J MED, V24, P98, DOI 10.1111/j.1445-5994.1994.tb04444.x; WOOD DA, 1987, LANCET, V1, P177; Yusuf S, 1996, CIRCULATION, V93, P1774, DOI 10.1161/01.CIR.93.10.1774	21	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV	1996	348			1			S20	S22		10.1016/S0140-6736(96)98007-1	http://dx.doi.org/10.1016/S0140-6736(96)98007-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918524				2022-12-28	WOS:A1996VU00800008
J	Pritchard, RS; Anthony, SP				Pritchard, RS; Anthony, SP			Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer - A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, non-small-cell lung; antineoplastic agents, combined; radiotherapy, adjuvant; quality of life; meta-analysis	PHASE-III TRIAL; HIGH-DOSE RADIATION; RANDOMIZED TRIAL; THERAPY; CISPLATIN	Background: Survival of patients with locally advanced, unresectable (stage III), non-small-cell lung cancer treated with radiotherapy is poor. Trials of the addition of chemotherapy to radiotherapy have produced conflicting results. Objective: To compare chemotherapy plus radiotherapy with radiotherapy alone in patients with stage III, nonsmall-cell lung cancer. Data Sources: English-language journal articles published between 1987 and 1995 identified in a MEDLINE search. Study Selection: Randomized trials that reported survival after previously untreated patients received chemotherapy plus radiotherapy or radiotherapy alone were reviewed. Data Extraction: For all eligible articles, reported survival curves were used to determine the relative risk for death in each of 3 years. These data were combined to determine a pooled estimate of the relative risk for death at 1, 2, and 3 years. Data Synthesis: Fourteen articles reporting on a total of 2589 patients were reviewed. Compared with radiotherapy, the combination of chemotherapy and radiotherapy reduced the risk for death at 1 year (relative risk, 0.88 [95% Cl, 0.80 to 0.96]), 2 years (relative risk, 0.87 [Cl, 0.81 to 0.94]), and 3 years (relative risk, 0.83 [Cl, 0.77 to 0.90]). This corresponded to a mean gain in life expectancy of about 2 months. The magnitude of the treatment effect was similar when trials of concurrently and sequentially administered chemotherapy were considered separately. Conclusion: The addition of chemotherapy to radiotherapy improves survival in patients with locally advanced, unresectable, non-small-cell lung cancer. The absolute benefit is relatively small, however, and should be balanced against the increased toxicity associated with the addition of chemotherapy.	DARTMOUTH HITCHCOCK MED CTR, HEMATOL ONCOL SECT, LEBANON, NH 03756 USA	Dartmouth College	Pritchard, RS (corresponding author), VET AFFAIRS MED CTR, DEPT MED 111, WHITE RIVER JCT, VT 05009 USA.							BLANKE C, 1995, J CLIN ONCOL, V13, P1425, DOI 10.1200/JCO.1995.13.6.1425; CRINO L, 1991, LUNG CANCER, V75, P161; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; GINSBERG RJ, 1993, CANC PRINCIPLES PRAC, P673; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; GREGOR A, 1993, J NATL CANCER I, V85, P997, DOI 10.1093/jnci/85.12.997; GRILLI R, 1993, J CLIN ONCOL, V11, P1866, DOI 10.1200/JCO.1993.11.10.1866; JEREMIC B, 1995, J CLIN ONCOL, V13, P452, DOI 10.1200/JCO.1995.13.2.452; JOHNSON DH, 1990, ANN INTERN MED, V113, P33, DOI 10.7326/0003-4819-113-1-33; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; MATTSON K, 1988, EUR J CANCER CLIN ON, V24, P477, DOI 10.1016/S0277-5379(98)90020-7; MIRA JG, 1990, P ASTRO, V19, P145; MORTON RF, 1991, ANN INTERN MED, V115, P681, DOI 10.7326/0003-4819-115-9-681; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PAYNE DG, 1988, J CLIN ONCOL, V6, P552, DOI 10.1200/JCO.1988.6.3.552; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAUSE WT, 1995, J NATL CANCER I, V87, P198, DOI 10.1093/jnci/87.3.198; SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805; SHEPHERD FA, 1994, SEMIN ONCOL, V21, P48; SORESI E, 1988, SEMIN ONCOL, V15, P20; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; TROVO MG, 1992, INT J RADIAT ONCOL, V24, P11, DOI 10.1016/0360-3016(92)91014-E; TROVO MG, 1990, CANCER, V65, P400, DOI 10.1002/1097-0142(19900201)65:3<400::AID-CNCR2820650304>3.0.CO;2-H; Van Houtte P, 1988, Antibiot Chemother (1971), V41, P131; WOLF M, 1994, SEMIN ONCOL, V21, P42	26	217	227	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					723	+		10.7326/0003-4819-125-9-199611010-00003	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929005				2022-12-28	WOS:A1996VQ07200003
J	Colwell, RR				Colwell, RR			Global climate and infectious disease: The cholera paradigm	SCIENCE			English	Article							FLUORESCENT-MONOCLONAL-ANTIBODY; VIBRIO-CHOLERAE; AQUATIC ENVIRONMENT; POLYPHASIC TAXONOMY; BANGLADESH WATERS; ESCHERICHIA-COLI; RAPID DETECTION; CHESAPEAKE BAY; LATIN-AMERICA; GENUS VIBRIO				Colwell, RR (corresponding author), UNIV MARYLAND,MARYLAND BIOTECHNOL INST,4321 HARTWICK RD,SUITE 550,COLLEGE PK,MD 20740, USA.				NIAID NIH HHS [SR01AI 1976-13] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barua D, 1988, VIBRIO CHOLERAE CHOL, P9; BARUA D, 1991, CURRENT TOPICS INFEC, P372; BECK LA, UNPUB; Beck Louisa R., 1995, GEOGRAPHIC INFOR SEP, P32; BIK EM, 1995, EMBO J, V14, P209, DOI 10.1002/j.1460-2075.1995.tb06993.x; BISHAGRATNA K, 1963, ENGLISH TRANSLATION, P352; BRAYTON P, 1986, 14 INT C MICR U MANC; BRAYTON PR, 1987, APPL ENVIRON MICROB, V53, P2862, DOI 10.1128/AEM.53.12.2862-2865.1987; BROCK JC, 1992, J GEOPHYS RES-OCEANS, V97, P733, DOI 10.1029/91JC02225; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; *CHOL WORK GROUP, 1993, LANCET, V342, P387; CITARELLA RV, 1970, J BACTERIOL, V104, P434, DOI 10.1128/JB.104.1.434-442.1970; Colwell Rita R., 1994, P117; Colwell RR, 1996, WORLD J MICROB BIOT, V12, P28, DOI 10.1007/BF00327795; COLWELL RR, 1995, CAN J MICROBIOL, V41, P946, DOI 10.1139/m95-131; COLWELL RR, 1970, J BACTERIOL, V104, P410, DOI 10.1128/JB.104.1.410-433.1970; COLWELL RR, 1990, ADV RES CHOLERA RELA, P327; COLWELL RR, UNPUB; Comstock LE, 1996, MOL MICROBIOL, V19, P815, DOI 10.1046/j.1365-2958.1996.407928.x; Ellms J., 1928, WATER PURIFICATION, V2nd ed.; FARUQUE S, 1994, J CLIN MICROBIOL, V31, P2513; FIELD J, 1994, AUST MICROBIOL, V15, P138; GLASS RI, 1985, J INFECT DIS, V151, P236, DOI 10.1093/infdis/151.2.236; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; GRIMES DJ, 1986, FEMS MICROBIOL LETT, V34, P161; HASAN JAK, 1994, FEMS MICROBIOL LETT, V120, P143, DOI 10.1016/0378-1097(94)00191-X; HASAN JAK, 1994, J CLIN MICROBIOL, V32, P249, DOI 10.1128/JCM.32.1.249-252.1994; HOOD MA, 1983, MICROBIAL ECOL, V9, P65, DOI 10.1007/BF02011581; HOOD MA, 1982, APPL ENVIRON MICROB, V43, P578, DOI 10.1128/AEM.43.3.578-584.1982; HOSMER D, 1987, APPL LOGISTICS REGRE; Huq A, 1996, APPL ENVIRON MICROB, V62, P2508, DOI 10.1128/AEM.62.7.2508-2512.1996; HUQ A, 1984, APPL ENVIRON MICROB, V48, P420, DOI 10.1128/AEM.48.2.420-424.1984; HUQ A, 1990, APPL ENVIRON MICROB, V56, P2370, DOI 10.1128/AEM.56.8.2370-2373.1990; HUQ A, 1995, LANCET, V345, P1249, DOI 10.1016/S0140-6736(95)92038-2; Huq A., 1984, VIBRIOS ENV, P521; ISLAM MS, 1989, J TROP MED HYG, V92, P396; ISLAM MS, 1994, T ROY SOC TROP MED H, V88, P298, DOI 10.1016/0035-9203(94)90085-X; ISLAM MS, 1990, T ROY SOC TROP MED H, V84, P422, DOI 10.1016/0035-9203(90)90345-F; ISLAM S, 1990, J TROP MED HYG, V93, P133; KANEKO T, 1973, J BACTERIOL, V113, P24, DOI 10.1128/JB.113.1.24-32.1973; KAPER J, 1979, APPL ENVIRON MICROB, V37, P91, DOI 10.1128/AEM.37.1.91-103.1979; KARAOLIS DKR, 1995, J BACTERIOL, V177, P3191, DOI 10.1128/jb.177.11.3191-3198.1995; KAY BA, 1994, VIBRIO CHOLERAE CHOL, pCH1; KLORBOE T, 1994, COPEPODS LIMNOL OCEA, V39, P493; KONDO K, 1994, FEMS MICROBIOL LETT, V123, P179, DOI 10.1016/0378-1097(94)90292-5; KOTOB SI, 1995, APPL ENV MICROBIOL, V61; LACEY SW, 1995, CLIN INFECT DIS, V20, P409; LEVINE M, 1981, ACUTE ENTERIC INFECT, pCH26; MATA L, 1994, ANN NY ACAD SCI, V740, P55, DOI 10.1111/j.1749-6632.1994.tb19853.x; MCCORMACK WM, 1969, AM J EPIDEMIOL, V89, P393, DOI 10.1093/oxfordjournals.aje.a120953; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; Munro PM, 1996, WATER RES, V30, P47, DOI 10.1016/0043-1354(95)00137-A; MUNRO PM, 1994, WATER RES, V30, P47; NAIR GB, 1994, J INFECT DIS, V169, P1029, DOI 10.1093/infdis/169.5.1029; NALIN DR, 1979, INFECT IMMUN, V25, P768, DOI 10.1128/IAI.25.2.768-770.1979; NISHIMURA M, 1992, B JAP SOC MICROBIOL, V7, P43; Okun DA, 1996, J ENVIRON ENG-ASCE, V122, P453, DOI 10.1061/(ASCE)0733-9372(1996)122:6(453); OLIVER JD, 1983, APPL ENVIRON MICROB, V45, P985, DOI 10.1128/AEM.45.3.985-998.1983; PALMER LM, 1991, APPL ENVIRON MICROB, V57, P1286, DOI 10.1128/AEM.57.5.1286-1293.1991; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; Peters JC, 1885, ASIATIC CHOLERA; POLLITZER R., 1959, Cholera; RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5; ROSZAK DB, 1987, MICROBIOL REV, V51, P365, DOI 10.1128/MMBR.51.3.365-379.1987; SACK RB, 1969, J BACTERIOL, V99, P688, DOI 10.1128/JB.99.3.688-695.1969; Seminario L, 1991, REV PER EPIDEMIOL PE, V4, P8; SHIBA T, 1995, APPL ENVIRON MICROB, V61, P2583, DOI 10.1128/AEM.61.7.2583-2588.1995; SHIMADA T, 1993, LANCET, V341, P1347; SIDDIQUE AK, 1994, TROP GEOGR MED, V46, P147; SINGLETON FL, 1982, APPL ENVIRON MICROB, V43, P1080, DOI 10.1128/AEM.43.5.1080-1085.1982; SINGLETON FL, 1982, APPL ENVIRON MICROB, V44, P1047, DOI 10.1128/AEM.44.5.1047-1058.1982; SOCHARD MR, 1979, APPL ENVIRON MICROB, V37, P7; SOUTHWARD AJ, 1995, J THERM BIOL, V20, P127, DOI 10.1016/0306-4565(94)00043-I; SPIRA WM, 1981, APPL ENVIRON MICROB, V42, P550, DOI 10.1128/AEM.42.3.550-553.1981; SURABHI G, 1994, FEMS IMMUNOL MED MIC, V8, P293; TAMPLIN ML, 1990, APPL ENVIRON MICROB, V56, P1977, DOI 10.1128/AEM.56.6.1977-1980.1990; Tibbetts J, 1996, BIOSCIENCE, V46, P566, DOI 10.2307/1312984; TRAMONT EC, 1995, INFECTIONS GASTROINT; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; Wachsmuth I.K., 1994, VIBRIO CHOLERAE CHOL; Wai SN, 1996, FEMS MICROBIOL LETT, V136, P187; WALDOR MK, 1994, P NATL ACAD SCI USA, V91, P11388, DOI 10.1073/pnas.91.24.11388; WENDT EC, 1885, TREATISE ASIATIC CHO, P403; XU HS, 1984, J MICROBIOL METH, V2, P221, DOI 10.1016/0167-7012(84)90017-4; XU HS, 1983, MICROB ECOL, V8, P213; YOHALEM D, 1991, 320 WAT SAN HLTH; 1992, MMWR-MORBID MORTAL W, V42, P89; 1995, JAPAN TIMES     1108, P1	89	830	887	6	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2025	2031		10.1126/science.274.5295.2025	http://dx.doi.org/10.1126/science.274.5295.2025			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953025				2022-12-28	WOS:A1996VY97400029
J	Song, LZ; Hobaugh, MR; Shustak, C; Cheley, S; Bayley, H; Gouaux, JE				Song, LZ; Hobaugh, MR; Shustak, C; Cheley, S; Bayley, H; Gouaux, JE			Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore	SCIENCE			English	Article							BETA-SHEET BARRELS; FORMING PROTEIN; MACROMOLECULAR CRYSTALLOGRAPHY; LIPID BILAYER; KEY RESIDUES; TOXIN GENE; AUREUS; MEMBRANE; CHANNEL; OLIGOMERIZATION	The structure of the Staphylococcus aureus alpha-hemolysin pore has been determined to 1.9 Angstrom resolution. Contained within the mushroom-shaped homo-oligomeric heptamer is a solvent-filled channel, 100 Angstrom in length, that runs along the sevenfold axis and ranges from 14 Angstrom to 46 Angstrom in diameter. The lytic, transmembrane domain comprises the lower half of a 14-strand antiparallel beta barrel, to which each protomer contributes two beta strands, each 65 Angstrom long. The interior of the beta barrel is primarily hydrophilic, and the exterior has a hydrophobic belt 28 Angstrom wide. The structure proves the heptameric subunit stoichiometry of the alpha-hemolysin oligomer, shows that a glycine-rich and solvent-exposed region of a water-soluble protein can self-assemble to form a transmembrane pore of defined structure, and provides insight into the principles of membrane interaction and transport activity of beta barrel pore-forming toxins.	WORCESTER FDN BIOMED RES,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research	Song, LZ (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.		Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360; Bayley, Hagan/0000-0003-2499-6116				ALOUF JE, 1991, SURCEBOOK BACTERIAL; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bayley H, 1995, BIOORG CHEM, V23, P340, DOI 10.1006/bioo.1995.1023; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRANKS NP, 1976, J MOL BIOL, V100, P345, DOI 10.1016/S0022-2836(76)80067-8; FUREY W, IN PRESS METHODS ENZ; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; HOBAUGH MR, UNPUB; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOUTHALL NT, UNPUB; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KASIANOWICZ JJ, 1995, BIOPHYS J, V69, P94, DOI 10.1016/S0006-3495(95)79879-4; KORCHEV YE, 1995, J MEMBRANE BIOL, V143, P143; KRASILNIKOV OV, 1988, GEN PHYSIOL BIOPHYS, V7, P467; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI J, 1992, CURR OPIN STRUC BIOL, V2, P545; MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; MENZIES BE, 1994, INFECT IMMUN, V62, P1843, DOI 10.1128/IAI.62.5.1843-1847.1994; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5; MURZIN AG, 1994, J MOL BIOL, V236, P1369, DOI 10.1016/0022-2836(94)90064-7; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PASTOR RW, 1991, P NATL ACAD SCI USA, V88, P892, DOI 10.1073/pnas.88.3.892; PAUPTIT RA, 1991, J STRUCT BIOL, V107, P136, DOI 10.1016/1047-8477(91)90017-Q; PEITSCH M C, 1991, Current Opinion in Cell Biology, V3, P710, DOI 10.1016/0955-0674(91)90045-Z; ROSSMAN MG, 1963, ACTA CRYSTALLOGR, V16, P39, DOI 10.1107/S0365110X63000062; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SONG L, 1996, METHOD ENZYMOL, V276, P60; SURGENOR DM, 1974, RED BLOOD CELL, V1; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TOMITA T, 1992, J BIOL CHEM, V267, P13391; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; VALEVA A, 1995, BBA-BIOMEMBRANES, V1236, P213, DOI 10.1016/0005-2736(95)00060-G; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WALKER B, 1995, PROTEIN ENG, V8, P491, DOI 10.1093/protein/8.5.491; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARD RJ, 1992, J STRUCT BIOL, V109, P129, DOI 10.1016/1047-8477(92)90044-B; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	61	1893	2008	9	440	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1859	1866		10.1126/science.274.5294.1859	http://dx.doi.org/10.1126/science.274.5294.1859			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943190				2022-12-28	WOS:A1996VY20000030
J	Jacobs, IJ; Skates, S; Davies, AP; Woolas, RP; Jeyerajah, A; Weidemann, P; Sibley, K; Oram, DH				Jacobs, IJ; Skates, S; Davies, AP; Woolas, RP; Jeyerajah, A; Weidemann, P; Sibley, K; Oram, DH			Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: A prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CA-125 LEVELS; MARKERS	Objective-To determine the risk of invasive epithelial ovarian cancer and fallopian tube cancer associated with a raised concentration of the tumour marker CA 125 in asymptomatic postmenopausal women. Design-Serum CA 125 concentration was measured annually in study participants for one to four years. Participants with a concentration greater than or equal to 30 U/ml were recalled for abdominal ultrasonography. Follow up was by annual postal questionnaire. Setting-General practice, occupational health departments, ovarian cancer screening unit in a teaching hospital. Subjects-22 000 volunteers, all postmenopausal women greater than or equal to 45 years of age; recruited between 1 June 1986 and 1 May 1990. Intervention-Surgical investigation if the ultrasound examination was abnormal. Main outcome measures-Cumulative and relative (invasive fallopian tube) after a specified CA 125 result. Results-49 index cancers developed in the study population during a mean follow up of 6.76 years. The overall cumulative risk of developing an index cancer was 0.0022 for the entire study population and was lower for women with a serum CA 125 concentration <30 U/ml (cumulative risk 0.0012) but was appreciably increased for women with a concentration greater than or equal to 30 U/ml (0.030) and >100 U/ml (0.149). Compared with the entire study population the relative risk of developing an index cancer within one year and five years was increased 35.9-fold (95% confidence interval 18.3 to 70.4) and 14.3-fold (8.5 to 24.3) respectively after a serum CA 125 concentration greater than or equal to 30 U/ml and 204.8-fold (79.0 to 530.7) and 74.5-fold (31.1 to 178.3) respectively after a concentration greater than or equal to 100 U/ml. Conclusion-CA 125 is a powerful index of risk of ovarian and fallopian tube cancer in asymptomatic postmenopausal women.	ROYAL LONDON HOSP, LONDON EC1A 7BE, ENGLAND; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA	Barts Health NHS Trust; Royal London Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Jacobs, IJ (corresponding author), ST BARTHOLOMEWS HOSP, DEPT GYNAECOL ONCOL, OVARIAN CANC SCREENING UNIT, LONDON EC1A 7BE, ENGLAND.		Jacobs, Ian J/F-1743-2013	Jacobs, Ian J/0000-0002-8112-4624; Jacobs, Ian/0000-0002-5005-2672				BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BOURNE TH, 1994, GYNECOL ONCOL, V52, P379, DOI 10.1006/gyno.1994.1065; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HELZLSOUER KJ, 1993, JAMA-J AM MED ASSOC, V269, P1123, DOI 10.1001/jama.269.9.1123; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; JACOBS IJ, 1992, OBSTET GYNECOL, V80, P396; Knapp RC., 1996, CONTEMP OBSTET GYNEC, V41, P99; *OFF POP CENS SURV, 1989, CANC STAT REG CAS DI; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P218; SKATES SJ, 1995, CANCER, V76, P2004, DOI 10.1002/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G; WOOLAS R, 1996, INT J GYNECOL CANCER, V4, P384; WOOLAS RP, 1993, JNCI-J NATL CANCER I, V85, P1748, DOI 10.1093/jnci/85.21.1748; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507	16	140	145	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	1996	313	7069					1355	1358		10.1136/bmj.313.7069.1355	http://dx.doi.org/10.1136/bmj.313.7069.1355			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW685	8956699	Green Published			2022-12-28	WOS:A1996VW68500021
J	Aker, PD; Gross, AR; Goldsmith, CH; Peloso, P				Aker, PD; Gross, AR; Goldsmith, CH; Peloso, P			Conservative management of mechanical neck pain: Systematic overview and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; ACUTE WHIPLASH INJURIES; DOUBLE-BLIND; CERVICAL-SPINE; MANUAL THERAPY; ELECTROMAGNETIC THERAPY; GENERAL-POPULATION; EARLY MOBILIZATION; OUTCOME MEASURES; PERSISTENT BACK	Objective-To review the efficacy of conservative management of mechanical neck disorders. Methods-Published and unpublished reports were identified through computerised and manual searches of bibliographical databases, reference lists from primary articles, and letters to authors, agencies, foundations, and content experts. Selection criteria were applied to blinded articles, and selected articles were scored for methodological quality. Effect sizes were calculated from raw pain scores and combined by using meta-analytic techniques when appropriate. Results-Twenty four randomised clinical trials met the selection criteria and were categorised by type of intervention: nine used manual treatments; 12 physical medicine methods; four drug treatment; and three education of patients (four trials investigated more than one form of intervention). The intervention strategies were summarised separately. Pooling of studies was considered only within each category. Five of the nine trials that used manual treatment in combination with other treatments were combined. One to four weeks after treatment the pooled effect size was -0.6 (95% confidence interval -0.9 to -0.4), equivalent to an improvement of 16 (6.9 to 23.1) points on a 100 point scale. Sensitivity analyses on study quality, chronicity, and data imputation did not alter this estimate. For other interventions, studies could not be combined to arrive at pooled estimates of effect. Conclusions-There is little information available from clinical trials to support many of the treatments for mechanical neck pain. In general, conservative interventions have not been studied in enough detail to assess efficacy or effectiveness adequately.	CANADIAN MEM CHIROPRACT COLL, DIV GRAD STUDIES & RES, TORONTO, ON, CANADA; MCMASTER UNIV, CHEDOKE MCMASTER HOSP & SCH REHABIL SCI, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; UNIV SASKATCHEWAN, DEPT MED, SASKATOON, SK S7N 0W0, CANADA	McMaster University; McMaster University; University of Saskatchewan			salimi, mehdi/D-1192-2009	Gross, Anita R/0000-0001-5187-7484				BARRY M, 1995, BRIT MED J, V310, P183, DOI 10.1136/bmj.310.6973.183; BASMAJIAN JV, 1978, ARCH PHYS MED REHAB, V59, P58; BERCEL NA, 1977, CURR THER RES CLIN E, V22, P462; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; Breslow N, 1980, STATISTICAL METHODS, V32; BRODIN H, 1984, INT J REHABIL RES, V7, P190, DOI 10.1097/00004356-198406000-00008; BRODIN H, 1985, INT J REHABIL RES, V2, P18; CASSIDY JD, 1992, J MANIP PHYSIOL THER, V15, P570; CASSIDY JD, 1993, J MANIP PHYSIOL THER, V16, P279; COLETTA R, 1988, INT J CLIN PHARM RES, V8, P295; FOLEYNOLAN D, 1990, ORTHOPEDICS, V13, P445; FOLEYNOLAN D, 1992, SCAND J REHABIL MED, V24, P51; GOLDIE I, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P117; GROSS A, 1995, MUSCULOSKELETAL MODU; GROSS AR, 1996, ONLINE J CURR C 0730, P5; HEDGES LV, 1985, STAT METHODS METAANA, P27; HORAL J, 1969, ACTA ORTHOP SCAND S, V118, P42; HULT L, 1954, ACTA ORTHOP SCAND S, V16, P12; HULT L, 1954, ACTA ORTHOP SCAND, V17, P175; JADAD AR, 1994, THESIS U OXFORD OXFO; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; KAMWENDO K, 1991, SCAND J REHABIL MED, V23, P143; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; KOES BW, 1992, SPINE, V17, P28, DOI 10.1097/00007632-199201000-00005; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOES BW, 1993, J MANIP PHYSIOL THER, V16, P211; Koes BW, 1992, THESIS CIP GEGEVENS; KVARNSTROM S, 1983, SCAND J REHABIL MED, P1; LEVOSKA S, 1993, ARCH PHYS MED REHAB, V74, P425; LEWITH GT, 1981, ACUPUNCTURE ELECTRO, V6, P277, DOI 10.3727/036012981816952180; LOY TT, 1983, MED J AUSTRALIA, V2, P32, DOI 10.5694/j.1326-5377.1983.tb142083.x; MCKINNEY LA, 1989, BRIT MED J, V299, P1006, DOI 10.1136/bmj.299.6706.1006; MCKINNEY LA, 1989, ARCH EMERG MED, V6, P27; MEALY K, 1986, BRIT MED J, V292, P656, DOI 10.1136/bmj.292.6521.656; *MICR CORP, 1982, METANAL VERS 4 01; NORDEMAR R, 1981, PAIN, V10, P93, DOI 10.1016/0304-3959(81)90050-6; PENNIE BH, 1990, J BONE JOINT SURG BR, V72, P277, DOI 10.1302/0301-620X.72B2.2312568; PETRIE JP, 1983, CLIN EXP RHEUMATOL, V1, P333; RUSH PJ, 1994, BRIT J RHEUMATOL, V33, P566; SLOOP PR, 1982, SPINE, V7, P532, DOI 10.1097/00007632-198211000-00003; SNOW CJ, 1992, PHYSIOTHERAPY CANADA, V44, pS8; SPITZER WO, 1987, SPINE, V12, pS1; Thorsen H, 1991, Ugeskr Laeger, V153, P1801; THORSEN H, 1992, SCAND J RHEUMATOL, V21, P139, DOI 10.3109/03009749209095086; Tollison CD, 1992, PAINFUL CERVICAL TRA; VANDERDONK J, 1991, J RHEUMATOL, V18, P1884; VERNON HT, 1990, J MANIP PHYSIOL THER, V13, P13; WAYLONIS GW, 1988, ARCH PHYS MED REHAB, V69, P1017	48	231	233	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	1996	313	7068					1291	1296						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942688				2022-12-28	WOS:A1996VV15300022
J	Metcalf, JV; Mitchison, HC; Palmer, JM; Jones, DE; Bassendine, MF; James, OFW				Metcalf, JV; Mitchison, HC; Palmer, JM; Jones, DE; Bassendine, MF; James, OFW			Natural history of early primary biliary cirrhosis	LANCET			English	Article							MITOCHONDRIAL AUTO-ANTIGENS; DISEASE; AUTOANTIBODIES; IDENTIFICATION; PROGNOSIS; SURVIVAL	Background In 1986, we reported a group of 29 patients who were positive in serum for antimitochondrial antibody (AMA), the disease-specific marker for primary biliary cirrhosis (PBC), but who had normal liver function test results and no symptoms of liver disease. However, liver histology was diagnostic or compatible with PBC in 24 patients and normal in only two. The aims of this 10-year follow-up study were to establish whether patients with AMA have very early PBC, to assess the outlook for such patients, and to follow the progression of the disease. Methods All patients were assessed every year at our PBC clinic: records were reviewed, cause of death verified when applicable, and current clinical and biochemical data collected, including repeat liver histology as indicated. Serum samples from the original study were located. Original and follow-up serum samples were tested by ELISA for E2 components of pyruvate dehydrogenase complex and 2-oxoglutarate dehydrogenase complex. Findings Five patients died during follow-up; no deaths were attributable to liver disease. Median follow-up of patients who survived was 17.8 years (range 11.0-23.9) from first-detected AMA to the last follow-up review. Overall, 22 (76%) developed symptoms of PBC and 24 (83%) had liver function tests persistently showing cholestasis. Repeat liver biopsy samples were obtained from ten patients; among these patients PBC progressed from Scheuer grade 1 to grade 2 in two and from grade 1 to grade 3 in two. No patient developed clinically apparent cirrhosis. ELISA of baseline serum samples from 27 patients was positive in 21, all of whom had original liver histology compatible with or diagnostic of PBC. Of the six patients who tested negative, only one had an original liver biopsy sample that was compatible with PBC. Interpretation This study confirms that before the advent of any clinical or biomedical indications, individuals positive for AMA do have PBC. This finding extends the natural history of PBC back in some cases for many years. What determines the eventual progression to biochemically and clinically apparent disease is not yet understood. During our study no patient developed clinically apparent portal hypertension or cirrhosis. Thus, although the finding of a solitary persistently raised AMA is confirmation of a diagnosis of PBC, patients with AMA but no other signs or symptoms of PBC seem to have slow progression of the disease.	UNIV NEWCASTLE UPON TYNE,SCH CLIN MED SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; CITY HOSP SUNDERLAND NHS TRUST,SUNDERLAND,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Sunderland Royal Hospital					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALASUBRAMANIAM K, 1990, GASTROENTEROLOGY, V98, P1567, DOI 10.1016/0016-5085(90)91091-J; BERG PA, 1992, DIGEST DIS, V10, P85, DOI 10.1159/000171347; CHRISTENSEN E, 1993, GASTROENTEROLOGY, V105, P1865, DOI 10.1016/0016-5085(93)91086-W; FUSSEY SPM, 1988, P NATL ACAD SCI USA, V85, P8654, DOI 10.1073/pnas.85.22.8654; HESELTINE L, 1990, GASTROENTEROLOGY, V99, P1786, DOI 10.1016/0016-5085(90)90488-M; JEFFREY GP, 1990, J GASTROEN HEPATOL, V5, P639, DOI 10.1111/j.1440-1746.1990.tb01118.x; LEHMANN AB, 1985, GERONTOLOGY, V31, P186, DOI 10.1159/000212701; LONG RG, 1977, GASTROENTEROLOGY, V72, P1104; MAHL TC, 1994, J HEPATOL, V20, P707, DOI 10.1016/S0168-8278(05)80139-4; MITCHISON HC, 1986, HEPATOLOGY, V6, P1279, DOI 10.1002/hep.1840060609; MITCHISON HC, 1990, GASTROENTEROLOGY, V99, P778, DOI 10.1016/0016-5085(90)90968-7; MUTIMER DJ, 1989, HEPATOLOGY, V10, P403, DOI 10.1002/hep.1840100402; NYBERG A, 1989, SCAND J GASTROENTERO, V24, P57, DOI 10.3109/00365528909092240; PALMER JM, 1993, CLIN SCI, V85, P289, DOI 10.1042/cs0850289; Portmann B. C., 1994, P477; ROLL J, 1983, NEW ENGL J MED, V301, P1; YEAMAN SJ, 1988, LANCET, V1, P1067	17	328	361	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1399	1402		10.1016/S0140-6736(96)04410-8	http://dx.doi.org/10.1016/S0140-6736(96)04410-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937278				2022-12-28	WOS:A1996VU98600009
J	Konig, L; Rabin, I; Schulze, W; Ertl, G				Konig, L; Rabin, I; Schulze, W; Ertl, G			Chemiluminescence in the agglomeration of metal clusters	SCIENCE			English	Article							RARE-GAS MATRICES	The agglomeration of copper or silver atoms in a matrix of noble gas atoms to form small clusters may be accompanied by the emission of visible light. Spectral analysis reveals the intermediate formation of electronically excited atoms and dimers as the source of the chemiluminescence. A mechanism is proposed, according to which the gain in binding energy upon cluster formation may even lead to the ejection of excited fragments as a result of unstable intermediate configurations. A similar concept was introduced in the field of nuclear reactions by Niels Bohr 60 years ago.	MAX PLANCK GESELL,D-14195 BERLIN,GERMANY	Max Planck Society								BECKER S, 1994, Z PHYS D ATOM MOL CL, V30, P341, DOI 10.1007/BF01426399; Bohr N., 1936, NATURE, V137, P344, DOI [10.1038/137344a0, DOI 10.1038/137344A0]; BONACICKOUTECKY V, 1993, Z PHYS D ATOM MOL CL, V26, P287, DOI 10.1007/BF01429171; BRECHIGNAC C, 1994, PHYS REV LETT, V72, P1636, DOI 10.1103/PhysRevLett.72.1636; FRANK F, 1985, SURF SCI, V156, P90, DOI 10.1016/0039-6028(85)90561-8; GOLE JL, 1982, J PHYS CHEM-US, V86, P2560, DOI 10.1021/j100211a003; HEBERT T, 1989, J CHEM PHYS, V91, P1417, DOI 10.1063/1.457101; HERVIEUX PA, 1995, Z PHYS D ATOM MOL CL, V33, P295, DOI 10.1007/BF01437510; KOLB DM, 1984, J CHEM PHYS, V80, P695, DOI 10.1063/1.446766; KONIG L, UNPUB; PRISANT MG, 1984, J CHEM PHYS, V81, P2699, DOI 10.1063/1.447981; SCHRITTENLACHER W, 1984, BER BUNSEN PHYS CHEM, V88, P492, DOI 10.1002/bbpc.19840880515; Weisskopf V, 1937, PHYS REV, V52, P0295, DOI 10.1103/PhysRev.52.295	13	100	107	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1353	1355		10.1126/science.274.5291.1353	http://dx.doi.org/10.1126/science.274.5291.1353			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910270				2022-12-28	WOS:A1996VU95400046
J	Hatsukami, DK; Fischman, MW				Hatsukami, DK; Fischman, MW			Crack cocaine and cocaine hydrochloride - Are the differences myth or reality?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FREE-BASE COCAINE; INTRAVENOUS COCAINE; USE PATTERNS; DRUG-USE; HUMANS; SMOKING; DEPENDENCE; ABUSERS; INTRANASAL; PYROLYSIS	Objective.-To review and discuss the differences and similarities between the use of crack cocaine and cocaine hydrochloride; and to determine how these findings might affect policies on the imprisonment and treatment of cocaine users. Data Sources.-English-language publications were identified through a computerized search (using MEDLINE) between 1976 and 1996 using the search terms ''smoked cocaine,'' ''crack cocaine,'' ''freebase,'' and ''cocaine-base.'' In addition, manual searches were conducted on references cited in original research articles, reviews, and an annotated bibliography, and on selected journals. Study Selection.-Only those articles that compared various routes of cocaine administration or types of cocaine (cocaine base or crack cocaine vs cocaine hydrochloride) were examined. Data Extraction.-Studies were reviewed to obtain information on the composition of the 2 forms of cocaine, and the prevalence, pharmacokinetics and pharmacodynamics, abuse liability, pattern of use, and consequences across the various routes of cocaine administration and forms of cocaine. Conclusion.-Cocaine hydrochloride is readily converted to base prior to use. The physiological and psychoactive effects of cocaine are similar regardless of whether it is in the form of cocaine hydrochloride or crack cocaine (cocaine base). However, evidence exists showing a greater abuse liability, greater propensity for dependence, and more severe consequences when cocaine is smoked (cocaine-base) or injected intravenously (cocaine hydrochloride) compared with intranasal use (cocaine hydrochloride). The crucial variables appear to be the immediacy, duration, and magnitude of cocaine's effect, as well as the frequency and amount of cocaine used rather than the form of the cocaine. Furthermore, cocaine hydrochloride used intranasally may be a gateway drug or behavior to using crack cocaine, Based on these findings, the federal sentencing guidelines allowing possession of 100 times more cocaine hydrochloride than crack cocaine to trigger mandatory minimum penalties is deemed excessive, Although crack cocaine has been linked with crime to a greater extent than cocaine hydrochloride, many of these crimes are associated with the addiction to cocaine. Therefore, those addicted individuals who are incarcerated for the sale or possession of cocaine are better served by treatment than prison.	NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PSYCHIAT, NEW YORK, NY USA	New York State Psychiatry Institute; Columbia University	Hatsukami, DK (corresponding author), UNIV MINNESOTA, DEPT PSYCHIAT, DIV NEUROSCI, BOX 392, UMHC, MINNEAPOLIS, MN 55455 USA.							BALSTER R L, 1973, Pharmacology Biochemistry and Behavior, V1, P67, DOI 10.1016/0091-3057(73)90057-9; Belenko S, 1993, CRACK EVOLUTION ANTI; BOOTH RE, 1993, AM J PUBLIC HEALTH, V83, P1144, DOI 10.2105/AJPH.83.8.1144; BRODY SL, 1990, AM J MED, V88, P325, DOI 10.1016/0002-9343(90)90484-U; BROWER KJ, 1986, HOSP COMMUNITY PSYCH, V37, P1229; BUNT G, 1990, AM J PSYCHIAT, V147, P1542; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P989; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P177; CAULKINS JP, 1993, RP193 RAND; CONE EJ, 1995, J ANAL TOXICOL, V19, P459, DOI 10.1093/jat/19.6.459; Cook CE, 1985, PHARMACOKINETICS PHA, P48; De Leon G, 1993, NIDA Res Monogr, V135, P163; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; EVANS SM, 1993, NATL I DRUG ABUSE RE, V132, P343; Fagan J, 1990, NIDA Res Monogr, V103, P8; FOLTIN RW, 1992, J PHARMACOL EXP THER, V261, P841; FOLTIN RW, 1991, J PHARMACOL EXP THER, V257, P247; Gawin F H, 1985, NIDA Res Monogr, V61, P182; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GOLD MS, 1987, MED TIMES, V115, P27; Goldstein P.J., 1989, CONTEMP DRUG PROBL, V16, P651; GORELICK DA, 1992, AM J DRUG ALCOHOL AB, V18, P13, DOI 10.3109/00952999209001607; GOSSOP M, 1994, BRIT J PSYCHIAT, V164, P660, DOI 10.1192/bjp.164.5.660; GRELLA CE, 1995, DRUG ALCOHOL DEPEN, V37, P15, DOI 10.1016/0376-8716(94)01059-T; HATSUKAMI DK, 1987, CLIN PHARMACOL THER, V41, P103, DOI 10.1038/clpt.1987.17; Helfrich A A, 1983, NIDA Res Monogr, V43, P343; HENDERSON DJ, 1994, RES NURS HEALTH, V17, P265, DOI 10.1002/nur.4770170405; HIGGINS ST, 1994, DRUG ALCOHOL DEPEN, V34, P87, DOI 10.1016/0376-8716(94)90128-7; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; HONER WG, 1987, LANCET, V2, P451; INCIARDI JA, 1994, J DRUG ISSUES, V24, P273, DOI 10.1177/002204269402400205; INCIARDI JA, 1991, J DRUG ISSUES, V21, P257, DOI 10.1177/002204269102100204; ISENSCHMID DS, 1992, J ANAL TOXICOL, V16, P311, DOI 10.1093/jat/16.5.311; JACOB P, 1990, J TOXICOL-CLIN TOXIC, V28, P121; JAVAID JI, 1983, BIOPHARM DRUG DISPOS, V4, P9, DOI 10.1002/bdd.2510040104; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; JEFFCOAT AR, 1989, DRUG METAB DISPOS, V17, P153; Johanson C E, 1988, NIDA Res Monogr, V88, P107; JOHNSON BD, 1994, J DRUG ISSUES, V24, P117, DOI 10.1177/002204269402400107; Jones R T, 1990, NIDA Res Monogr, V99, P30; KANDEL D, 1993, AM J PUBLIC HEALTH, V83, P851, DOI 10.2105/AJPH.83.6.851; Kandel DB, 1996, ARCH GEN PSYCHIAT, V53, P71; KHALSA HK, 1993, NATL I DRUG ABUSE RE, V135, P218; KLEINMAN PH, 1990, J NERV MENT DIS, V178, P442, DOI 10.1097/00005053-199007000-00005; Leukefeld C G, 1988, NIDA Res Monogr, V86, P236; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; MARTIN BR, 1989, J ANAL TOXICOL, V13, P158, DOI 10.1093/jat/13.3.158; Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507; Mieczkowksi T., 1990, CONTEMP DRUG PROBL, V17, P9; MILLER NS, 1994, INT J ADDICT, V29, P1069, DOI 10.3109/10826089409047928; NAKAHARA Y, 1991, J ANAL TOXICOL, V15, P105, DOI 10.1093/jat/15.3.105; NOVAK M, 1984, B NARCOTICS, V36, P79; PEREZREYES M, 1982, CLIN PHARMACOL THER, V32, P459, DOI 10.1038/clpt.1982.189; PETERS RH, 1992, AM J DRUG ALCOHOL AB, V18, P355, DOI 10.3109/00952999209026072; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; POTTIEGER AE, 1992, J PSYCHOACTIVE DRUGS, V24, P399, DOI 10.1080/02791072.1992.10471664; POTTIEGER AE, 1995, J PSYCHOACTIVE DRUGS, V27, P27, DOI 10.1080/02791072.1995.10471670; RESNICK RB, 1977, SCIENCE, V195, P696, DOI 10.1126/science.841307; REUTER P, 1988, PUBLIC INTEREST, P51; RICHARDSON GA, 1991, NEUROTOXICOL TERATOL, V13, P455, DOI 10.1016/0892-0362(91)90095-E; RINGWALT CL, 1989, ADOLESCENCE, V24, P851; ROUNSAVILLE BJ, 1991, ARCH GEN PSYCHIAT, V48, P43; Rydell CP, 1994, CONTROLLING COCAINE; Schnoll S H, 1985, NIDA Res Monogr, V61, P171; SCHWARCZ SK, 1992, SEX TRANSM DIS, V19, P7, DOI 10.1097/00007435-199201000-00002; Siegel R K, 1984, NIDA Res Monogr, V50, P92; SMART RG, 1991, AM J DRUG ALCOHOL AB, V17, P13, DOI 10.3109/00952999108992806; SMART RG, 1988, AM J EPIDEMIOL, V127, P1315, DOI 10.1093/oxfordjournals.aje.a114925; STRANG J, 1990, BRIT J ADDICT, V85, P193; TIMS FM, 1993, NATL I DRUG ABUSE RE, V135; TURNER CE, 1988, COCAINE ANNOTATED BI; *US DEP HLTH HUM S, 1995, NAT HOUS SURV DRUG A; *US DEP HLTH HUM S, 1993, NAT HOUS SURV DRUG A; *US DEP HLTH HUM S, 1994, NAT I DRUG AB SER, V1; *US DEP HLTH HUM S, 1988, NAT HOUS SURV DRUG A; *US DEP HLTH HUM S, 1994, NATL I DRUG AB SER, V1; *US SENT COMM, 1995, COC FED SENT POL; VEREBEY K, 1988, PSYCHIAT ANN, V18, P513, DOI 10.3928/0048-5713-19880901-06; Washton A M, 1984, NIDA Res Monogr, V49, P247; WASHTON AM, 1986, POSTGRAD MED, V80, P52, DOI 10.1080/00325481.1986.11699554; WASHTON AM, 1987, ADV ALCOHOL SUBST AB, V6, P31; WILKINSON P, 1980, CLIN PHARMACOL THER, V27, P386, DOI 10.1038/clpt.1980.52; Yawn B P, 1994, Arch Fam Med, V3, P520, DOI 10.1001/archfami.3.6.520; YOUNG SL, 1992, PHARMACOTHERAPY, V12, P2; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	85	188	198	3	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1580	1588						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT025	8918856				2022-12-28	WOS:A1996VT02500031
J	Wallwork, J; Schofield, P; Caine, N; Sharples, L; Buxton, M				Wallwork, J; Schofield, P; Caine, N; Sharples, L; Buxton, M			Health technology assessment: TMR trials and tribulations	LANCET			English	Letter									UNIV FORVIE SITE,INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND	MRC Biostatistics Unit; University of Cambridge; Brunel University	Wallwork, J (corresponding author), PAPWORTH HOSP NHS TRUST,PAPWORTH EVERARD CB3 8RE,CAMBRIDGESHIRE,ENGLAND.			Sharples, Linda/0000-0003-0894-966X					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1386	1386		10.1016/S0140-6736(05)65454-2	http://dx.doi.org/10.1016/S0140-6736(05)65454-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918301				2022-12-28	WOS:A1996VT33200059
J	Bretscher, MS				Bretscher, MS			Getting membrane flow and the cytoskeleton to cooperate in moving cells	CELL			English	Review							GIANT HELA-CELLS; LEADING LAMELLA; ACTIN-FILAMENTS; SURFACE; FIBROBLASTS; RECEPTORS; LOCOMOTION; GROWTH; MICROTUBULES; TRANSFERRIN				Bretscher, MS (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							ABERCROMBIE M, 1970, EXP CELL RES, V62, P389, DOI 10.1016/0014-4827(70)90570-7; ABERCROMBIE M, 1972, EXP CELL RES, V73, P536, DOI 10.1016/0014-4827(72)90090-0; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BRETSCHER MS, 1984, SCIENCE, V224, P681, DOI 10.1126/science.6719108; BRETSCHER MS, 1976, NATURE, V260, P21, DOI 10.1038/260021a0; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRETSCHER MS, 1983, P NATL ACAD SCI-BIOL, V80, P454, DOI 10.1073/pnas.80.2.454; BRETSCHER MS, 1983, EMBO J, V2, P599, DOI 10.1002/j.1460-2075.1983.tb01469.x; CAO LG, 1993, J CELL BIOL, V123, P173, DOI 10.1083/jcb.123.1.173; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; DAI JW, 1995, CELL, V83, P693; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; de Petris S., 1977, Dynamic aspects of cell surface organization, P643; DEPETRIS S, 1978, J CELL BIOL, V79, P235, DOI 10.1083/jcb.79.1.235; EKBLOM P, 1983, INT J CANCER, V31, P111, DOI 10.1002/ijc.2910310118; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; HARRIS A, 1972, EXP CELL RES, V73, P519, DOI 10.1016/0014-4827(72)90084-5; Harris A K, 1973, Ciba Found Symp, V14, P3; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; INGRAM VM, 1969, NATURE, V222, P641, DOI 10.1038/222641a0; JAY PY, 1992, NATURE, V356, P438, DOI 10.1038/356438a0; LAMOUREUX P, 1990, J CELL BIOL, V110, P71, DOI 10.1083/jcb.110.1.71; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lin CH, 1996, NEURON, V16, P769, DOI 10.1016/S0896-6273(00)80097-5; MARCUS PI, 1962, COLD SPRING HARB SYM, V27, P351, DOI 10.1101/SQB.1962.027.001.033; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; TAYLOR RB, 1971, NATURE-NEW BIOL, V2335, P225; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TRINKAUS JP, 1984, CELLS ORGANS, P197; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5	41	158	160	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					601	606		10.1016/S0092-8674(00)81380-X	http://dx.doi.org/10.1016/S0092-8674(00)81380-X			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929529	Bronze			2022-12-28	WOS:A1996VU03500003
J	Schuler, GD; Boguski, MS; Hudson, TJ; Hui, L; Ma, J; Castle, AB; Wu, X; Silva, J; Nusbaum, HC; Birren, BB; Slonim, DK; Rozen, S; Stein, LD; Page, D; Lander, ES; Stewart, EA; Aggarwal, A; Bajorek, E; Brady, S; Chu, A; Fang, N; Hadley, D; Harris, M; Hussain, S; Maratukulam, A; Perkins, S; Piercy, M; Qin, F; Reif, T; Sanders, C; She, X; Sun, WL; Tabar, P; Voyticky, S; Mader, C; McKusick, KB; Fan, JB; Cowles, S; Quackenbush, J; Vollrath, D; Myers, RM; Cox, DR; Butler, A; Clee, C; Dibling, T; East, C; Edwards, C; Garrett, C; Green, L; Harrison, P; Hicks, A; Holloway, E; Ranby, S; MacGilvery, A; Mungall, A; Peck, A; Wilmer, T; Soderlund, C; Rice, K; Dunham, I; Bentley, D; Deloukas, P; Gyapay, G; Chiannilkulchai, N; Fizames, C; Bentolila, S; Duprat, S; VegaCzarny, N; Muselet, D; Drouot, N; Morissette, J; Weissenbach, J; Morissette, J; James, MR; White, RE; Thangarajah, T; LouisDitSully, C; Day, PJR; Goodfellow, PN; Schmitt, K; Walter, NAR; Berry, R; Iorio, KR; Sikela, JM; Polymeropoulos, MH; Torres, R; Ide, SE; Dehejia, A; Houlgatte, R; Auffray, C; Adams, MD; Phillips, C; Brandon, R; Sandusky, M; Venter, JC; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; RodriguezTome, P; Matise, TC; Lee, WY; Swanson, KA; Hudson, JR				Schuler, GD; Boguski, MS; Hudson, TJ; Hui, L; Ma, J; Castle, AB; Wu, X; Silva, J; Nusbaum, HC; Birren, BB; Slonim, DK; Rozen, S; Stein, LD; Page, D; Lander, ES; Stewart, EA; Aggarwal, A; Bajorek, E; Brady, S; Chu, A; Fang, N; Hadley, D; Harris, M; Hussain, S; Maratukulam, A; Perkins, S; Piercy, M; Qin, F; Reif, T; Sanders, C; She, X; Sun, WL; Tabar, P; Voyticky, S; Mader, C; McKusick, KB; Fan, JB; Cowles, S; Quackenbush, J; Vollrath, D; Myers, RM; Cox, DR; Butler, A; Clee, C; Dibling, T; East, C; Edwards, C; Garrett, C; Green, L; Harrison, P; Hicks, A; Holloway, E; Ranby, S; MacGilvery, A; Mungall, A; Peck, A; Wilmer, T; Soderlund, C; Rice, K; Dunham, I; Bentley, D; Deloukas, P; Gyapay, G; Chiannilkulchai, N; Fizames, C; Bentolila, S; Duprat, S; VegaCzarny, N; Muselet, D; Drouot, N; Morissette, J; Weissenbach, J; Morissette, J; James, MR; White, RE; Thangarajah, T; LouisDitSully, C; Day, PJR; Goodfellow, PN; Schmitt, K; Walter, NAR; Berry, R; Iorio, KR; Sikela, JM; Polymeropoulos, MH; Torres, R; Ide, SE; Dehejia, A; Houlgatte, R; Auffray, C; Adams, MD; Phillips, C; Brandon, R; Sandusky, M; Venter, JC; Seki, N; Nagase, T; Ishikawa, K; Nomura, N; RodriguezTome, P; Matise, TC; Lee, WY; Swanson, KA; Hudson, JR			Genome maps .7. The human transcript map	SCIENCE			English	Article									WHITEHEAD INST,CTR GENOME RES,CAMBRIDGE,MA 02142; STANFORD HUMAN GENOME CTR,STANFORD,CA; SANGER CTR,CAMBRIDGE,ENGLAND; CNRS,GENETHON,EVRY,FRANCE; CHU LAVAL,CTR RECH,LAVAL,PQ,CANADA; WELLCOME TRUST CTR HUMAN GENET,OXFORD,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CB2 1TN,ENGLAND; UNIV COLORADO,HLTH SCI CTR,DENVER,CO; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; CNRS,GENEXPRESS,VILLEJUIF,FRANCE; INST GENOM RES,ROCKVILLE,MD; KAZUSA DNA RES INST,KISARAZU,JAPAN; EUROPEAN MOL BIOL LAB OUTSTN,EUROPEAN BIOINFORMAT INST,CAMBRIDGE,ENGLAND; ROCKEFELLER UNIV,NEW YORK,NY; RES GENET,HUNTSVILLE,AL	Massachusetts Institute of Technology (MIT); Whitehead Institute; Stanford University; Wellcome Trust Sanger Institute; Centre National de la Recherche Scientifique (CNRS); Laval University; University of Oxford; Wellcome Centre for Human Genetics; University of Cambridge; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Centre National de la Recherche Scientifique (CNRS); J. Craig Venter Institute; Kazusa DNA Research Institute; European Molecular Biology Laboratory (EMBL); Rockefeller University	Schuler, GD (corresponding author), NATL LIB MED,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894, USA.		Deloukas, Panos/B-2922-2013; Mungall, Andrew J./U-7067-2018; Houlgatte, Remi/P-3020-2017; Rozen, Steven G./J-5939-2013	Deloukas, Panos/0000-0001-9251-070X; Mungall, Andrew J./0000-0002-0905-2742; Slonim, Donna/0000-0003-3357-437X; Rozen, Steven G./0000-0002-4288-0056				RES GENETICS RESOURC, V3, P1	1	32	32	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					547	558						12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928009				2022-12-28	WOS:A1996VN91900039
J	Baldock, C; Rafferty, JB; Sedelnikova, SE; Baker, PJ; Stuitje, AR; Slabas, AR; Hawkes, TR; Rice, DW				Baldock, C; Rafferty, JB; Sedelnikova, SE; Baker, PJ; Stuitje, AR; Slabas, AR; Hawkes, TR; Rice, DW			A mechanism of drug action revealed by structural studies of enoyl reductase	SCIENCE			English	Article							ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; DIHYDROFOLATE-REDUCTASE; CRYSTAL-STRUCTURES; TRANSITION-STATE; AREA DETECTOR; PROGRAM; DIFFRACTOMETER; ANALOGS; BINDING	Enoyl reductase (ENR), an enzyme involved in fatty acid biosynthesis, is the target for antibacterial diazaborines and the front-line antituberculosis drug isoniazid. Analysis of the structures of complexes of Escherichia coli ENR with nicotinamide adenine dinucleotide and either thienodiazaborine or benzodiazaborine revealed the formation of a covalent bond between the 2' hydroxyl of the nicotinamide ribose and a boron atom in the drugs to generate a tight, noncovalently bound bisubstrate analog. This analysis has implications for the structure-based design of inhibitors of ENR, and similarities to other oxidoreductases suggest that mimicking this molecular linkage may have generic applications in other areas of medicinal chemistry.	UNIV SHEFFIELD,DEPT MOL BIOL & BIOTECHNOL,KREBS INST BIOMOL RES,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; VRIJE UNIV AMSTERDAM,BIOCTR AMSTERDA,INST MOL BIOL STUDIES IMBW,DEPT GENET,NL-1081 HV AMSTERDAM,NETHERLANDS; UNIV DURHAM,DEPT BIOL SCI,DURHAM DH1 3LE,ENGLAND; ZENECA AGROCHEM,JEALOTTS HILL RES STN,DEPT EXPLORATORY PLANT SCI,BRACKNELL RG12 6EY,BERKS,ENGLAND	University of Sheffield; Vrije Universiteit Amsterdam; Durham University			Heterocycles, BoronNitrogen/Q-1699-2019; Liu, Shih/Q-1672-2019	Baldock, Clair/0000-0003-3497-1959; Baker, Patrick/0000-0003-1995-5643; Rafferty, John/0000-0003-1183-7474				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BALDOCK C, IN PRESS ACTA CRYSTA; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; Bull HG, 1996, J AM CHEM SOC, V118, P2359, DOI 10.1021/ja953069t; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; Cole Stewart T., 1994, Trends in Microbiology, V2, P411, DOI 10.1016/0966-842X(94)90621-1; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; ESNOUF R, COMMUNICATION; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HOGENAUER G, 1981, NATURE, V293, P662, DOI 10.1038/293662a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KATER MM, 1994, PLANT MOL BIOL, V25, P771, DOI 10.1007/BF00028873; KLEYWEGT GJ, 1993, ESF CCP4 NEWSL, P56; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, CCP4 ESF EACBM NEWSL; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RAFFERTY JB, 1995, STRUCTURE, V3, P927, DOI 10.1016/S0969-2126(01)00227-1; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; Taillefumier C, 1996, BIOORG MED CHEM LETT, V6, P615, DOI 10.1016/0960-894X(96)00077-7; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZHONG S, 1991, J AM CHEM SOC, V113, P9429, DOI 10.1021/ja00025a001	30	212	224	3	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2107	2110		10.1126/science.274.5295.2107	http://dx.doi.org/10.1126/science.274.5295.2107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953047				2022-12-28	WOS:A1996VY97400057
J	Yamazaki, D; Kato, T; Ohtani, E; Toriumi, M				Yamazaki, D; Kato, T; Ohtani, E; Toriumi, M			Grain growth rates of MgSiO3 perovskite and periclase under lower mantle conditions	SCIENCE			English	Article							OLIVINE; TRANSFORMATIONS; SUPERPLASTICITY; RHEOLOGY; CERAMICS; SYSTEM; SLAB; ZNO	The grain growth rates of MgSiO3 perovskite and periclase in aggregates have been determined at 25 gigapascals and 1573 to 2173 kelvin. The average grain size (G) was fitted to the rate equation, and the grain growth rates of perovskite and periclase were G(10.6) = 1 X 10(-57.4) t exp(-320.8/RT) and G(10.8) = 1 X 10(-62.3) t exp(-247.0/RT), respectively, where t is the time, R is the gas constant, and T is the absolute temperature. These growth rates provide insight into the mechanism for grain growth in minerals relevant to the Earth's lower mantle that will ultimately help define the theology of the lower mantle.	UNIV TSUKUBA,INST GEOSCI,TSUKUBA,IBARAKI 305,JAPAN; TOHOKU UNIV,INST MINERAL PETROL & ECON GEOL,SENDAI,MIYAGI 98077,JAPAN	University of Tsukuba; Tohoku University	Yamazaki, D (corresponding author), UNIV TOKYO,FAC SCI,INST GEOL,BUNKYO KU,TOKYO 113,JAPAN.		Ohtani, Eiji/AAD-8011-2019	Ohtani, Eiji/0000-0001-8631-0736				BALDO JB, 1988, J AM CERAM SOC, V71, P720, DOI 10.1111/j.1151-2916.1988.tb06404.x; BASS JD, 1984, PHYS EARTH PLANET IN, V36, P145, DOI 10.1016/0031-9201(84)90015-3; Brook R. J., 1976, TREATISE MATERIALS S, P331; Burke J. E., 1949, GRAIN CONTROL IND ME, P1; CHEN IW, 1990, J AM CERAM SOC, V73, P2585, DOI 10.1111/j.1151-2916.1990.tb06734.x; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; FISCHER KM, 1988, J GEOPHYS RES-SOLID, V93, P4773, DOI 10.1029/JB093iB05p04773; FOURNELLE RA, 1972, METALL TRANS, V3, P2757, DOI 10.1007/BF02652842; GLAESER AM, 1984, J CERAM SOC JPN, V92, P538; GUPTA TK, 1971, J AM CERAM SOC, V54, P413, DOI 10.1111/j.1151-2916.1971.tb12336.x; HANITZSC.E, 1968, Z PHYS CHEM NEUE FOL, V57, P145, DOI 10.1524/zpch.1968.57.3_6.145; HARKULICH TM, 1966, J AM CERAM SOC, V49, P295, DOI 10.1111/j.1151-2916.1966.tb13266.x; HILLERT M, 1965, ACTA METALL MATER, V13, P227, DOI 10.1016/0001-6160(65)90200-2; HOSHIKUMA A, 1995, J SEISMOL SOC JAPAN, V48, P159; ITO E, 1991, NATURE, V351, P140, DOI 10.1038/351140a0; ITO E, 1989, J GEOPHYS RES-SOLID, V94, P10637, DOI 10.1029/JB094iB08p10637; KARATO S, 1992, SCIENCE, V255, P1238, DOI 10.1126/science.255.5049.1238; KARATO S, 1988, PHYS EARTH PLANET IN, V51, P107, DOI 10.1016/0031-9201(88)90029-5; KARATO S, 1995, SCIENCE, V270, P458, DOI 10.1126/science.270.5235.458; KARATO SI, 1986, J GEOPHYS RES-SOLID, V91, P8151, DOI 10.1029/JB091iB08p08151; KATO T, 1995, J GEOPHYS RES-SOL EA, V100, P20475, DOI 10.1029/95JB01688; MEADE C, 1995, GEOPHYS RES LETT, V22, P1293, DOI 10.1029/95GL01091; NICHOLS FA, 1966, J APPL PHYS, V37, P4599, DOI 10.1063/1.1708102; NICHOLSON GC, 1966, J AM CERAM SOC, V49, P47, DOI 10.1111/j.1151-2916.1966.tb13148.x; OISHI Y, 1960, J CHEM PHYS, V33, P905, DOI 10.1063/1.1731286; POIRIER JP, 1986, NATURE, V321, P603, DOI 10.1038/321603a0; RINGWOOD AE, 1991, GEOCHIM COSMOCHIM AC, V55, P2083, DOI 10.1016/0016-7037(91)90090-R; Saltykov, 1958, STEREOMETRIC METALLO, P446; SENDA T, 1990, J AM CERAM SOC, V73, P106, DOI 10.1111/j.1151-2916.1990.tb05099.x; SILVER PG, 1986, J GEOPHYS RES-SOLID, V91, P13787, DOI 10.1029/JB091iB14p13787; VANDERHILST R, 1991, NATURE, V353, P37, DOI 10.1038/353037a0; YAGENEHHAERI A, 1989, SCIENCE, V243, P787	32	68	68	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2052	2054		10.1126/science.274.5295.2052	http://dx.doi.org/10.1126/science.274.5295.2052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953030				2022-12-28	WOS:A1996VY97400040
J	Douglas, RG				Douglas, RG			The heritage of hepatitis B vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRANSGENIC PLANTS; VIRUS; IMMUNIZATION; PARTICLES; EFFICACY; TRIAL	Pioneering development of the plasma-derived and yeast-derived recombinant hepatitis B Vaccines represents a major contribution to preventive health care of this century. Current and expanding worldwide application of hepatitis B vaccine promises to eliminate and eventually eradicate hepatitis B infection from the human population and, with it, many cases of cirrhosis and cancer of the liver.			Douglas, RG (corresponding author), MERCK & CO INC, MERCK VACCINE DIV, 1 MERCK DR, POB 100, WHITEHOUSE STN, NJ 08889 USA.							[Anonymous], 1947, LANCET, V253, P691; BEASLEY RP, 1984, SEMIN LIVER DIS, V4, P113, DOI 10.1055/s-2008-1040651; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; BUYNAK EB, 1976, JAMA-J AM MED ASSOC, V235, P2832, DOI 10.1001/jama.235.26.2832; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P574; DANE DS, 1970, LANCET, V1, P695; FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; Hilleman M, 1993, HEPATITIS B VACCINES, P17; KANE M, 1995, VACCINE S1, V13, P547; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; KRUGMAN S, 1967, J AMER MED ASSOC, V200, P365, DOI 10.1001/jama.200.5.365; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; MOFFAT AS, 1995, SCIENCE, V268, P658, DOI 10.1126/science.7732373; PRINCE AM, 1968, P NATL ACAD SCI USA, V60, P814, DOI 10.1073/pnas.60.3.814; SCHIRMBECK R, 1994, J IMMUNOL, V152, P1110; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	19	10	10	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1796	1798		10.1001/jama.276.22.1796	http://dx.doi.org/10.1001/jama.276.22.1796			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946890				2022-12-28	WOS:A1996VV99700014
J	Kessler, DA; Hass, AE; Feiden, KL; Lumpkin, M; Temple, R				Kessler, DA; Hass, AE; Feiden, KL; Lumpkin, M; Temple, R			Approval of new drugs in the United States - Comparison with the United Kingdom, Germany, and Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In a study reported herein, the marketing approval dates of 214 drugs newly introduced into the world market from January 1990 through December 1994 were compared in 4 countries. The analysis reveals that the United States and the United Kingdom have similar patterns of drug availability, although the United States has a number of therapies with significant public health benefits that are not yet available in the United Kingdom. The findings also show that the United States outpaces both Germany and Japan in approving important new drugs. Various strategies adopted by the Food and Drug Administration to expedite its pharmaceutical review process, including the use of industry user fees, are described.	US FDA, OFF PLANNING & EVALUAT, ROCKVILLE, MD 20857 USA; US FDA, CTR DRUG EVALUAT & RES, ROCKVILLE, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Kessler, DA (corresponding author), US FDA, OFF COMMISSIONER, 5600 FISHERS LN, ROCKVILLE, MD 20857 USA.							DAVIES J, 1992, CIBA F SYMP, V171, P24; DAVIS J, 1991, SCRIP WORLD PHAR JAN, P20; DAVIS J, 1993, SCRIP WORLD PHAR JAN, P20; DAVIS J, 1994, SCRIP MAGAZINE   JAN, P42; DAVIS J, 1995, SCRIP MAGAZINE   JAN, P42; Kaitin KI, 1995, DRUG INF J, V29, P361; KESSLER DA, 1995, SCI AM           MAR, P26	7	27	27	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1826	1831		10.1001/jama.276.22.1826	http://dx.doi.org/10.1001/jama.276.22.1826			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946904				2022-12-28	WOS:A1996VV99700033
J	Kind, R; Ni, J; Zhao, WJ; Wu, JX; Yuan, XH; Zhao, LS; Sandvol, E; Reese, C; Nabelek, J; Hearn, T				Kind, R; Ni, J; Zhao, WJ; Wu, JX; Yuan, XH; Zhao, LS; Sandvol, E; Reese, C; Nabelek, J; Hearn, T			Evidence from earthquake data for a partially molten crustal layer in southern Tibet	SCIENCE			English	Article								Earthquake data collected by the INDEPTH-II Passive-Source Experiment show that there is a substantial south to north variation in the velocity structure of the crustal beneath southern Tibet. North of the Zangbo suture, beneath the southern Lhasa block, a mid-crustal low-velocity zone is revealed by inversion of receiver functions, Rayleigh-wave phase velocities, and modeling of the radial component of teleseismic P-waveforms, Conversely, to the south beneath the Tethyan Himalaya, no low-velocity zone was; observed, The presence of the midcrustal low-velocity zone in the north implies that a partially molten layer is in the middle crust beneath the northern Yadong-Gulu rift and possibly much of southern Tibet.	NEW MEXICO STATE UNIV,DEPT PHYS,LAS CRUCES,NM 88003; GEOFORSCHUNGSZENTRUM POTSDAM,D-14473 POTSDAM,GERMANY; CHINESE ACAD GEOL SCI,BEIJING,PEOPLES R CHINA; UNIV TEXAS,INST GEOPHYS,AUSTIN,TX 78759; CORNELL UNIV,DEPT GEOL SCI,ITHACA,NY 14853; OREGON STATE UNIV,COLL OCEANOG,CORVALLIS,OR 97331	New Mexico State University; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Chinese Academy of Geological Sciences; University of Texas System; University of Texas Austin; Cornell University; Oregon State University			Yuan, Xiaohui/G-5149-2010	Yuan, Xiaohui/0000-0002-2891-1354				Brown LD, 1996, SCIENCE, V274, P1688, DOI 10.1126/science.274.5293.1688; HASKELL NA, 1962, J GEOPHYS RES, V67, P4751, DOI 10.1029/JZ067i012p04751; KIND R, 1995, GEOPHYS J INT, V121, P191, DOI 10.1111/j.1365-246X.1995.tb03520.x; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; WU J, 1995, EOS, V76, pF392; Zhao LS, 1996, GEOPHYS J INT, V125, P355, DOI 10.1111/j.1365-246X.1996.tb00004.x; Zhao LS, 1996, GEOPHYS J INT, V124, P525, DOI 10.1111/j.1365-246X.1996.tb07035.x	7	222	265	4	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1692	1694		10.1126/science.274.5293.1692	http://dx.doi.org/10.1126/science.274.5293.1692			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939854				2022-12-28	WOS:A1996VW71200053
J	Blumenthal, D; Campbell, EG; Causino, N; Louis, KS				Blumenthal, D; Campbell, EG; Causino, N; Louis, KS			Participation of life-science faculty in research relationships with industry	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Recent research on academic-industrial research relationships in the life sciences has examined their frequency, benefits, risks, and evolution from the standpoint of industrial sponsors of research. We collected information on the extent and effects of academic-industrial research relationships from the standpoint of faculty members who participate in them. Methods We used a mailed questionnaire to collect data between October 1994 and April 1995 from 2052 faculty members (of 3169 eligible respondents; response rate, 65 percent) in the life sciences at the 50 U.S. universities receiving the most research funding from the National Institutes of Health. Results Twenty-eight percent of the respondents received research support from industry. Faculty members receiving industrial funds had more peer-reviewed articles published in the previous three years, participated in more administrative activities in their institutions or disciplines, and were more commercially active than faculty members without such funding. However, faculty members receiving more than two thirds of their research support from industry were less academically productive than those receiving a lower level of industrial support, and their articles were less influential than those by researchers with no industrial support. Faculty members with industrial support were significantly more likely than those without industrial support to report that trade secrets had resulted from their work (14.5 percent vs. 4.7 percent, P<0.001) and that they had taken commercial considerations into account when choosing research topics (35 percent vs. 14 percent, P<0.001). Conclusions Faculty members with industrial research support are at least as productive academically as those without such support and are more productive commercially. However, faculty members who have research relationships with industry are more likely to restrict their communication with colleagues, and high levels of industrial support may be associated with less academic activity without evidence of proportional increases in commercial productivity. (C) 1996, Massachusetts Medical Society.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; UNIV MINNESOTA,COLL EDUC,MINNEAPOLIS,MN 55455	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities	Blumenthal, D (corresponding author), MASSACHUSETTS GEN HOSP,DIV GEN INTERNAL MED,HLTH POLICY RES & DEV UNIT,50 STANIFORD ST,BOSTON,MA 02114, USA.			Seashore, Karen/0000-0003-1070-0273	NHGRI NIH HHS [HG00724-01] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000724, R55HG000724] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Blumenthal D, 1996, NEW ENGL J MED, V334, P368, DOI 10.1056/NEJM199602083340606; BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; BLUMENTHAL D, 1992, JAMA-J AM MED ASSOC, V268, P3344, DOI 10.1001/jama.268.23.3344; COHEN W, 1994, U IND RES RELATIONSH; PINSKI G, 1976, INFORM PROCESS MANAG, V12, P297, DOI 10.1016/0306-4573(76)90048-0; 1994, PETERSONS GUIDE GRAD	6	282	286	6	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1734	1739		10.1056/NEJM199612053352305	http://dx.doi.org/10.1056/NEJM199612053352305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929266				2022-12-28	WOS:A1996VW79500005
J	Sinha, P; Poggio, T				Sinha, P; Poggio, T			Role of learning in three-dimensional form perception	NATURE			English	Article							OBJECT; RECOGNITION; VIEW	ONE Of the most remarkable characteristics of the human visual system is its ability to perceive specific three-dimensional forms in single two dimensional contour images. This has often been attributed to a few general purpose and possibly innately specified shape biases(1,6), such as those favouring symmetry and other structural regularities (Fig, 1). An alternative approach proposed by the early empiricists(7-10) and since tested(11) suggests that this ability may also be acquired from visual experience, with the three-dimensional percept being the manifestation of a learned association between specific two dimensional projections and the correlated three-dimensional structures. These studies of shape learning have been considered inconclusive, however, because their results can potentially be accounted for as cognitive decisions that might have little to do with shape perception per se, Here we present an experimental system that enables objective verification of the role of learning in shape perception by rendering the learning to be perceptually manifest. We show that the human visual system can learn associations between arbitrarily paired two-dimensional pictures and (projectionally consistent) three-dimensional structures. These results implicate high-level recognition processes in the task of shape perception.			Sinha, P (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CTR BIOL & COMPUTAT LEARNING, E25-201, 45 CARLETON ST, CAMBRIDGE, MA 02142 USA.							Ames A., 1951, PSYCHOL MONOGR-GEN A, V65, pi, DOI [10.1037/h0093600, DOI 10.1037/H0093600]; ATTNEAVE F, 1969, PERCEPT PSYCHOPHYS, V6, P391, DOI 10.3758/BF03212797; Beymer D, 1996, SCIENCE, V272, P1905, DOI 10.1126/science.272.5270.1905; BULTHOFF HH, 1992, P NATL ACAD SCI USA, V89, P60, DOI 10.1073/pnas.89.1.60; CAVANAGH P, 1991, REPRESENTATIONS VISI; deCondillac E. B., 1982, PHILOS WRITINGS E BO; FISCHLER MA, 1992, P DARPA IM UND WORKS; GREGORY RL, 1974, PERCEPTIONS HYPOTHES, pCH9; HOCHBERG J, 1953, J EXP PSYCHOL, V46, P361, DOI 10.1037/h0055809; Hume D., 1738, TREATISE HUMAN NATUR; KANADE T, 1981, ARTIF INTELL, V17, P409, DOI 10.1016/0004-3702(81)90031-X; Koffka K, 1935, PRINCIPLES GESTALT P; KOHLER W, 1920, PHYSICAL GESTALTEN; LOCKE J, 1939, ESSAY HUMAN UNDERSTA; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; Marr D., 1982, VISION; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; Morgan MichaelJ., 1977, MOLYNEUXS QUESTION V; POGGIO T, 1990, NATURE, V343, P263, DOI 10.1038/343263a0; ROCK I, 1987, COGNITIVE PSYCHOL, V19, P280, DOI 10.1016/0010-0285(87)90013-2; STRYKER MP, 1991, NATURE, V354, P108, DOI 10.1038/354108d0; TARR MJ, 1991, PSYCHOL SCI, V2, P207, DOI 10.1111/j.1467-9280.1991.tb00135.x; Ullman S., 1979, PROC R SOC SER B-BIO, DOI 10.7551/mitpress/3877.003.0009; VONHELMHOLTZ H, 1909, HELMHOLTZS PHYSL OPT; WALLACH H, 1953, J EXP PSYCHOL, V45, P205, DOI 10.1037/h0056880; WALLACH H, 1953, J EXP PSYCHOL, V45, P360, DOI 10.1037/h0063368	26	92	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					460	463		10.1038/384460a0	http://dx.doi.org/10.1038/384460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945472				2022-12-28	WOS:A1996VW68700062
J	Hardcastle, JD; Chamberlain, JO; Robinson, MHE; Moss, SM; Amar, SS; Balfour, TW; James, PD; Mangham, CM				Hardcastle, JD; Chamberlain, JO; Robinson, MHE; Moss, SM; Amar, SS; Balfour, TW; James, PD; Mangham, CM			Randomised controlled trial of faecal-occult-blood screening for colorectal cancer	LANCET			English	Article							MORTALITY; SURVIVAL; DENMARK; FUNEN; DEATH	Background There is growing evidence that faecal-occult-blood (FOE) screening may reduce colorectal cancer (CRC) mortality, but this reduction in CRC mortality has not been shown in an unselected population-based randomised controlled trial. The aim of this study was to assess the effect of FOE screening on CRC mortality in such a setting. Methods Between February, 1981, and January, 1991, 152 850 people aged 45-74 years who lived in the Nottingham area of the UK were recruited to our study. Participants were randomly allocated FOE screening (76 466) or no screening (controls; 76 384). Controls were not told about the study and received no intervention. Screening-group participants were sent a Haemoccult FOE test kit with instructions from their family doctor. FOE tests were not rehydrated and dietary restrictions were imposed only for retesting borderline results. Individuals with negative FOE tests at the first screening, together with those who tested positive but in whom no neoplasia was found on colonoscopy, were invited to take part in further screening every 2 years. Screening was stopped in February, 1995, by which time screening-group participants had been offered FOE tests between three and six times. Screening-group participants who had a positive test were offered full colonoscopy. All participants were followed up until June, 1995. The primary outcome measure was CRC mortality. Findings Of the 152 850 individuals recruited to the study, 2599 could not be traced or had emigrated and were excluded from the analysis. Thus, there were 75 253 participants in the screening group and 74 998 controls. 44 838 (59.6%) screening-group participants completed at least one screening. 28 720 (38.2%) of these individuals completed all the FOE tests they were offered and 16 118 (21.4%) completed at least one screening but not all the tests they were offered. 30 415 (40.4%) did not complete any test. Of 893 cancers (20% stage A) diagnosed in screening-group participants (CRC incidence of 1.49 per 1000 person-years), 236 (26.4%) were detected by FOE screening, 249 (27.9%) presented after a negative FOE test or investigation, and 400 (44.8%) presented in nonresponders. The incidence of cancer in the control group (856 cases, 11% stage A) was 1.44 per 1000 person-years. Median follow-up was 7.8 years (range 4.5-14.5). 360 people died from CRC in the screening group compared with 420 in the control group-a 15% reduction in cumulative CRC mortality in the screening group (odds ratio=0.85 [95% Cl 0.74-0.98], p=0.026). Interpretation Our findings together with evidence from other trials suggest that consideration should be given to a national programme of FOE screening to reduce CRC mortality in the general population.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT RADIOL,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT HISTOPATHOL,NOTTINGHAM NG7 2UH,ENGLAND; INST CANC RES,CANC SCREENING EVALUAT UNIT,SUTTON,SURREY,ENGLAND	University of Nottingham; University of Nottingham; University of London; Institute of Cancer Research - UK	Hardcastle, JD (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT SURG,NOTTINGHAM NG7 2UH,ENGLAND.							CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; DAY NE, 1985, J EPIDEMIOL COMMUN H, V39, P364, DOI 10.1136/jech.39.4.364; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; GILBERTSEN VA, 1980, CANCER, V45, P2899, DOI 10.1002/1097-0142(19800601)45:11<2899::AID-CNCR2820451132>3.0.CO;2-M; GILL PG, 1978, BRIT J SURG, V65, P17, DOI 10.1002/bjs.1800650105; HARDCASTLE JD, 1980, LANCET, V1, P791; HARDCASTLE JD, 1989, LANCET, V1, P1160; HARDCASTLE JD, 1983, LANCER, V1, P1; *INT CLASS DISS, 1977, MAN INT STAT CLASS D, V1, P699; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; KRONBORG O, 1987, SCAND J GASTROENTERO, V22, P677, DOI 10.3109/00365528709011142; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; MACRAE FA, 1983, GUT, V24, P376, DOI 10.1136/gut.24.5.376; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MOSS S, 1987, INT J EPIDEMIOL, V16, P104, DOI 10.1093/ije/16.1.104; *OFF POP CENS SURV, 1995, MORT STAT CAUS E DH2, V20; Robinson M H, 1995, J Med Screen, V2, P41; Robinson M H, 1993, Eur J Surg Oncol, V19, P539; SAITO H, 1995, INT J CANCER, V61, P465, DOI 10.1002/ijc.2910610406; SELBY JV, 1993, ANN INTERN MED, V118, P1294; STOWER MJ, 1985, EUR J SURG ONCOL, V11, P119; THOMAS WM, 1990, BRIT J SURG, V77, P277, DOI 10.1002/bjs.1800770313; TURNBULL RB, 1967, ANN SURG, V166, P420; *UK TRIAL EARL DET, 1988, LANCET, V2, P411; UMPLEBY HC, 1984, DIS COLON RECTUM, V27, P803, DOI 10.1007/BF02553944; VELLACOTT KD, 1984, J ROY SOC MED, V77, P22; Wahrendorf J, 1993, Eur J Cancer Prev, V2, P221, DOI 10.1097/00008469-199305000-00005; WALKER A, 1991, J EPIDEMIOL COMMUN H, V45, P220, DOI 10.1136/jech.45.3.220	30	2138	2201	0	74	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1472	1477		10.1016/S0140-6736(96)03386-7	http://dx.doi.org/10.1016/S0140-6736(96)03386-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942775				2022-12-28	WOS:A1996VV46300008
J	Lieberman, D; Sleisenger, MH				Lieberman, D; Sleisenger, MH			Is it time to recommend screening for colorectal cancer?	LANCET			English	Editorial Material							MORTALITY		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco	Lieberman, D (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97207, USA.							Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; LIEBERMAN DA, 1995, VA COOPERATIVE S DEC; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Wagner JL, 1996, PREVENTION EARLY DET, P321; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	6	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1463	1464		10.1016/S0140-6736(05)65886-2	http://dx.doi.org/10.1016/S0140-6736(05)65886-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942770				2022-12-28	WOS:A1996VV46300003
J	Sakai, S; Miyauchi, T; Kobayashi, M; Yamaguchi, I; Goto, K; Sugishita, Y				Sakai, S; Miyauchi, T; Kobayashi, M; Yamaguchi, I; Goto, K; Sugishita, Y			Inhibition of myocardial endothelin pathway improves long-term survival in heart failure	NATURE			English	Article							PULMONARY-HYPERTENSION; INFARCTION; RATS; LOCALIZATION; RECEPTOR; POTENT	OCCLUSION Of the diseased coronary artery in humans causes acute myocardial infarction, survivors of which have a high risk for the development of chronic heart failure(1). Cardiac myocytes and vascular endothelial cells produce endothelin-1 (refs 2-4), which increases the contractility of cardiac muscle and of vascular smooth muscle cells(2,3,5). Endothelin-1 also exerts long-term effects such as myocardial hypertrophy, and causes cellular injury in cardiac myocytes(3,5-7). Production of endothelin-l is markedly increased in the myocardium of rats with heart failure, and acute application of an endothelin-receptor antagonist decreases myocardial contractility in such rats, indicating that myocardial endothelin-1 may help to support contractility of the failing heart(8). But we report here that the upregulated myocardial endothelin system may contribute to the progression of chronic heart failure, because long-term treatment with an endothelin-receptor antagonist greatly improved the survival of rats with chronic heart failure, This beneficial effect was accompanied by significant amelioration of left ventricular dysfunction and prevention of ventricular remodelling, in which there is usually an increase in the ventricular mass and cavity enlargement of the ventricle.	UNIV TSUKUBA,INST CLIN MED,DEPT INTERNAL MED,DIV CARDIOVASC,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TSUKUBA,IBARAKI 305,JAPAN; BANYU PHARMACEUT CO LTD,TSUKUBA RES INST,TSUKUBA,IBARAKI 30033,JAPAN	University of Tsukuba; University of Tsukuba; Merck & Company; Novartis								GOTO K, 1995, NATURE, V375, P539, DOI 10.1038/375539a0; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA S, 1995, J THORAC CARDIOV SUR, V110, P271, DOI 10.1016/S0022-5223(05)80036-4; KATZ AM, 1986, CIRCULATION, V73, P184; KOBAYASHI M, 1995, ACTA HISTOCHEM CYTOC, V28, P129, DOI 10.1267/ahc.28.129; KOWSKI W, 1995, LANCET, V346, P732; Melillo G, 1996, CIRCULATION, V93, P1447, DOI 10.1161/01.CIR.93.7.1447; MIYAUCHI T, 1993, CIRC RES, V73, P887, DOI 10.1161/01.RES.73.5.887; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PFEFFER JM, 1995, ANNU REV PHYSIOL, V57, P805, DOI 10.1146/annurev.ph.57.030195.004105; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; PFEFFER MA, 1995, ANNU REV MED, V46, P455, DOI 10.1146/annurev.med.46.1.455; PRASAD MR, 1991, BIOCHEM BIOPH RES CO, V174, P952, DOI 10.1016/0006-291X(91)91511-A; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Sakai S, 1996, CIRCULATION, V93, P1214, DOI 10.1161/01.CIR.93.6.1214; STEWART DJ, 1992, CIRCULATION, V85, P510, DOI 10.1161/01.CIR.85.2.510; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V191, P823, DOI 10.1006/bbrc.1993.1291; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YORIKANE R, 1993, FEBS LETT, V332, P31, DOI 10.1016/0014-5793(93)80476-B; YORIKANE R, 1990, JPN J PHARMACOL, V53, P259, DOI 10.1254/jjp.53.259	22	528	537	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					353	355		10.1038/384353a0	http://dx.doi.org/10.1038/384353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934519				2022-12-28	WOS:A1996VV27100047
J	Wagner, M				Wagner, M			IVF: Out-of-date evidence, or not	LANCET			English	Editorial Material							INTRACYTOPLASMIC SPERM INJECTION											HEDGES A, 1993, FERTIL STERIL, V61, P720; *MED RES INT SOC A, 1989, FERTIL STERIL, V51, P13; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055, DOI 10.1093/oxfordjournals.humrep.a138191	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1394	1394		10.1016/S0140-6736(05)67494-6	http://dx.doi.org/10.1016/S0140-6736(05)67494-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937272				2022-12-28	WOS:A1996VU98600002
J	Tajbakhsh, S; Rocancourt, D; Buckingham, M				Tajbakhsh, S; Rocancourt, D; Buckingham, M			Muscle progenitor cells failing to respond to positional cues adopt non-myogenic fates in myf-5 null mice	NATURE			English	Article							SKELETAL-MUSCLE; REGULATORY GENE; MOUSE; DIFFERENTIATION; INACTIVATION; PROTEIN; EMBRYO; MYOD; LIMB	MICE that have mutations in both myogenic transcription factors Myf-5 and MyoD totally lack skeletal muscle fibres and their precursor myoblasts(1), whereas with either mutation alone, muscle is present(2,3). Skeletal muscle in the vertebrate body is derived from epithelial somites that respond to environmental signals to form the dorsal epithelial dermomyotome (dermis, muscle) and ventral mesenchymal sclerotome (axial skeleton, ribs)(4,5). The first muscle, the myotome, forms centrally in the somite, when only myf-5 is programming myogenesis. By targeting the nlacZ reporter gene into the myf-5 locus, we demonstrate that beta-galactosidase(+) muscle progenitor cells are present in the dermomyotome of myf-5 null embryos, and that they undergo a normal epithelial-mesenchymal transition; however, they migrate aberrantly. Dorsally, they accumulate under the ectoderm and express a non-muscle dermal marker, Dermo-1, Ventrally, beta-galactosidase(+) cells also fail to localize correctly, express a cartilage marker scleraxis, and are subsequently found in ribs, Therefore Myf-5 protein is necessary for cells to respond correctly to positional cues in the embryo and to adopt their myogenic fate, In its absence, muscle progenitors, having activated myf-5, remain multipotent and differentiate into other semitic derivatives according to their local environment.			Tajbakhsh, S (corresponding author), INST PASTEUR,DEPT MOL BIOL,CNRS,URA 1947,UNITE GENET MOL DEV,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							BOBER E, 1994, DEVELOPMENT, V120, P3073; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; COSSU G, 1995, P NATL ACAD SCI USA, V92, P2254, DOI 10.1073/pnas.92.6.2254; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; Grass S, 1996, DEVELOPMENT, V122, P141; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; Hay ED, 1993, CURR OPIN CELL BIOL, V5, P1029, DOI 10.1016/0955-0674(93)90088-8; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; OTT MO, 1991, DEVELOPMENT, V111, P1097; Pownall ME, 1996, DEVELOPMENT, V122, P1475; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; Tajbakhsh S, 1995, DEVELOPMENT, V121, P4077; Tajbakhsh S, 1996, DEV DYNAM, V206, P291, DOI 10.1002/(SICI)1097-0177(199607)206:3<291::AID-AJA6>3.0.CO;2-D; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; TAJBAKHSH S, 1995, TRENDS GENET, V11, P42, DOI 10.1016/S0168-9525(00)88994-5; TOSNEY KW, 1994, DEV BIOL, V163, P389, DOI 10.1006/dbio.1994.1157; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yang XM, 1996, DEVELOPMENT, V122, P2163	27	242	249	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					266	270		10.1038/384266a0	http://dx.doi.org/10.1038/384266a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918877				2022-12-28	WOS:A1996VU38100052
J	Hooper, E; Hamilton, WD				Hooper, E; Hamilton, WD			1959 Manchester case of syndrome resembling AIDS	LANCET			English	Editorial Material							ACQUIRED IMMUNODEFICIENCY; HIV-INFECTION		UNIV OXFORD,DEPT ZOOL,OXFORD OX1 2JD,ENGLAND	University of Oxford								ALDHOUS P, 1991, NATURE, V349, P359; Bailey AS, 1996, LANCET, V347, P189, DOI 10.1016/S0140-6736(96)90371-2; *BUR CENS, 1994, HIV AIDS SURV DAT; CONNOR S, 1995, INDEPENDENT     0324; CORBITT G, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91561-N; GARFIELD S, 1994, END INNOCENCE BRITAI, P10; LAURENCE J, 1992, LANCET, V340, P273, DOI 10.1016/0140-6736(92)92359-N; REZZA G, 1995, BRIT MED J, V311, P785, DOI 10.1136/bmj.311.7008.785; THOMSON JD, 1991, SCIENCE, V254, P1214, DOI 10.1126/science.254.5035.1214; TSUJI K, 1992, P 11 INT HIST WORKSH, V1; WEISS RA, 1991, NATURE, V349, P374, DOI 10.1038/349374b0; WILLIAMS G, 1960, LANCET, V2, P951; ZHU TF, 1995, NATURE, V374, P503, DOI 10.1038/374503a0; 1992, BRIT MED J, V305, P271	14	9	9	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1363	1365		10.1016/S0140-6736(96)07063-8	http://dx.doi.org/10.1016/S0140-6736(96)07063-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT332	8918282				2022-12-28	WOS:A1996VT33200016
J	Julian, DG				Julian, DG			If I woke with central chest pain	LANCET			English	Article							TRIALS; INFARCTION											ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1986, Lancet, V2, P57; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; *BET BLOCK POOL PR, 1988, J HYPERTENS       S4, V9, P8; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; COLLINS R, 1995, LANCET, V345, P669; DEVITA C, 1994, LANCET, V343, P1115; HUNT D, 1992, LANCET, V339, P753; LEIZOROVICZ A, 1988, EUR HEART J, V9, P8; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; PEDERSEN TR, 1994, LANCET, V344, P1383; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71; WALSH JT, 1995, BRIT HEART J, V73, P470; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1993, J HYPERTENS, V11, pS61	16	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV	1996	348			1			S29	S31		10.1016/S0140-6736(96)98010-1	http://dx.doi.org/10.1016/S0140-6736(96)98010-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918527				2022-12-28	WOS:A1996VU00800011
J	Genain, CP; Abel, K; Belmar, N; Villinger, F; Rosenberg, DP; Linington, C; Raine, CS; Hauser, SL				Genain, CP; Abel, K; Belmar, N; Villinger, F; Rosenberg, DP; Linington, C; Raine, CS; Hauser, SL			Late complications of immune deviation therapy in a nonhuman primate	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; T-CELL CLONES; MULTIPLE-SCLEROSIS; OLIGODENDROCYTE GLYCOPROTEIN; DEMYELINATING DISEASES; EXPRESSION; CYTOKINES; INVITRO	The administration of antigens in soluble form can induce antigen-specific immune tolerance and suppress experimental autoimmune diseases, In a marmoset model of multiple sclerosis induced by myelin oligodendrocyte glycoprotein (MOG), marmosets tolerized to MOG were protected against acute disease, but after tolerization treatment a lethal demyelinating disorder emerged. In these animals, MOG-specific T cell proliferative responses were transiently suppressed, cytokine production was shifted from a T helper type 1 (T(H)1) to a T(H)2 pattern, and titers of autoantibodies to MOG were enhanced. Thus, immune deviation can increase concentrations of pathogenic autoantibodies and in some circumstances exacerbate autoimmune disease.	EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; MAX PLANCK INST PSYCHIAT,DEPT NEUROIMMUNOL,D-8033 MARTINSRIED,GERMANY; ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461	Emory University; Max Planck Society; Yeshiva University; Albert Einstein College of Medicine	Genain, CP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.		Hauser, Stephen L/J-2978-2016; Linington, Chris/M-4883-2019	Linington, Christopher/0000-0002-0937-9526	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030727, R01NS008952, P01NS011920, P50NS011920] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30727, NS 08952, NS 11920] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMOR S, 1994, J IMMUNOL, V153, P4349; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COMPSTON DAS, 1989, NEUROPATH APPL NEURO, V15, P307, DOI 10.1111/j.1365-2990.1989.tb01231.x; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; CROSS AH, 1995, J CLIN INVEST, V95, P2783, DOI 10.1172/JCI117982; DALCANTO MC, 1975, J NEUROL SCI, V24, P313, DOI 10.1016/0022-510X(75)90251-8; DEROSBO NK, 1993, J CLIN INVEST, V92, P2602, DOI 10.1172/JCI116875; GARDINIER MV, 1992, J NEUROSCI RES, V33, P177, DOI 10.1002/jnr.490330123; GENAIN CP, 1994, J CLIN INVEST, V94, P1339, DOI 10.1172/JCI117454; Genain CP, 1995, J CLIN INVEST, V96, P2966, DOI 10.1172/JCI118368; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; HILTON AA, 1995, J NEUROCHEM, V65, P309; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KUCHROO VK, 1993, J IMMUNOL, V151, P4371; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MASSACESI L, 1995, ANN NEUROL, V37, P519, DOI 10.1002/ana.410370415; MILLER A, 1993, J NEUROIMMUNOL, V46, P73, DOI 10.1016/0165-5728(93)90235-Q; MILLER SD, 1994, IMMUNOL TODAY, V15, P356, DOI 10.1016/0167-5699(94)90173-2; MONDINO A, 1996, P NATL ACAD SCI USA, V93, P225; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PANITCH HS, 1980, ARCH NEUROL-CHICAGO, V37, P206, DOI 10.1001/archneur.1980.00500530044005; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; PHAMDINH D, 1994, J NEUROCHEM, V63, P2353; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Raine C. S., 1983, MULTIPLE SCLEROSIS P, P413; RAINE CS, 1970, J NEUROPATH EXP NEUR, V29, P177, DOI 10.1097/00005072-197004000-00002; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; ROTT O, 1994, EUR J IMMUNOL, V24, P1434, DOI 10.1002/eji.1830240629; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SIELING PA, 1993, J IMMUNOL, V150, P5501; TAGA K, 1992, J IMMUNOL, V148, P1143; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; WARREN KG, 1994, ANN NEUROL, V35, P280, DOI 10.1002/ana.410350307; XIAO BG, 1991, J NEUROIMMUNOL, V31, P91, DOI 10.1016/0165-5728(91)90014-X	43	294	300	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2054	2057		10.1126/science.274.5295.2054	http://dx.doi.org/10.1126/science.274.5295.2054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953031				2022-12-28	WOS:A1996VY97400041
J	Hikida, M; Mori, M; Takai, T; Tomochika, K; Hamatani, K; Ohmori, H				Hikida, M; Mori, M; Takai, T; Tomochika, K; Hamatani, K; Ohmori, H			Reexpression of RAG-1 and RAG-2 genes in activated mature mouse B cells	SCIENCE			English	Article							V(D)J RECOMBINATION; BONE-MARROW; EXPRESSION; LYMPHOCYTES; MICE; REARRANGEMENT; RESPONSES; ANTIBODY; RECEPTOR; SYSTEM	Recombination activating genes (RAG-1 and RAG-2), involved in V(D)J rearrangement of immunoglobulin genes, have been thought to be expressed only in immature stages of B-cell development. However, RAG-1 and RAG-2 transcripts were found to be reexpressed in mature mouse B cells after culture with interleukin-4 in association with several different co-stimuli. Reexpression was also detected in draining lymph nodes from immunized mice, RAG-1 and RAG-2 proteins could be detected by immunofluorescence microscopy in the nuclei of B cells cultured in vitro and in the germinal centers of draining lymph nodes. These findings suggest that RAG gene products play a heretofore unsuspected role in mature B cells.	OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,OKAYAMA 700,JAPAN; OKAYAMA PREFECTURAL UNIV,FAC HLTH & WELF SCI,SOJA,OKAYAMA 71911,JAPAN; OKAYAMA UNIV,FAC PHARMACEUT SCI,OKAYAMA 700,JAPAN; RADIAT EFFECTS RES FDN,HIROSHIMA 732,JAPAN	Okayama University; Okayama Prefectural University; Okayama University; Radiation Effects Research Foundation - Japan								ABE M, 1991, INT IMMUNOL, V3, P105; CHEN C, 1994, J IMMUNOL, V152, P1970; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; GHIA P, 1995, EUR J IMMUNOL, V25, P3108, DOI 10.1002/eji.1830251118; GOODMAN MG, 1983, J IMMUNOL, V130, P2580; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HARUNA K, 1993, CELL IMMUNOL, V151, P52, DOI 10.1006/cimm.1993.1221; Hikida M, 1996, J IMMUNOL, V156, P2730; HIKIDA M, UNPUB; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OHMORI H, UNPUB; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; VERKOCZY LK, 1995, J IMMUNOL, V154, P5136; WILSON A, 1994, J EXP MED, V179, P1355, DOI 10.1084/jem.179.4.1355; YAMAMOTO A, 1992, CELL BIOCHEM FUNCT, V10, P71, DOI 10.1002/cbf.290100202	30	191	200	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2092	2094		10.1126/science.274.5295.2092	http://dx.doi.org/10.1126/science.274.5295.2092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953042				2022-12-28	WOS:A1996VY97400052
J	Gieseche, J				Gieseche, J			Surveillance of infectious diseases in the European Union	LANCET			English	Editorial Material											Gieseche, J (corresponding author), SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1534	1534		10.1016/S0140-6736(05)66167-3	http://dx.doi.org/10.1016/S0140-6736(05)66167-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950878				2022-12-28	WOS:A1996VX02300006
J	Mittelman, MS; Ferris, SH; Shulman, E; Steinberg, G; Levin, B				Mittelman, MS; Ferris, SH; Shulman, E; Steinberg, G; Levin, B			A family intervention to delay nursing home placement of patients with Alzheimer disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIKELIHOOD ANALYSIS; SPOUSE-CAREGIVERS; DEMENTIA; SUPPORT; INSTITUTIONALIZATION; PROGRAM	Objective.-To determine the long-term effectiveness of comprehensive support and counseling for spouse-caregivers and families in postponing or preventing nursing home placement of patients with Alzheimer disease (AD). Design.-Randomized controlled intervention study. Setting.-Outpatient research clinic in the New York City metropolitan area. Participants.-Referred, volunteer sample of 206 spouse-caregivers of AD patients who enrolled in the study during a 31/2-year period. All patients were living at home at baseline and had at least 1 relative living in the area. Intervention.-Caregivers in the treatment group were provided with 6 sessions of individual and family counseling within 4 months of enrollment in the study and were required to join support groups. In addition, counselors were available for further counseling at any time. Main Outcome Measure.-Time from enrollment of caregivers in the study to placement of the AD patients in a nursing home. Results.-Using Kaplan-Meier survival analysis, we estimated that the median time (weighted average of estimates for male and female caregivers) from baseline to nursing home placement of AD patients was 329 days longer in the treatment group than in the control group (z=2.29; P=.02). The relative risk (RR) from a Cox proportional hazard model of nursing home placement (intent-to-treat estimate) after adjusting for caregiver sex, patient age, and patient income was 0.65 (95% confidence interval [CI], 0.45 to 0.94; P=.02), indicating that caregivers were approximately two thirds as likely to place their spouses in nursing homes at any point in time if they were in the treatment group than if they were in the control group. Treatment had the greatest effect on risk of placement for patients who were mildly demented (RR, 0.18; 95% CI, 0.04 to 0.77) or moderately demented (RR, 0.38; 95% CI, 0.17 to 0.82). Conclusions.-A program of counseling and support can substantially increase the time spouse-caregivers are able to care for AD patients at home, particularly during the early to middle stages of dementia when nursing home placement is generally least appropriate.	COLUMBIA UNIV,SCH PUBL HLTH,GERTRUDE H SERGIEVSKY CTR,DIV BIOSTAT,NEW YORK,NY; NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032	Columbia University; New York State Psychiatry Institute	Mittelman, MS (corresponding author), NYU,MED CTR,AGING & DEMENTIA RES CTR,550 1ST AVE,THN 312C,NEW YORK,NY 10016, USA.			Mittelman, Mary/0000-0002-4074-8537; Ferris, Steven/0000-0001-8641-6223	NIMH NIH HHS [1R01 MH42216] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH042216] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRODATY H, 1993, ARCH NEUROL-CHICAGO, V50, P643, DOI 10.1001/archneur.1993.00540060073021; BRODATY H, 1989, BMJ-BRIT MED J, V299, P1375, DOI 10.1136/bmj.299.6712.1375; COX DR, 1972, J R STAT SOC B, V34, P187; Duke University Center for the Study of Aging and Human Development, 1978, MULT FUNCT ASS OARS; KRAEMER HC, 1994, ARCH NEUROL-CHICAGO, V51, P275, DOI 10.1001/archneur.1994.00540150069019; LAWTON MP, 1989, GERONTOLOGIST, V29, P8, DOI 10.1093/geront/29.1.8; LEVIN B, 1990, BIOMETRIKA, V77, P275, DOI 10.1093/biomet/77.2.275; LEVIN B, 1987, COMMUN STAT SIMULAT, V16, P699, DOI 10.1080/03610918708812614; MITTELMAN MS, 1995, GERONTOLOGIST, V35, P792, DOI 10.1093/geront/35.6.792; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; MITTELMAN MS, 1995, ALZHEIMERS DIS; MOHIDE EA, 1990, J AM GERIATR SOC, V38, P446, DOI 10.1111/j.1532-5415.1990.tb03544.x; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; STOKES JP, 1983, AM J COMMUN PSYCHOL, V11, P141, DOI 10.1007/BF00894363; YESAVAGE JA, 1983, ASSESSMENT GERIATRIC, P153; Zarit S.H, 1985, FAMILIES STRESS CARI; [No title captured]	17	596	598	0	47	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1725	1731		10.1001/jama.276.21.1725	http://dx.doi.org/10.1001/jama.276.21.1725			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV566	8940320				2022-12-28	WOS:A1996VV56600029
J	Mitchell, EA				Mitchell, EA			Co-sleeping and sudden infant death syndrome	LANCET			English	Editorial Material							SMOKING				Mitchell, EA (corresponding author), UNIV AUCKLAND,DEPT PAEDIAT,AUCKLAND,NEW ZEALAND.							Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; LEWIS KW, 1995, J PEDIATR-US, V127, P691, DOI 10.1016/S0022-3476(95)70155-9; MCKENNA JJ, 1993, SLEEP, V16, P263, DOI 10.1093/sleep/16.3.263; MCKENNA JJ, IN PRESS PEDIATRICS; Mitchell E. A., 1995, P266; MITCHELL EA, 1994, NEW ZEAL MED J, V107, P466; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; TUFFNELL CS, 1966, ARCH DIS CHILD, V75, P249	10	11	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1466	1466		10.1016/S0140-6736(05)65889-8	http://dx.doi.org/10.1016/S0140-6736(05)65889-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942773				2022-12-28	WOS:A1996VV46300006
J	Li, P; McLeod, M				Li, P; McLeod, M			Molecular mimicry in development: Identification of ste11(+) as a substrate and mei3(+) as a pseudosubstrate inhibitor of ran1(+) kinase	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; PREMEIOTIC DNA-SYNTHESIS; MATING-TYPE GENES; FISSION YEAST; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATOR; G(1) ARREST; MEIOSIS; SPORULATION; MUTANTS	ran1(+) (pat1(+)) kinase inhibits exit from the mitotic cell cycle and entry into meiosis. Inactivation of ran1(+) by mei3(+) is sufficient to precipitate the entire meiotic developmental program. Here, we show that the ste11(+) transcription factor is a substrate for ran1(+) in vitro and that this reaction is directly inhibited by mei3(+). Sequence comparison reveals that ste11(+) contains two domains homologous to each other and to a domain of mei3(+). Mutagenesis studies reveal that the regions of homology contain substrate specificity determinants. These results identify sequences critical for phosphorylation of ste11(+) by ran1(+) and suggest that mei3(+) employs a pseudosubstrate mechanism for its inhibitory function.			Li, P (corresponding author), SUNY HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL, MORSE INST MOL BIOL & GENET, BROOKLYN, NY 11203 USA.							Alfa C., 1993, EXPT FISSION YEAST; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DAVEY J, 1994, CURR GENET, V26, P105, DOI 10.1007/BF00313796; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; EGEL R, 1973, MOL GEN GENET, V121, P277, DOI 10.1007/BF00267055; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Hardie G., 1995, PROTEIN KINASE FACTS; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; IMAI Y, 1994, GENE DEV, V8, P328, DOI 10.1101/gad.8.3.328; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; NIELSEN O, 1990, EMBO J, V9, P1401, DOI 10.1002/j.1460-2075.1990.tb08255.x; Nielsen Olaf, 1993, Trends in Cell Biology, V3, P60, DOI 10.1016/0962-8924(93)90162-T; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; RUSSELL RP, 1993, NATURE, V301, P167; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SIPICZKI M, 1988, MOL GEN GENET, V14, P4712; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WILLER M, 1995, MOL CELL BIOL, V15, P4964; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	35	69	71	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					869	880		10.1016/S0092-8674(00)81994-7	http://dx.doi.org/10.1016/S0092-8674(00)81994-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945514	Bronze			2022-12-28	WOS:A1996VV77400013
J	MaloneLee, J				MaloneLee, J			Is detrusor instability and hypertrophy a smooth-muscle disease of the lower urinary tract?	LANCET			English	Editorial Material											MaloneLee, J (corresponding author), UCL HOSP, GERIATR MED CTR, LONDON NW1 0PE, ENGLAND.							BRADING AF, 1994, BRIT J UROL, V73, P3, DOI 10.1111/j.1464-410X.1994.tb07447.x; ELBADAWI A, 1993, J UROLOGY, V150, P1650, DOI 10.1016/S0022-5347(17)35866-4; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; Khullar V, 1996, BRIT J OBSTET GYNAEC, V103, P904, DOI 10.1111/j.1471-0528.1996.tb09910.x; LIER PK, 1993, NEUROUROL URODYNAM, V12, P308; VANDOORN ESCV, 1995, CURR OPIN OBSTET GYN, V7, P378; Wagg A. S., 1996, Neurourology and Urodynamics, V15, P279	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1395	1395		10.1016/S0140-6736(05)67496-X	http://dx.doi.org/10.1016/S0140-6736(05)67496-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937274				2022-12-28	WOS:A1996VU98600004
J	Goldberg, L; Elliot, D; Clarke, GN; MacKinnon, DP; Moe, E; Zoref, L; Green, C; Wolf, SL; Greffrath, E; Miller, DJ; Lapin, A				Goldberg, L; Elliot, D; Clarke, GN; MacKinnon, DP; Moe, E; Zoref, L; Green, C; Wolf, SL; Greffrath, E; Miller, DJ; Lapin, A			Effects of a multidimensional anabolic steroid prevention intervention - The adolescents training and learning to avoid steroids (ATLAS) program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE PREVENTION; DRUG-ABUSE; EDUCATION; PREVALENCE; EFFICACY; TOBACCO; ISSUES	Objective.-To test a team-based, educational intervention designed to reduce adolescent athletes' intent to use anabolic androgenic steroids (AAS). Design.-Randomized prospective trial. Setting.-Thirty-one high school football teams in the Portland, Ore, area. Participants.-Seven hundred two adolescent football players at experimental schools; 804 players at control schools. Intervention.-Seven weekly, 50-minute class sessions were delivered by coaches and student team leaders, addressing AAS effects, sports nutrition and strength-training alternatives to AAS use, drug refusal role play, and anti-AAS media messages. Seven weight-room sessions were taught by research staff. Parents received written information and were invited to a discussion session. Main Outcome Measures.-Questionnaires before and after intervention and at 9- or 12-month follow-up, assessing AAS use risk factors, knowledge and attitudes concerning AAS, sports nutrition and exercise knowledge and behaviors, and intentions to use AAS. Results.-Compared with controls, experimental subjects at the long-term follow-up had increased understanding of AAS effects, greater belief in personal vulnerability to the adverse consequences of AAS, improved drug refusal skills, less belief in AAS-promoting media messages, increased belief in the team as an information source, improved perception of athletic abilities and strength-training self-efficacy, improved nutrition and exercise behaviors, and reduced intentions to use AAS. Many other beneficial program effects remained significant at the long-term follow-up. Conclusions.-This AAS prevention program enhanced healthy behaviors, reduced factors that encourage AAS use, and lowered intent to use AAS. These changes were sustained over the period of 1 year. Team-based interventions appear to be an effective approach to improve adolescent behaviors and reduce drug use risk factors.	KAISER PERMANENTE CTR HLTH RES, PORTLAND, OR USA; ARIZONA STATE UNIV, DEPT PSYCHOL, TEMPE, AZ 85287 USA	Kaiser Permanente; Arizona State University; Arizona State University-Tempe	Goldberg, L (corresponding author), OREGON HLTH SCI UNIV, DEPT MED, 3181 SW SAM JACKSON PK RD, CB 615, PORTLAND, OR 97201 USA.		Wolf, Steve/F-6588-2010; MacKinnon, David P./D-8727-2013	Wolf, Steve/0000-0002-9446-8995; Moe, Esther/0000-0002-9491-9741; MacKinnon, David/0000-0003-0866-6010	NIDA NIH HHS [DA-07356] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007356] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMBRE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2923; [Anonymous], 1987, MED SCI SPORT EXER, V19, P534; ARY DV, 1990, J BEHAV MED, V13, P281, DOI 10.1007/BF00846835; BANGERTDROWNS RL, 1988, J DRUG EDUC, V18, P243, DOI 10.2190/8U40-WP3D-FFWC-YF1U; Beckett A H, 1978, Br J Sports Med, V12, P185; BENTS R, 1990, Medicine and Science in Sports and Exercise, V22, pS64, DOI 10.1249/00005768-199004000-00382; BIERLY JR, 1987, POSTGRAD MED, V82, P67, DOI 10.1080/00325481.1987.11699949; BOTVIN GJ, 1992, J DEV BEHAV PEDIATR, V13, P290; BOTVIN GJ, 1983, J BEHAV MED, V6, P359, DOI 10.1007/BF00846324; BOTVIN GJ, 1986, J SCHOOL HEALTH, V56, P369, DOI 10.1111/j.1746-1561.1986.tb05775.x; BOTVIN GJ, 1992, PSYCHOL REP, V70, P171, DOI 10.2466/PR0.70.1.171-178; BUCKLEY WE, 1988, JAMA-J AM MED ASSOC, V260, P3441; BULL NL, 1992, J ADOLESCENT HEALTH, V13, P384, DOI 10.1016/1054-139X(92)90034-9; *CHANN L BET CO, 1994, STER; CLEARY B, 1992, MED SCI SPORTS EXERC, V24, P545; *COMM SPORTS MED, 1989, PEDIATRICS, V83, P127; COSTILL DL, 1984, PHYSICIAN SPORTSMED, V266, P112; COWART VS, 1990, JAMA-J AM MED ASSOC, V264, P1641, DOI 10.1001/jama.264.13.1641; DeVellis R. F., 2016, SCALE DEV THEORY APP, V4th; DURANT RH, 1995, PEDIATRICS, V96, P23; FINIGAN M, 1995, 1994 OREGON PUBLIC S; FUENTES RJ, 1995, ATHLETIC DRUG REFERE; Gaa Gregory L., 1994, Journal of Athletic Training, V29, P216; GLAZER G, 1991, ARCH INTERN MED, V151, P1925, DOI 10.1001/archinte.151.10.1925; GOLDBERG L, 1991, PEDIATRICS, V87, P283; GOLDBERG L, 1990, J ADOLESCENT HEALTH, V11, P210, DOI 10.1016/0197-0070(90)90350-B; Goldberg L, 1996, ARCH PEDIAT ADOL MED, V150, P713, DOI 10.1001/archpedi.1996.02170320059010; GOLDBERG L, 1996, CHILDREN ADOLESCENTS, P103; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; HENDEE WR, 1988, JAMA-J AM MED ASSOC, V259, P1703; HOPKINS KD, 1982, AM EDUC RES J, V19, P5, DOI 10.2307/1162366; HUIE MJ, 1994, MED SCI SPORT EXER, V26, P408; JOHNSON MD, 1989, PEDIATRICS, V83, P921; JOHNSTON LD, 1987, J ADOLESCENT HEALTH, V8, P36, DOI 10.1016/0197-0070(87)90245-2; Johnston LD, 1995, NATL SURVEY RESULTS; KLEPP KI, 1986, J SCHOOL HEALTH, V56, P407, DOI 10.1111/j.1746-1561.1986.tb05783.x; MELCHERT RB, 1995, MED SCI SPORT EXER, V27, P1252; POPE HG, 1988, AM J PSYCHIAT, V145, P487; RESNICOW K, 1993, PREV MED, V22, P484, DOI 10.1006/pmed.1993.1039; SCOTT MJ, 1989, JAMA-J AM MED ASSOC, V262, P207, DOI 10.1001/jama.1989.03430020049017; Smith G M, 1980, NIDA Res Monogr, V30, P50; THOMPSON H, 1991, Medicine and Science in Sports and Exercise, V23, pS18; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; *US DEP HHS, 1991, PUBL US DEPT HLTH HU; WEINSTEIN ND, 1987, J BEHAV MED, V10, P481, DOI 10.1007/BF00846146; WILSON JD, 1980, METABOLISM, V29, P1278, DOI 10.1016/0026-0495(80)90159-6; YESALIS CE, 1995, SPORTS MED, V19, P326, DOI 10.2165/00007256-199519050-00003	47	152	152	1	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1555	1562		10.1001/jama.276.19.1555	http://dx.doi.org/10.1001/jama.276.19.1555			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT025	8918852				2022-12-28	WOS:A1996VT02500027
J	Ericson, J; Morton, S; Kawakami, A; Roelink, H; Jessell, TM				Ericson, J; Morton, S; Kawakami, A; Roelink, H; Jessell, TM			Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identify	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; MIDBRAIN DOPAMINERGIC-NEURONS; FLOOR PLATE DIFFERENTIATION; TERMINAL CLEAVAGE PRODUCT; CELL PATTERN; POLARIZING ACTIVITY; FROG EMBRYOS; SPINAL-CORD; INDUCTION; EXPRESSION	Antibodies that block Sonic Hedgehog (SHH) signaling have been used to show that SHH activity is required for the induction of floor plate differentiation by the notochord and independently for the induction of motor neurons by both the notochord and midline neural eels. Motor neuron generation depends on two critical periods of SHH signaling: an early period during which naive neural plate cells are converted into ventralized progenitors and a late period that extends well into S phase of the final progenitor cell division, during which SHH drives the differentiation of ventralized progenitors into motor neurons. The ambient SHH concentration during the late period determines whether ventralized progenitors differentiate into motor neurons or interneurons, thus defining the pattern of neuronal cell types generated in the neural tube.	NAGOYA UNIV, DIV BIOL SCI, NAGOYA, AICHI, JAPAN; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA	Nagoya University; University of Washington; University of Washington Seattle	Ericson, J (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA.		Kawakami, Atsushi/D-3785-2019	Kawakami, Atsushi/0000-0001-9461-6372; Ericson, Johan/0000-0002-8019-7127; Roelink, Henk/0000-0002-5260-3634				ALTABA AR, 1995, DEV BIOL, V170, P299; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JESSELL TM, 1992, HARVEY LECT, V86, P87; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEBER SM, 1990, J NEUROSCI, V10, P2451; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1995, CURR OPIN GENET DEV, V5, P499, DOI 10.1016/0959-437X(95)90055-L; PLACZEK M, 1991, DEVELOPMENT, P105; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	735	766	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					661	673		10.1016/S0092-8674(00)81386-0	http://dx.doi.org/10.1016/S0092-8674(00)81386-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929535	hybrid			2022-12-28	WOS:A1996VU03500009
J	Kuzin, B; Roberts, I; Peunova, N; Enikolopov, G				Kuzin, B; Roberts, I; Peunova, N; Enikolopov, G			Nitric oxide regulates cell proliferation during Drosophila development	CELL			English	Article							NEURONAL NADPH DIAPHORASE; RIBONUCLEOTIDE REDUCTASE; NERVOUS-SYSTEM; SYNTHASE; EXPRESSION; PROTEIN; GROWTH; DEATH; TRANSIENT; CYCLE	Cell division and subsequent programmed cell death in imaginal discs of Drosophila larvae determine the final size of organs and structures of the adult fly. We show here that nitric oxide (NO) is involved in controlling the size of body structures during Drosophila development. We have found that NO synthase (NOS) is expressed at high levels in developing imaginal discs. Inhibition of NOS in larvae causes hypertrophy of organs and their segments in adult flies, whereas ectopic expression of NOS in larvae has the opposite effect. Blocking apoptosis in eye imaginal discs unmasks surplus cell proliferation and results in an increase in the number of ommatidia and component cells of individual ommatidia. These results argue that NO acts as an antiproliferative agent during Drosophila development, controlling the balance between cell proliferation and cell differentiation.	UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE, ENGLAND; RUSSIAN ACAD SCI, NK KOLTSOV DEV BIOL INST, MOSCOW 117808, RUSSIA	University of Cambridge; Russian Academy of Sciences	Kuzin, B (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917; Kuzin, Boris/0000-0001-9951-1553				BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BLOTTNER D, 1995, HISTOCHEM J, V27, P785; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; BRYANT PJ, 1990, J CELL SCI, P169; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; Cohen Stephen M., 1993, P747; COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305; CRAMER KS, 1995, J COMP NEUROL, V353, P306, DOI 10.1002/cne.903530211; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DECKER KF, 1995, J GASTROEN HEPATOL, V10, pS12, DOI 10.1111/j.1440-1746.1995.tb01789.x; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; Forstermann U, 1995, Adv Pharmacol, V34, P171; Fristrom D, 1993, DEV DROSOPHILA MELAN, P843; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HORTELANO S, 1995, HEPATOLOGY, V21, P776; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER U, 1994, EUR J NEUROSCI, V6, P1362, DOI 10.1111/j.1460-9568.1994.tb00327.x; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; ROSKAMS AJ, 1994, NEURON, V13, P289; SCHUBIGER M, 1987, DEV BIOL, V123, P145, DOI 10.1016/0012-1606(87)90436-2; Shaul P W, 1995, Adv Pediatr, V42, P367; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRADLING AC, 1986, DROSOPHILA PRACTICAL, P60; Thummel CS, 1992, DROS INF SERV, V71, P150; Wang Y, 1995, Adv Pharmacol, V34, P71; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WETTS R, 1995, DEV DYNAM, V202, P215, DOI 10.1002/aja.1002020302; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277	51	220	229	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 15	1996	87	4					639	649		10.1016/S0092-8674(00)81384-7	http://dx.doi.org/10.1016/S0092-8674(00)81384-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929533	Bronze			2022-12-28	WOS:A1996VU03500007
J	Ross, JDC; Sutherland, S; Coia, J				Ross, JDC; Sutherland, S; Coia, J			Genital Chlamydia trachomatis infections in primary care	BRITISH MEDICAL JOURNAL			English	Article									UNIV EDINBURGH,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Coia, John/AAP-5379-2020	Coia, John/0000-0002-4966-8453; Ross, Jonathan/0000-0002-4193-6919				MARDH PA, 1977, NEW ENGL J MED, V296, P1377, DOI 10.1056/NEJM197706162962403; REES E, 1980, AM J OBSTET GYNECOL, V138, P1042, DOI 10.1016/0002-9378(80)91105-9; WHITE D, 1991, BR J GEN PRACT, V41, P234	3	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1192	1193		10.1136/bmj.313.7066.1192a	http://dx.doi.org/10.1136/bmj.313.7066.1192a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916755	Green Published			2022-12-28	WOS:A1996VR90700028
J	Pasvol, G				Pasvol, G			Malaria and resistance genes - They work in wondrous ways	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM; ALPHA-THALASSEMIA; RED-CELLS; SUSCEPTIBILITY; ERYTHROCYTES				Pasvol, G (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,DEPT INFECT & TROP MED,HARROW HA1 3UJ,MIDDX,ENGLAND.							[Anonymous], 1995, EVOLUTION HEALING NE; CARLSON J, 1994, BLOOD, V84, P3909, DOI 10.1182/blood.V84.11.3909.bloodjournal84113909; FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0; HALDANE JBS, 1949, 8TH P INT C GEN, P267; HILL AV, 1994, BIOCHEM SOC T, P282; LUZZI GA, 1990, BRIT J HAEMATOL, V74, P519, DOI 10.1111/j.1365-2141.1990.tb06344.x; LUZZI GA, 1991, J EXP MED, V173, P785, DOI 10.1084/jem.173.4.785; NAGEL RL, 1990, BLOOD CELLS, V16, P321; PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0; PASVOL G, 1978, NATURE, V274, P701, DOI 10.1038/274701a0; PASVOL G, 1980, BRIT J HAEMATOL, V45, P285, DOI 10.1111/j.1365-2141.1980.tb07148.x; Williams TN, 1996, NATURE, V383, P522, DOI 10.1038/383522a0	12	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1532	1534		10.1016/S0140-6736(05)66166-1	http://dx.doi.org/10.1016/S0140-6736(05)66166-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950877				2022-12-28	WOS:A1996VX02300005
J	Peer, G; Kivity, S; Agami, O; Fireman, E; Silverberg, D; Blum, M; Iaina, A				Peer, G; Kivity, S; Agami, O; Fireman, E; Silverberg, D; Blum, M; Iaina, A			Randomised crossover trial of naltrexone in uraemic pruritus	LANCET			English	Article							PROPHYLACTIC ORAL NALTREXONE; UREMIC PRURITUS; BETA-ENDORPHIN; INTRATHECAL MORPHINE; NALOXONE INFUSIONS; EPIDURAL MORPHINE; HISTAMINE-RELEASE; ADVERSE REACTIONS; CHOLESTASIS; PLASMA	Background Most dialysis patients develop pruritus, for which current treatment is unsatisfactory. Endogenous opioids may be involved in this pruritus. We studied the effect of the opioid antagonist naltrexone on the pruritus of haemodialysis patients. Methods Naltrexone 50 mg per day by mouth was given to 15 haemodialysis patients with severe resistant pruritus in a randomised, double-blind, placebo-controlled crossover trial. The naltrexone or placebo periods lasted 7 days each with a 7-day washout between the two periods. Pruritus was assessed by the patients on a visual analogue scale from 0 (no pruritus) to 10 (maximum), and mean daily scores were calculated. Plasma histamine and beta-endorphin levels were measured, and spontaneous and stimulated basophil histamine-release were determined. Findings The median pruritus scores at the end of the naltrexone treatment were 2.1 (interquartile range 1.5-2.15) for the naltrexone-placebo sequence and 1.0 (0.4-1.15) for the placebo-naltrexone sequence. The respective values before naltrexone was given were 9.9 (9.85-9.95) and 9.9 (9.3-10.0). Plasma beta-endorphin levels were normal and remained unchanged during the study. Plasma histamine levels were high (mean 2.32 [SD 0.11] ng/mL, normal <1.0) and decreased after naltrexone (to 1.8 [0.09], p<0.01). Basophils from haemodialysis patients stimulated by interleukin-3 plus IgE antibodies released high amounts of histamine. The increase was 78.3 (19.3)% compared with 26.6 (16.3)% for five normal controls (p<0.01). Incubation of the basophils with naloxone, another opioid antagonist, prevented this effect. Interpretation Our data suggest short-term efficacy with few side-effects for the amelioration of uraemic pruritus with naltrexone.	TEL AVIV MED CTR & SCH MED,ICHILOV HOSP,DEPT NEPHROL,IL-64239 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine								ABBOUD TK, 1990, ANESTH ANALG, V71, P367; ABBOUD TK, 1990, ANESTHESIOLOGY, V72, P233, DOI 10.1097/00000542-199002000-00004; ANDERSEN LW, 1984, CLIN NEPHROL, V21, P355; ARONIN N, 1983, CLIN ENDOCRINOL, V18, P459, DOI 10.1111/j.1365-2265.1983.tb02875.x; BALASKAS EV, 1992, DIALYSIS TRANSPLANT, V21, P192; BALASKAS EV, 1992, DIALYSIS TRANSPLANT, V21, P278; BARKE KE, 1993, LIFE SCI, V53, P1391, DOI 10.1016/0024-3205(93)90581-M; BERGASA NV, 1992, GASTROENTEROLOGY, V102, P544, DOI 10.1016/0016-5085(92)90102-5; BERGASA NV, 1995, ANN INTERN MED, V123, P161, DOI 10.7326/0003-4819-123-3-199508010-00001; BORGEAT A, 1992, ANESTHESIOLOGY, V76, P510, DOI 10.1097/00000542-199204000-00004; Carson KL, 1996, AM J GASTROENTEROL, V91, P1022; CIARDELLA F, 1989, NEPHRON, V53, P129, DOI 10.1159/000185724; COHEN SE, 1992, ANESTH ANALG, V75, P747; DEMARCHI S, 1992, NEW ENGL J MED, V326, P969; ELIAS AN, 1986, NEPHRON, V43, P173, DOI 10.1159/000183825; GREAVES MW, 1992, NEW ENGL J MED, V326, P1016, DOI 10.1056/NEJM199204093261509; JONES EA, 1992, JAMA-J AM MED ASSOC, V268, P3359, DOI 10.1001/jama.268.23.3359; KAYSER V, 1994, PHARM ASPECTS PERIPH, P137; KIVITY S, 1994, IMMUNOL LETT, V42, P1, DOI 10.1016/0165-2478(94)90026-4; KOENIGSTEIN H, 1948, ARCH DERMATOL SYPH, V57, P828, DOI 10.1001/archderm.1948.01520180045006; Ponticelli C, 1995, NEPHROL DIAL TRANSPL, V10, P2174, DOI 10.1093/ndt/10.12.2174; PONTICELLI C, 1992, NEPHRON, V60, P1, DOI 10.1159/000186696; SCOTT PV, 1982, BRIT MED J, V284, P1015, DOI 10.1136/bmj.284.6321.1015; STAHLEBACKDAHL M, 1988, ACTA MED SCAND, V224, P55; STEIN C, 1995, NEW ENGL J MED, V332, P1695; SWAIN MG, 1992, GASTROENTEROLOGY, V103, P630, DOI 10.1016/0016-5085(92)90857-U; THOMAS DA, 1993, ANESTHESIOLOGY, V79, P548, DOI 10.1097/00000542-199309000-00019; TOREBJOR.HE, 1974, ACTA PHYSIOL SCAND, V92, P374, DOI 10.1111/j.1748-1716.1974.tb05755.x	28	217	231	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1552	1554		10.1016/S0140-6736(96)04176-1	http://dx.doi.org/10.1016/S0140-6736(96)04176-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950882				2022-12-28	WOS:A1996VX02300010
J	Krapp, HG; Hengstenberg, R				Krapp, HG; Hengstenberg, R			Estimation of self-motion by optic flow processing in single visual interneurons	NATURE			English	Article							BLOWFLY CALLIPHORA-ERYTHROCEPHALA; GIANT VERTICAL CELLS; LOBULA PLATE; DROSOPHILA; DIRECTION; BEHAVIOR; NEURONS; FIELD	HUMANS, animals and some mobile robots use visual motion cues for object detection and navigation in structured surroundings(1-4). Motion is commonly sensed by large arrays of small field movement detectors, each preferring motion in a particular direction(5,6), Self-motion generates distinct 'optic flow fields' in the eyes that depend on the type and direction of the momentary locomotion (rotation, translation)(7). To investigate how the optic flow is processed at the neuronal level, we recorded intracellularly from identified interneurons in the third visual neuropile of the blowfly(8). The distribution of local motion tuning over their huge receptive fields was mapped in detail. The global structure of the resulting 'motion response fields' is remarkably similar to optic flow fields. Thus, the organization of the receptive fields of the so-called VS neurons(9,10) strongly suggests that each of these neurons specifically extracts the rotatory component of the optic flow around a particular horizontal axis. Other neurons are probably adapted to extract translatory flow components. This study shows how complex visual discrimination can be achieved by task-oriented preprocessing in single neurons.	MAX PLANCK INST BIOL CYBERNET, D-72076 TUBINGEN, GERMANY	Max Planck Society								BORST A, 1992, P NATL ACAD SCI USA, V89, P4139, DOI 10.1073/pnas.89.9.4139; BORST A, 1993, VISUAL MOTION ITS RO, P3; COLLETT T, 1993, VISUAL MOTION ITS RO, P239; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; EGELHAAF M, 1989, J OPT SOC AM A, V6, P1070, DOI 10.1364/JOSAA.6.001070; FRANCESCHINI N, 1992, PHILOS T R SOC B, V337, P283, DOI 10.1098/rstb.1992.0106; GEIGER G, 1981, NATURE, V293, P398, DOI 10.1038/293398a0; Gibson JJ, 1950, PERCEPTION VISUAL WO; GOTZ KG, 1979, BIOL CYBERN, V35, P101, DOI 10.1007/BF00337435; HAUSEN K, 1983, PROC R SOC SER B-BIO, V219, P211, DOI 10.1098/rspb.1983.0068; HAUSEN K, 1993, VISUAL MOTION ITS RO, P203; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P179, DOI 10.1007/BF00619212; Hengstenberg R., 1991, Seminars in the Neurosciences, V3, P19, DOI 10.1016/1044-5765(91)90063-T; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P163, DOI 10.1007/BF00619211; Hengstenberg R., 1983, Springer Series in Experimental Entomology, V1983, P183; HENGSTENBERG R, 1995, P 4 INT C NEUR, P255; KOENDERINK JJ, 1987, BIOL CYBERN, V56, P247, DOI 10.1007/BF00365219; KRAPP H, 1995, P 4 INT C NEUR, P264; KRAPP HG, IN PRESS VISION RES; KRAPP HG, 1995, THESIS U TUBINGEN; MORRONE MC, 1995, NATURE, V376, P507, DOI 10.1038/376507a0; NAKAYAMA K, 1985, VISION RES, V25, P625, DOI 10.1016/0042-6989(85)90171-3; NAKAYAMA K, 1974, PERCEPTION, V3, P63, DOI 10.1068/p030063; PFLUGFELDER GO, 1995, COMP BIOCHEM PHYS A, V110, P185, DOI 10.1016/0300-9629(94)00159-Q; REICHARDT W, 1987, J COMP PHYSIOL A, V161, P533, DOI 10.1007/BF00603660; SRINIVASAN MV, 1993, BIOL CYBERN, V68, P1299; Strausfeld N.J., 1983, Springer Series in Experimental Entomology, V1983, P132; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0; Wehner R, 1981, COMP PHYS EVOLUTION, VVII/ 6C, P287, DOI DOI 10.1007/978-3642-67868-4	30	270	270	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					463	466		10.1038/384463a0	http://dx.doi.org/10.1038/384463a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945473				2022-12-28	WOS:A1996VW68700063
J	Dannenberg, AL; McNeil, JG; Brundage, JF; Brockmeyer, R				Dannenberg, AL; McNeil, JG; Brundage, JF; Brockmeyer, R			Suicide and HIV infection - Mortality follow-up of 4147 HIV-seropositive military service applicants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NATIONAL-DEATH-INDEX; SCREENING-PROGRAM; AIDS; RISK; CERTIFICATES; IMPACT	Objective.-To examine the risk of suicide among individuals positive for the human immunodeficiency virus (HIV) following screening for evidence of HIV infection. Prior studies have reported a 7- to 36-fold increased risk of suicide for persons with the acquired immunodeficiency syndrome. Design.-Prospective cohort study. Setting.-Military service applicants from throughout the United States. Main Outcome Measure.-Death from suicide. Methods.-The National Death Index was searched for mortality among 4147 HIV-positive military service applicants and 12437 HIV-negative applicants disqualified from military service due to other medical conditions (matched 1:3 on age, race, sex, and screening date and location) identified by the US Department of Defense between October 1985 and December 1993. Death certificates were obtained from individual states. Identifiers and HIV status of living applicants were known only by the Department of Defense. Results.-The HIV-positive applicants were 92% male, 37% white, and 56% black. Median age was 24 years (range, 17-57 years). Median follow-up time was 70 months (range, 0-99 months). Ten HIV-positive (49 per 100 000 person-years) and 24 HIV-negative applicants (36 per 100 000 person-years) died of suicide (rate ratio [RR], 1.35; 95% confidence interval [CI]= 0.58-2.93). Suicide rates among both HIV-positive (RR, 2.08; 95% CI, 1.00-3.82) and HIV-negative (RR, 1.67; 95% CI, 1.07-2.48) applicants are marginally higher than those for the US general population, after adjustment for age, race, and sex. Time from screening to death was less than 3 months for 3 of 10 HIV-positive and 2 of 24 HIV-negative applicants who died of suicide. Conclusions.-The HIV-positive individuals do not appear to have a significantly increased risk of death from suicide in the months following HIV screening in this study population. Because suicide risk is reported to be greatly increased after symptomatic HIV disease is present, clinicians should consider asking persons with HIV infection about suicide risk factors during both initial counseling and subsequent medical care.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR INJURY RES & POLICY,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD; WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV PREVENT MED,WASHINGTON,DC 20307; HENRY M JACKSON FDN ADVANCEMENT MIL MED,ROCKVILLE,MD	Johns Hopkins University; Johns Hopkins University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc			Brundage, John/Q-9244-2019		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047756] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH47756] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALFONSO CA, 1994, PSYCHOSOMATICS, V35, P368, DOI 10.1016/S0033-3182(94)71758-8; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; BURKE DS, 1987, NEW ENGL J MED, V317, P131, DOI 10.1056/NEJM198707163170302; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P677; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P779; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P773; CHU SY, 1993, AM J PUBLIC HEALTH, V83, P1429, DOI 10.2105/AJPH.83.10.1429; COPELAND AR, 1993, MED SCI LAW, V33, P21, DOI 10.1177/002580249303300105; COTE TR, 1992, JAMA-J AM MED ASSOC, V268, P2066, DOI 10.1001/jama.268.15.2066; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; FARBEROW NL, 1977, PUBLIC HEALTH REP, V92, P223; FLAVIN D K, 1987, Advances in Alcohol and Substance Abuse, V6, P23; FRIERSON RL, 1988, PSYCHOSOMATICS, V29, P226, DOI 10.1016/S0033-3182(88)72403-2; GALA C, 1992, ACTA PSYCHIAT SCAND, V86, P70, DOI 10.1111/j.1600-0447.1992.tb03229.x; GLASS RM, 1988, JAMA-J AM MED ASSOC, V259, P1369, DOI 10.1001/jama.259.9.1369; HARDY AM, 1987, PUBLIC HEALTH REP, V102, P386; HELMKAMP JC, 1995, MIL MED, V160, P45, DOI 10.1093/milmed/160.2.45; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; KIZER KW, 1988, JAMA-J AM MED ASSOC, V260, P1881, DOI 10.1001/jama.1988.03410130075021; KOCHANEK KD, 1995, MON VITL STAT REP S, V43; LYKETSOS CG, 1995, EPIDEMIOL REV, V17, P152, DOI 10.1093/oxfordjournals.epirev.a036171; MACMAHON B, 1983, AM J PUBLIC HEALTH, V73, P1247, DOI 10.2105/AJPH.73.11.1247; MARZUK P M, 1991, International Review of Psychiatry, V3, P365, DOI 10.3109/09540269109072143; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MCKEGNEY FP, 1992, AM J PSYCHIAT, V149, P396; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; *NAT CTR HLTH STAT, 1982, DHHS PUBL, V2; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2; Nightingale SL, 1996, JAMA-J AM MED ASSOC, V276, P14; PERRY S, 1990, JAMA-J AM MED ASSOC, V263, P679, DOI 10.1001/jama.263.5.679; PIERCE C, 1987, CLIN PSYCHIAT NEWS, V10, P1; PRIER RE, 1991, HOSP COMMUNITY PSYCH, V42, P619; PUGH K, 1993, AIDS CARE, V5, P391, DOI 10.1080/09540129308258009; RAJS J, 1992, ACTA PSYCHIAT SCAND, V85, P234, DOI 10.1111/j.1600-0447.1992.tb08601.x; RUNDELL JR, 1992, PSYCHOSOMATICS, V33, P24, DOI 10.1016/S0033-3182(92)72017-9; SCHNEIDER SG, 1991, J PERS SOC PSYCHOL, V61, P776, DOI 10.1037/0022-3514.61.5.776; Starace F, 1993, Int J Soc Psychiatry, V39, P64, DOI 10.1177/002076409303900107; VANHAASTRECHT HJA, 1994, AIDS, V8, P1721, DOI 10.1097/00002030-199412000-00013	38	41	43	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1743	1746		10.1001/jama.276.21.1743	http://dx.doi.org/10.1001/jama.276.21.1743			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV566	8940323				2022-12-28	WOS:A1996VV56600032
J	Gallant, P; Shiio, Y; Cheng, PF; Parkhurst, SM; Eisenman, RN				Gallant, P; Shiio, Y; Cheng, PF; Parkhurst, SM; Eisenman, RN			Myc and max homologs in Drosophila	SCIENCE			English	Article							C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC-CELLS; N-MYC; PROTEIN; GENE; DIMERIZATION; FAMILY; ONCOPROTEIN	The proteins encoded by the myc proto-oncogene family are involved in cell proliferation, apoptosis, differentiation, and neoplasia. Myc acts through dimerization with Max to bind DNA and activate transcription. Homologs of the myc and mau genes were cloned from the fruit fly Drosophila melanogaster and their protein products (dMyc and dMax) were shown to heterodimerize, recognize the same DNA sequence as their vertebrate homologs, and activate transcription. The dMyc protein is likely encoded by the Drosophila gene diminutive (dm), a mutation in which results in small body size and female sterility caused by degeneration of the ovaries. These findings indicate a potential role for Myc in germ cell development and set the stage for genetic analysis of Myc and Max.	FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047852] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47138] Funding Source: Medline; NIGMS NIH HHS [R01GM47852] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; AUSUBEL FM, 1995, CURRENT PROTOCOLS S, V29; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALLANT P, UNPUB; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHERTY CD, UNPUB; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MODOLELL J, 1983, P NATL ACAD SCI-BIOL, V80, P1678, DOI 10.1073/pnas.80.6.1678; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PARKHURST SM, 1985, CELL, V41, P429, DOI 10.1016/S0092-8674(85)80016-7; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	48	145	151	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1523	1527		10.1126/science.274.5292.1523	http://dx.doi.org/10.1126/science.274.5292.1523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929412				2022-12-28	WOS:A1996VV77500047
J	Subramanya, HS; Bird, LE; Brannigan, JA; Wigley, DB				Subramanya, HS; Bird, LE; Brannigan, JA; Wigley, DB			Crystal structure of a DExx box DNA helicase	NATURE			English	Article							REPLICATION PROTEIN PRIA; COLI REP HELICASE; ESCHERICHIA-COLI; RNA HELICASE; BINDING; OVEREXPRESSION; DIMERIZATION; COMPONENT; MUTATIONS; PRIMOSOME	THERE are a wide variety of helicases that unwind helical DNA(1) and RNA substrates(2). The twelve helicases that have been identified in Escherichia coli(1) play a role in almost all cellular processes involving nucleic acids, We have solved the crystal structure of a monomeric form of a DNA helicase from Bacillus stearothermophilus, alone and in a complex with ADP, at 2.5 and 2.9 Angstrom resolution, respectively, The enzyme comprises two domains with a deep cleft running between them, The ATP-binding site, which is situated at the bottom of this cleft, is formed by motifs that are conserved across the superfamily of related helicases, Unexpected structural homology with the DNA recombination protein, RecA, suggests how ATP binding and hydrolysis may drive conformational changes of the enzyme during catalysis, and implies that there is a common mechanism for all helicases.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of Oxford; University of York - UK				Bird, Louise/0000-0002-9846-5716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; Egelman EH, 1996, STRUCTURE, V4, P759, DOI 10.1016/S0969-2126(96)00081-0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; OPPERMAN T, 1994, J BACTERIOL, V176, P6033; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Yu X, 1995, BIOPHYS J, V69, P2728, DOI 10.1016/S0006-3495(95)80144-X; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZHU L, 1988, VIROLOGY, V166, P366, DOI 10.1016/0042-6822(88)90507-7	30	382	385	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					379	383		10.1038/384379a0	http://dx.doi.org/10.1038/384379a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934527				2022-12-28	WOS:A1996VV27100055
J	Harrison, TW; Knox, AJ; Bessell, EM; Haynes, AP; MacFarlane, JT; Morris, GK; Pavord, ID				Harrison, TW; Knox, AJ; Bessell, EM; Haynes, AP; MacFarlane, JT; Morris, GK; Pavord, ID			A rare cause of superior vena cava obstruction - A rare problem presenting in an unusual way	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MALIGNANT-LYMPHOMA; CARDIOTOXICITY; HEART				Harrison, TW (corresponding author), CITY HOSP NOTTINGHAM, DIV RESP MED, HUCKNALL RD, NOTTINGHAM NG5 1PB, ENGLAND.							BILLINGHAM ME, 1977, AM J SURG PATHOL, V1, P17, DOI 10.1097/00000478-197701010-00002; BRISTOW MR, 1978, ANN INTERN MED, V88, P168, DOI 10.7326/0003-4819-88-2-168; CORTES EP, 1975, CANCER CHEMOTH REP 3, V6, P215; Escalante C P, 1993, Oncology (Williston Park), V7, P61; HAMADA S, 1988, J NUCL MED, V29, P1868; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; PAVLIDIS NA, 1994, MED PEDIATR ONCOL, V22, P287, DOI 10.1002/mpo.2950220415; TAKAGI M, 1992, J CARDIOVASC SURG, V33, P570; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710	9	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	1996	313	7068					1324	1326						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942696				2022-12-28	WOS:A1996VV15300034
J	Stiller, CA; Boyle, J				Stiller, CA; Boyle, J			Effect of population mixing and socioeconomic status in England and Wales, 1979-85, on lymphoblastic leukaemia in children	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; CHILDHOOD LEUKEMIA; INFECTIVE BASIS; NUCLEAR SITE; BRITAIN	Objectives-To examine the effects of migration, diversity of migrant origins, commuting, and socioeconomic status on the incidence of acute lymphoblastic leukaemia in childhood. Design-Poisson regression analysis of incidence rates in relation to the variables of interest. Setting-The 403 county districts of England and Wales during 1979-85. Subjects-Children aged under 15 years. Results-There were significant trends in the incidence of lymphoblastic leukaemia at ages 0-4 and 5-9 years with the proportion of children in a district who had recently entered the district. While there was no consistent relation between the proportion of recent incomers in the total population of a district and its incidence rate, the combination of higher migration with greater diversity of origins or distance moved was associated with higher incidence in both age groups. Incidence increased significantly at age 0-4 with the level of employment in a district and at age 5-9 with the proportion of households with access to a car. No significant trends were found with commuting. Conclusions-The results for level of child migration and diversity of total migration provide evidence of an effect of population mi ring on the incidence of childhood leukaemia which is not restricted to areas experiencing the most extreme levels of mixing.	UNIV LEEDS, SCH GEOG, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	Stiller, CA (corresponding author), UNIV OXFORD, CHILDHOOD CANC RES GRP, S PARKS RD, OXFORD OX2 6HJ, ENGLAND.			Stiller, Charles/0000-0002-3006-7869				ALEXANDER FE, 1993, J PUBLIC HEALTH MED, V15, P9, DOI 10.1093/oxfordjournals.pubmed.a042826; ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; ALEXANDER FE, 1992, BRIT J CANCER, V65, P589, DOI 10.1038/bjc.1992.119; DRAPER GJ, 1991, STUDIES MED POPULATI, V53, P37; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1995, BMJ-BRIT MED J, V310, P763, DOI 10.1136/bmj.310.6982.763; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KNOX EG, 1992, J EPIDEMIOL COMMUN H, V46, P566, DOI 10.1136/jech.46.6.566; LANGFORD I, 1991, SOC SCI MED, V33, P435, DOI 10.1016/0277-9536(91)90325-7; MCWHIRTER WR, 1982, BRIT J CANCER, V46, P640, DOI 10.1038/bjc.1982.249; Rodrigues L, 1991, STUDIES MED POPULATI, P47; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; STILLER CA, 1991, OPCS STUDIES MED POP, V53, P7	18	61	61	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	1996	313	7068					1297	1300						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942689	Green Published			2022-12-28	WOS:A1996VV15300023
J	Iezzoni, LI				Iezzoni, LI			When walking fails	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL DISABILITY; AMBULATORY PATIENTS; ELDERLY POPULATION; PHYSICIANS; FALLS; MOBILITY; IMPACT; TRIAL		CHARLES A DANA RES INST, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, HARVARD THORNDIKE LAB, BOSTON, MA 02215 USA	Harvard University; Harvard University; Beth Israel Deaconess Medical Center	Iezzoni, LI (corresponding author), HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02215 USA.							Avillion A E, 1986, Rehabil Nurs, V11, P11; BARNARD D, 1995, CHRONIC ILLNESS EXPE, P39; CALKINS DR, 1994, J GEN INTERN MED, V9, P590, DOI 10.1007/BF02599291; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; CORBET B, 1991, WESTERN J MED, V154, P514; DEJONG G, 1989, MILBANK Q, V67, P311, DOI 10.2307/3350148; Dubus A., 1996, DANCING HOURS; Kovar M G, 1995, Vital Health Stat 5, P1; LaPlante M P, 1992, Adv Data, P1; Miles-Tapping C, 1995, PHYSICAL OCCUPATIONA, V12, P31, DOI DOI 10.1080/J148V12N04_03; *NAT CTR HLTH STAT, 1987, DHHS PHS PUBL; NELSON E, 1983, JAMA-J AM MED ASSOC, V249, P3331, DOI 10.1001/jama.249.24.3331; NELSON E, 1987, J CHRON DIS, V40, pS55, DOI 10.1016/S0021-9681(87)80033-4; POPE AM, 1991, DISABILITY AM NATL A; Price Reynolds, 1995, WHOLE NEW LIFE ILLNE; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; REDFORD JB, 1993, ARCH PHYS MED REHAB, V74, P877, DOI 10.1016/0003-9993(93)90016-4; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART MA, 1977, MED CARE, V15, P578, DOI 10.1097/00005650-197707000-00005; STUDENSKI S, 1994, J AM GERIATR SOC, V42, P297, DOI 10.1111/j.1532-5415.1994.tb01755.x; TOOMBS SK, 1995, CHRONIC ILLNESS EXPE, P17; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223; Wald J S, 1995, Proc Annu Symp Comput Appl Med Care, P147; WARTMAN SA, 1983, PUBLIC HEALTH REP, V98, P141; WASSON J, 1992, MED CARE, V30, pMS42, DOI 10.1097/00005650-199205001-00004; Zola I. K., 2003, MISSING PIECES CHRON; ZOLA IK, 1979, ARCH PHYS MED REHAB, V60, P452	28	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1609	1613		10.1001/jama.276.19.1609	http://dx.doi.org/10.1001/jama.276.19.1609			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT025	8918860				2022-12-28	WOS:A1996VT02500037
J	Riordan, FAI; Thomson, APJ; Sills, JA; Hart, CA				Riordan, FAI; Thomson, APJ; Sills, JA; Hart, CA			Lesson of the week - Who spots the spots? Diagnosis and treatment of early meningococcal disease in children	BRITISH MEDICAL JOURNAL			English	Article							PARENTERAL PENICILLIN; RASH		UNIV LIVERPOOL,INST CHILD HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT MED MICROBIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool; University of Liverpool								CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; *DEP HLTH NAT MEN, 1994, KNOW MEN SEPT; FARMER G, 1993, BRIT MED J, V307, P127, DOI 10.1136/bmj.307.6896.127-a; GOSSAIN S, 1992, BRIT MED J, V305, P523, DOI 10.1136/bmj.305.6852.523-c; MARZOUK O, 1991, ARCH DIS CHILD, V66, P485, DOI 10.1136/adc.66.4.485; OAKLEY JR, 1979, BRIT MED J, V2, P468, DOI 10.1136/bmj.2.6188.468; RIORDAN FAI, 1995, EUR J PEDIATR, V154, P472; RIORDAN FAI, 1993, ARCH DIS CHILD, V69, P7117; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; SORENSEN HT, 1992, J CLIN EPIDEMIOL, V11, P1289; THOMSON AP, 1993, ARCH DIS CHILD, V69, P166, DOI 10.1136/adc.69.1.166; WATKINSON M, 1995, BRIT MED J, V311, P1504; WELSBY PD, 1990, BRIT MED J, V300, P1150, DOI 10.1136/bmj.300.6733.1150	13	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1255	1256		10.1136/bmj.313.7067.1255	http://dx.doi.org/10.1136/bmj.313.7067.1255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939123	Green Published			2022-12-28	WOS:A1996VU20800035
J	Davidson, MJF				Davidson, MJF			ABC of work related disorders - Legal aspects	BRITISH MEDICAL JOURNAL			English	Article											Davidson, MJF (corresponding author), JOHN LEWIS PARTNERSHIP,MED SERV,LONDON,ENGLAND.							Brazier M., 1992, MED PATIENTS LAW; *JUD STUD BOARD, 1994, GUID ASS GEN DAM PI; KENNEDY I, 1994, MED LAW; KLOSS D, 1994, OCCUPATIONAL HLTH LA; WIKELEY N, 1993, COMPENSATION IND DIS	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1136	1140		10.1136/bmj.313.7065.1136	http://dx.doi.org/10.1136/bmj.313.7065.1136			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916705	Green Published			2022-12-28	WOS:A1996VR21700033
J	Tanida, N				Tanida, N			What happened to elderly people in the great Hanshin earthquake	BRITISH MEDICAL JOURNAL			Russian	Article								The great Hanshin earthquake on 17 January 1995 hit the elderly population of an urban society particularly hard. More than half of the fatalities were among those over 60 years old, and in this age group female fatalities were almost double those of men. Surviving elderly people were largely left to their own devices and became relegated to the marginal space in shelters. Elderly people tended not to proclaim their problems, and so their suffering tended to be underestimated. Again, as survivors rebuilt their homes and moved back, elderly people and other vulnerable groups tended to be left behind in temporary accommodation. This tragedy has shown that special attention and continuous care is necessary for elderly and vulnerable people after such disasters.			Tanida, N (corresponding author), HYOGO MED UNIV,DEPT INTERNAL MED 4,JAPANESE SOC HOSPICE & HOME CARE,1-1 MUKOGAWACHO,NISHINOMIYA,HYOGO 663,JAPAN.							BOLIN R, 1982, INT J AGING HUM DEV, V16, P283; OKAMOTO Y, 1992, BRIT MED J, V305, P403, DOI 10.1136/bmj.305.6850.403; RAPHAEL B, 1986, WHEN DISASTER STRIKE; SHIOZAKI Y, 1995, RECORDS 100 DAYS GRE, P49; SHIRO H, 1995, RECORDS 100 DAYS GRE, P167; *STAT INF DEP MIN, 1995, PROF CAS GREAT HANSH	6	77	80	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1133	1135		10.1136/bmj.313.7065.1133	http://dx.doi.org/10.1136/bmj.313.7065.1133			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VR217	8916704	Green Published			2022-12-28	WOS:A1996VR21700031
J	Han, SH; Zheng, B; Schatz, DG; Spanopoulou, E; Kelsoe, G				Han, SH; Zheng, B; Schatz, DG; Spanopoulou, E; Kelsoe, G			Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; V(D)J RECOMBINATION; SOMATIC DIVERSIFICATION; FOLLICULAR LYMPHOMA; CHROMOSOMAL TRANSLOCATION; RECIPROCAL PARTNERS; PEANUT AGGLUTININ; GENE CONVERSION; CHAIN GENE; ANTIGEN	The products of the Rag1 and Rag2 genes drive genomic V(D)J rearrangements that assemble functional immunoglobulin and T cell antigen receptor genes. Expression of the Rag genes has been thought to be limited to developmentally immature lymphocyte populations that in normal adult animals are primarily restricted to the bone marrow and thymus. Abundant RAGI and RAG2 protein and messenger RNA was detected in the activated B cells that populate murine splenic and Peyer's patch germinal centers. Germinal center B cells thus share fundamental characteristics of immature lymphocytes, raising the possibility that antigen-dependent secondary V(D)J rearrangements modify the peripheral antibody repertoire.	UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; MT SINAI CANC CTR,NEW YORK,NY 10021	University System of Maryland; University of Maryland Baltimore; Howard Hughes Medical Institute; Yale University; Icahn School of Medicine at Mount Sinai			Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032524, R01AI024335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010207] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32524, AI24335] Funding Source: Medline; NIA NIH HHS [AG10207] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CLEARY ML, 1986, CELL, V44, P97, DOI 10.1016/0092-8674(86)90488-5; COICO RF, 1983, J IMMUNOL, V131, P2254; COTTER F, 1990, BLOOD, V76, P131; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; GIACHINO C, 1995, J EXP MED, V181, P1245, DOI 10.1084/jem.181.3.1245; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; GRAY D, 1993, J EXP MED, V177, P999; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; HAN SH, 1995, J IMMUNOL, V155, P556; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HODES R, COMMUNICATION; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KELSOE G, 1980, J EXP MED, V151, P289, DOI 10.1084/jem.151.2.289; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KNIGHT KL, 1990, CELL, V60, P963, DOI 10.1016/0092-8674(90)90344-E; LANZAVECCHIA A, COMMUNITY; LAZLO G, 1993, J IMMUNOL, V150, P5252; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEVY R, 1987, IMMUNOL REV, V96, P43, DOI 10.1111/j.1600-065X.1987.tb00508.x; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN WC, 1995, IMMUNOL TODAY, V16, P279, DOI 10.1016/0167-5699(95)80182-0; LINTON PJ, 1992, EUR J IMMUNOL, V22, P1293, DOI 10.1002/eji.1830220526; LINTON PJ, 1989, CELL, V59, P1049, DOI 10.1016/0092-8674(89)90761-7; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MILLER C, 1995, J EXP MED, V181, P1319, DOI 10.1084/jem.181.4.1319; Miller Carla, 1994, Aging Immunology and Infectious Disease, V5, P249; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RADIC MZ, 1993, J EXP MED, V177, P116; REISNER Y, 1979, P NATL ACAD SCI USA, V76, P447, DOI 10.1073/pnas.76.1.447; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1995, CELL, V80, P115, DOI 10.1016/0092-8674(95)90456-5; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROSE ML, 1980, NATURE, V284, P364, DOI 10.1038/284364a0; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SKLAR J, 1984, NEW ENGL J MED, V311, P20, DOI 10.1056/NEJM198407053110104; Spanopoulou E, 1995, IMMUNITY, V3, P715, DOI 10.1016/1074-7613(95)90061-6; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; WEINSTEIN PD, 1991, INT IMMUNOL, V3, P1253, DOI 10.1093/intimm/3.12.1253; WEINSTEIN PD, 1994, IMMUNITY, V1, P647, DOI 10.1016/1074-7613(94)90036-1; WU HY, 1995, SCAND J IMMUNOL, V42, P52, DOI 10.1111/j.1365-3083.1995.tb03625.x; ZELENETZ AD, 1992, J EXP MED, V176, P1137, DOI 10.1084/jem.176.4.1137; Zheng B, 1996, J EXP MED, V184, P1083, DOI 10.1084/jem.184.3.1083; ZHENG B, UNPUB; ZHENG B, IN PRESS NATURE	57	244	247	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2094	2097		10.1126/science.274.5295.2094	http://dx.doi.org/10.1126/science.274.5295.2094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953043				2022-12-28	WOS:A1996VY97400053
J	Livingstone, JR				Livingstone, JR			Antibody characterization by isothermal titration calorimetry	NATURE			English	Article							THERMODYNAMICS; BINDING	Isothermal titration calorimetry is a useful tool for the characterization of antibodies and antibody-related products, which uses heat as a detection medium, circumventing the problems associated with other analytical methods.			Livingstone, JR (corresponding author), MICROCAL INC, TECH SERV, 22 IND DR E, NORTHAMPTON, MA 01060 USA.			Livingstone, Jeff/0000-0002-2824-3982				BUNDLE DR, 1994, METHOD ENZYMOL, V247, P288; Fisher HF, 1995, METHOD ENZYMOL, V259, P194; FREIRE E, 1990, ANAL CHEM, V62, pA950, DOI 10.1021/ac00217a002; GOLDBERG ME, 1993, CURR OPIN IMMUNOL, V5, P278, DOI 10.1016/0952-7915(93)90018-N; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; WISEMAN T, 1993, ANAL BIOCHEM, V179, P5434	11	21	21	6	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					491	492		10.1038/384491a0	http://dx.doi.org/10.1038/384491a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945480				2022-12-28	WOS:A1996VW68700070
J	Clark, IA; AlYaman, FM; Cowden, WB; Rockett, KA				Clark, IA; AlYaman, FM; Cowden, WB; Rockett, KA			Does malarial tolerance, through nitric oxide, explain the low incidence of autoimmune disease in tropical Africa?	LANCET			English	Article							FALCIPARUM MALARIA; MACROPHAGES; SUPPRESSION; LIPOPOLYSACCHARIDE; IMMUNITY; PATHWAY	Autoimmune disease is generally rare in tropical rural populations. Plasma concentrations of nitrite plus nitrate (reactive nitrogen intermediates), reflecting high nitric-oxide production somewhere in the body, can be high in patients who have cerebral malaria, but even higher in symptom-free parasitised individuals, who are termed malaria-tolerant. We propose that the nitric oxide causing high serum levels of reactive nitrogen intermediates in malaria-tolerant individuals is generated in macrophages during the establishment and maintenance of malarial tolerance, and makes autoimmune disease rare in many tropical rural populations by minimising proliferation of autoreactive T cells. Conversely, innately low levels of nitric-oxide generation in these populations, selected by malarial disease in tropical areas, could rationalise their high frequency of autoimmune disease and hypertension when living in western societies.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,CANBERRA,ACT 2601,AUSTRALIA; JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND	Australian National University; John Curtin School of Medical Research; University of Oxford	Clark, IA (corresponding author), AUSTRALIAN NATL UNIV,SCH LIFE SCI,DIV BIOCHEM & MOL BIOL,CANBERRA,ACT 0200,AUSTRALIA.		Clark, Ian A./K-2069-2012					ALYAMAN F, IN PRESS T R SOC TRO; AlYaman FM, 1996, T ROY SOC TROP MED H, V90, P270, DOI 10.1016/S0035-9203(96)90243-6; Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; BATE CAW, 1990, IMMUNOLOGY, V70, P315; CLARK IA, 1992, LANCET, V340, P894, DOI 10.1016/0140-6736(92)93295-X; FAHMI H, 1995, INFECT IMMUN, V63, P1863, DOI 10.1128/IAI.63.5.1863-1869.1995; GREENWOO.BM, 1968, LANCET, V2, P380; ISOBE KI, 1992, INFECT IMMUN, V60, P4832, DOI 10.1128/IAI.60.11.4832-4837.1992; JOHNSON AE, 1995, ARTHRITIS RHEUM, V38, P551, DOI 10.1002/art.1780380415; Kitchen S. F., 1949, MALARIOLOGY, V2, P966; Kremsner PG, 1996, T ROY SOC TROP MED H, V90, P44, DOI 10.1016/S0035-9203(96)90476-9; MILLS CD, 1991, J IMMUNOL, V146, P2719; MURRAY HW, 1992, J INFECT DIS, V165, P513, DOI 10.1093/infdis/165.3.513; NUSSLER AK, 1994, J INFECT DIS, V169, P1418, DOI 10.1093/infdis/169.6.1418; POWELL RD, 1972, P HELM SOC WASH, V39, P51; ROCKETT KA, 1994, PARASITE IMMUNOL, V16, P243, DOI 10.1111/j.1365-3024.1994.tb00346.x; ROJAS A, 1993, BIOCHEM BIOPH RES CO, V191, P441, DOI 10.1006/bbrc.1993.1237; RUBENSTEIN M, 1965, P SOC EXP BIOL MED, V118, P238; RUTLEDGE DR, 1994, DRUGS, V47, P914, DOI 10.2165/00003495-199447060-00005; Ruuls SR, 1996, CLIN EXP IMMUNOL, V103, P467; SCAMMELL TE, 1996, AM J PHYSIOL, V40, pR333; STERNBERG J, 1992, EUR J IMMUNOL, V22, P2741, DOI 10.1002/eji.1830221041; TAYLOR DW, 1978, AM J TROP MED HYG, V27, P738, DOI 10.4269/ajtmh.1978.27.738; VONMULLER CS, 1978, EUR J IMMUNOL, V8, P771, DOI 10.1002/eji.1830081104; WEINBERG JB, 1995, BLOOD, V86, P1184; WILLIAMSON WA, 1978, LANCET, V1, P1328; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13; ZINGARELLI B, 1995, SHOCK, V3, P102, DOI 10.1097/00024382-199503020-00004	28	36	38	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1492	1494		10.1016/S0140-6736(96)07342-4	http://dx.doi.org/10.1016/S0140-6736(96)07342-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942781				2022-12-28	WOS:A1996VV46300014
J	Jenny, A; MinvielleSebastia, L; Preker, PJ; Keller, W				Jenny, A; MinvielleSebastia, L; Preker, PJ; Keller, W			Sequence similarity between the 73-kilodalton protein of mammalian CPSF and a subunit of yeast polyadenylation factor I	SCIENCE			English	Article							PRE-MESSENGER-RNA; SPECIFICITY FACTOR; POLY(A) POLYMERASE; CLEAVAGE; 3'-END; CLONING; PURIFICATION; GENE	The 3' ends of most eukaryotic messenger RNAs are generated by endonucleolytic cleavage and polyadenylation. In mammals, the cleavage and polyadenylation specificity factor (CPSF) plays a central role in both steps of the processing reaction. Here, the cloning of the 73-kilodalton subunit of CPSF is reported. Sequence analyses revealed that a yeast protein (Ysh1) was highly similar to the 73-kD polypeptide. Ysh1 constitutes a new subunit of polyadenylation factor I (PFI), which has a role in yeast pre-mRNA 3'-end formation. This finding was unexpected because in contrast to CPSF, PFI is only required for the polyadenylation reaction. These results contribute to the understanding of how 3'-end processing factors may have evolved.	UNIV BASEL,BIOZENTRUM,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel			Minvielle-Sebastia, Lionel/M-7154-2014					ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; BARABINO SML, UNPUB; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHANFREAU G, COMMUNICATION; CHANFREAU G, UNPUB; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; Harlow E., 1988, ANTIBODIES LAB MANUA; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; JENNY A, UNPUB; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Noble SM, 1996, GENETICS, V143, P67; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; PREKER PJ, UNPUB; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Sambrook J., 1989, MOL CLONING; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; VARSHAVSKY A, 1996, COLD SPRING HARB SYM, V60, P461; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J	31	94	98	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1514	1517		10.1126/science.274.5292.1514	http://dx.doi.org/10.1126/science.274.5292.1514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929409				2022-12-28	WOS:A1996VV77500044
J	MuellerSchoop, JW; Meyer, M				MuellerSchoop, JW; Meyer, M			Total alopecia, diabetes mellitus, and falls	LANCET			English	Article									NEUROL ZENTRUM HLRSLANDEN,ZURICH,SWITZERLAND		MuellerSchoop, JW (corresponding author), ROTKRUEZSPITAL,GLORIASTR 18,CH-8028 ZURICH,SWITZERLAND.							RABINOWE SL, 1986, ADV INTERNAL MED, V31, P293; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; WILLIAMS AC, 1988, LANCET, V2, P222	4	1	2	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1420	1420		10.1016/S0140-6736(96)08528-5	http://dx.doi.org/10.1016/S0140-6736(96)08528-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937282				2022-12-28	WOS:A1996VU98600014
J	Eng, C; Clayton, D; Schuffenecker, I; Lenoir, G; Cote, G; Gagel, RF; vanAmstel, HKP; Lips, CJM; Nishisho, I; Takai, SI; Marsh, DJ; Robinson, BG; FrankRaue, K; Raue, F; Xue, FY; Noll, WW; Romei, C; Pacini, F; Fink, M; Niederle, B; Zedenius, J; Nordenskjold, M; Komminoth, P; Hendy, GN; Gharib, H; Thibodeau, SN; Lacroix, A; Frilling, A; Ponder, BAJ; Mulligan, LM				Eng, C; Clayton, D; Schuffenecker, I; Lenoir, G; Cote, G; Gagel, RF; vanAmstel, HKP; Lips, CJM; Nishisho, I; Takai, SI; Marsh, DJ; Robinson, BG; FrankRaue, K; Raue, F; Xue, FY; Noll, WW; Romei, C; Pacini, F; Fink, M; Niederle, B; Zedenius, J; Nordenskjold, M; Komminoth, P; Hendy, GN; Gharib, H; Thibodeau, SN; Lacroix, A; Frilling, A; Ponder, BAJ; Mulligan, LM			The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; MEN 2A; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNG DISEASE; POINT MUTATION; FMTC; FAMILIES	Objective.-Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant disorder. The 3 recognized subtypes include MEN 2A, characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (pheo), and hyperparathyroidism (HPT); MEN 2B, by MTC, pheo, and characteristic stigmata; and familial MTC (FMTC), by the presence of MTC only. The purpose of this study was to establish the relationship between specific mutations and the presence of certain disease features in MEN 2 which could help in clinical decision making. Design.-Correlative survey study of 477 MEN 2 families. Setting.-Eighteen tertiary referral centers worldwide. Patients.-A total of 477 independent MEN 2 families. Main Outcome Measures.-Association between the position and type of germline mutation in the RET proto-oncogene and the presence or absence of MTC, pheo, HPT, and/or other features in a family. Results.-There is a statistically significant association between the presence of any mutation at a specific position (codon 634) and the presence of pheo and HPT. The presence of a specific mutation, CGC at codon 634, has yet to be associated with FMTC, Conversely, mutations at codons 768 and 804 are thus far seen only with FMTC, while codon 918 mutation is MEN 2B-specific. Rare families with both MEN 2 and Hirschsprung disease were found to have MEN 2-specific codon mutations. Patients with Hirschsprung disease presenting with such mutations should be monitored for the possible development of MEN 2 tumors. Conclusions.-This consortium analysis suggests that genotype-phenotype correlations do exist and, if made reliably absolute, could prove useful in the future in clinical management with respect to screening, surveillance, and prophylaxis, as well as provide insight into the genetic effects of particular mutations.	QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; UNIV CAMBRIDGE,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1TN,ENGLAND; UNIV CAMBRIDGE,INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 1TN,ENGLAND; INT AGCY RES CANC,F-69372 LYON,FRANCE; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX; UNIV UTRECHT,DEPT INTERNAL MED,UTRECHT,NETHERLANDS; UNIV UTRECHT,CLIN GENET CTR,UTRECHT,NETHERLANDS; OSAKA UNIV,SCH MED,DEPT MED GENET,OSAKA,JAPAN; UNIV SYDNEY,ROYAL N SHORE HOSP,KOLLING INST MED RES,MOL GENET UNIT,ST LEONARDS,NSW 2065,AUSTRALIA; UNIV HEIDELBERG,DEPT INTERNAL MED 1,HEIDELBERG,GERMANY; DARTMOUTH HITCHCOCK MED CTR,DEPT PATHOL,LEBANON,NH 03766; UNIV PISA,INST ENDOCRINOL,PISA,ITALY; UNIV VIENNA,DEPT SURG,A-1010 VIENNA,AUSTRIA; KAROLINSKA HOSP,DEPT MOL MED,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT SURG,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT CLIN GENET,S-10401 STOCKHOLM,SWEDEN; UNIV ZURICH,DEPT PATHOL,CH-8006 ZURICH,SWITZERLAND; ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3A 1A1,CANADA; MAYO CLIN,DIV ENDOCRINOL,ROCHESTER,MN; HOP HOTEL DIEU,CTR RECH,MONTREAL,PQ,CANADA; UNIV HAMBURG,DEPT SURG,HAMBURG,GERMANY; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON,CANADA	Queens University - Canada; CRUK Cambridge Institute; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; World Health Organization; International Agency for Research on Cancer (IARC); University of Texas System; UTMD Anderson Cancer Center; Utrecht University; Utrecht University; Osaka University; Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research; Ruprecht Karls University Heidelberg; Dartmouth College; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa; University of Vienna; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Zurich; McGill University; Royal Victoria Hospital; Mayo Clinic; Universite de Montreal; University of Hamburg; Queens University - Canada; Queens University - Canada	Eng, C (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.		Marsh, Deborah J/I-1491-2014; Lacroix, Andre/AAI-5645-2020; Raue, Friedhelm/ABD-6150-2021	Marsh, Deborah J/0000-0001-5899-4931; Raue, Friedhelm/0000-0002-7700-1648; Niederle, Bruno/0000-0001-8107-4068; Nordenskjold, Magnus/0000-0002-4974-425X; Eng, Charis/0000-0002-3693-5145				ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; BORST MJ, 1995, SURGERY, V117, P386, DOI 10.1016/S0039-6060(05)80057-1; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1995, CLIN ENDOCRINOL, V43, P123, DOI 10.1111/j.1365-2265.1995.tb01903.x; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, IN PRESS HUM MUTAT; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; FRILLING A, 1992, H FORD HOSP MED J, V40, P233; GAGEL RF, 1989, ANN INTERN MED, V111, P802, DOI 10.7326/0003-4819-111-10-802; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; Hofstra R. M. W., 1994, American Journal of Human Genetics, V55, pA60; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KOMMINOTH P, 1995, CANCER, V76, P479; Komminoth P, 1996, J CLIN ENDOCR METAB, V81, P2041, DOI 10.1210/jc.81.6.2041; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P213, DOI 10.1046/j.1365-2265.1996.505292.x; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1995, J INTERN MED, V238, P343, DOI 10.1111/j.1365-2796.1995.tb01208.x; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Noorani HZ, 1996, AM J HUM GENET, V59, P301; Okamoto E, 1967, J PEDIATR SURG, V2, P437; Pausova Z, 1996, J CLIN ENDOCR METAB, V81, P2711, DOI 10.1210/jc.81.7.2711; PONDER BAJ, 1988, Q J MED, V67, P299; Reynolds Lucinda F., 1995, Current Opinion in Pediatrics, V7, P702; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHIMKE RN, 1968, NEW ENGL J MED, V279, P1, DOI 10.1056/NEJM196807042790101; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; THAKKER RV, 1988, CLIN ENDOCRINOL META, V28, P1031; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; ZEDENIUS J, 1995, J CLIN ENDOCR METAB, V80, P3088, DOI 10.1210/jc.80.10.3088	35	855	884	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1575	1579		10.1001/jama.276.19.1575	http://dx.doi.org/10.1001/jama.276.19.1575			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918855				2022-12-28	WOS:A1996VT02500030
J	Bowman, RJC; Bennett, HGB; Houston, CA; Aitchison, TC; Dutton, GN				Bowman, RJC; Bennett, HGB; Houston, CA; Aitchison, TC; Dutton, GN			Waiting times for and attendance at paediatric ophthalmology outpatient appointments	BRITISH MEDICAL JOURNAL			English	Article									GLASGOW EYE INFIRM,GLASGOW G3 8JE,LANARK,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW G12 8AG,LANARK,SCOTLAND	University of Glasgow	Bowman, RJC (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,TENNENT INST OPHTHALMOL,GLASGOW G11 6NT,LANARK,SCOTLAND.							ALPERT JJ, 1964, PEDIATRICS, V34, P127; CARSTAIRS V, 1992, DEPRIVATION HLTH SCO; MCCARRON PG, 1994, BRIT MED J, V309, P1481, DOI 10.1136/bmj.309.6967.1481	3	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1244	1244		10.1136/bmj.313.7067.1244	http://dx.doi.org/10.1136/bmj.313.7067.1244			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939117	Green Published			2022-12-28	WOS:A1996VU20800026
J	Roberts, I; Campbell, F; Hollis, S; Yates, D				Roberts, I; Campbell, F; Hollis, S; Yates, D			Reducing accident death rates in children and young adults: The contribution of hospital care	BRITISH MEDICAL JOURNAL			English	Article							INJURY SEVERITY SCORE; MAJOR TRAUMA	Objective-To assess the contribution of trauma care to the recent decline in accident death rates among children and young people. Design-Logistic regression modelling of temporal trends in the probability of death in patients admitted to hospital for the treatment of severe injury. Setting-Hospitals participating the United Kingdom major trauma outcome study. Subjects-3230 patients with an injury severity score of 16 or more, who were admitted for more than three days, transferred or admitted to intensive care, or died from their injuries. Main outcome measures-Death or survival in hospital within three months of injury. Results-Over the seven year period 1989-95 there was a substantial decline in the probability of death among children and young adults admitted to hospital after severe injury. The overall estimate of the reduction in the odds of death was 16% per year (odds ratio for the yearly trend 0.84; 95% cofidence interval 0.79 to 0.89). This decline did not differ significantly between age groups. (0-4 years 0.79; 5-14 years 0.87; 15-24 years 0.83). Conclusions-Reductions in hospital case fatality have made an important contribution to reaching the Health of the Nation targets. The contribution of hospital care in the reduction of accident mortality should be taken into account in decisions about the allocation of resources to preventive and curative services.	UNIV LONDON,INST CHILD HLTH,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND; UNIV MANCHESTER,MAJOR TRAUMA OUTCOME STUDY,SALFORD M6 8HD,LANCS,ENGLAND; UNIV LANCASTER,MED STAT UNIT,LANCASTER LA1 4YF,ENGLAND; UNIV MANCHESTER,MANCHESTER M6 8HD,LANCS,ENGLAND	University of London; University College London; University of Manchester; Lancaster University; University of Manchester				Hollis, Sally/0000-0003-0156-9189				BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHAMPION HR, 1987, J TRAUMA, V27, P370; *DEP HLTH, 1991, HLTH NATION; *DEP HLTH, 1995, FIT FUTURE 2 PROGR R; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; YATES DW, 1990, BRIT MED J, V301, P1090, DOI 10.1136/bmj.301.6760.1090; ZOLTIE N, 1993, BMJ-BRIT MED J, V307, P906, DOI 10.1136/bmj.307.6909.906	9	66	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1239	1241		10.1136/bmj.313.7067.1239	http://dx.doi.org/10.1136/bmj.313.7067.1239			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939113	Green Published			2022-12-28	WOS:A1996VU20800022
J	Walker, MC; Li, LM; Sander, JWAS				Walker, MC; Li, LM; Sander, JWAS			Long term use of lamotrigine and vigabatrin in in severe refractory epilepsy: Audit of outcome	BRITISH MEDICAL JOURNAL			English	Article									NATL SOC EPILEPSY,CHALFONT ST PETER SL9 0RJ,BUCKINGHAMSHIRE,ENGLAND				Li, Li/AEM-3636-2022; li, li/GPX-3938-2022; LI, LI QING/GRR-8855-2022; li, li/AAT-2097-2020; Sander, Josemir W/C-1576-2008; Walker, Matthew C/C-1577-2008; Li, Li/C-4916-2013	Sander, Josemir W/0000-0001-6041-9661; Walker, Matthew C/0000-0002-0812-0352; Li, Li/0000-0001-6062-4649	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		KLENERMAN P, 1993, J NEUROL NEUROSUR PS, V56, P149, DOI 10.1136/jnnp.56.2.149; NASHEF L, 1995, J NEUROL NEUROSUR PS, V58, P462, DOI 10.1136/jnnp.58.4.462; SANDER JWAS, 1990, EPILEPSY RES, V7, P226, DOI 10.1016/0920-1211(90)90019-R; SANDER JWAS, 1990, J NEUROL NEUROSUR PS, V53, P1008, DOI 10.1136/jnnp.53.11.1008; Walker MC, 1996, NEUROLOGY, V46, P912, DOI 10.1212/WNL.46.4.912	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1184	1185		10.1136/bmj.313.7066.1184	http://dx.doi.org/10.1136/bmj.313.7066.1184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916751	Green Published			2022-12-28	WOS:A1996VR90700024
J	Wessely, S; Brugha, T; Cowen, P; Smith, L; Paykel, S				Wessely, S; Brugha, T; Cowen, P; Smith, L; Paykel, S			Do authors know who refereed their paper? A questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,DEPT PSYCHIAT,LEICESTER LE5 4PW,LEICS,ENGLAND; LITTLEMORE HOSP,OXFORD OX4 4XN,ENGLAND; ADDENBROOKES HOSP,DEPT PSYCHIAT,CAMBRIDGE CB2 2QQ,ENGLAND	University of Leicester; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Wessely, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED,DEPT PSYCHOL MED,LONDON SE5 8AZ,ENGLAND.		Brugha, Traolach/T-9326-2019; Wessely, Simon C/A-8713-2008	Brugha, Traolach/0000-0002-9786-9591; Wessely, Simon Charles/0000-0002-6743-9929				CICCHETTI DV, 1991, BEHAV BRAIN SCI, V14, P119, DOI 10.1017/S0140525X00065675; FISHER M, 1994, JAMA-J AM MED ASSOC, V272, P143, DOI 10.1001/jama.272.2.143; LOCK S, 1991, DIFFICULT BALANCE ED; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; SWEITZER BJ, 1994, JAMA-J AM MED ASSOC, V272, P152, DOI 10.1001/jama.272.2.152	5	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1185	1185		10.1136/bmj.313.7066.1185	http://dx.doi.org/10.1136/bmj.313.7066.1185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916752	Green Published			2022-12-28	WOS:A1996VR90700025
J	Hamsten, A				Hamsten, A			Molecular genetics as the route to understanding, prevention, and treatment	LANCET			English	Article							CORONARY HEART-DISEASE; LIPOPROTEIN DISORDERS											BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; DAMMERMAN M, 1995, CIRCULATION, V91, P505, DOI 10.1161/01.CIR.91.2.505; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GREEN F, 1995, BAILLIERE CLIN HAEM, V8, P345; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; Kontula K, 1996, CURR OPIN LIPIDOL, V7, P64, DOI 10.1097/00041433-199604000-00003; RUIZ J, 1995, LANCET, V346, P869, DOI 10.1016/S0140-6736(95)92709-3; Schoonjans K, 1996, J LIPID RES, V37, P907; Singer DRJ, 1996, CIRCULATION, V94, P236, DOI 10.1161/01.CIR.94.3.236; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	14	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV	1996	348			1			S17	S19		10.1016/S0140-6736(96)98006-X	http://dx.doi.org/10.1016/S0140-6736(96)98006-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918523				2022-12-28	WOS:A1996VU00800007
J	Chen, LM; Hobbie, S; Galan, JE				Chen, LM; Hobbie, S; Galan, JE			Requirement of CDC42 for Salmonella-induced cytoskeletal and nuclear responses	SCIENCE			English	Article							GROWTH-FACTOR-RECEPTOR; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; RAC; TYPHIMURIUM; ACTIVATION; INVASION; RHO; BINDING	The bacterial pathogen Salmonella typhimurium triggers host cell signaling pathways that lead to cytoskeletal and nuclear responses required for pathogenesis. Here, the role of the small guanosine triphosphate (GTP)-binding protein CDC42Hs in these responses was examined. Expression of a dominant interfering mutant of CDG42 (CDC42HsN17) prevented S. typhimurium-induced cytoskeletal reorganization and subsequent macropinocytosis and bacterial internalization into host cells. Cells expressing constitutively active CDC42 (CDC42HsV12) internalized an S. typhimurium mutant unable to trigger host cell responses. Furthermore, expression of CDC42HsN17 prevented S. typhimurium-induced JNK kinase activation. These results indicate that CDC42 is required for bacterial invasion and induction of nuclear responses in host cells.	SUNY STONY BROOK, SCH MED, DEPT MOL GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chen LM, 1996, MOL MICROBIOL, V21, P1101, DOI 10.1046/j.1365-2958.1996.471410.x; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Denoyelle S., SYNTHESIS SAR STUDY; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1995, CURR TOP MICROBIOL I, V209, P43; Galan Jorge E., 1994, Trends in Cell Biology, V4, P196, DOI 10.1016/0962-8924(94)90136-8; GARCIADELPORTILLO F, 1994, INFECT IMMUN, V62, P4641, DOI 10.1128/IAI.62.10.4641-4645.1994; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOBBIE S, UNPUB; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JONES BD, 1993, P NATL ACAD SCI USA, V90, P10390, DOI 10.1073/pnas.90.21.10390; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P77; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANPUTTEN JPM, 1994, METHOD ENZYMOL, V236, P420; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	38	242	251	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1996	274	5295					2115	2118		10.1126/science.274.5295.2115	http://dx.doi.org/10.1126/science.274.5295.2115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953049				2022-12-28	WOS:A1996VY97400059
J	Murphy, C; Saffrich, R; Grummt, W; Gournier, H; Rybin, V; Rubino, M; Auvinen, P; Lutcke, A; Parton, RG; Zerial, M				Murphy, C; Saffrich, R; Grummt, W; Gournier, H; Rybin, V; Rubino, M; Auvinen, P; Lutcke, A; Parton, RG; Zerial, M			Endosome dynamics regulated by a Rho protein	NATURE			English	Article							ACTIN STRESS FIBERS; MEMBRANE; ENDOCYTOSIS; GTPASES; CELLS; CDC42; MICROFILAMENTS; CYTOCHALASIN; INHIBITION; FUSION	Vesicular transport is a dynamic process that requires coordinated interactions between membrane and cytoskeleton. The mechanisms and molecules integrating these interactions are unclear. A Rho protein, RhoD, might provide a molecular link between membrane traffic and the cytoskeleton. Activated RhoD causes rearrangements of the actin cytoskeleton and cell surface, and governs early endosome motility and distribution.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Murphy, Carol/ABE-4282-2021; Parton, Robert G/C-5673-2009; Auvinen, Petri/D-5044-2009; Auvinen, Petri/AAP-8117-2021	Murphy, Carol/0000-0003-1353-8558; Parton, Robert G/0000-0002-7494-5248; Auvinen, Petri/0000-0002-3947-4778; Saffrich, Rainer/0000-0002-0547-4550				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ALLAN V, 1995, FEBS LETT, V369, P101, DOI 10.1016/0014-5793(95)00615-G; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JACKMAN MR, 1994, J CELL SCI, V107, P2547; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riezman Howard, 1993, Trends in Cell Biology, V3, P273, DOI 10.1016/0962-8924(93)90056-7; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sheetz MP, 1996, TRENDS CELL BIOL, V6, P85, DOI 10.1016/0962-8924(96)80993-7; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1028, P146; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Wirth JA, 1996, J CELL SCI, V109, P653; YAMASHIRO DJ, 1984, CELL, V37, P389; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	38	192	199	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					427	432		10.1038/384427a0	http://dx.doi.org/10.1038/384427a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945468				2022-12-28	WOS:A1996VW68700052
J	Corne, J				Corne, J			Diffuse panbronchiolitis - A new Japanese export?	LANCET			English	Editorial Material											Corne, J (corresponding author), SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							Fitzgerald JE, 1996, AM J RESP CRIT CARE, V154, P497, DOI 10.1164/ajrccm.154.2.8756828; FUJII T, 1995, THORAX, V50, P1246, DOI 10.1136/thx.50.12.1246; HOMER RJ, 1995, CHEST, V107, P1176, DOI 10.1378/chest.107.4.1176; HOMMA H, 1983, CHEST, V83, P63, DOI 10.1378/chest.83.1.63; IWATA M, 1994, HUM PATHOL, V25, P357, DOI 10.1016/0046-8177(94)90143-0; NISHIMURA K, 1992, RADIOLOGY, V184, P779, DOI 10.1148/radiology.184.3.1509067; SUGIYAMA Y, 1990, AM REV RESPIR DIS, V141, P1459, DOI 10.1164/ajrccm/141.6.1459	7	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1465	1466		10.1016/S0140-6736(05)65888-6	http://dx.doi.org/10.1016/S0140-6736(05)65888-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942772				2022-12-28	WOS:A1996VV46300005
J	Geballe, TR; Oka, T				Geballe, TR; Oka, T			Detection af H-3(+) in interstellar space	NATURE			English	Article							INFRARED-SPECTRUM; H-3+; CLOUDS; GAS; MOLECULES; FEATURES; SEARCH; LINES; CO	THE H-3(+) ion is widely believed to play an important role in interstellar chemistry, by initiating the chains of reactions that lead to the production of many of the complex molecular species observed in the interstellar medium(1-5). The presence of H-3(+) in the interstellar medium was first suggested(6) in 1961, and its infrared spectrum was measured(7) in the laboratory in 1980. But attempts(8-11) to detect it in interstellar space have hitherto proved unsuccessful, Here we report the detection of H-3(+) absorption in the spectra of two molecular clouds. Ali-hough the present results do not permit an accurate determination of the H-3(+) abundances, these ions appear nevertheless to be present in sufficient quantities to drive much of the chemistry in molecular clouds, It should soon be possible to obtain more accurate measurements, and thus better quantify the role of ion-neutral reactions in the chemical evolution of molecular clouds.	UNIV CHICAGO, DEPT CHEM, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA; UNIV CHICAGO, ENRICO FERMI INST, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	Geballe, TR (corresponding author), JOINT ASTRON CTR, UNIV PK, HILO, HI 96720 USA.							AMANO T, 1988, ASTROPHYS J, V329, pL121, DOI 10.1086/185190; ANICICH VG, 1986, ASTROPHYS J SUPPL S, V62, P553, DOI 10.1086/191151; BLACK JH, 1990, ASTROPHYS J, V358, P459, DOI 10.1086/168999; DALGARNO A, 1976, REP PROG PHYS, V39, P573, DOI 10.1088/0034-4885/39/6/002; DROSSART P, 1989, NATURE, V340, P539, DOI 10.1038/340539a0; GEBALLE TR, 1993, ASTROPHYS J, V408, pL109, DOI 10.1086/186843; GEBALLE TR, 1989, ASTROPHYS J, V342, P855, DOI 10.1086/167641; GEBALLE TR, 1985, ASTRON ASTROPHYS, V146, pL6; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; Lee HH, 1996, ASTRON ASTROPHYS SUP, V119, P111, DOI 10.1051/aas:1996232; LEPP S, 1987, ASTROPHYS J, V321, P383, DOI 10.1086/165636; MAILLARD JP, 1995, SPECTROCHIM ACTA A, V51, P1105, DOI 10.1016/0584-8539(94)00014-3; MARTIN DW, 1961, ASTROPHYS J, V134, P1012, DOI 10.1086/147232; MILLER S, 1992, NATURE, V355, P420, DOI 10.1038/355420a0; MILLER S, 1994, CAN J PHYS, V72, P760, DOI 10.1139/p94-100; MITCHELL GF, 1990, ASTROPHYS J, V363, P554, DOI 10.1086/169365; OKA T, 1981, PHILOS T R SOC A, V303, P543, DOI 10.1098/rsta.1981.0223; OKA T, 1980, PHYS REV LETT, V45, P531, DOI 10.1103/PhysRevLett.45.531; Schutte WA, 1996, ASTRON ASTROPHYS, V309, P633; SPITZER L, 1975, ANNU REV ASTRON ASTR, V13, P133, DOI 10.1146/annurev.aa.13.090175.001025; SUZUKI H, 1979, PROG THEOR PHYS, V62, P936, DOI 10.1143/PTP.62.936; TIELENS AGGM, 1991, ASTROPHYS J, V381, P181, DOI 10.1086/170640; TRAFTON LM, 1993, ASTROPHYS J, V405, P761, DOI 10.1086/172404; WATSON WD, 1973, ASTROPHYS J, V183, pL17, DOI 10.1086/181242; WATSON WD, 1976, REV MOD PHYS, V48, P513, DOI 10.1103/RevModPhys.48.513	25	301	304	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 28	1996	384	6607					334	335		10.1038/384334a0	http://dx.doi.org/10.1038/384334a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934516				2022-12-28	WOS:A1996VV27100040
J	Sornson, MW; Wu, W; Dasen, JS; Flynn, SE; Norman, DJ; OConnell, SM; Gukovsky, I; Carriere, C; Ryan, AK; Miller, AP; Zuo, L; Gleiberman, AS; Andersen, B; Beamer, WG; Rosenfeld, MG				Sornson, MW; Wu, W; Dasen, JS; Flynn, SE; Norman, DJ; OConnell, SM; Gukovsky, I; Carriere, C; Ryan, AK; Miller, AP; Zuo, L; Gleiberman, AS; Andersen, B; Beamer, WG; Rosenfeld, MG			Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism	NATURE			English	Article							GENE; EXPRESSION; MICE; DNA; DROSOPHILA; MUTATION; ARISTALESS; FRAGMENTS; SEQUENCE; CONTAINS	The gene apparently responsible for a heritable form of murine pituitary-dependent dwarfism (Ames dwarf, df) has been positionally cloned, identifying a novel, tissue-specific, paired-like homeodomain transcription factor, termed Prophet of Pit-1 (Prop-1). The df phenotype results from an apparent failure of initial determination of the Pit-1 lineage required for production of growth hormone, prolactin or thyroid-stimulating hormone, resulting in dysmorphogenesis and failure to activate Pit-1 gene expression. These results imply that a cascade of tissue-specific regulators is responsible for the determination and differentiation of specific cell lineages in pituitary organogenesis.	UNIV CALIF SAN DIEGO,DEPT & SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT & SCH MED,BIOL GRAD PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT & SCH MED,BIOMED SCI GRAD PROGRAM,LA JOLLA,CA 92093; SEQUANA THERAPEUT INC,LA JOLLA,CA 92037; JACKSON LAB,BAR HARBOR,ME 04609	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Jackson Laboratory				gleiberman, anatoli/0000-0001-8491-0826				Andersen B, 1995, DEV BIOL, V172, P495, DOI 10.1006/dbio.1995.8040; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BARTKE A, 1965, MOUSE NEWSLETT, V32, P52; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BUCKWALTER MS, 1991, GENOMICS, V10, P515, DOI 10.1016/0888-7543(91)90430-M; BUM TC, 1995, GENE, V161, P183; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; COULY G, 1988, DEVELOPMENT, V103, P101; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gage PJ, 1996, DEVELOPMENT, V122, P151; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HEMESZ E, 1996, DEVELOPMENT, V122, P41; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; KEYNES R, 1994, ANNU REV NEUROSCI, V17, P109, DOI 10.1146/annurev.ne.17.030194.000545; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LISITSYN NA, 1994, NAT GENET, V6, P57, DOI 10.1038/ng0194-57; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; Oliver G, 1995, DEVELOPMENT, V121, P4045; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; Schaible R., 1961, Genetics, V46, P896; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SZETO DP, 1996, P NATL ACAD SCI USA, V15, P7706; THOMAS PQ, 1995, J BIOL CHEM, V270, P3869, DOI 10.1074/jbc.270.8.3869; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WATANABE YG, 1982, CELL TISSUE RES, V227, P257, DOI 10.1007/BF00210884; WIJNHOLDS J, 1995, DEV BIOL, V171, P73, DOI 10.1006/dbio.1995.1261; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0	48	560	573	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					327	333		10.1038/384327a0	http://dx.doi.org/10.1038/384327a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934515				2022-12-28	WOS:A1996VV27100039
J	Carrington, A				Carrington, A			Microwave spectroscopy at the dissociation limit	SCIENCE			English	Article							VIBRATION-ROTATION LEVELS; ELECTRONIC-SPECTRUM; ION; H-2(+); STATE; HEH2+; HD+	An ion beam technique has been developed that combines some of the methods of mass spectrometry and molecular spectroscopy and is designed for the study of molecular ions at energy levels lying very close to the lowest dissociation limit. Microwave radiation is used to drive spectroscopic transitions, and electric field dissociation of the weakly bound levels provides a high degree of state selection for sensitive detection of the spectra. The analysis of the spectra requires unconventional approaches to the description of the long-range levels and their spectroscopic study and provides stringent tests of ab initio theories.			Carrington, A (corresponding author), UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND.							CARRINGTON A, 1993, J CHEM SOC FARADAY T, V89, P603, DOI 10.1039/ft9938900603; CARRINGTON A, 1993, J CHEM PHYS, V98, P5290, DOI 10.1063/1.464928; CARRINGTON A, 1995, J CHEM PHYS, V102, P5979, DOI 10.1063/1.469332; CARRINGTON A, 1995, J CHEM PHYS, V102, P2379, DOI 10.1063/1.468670; Carrington A, 1996, CHEM PHYS LETT, V260, P395, DOI 10.1016/0009-2614(96)00860-3; CARRINGTON A, 1995, CHEM PHYS LETT, V241, P611, DOI 10.1016/0009-2614(95)00644-J; CARRINGTON A, 1989, MOL PHYS, V66, P1279, DOI 10.1080/00268978900100881; CARRINGTON A, 1995, J CHEM SOC FARADAY T, V91, P1887, DOI 10.1039/ft9959101887; CARRINGTON A, IN PRESS CHEM PHYS L; CARRINGTON A, IN PRESS J CHEM PHYS; CARRINGTON A, UNPUB; Coulson CA, 1941, P ROY SOC EDINB A, V61, P20, DOI 10.1017/s0080454100006038; Falcetta MF, 1996, MOL PHYS, V88, P647, DOI 10.1080/00268979650026190; Herzberg G, 2008, MOL SPECTRA MOL STRU, VI; HUTSON JM, 1994, COMPUT PHYS COMMUN, V84, P1, DOI 10.1016/0010-4655(94)90200-3; JEFFERTS KB, 1968, PHYS REV LETT, V20, P39, DOI 10.1103/PhysRevLett.20.39; JEFFERTS KB, 1969, PHYS REV LETT, V23, P1476, DOI 10.1103/PhysRevLett.23.1476; MCLAUGHLIN DR, 1979, J CHEM PHYS, V70, P2748, DOI 10.1063/1.437861; MOSS RE, 1993, MOL PHYS, V78, P371, DOI 10.1080/00268979300100291; MOSS RE, 1993, MOL PHYS, V80, P1541, DOI 10.1080/00268979300103211; PEAK JM, 1969, J CHEM PHYS, V50, P4595; SPIRKO V, 1995, J MOL SPECTROSC, V172, P265, DOI 10.1006/jmsp.1995.1174; Teller E, 1930, Z PHYS, V61, P458, DOI 10.1007/BF01330302; TENNYSON J, 1987, J CHEM PHYS, V87, P6648, DOI 10.1063/1.453399; YU N, 1987, PHYS REV LETT, V59, P2055, DOI 10.1103/PhysRevLett.59.2055	25	28	28	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1327	1331		10.1126/science.274.5291.1327	http://dx.doi.org/10.1126/science.274.5291.1327			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910262				2022-12-28	WOS:A1996VU95400038
J	Alavanja, MCR; Brownson, RC; Berger, E; Lubin, J; Modigh, C				Alavanja, MCR; Brownson, RC; Berger, E; Lubin, J; Modigh, C			Avian exposure acid risk of lung cancer in women in Missouri: Population based case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSMOKING WOMEN; UNITED-STATES; PET BIRDS	Objective-To investigate the association, previously reported in three European studies, between ownership of pet birds and the risk of lung cancer. Design-A population based case-control study with a structured questionnaire administered by telephone. Setting-Missouri, a midwestern state in the United States with a population of about 5 million. Subjects-All newly diagnosed cases of primary lung cancer in women aged 30-84 years in Missouri from 1 January 1993 to 31 January 1994 reported to the state cancer registry were invited to participate (n = 652); and 629 population based controls. Main outcome measures-Odds ratios were computed in relation to whether or not the study subject ever kept pet birds, the type of bird kept, and several measures of intensity or duration of exposure. Odds ratios were adjusted for smoking. Results-The odds ratio (95% confidence interval) for the development of lung cancer associated with keeping pet birds was 0.84 (0.65 to 1.09). The results were similar for the type of pet bird kept, the number of birds kept, the location of the bird in the house, and the duration of ownership. Conclusion-The keeping of pet birds carries no excess risk for the development of lung cancer.	ST LOUIS UNIV, SCH PUBL HLTH, DEPT COMMUNITY MED, ST LOUIS, MO 63108 USA; INFORMAT MANAGEMENT SERV INC, ROCKVILLE, MD 20904 USA; GOTHENBURG UNIV, GOTHENBURG, SWEDEN	Saint Louis University; Information Management Services, Inc.; University of Gothenburg	Alavanja, MCR (corresponding author), NCI, EPIDEMIOL & BIOSTAT PROGRAM, DIV CANC EPIDEMIOL & GENET, EXECUT PLAZA N, ROOM 430, ROCKVILLE, MD 20852 USA.				NCI NIH HHS [CP-95654-13] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623, DOI 10.1093/oxfordjournals.aje.a116542; ALAVANJA MCR, 1994, J NATL CANCER I, V86, P1829, DOI 10.1093/jnci/86.24.1829; ALAVANJA MCR, 1993, J NATL CANCER I, V85, P1906, DOI 10.1093/jnci/85.23.1906; ALAVANJA MCR, 1995, CANCER CAUSE CONTROL, V6, P209, DOI 10.1007/BF00051792; [Anonymous], 1982, AM J CLIN PATHOL, V77, P123; BLAIR A, 1991, OCCUP MED, V6, P335; BOURNE WRP, 1975, PRACTITIONER, V215, P165; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BROWNSON RC, 1993, CANCER CAUSE CONTROL, V4, P449, DOI 10.1007/BF00050864; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P1525, DOI 10.2105/AJPH.82.11.1525; GARDINER AJS, 1992, BRIT MED J, V305, P989, DOI 10.1136/bmj.305.6860.989; GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.1093/biomet/57.3.471; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; KOHLMEIER L, 1992, BMJ-BRIT MED J, V305, P986, DOI 10.1136/bmj.305.6860.986; KOSS IG, 1979, DIAGNOSTIC CYTOLOGY, P6; MARTIN G, 1989, HCFA PUBLICATION, P181; Modigh C, 1996, BMJ-BRIT MED J, V313, P1236, DOI 10.1136/bmj.313.7067.1236; WEINBERG CR, 1991, AM J EPIDEMIOL, V134, P421, DOI 10.1093/oxfordjournals.aje.a116104; WEINBERG CR, 1990, BIOMETRICS, V46, P963, DOI 10.2307/2532441	19	22	22	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1996	313	7067					1233	1235		10.1136/bmj.313.7067.1233	http://dx.doi.org/10.1136/bmj.313.7067.1233			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939111	Green Published			2022-12-28	WOS:A1996VU20800020
J	Hanein, D; Matlack, KES; Jungnickel, B; Plath, K; Kalies, KU; Miller, KR; Rapoport, TA; Akey, CW				Hanein, D; Matlack, KES; Jungnickel, B; Plath, K; Kalies, KU; Miller, KR; Rapoport, TA; Akey, CW			Oligomeric rings of the Sec61p complex induced by ligands required for protein translocation	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SECRETORY PROTEINS; CONDUCTING CHANNEL; ER-MEMBRANE; YEAST; INSERTION; COMPONENTS; RIBOSOMES; POLYPEPTIDES; TRANSPORT	The heterotrimeric Sec61p complex is a major component of the protein-conducting channel of the endoplasmic reticulum (ER) membrane, associating with either ribosomes or the Sec62/63 complex to perform co- and posttranslational transport, respectively. We show by electron microscopy that purified mammalian and yeast Sec61p complexes in detergent form cylindrical oligomers with a diameter of similar to 85 Angstrom and a central pore of similar to 20 Angstrom. Each oligomer contains 3-4 heterotrimers. Similar ring structures are seen in reconstituted proteoliposomes and native membranes. Oligomer formation by the reconstituted Sec61p complex is stimulated by its association with ribosomes or the Sec62/63p complex. We propose that these cylindrical oligomers represent protein-conducting channels of the ER, formed by ligands specific for co- and posttranslational transport.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912	Harvard University; Harvard Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Brown University	Hanein, D (corresponding author), BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02218, USA.			Plath, Kathrin/0000-0001-7796-3372; Akey, Christopher/0000-0002-3059-3121				AKEY CW, 1995, J MOL BIOL, V248, P273, DOI 10.1016/S0022-2836(95)80050-6; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; FRANK J, 1988, J MICROSC-OXFORD, V150, P99, DOI 10.1111/j.1365-2818.1988.tb04602.x; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GIDDINGS TH, 1980, J CELL BIOL, V85, P147, DOI 10.1083/jcb.85.1.147; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NICCHITTA CV, 1995, J CELL BIOL, V129, P957, DOI 10.1083/jcb.129.4.957; OJAKIAN GK, 1977, J CELL BIOL, V72, P530, DOI 10.1083/jcb.72.3.530; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; RAPOPORT TA, 1985, FEBS LETT, V187, P1, DOI 10.1016/0014-5793(85)81202-3; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; [No title captured]	38	275	280	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					721	732		10.1016/S0092-8674(00)81391-4	http://dx.doi.org/10.1016/S0092-8674(00)81391-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929540	hybrid			2022-12-28	WOS:A1996VU03500014
J	Mason, D; Kerry, S; Oakeshott, P				Mason, D; Kerry, S; Oakeshott, P			Postal survey of management of cervical Chlamydia trachomatis infection in English and Welsh general practices	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,DEPT GEN PRACTICE & PRIMARY CARE,LONDON SW17 0RE,ENGLAND	St Georges University London				Oakeshott, Pippa/0000-0003-2568-8211				*BRIT MED ASS ROYA, 1995, BRIT NAT FORM, P236; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; OWEN PA, 1991, BRIT J GEN PRACT, V41, P279; SOUTHGATE LJ, 1983, BRIT MED J, V287, P879, DOI 10.1136/bmj.287.6396.879; TAYLORROBINSON D, 1994, BMJ-BRIT MED J, V308, P150, DOI 10.1136/bmj.308.6922.150	5	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1193	1194		10.1136/bmj.313.7066.1193	http://dx.doi.org/10.1136/bmj.313.7066.1193			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916756	Green Published			2022-12-28	WOS:A1996VR90700029
J	Rous, E; Coppel, A; Haworth, J; Noyce, S				Rous, E; Coppel, A; Haworth, J; Noyce, S			A purchaser experience of managing new expensive drugs: Interferon beta	BRITISH MEDICAL JOURNAL			English	Article							CYSTIC-FIBROSIS	Interferon beta is a new and expensive drug for treating multiple sclerosis. One published trial has shown that it reduces the exacerbation rate in patients who have relapsing-remitting disease without important disability. This paper describes the development of a strategy for purchasing the drug in one region of England before its licensing. Purchasers felt unable to decline funding for this marginally effective drug and thereby undertake explicit rationing. To ensure prescribing was within the guidelines, a vast communication network had to be sustained with managers, general practitioners, neurologists, the Multiple Sclerosis Society, and professional advisers in all the purchasing authorities. The workload involved was considerable. The dilemma of rationing in a public service with a high political profile is demonstrated.	E LANCASHIRE HLTH COMMISS,NELSON,LANCS,ENGLAND; SEFTON HLTH,LIVERPOOL L22 0QB,MERSEYSIDE,ENGLAND		Rous, E (corresponding author), STOCKPORT HLTH AUTHOR,SPRINGWOOD HOUSE,STOCKPORT SK7 5BY,ENGLAND.							DAVIES LM, 1990, PSYCHIATRIC B, V14, P522; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; MCDONALD WI, 1995, BRIT MED J, V310, P345, DOI 10.1136/bmj.310.6976.345; MELTZER HY, 1993, AM J PSYCHIAT, V150, P1630; The IFNb Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WALLEY T, 1995, BRIT MED J, V311, P796, DOI 10.1136/bmj.311.7008.796	7	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1195	1196		10.1136/bmj.313.7066.1195	http://dx.doi.org/10.1136/bmj.313.7066.1195			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916757	Green Published			2022-12-28	WOS:A1996VR90700030
J	Stock, J				Stock, J			Signalling across membranes: A one and a two and a ...	SCIENCE			English	Editorial Material							ASPARTATE RECEPTOR; TRANSDUCTION; BACTERIA; CELL				Stock, J (corresponding author), PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544, USA.							Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KIM SH, 1994, PROTEIN SCI, V3, P159; MADDOCK JR, 1993, SCIENCE, V259, P1717; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141	19	15	15	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					370	371		10.1126/science.274.5286.370	http://dx.doi.org/10.1126/science.274.5286.370			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8927993				2022-12-28	WOS:A1996VN17300037
J	Selby, JV; Fireman, BH; Lundstrom, RJ; Swain, BE; Truman, AF; Wong, CC; Froelicher, ES; Barron, HV; Hlatky, MA				Selby, JV; Fireman, BH; Lundstrom, RJ; Swain, BE; Truman, AF; Wong, CC; Froelicher, ES; Barron, HV; Hlatky, MA			Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY BYPASS-SURGERY; UNITED-STATES; CANADA; MANAGEMENT; RATES; AGE	Background Wide geographic variation in the use of coronary angiography after myocardial infarction has been documented internationally and within the United States. An associated variation in clinical outcomes has not been consistently demonstrated. Methods We assessed the risk of death from heart disease and of any heart disease event (death, reinfarction, or rehospitalization) over a follow-up period of one to four years in 6851 patients hospitalized with acute myocardial infarction at 16 Kaiser Permanente hospitals from 1990 through 1992. The percentage age of patients who underwent angiography within three months after infarction ranged from 30 to 77 percent. We selected a subcohort of 1109 patients from three hospitals with higher rates of angiography and four with lower rates for a record review to assess the severity of infarction, the number of coexisting conditions, treatments received, and the appropriateness and necessity of angiography, using established criteria. Results The rates of angiography were inversely related to the risk of death from heart disease (P=0.03) and the risk of heart disease events (P<0.001) among the 16 hospitals after adjustment for age, sex, race, coexisting conditions, and the location of the infarction (subendocardial vs. transmural). In the subcohort 440 patients met criteria indicating that angiography was necessary and 669 did not. Among the former, patients treated at hospitals with higher rates of angiography had a lower risk of death and of any heart disease event than those treated at hospitals with lower rates (hazard ratios, 0.67 and 0.72, respectively). Among the latter, the apparent benefits of being treated at hospitals with higher angiography rates were smaller (hazard ratios, 0.85 to 0.90 for death and any heart disease event, respectively). Conclusions During the one to four years after myocardial infarction, patients treated at hospitals with higher rates of angiography had more favorable outcomes than those treated at hospitals with lower rates. This association was stronger among patients for whom published criteria indicated that angiography was necessary.	KAISER PERMANENTE MED CTR,DIV CARDIOL,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL NURSING,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; STANFORD UNIV,MED CTR,SCH MED,DEPT HLTH RES & POOLICY,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University	Selby, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM NO CALIF REG,DIV RES,3505 BROADWAY,OAKLAND,CA 94611, USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Hlatky, Mark/0000-0003-4686-9441	AHRQ HHS [HS08362] Funding Source: Medline; NHLBI NIH HHS [HL02942] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008362] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM COLL CARD AM H, 1987, CIRCULATION, V76, pA963; ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; BERNSTEIN SJ, 1992, RAND PUBLICATION; Brook Robert H., 1991, CORONARY ARTERY BYPA, P13; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; Hilborne LH, 1991, RAND PUBLICATION; KAHAN JP, 1994, MED CARE, V32, P357, DOI 10.1097/00005650-199404000-00004; KUHN EM, 1995, HEALTH SERV RES, V30, P425; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907	13	155	155	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1888	1896		10.1056/NEJM199612193352506	http://dx.doi.org/10.1056/NEJM199612193352506			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948565				2022-12-28	WOS:A1996VX87400006
J	Husmann, S; Jin, DS; Zastavker, YV; Rosenbaum, TF; Yao, X; Honig, JM				Husmann, S; Jin, DS; Zastavker, YV; Rosenbaum, TF; Yao, X; Honig, JM			Dynamical signature of the Mott-Hubbard transition in Ni(S,SE)(2)	SCIENCE			English	Article							METAL-INSULATOR-TRANSITION; NIS2-XSEX SYSTEM; DISORDERED-SYSTEMS; PHASE; NIS2	The transition metal chalcogenide Ni(S,Se)(2) is one of the few highly correlated, Mott-Hubbard systems without a strong first-order structural distortion that normally cuts off the critical behavior at the metal-insulator transition. The zero-temperature (T) transition was tuned with pressure, and significant deviations were found near the quantum critical point from the usual T-1/2 behavior of the conductivity characteristic of electron-electron interactions in the presence of disorder. The transport data for pressure and temperature below 1 kelvin could be collapsed onto a universal scaling curve.	UNIV CHICAGO,JAMES FRANCK INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHYS,CHICAGO,IL 60637; PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	University of Chicago; University of Chicago; Purdue University System; Purdue University; Purdue University West Lafayette Campus								ALTSHULER BL, 1980, PHYS REV LETT, V44, P1288, DOI 10.1103/PhysRevLett.44.1288; BELITZ D, 1994, REV MOD PHYS, V66, P261, DOI 10.1103/RevModPhys.66.261; BOUCHARD RJ, 1973, MATER RES BULL, V8, P489, DOI 10.1016/0025-5408(73)90124-4; BRINKMAN WF, 1971, PHYS REV LETT, V27, P941; CARTER SA, 1993, PHYS REV B, V48, P16841, DOI 10.1103/PhysRevB.48.16841; CASTELLANI C, 1987, PHYS REV LETT, V59, P323, DOI 10.1103/PhysRevLett.59.323; ENDO S, 1973, PHYS LETT A, VA 46, P29, DOI 10.1016/0375-9601(73)90671-3; Finkelstein A. M., 1990, SOV SCI REV 2, V14, P1; FINKELSTEIN AM, 1983, ZH EKSP TEOR FIZ, V57, P97; GAUTIER F, 1975, PHYS LETT A, VA 53, P31, DOI 10.1016/0375-9601(75)90333-3; JARRETT HS, 1973, MATER RES BULL, V8, P877, DOI 10.1016/0025-5408(73)90071-8; KIRKPATRICK TR, 1994, PHYS REV LETT, V73, P862, DOI 10.1103/PhysRevLett.73.862; KIRKPATRICK TR, 1995, PHYS REV LETT, V74, P1178, DOI 10.1103/PhysRevLett.74.1178; KLEMM DD, 1962, JB MINERAL MONATSH J, V32; KLEMM DD, 1962, JB MINERAL MONATSH J, P32; KOURTAKIS K, 1988, J SOLID STATE CHEM, V76, P186, DOI 10.1016/0022-4596(88)90206-X; KRILL G, 1980, J PHYS CHEM SOLIDS, V41, P531, DOI 10.1016/0022-3697(80)90002-5; KWIZERA P, 1980, PHYS REV B, V21, P2328, DOI 10.1103/PhysRevB.21.2328; LEE PA, 1985, REV MOD PHYS, V57, P287, DOI 10.1103/RevModPhys.57.287; Matsuura AY, 1996, PHYS REV B, V53, pR7584, DOI 10.1103/PhysRevB.53.R7584; MCWHAN DB, 1969, PHYS REV LETT, V22, P887, DOI 10.1103/PhysRevLett.22.887; MIYADAI T, 1992, J MAGN MAGN MATER, V104, P1953, DOI 10.1016/0304-8853(92)91619-5; Mori N., 1985, Solid State Physics under Pressure: Recent Advance with Anvil Devices, P247; ROSENBAUM TF, 1981, PHYS REV LETT, V46, P568, DOI 10.1103/PhysRevLett.46.568; Rosenbaum TF, 1996, REV SCI INSTRUM, V67, P617, DOI 10.1063/1.1146619; ROSENBAUM TF, 1995, METAL NONMETAL TRANS, P105; SUDO S, 1992, J MAGN MAGN MATER, V114, P57, DOI 10.1016/0304-8853(92)90332-I; SUDO S, 1986, J PHYS SOC JPN, V55, P1806, DOI 10.1143/JPSJ.55.1806; TOKURA Y, 1993, PHYS REV LETT, V70, P2126, DOI 10.1103/PhysRevLett.70.2126; WEGNER FJ, 1976, Z PHYS B CON MAT, V25, P327, DOI 10.1007/BF01315248; Wilson J. A., 1985, METALLIC NONMETALLIC, P215; WILSON JA, 1971, PHILOS MAG, V23, P1297, DOI 10.1080/14786437108217003; YAO X, 1995, METAL NONMETAL TRANS, P129; YAO X, PREPRINT; YAO XQ, 1994, MATER RES BULL, V29, P709, DOI 10.1016/0025-5408(94)90195-3; ZAANEN J, 1985, PHYS REV LETT, V55, P418, DOI 10.1103/PhysRevLett.55.418; ZHANG XY, 1993, PHYS REV LETT, V70, P1666, DOI 10.1103/PhysRevLett.70.1666	37	54	60	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1874	1876		10.1126/science.274.5294.1874	http://dx.doi.org/10.1126/science.274.5294.1874			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943193				2022-12-28	WOS:A1996VY20000033
J	Buynak, EB; Roehm, RR; Tytell, AA; Bertland, AU; Lampson, GP; Hilleman, MR				Buynak, EB; Roehm, RR; Tytell, AA; Bertland, AU; Lampson, GP; Hilleman, MR			Vaccine against human hepatitis B (Reprinted from JAMA, vol 235, pg 2832-2834, 1976)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint							AUSTRALIA-ANTIGEN; VIRUS; SERUM; CR326	A highly purified and inactivated Vaccine was made of hepatitis B virus surface antigen. The vaccine was tested exhaustively for safety by ordinary procedures and additionally in chimpanzees and marmosets. It was highly potent and induced antibody in guinea pigs, grivet monkeys, and chimpanzees after three doses of vaccine were given subcutaneously. Chimpanzees given three doses of vaccine were protected against challenge with 1,000 chimpanzee-infectious doses of live human hepatitis a virus given intravenously in controlled studies, Tests of the vaccine for control of hepatitis a in man are to be carried out.	MERCK INST THERAPEUT RES, DIV VIRUS & CELL BIOL RES, W POINT, PA 19456 USA									BARKER LF, 1973, J INFECT DIS, V127, P648, DOI 10.1093/infdis/127.6.648; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; BLUMBERG BS, 1967, ANN INTERN MED, V66, P924, DOI 10.7326/0003-4819-66-5-924; BUYNAK EB, 1976, JAMA-J AM MED ASSOC, V235, P2832, DOI 10.1001/jama.235.26.2832; DANE DS, 1970, LANCET, V1, P695; GERIN JL, 1971, J VIROL, V7, P569, DOI 10.1128/JVI.7.5.569-576.1971; HILLEMAN MR, 1975, AM J MED SCI, V270, P401, DOI 10.1097/00000441-197509000-00025; HOFFNAGLE JH, 1973, LANCET, V2, P869; KRUGMAN S, 1971, J AMER MED ASSOC, V217, P41, DOI 10.1001/jama.217.1.41; MAYNARD JE, 1972, NATURE, V237, P514, DOI 10.1038/237514a0; MILLER WJ, 1975, P SOC EXP BIOL MED, V149, P254; PRINCE AM, 1968, P NATL ACAD SCI USA, V60, P814, DOI 10.1073/pnas.60.3.814; PROVOST PJ, 1975, P SOC EXP BIOL MED, V148, P532; PROVOST PJ, 1973, P SOC EXP BIOL MED, V142, P1257, DOI 10.3181/00379727-142-37220; PURCELL RH, 1969, J INFECT DIS, V120, P383, DOI 10.1093/infdis/120.3.383	15	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1793	1795		10.1001/jama.276.22.1793	http://dx.doi.org/10.1001/jama.276.22.1793			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946889				2022-12-28	WOS:A1996VV99700013
J	Black, DM; Cummings, SR; Karpf, DB; Cauley, JA; Thompson, DE; Nevitt, MC; Bauer, DC; Genant, HK; Haskell, WL; Marcus, R; Ott, SM; Torner, JC; Quandt, SA; Reiss, TF; Ensrud, KE				Black, DM; Cummings, SR; Karpf, DB; Cauley, JA; Thompson, DE; Nevitt, MC; Bauer, DC; Genant, HK; Haskell, WL; Marcus, R; Ott, SM; Torner, JC; Quandt, SA; Reiss, TF; Ensrud, KE			Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures	LANCET			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; BONE MASS; ETIDRONATE TREATMENT; HIP-FRACTURES; ELDERLY WOMEN; THERAPY; CALCIUM; FLUORIDE; DISEASE	Background Previous studies have shown that alendronate can increase bone mineral density (BMD) and prevent radiographically defined (morphometric) vertebral fractures. The Fracture Intervention Trial aimed to investigate the effect of alendronate on the risk of morphometric as well as clinically evident fractures in postmenopausal women with low bone mass. Methods Women aged 55-81 with low femoral-neck BMD were enrolled in two study groups based on presence or absence of an existing vertebral fracture. Results for women with at least one vertebral fracture at baseline are reported here. 2027 women were randomly assigned placebo (1005) or alendronate (1022) and followed up for 36 months. The dose of alendronate (initially 5 mg daily) was increased (to 10 mg daily) at 24 months, with maintenance of the double blind. Lateral spine radiography was done at baseline and at 24 and 36 months. New vertebral fractures, the primary endpoint, were defined by morphometry as a decrease of 20% (and at least 4 mm) in at least one vertebral height between the baseline and latest follow-up radiograph. Non-spine clinical fractures were confirmed by radiographic reports, New symptomatic vertebral fractures were based on self-report and confirmed by radiography. Findings Follow-up radiographs were obtained for 1946 women (98% of surviving participants). 78 (8.0%) of women in the alendronate group had one or more new morphometric vertebral fractures compared with 145 (15.0%) in the placebo group (relative risk 0.53 [95% CI 0.41-0.68]). For clinically apparent vertebral fractures, the corresponding numbers were 23 (2.3%) alendronate and 50 (5.0%) placebo (relative hazard 0.45 [0.27-0.72]). The risk of any clinical fracture, the main secondary endpoint, was lower in the alendronate than in the placebo group (139 [13.6%] vs 183 [18.2%]; relative hazard 0.72 [0.58-0.90]). The relative hazards for hip fracture and wrist fracture for alendronate versus placebo were 0.49 (0.23-0.99) and 0.52 (0.31-0.87). There was no significant difference between the groups in numbers of adverse experiences, including upper-gastrointestinal disorders. Interpretation We conclude that among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebral fractures, as well as other clinical fractures.	MERCK RES LABS,RAHWAY,NJ; UNIV PITTSBURGH,PITTSBURGH,PA; STANFORD UNIV,PALO ALTO,CA 94304; VET ADM MED CTR,PALO ALTO,CA 94304; UNIV WASHINGTON,SEATTLE,WA 98195; UNIV IOWA,IOWA CITY,IA; WAKE FOREST UNIV,WINSTON SALEM,NC 27109; UNIV MINNESOTA,VET ADM MED CTR,MINNEAPOLIS,MN 55455	Merck & Company; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Iowa; Wake Forest University; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Black, DM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,BOX 0886,SAN FRANCISCO,CA 94143, USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408; Ensrud, Kristine/0000-0002-9069-3036				BLACK DM, 1993, OSTEOPOROSIS INT, V3, pS29; BLACK DM, 1995, J BONE MINER RES, V10, P890; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COOPER C, 1992, BRIT MED J, V304, P793, DOI 10.1136/bmj.304.6830.793; COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184; Cox D. R., 1984, ANAL SURVIVAL DATA; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; DAWSONHUGHES B, 1990, CALCIFIED TISSUE INT, V46, P280, DOI 10.1007/BF02555008; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; GENANT HK, 1995, VERTEBRAL FRACTURE O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENSPAN SL, 1994, J BONE MINER RES, V9, P1959, DOI 10.1002/jbmr.5650091216; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOTOWICZ MA, 1994, J BONE MINER RES, V9, P599; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LINDSAY R, 1987, BRIT MED J, V294, P1261; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; *NAT OST FDN WORK, 1995, J BONE MINER RES, V10, P518; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; PAK CYC, 1995, ANN INTERN MED, V123, P401, DOI 10.7326/0003-4819-123-6-199509150-00001; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	30	2882	2994	5	126	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1535	1541		10.1016/S0140-6736(96)07088-2	http://dx.doi.org/10.1016/S0140-6736(96)07088-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950879				2022-12-28	WOS:A1996VX02300007
J	Pilsczek, FH				Pilsczek, FH			A visiting doctor's perspective in Afghanistan: Poverty, civil war, and private medicine	LANCET			English	Article								Starvation, disease, death, war, and migration in many developing countries underscore the need for support from the richer nations of the world. In Afghanistan, for example, resources for hospital medicine are appallingly few, as I witnessed during a visit to the department of internal medicine in the Public Health Hospital, Jalalabad, during 1994-95. Infectious disease accounted for more than half of all admissions (mostly malaria and typhoid), and giving multiple drugs was common. According to a WHO report in 1994, conditions in the wards of the department were ''the worst...anywhere in the world''. Doctors' salaries were so low that income was supplemented by work in private clinics, where only the better-off could afford to pay for consultation and laboratory tests. While poverty and political instability remain, there is little hope for Afghanistan.			Pilsczek, FH (corresponding author), TYRONE CTY HOSP,DEPT MED,OMAGH BT79 0AP,NORTH IRELAND.							DELAMOTHE T, 1995, BRIT MED J, V310, P1343, DOI 10.1136/bmj.310.6991.1343; Edwards CRW, 1991, DAVIDSONS PRINCIPLES; GERMAN T, 1995, REALITY AID 95 INDEP; ISSELBACHER KJ, 1994, HARRISONS PRINCIPLES; KAKAR F, 1995, DIIRECT INDIRECT CON; King M, 1995, HEALTH POLICY PLANN, V10, P376, DOI 10.1093/heapol/10.4.376; *MIN PUBL HLTH, 1995, REG PLAN ACT E REG 1; ROBERTSON AJ, 1994, PHYSICIANS VIEW AFGH; ROBERTSON AJ, 1995, PHYSICIANS VIEW AFGH; TIERNEY LM, 1995, CURRENT MED DIAGNOSI; *UN, 1944, STAT YB; UNITED NATIONS, 1993, STAT YB; *UNOCHA, 1994, MIN CLEAR PROGR MID; *US DEP STAT, 1993, HIDD KILL GLOB PROBL	14	5	5	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1566	1568		10.1016/S0140-6736(96)05460-8	http://dx.doi.org/10.1016/S0140-6736(96)05460-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950886				2022-12-28	WOS:A1996VX02300014
J	Vatten, L				Vatten, L			Can prenatal factors influence future breast cancer risk?	LANCET			English	Editorial Material											Vatten, L (corresponding author), UNIV TRONDHEIM,MED CTR,N-7005 TRONDHEIM,NORWAY.		Vatten, Lars/AAF-9380-2022; Vatten, Lars/AFK-2073-2022					Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Rosner B, 1996, J NATL CANCER I, V88, P359, DOI 10.1093/jnci/88.6.359; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007	4	7	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1531	1531		10.1016/S0140-6736(05)66164-8	http://dx.doi.org/10.1016/S0140-6736(05)66164-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950875				2022-12-28	WOS:A1996VX02300003
J	Egglin, TKP; Feinstein, AR				Egglin, TKP; Feinstein, AR			Context bias - A problem in diagnostic radiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL HISTORY; TESTS; SPECTRUM; DISEASE; CT	Objective.-To determine whether radiologists' interpretations of images are biased by their context and by prevalence of disease in other recently observed cases. Methods.-A test set of 24 right pulmonary arteriograms with a 33% prevalence of pulmonary emboli (PE) was assembled and embedded in 2 larger groups of films. Group A contained 16 additional arteriograms, all showing PE involving the right lung, so that total prevalence was 60%. Group B contained 16 additional arteriograms without PE so that total prevalence was 20%. Six radiologists were randomly assigned to see either group first and then ''cross over'' to review the other group after a hiatus of at least 8 weeks. The direction of changes in a 5-point rating scale for the 2 readings of each film in the test set was compared with the sign test; mean sensitivity, specificity, and areas under receiver operating characteristic (ROC) curves were compared with the paired t test. Results.-In the context of group A's higher disease prevalence, radiologists shifted more of their diagnoses toward higher suspicion than expected by chance (P=.03, sign test). In group A, mean sensitivity for diagnosing PE was significantly higher (75% vs 60%; P=.04), and area under the ROC curve was significantly larger (0.88 vs 0.82; P=.02). Conclusions.-Radiologists' diagnoses are significantly influenced by the context of interpretation, even when spectrum and verification bias are avoided. This ''context bias'' effect is unique to the evaluation of subjectively interpreted tests, and illustrates the difficulty of obtaining unbiased estimates of diagnostic accuracy for both new and existing technologies.	YALE UNIV,SCH MED,DEPT INTERNAL MED & EPIDEMIOL,NEW HAVEN,CT 06520	Yale University	Egglin, TKP (corresponding author), YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,333 CEDAR ST,POB 208042,NEW HAVEN,CT 06520, USA.		SALAZAR, ANTONIO/A-5806-2013	SALAZAR, ANTONIO/0000-0003-2639-2340				BABCOOK CJ, 1993, INVEST RADIOL, V28, P214, DOI 10.1097/00004424-199303000-00005; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; BARON JA, 1994, MED DECIS MAKING, V14, P46, DOI 10.1177/0272989X9401400106; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; BERBAUM KS, 1988, RADIOLOGY, V168, P507, DOI 10.1148/radiology.168.2.3393672; BLACK WC, 1986, AM J ROENTGENOL, V147, P1313, DOI 10.2214/ajr.147.6.1313; BRENNER H, 1993, AM J EPIDEMIOL, V138, P1007, DOI 10.1093/oxfordjournals.aje.a116805; Castagnone D, 1996, AM J ROENTGENOL, V166, P203, DOI 10.2214/ajr.166.1.8571877; CHALMERS TC, 1988, JAMA-J AM MED ASSOC, V260, P2713, DOI 10.1001/jama.260.18.2713; COOPER LS, 1988, JAMA-J AM MED ASSOC, V259, P3277, DOI 10.1001/jama.259.22.3277; EGGLIN TK, 1990, RADIOLOGY, V176, P107, DOI 10.1148/radiology.176.1.2162067; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P109, DOI 10.1016/0895-4356(90)90064-V; GREENES RA, 1985, INVEST RADIOL, V20, P751, DOI 10.1097/00004424-198510000-00018; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Kang EY, 1996, AM J ROENTGENOL, V166, P15, DOI 10.2214/ajr.166.1.8571866; Kovanlikaya A, 1996, RADIOLOGY, V198, P781, DOI 10.1148/radiology.198.3.8628871; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; MCNEIL BJ, 1983, RADIOLOGY, V149, P75, DOI 10.1148/radiology.149.1.6611955; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SCHREIBER MH, 1963, JAMA-J AM MED ASSOC, V185, P137; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SHEMESH J, 1995, RADIOLOGY, V197, P779, DOI 10.1148/radiology.197.3.7480756; SOX HC, 1988, MED DECIS MAKING, P103; Sugimoto H, 1996, RADIOLOGY, V198, P185, DOI 10.1148/radiology.198.1.8539375; Weinstein MC, 1980, CLIN DECISION ANAL, P75; WESTRA SJ, 1995, AM J ROENTGENOL, V165, P167, DOI 10.2214/ajr.165.1.7785579; Zar JH., 1999, BIOSTAT ANAL	28	141	142	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1752	1755		10.1001/jama.276.21.1752	http://dx.doi.org/10.1001/jama.276.21.1752			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940325				2022-12-28	WOS:A1996VV56600034
J	Frankel, S; Elwood, P; Sweetnam, P; Yarnell, J; Smith, GD				Frankel, S; Elwood, P; Sweetnam, P; Yarnell, J; Smith, GD			Birthweight, body-mass index in middle age, and incident coronary heart disease	LANCET			English	Article							BIRTH-WEIGHT; RISK	Background Several studies have shown a relation between fetal development, as shown by birthweight, and later coronary heart disease. This study investigated whether this relation is predominantly the consequence of early life exposures, or can best be explained in terms of an interaction between influences in early life and in adulthood. Methods This prospective study in Caerphilly, South Wales, included 1258 men, aged 45-59 at initial screening, who were able to provide birthweight data. These men are from an initial cohort of 2512 men, from whom information has been obtained in a series of examinations since 1979 on health-related behaviours, incidence of coronary heart disease, and risk factors. The main outcome measure was fatal and non-fatal coronary heart disease during 10 years of follow-up. Findings Higher birthweight was related to lower risk of coronary heart disease during the follow-up period: coronary heart disease occurred in 46 (11.6%) men in the lowest birthweight tertile, 44 (12.0%) of those in the middle tertile, and 38 (9.1%) of those in the highest tertile (p=0.03). Stratification of the cohort by body-mass index (BMI) revealed a significant interaction such that the inverse association between birthweight and risk of coronary heart disease was restricted to men in the top tertile of BMI (interaction test p=0.048 adjusted for age, and p=0.012 fully adjusted). Within the top BMI tertile, coronary heart disease occurred in 19 (16.4%) of men in the lowest birthweight tertile, 13 (12.6%) of those in the middle tertile, and 13 (7.5%) of those in the highest tertile (p=0.0005). These associations were not changed substantially by adjustment for age, father's social class, own social class, marital status, fibrinogen and cholesterol concentrations, systolic blood pressure, and smoking history. Interpretation The association between birthweight and risk of coronary heart disease cannot be explained by associations with childhood or adulthood socioeconomic status. Nor do conventional risk factors for coronary heart disease in adulthood account for the association. However, there is an important interaction between birthweight and BMI such that the increased risk of coronary heart disease associated with low birthweight is restricted to people who have high BMI in adulthood. Risk of coronary heart disease seems to be defined by the combined effect of early-life and later-life exposures.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND; LLANDOUGH HOSP, EPIDEMIOL UNIT, MRC, PENARTH, S GLAM, WALES; QUEENS UNIV BELFAST, DEPT EPIDEMIOL & PUBL HLTH, BELFAST, ANTRIM, NORTH IRELAND	University of Bristol; Queens University Belfast			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; POND WG, 1985, J NUTR, V115, P179, DOI 10.1093/jn/115.2.179; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; RICHEDWARDS J, 1995, AM J EPIDEMIOL, V141, pS78; ROTHWELL PM, 1994, LANCET, V343, P731, DOI 10.1016/S0140-6736(94)91610-1; YARNELL JWG, 1992, EUR HEART J, V13, P1602, DOI 10.1093/oxfordjournals.eurheartj.a060111	10	345	353	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 30	1996	348	9040					1478	1480		10.1016/S0140-6736(96)03482-4	http://dx.doi.org/10.1016/S0140-6736(96)03482-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942776				2022-12-28	WOS:A1996VV46300009
J	Faden, RR; Lederer, SE; Moreno, JD				Faden, RR; Lederer, SE; Moreno, JD			US medical researchers, the Nuremberg Doctors Trial, and the Nuremberg Code - A review of findings of the Advisory Committee on Human Radiation Experiments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The Advisory Committee on Human Radiation Experiments (ACHRE), established to review allegations of abuses of human subjects in federally sponsored radiation research, was charged with identifying appropriate standards to evaluate the ethics of cold war radiation experiments. One central question for ACHRE was to determine what role, if any, the Nuremberg Code played in the norms and practices of US medical researchers. Based on the evidence from ACHRE's Ethics Oral History Project and extensive archival research, we conclude that the Code, at the time it was promulgated, had little effect on mainstream medical researchers engaged in human subjects research. Although some clinical investigators raised questions about the conduct of research involving human beings, the medical profession did not pursue this issue until the 1960s.	PENN STATE UNIV, COLL MED, DEPT HUMANITIES, HERSHEY, PA USA; SUNY HLTH SCI CTR, DIV MED, BROOKINGS, SD USA; GEORGETOWN UNIV, KENNEDY INST ETH, WASHINGTON, DC 20057 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Georgetown University	Faden, RR (corresponding author), JOHNS HOPKINS UNIV, BIOETH INST, 624 N BROADWAY, HAMPTON HOUSE 511, BALTIMORE, MD 21205 USA.							ABRAMS H, 1995, FINAL REPORT ADVISOR; *ACHRE, 1995, ACHRE PUBL; *ADV COMM HUM RAD, 1996, ROTH, P85; Annas G., 1992, NAZI DOCTORS NUREMBE, P227; ARNOLD J, 1995, FINAL REPORT ADVISOR; BEECHER HK, 1959, JAMA-J AM MED ASSOC, V169, P461, DOI 10.1001/jama.1959.73000220003010; BEECHER HK, 1995, ACHRE PUBLICATION; BENISON S, 1967, REFLECTIONS LIFE MED, P498; Faden RR, 1996, JAMA-J AM MED ASSOC, V276, P403; FADEN RR, 1993, HIST THEORY INFORMED, P156; FOX RC, 1974, EXPT PERILOUS PHYSIC; GARDELLA JW, 1962, ACHRE PUBLICATION; GARDELLA JW, 1995, ACHRE PUBL; KORITZ T, 1953, SATURDAY EVENIN 0725, V27, P79; LAFOLLETTE MC, 1990, MAKING SCI OUR OWN P, P138; LEVENSON D, 1984, MONTEFIORE HOSP SOCI, P154; MCNEILL PM, 1993, ETHICS POLITICS HUMA, P44; *NAT SOC MED RES, 1959, NAT C LEG ENV MED SC, P88; OHARA JL, 1948, READERS DIGEST   MAY, P30; PIUS XII, 1952, P 1 INT C NEUR SEPT; POFTER RD, 1949, SATURDAY EVENIN 0115; REGAN LJ, 1949, DOCTOR PATIENT LAW, P398; REGAN LJ, 1956, DOCTOR PATIENT LAW, P370; RICKHAM PP, 1964, BRIT MED J, V2, P173; ROTHMAN DJ, 1994, STRANGERS BEDSIDE HI, P62; SHIMKIN MB, 1983, MEMORY SERVES 6 ESSA, P127; SHUSTER A, 1958, NY TIMES MAGAZI 0413, P62; SILVERMAN W, 1995, FINAL REPORT ADVISOR; SIMONS H, 1960, SATURDAY EVENIN 0326, V33, P87; WHARTON D, 1954, READERS DIGEST   DEC, P49; *WORLD MED ASS, 1964, 18 WORLD MED ASS JUN; 1948, SCI NEWSLETT    0221, V53, P117; 1954, IRISH ECCLESIASTICAL, V86, P222; 1954, CHRISTIAN CENTU 1020, P1260; 1952, LINACRE Q OFFICIAL J, V19, P98; 1962, BRIT MED J, V2, P1119	36	45	45	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1667	1671		10.1001/jama.276.20.1667	http://dx.doi.org/10.1001/jama.276.20.1667			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU209	8922454				2022-12-28	WOS:A1996VU20900035
J	Gordon, HS; Harper, DL; Rosenthal, GE				Gordon, HS; Harper, DL; Rosenthal, GE			Racial variation in predicted and observed in-hospital death - A regional analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; INTENSIVE-CARE UNIT; MEDICARE PATIENTS; MORTALITY; BLACK; WHITE; QUALITY; RACE; ADMISSION; SURVIVAL	Objective.-To compare observed, predicted, and risk-adjusted hospital mortality rates in white and African-American patients and to determine whether, as prior studies suggest, African-American patients would have higher predicted risks of death and similar or higher risk-adjusted mortality. Design.-Retrospective cohort study. Setting.-Thirty hospitals in northeast Ohio. Patients.-A total of 88 205 eligible patients consecutively discharged in the years 1991 through 1993 with the following 6 diagnoses: acute myocardial infarction, congestive heart failure, obstructive airways disease, gastrointestinal hemorrhage, pneumonia, and stroke. Methods.-We measured predicted risks of death at admission for each diagnosis using Validated multivariable models based on standard clinical data abstracted from patients' medical records. We then adjusted in-hospital mortality rates in white and African-American patients for predicted risk of death and other covariates using logistic regression analysis. Main Outcome Measures.-Predicted risk of death at admission and observed hospital mortality in white and African-American patients. Results.-Predicted risks of death were lower (P<.001) in African Americans for 4 of the 6 diagnoses. Adjusted odds of hospital death were lower (P<.01) in African Americans for 2 of the 6 diagnoses (congestive heart failure and obstructive airways disease) and similar for the other 4 diagnoses, For all diagnoses, in aggregate, the adjusted odds of hospital death were 13% lower in African-American compared with white patients (multivariable odds ratio, 0.87; 95% confidence interval, 0.80-0.94). Findings were similar if further adjustments were made for differences in length of stay, site of hospitalization, or discharge triage practices. Conclusion.-Contrary to our a priori hypotheses, predicted risks of death and risk-adjusted mortality rates were generally lower in African-American patients. Our finding of lower predicted risk may reflect racial differences in hospital admission practices or in access to outpatient care. However, our findings suggest that, once hospitalized, African-American patients attained similar or better outcomes, as measured by an important measure-hospital mortality.	CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND VET AFFAIRS MED CTR,DEPT MED,DIV GEN INTERNAL MED,CLEVELAND,OH 44106; CLEVELAND HLTH QUAL CHOICE COALIT,CLEVELAND,OH	Case Western Reserve University			Gordon, Howard S/E-4420-2010	Gordon, Howard S/0000-0002-6712-5954				AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BLACK HR, 1986, AM J MED, V81, P479, DOI 10.1016/0002-9343(86)90303-7; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BUCKLE JM, 1992, ARCH INTERN MED, V152, P1596, DOI 10.1001/archinte.152.8.1596; CHASSIN MR, 1989, HEALTH SERV RES, V24, P1; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Gordon HS, 1996, MED CARE, V34, P295, DOI 10.1097/00005650-199604000-00002; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HORNER RD, 1991, HEALTH SERV RES, V26, P531; HOSMER DW, 1989, APPL LOGISTIC REGRES; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P119; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KUHLEMEIER KV, 1994, STROKE, V25, P2126, DOI 10.1161/01.STR.25.11.2126; MAYNARD C, 1987, AM J CARDIOL, V60, P513, DOI 10.1016/0002-9149(87)90296-7; MCCLISH DK, 1987, MED DECIS MAKING, V7, P149, DOI 10.1177/0272989X8700700305; MILLER MG, 1994, JAMA-J AM MED ASSOC, V271, P1493, DOI 10.1001/jama.271.19.1493; MYERS AH, 1991, AM J EPIDEMIOL, V134, P1128, DOI 10.1093/oxfordjournals.aje.a116016; NICKENS HW, 1995, HEALTH SERV RES, V30, P151; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PUI CH, 1995, JAMA-J AM MED ASSOC, V273, P633, DOI 10.1001/jama.273.8.633; ROSENTHAL GE, 1994, JOINT COMM J QUAL IM, V20, P425, DOI 10.1016/S1070-3241(16)30088-8; SCHULMAN KA, 1995, HLTH SERV RES, V30, P151; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; SULLIVAN LW, 1993, MEDICARE HOSP INFORM; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US BUR CENS, 1992, CENS POP HOUS; *US DEPT HHS, 1988, INT CLASS DIS 9 REV; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; WILLIAMS DR, 1994, HEALTH SERV RES, V29, P261; WILLIAMS JF, 1995, CRIT CARE MED, V23, P626, DOI 10.1097/00003246-199504000-00009	44	62	62	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1639	1644		10.1001/jama.276.20.1639	http://dx.doi.org/10.1001/jama.276.20.1639			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922449				2022-12-28	WOS:A1996VU20900030
J	Colgan, DF; Murthy, KGK; Prives, C; Manley, JL				Colgan, DF; Murthy, KGK; Prives, C; Manley, JL			Cell-cycle related regulation poly(A) polymerase by phosphorylation	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; MESSENGER-RNA; DEPENDENT KINASES; MATURATION; EXPRESSION; CLEAVAGE	THE poly(A) tail found on almost all eukaryotic messenger RNAs(1,2) is important in enhancing translation initiation and determining mRNA stability(3,4). Control of poly(A)-tail synthesis thus has the potential to be a key regulatory step in gene expression and is indeed known to be important during early development in many organisms(5). To study a possible basis for such regulation, we examined phosphorylation of poly(A) polymerase (PAP) by p34(cdc2)/cyclin B (maturation/mitosis-promoting factor, MPF). We show here that PAP can be phosphorylated in vivo and in vitro by MPF. Consistent with this, PAP becomes hyperphosphorylated both during meiotic maturation of Xenopus laevis oocytes and in HeLa cells arrested at M phase, times in the cell-cycle when MPF is known to be active(6,7). We show further that hyperphosphorylation by MPF dramatically reduces the activity of purified PAP, and that PAP isolated from mitotic HeLa cells is similarly inhibited by hyperphosphorylation. This repression probably contributes to the well established reductions in poly(A)(+) RNA and/or protein synthesis known to occur in M-phase cells(8-15).	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University				Manley, James/0000-0002-8341-1459				BALLANTYNE S, 1995, RNA, V1, P64; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAMBROUGH C, 1979, DEV BIOL, V71, P323; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; KANKI JP, 1991, DEV BIOL, V146, P198, DOI 10.1016/0012-1606(91)90460-K; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAWLOWSKI PJ, 1974, DEV BIOL, V40, P71, DOI 10.1016/0012-1606(74)90108-0; PRIVES C, 1991, METHOD CELL BIOL, V36, P185; RAABE T, 1994, MOL CELL BIOL, V14, P2946, DOI 10.1128/MCB.14.5.2946; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; SAGATA N, 1980, DEV BIOL, V77, P431, DOI 10.1016/0012-1606(80)90486-8; SLATER DW, 1972, NATURE, V240, P333, DOI 10.1038/240333a0; STEWARD DL, 1968, SCIENCE, V161, P791, DOI 10.1126/science.161.3843.791; THURESSON AC, 1994, P NATL ACAD SCI USA, V91, P979, DOI 10.1073/pnas.91.3.979; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WILT FH, 1977, CELL, V11, P673, DOI 10.1016/0092-8674(77)90084-8; Zhao WQ, 1996, MOL CELL BIOL, V16, P2378	30	133	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					282	285		10.1038/384282a0	http://dx.doi.org/10.1038/384282a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918882				2022-12-28	WOS:A1996VU38100057
J	Kellett, JM				Kellett, JM			An ethical dilemma - A nurse is suspended	BRITISH MEDICAL JOURNAL			English	Article								A day hospital sister was suspended and given a final formal warning for obeying the request of her consultant to give a patient tranquillising medication in disguise. Though a disciplinary inquiry exonerated the consultant, the action on the nurse has not been rescinded. This case questions the authority of the multidisciplinary team and the role of nursing managers. We asked two geriatricians and forensic scientists to comment on the case.			Kellett, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT GERIATR MED,LONDON SW17 0RE,ENGLAND.								0	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1249	1250		10.1136/bmj.313.7067.1249	http://dx.doi.org/10.1136/bmj.313.7067.1249			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939119	Green Published			2022-12-28	WOS:A1996VU20800029
J	Wise, P; Drury, M				Wise, P; Drury, M			Pharmaceutical trials in general practice: The first 100 protocols. An audit by the clinical research ethics committee of the Royal College of General Practitioners	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the outcome of 100 general practice based, multicentre research projects submitted to the ethics committee of the Royal College of General Practitioners by pharmaceutical companies or their agents between 1984 and 1989. Design-Analysis of consecutive submitted protocols for stated objectives, study design, and outcomes; detailed review of committee minutes and correspondence in relation to amendment and approval; assessment of final reports submitted at conclusion of studies. Subjects-82 finally approved protocols, embracing 34 523 proposed trial subjects and 1195 proposed general practice investigators. Main outcome measures-Success at enrolling subjects and investigators; commencement and completion data; validity of final report's assessment of efficacy, safety, tolerability, and acceptability; and method of use and dissemination of findings. Results-18 studies were not approved and 45 had to be amended. Randomised controlled trials comprised 46 of the original submissions. Remuneration considerations, inadequate information or consent sheets, pregnancy safety, the need to discontinue existing therapy, and suboptimal scientific content were major reasons for rejecting studies or asking for amendments. Of the 82 approved studies 8 were not started. Shortfalls of investigators (of 39%) and trial subjects (of 37%) and an overall 23% withdrawal rate were responsible for a significant incidence of inconclusive results. Within the six gear follow up interval, only 19 of the studies had been formally published. Conclusions-This audit identified substantial ethical concerns in the process of approving multicentre general practice pharmaceutical research.			Wise, P (corresponding author), ROYAL COLL GEN PRACTITIONERS,CLIN RES ETH COMM,LONDON SW7 1PU,ENGLAND.							EICHLER HG, 1995, LANCET, V346, P115; Gunning R., 1952, TECHNIQUE CLEAR WRIT; MEADE TW, 1994, J ROY COLL PHYS LOND, V28, P102; PEARN J, 1995, BRIT MED J, V310, P1313, DOI 10.1136/bmj.310.6990.1313; Royal College of Physicians, 1990, GUID PRACT ETH COMM	5	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1245	1248		10.1136/bmj.313.7067.1245	http://dx.doi.org/10.1136/bmj.313.7067.1245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939118	Green Published			2022-12-28	WOS:A1996VU20800027
J	Marson, AG; Kadir, ZA; Chadwick, DW				Marson, AG; Kadir, ZA; Chadwick, DW			New antiepileptic drugs: A systematic review of their efficacy and tolerability	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MULTICENTER COMPARATIVE TRIAL; RESISTANT PARTIAL SEIZURES; TONIC CLONIC SEIZURES; ADD-ON TREATMENT; DOUBLE-BLIND; SODIUM VALPROATE; PARTIAL EPILEPSY; LAMOTRIGINE; CARBAMAZEPINE; CROSSOVER	Objectives-To evaluate the efficacy and tolerability of the newly developed antiepileptic drugs gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide in patients with refractory partial epilepsy. Design-Systematic review of published and unpublished randomised controlled trials of add-on treatment with new antiepileptic drugs. Subjects-20 published and eight unpublished trials representing 3883 patients with refractory partial epilepsy. Main outcome measures-Proportion of patients who (a) showed 50% or greater reduction in frequency of seizures (50% responders) and (b) withdrew from each study for any reason. Results-Odds ratios (95% confidence intervals) relative to placebo for 50% responders were 2.29 (1.53 to 3.43) for gabapentin, 2.32 (1.47 to 3.68) for lamotrigine, 3.03 (2.01 to 4.58) for tiagabine, 4.22 (2.80 to 6.35) for topiramate, 3.68 (2.45 to 5.51) for vigabatrin, and 2.47 (1.36 to 4.47) for zonisamide. Odds ratios for withdrawal were 1.36 (0.75 to 2.49) for gabapentin, 1.19 (0.79 to 1.79) for lamotrigine, 1.81 (1.21 to 2.70) for tiagabine, 2.42 (1.43 to 4.11) for topiramate, 2.58 (1.26 to 5.27) for vigabatrin, and 5.70 (1.76 to 18.49) for zonisamide. Comparing results for each drug showed that all of the 95% confidence intervals overlapped, indicating that they were not significantly different in terms of efficacy and tolerability. Conclusions-All six drugs were significantly better than placebo at reducing frequency of seizures. These results do not allow an evidence based choice between these drugs as we have no conclusive indication of differences in efficacy or tolerability.			Marson, AG (corresponding author), UNIV LIVERPOOL, WALTON CTR NEUROL & NEUROSURG, DEPT NEUROL SCI, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND.		Marson, Anthony/AAW-9776-2020	Marson, Anthony/0000-0002-6861-8806	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANHUT H, 1994, EPILEPSIA, V35, P795, DOI 10.1111/j.1528-1157.1994.tb02513.x; BenMenachem E, 1996, EPILEPSIA, V37, P539, DOI 10.1111/j.1528-1157.1996.tb00606.x; BINNIE CD, 1989, EPILEPSY RES, V4, P222, DOI 10.1016/0920-1211(89)90007-7; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; CHADWICK D, 1990, LANCET, V335, P1114; CHADWICK D, IN PRESS EPILEPSIA; COCKERELL OC, 1995, LANCET, V346, P140, DOI 10.1016/S0140-6736(95)91208-8; Faught E, 1996, NEUROLOGY, V46, P1684, DOI 10.1212/WNL.46.6.1684; French JA, 1996, NEUROLOGY, V46, P54, DOI 10.1212/WNL.46.1.54; GRAM L, 1994, EPILEPSIA, V35, P94; GRUNEWALD RA, 1994, J NEUROL NEUROSUR PS, V57, P1057, DOI 10.1136/jnnp.57.9.1057; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; JAWAD S, 1989, EPILEPSIA, V30, P356, DOI 10.1111/j.1528-1157.1989.tb05309.x; LOISEAU P, 1990, EPILEPSY RES, V7, P136, DOI 10.1016/0920-1211(90)90099-H; Marson AG, 1996, CURR OPIN NEUROL, V9, P103, DOI 10.1097/00019052-199604000-00008; Marson AG, 1996, EPILEPSIA, V37, P377, DOI 10.1111/j.1528-1157.1996.tb00575.x; MATSUO F, 1993, NEUROLOGY, V43, P2284, DOI 10.1212/WNL.43.11.2284; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MESSENHEIMER J, 1994, EPILEPSIA, V35, P113, DOI 10.1111/j.1528-1157.1994.tb02920.x; OOMMEN K, 1993, NEUROLOGY, V43, P2292; Penry J. Kiffin, 1993, Epilepsia, V34, P67; Privitera M, 1996, NEUROLOGY, V46, P1678, DOI 10.1212/WNL.46.6.1678; REYNOLDS EH, 1981, EPILEPSIA, V22, P475, DOI 10.1111/j.1528-1157.1981.tb06158.x; RICHENS A, 1994, J NEUROL NEUROSUR PS, V57, P682, DOI 10.1136/jnnp.57.6.682; RING HA, 1990, J NEUROL NEUROSUR PS, V53, P1051, DOI 10.1136/jnnp.53.12.1051; SCHAPEL GJ, 1993, J NEUROL NEUROSUR PS, V56, P448, DOI 10.1136/jnnp.56.5.448; SCHMIDT D, 1993, EPILEPSY RES, V15, P67, DOI 10.1016/0920-1211(93)90011-U; SIVENIUS J, 1991, EPILEPSIA, V32, P539, DOI 10.1111/j.1528-1157.1991.tb04689.x; SMITH D, 1993, EPILEPSIA, V34, P312, DOI 10.1111/j.1528-1157.1993.tb02417.x; SPILKER B, 1984, EPILEPSIA, V25, P443, DOI 10.1111/j.1528-1157.1984.tb03441.x; Tassinari CA, 1996, EPILEPSIA, V37, P763, DOI 10.1111/j.1528-1157.1996.tb00649.x; VERITY CM, 1995, DEV MED CHILD NEUROL, V37, P97; WILDER BJ, 1986, DOUBLE BLIND MULTICE; Willmore LJ, 1996, NEUROLOGY, V46, P49, DOI 10.1212/WNL.46.1.49	36	214	216	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	1996	313	7066					1169	1174		10.1136/bmj.313.7066.1169	http://dx.doi.org/10.1136/bmj.313.7066.1169			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916746	Green Published			2022-12-28	WOS:A1996VR90700019
J	Arlett, PR; Scott, J; Hughes, JMB; Cohen, J; Rogers, T; Bloom, SR; Pusey, C; Friedland, JS; Lynn, WA				Arlett, PR; Scott, J; Hughes, JMB; Cohen, J; Rogers, T; Bloom, SR; Pusey, C; Friedland, JS; Lynn, WA			Grand rounds - Hammersmith Hospital - A case of laboratory acquired brucellosis - A rare condition, but laboratory transmission is a risk	BRITISH MEDICAL JOURNAL			English	Editorial Material							INFECTION				Arlett, PR (corresponding author), HAMMERSMITH HOSP,LONDON W12 0NN,ENGLAND.							CARON E, 1994, INFECT IMMUN, V62, P5267, DOI 10.1128/IAI.62.12.5267-5274.1994; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; JIANG XS, 1993, INFECT IMMUN, V61, P124, DOI 10.1128/IAI.61.1.124-134.1993; LUZZI GA, 1993, T ROY SOC TROP MED H, V87, P138, DOI 10.1016/0035-9203(93)90460-8; Nicoletti P, 1990, Adv Biotechnol Processes, V13, P147; PHILPOTT M, 1993, BRIT VET J, V149, P339, DOI 10.1016/S0007-1935(05)80075-2; SMITH LD, 1990, CRIT REV MICROBIOL, V17, P209, DOI 10.3109/10408419009105726; SVETIC A, 1991, REV INFECT DIS, V13, P359; ZHAN YF, 1991, INFECT IMMUN, V59, P1790, DOI 10.1128/IAI.59.5.1790-1794.1991; 1991, COMMUN DIS REP CDR W, V1, P47	10	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1130	1132						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916703	Green Published			2022-12-28	WOS:A1996VR21700029
J	Brown, LD; Zhao, WJ; Nelson, DK; Hauck, M; Alsdorf, D; Ross, A; Cogan, M; Clark, M; Liu, XW; Che, JK				Brown, LD; Zhao, WJ; Nelson, DK; Hauck, M; Alsdorf, D; Ross, A; Cogan, M; Clark, M; Liu, XW; Che, JK			Bright spots, structure, and magmatism in southern Tibet from INDEPTH seismic reflection profiling	SCIENCE			English	Article							EXTENSION; BENEATH	INDEPTH seismic refection profiling shows that the decollement beneath which Indian lithosphere underthrusts the Himalaya extends al least 225 kilometers north of the Himalayan deformation front to a depth of similar to 50 kilometers, Prominent reflections appear at depths of 15 to 18 kilometers near where the decollement reflector apparently terminates. These reflections extend north of the Zangbo suture to the Damxung graben of the Tibet Plateau, Some of these reflections have locally anomalous amplitudes (bright spots) and coincident negative polarities implying that they are produced by fluids in the crust, The presence of geothermal activity and high heat flow in the regions of these reflections and the tectonic setting suggest that the bright spots mark granitic magmas derived by partial melting of the tectonically thickened crust.	CHINESE ACAD GEOL SCI, BEIJING 100037, PEOPLES R CHINA; SYRACUSE UNIV, DEPT EARTH SCI, SYRACUSE, NY 13244 USA; MINIST GEOL & MINERAL RESOURCES, BEIJING COMP CTR, BEIJING 100083, PEOPLES R CHINA	Chinese Academy of Geological Sciences; Syracuse University	Brown, LD (corresponding author), CORNELL UNIV, INST STUDY CONTINENTS, ITHACA, NY 14853 USA.							ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; Batini F., 1983, SOC GEOL ITAL MEM, V25, P219; Chen LH, 1996, SCIENCE, V274, P1694, DOI 10.1126/science.274.5293.1694; DEVOOGD B, 1988, GEOL SOC AM BULL, V100, P1550, DOI 10.1130/0016-7606(1988)100<1550:CEAMPC>2.3.CO;2; FRANCHETEAU J, 1984, NATURE, V307, P32, DOI 10.1038/307032a0; Hammer PTC, 1996, J GEOPHYS RES-SOL EA, V101, P20119, DOI 10.1029/96JB01646; HIRN A, 1984, NATURE, V307, P23, DOI 10.1038/307023a0; Hochstein M. P., 1995, TERRESTRIAL HEAT FLO, P331; JARCHOW CM, 1993, J GEOPHYS RES-SOL EA, V98, P22095, DOI 10.1029/93JB02021; Kind R, 1996, SCIENCE, V274, P1692, DOI 10.1126/science.274.5293.1692; LUSCHEN E, 1987, J GEOPHYS-Z GEOPHYS, V62, P1; Makovsky Y, 1996, SCIENCE, V274, P1690, DOI 10.1126/science.274.5293.1690; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; PAN Y, 1992, GEOLOGY, V20, P775, DOI 10.1130/0091-7613(1992)020<0775:NSZALM>2.3.CO;2; Sanford A. R., 1977, EARTHS CRUST ITS NAT, P385; SCHELLING D, 1991, TECTONICS, V10, P851, DOI 10.1029/91TC01011; Sheriff R. E., 1975, Geophysical Prospecting, V23, P125, DOI 10.1111/j.1365-2478.1975.tb00685.x; YIN A, 1994, J GEOPHYS RES-SOL EA, V99, P18175, DOI 10.1029/94JB00504; ZHAO WJ, 1993, NATURE, V366, P557, DOI 10.1038/366557a0	19	290	356	5	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1688	1690		10.1126/science.274.5293.1688	http://dx.doi.org/10.1126/science.274.5293.1688			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939852				2022-12-28	WOS:A1996VW71200051
J	Cunnion, RE; Masur, H				Cunnion, RE; Masur, H			Physician staffing in intensive-care units	LANCET			English	Editorial Material							IMPACT				Cunnion, RE (corresponding author), NATL INST HLTH,DEPT CRIT CARE MED,BETHESDA,MD 20892, USA.							AYERS SM, 1983, JAMA-J AM MED ASSOC, V250, P798; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1464	1465		10.1016/S0140-6736(05)65887-4	http://dx.doi.org/10.1016/S0140-6736(05)65887-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942771				2022-12-28	WOS:A1996VV46300004
J	Kouskoff, V; Korganow, AS; Duchatelle, V; Degott, C; Benoist, C; Mathis, D				Kouskoff, V; Korganow, AS; Duchatelle, V; Degott, C; Benoist, C; Mathis, D			Organ-specific disease provoked by systemic autoimmunity	CELL			English	Article							FIBROBLAST-LIKE SYNOVIOCYTES; TUMOR-NECROSIS-FACTOR; CLASS-II MOLECULES; T-CELL; RHEUMATOID-ARTHRITIS; TRANSGENIC MICE; GENE-EXPRESSION; INDUCTION; ANTIGEN; MOUSE	Rheumatoid arthritis (RA) is a chronic joint disease characterized by leukocyte invasion and synoviocyte activation followed by cartilage and bone destruction. Its etiology and pathogenesis are poorly understood. We describe a spontaneous mouse model of this syndrome, generated fortuitously by crossing a T cell receptor (TCR) transgenic line with the NOD strain. All offspring develop a joint disease highly reminiscent of RA in man. The trigger for the murine disorder is chance recognition of a NOD-derived major histocompatibility complex (MHC) class II molecule by the transgenic TCR; progression to arthritis involves CD4+ T, B, and probably myeloid cells. Thus, a joint-specific disease need not arise from response to a joint-specific antigen but can be precipitated by a breakdown in general mechanisms of self-tolerance resulting in systemic self-reactivity. We suggest that human RA develops by an analogous mechanism.	HOP BEAUJON,SERV ANAT PATHOL,F-92110 CLICHY,FRANCE; ULP,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)				Korganow, Anne-Sophie/0000-0002-1664-6311				ALVAROGRACIA JM, 1989, J EXP MED, V170, P865, DOI 10.1084/jem.170.3.865; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; COLE BC, 1995, MECH MODELS RHEUMATO, P47; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIDAMELINE J, 1996, IN PRESS SELECTION T; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Henderson B., 1995, MECH MODELS RHEUMATO; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IVANOV V, 1993, J IMMUNOL, V151, P4694; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOUSKOFF V, 1994, THESIS U L PASTEUR S; KRAAL G, 1986, IMMUNOLOGY, V58, P665; MEHINDATE K, 1994, J BIOL CHEM, V269, P32063; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; NORDLING C, 1992, ARTHRITIS RHEUM, V35, P717, DOI 10.1002/art.1780350619; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; Schmidt D, 1996, J CLIN INVEST, V97, P2027, DOI 10.1172/JCI118638; SCOTET E, 1996, IN PRESS J EXP MED; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TREDE NS, 1991, J IMMUNOL, V146, P2310; WANG B, 1996, J EXP MED, V183, P1; WICKER LS, 1995, ANNU REV IMMUNOL, V13, P179, DOI 10.1146/annurev.iy.13.040195.001143; WORDSWORTH P, 1992, CURR OPIN IMMUNOL, V4, P766, DOI 10.1016/0952-7915(92)90059-N	33	689	729	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					811	822		10.1016/S0092-8674(00)81989-3	http://dx.doi.org/10.1016/S0092-8674(00)81989-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945509	Bronze			2022-12-28	WOS:A1996VV77400008
J	Grilli, M; Pizzi, M; Memo, M; Spano, P				Grilli, M; Pizzi, M; Memo, M; Spano, P			Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappa B activation	SCIENCE			English	Article							CEREBELLAR GRANULE CELLS; GLUTAMATE; NEUROTOXICITY; NEURONS; DEPENDENCE; CULTURES	Aspirin (acetylsalicylic acid) is a commonly prescribed drug with a wide pharmacological spectrum. At concentrations compatible with amounts in plasma during chronic antiinflammatory therapy, acetylsalicylic acid and its metabolite sodium salicylate were found to be protective against neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures and hippocampal slices. The site of action of the drugs appeared to be downstream of glutamate receptors and to involve specific inhibition of glutamate-mediated induction of nuclear factor kappa B. These results may contribute to the emerging theme of anti-inflammatory drugs and neurodegeneration.			Grilli, M (corresponding author), UNIV BRESCIA,SCH MED,DEPT BIOMED SCI & BIOTECHNOL,I-25123 BRESCIA,ITALY.		grilli, mariagrazia/ABF-1542-2020; Spano, Pier Franco F/J-9944-2016; Pizzi, Marina/C-1452-2011; Memo, Maurizio/C-2555-2011; Memo, Maurizio/AAK-7197-2020; Spano, Pier Franco A/E-7621-2010; Pizzi, Marina/K-2064-2016	grilli, mariagrazia/0000-0001-9165-5827; Spano, Pier Franco F/0000-0002-9906-0964; MEMO, Maurizio/0000-0002-7543-0289; Pizzi, Marina/0000-0002-4857-5204				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barger SW, 1996, MOL BRAIN RES, V40, P116; CHOI DW, 1987, J NEUROSCI, V7, P369; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FAMAEY JP, 1992, THERAPEUTIC APPL NSA; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; GARTHWAITE G, 1989, NEUROSCI LETT, V97, P316, DOI 10.1016/0304-3940(89)90617-4; GRILLI M, 1995, J BIOL CHEM, V270, P26774, DOI 10.1074/jbc.270.45.26774; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRILLI M, UNPUB; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Hardman J.G., 1996, GOODMAN GILSMANS PHA, P617; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Memo M, 1995, INT REV PSYCHIATR, V7, P339, DOI 10.3109/09540269509022986; PIZZI M, 1993, J NEUROCHEM, V61, P683; Pizzi M, 1996, MOL PHARMACOL, V49, P586; Rainsford K.D., 1984, ASPIRIN SALICYLATES; WEISMANN G, 1991, SCI AM, V84, P264	28	708	743	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1383	1385		10.1126/science.274.5291.1383	http://dx.doi.org/10.1126/science.274.5291.1383			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910280				2022-12-28	WOS:A1996VU95400056
J	Jenkins, C; Campbell, J				Jenkins, C; Campbell, J			Catchment areas in general practice and their relation to size and quality of practice and deprivation: A descriptive study in one London borough	BRITISH MEDICAL JOURNAL			English	Article							PRACTITIONER; ENGLAND	Objective-To relate the sizes of general practice catchment areas in one London borough to list size, deprivation payments, medical staffing, and locally and nationally recognised measures of quality. Design-Study of general practice catchment area maps. Setting-London borough of Lambeth. Subjects-60 out of the 71 general practices in Lambeth. Main outcome measures-Practice catchment area size with corrections for numbers of doctors and patients. Results-Catchment area size varied greatly between practices, showing an almost 150-fold difference between the largest and smallest practices. This size differential was even more marked when the size of the catchment area was corrected for the number of general practitioners in the practice, where a 300-fold difference was found. Substantial differences existed between practices in each of the four locally assigned quality bands. The weakest practices had catchment areas three times as large as those of the strongest practices. When corrected for medical staffing, the difference was eight times as great. A calculated measure of patient dispersion showed that the practice population of the strongest practices was four times as densely clustered as that of the weakest practices, whose patients were more widely geographically dispersed. Conclusions-Large variations exist in the size of catchment areas of inner city practices even when corrected for numbers of doctors and patients. These differences are associated with variations in quality of care.			Jenkins, C (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND.		Campbell, John/A-5792-2011	Campbell, John/0000-0002-6752-3493				BILLINGHURST B, 1993, BRIT J GEN PRACT, V43, P336; Campbell JL, 1996, BRIT J GEN PRACT, V46, P465; *DEP HLTH, 1989, TERMS SERV DOCT GEN; HAYNES RM, 1982, SOC SCI MED, V16, P561, DOI 10.1016/0277-9536(82)90309-4; Joseph A., 1984, ACCESSIBILITY UTILIZ; Knox P. L., 1979, BR J GEN PRACT, V29, P160; *LAMB SOUTHW LEW H, 1995, FUT PRIM HLTH CAR S; *LOND HLTH PLANN C, 1981, PRIM HLTH CAR INN LO; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; MURRAY SA, 1995, BRIT MED J, V310, P100, DOI 10.1136/bmj.310.6972.100; PARKIN D, 1979, EPIDEMIOLOGY COMMUNI, V33, P96; PHILLIPS DR, 1980, BR J GEN PRACT, V30, P688; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; ROBSON J, 1995, BRIT MED J, V310, P73, DOI 10.1136/bmj.310.6972.73; SALISBURY CJ, 1989, BRIT MED J, V299, P608, DOI 10.1136/bmj.299.6699.608; WILLIAMSON V, 1989, J ROY COLL GEN PRACT, V39, P452	16	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1189	1192		10.1136/bmj.313.7066.1189	http://dx.doi.org/10.1136/bmj.313.7066.1189			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916754	Green Published			2022-12-28	WOS:A1996VR90700027
J	Sheen, J				Sheen, J			Ca2+-dependent protein kinases and stress signal transduction in plants	SCIENCE			English	Article							STOMATAL GUARD-CELLS; ABSCISIC-ACID; ARABIDOPSIS-THALIANA; GENE-EXPRESSION; MOLECULAR RESPONSES; PROMOTER ACTIVITY; SEED MATURATION; LOW-TEMPERATURE; OSMOTIC-STRESS; SALT STRESS	Stress responses in plants involve changes in the transcription of specific genes. The constitutively active mutants of two related Ca2+-dependent protein kinases (CDPK1 and CDPK1a) activate a stress-inducible promoter, bypassing stress signals. Six other plant protein kinases, including two distinct CDPKs, fail to mimic this stress signaling, The activation is abolished by a CDPK1 mutation in the kinase domain and diminished by a constitutively active protein phosphatase 2C that is capable of blocking responses to the stress hormone abscisic acid. A variety of functions are mediated by different CDPKs. CDPK1 and CDPK1a may be positive regulators controlling stress signal transduction in plants.	MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	Sheen, J (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA.							ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; ARMSTRONG F, 1995, P NATL ACAD SCI USA, V92, P9520, DOI 10.1073/pnas.92.21.9520; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; Bethke Paul C., 1995, P298; BRAAM J, 1992, P NATL ACAD SCI USA, V89, P3213, DOI 10.1073/pnas.89.8.3213; BRAY EA, 1993, PLANT PHYSIOL, V103, P1035, DOI 10.1104/pp.103.4.1035; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; Daugherty C.J., 1994, ARABIDOPSIS, P769; DEVETTEN NC, 1995, PLANT J, V7, P589, DOI 10.1046/j.1365-313X.1995.7040589.x; ESTRUCH JJ, 1994, P NATL ACAD SCI USA, V91, P8837, DOI 10.1073/pnas.91.19.8837; FINKELSTEIN RR, 1993, MOL GEN GENET, V238, P401, DOI 10.1007/BF00291999; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; GIRAUDAT J, 1994, PLANT MOL BIOL, V26, P1557, DOI 10.1007/BF00016490; GOSTI F, 1995, MOL GEN GENET, V246, P10, DOI 10.1007/BF00290128; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HATTORI T, 1995, PLANT J, V7, P913, DOI 10.1046/j.1365-313X.1995.07060913.x; HATTORI T, 1992, GENE DEV, V6, P609, DOI 10.1101/gad.6.4.609; HOECKER U, 1995, GENE DEV, V9, P2459, DOI 10.1101/gad.9.20.2459; HOLAPPA LD, 1995, PLANT PHYSIOL, V108, P1203, DOI 10.1104/pp.108.3.1203; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KNIGHT CD, 1995, PLANT CELL, V7, P499, DOI 10.1105/tpc.7.5.499; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Lu GH, 1996, PLANT CELL, V8, P847, DOI 10.1105/tpc.8.5.847; LUEHRSEN KR, 1992, METHOD ENZYMOL, V216, P397; MCAINSH MR, 1992, PLANT CELL, V4, P1113, DOI 10.2307/3869479; MCCARTY DR, 1995, ANNU REV PLANT PHYS, V46, P71, DOI 10.1146/annurev.pp.46.060195.000443; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MINET M, 1992, PLANT J, V2, P417; MONROY AF, 1995, PLANT CELL, V7, P321, DOI 10.1105/tpc.7.3.321; Nakagawa H, 1996, PLANT J, V9, P217, DOI 10.1046/j.1365-313X.1996.09020217.x; NAMBARA E, 1995, DEVELOPMENT, V121, P629; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PARK YS, 1993, PLANT MOL BIOL, V22, P615, DOI 10.1007/BF00047402; PLA M, 1993, PLANT MOL BIOL, V21, P259, DOI 10.1007/BF00019942; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROCK CD, 1994, CURR BIOL, V4, P1013, DOI 10.1016/S0960-9822(00)00229-3; SCHROEDER JI, 1991, PLANT CELL, V3, P555, DOI 10.2307/3869184; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHEEN J, UNPUB; SHEN QX, 1995, PLANT CELL, V7, P295, DOI 10.1105/tpc.7.3.295; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STRAUB PF, 1994, PLANT MOL BIOL, V26, P617, DOI 10.1007/BF00013748; SUEN KL, 1991, PLANT MOL BIOL, V17, P581, DOI 10.1007/BF00037045; TAYLOR JE, 1995, PLANT J, V7, P129, DOI 10.1046/j.1365-313X.1995.07010129.x; THOMAS JC, 1993, PLANT PHYSIOL, V103, P1299, DOI 10.1104/pp.103.4.1299; THOMAS TL, 1993, PLANT CELL, V5, P1401, DOI 10.1105/tpc.5.10.1401; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; TREWAVAS A, 1994, PLANT MOL BIOL, V26, P1329, DOI 10.1007/BF00016478; URAO T, 1994, MOL GEN GENET, V244, P331, DOI 10.1007/BF00286684; URAO T, 1994, PLANT PHYSIOL, V105, P1461, DOI 10.1104/pp.105.4.1461; WARD JM, 1994, PLANT CELL, V6, P669; Xu DP, 1996, PLANT PHYSIOL, V110, P249, DOI 10.1104/pp.110.1.249; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	65	454	550	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 13	1996	274	5294					1900	1902		10.1126/science.274.5294.1900	http://dx.doi.org/10.1126/science.274.5294.1900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943201				2022-12-28	WOS:A1996VY20000041
J	Duina, AA; Chang, HCJ; Marsh, JA; Lindquist, S; Gaber, RF				Duina, AA; Chang, HCJ; Marsh, JA; Lindquist, S; Gaber, RF			A cyclophilin function in Hsp90-dependent signal transduction	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; STEROID-RECEPTOR; SACCHAROMYCES-CEREVISIAE; PROGESTERONE-RECEPTOR; GLUCOCORTICOID RECEPTOR; CYCLOSPORINE-A; HOMOLOG NINAA; HSP90; BINDING; DOMAIN	Cpr6 and Cpr7, the Saccharomyces cerevisiae homologs of cyclophilin-40 (CyP-40), were shown to form complexes with Hsp90, a protein chaperone that functions in several signal transduction pathways, Deletion of CPR7 caused severe growth defects when combined with mutations that decrease the amount of Hsp90 or Sti1, another component of the Hsp90 chaperone machinery. The activities of two heterologous Hsp90-dependent signal transducers expressed in yeast, glucocorticoid receptor and pp60(v-src) kinase, were adversely affected by cpr7 null mutations. These results suggest that CyP-40 cyclophilins play a general role in Hsp90-dependent signal transduction pathways under normal growth conditions.	NORTHWESTERN UNIV,DEPT BIOCHEM MOL BIOL & CELL BIOL,EVANSTON,IL 60208; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Northwestern University; Howard Hughes Medical Institute; University of Chicago			Foreman, Hui-Chen (Jane)/GMW-4448-2022	Foreman, Hui-Chen (Jane)/0000-0001-9640-9780	NIGMS NIH HHS [GM45739, GM25874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025874, R01GM025874, R01GM045739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CHANG H, UNPUB; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHANG HCJ, IN PRESS MOL CELL BI; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; DUINA AA, UNPUB; FREEMAN BC, 1996, EMBO J, V12, P2969; FREEMAN BC, 1996, SCIENCE, V274; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HINKO A, 1993, ENDOCRINOLOGY, V133, P1511, DOI 10.1210/en.133.4.1511; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; MILAD M, 1995, MOL ENDOCRINOL, V9, P838, DOI 10.1210/me.9.7.838; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	36	184	190	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 6	1996	274	5293					1713	1715		10.1126/science.274.5293.1713	http://dx.doi.org/10.1126/science.274.5293.1713			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939862				2022-12-28	WOS:A1996VW71200061
J	Peyroche, A; Paris, S; Jackson, CL				Peyroche, A; Paris, S; Jackson, CL			Nucleotide exchange on ARF mediated by yeast Gea1 protein	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; GUANINE-NUCLEOTIDE; GOLGI-APPARATUS; TRANSPORT; COATOMER; ENCODES; VACUOLE; MUTANT; GENES	THE ADP-ribosylation factor ARF is a small GTP-binding protein that is involved in the transport of vesicles between the endoplasmic reticulum (ER) and Golgi complex and within the Golgi complex itself(1-4), ARF cycles between inactive and membrane-associated active forms as a result of exchange of bound GDP for GTP; the GTP-bound form is an essential participant in the formation of transport vesicles(4). This nucleotide exchange is inhibited by the fungal metabolite brefeldin A (BFA)(5,6), Here we identify a protein (Gea1) from Saccharomyces cerevisiae that is a component of a complex possessing guanine-nucleotide-exchange activity for ARF: We show that the activity of the complex is sensitive to brefeldin A and that Gea1 function is necessary for ER-Golgi transport in vivo, Gea1 contains a domain that is similar to a domain of Sec7, a protein necessary for intra-Golgi transport. We propose that Gea1 and ARNO, a human protein with a homologous Sed domain(7), are members of a new family of ARF guanine-nucleotide exchange factors.	CEA SACLAY,DEPT BIOL CELLULAIRE & MOL,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE; CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			PEYROCHE, Anne/C-5548-2014; Jackson, Catherine/T-5688-2019; Jackson, Catherine/A-3421-2013	PEYROCHE, Anne/0000-0002-8808-8785; Jackson, Catherine/0000-0002-0843-145X				BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Deitz SB, 1996, MOL CELL BIOL, V16, P3275; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; FRANZUSOFF A, 1992, NATURE, V355, P173, DOI 10.1038/355173a0; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; FUJIMURA K, 1993, MOL GEN GENET, V241, P280, DOI 10.1007/BF00284679; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; JACKSON CL, 1994, GENETICS, V137, P423; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; ZAGULSKI M, 1995, YEAST, V11, P1179, DOI 10.1002/yea.320111208	28	231	235	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					479	481		10.1038/384479a0	http://dx.doi.org/10.1038/384479a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945477				2022-12-28	WOS:A1996VW68700067
J	Greaves, RRSH; Brown, RL; Farthing, MJG				Greaves, RRSH; Brown, RL; Farthing, MJG			An air stewardess with puzzling diarrhoea	LANCET			English	Article							SORBITOL		FRIMLEY PK NHS TRUST,DEPT GASTROENTEROL,CAMBERLEY,SURREY,ENGLAND		Greaves, RRSH (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON HOSP,SCH MED & DENT,DIGEST DIS RES CTR,TURNER ST,LONDON E1 2AD,ENGLAND.							BYTZER P, 1989, GUT, V30, P1379, DOI 10.1136/gut.30.10.1379; EHERER AJ, 1992, GASTROENTEROLOGY, V103, P545, DOI 10.1016/0016-5085(92)90845-P; HYAMS JS, 1983, GASTROENTEROLOGY, V84, P30; JOHNSTON KR, 1994, AM J MED, V97, P185, DOI 10.1016/0002-9343(94)90029-9	4	4	4	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1488	1488		10.1016/S0140-6736(96)08190-1	http://dx.doi.org/10.1016/S0140-6736(96)08190-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942779				2022-12-28	WOS:A1996VV46300012
J	Fainzilber, M; Smit, AB; Syed, NI; Wildering, WC; Hermann, PM; vanderSchors, RC; Jimenez, C; Li, KW; vanMinnen, J; Bulloch, AGM; Ibanez, CF; Geraerts, WPM				Fainzilber, M; Smit, AB; Syed, NI; Wildering, WC; Hermann, PM; vanderSchors, RC; Jimenez, C; Li, KW; vanMinnen, J; Bulloch, AGM; Ibanez, CF; Geraerts, WPM			CRNF, a molluscan neurotrophic factor that interacts with the p75 neurotrophin receptor	SCIENCE			English	Article							NERVE GROWTH-FACTOR; LYMNAEA-STAGNALIS; NEURONS; EVOLUTIONARY; EXPRESSION; FAMILY; SNAIL; NGF	A 13.1-kilodalton protein, cysteine-rich neurotrophic factor (CRNF), was purified from the mollusk Lymnaea stagnalis by use of a binding assay on the p75 neurotrophin receptor. CRNF bound to p75 with nanomolar affinity but was not similar in sequence to neurotrophins or any other known gene product. CRNF messenger RNA expression was highest in adult foot subepithelial cells; in the central nervous system, expression was regulated by lesion. The factor evoked neurite outgrowth and modulated calcium currents in pedal motor neurons. Thus, CRNF may be involved in target-derived trophic support for motor neurons and could represent the prototype of another family of p75 ligands.	VRIJE UNIV AMSTERDAM,INST NEUROSCI,GRAD SCH NEUROSCI,NL-1081 HV AMSTERDAM,NETHERLANDS; UNIV CALGARY,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; University of Calgary	Fainzilber, M (corresponding author), KAROLINSKA INST,MOL NEUROBIOL LAB,DEPT NEUROSCI,BERZELIUS LABS BLDG,DOKTORSRINGEN 12A,S-17177 STOCKHOLM,SWEDEN.		Smit, August B/E-8410-2011	Fainzilber, Mike/0000-0001-8173-8557				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1994, J NEUROBIOL, V25, P1373; BARDE YA, 1994, J NEUROBIOL, V25, P1329, DOI 10.1002/neu.480251102; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BULLOCH AGM, UNPUB; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GOTZ R, 1992, J NEUROCHEM, V59, P432, DOI 10.1111/j.1471-4159.1992.tb09389.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; IBANEZ CF, 1995, LIFE DEATH NERVOUS S; JACKSON AR, 1995, CELL TISSUE RES, V281, P507, DOI 10.1007/s004410050446; JIMENEZ CR, 1994, J NEUROCHEM, V62, P404; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KORSCHING S, 1993, J NEUROSCI, V13, P2739; MAROIS R, 1990, J NEUROBIOL, V21, P1053, DOI 10.1002/neu.480210710; RIDGWAY RL, 1991, J NEUROBIOL, V22, P377, DOI 10.1002/neu.480220406; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SYED NI, 1989, COMP BIOCHEM PHYS A, V93, P633, DOI 10.1016/0300-9629(89)90024-8; SYED NI, 1992, NEURON, V8, P767, DOI 10.1016/0896-6273(92)90097-W; SYED NI, 1990, SCIENCE, V250, P282, DOI 10.1126/science.2218532; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Wildering WC, 1995, J NEUROPHYSIOL, V74, P2778, DOI 10.1152/jn.1995.74.6.2778	26	71	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1540	1543		10.1126/science.274.5292.1540	http://dx.doi.org/10.1126/science.274.5292.1540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929417				2022-12-28	WOS:A1996VV77500052
J	Timmerman, D; Vergote, I				Timmerman, D; Vergote, I			Tamoxifen-induced endometrial polyp	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Timmerman, D (corresponding author), KATHOLIEKE UNIV LEUVEN HOSP,B-3000 LOUVAIN,BELGIUM.		Timmerman, Dirk/AAD-2363-2019	Timmerman, Dirk/0000-0002-3707-6645					0	8	8	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1650	1650		10.1056/NEJM199611283352205	http://dx.doi.org/10.1056/NEJM199611283352205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929362				2022-12-28	WOS:A1996VV93600005
J	Sehgal, AR; Weisheit, C; Miura, Y; Butzlaff, M; Kielstein, R; Taguchi, Y				Sehgal, AR; Weisheit, C; Miura, Y; Butzlaff, M; Kielstein, R; Taguchi, Y			Advance directives and withdrawal of dialysis in the United States, Germany, and Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL REPLACEMENT THERAPY; EXPERIENCE; PATIENT; DISEASE; PHYSICIANS; ATTITUDES; DECISIONS; DEATH; CARE	Objective.-To determine the role of advance directives in decisions to withdraw chronic dialysis in the United States, Germany, and Japan. Design.-Survey by questionnaire. Participants.-Seventy-two American, 87 German, and 73 Japanese nephrologists. Main Outcome Measures.-Each nephrologist's total number of (1) dialysis patients, (2) cases of withdrawal of dialysis, (3) patients with advance directives, and (4) uses of such directives, Nephrologists also stated whether they would continue or stop dialysis in 8 hypothetical cases. Results.-American, German, and Japanese nephrologists reported withdrawing dialysis for 5.1%, 1.6%, and 0.7% of their patients in the last year, respectively. Thirty percent of American patients had advance directives, and such directives were used in decision making for 3.2% of all patients. Only 0.3% of German and Japanese patients had advance directives, and such directives were used in decision making for 0.09% of patients. When asked about a hypothetical mentally incompetent patient whose family requests withdrawal of dialysis, American nephrologists were much more likely to stop dialysis in the absence of an advance directive than German or Japanese nephrologists, However, almost all nephrologists from the 3 countries would stop dialysis when a family request to withdraw was supported by a patient advance directive. Conclusions-There is a high prevalence of advance directives among American dialysis patients, and such directives frequently play a role in decision making. German and Japanese nephrologists appear willing to follow advance directives, but the low prevalence of such directives limits the frequency of their use.	CASE WESTERN RESERVE UNIV, METROHLTH MED CTR, DEPT MED, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, CTR BIOMED ETH, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; SAKURA NATL HOSP, DEPT INTERNAL MED, CHIBA, JAPAN; OTTO VON GUERICKE UNIV, DIV NEPHROL, DEPT INTERNAL MED, MAGDEBURG, GERMANY; TOHOKU UNIV, CTR INT STUDIES, SENDAI, MIYAGI 980, JAPAN	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Otto von Guericke University; Tohoku University	Sehgal, AR (corresponding author), CASE WESTERN RESERVE UNIV, METROHLTH MED CTR, DIV NEPHROL, 2500 METROHEALTH CR, CLEVELAND, OH 44109 USA.							Beauchamp T.L., 1979, PRINCIPLES BIOMEDICA, V1st; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; ESER A, 1991, MAT STERBEHILFE INT; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FRIEDMAN EA, 1994, NEPHROL DIAL TRANSPL, V9, P242; FUKAURA A, 1995, NEW ENGL J MED, V333, P805, DOI 10.1056/NEJM199509213331218; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HIRSCH DJ, 1994, AM J KIDNEY DIS, V23, P463, DOI 10.1016/S0272-6386(12)81012-2; KAI I, 1993, SOC SCI MED, V36, P1151, DOI 10.1016/0277-9536(93)90235-V; KEATING RF, 1994, J AM SOC NEPHROL, V4, P1879; Kielstein Rita, 1993, Kennedy Institute of Ethics Journal, V3, P303; KIMURA R, 1991, ETHICS, TRUST, AND THE PROFESSIONS, P235; KJELLSTRAND C, 1993, DEV NEPHROL, V34, P563; KJELLSTRAND C, 1992, ETHICAL PROBLEMS DIA, P563; LEVENSON JL, 1991, PSYCHOSOMATICS, V32, P382, DOI 10.1016/S0033-3182(91)72038-0; MAILLOUX LU, 1993, J AM SOC NEPHROL, V3, P1631; MALLICK NP, 1995, AM J KIDNEY DIS, V25, P176, DOI 10.1016/0272-6386(95)90642-8; MCKENZIE J, 1994, J AM SOC NEPHROL, V5, P465; *MIN HLTH WELF, 1994, REP SURV JAP GEN PUB; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; OREOPOULOS DG, 1995, LANCET, V346, P3, DOI 10.1016/S0140-6736(95)92645-3; ROBERTS JC, 1988, ACTA MED SCAND, V223, P181; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SCHONESEIFERT B, 1991, HASTINGS CENT REP, V21, P20, DOI 10.2307/3562359; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SINGER PA, 1995, J AM SOC NEPHROL, V6, P1410; SINGER PA, 1992, J AM SOC NEPHROL, V2, P1235; STERLING J, 1993, GENET ENG NEWS, V13, P1; TERAOKA S, 1995, AM J KIDNEY DIS, V25, P151, DOI 10.1016/0272-6386(95)90640-1; THIELER H, 1995, CLIN NEPHROL, V44, P108; United States Renal Data System, 1994, USRDS 1994 ANN DAT R; WING AJ, 1988, NEPHROL DIAL TRANSPL, V3, P714; 1993, YOMIURI SIMBUN  0707, P14	33	65	67	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1652	1656		10.1001/jama.276.20.1652	http://dx.doi.org/10.1001/jama.276.20.1652			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922451				2022-12-28	WOS:A1996VU20900032
J	vanWeel, C				vanWeel, C			Primary care: Political favourite or scientific discipline?	LANCET			English	Article											vanWeel, C (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				BADIA JG, 1996, ALLMANMEDICIN S18, V17, P22; BAUMGARTEN M, 1989, J CLIN EPIDEMIOL, V38, P296; BOLAND M, 1996, ALLMANMEDICIN S18, V17, P16; Donaldson M, 1994, DEFINING PRIMARY CAR; FRY J, 1944, PRIMARY HLTH CARE IN; Grol R, 1992, Qual Health Care, V1, P184, DOI 10.1136/qshc.1.3.184; *KNAW, 1994, GEN PRACT RES DUTCH; SCHELLEVIS FG, 1993, J CLIN EPIDEMIOL, V46, P469, DOI 10.1016/0895-4356(93)90024-U; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; Tarino E., 1995, PRIMARY HLTH CARE CO; VANWEEL C, 1992, BRIT J GEN PRACT, V42, P206; VANWEEL C, 1995, EUR J GEN PRACT, V1, P6	12	14	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1431	1432		10.1016/S0140-6736(96)08116-0	http://dx.doi.org/10.1016/S0140-6736(96)08116-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937286				2022-12-28	WOS:A1996VU98600018
J	Liu, ZG; Baskaran, R; LeaChou, ET; Wood, LD; Chen, Y; Karin, M; Wang, JYJ				Liu, ZG; Baskaran, R; LeaChou, ET; Wood, LD; Chen, Y; Karin, M; Wang, JYJ			Three distinct signalling responses by murine fibroblasts to genotoxic stress	NATURE			English	Article							ABL TYROSINE KINASE; ACTIVATED PROTEIN-KINASES; C-ABL; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; PHOSPHORYLATION; DOMAIN; TRANSDUCTION; AGENTS	GENOTOXIC stress triggers signalling pathways that mediate either the protection or killing of affected cells, Whereas induction of p53 involves events in the cell nucleus(1), the activation of transcription factors AP-1 and NF-kappa B by ultraviolet radiation is mediated through membrane-associated signalling proteins, ruling out a nuclear signal(2-6), An early event in AP-1 induction by ultraviolet radiation is activation of Jun kinases (JNKs)(3,7), which mediate the induction of the immediate-early genes c-jun and c-fos(7-13). The JNKs have also been proposed to mediate the apoptopic response to genotoxins(14). The non-receptor tyrosine kinase c-Abl is also activated by genotoxic stress(15,16), To understand the relationship between these events, we compared the activation of p53, JNK and c-Abl by several DNA-damaging agents in murine fibroblasts. We found that whereas p53 was induced by every genotoxic stimulus tested, c-Abl was activated by most stimuli except ultraviolet irradiation and JNK was strongly stimulated only by ultraviolet light and the alkylating agent methyl methanesulphonate. Activation of JNK by this alkylating agent was normal in c-Abl-null cells but was reduced in c-Src-null cells, Unlike p53 induction, c-Abl activation occurs in the S phase of the cell cycle and does not affect cell proliferation, These findings show that signals generated by genotoxins are transduced by multiple, independent pathways. Only p53 appears to be a universal sensor of genotoxic stress.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Wood, Laura/ABF-1531-2020		NATIONAL CANCER INSTITUTE [R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KHARBANDA S, 1995, J BIOL CHEM, V270, P30178; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; ROSETTE CL, IN PRESS SCIENCE; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	30	340	344	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					273	276		10.1038/384273a0	http://dx.doi.org/10.1038/384273a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918879				2022-12-28	WOS:A1996VU38100054
J	Zheng, B; Han, SH; Zhu, Q; Goldsby, R; Kelsoe, G				Zheng, B; Han, SH; Zhu, Q; Goldsby, R; Kelsoe, G			Alternative pathways for the selection of antigen-specific peripheral T cells	NATURE			English	Article							GERMINAL-CENTERS; IN-VIVO; B-CELLS; RECEPTOR; DEATH; APOPTOSIS; ANTIBODIES; IMMUNITY; INVIVO; NUR77	IN the thymus, maturing lymphocytes receive activation signals mediated by the T-cell antigen receptor (TCR) that either promote clonal survival (positive selection) or induce apoptosis (negative selection), This balance between life and death is mirrored by the sensitivity of cortical thymocytes to apoptotic death induced by antibodies against the CD3 component of the TCR signal-transduction complex, bacterial superantigens that bind to the TCR beta-chain, and corticosteroids(1-3). In contrast, mature peripheral T cells are positively activated by anti-CD3 antibody or superantigens and are resistant to steroid-induced death(4,5). Here we show that in splenic germinal centres, T cells regain thymocyte-like sensitivity to TCR- and steroid-induced apoptosis and undergo antigen-driven positive and negative selection, T-cell responses elsewhere in the spleen are unaccompanied by programmed cell death, Our observations define a new differentiation pathway for peripheral T cells and suggest that germinal centres induce a lymphocyte phenotype necessary for the maintenance of self-tolerance.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; AMHERST COLL, DEPT BIOL, AMHERST, MA 01002 USA	University System of Maryland; University of Maryland Baltimore; Amherst College			Goldsby, Robert/O-8363-2019					COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; FULLER KA, 1993, J IMMUNOL, V151, P4505; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUBRANSONJUDGE A, 1996, EUR J IMMUNOL, V26, P1830; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JAMESON SC, 1991, J IMMUNOL, V147, P3185; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; KELSOE G, 1993, CURR OPIN IMMUNOL, V5, P418, DOI 10.1016/0952-7915(93)90062-W; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; PUTLEN AM, 1988, NATURE, V335, P796; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SURTH CD, 1994, NATURE, V372, P100; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WYLIE AH, 1989, NATURE, V284, P555; Zheng B, 1996, J EXP MED, V184, P1083, DOI 10.1084/jem.184.3.1083; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0	29	77	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 21	1996	384	6606					263	266		10.1038/384263a0	http://dx.doi.org/10.1038/384263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918876				2022-12-28	WOS:A1996VU38100051
J	NicolSmith, L				NicolSmith, L			Causality, menopause, and depression: A critical review of the literature	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY; INFERENCE; SYMPTOMS; IMPACT; WOMEN	Objective-To assess whether causal criteria can be used to find out whether there is support in published research for maintaining that menopause causes depression. Design-Ninety four articles from 30 years of research examining the relation of natural menopause to depression were traced by using Medline and systematic follow up of reference lists. Specified exclusion and inclusion criteria were applied, and the resulting 43 epidemiological primary research articles were classified and tabulated according to sample and measures used and the researchers' own conclusion as to whether or not an association had been established. This material was qualitatively evaluated with Hill's nine criteria for causality. Result-There is insufficient evidence at present to maintain that menopause causes depression. In addition to methodological and statistical problems, a temporal problem in the menopause concept hinders research in this area. Conclusion-Causal criteria can usefully be used to structure a literature review. Further theoretical work is required to integrate standard clinical epidemiological concepts.	UNIV OSLO, DEPT PSYCHOL, OSLO, NORWAY	University of Oslo								ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BRAMBILLA DJ, 1994, AM J EPIDEMIOL, V140, P1091, DOI 10.1093/oxfordjournals.aje.a117209; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; DALY E, 1993, BRIT MED J, V307, P836, DOI 10.1136/bmj.307.6908.836; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; GRAY JAM, 1994, J EPIDEMIOL COMMUN H, V48, P4; HARLOW BL, 1995, AM J EPIDEMIOL, V141, P1170, DOI 10.1093/oxfordjournals.aje.a117390; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOLLAND PW, 1986, J AM STAT ASSOC, V81, P945, DOI 10.2307/2289064; Hume David, 1984, TREATISE HUMAN NATUR; KAUFERT P, 1981, SOC SCI MED-MED PSYC, V15, P173, DOI 10.1016/0271-5384(81)90011-9; KAUFERT PA, 1988, MATURITAS, V10, P117, DOI 10.1016/0378-5122(88)90156-9; KAUFERT PA, 1994, EXP GERONTOL, V29, P343, DOI 10.1016/0531-5565(94)90014-0; KULLER LH, 1994, EXP GERONTOL, V29, P495, DOI 10.1016/0531-5565(94)90030-2; MATTHEWS KA, 1994, EXP GERONTOL, V29, P337, DOI 10.1016/0531-5565(94)90013-2; MCKINLAY SM, 1994, EXP GERONTOL, V29, P479, DOI 10.1016/0531-5565(94)90029-9; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P772, DOI 10.1016/S0002-9378(12)90817-0; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PETERSON HB, 1991, OBSTET GYNECOL, V78, P710; POCOCK SJ, 1991, CONTROL CLIN TRIALS, V12, pS257, DOI 10.1016/S0197-2456(05)80029-7; RENTON A, 1994, J EPIDEMIOL COMMUN H, V48, P79, DOI 10.1136/jech.48.1.79; Rothman K, 1986, MODERN EPIDEMIOLOGY; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SUSSER M, 1991, AM J EPIDEMIOL, V133, P635, DOI 10.1093/oxfordjournals.aje.a115939; WEED DL, 1986, AM J EPIDEMIOL, V123, P965, DOI 10.1093/oxfordjournals.aje.a114349; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	28	68	72	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1996	313	7067					1229	1232		10.1136/bmj.313.7067.1229	http://dx.doi.org/10.1136/bmj.313.7067.1229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939110	Green Published			2022-12-28	WOS:A1996VU20800019
J	Cornuz, J; Pearson, SD; Creager, MA; Cook, EF; Goldman, L				Cornuz, J; Pearson, SD; Creager, MA; Cook, EF; Goldman, L			Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; ultrasonography, Doppler duplex; comorbidity; neoplasms; physical examination	VEIN THROMBOSIS; OCCULT CANCER; DIAGNOSIS	Background: The relation between thrombosis and cancer is well documented, but the clinical evaluation appropriate for detecting underlying cancer in patients with deep venous thrombosis remains unknown. Objectives: To 1) determine the appropriate initial evaluation for cancer in patients with idiopathic deep venous thrombosis and 2) estimate the incidence of subsequently diagnosed cancer in patients who were not found to have cancer when deep venous thrombosis was diagnosed. Design: Retrospective cohort study. Setting: Urban, tertiary care teaching hospital. Patients: 986 consecutive patients (637 women and 349 men; mean age +/- SD, 53 +/- 17 years) who had no risk factors for venous disease and had venous ultrasonography because idiopathic deep venous thrombosis was suspected. Measurements: Initial clinical evaluation was assessed by using chart review. The incidence of cancer at a median of 34 months after diagnosis of deep venous thrombosis was obtained through hospital chart review (38%), computerized record extraction (54%), mailed questionnaires (6%), telephone interviews (1%), or a death registry (1%). Results: Deep venous thrombosis was diagnosed in 142 patients (14%); 136 of the 142 were hospitalized. Cancer was diagnosed in 16 of these 136 patients (12%) during the index hospitalization. All 16 of these patients had one or more abnormalities on at least one of the four components of the clinical examination: history, physical examination, basic laboratory testing, or chest radiography. The probability of detecting cancer increased as the number of findings suggestive of cancer on the four components of the clinical evaluation increased. Cancer was diagnosed in none of the 56 patients with deep venous thrombosis who did not have findings on the clinical evaluation. The probability of cancer-free survival during follow-up (median, 34 months) was similar in patients with (3 of 122 [2.5%]) and without (23 of 844 [2.7%]) deep venous thrombosis and in the age- and sex-matched U.S. population. Conclusions: A clinical evaluation that includes a comprehensive medical history, physical examination, routine laboratory testing, and chest radiography seems to be appropriate for detecting cancer in these patients. Additional testing should be guided by any abnormalities detected by this clinical evaluation.	HARVARD COMMUNITY HLTH PLAN, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV GEN MED, CLIN EPIDEMIOL SECT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC, VASC DIAGNOST LAB, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco	Cornuz, J (corresponding author), UNIV LAUSANNE HOSP, DEPT INTERNAL MED, BUGNON AVE, CH-1011 LAUSANNE, SWITZERLAND.				NHLBI NIH HHS [HL02663] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADERKA D, 1986, CANCER, V57, P1846, DOI 10.1002/1097-0142(19860501)57:9<1846::AID-CNCR2820570925>3.0.CO;2-3; ANLYAN WG, 1956, JAMA-J AM MED ASSOC, V161, P964, DOI 10.1001/jama.1956.62970100002009a; Bounameaux H, 1988, Vasa Suppl, V25, P1; CORNUZ J, 1995, RADIOLOGY, V197, P434; *EARL DET BRANC, 1987, WORK GUID EARL CANC; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR, P39; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HIRSCH DR, 1993, PREVENTION VENOUS TH, P485; LEVINE M, 1990, SEMIN ONCOL, V17, P160; Miller A B, 1993, J Public Health Policy, V14, P403, DOI 10.2307/3342875; MILLER AB, 1993, CANCER PRINCIPLES PR, P564; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; POLAK JF, 1991, CHEST, V99, pS165, DOI 10.1378/chest.99.4.165S; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; RICKLES FR, 1983, BLOOD, V62, P14; RIES LAG, 1994, NIH PUB; ROSE SC, 1990, RADIOLOGY, V175, P639, DOI 10.1148/radiology.175.3.2188293; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P458; SILVERSTEIN RL, 1992, NEW ENGL J MED, V327, P1163, DOI 10.1056/NEJM199210153271611; SIMONS GR, 1995, AM J MED, V99, P43, DOI 10.1016/S0002-9343(99)80103-X; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; YUCEL EK, 1991, RADIOLOGY, V179, P443, DOI 10.1148/radiology.179.2.2014289	26	113	123	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					785	+		10.7326/0003-4819-125-10-199611150-00001	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928984				2022-12-28	WOS:A1996VU52400004
J	Freeman, M				Freeman, M			Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN TYROSINE KINASE; DORSAL-VENTRAL AXIS; FAINT-LITTLE-BALL; SIGNAL TRANSDUCTION; MAP KINASE; PC12 CELLS; PHOTORECEPTOR CELLS; IMAGINAL DISKS; FATE DECISIONS	The Drosophila eye has contributed much to our knowledge of cell differentiation. This understanding has primarily come from the study of the R7 photoreceptor; much less is known about the development of the other classes of photoreceptor or the nonneuronal cone or pigment cells. I have used a dominant-negative form of the Drosophila epidermal growth factor receptor (DER) to show that this receptor tyrosine kinase (RTK) is required for the differentiation of all these cell types, and I have also shown that DER is sufficient to trigger their development. DER is even required in R7, where it can replace Sevenless, another RTK. These results broaden our view of eye development to include the whole ommatidium and suggest that reiterative activation of DER is critical for triggering the differentiation of all cell types.			Freeman, M (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Freeman, Matthew/0000-0003-0410-5451				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BAUMANN P, 1993, DEVELOPMENT, V119, P65; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CLIFFORD RJ, 1989, GENETICS, V123, P771; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; ELLIS MC, 1993, DEVELOPMENT, V119, P855; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FREEMAN M, 1994, DEVELOPMENT, V120, P2297; FREEMAN M, 1992, DEVELOPMENT, V116, P335; FREEMAN M, 1994, MECH DEVELOP, V48, P25, DOI 10.1016/0925-4773(94)90003-5; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; Golembo M, 1996, DEVELOPMENT, V122, P223; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1993, DEV BIOL, V160, P51, DOI 10.1006/dbio.1993.1285; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOLODKIN AL, 1994, DEVELOPMENT, V120, P1731; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; RUOHOLABAKER H, 1993, CELL, V73, P953, DOI 10.1016/0092-8674(93)90273-S; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SAWAMOTO K, 1994, DEV BIOL, V164, P267, DOI 10.1006/dbio.1994.1197; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STURTEVANT MA, 1994, DEVELOPMENT, V120, P2593; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TIO M, 1994, MECH DEVELOP, V48, P13, DOI 10.1016/0925-4773(94)90002-7; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; VASSIN H, 1987, EMBO J, V6, P3433; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WOLFF T, 1991, DEVELOPMENT, V113, P825; XU T, 1993, DEVELOPMENT, V117, P1223; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	68	678	684	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					651	660		10.1016/S0092-8674(00)81385-9	http://dx.doi.org/10.1016/S0092-8674(00)81385-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929534	Bronze			2022-12-28	WOS:A1996VU03500008
J	Walker, A				Walker, A			Environment - A new key area for Health of the Nation?	BRITISH MEDICAL JOURNAL			English	Article								Later this month the government will be consulting on whether the environment should be adopted as a new key area for their Health of the Nation strategy. It is proposing to have five topic areas and to adopt 10-15 environmental targets. This would reaffirm its commitment to linking environmental policy and health policy following publication earlier this year of its environmental health action plan. Critics may respond to the consultation document with suggestions for more far reaching targets-based, for example, on the ''Health for All'' targets from the World Health Organisation, or those arising out of Agenda 21 from the earth summit in Rio De Janeiro. Whatever the criticism, this move will be a chance to Link environmental and health agendas at both national and local level.			Walker, A (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, MORTIMER MARKET CTR, LONDON WC1E 6AU, ENGLAND.							*CHART I ENV HLTH, 1995, ENV HLTH SUST DEV; *CHART I ENV HLTH, 1995, UK ENV HLTH ACT PLAN; DAVEYSMITH G, 1994, BRIT MED J, V309, P1453; *DEP ENV SCOTT OFF, 1996, UK NAT AIR QUAL STRA; *DEP HLTH, 1995, VAR HLTH WHAT CAN DE; *DEP HLTH DEP ENV, 1996, UK NAT ENV HLTH ACT; Department of Health, 1992, HLTH NAT STRAT HLTH; *FRIENDS EARTH, 1995, RESP PUBL CONS DRAFT; *GOV UN, 1992, AG 21 PROGR ACT SUST; McMichael A J, 1993, PLANETARY OVERLOAD G; 1996, TIMES           0411	11	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1197	1199		10.1136/bmj.313.7066.1197	http://dx.doi.org/10.1136/bmj.313.7066.1197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916758	Green Published			2022-12-28	WOS:A1996VR90700031
J	Lander, ES				Lander, ES			The new genomics: Global views of biology	SCIENCE			English	Editorial Material									MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.		Peng, Bo/A-6920-2009	Peng, Bo/0000-0001-8225-2284				Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOLLAND PWH, 1994, DEVELOPMENT, P125; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; LOCKHART D, IN PRESS NATURE BIOT; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHULER GD, 1996, SCIENCE, V274, P540	13	798	957	10	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 25	1996	274	5287					536	539		10.1126/science.274.5287.536	http://dx.doi.org/10.1126/science.274.5287.536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN919	8928008				2022-12-28	WOS:A1996VN91900036
J	Kuzmenko, I; Buller, R; Bouwman, WG; Kjaer, K; AlsNielsen, J; Lahav, M; Leiserowitz, L				Kuzmenko, I; Buller, R; Bouwman, WG; Kjaer, K; AlsNielsen, J; Lahav, M; Leiserowitz, L			Formation of chiral interdigitated multilayers at the air-liquid interface through acid-base interactions	SCIENCE			English	Article							SALTS	Thin interdigitated films composed of a long-chain, water-insoluble chiral acid (p-pentadecylmandelic acid of absolute configuration R) and a water-soluble chiral base (phenylethylamine, R') were constructed at the air-solution interface. The (R, R') structure was characterized to near-atomic resolution by grazing-incidence x-ray diffraction (GIXD). The two diastereomeric systems, (R, R') and (R, S'), demonstrate similar surface pressure-molecular area isotherms, but their structures are completely different on the molecular level, as monitored by GIXD, Complementary data on these two architectures were provided by atomic force microscopy.	WEIZMANN INST SCI,DEPT MAT & INTERFACES,IL-76100 REHOVOT,ISRAEL; RISO NATL LAB,DEPT SOLID STATE PHYS,DK-4000 ROSKILDE,DENMARK; UNIV COPENHAGEN,NIELS BOHR INST,HC ORSTED LAB,DK-2100 COPENHAGEN,DENMARK	Weizmann Institute of Science; Technical University of Denmark; University of Copenhagen; Niels Bohr Institute			Bouwman, Wim/C-8669-2009	Bouwman, Wim/0000-0002-5331-8085				Als-Nielsen J., 1994, Physics Reports, V246, P251, DOI 10.1016/0370-1573(94)90046-9; BRIANSO MC, 1979, ACTA CRYSTALLOGR B, V35, P2751, DOI 10.1107/S0567740879010438; DIEGO H, 1994, ACTA CHEM SCAND, V48, P306; ITOH O, 1984, B CHEM SOC JPN, V57, P810, DOI 10.1246/bcsj.57.810; IWAGAMI H, 1991, B CHEM SOC JPN, V64, P175, DOI 10.1246/bcsj.64.175; LARSEN S, 1993, ACTA CRYSTALLOGR B, V49, P303, DOI 10.1107/S0108768192007377; Liu YH, 1996, LANGMUIR, V12, P1235, DOI 10.1021/la950504o; MAJEWSKI J, 1995, CHEM-EUR J, V1, P304, DOI 10.1002/chem.19950010507; SLATER JL, 1988, PROG LIPID RES, V27, P325, DOI 10.1016/0163-7827(88)90010-0; ZINGG SP, 1988, J AM CHEM SOC, V110, P1565, DOI 10.1021/ja00213a033	10	26	30	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2046	2049		10.1126/science.274.5295.2046	http://dx.doi.org/10.1126/science.274.5295.2046			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953028				2022-12-28	WOS:A1996VY97400038
J	Sicinski, P; Donaher, JL; Geng, Y; Parker, SB; Gardner, H; Park, MY; Robker, RL; Richards, JS; McGinnis, LK; Biggers, JD; Eppig, JJ; Bronson, RT; Elledge, SJ; Weinberg, RA				Sicinski, P; Donaher, JL; Geng, Y; Parker, SB; Gardner, H; Park, MY; Robker, RL; Richards, JS; McGinnis, LK; Biggers, JD; Eppig, JJ; Bronson, RT; Elledge, SJ; Weinberg, RA			Cyclin DZ is an FSH responsive gene involved in gonadal cell proliferation and oncogenesis	NATURE			English	Article							HUMAN BREAST-CANCER; EXPRESSION; D1; ORGANIZATION; TUMORS	THE D type cyclins (D1, D2 and D3) are critical governors of the cell-cycle clock apparatus during the G1 phase of the mammalian cell cycle. These three D-type cyclins are expressed in overlapping, apparently redundant fashion in the proliferating tissues(1,2). To investigate why mammalian cells need three distinct D-type cyclins, we have generated mice bearing a disrupted cyclin D2 gene by using gene targeting in embryonic stem cells. Cyclin D2-deficient females are sterile owing to the inability of ovarian granulosa cells to proliferate normally in response to follicle-stimulating hormone (FSH), whereas mutant males display hypoplastic testes. In ovarian granulosa cells, cyclin D2 is specifically induced by FSH via a cycllc-AMP dependent pathway, indicating that expression of the various D-type cyclins is under control of distinct intracellular signalling pathways. The hypoplasia seen in cyclin D2(-/-) ovaries and testes prompted us to examine human cancers deriving from corresponding tissues. We find that some human ovarian and testicular tumours contain high levels of cyclin D2 messenger RNA.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Scripps Research Institute; Harvard University; Harvard Medical School; Jackson Laboratory; Tufts University; Tufts University			McGinnis, Lynda/AAG-7484-2020	McGinnis, Lynda/0000-0001-7910-9655; Robker, Rebecca/0000-0002-1538-4604				BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BOLAND NI, 1994, J REPROD FERTIL, V101, P369, DOI 10.1530/jrf.0.1010369; BOSL GJ, 1989, J NATL CANCER I, V81, P1874; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Desjardins C, 1993, CELL MOL BIOL TESTIS; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Hogan B, 1994, MANIPULATING MOUSE E; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JOHNSON LD, 1995, J REPROD FERTIL, V104, P277, DOI 10.1530/jrf.0.1040277; Moore DD, 1995, GLOB MOB SURV; Nakayama H, 1996, DEV GROWTH DIFFER, V38, P141, DOI 10.1046/j.1440-169X.1996.t01-1-00003.x; OBRIEN MJ, 1993, METHODS TOXICOL, V38, P128; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PETERS G, 1994, J CELL SCI, P89; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SULJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V101, P85	22	573	579	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 5	1996	384	6608					470	474		10.1038/384470a0	http://dx.doi.org/10.1038/384470a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945475				2022-12-28	WOS:A1996VW68700065
J	Lembke, A				Lembke, A			A letter from the foreign legion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1704	1704						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940304				2022-12-28	WOS:A1996VV56600003
J	Gellene, GI				Gellene, GI			An explanation for symmetry-induced isotopic fractionation in ozone	SCIENCE			English	Article							DIATOM DIATOM REACTIONS; THEORETICAL-ANALYSIS; HEAVY OZONE; OXYGEN; RESTRICTIONS; DISCHARGE; PRESSURE; O-2	Application of a theory of nuclear symmetry-based reaction restrictions to the O-2 + O --> O-3 reaction provides a potential explanation for the symmetry-induced isotopic enrichment observed for laboratory and atmospherically produced O-3. Within this theory, the rate of formation of O-3 from collisions of O and isotopically homonuclear O-2 depends on whether the O-2 molecule is in an f (allowed) or an e (restricted) parity label state. The restriction can be relaxed by various potential energy surface coupling terms, and the assumption that approximately 78 percent of the restricted O-2(e) levels produce O-3 with the same efficiency as the allowed O-2(f) levels can account for laboratory-observed isotopic fractionation. In particular, the theory explains the special enhanced formation of the completely asymmetric isotopomer (OOO)-O-16-O-17-O-18.			Gellene, GI (corresponding author), TEXAS TECH UNIV,DEPT CHEM & BIOCHEM,LUBBOCK,TX 79409, USA.							ANDERSON SM, 1989, CHEM PHYS LETT, V156, P175, DOI 10.1016/S0009-2614(89)87115-5; BATES DR, 1990, J CHEM PHYS, V93, P8739, DOI 10.1063/1.459262; Bunker P.R., 2006, MOL SYMMETRY SPECTRO; Chapman S, 1930, PHILOS MAG, V10, P345; GELLENE GI, 1993, J PHYS CHEM-US, V97, P34, DOI 10.1021/j100103a009; GELLENE GI, 1992, J CHEM PHYS, V96, P4387, DOI 10.1063/1.462830; GELLENE GI, 1996, ADV GAS P I, V2, P161; GOLDMAN A, 1989, J GEOPHYS RES-ATMOS, V94, P8467, DOI 10.1029/JD094iD06p08467; GRIFFITH KS, 1992, J CHEM PHYS, V96, P4403, DOI 10.1063/1.462831; Irion FW, 1996, GEOPHYS RES LETT, V23, P2377, DOI 10.1029/96GL01695; KAYE JA, 1986, J GEOPHYS RES-ATMOS, V91, P7865, DOI 10.1029/JD091iD07p07865; KRANKOWSKY D, 1995, GEOPHYS RES LETT, V22, P1713, DOI 10.1029/95GL01436; MAUERSBERGER K, 1981, GEOPHYS RES LETT, V8, P935, DOI 10.1029/GL008i008p00935; MAUERSBERGER K, 1993, GEOPHYS RES LETT, V20, P1031, DOI 10.1029/93GL01080; Meier A, 1996, GEOPHYS RES LETT, V23, P551, DOI 10.1029/96GL00374; MORTON J, 1989, CHEM PHYS LETT, V154, P143, DOI 10.1016/S0009-2614(89)87276-8; RINSLAND CP, 1985, J GEOPHYS RES-ATMOS, V90, P10719, DOI 10.1029/JD090iD06p10719; SCHUELER B, 1990, GEOPHYS RES LETT, V17, P1295, DOI 10.1029/GL017i009p01295; THIEMENS MH, 1988, GEOPHYS RES LETT, V15, P639, DOI 10.1029/GL015i007p00639; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; THIEMENS MH, 1990, GEOPHYS RES LETT, V17, P717, DOI 10.1029/GL017i006p00717; VALENTINI JJ, 1987, J CHEM PHYS, V86, P6757, DOI 10.1063/1.452375; YANG JM, 1987, GEOCHIM COSMOCHIM AC, V51, P2011, DOI 10.1016/0016-7037(87)90189-X; YANG JM, 1987, GEOCHIM COSMOCHIM AC, V51, P2019, DOI 10.1016/0016-7037(87)90190-6; Yoo RK, 1996, J CHEM PHYS, V105, P177, DOI 10.1063/1.471855; YOO RK, 1995, J CHEM PHYS, V102, P3227, DOI 10.1063/1.468633	26	56	56	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1344	1346		10.1126/science.274.5291.1344	http://dx.doi.org/10.1126/science.274.5291.1344			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910267				2022-12-28	WOS:A1996VU95400043
J	Agulnick, AD; Taira, M; Breen, JJ; Tanaka, T; Dawid, IB; Westphal, H				Agulnick, AD; Taira, M; Breen, JJ; Tanaka, T; Dawid, IB; Westphal, H			Interactions of the LIM-domain-binding factor Ldb1 with LIM homeodomain proteins	NATURE			English	Article							GENE; ORGANIZER; MUSCLE; XENOPUS; XLIM-1; ZYXIN	THE LIM homeodomain (LIM-HD) proteins, which contain two tandem LIM domains followed by a homeodomain, are critical transcriptional regulators of embryonic development(1-5). The LIM domain is a conserved cysteine-rich zinc-binding motif found in LIM-HD and LMO (rhombotin or Ttg) proteins, cytoskeletal components, LIM kinases and other proteins(1). LIM domains are protein-protein interaction motifs(1), can binding of LIM-HD proteins to DNA(6,7) and can negatively regulate LIM-HD protein function(8). How LIM domains exert these regulatory effects is not known. We have now isolated a new LIM-domain-binding factor, LdB1, on the basis of tis ability to interact with the LIM-HD protein Lhx1 (Lim1)(9). High-affinity binding by Ldb1 requires paired LIM domains and is restricted to the related subgroup of LIM domains found in LIM-HD and LMO proteins. The highly conserved Xenopus Lbd protein XLbd1, interacts with Xlim-1, the Xenopus orthologue of Lhx1. When injected into Xenopus embryos, XLbd1 (or Lbd1) can synergize with Xlim-1 in the formation of partial secondary axes and in activation of the genes encoding goosecoid (gsc), chordin, NCAM and XCG7, demonstrating a functional as well as a physical interaction between the two proteins.	NICHHD,GENET MOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Agulnick, AD (corresponding author), NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892, USA.							ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HARPER JW, 1993, CELL, V75, P805; Karavanov AA, 1996, INT J DEV BIOL, V40, P453; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; NUNOUE K, 1995, ONCOGENE, V11, P701; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; TAIRA M, 1995, TRENDS GENET, V11, P431, DOI 10.1016/S0168-9525(00)89139-8; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	23	284	295	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					270	272		10.1038/384270a0	http://dx.doi.org/10.1038/384270a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918878				2022-12-28	WOS:A1996VU38100053
J	Endres, MJ; Clapham, PR; Marsh, M; Ahuja, M; Turner, JD; McKnight, A; Thomas, JF; StoebenauHaggarty, B; Choe, S; Vance, PJ; Wells, TNC; Power, CA; Sutterwala, SS; Doms, RW; Landau, NR; Hoxie, JA				Endres, MJ; Clapham, PR; Marsh, M; Ahuja, M; Turner, JD; McKnight, A; Thomas, JF; StoebenauHaggarty, B; Choe, S; Vance, PJ; Wells, TNC; Power, CA; Sutterwala, SS; Doms, RW; Landau, NR; Hoxie, JA			CD4-independent infection by HIV-2 is mediated by Fusin/CXCR4	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN CELL-LINES; ENVELOPE GLYCOPROTEIN; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; CD4; RECEPTOR; TYPE-1; INTERNALIZATION; LOCALIZATION	Several members of the chemokine receptor family have been shown to function in association with CD4 to permit HIV-1 entry and infection. However, the mechanism by which these molecules serve as CD4-associated cofactors is unclear. In the present report, we show that one member of this family, termed Fusin/ CXCRL1, is able to function as an alternative receptor for some isolates of HIV-2 in the absence of CD4. This conclusion is supported by the finding that (1) CD4-independent infection by these viruses is inhibited by an anti-fusin monoclonal antibody, (2) Fusin expression renders human and nonhuman CD4-negative cell lines sensitive to HIV-P-induced syncytium induction and/or infection, and (3) Fusin is selectively downregulated from the cell surface following HIV-2 infection. The finding that one chemokine receptor can function as a primary viral receptor strongly suggests that the HIV envelope glycoprotein contains a binding site for these proteins and that differences in the affinity and/or the availability of this site can extend the host range of these viruses to include a number of CD4-negative cell types.	INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; UCL, DEPT BIOCHEM, MRC, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; GLAXO WELLCOME RES & DEV SA, GENEVA BIOMED RES INST, CH-1228 PLAN LES OUATES, GENEVA, SWITZERLAND; UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; ROCKEFELLER UNIV, AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London; GlaxoSmithKline; University of Pennsylvania; Rockefeller University	Endres, MJ (corresponding author), UNIV PENN, DIV HEMATOL ONCOL, CLIN RES BLDG, PHILADELPHIA, PA 19104 USA.		Marsh, Mark/B-4105-2009; Good (formerly Turner), Julie/I-8305-2018	Marsh, Mark/0000-0002-0213-3259; Wells, Timothy/0000-0001-9796-847X; McKnight, Aine/0000-0002-8113-817X	Medical Research Council [G117/547] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; Dean GA, 1996, J VIROL, V70, P5646, DOI 10.1128/JVI.70.8.5646-5650.1996; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1995, J VIROL, V69, P1013, DOI 10.1128/JVI.69.2.1013-1018.1995; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; GOLDING H, 1994, J VIROL, V68, P1962, DOI 10.1128/JVI.68.3.1962-1969.1994; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HOXIE JA, 1988, J VIROL, V62, P2557, DOI 10.1128/JVI.62.8.2557-2568.1988; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; IKEUCHI K, 1990, J VIROL, V64, P4226, DOI 10.1128/JVI.64.9.4226-4231.1990; JABBAR MA, 1990, J VIROL, V64, P6296; KOGA Y, 1990, J VIROL, V64, P4661, DOI 10.1128/JVI.64.10.4661-4671.1990; LABRANCHE CC, 1994, J VIROL, V68, P5509, DOI 10.1128/JVI.68.9.5509-5522.1994; LABRANCHE CC, 1995, J VIROL, V69, P5217, DOI 10.1128/JVI.69.9.5217-5227.1995; Livingstone WJ, 1996, LANCET, V348, P649, DOI 10.1016/S0140-6736(96)02091-0; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MANKOWSKI JL, 1994, J VIROL, V68, P8202, DOI 10.1128/JVI.68.12.8202-8208.1994; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; Power CA, 1996, TRENDS PHARMACOL SCI, V17, P209, DOI 10.1016/0165-6147(96)10019-5; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; REEVES JD, 1996, IN PRESS J VIROL; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHNEIDERSCHAULIES J, 1995, P NATL ACAD SCI USA, V92, P3943, DOI 10.1073/pnas.92.9.3943; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WEISS RA, 1993, JRETROVIRIDAE, P1; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	49	593	626	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 15	1996	87	4					745	756		10.1016/S0092-8674(00)81393-8	http://dx.doi.org/10.1016/S0092-8674(00)81393-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929542	hybrid			2022-12-28	WOS:A1996VU03500016
J	Dahlquist, G; Bennich, SS; Kallen, B				Dahlquist, G; Bennich, SS; Kallen, B			Intrauterine growth pattern and risk of childhood onset insulin dependent (type I) diabetes: Population based case-control study	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL BIRTH REGISTRY; MELLITUS; WEIGHT; LIFE; AGE	Objective-To investigate whether prenatal growth affects the risk of development of childhood onset insulin dependent (type I) diabetes mellitus. Design-Population based case-control study. Setting-Data from a nationwide childhood diabetes case register were linked with data from the nationwide Swedish Medical Birth Registry. Subjects-Data from a total of 4584 diabetic children born after 1973 and diagnosed with diabetes from 1978 to 1992 were studied. For each child with insulin dependent diabetes three control children were randomly selected from among all infants born in the same year and at the same hospital as the proband. Main outcome measures-Birth, weight, gestation, maternal age and parity, number of previous spontaneous abortions, and sex specific birth weight by gestational week expressed as multiples of the standard deviation (SD). Results-There was a clear trend in the odds ratio for childhood onset diabetes according to SD of birth weight. The odds ratio (95% confidence interval) for small for gestational age after stratification for maternal age, parity, smoking habits, and maternal diabetes was 0.81 (0.65 to 0.99) and for large for gestational age after similar stratification was 1.20 (1.02 to 1.42). Conclusions-Intrauterine conditions that affect prenatal growth seem also to affect the risk of development of childhood diabetes in the way previously described for postnatal growth: a poor growth decreases and an excess growth increases the risk. The mechanism for this association is unclear.	UMEA UNIV,DEPT EPIDEMIOL & PUBL HLTH,S-90185 UMEA,SWEDEN; UNIV UPPSALA,DEPT INTERNAL MED,UPPSALA,SWEDEN; LUND UNIV,TORNBLAD INST,LUND,SWEDEN	Umea University; Uppsala University; Lund University	Dahlquist, G (corresponding author), UMEA UNIV,DEPT PAEDIAT,S-90185 UMEA,SWEDEN.							ANDERSSON DKG, 1991, DIABETIC MED, V8, P428, DOI 10.1111/j.1464-5491.1991.tb01626.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BLOM L, 1992, DIABETOLOGIA, V35, P528, DOI 10.1007/BF00400480; BLOM L, 1989, DIABETOLOGIA, V32, P7; Breslow N., 1980, SCI PUBLICATIONS INT, V32; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; DAHLQUIST G, 1991, ACTA PAEDIATR SCAND, V80, P583, DOI 10.1111/j.1651-2227.1991.tb11914.x; DAHLQUIST G, 1992, DIABETOLOGIA, V35, P671, DOI 10.1007/BF00400261; DAHLQUIST G, 1982, ACTA PAEDIATR SCAND, V71, P7, DOI 10.1111/j.1651-2227.1982.tb09364.x; DAHLQUIST G, 1994, INT J EPIDEMIOL, V23, P1239; DORNER G, 1985, EXP CLIN ENDOCRINOL, V85, P1; JOHANSSON C, 1994, DIABETOLOGIA, V37, P91; KALLEN B, 1995, EUR J EPIDEMIOL, V11, P601, DOI 10.1007/BF01719316; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; MANTEL N, 1963, JNCI-J NATL CANCER I, V32, P719; NYSTROM L, 1990, INT J EPIDEMIOL, V19, P141, DOI 10.1093/ije/19.1.141; SOTHHILL JF, 1983, PAEDIAT IMMUNOLOGY	17	106	107	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1174	1177		10.1136/bmj.313.7066.1174	http://dx.doi.org/10.1136/bmj.313.7066.1174			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916747	Green Published			2022-12-28	WOS:A1996VR90700020
J	Mills, CM; Llewelyn, MB; Kelly, DR; Holt, P				Mills, CM; Llewelyn, MB; Kelly, DR; Holt, P			A man who pricked his finger and smelled putrid for 5 years	LANCET			English	Article									UNIV WALES HOSP,DEPT DERMATOL,CARDIFF CF4 4XW,S GLAM,WALES; UNIV WALES HOSP,DEPT INFECT DIS,CARDIFF CF4 4XW,S GLAM,WALES; UNIV WALES COLL CARDIFF,DEPT CHEM,CARDIFF CF1 3NS,S GLAM,WALES	Cardiff University; Cardiff University; Cardiff University			Llewelyn, Martin/A-7194-2011	Llewelyn, Martin/0000-0002-6811-1124				Finegold S.M., 1983, HUMAN INTESTINAL MIC, P3, DOI DOI 10.1016/B978-0-12-341280-5.50007-0; FINEGOLD SM, 1995, PRINCIPLES PRACTICE, P2156; LUTACS A, 1991, DERMATOLOGICA, V182, P32; PETERSON EH, 1964, POULTRY SCI, V43, P1062, DOI 10.3382/ps.0431062; RENNIE PJ, 1991, BRIT J DERMATOL, V124, P596, DOI 10.1111/j.1365-2133.1991.tb04958.x	5	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1282	1282		10.1016/S0140-6736(96)06408-2	http://dx.doi.org/10.1016/S0140-6736(96)06408-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909382				2022-12-28	WOS:A1996VR55500012
J	Ostergaard, L; Moller, JK; Andersen, B; Olesen, F				Ostergaard, L; Moller, JK; Andersen, B; Olesen, F			Diagnosis of urogenital Chlamydia trachomatis infection in women based on mailed samples obtained at home: Multipractice comparative study	BRITISH MEDICAL JOURNAL			English	Article							LIGASE CHAIN-REACTION; URINE SPECIMENS; REACTION ASSAY; MEN; PREVALENCE; URETHRITIS; TESTS	Objective-To compare urine and vaginal flush samples collected by women at home with endocervical and urethral swabs obtained by general practitioners for their efficacy in the diagnosis of urogenital Chlamydia trachomatis infection. Design-Multipractice comparative study. Setting-33 general practices and a central department of clinical microbiology in Aarhus County, Denmark. Subjects-222 women aged 18-25 years who for any reason had a gynaecological examination. Interventions-Endocervical and urethral swabs were obtained by the women's general practitioners. The same women when at home then collected a first void urine sample, a midstream urine sample, and a vaginal flush sample (using a vaginal pipette) and mailed them to the laboratory. Main outcome measures-C trachomatis detected by the polymerase chain reaction and the ligase chain reaction. Eight tests for C trachomatis were performed for every woman. When two of the eight yielded positive results the patient was considered infected. Results-The overall prevalence of C trachomatis infection was 11.2% (23/205 women). Test sensitivities in samples obtained by general practitioners, samples obtained at home subjected to polymerase chain reaction, and samples obtained at home subjected to ligase chain reaction were 91%, 96%, and 100% respectively. The corresponding specificities were 100%, 92.9%, and 99.5%. Conclusions-The diagnostic efficacy of samples obtained by women at home acid mailed to the laboratory was as good as for samples obtained by a general practitioner when using the ligase chain reaction. This may have important implications for the practicability of screening for this common, often asymptomatic, and treatable infection.	AARHUS UNIV HOSP,DEPT CLIN MICROBIOL,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,RES UNIT GEN PRACTICE,DK-8000 AARHUS C,DENMARK	Aarhus University; Aarhus University	Ostergaard, L (corresponding author), AARHUS UNIV HOSP,DEPT INFECT DIS,PP ORUMSGADE 11,DK-8000 AARHUS C,DENMARK.		Ostergaard, Lars/AAA-3020-2020; Andersen, Berit/J-3402-2017	Ostergaard, Lars/0000-0003-2459-0511; Andersen, Berit/0000-0003-4074-6504; Moller, Jens Kjolseth/0000-0002-5547-5498; Ostergaard, Lars/0000-0002-7619-605X				ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; BASSIRI M, 1995, J CLIN MICROBIOL, V33, P898, DOI 10.1128/JCM.33.4.898-900.1995; BRUNHAM RC, 1984, NEW ENGL J MED, V311, P1, DOI 10.1056/NEJM198407053110101; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; Genc M, 1996, ANN INTERN MED, V124, P1, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00001; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HAY PE, 1994, GENITOURIN MED, V70, P97; HILLIS SD, 1994, AM J OBSTET GYNECOL, V170, P801, DOI 10.1016/S0002-9378(94)70286-1; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; Moller J. K., 1994, Immunology and Infectious Diseases (Oxford), V4, P191; MORRIS RE, 1993, SEX TRANSM DIS, V20, P198, DOI 10.1097/00007435-199307000-00004; OSTERGAARD L, 1990, J CLIN MICROBIOL, V28, P1254, DOI 10.1128/JCM.28.6.1254-1260.1990; OSTERGAARD L, 1991, EUR J CLIN MICROBIOL, V10, P1057, DOI 10.1007/BF01984929; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; VANDOORNUM GJJ, 1995, J CLIN MICROBIOL, V33, P2042, DOI 10.1128/JCM.33.8.2042-2047.1995; WIENSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41; WIESENFELD HC, 1994, SEX TRANSM DIS, V21, P268, DOI 10.1097/00007435-199409000-00004	22	82	82	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1186	1189		10.1136/bmj.313.7066.1186	http://dx.doi.org/10.1136/bmj.313.7066.1186			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916753	Green Published			2022-12-28	WOS:A1996VR90700026
J	Shelley, M; Croft, P; Chapman, S; Pantin, C				Shelley, M; Croft, P; Chapman, S; Pantin, C			As the ratio of inhaled corticosteroid to bronchodilator a good indicator of the quality of asthma prescribing? Cross sectional study linking prescribing data to data on admissions	BRITISH MEDICAL JOURNAL			English	Article							POVERTY	Objective-To investigate the ratio of inhaled corticosteroid to bronchodilator as a measure of the quality of asthma prescribing by general practitioners. Design-Ecological cross sectional study linking general practitioner asthma prescribing with hospital admission data and a measure of deprivation. Subject-11 family health services authorities in the West Midlands region and 99 general practices North Staffordshire. Main outcome measures-Hospital admission rates for asthma; the ratio of inhaled corticosteroid to bronchodilator; and Townsend deprivation scores. Results-No overall significant correlation was found between admission rates for asthma and corticosteroid:bronchodilator ratios for family health services authorities (Spearman's r(s) = -0.109, P = 0.750) or general practices (r(s) = -0.084, P = 0.407). In deprived family health services authority areas and general practices an inverse non-significant correlation existed between admission rates for asthma and corticosteroid:bronchodilator ratios (r(s) = -0.300, P = 0.624; r(s) = -0.218, P = 0.136). In contrast, in more affluent areas and general practices a positive non-significant correlation existed between admission rates and corticosteroid:bronchodilator ratios (r(s) = 0.371, P = 0.468; r(s) = 0.038, P = 0.792). Conclusion-Although the corticosteroid:bronchodilator ratio may be a valid indicator of the quality of prescribing for individual patients with asthma, caution should be applied in interpreting aggregated ratios, Differences in the severity of asthma or the prevalence of chronic obstructive pulmonary disease may explain inconsistent associations between admission rates for asthma and corticosteroid:bronchodilator ratios in family health services authorities and general practices with different deprivation scares.	UNIV KEELE,DEPT MED MANAGEMENT,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University	Shelley, M (corresponding author), KEELE UNIV,N STAFFORDSHIRE MED INST,POSTGRAD MED SCH,IND & COMMUNITY HLTH RES CTR,STOKE ON TRENT ST4 7NY,STAFFS,ENGLAND.							Andersen H. R., 1994, Logical Foundations of Computer Science. Third International Symposium, LFCS '94 Proceedings, P8; *AUD COMM, 1994, PRESCR IMPR MOR RAT, P26; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; *BRIT THOR SOC, 1993, THORAX, V48, pS1; *CAMD ISL FAM HLTH, 1995, HLTH NEEDS ASS YOUR; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570, DOI 10.1164/ajrccm.152.2.7633709; GORDON D, 1995, PEOPLE PLACES, V2; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HALFON N, 1993, PEDIATRICS, V91, P56; Kleinschmidt I, 1995, J EPIDEMIOL COMMUN H, V49, pS72, DOI 10.1136/jech.49.Suppl_2.S72; LITTLEJOHNS P, 1993, RESP MED, V87, P139, DOI 10.1016/0954-6111(93)90142-M; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; Townsend PP., 1988, HLTH DEPRIVATION INE; *W MIDL REG HLTH A, 1992, PARTN HLTH REP REG D, P16; *WHO COLL CTR DRUG, 1993, AN THER CHEM ATC CLA, P102	16	46	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1124	1126		10.1136/bmj.313.7065.1124	http://dx.doi.org/10.1136/bmj.313.7065.1124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916701	Green Published			2022-12-28	WOS:A1996VR21700027
J	Fuster, V; Fallon, JT; Nemerson, Y				Fuster, V; Fallon, JT; Nemerson, Y			Coronary thrombosis	LANCET			English	Article							HUMAN ATHEROSCLEROTIC PLAQUES; MYOCARDIAL-INFARCTION; ARTERY DISEASE; RUPTURE; METALLOPROTEINASES; PATHOGENESIS; MECHANISMS; MACROPHAGE						Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986; Fallon, John/0000-0002-7677-4868				AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; DAVIES MJ, 1993, BRIT HEART J, V69, P377; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FUSTER V, 1995, EUR HEART J, V16, P6, DOI 10.1093/eurheartj/16.suppl_E.6; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; LITLE WC, 1988, CIRCULATION, V78, P1157; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; MORENO PR, IN PRESS CIRCULATION; RICHARDSON PD, 1989, LANCET, V2, P1462; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHAH PK, 1995, CIRCULATION, V92, P1565; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; Stroke Prevention in Atrial Fibrillation Investigators, 1996, LANCET, V348, P633; THIRUVIKRAMAN SV, IN PRESS LAB INVEST; TOSCHI V, IN PRESS CIRCULATION	20	64	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV	1996	348			1			S7	S10		10.1016/S0140-6736(96)98003-4	http://dx.doi.org/10.1016/S0140-6736(96)98003-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918520				2022-12-28	WOS:A1996VU00800004
J	Vieira, AV; Lamaze, C; Schmid, SL				Vieira, AV; Lamaze, C; Schmid, SL			Control of EGF receptor signaling by clathrin-mediated endocytosis	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; MUTANT; CELLS; DYNAMIN; PHOSPHORYLATION; RECRUITMENT; BINDING; SITES; SHC	Epidermal growth factor receptor (EGFR) signaling was analyzed in mammalian cells conditionally defective for receptor-mediated endocytosis. EGF-dependent cell proliferation was enhanced in endocytosis-defective cells. However, early EGF-dependent signaling events were not uniformly up-regulated. A subset of signal transducers required the normal endocytic trafficking of EGFR for full activation. Thus, endocytic trafficking of activated EGFR plays a critical role not only in attenuating EGFR signaling but also in establishing and controlling specific signaling pathways.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Lamaze, Christophe/M-4912-2017	Schmid, Sandra/0000-0002-1690-7024; , A. Vieira/0000-0002-8906-1293; LAMAZE, Christophe/0000-0001-5430-2707	NCI NIH HHS [CA69099, CA58689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689, R01CA069099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1995, ONCOGENE, V11, P2525; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P5730; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUI H, 1991, CANCER RES, V51, P6170; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHPETNER H, 1996, J CELL BIOL, V132, P595; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VIEIRA AJS, UNPUB; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083	34	789	801	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2086	2089		10.1126/science.274.5295.2086	http://dx.doi.org/10.1126/science.274.5295.2086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953040				2022-12-28	WOS:A1996VY97400050
J	Bose, HS; Sugawara, T; Strauss, JF; Miller, WL				Bose, HS; Sugawara, T; Strauss, JF; Miller, WL			The pathophysiology and genetics of congenital lipoid adrenal hyperplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIDE-CHAIN CLEAVAGE; ACUTE REGULATORY PROTEIN; LEYDIG TUMOR-CELLS; GONADAL DEVELOPMENT; COS-1 CELLS; MITOCHONDRIAL; EXPRESSION; PATIENT; P450SCC; GENES	Background Congenital lipoid adrenal hyperplasia results in severe impairment of steroid biosynthesis in the adrenal glands and gonads that is manifested both in utero and postnatally. We recently found mutations in the gene for the steroidogenic acute regulatory protein in four patients with this syndrome, but it was not clear whether all patients have such mutations or why there is substantial clinical variation in these patients. Methods We directly sequenced the gene for steroidogenic acute regulatory protein in 15 patients with congenital lipoid adrenal hyperplasia from 10 countries. Identified mutations were confirmed and recreated in expression vectors, transfected into cultured cells, and assayed for the presence and activity of steroidogenic acute regulatory protein. Results Fifteen different mutations in the gene for steroidogenic acute regulatory protein were found in 14 patients; the mutation Gln258Stop was found in 80 percent of affected alleles from Japanese and Korean patients, and the mutation Arg182Leu was found in 78 percent of affected alleles from Palestinian patients. We developed diagnostic tests for these and eight other mutations. Thirteen of the 15 mutations were in exons 5, 6, or 7, and all rendered the steroidogenic acute regulatory protein inactive in functional assays. Some mutants with amino acid replacements were capable of normal mitochondrial processing, indicating that the activity of steroidogenic acute regulatory protein is not associated with its translocation into mitochondria. Steroidogenic cells lacking the protein retained low levels of steroidogenesis. This explains the secretion of some steroid hormones by the ovaries after puberty before affected cells accumulate large amounts of cholesterol esters. Conclusions The congenital lipoid adrenal hyperplasia phenotype is the result of two separate events, an initial genetic toss of steroidogenesis that is dependent on steroidogenic acute regulatory protein and a subsequent loss of steroidogenesis that is independent of the protein due to cellular damage from accumulated cholesterol esters.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV PENN,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104	University of California System; University of California San Francisco; University of Pennsylvania			Miller, Walter L/J-3696-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042154, R01DK037922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42154, DK37922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKANE F, 1996, P NATL ACAD SCI USA, V93, P13731; CAMACHO AM, 1968, J CLIN ENDOCR METAB, V28, P153, DOI 10.1210/jcem-28-2-153; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; DEGENHART HJ, 1972, ACTA ENDOCRINOL-COP, V71, P513; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Fukami M., 1995, CLIN PEDIAT ENDOCRIN, V4, P39, DOI [10.1297/cpe.4.39, DOI 10.1297/CPE.4.39]; Hall PF, 1995, J STEROID BIOCHEM, V55, P601, DOI 10.1016/0960-0760(95)00211-1; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HATANO O, 1994, DEVELOPMENT, V120, P2787; HAUFFA BP, 1985, CLIN ENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2265.1985.tb01107.x; KIRKLAND RT, 1973, J CLIN ENDOCR METAB, V36, P488, DOI 10.1210/jcem-36-3-488; KOIZUMI S, 1977, CLIN CHIM ACTA, V77, P301; KONDO T, 1986, JPN J PEDIAT S, V34, P1223; KONDO T, 1993, CLIN ENDOCRINOL S, V41, P163; KONDO T, 1986, CLIN ENDOCRINOL, V34, P322; LIN D, 1993, GENOMICS, V18, P643, DOI 10.1016/S0888-7543(05)80367-2; LIN D, 1991, J CLIN INVEST, V88, P1955, DOI 10.1172/JCI115520; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Matsuo N., 1994, HORM RES S, V41, P106; MATTESON KJ, 1986, ENDOCRINOLOGY, V118, P1296, DOI 10.1210/endo-118-4-1296; MESIANO S, 1993, J CLIN ENDOCR METAB, V77, P1184, DOI 10.1210/jc.77.5.1184; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MULLER J, 1991, HORM RES, V36, P203, DOI 10.1159/000182162; PRADER A, 1955, Helv Paediatr Acta, V10, P397; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; SAENGER P, 1993, J STEROID BIOCHEM, V45, P87, DOI 10.1016/0960-0760(93)90127-I; SAKAI Y, 1994, J CLIN ENDOCR METAB, V79, P1198, DOI 10.1210/jc.79.4.1198; SANDISON AT, 1955, ARCH DIS CHILD, V30, P538, DOI 10.1136/adc.30.154.538; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TEE MK, 1995, HUM MOL GENET, V4, P2299, DOI 10.1093/hmg/4.12.2299; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	37	444	460	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1870	1878		10.1056/NEJM199612193352503	http://dx.doi.org/10.1056/NEJM199612193352503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948562				2022-12-28	WOS:A1996VX87400003
J	Swisher, CC; Rink, WJ; Anton, SC; Schwarcz, HP; Curtis, GH; Suprijo, A; Widiasmoro				Swisher, CC; Rink, WJ; Anton, SC; Schwarcz, HP; Curtis, GH; Suprijo, A; Widiasmoro			Latest Homo erectus of Java: Potential contemporaneity with Homo sapiens in southeast Asia	SCIENCE			English	Article							HUMAN OCCUPATION SITE; U-SERIES; TOOTH ENAMEL; EVOLUTION; ARTIFACTS; EUROPE; ORIGIN; DATES; SPAIN; CAVE	Hominid fossils from Ngandong and Sambungmacan, Central Java, are considered the most morphologically advanced representatives of Homo erectus. Electron spin resonance (ESR) and mass spectrometric U-series dating of fossil bovid teeth collected from the hominid-bearing levels at these sites gave mean ages of 27 +/- 2 to 53.3 +/- 4 thousand years ago; the range in ages reflects uncertainties in uranium migration histories. These ages are 20,000 to 400,000 years younger than previous age estimates for these hominids and indicate that H. erectus may have survived on Java at least 250,000 years longer than on the Asian mainland, and perhaps 1 million years longer than in Africa. The new ages raise the possibility that H. erectus overlapped in time with anatomically modern humans (H. sapiens) in Southeast Asia.	MCMASTER UNIV, DEPT GEOL, HAMILTON, ON L8S 4M1, CANADA; UNIV FLORIDA, DEPT ANTHROPOL, GAINESVILLE, FL 32611 USA; GADJAH MADA UNIV, LAB BIOANTHROPOL & PALEOANTHROPOL, YOGYAKARTA 55281, INDONESIA	McMaster University; State University System of Florida; University of Florida; Gadjah Mada University	Swisher, CC (corresponding author), BERKELEY GEOCHRONOL CTR, 2455 RIDGE RD, BERKELEY, CA 94709 USA.		Klein, Richard G/B-5910-2009					ANTON SC, UNPUB; AZIZ F, COMMUNICATION; Bahn PG, 1996, NATURE, V383, P577, DOI 10.1038/383577a0; BARTSIOKAS A, 1993, P ROY SOC B-BIOL SCI, V252, P115, DOI 10.1098/rspb.1993.0054; Bartstra G.-J., 1989, Palaeohistoria, V29, P1; BARTSTRA GJ, 1988, J HUM EVOL, V17, P325, DOI 10.1016/0047-2484(88)90074-7; BISCHOFF JL, 1989, J ARCHAEOL SCI, V16, P553; BOWLER JM, 1972, NATURE, V240, P48, DOI 10.1038/240048a0; Brauer G., 1992, CONTINUITY REPLACEME, P83; BRENNAN BJ, IN PRESS RADIA MEAS; BROTHWELL DR, 1960, J SARAWAK MUS, V323, P1; BROWN P, 1993, PHILOS T R SOC; Brown P., 1981, ARCHAEOL OCEAN, V16, P156; BROWN P, 1989, TERRA AUST, V13; CARBONELL E, 1995, SCIENCE, V269, P826, DOI 10.1126/science.7638598; de Lumley H, 1971, CR HEBD ACAD SCI, P1729; Frayer D.W., 1992, CONTINUITY REPLACEME, P179; FULLAGER RLK, IN PRESS ANTIQUITY; GROUBE L, 1986, NATURE, V324, P453, DOI 10.1038/324453a0; GRUN R, 1994, QUATERNARY SCI REV, V13, P121, DOI 10.1016/0277-3791(94)90037-X; GRUN R, 1987, CAN J EARTH SCI, V24, P1022, DOI 10.1139/e87-099; GRUN R, 1988, NUCL TRACKS RAD MEAS, V14, P237; GRUN R, 1991, ARCHAEOMETRY, V33, P153, DOI 10.1111/j.1475-4754.1991.tb00696.x; Grun R., 1996, ANCIENT TL, V14, P21; GUANJUN S, 1991, ACTA ANTHR SIN, V10, P273; HOWELL FC, 1994, INTERD CONT, P253; HOWELL FC, 1986, ANTHROPOLOGIE, V90, P447; HUBLIN JJ, 1995, CR ACAD SCI II A, V321, P931; Hublin JJ, 1996, NATURE, V381, P224, DOI 10.1038/381224a0; ITIHARA M, 1985, SPEC PUBL GEOLOGICAL, V4, P63; JACOB T, 1975, CATALOGUE FOSSIL H 3, P103; JACOB T, 1981, PAPERS HONOR D BLACK, P87; KLEIN RG, 1989, HUMAN CAREER; KOZLOWSKI J, 1982, EXCAVATIONS BACHO KI; KU RT, COMMUNICATION; LAHR MM, 1994, J HUM EVOL, V26, P23, DOI 10.1006/jhev.1994.1003; LI WX, 1989, NATURE, V339, P534, DOI 10.1038/339534a0; MACINTOSH N W G, 1972, Archaeology and Physical Anthropology in Oceania, V7, P1; MATSU'URA S, 1990, Bulletin of the National Science Museum Series D (Anthropology), V16, P19; MCDERMOTT F, 1993, NATURE, V363, P252, DOI 10.1038/363252a0; MCKINNEY CR, 1991, THESIS SE METHODISTU; MILARD A, 1995, ARCHAEOL SCI, V22, P200; MOELYADI I, 1982, PROY PENEL PALEOANTH; NITIHAMINOTO G, 1977, PUSAT PENEL PURBAK P, P1; OAKLEY KP, 1975, CATALOGUE FOSSIL H 3; Oppenoorth W. F. F., 1932, Natur a Museum, V62, P269; Oppenoorth W. F.. F., 1932, Wetens Meded Mijnb Batavia, Vno. 20, P49; OPPENOORTH WFF, 1936, KON NED AARDR GENOOT, V53, P399; RELETHFORD JH, UNPUB; Rightmire G. Philip, 1994, Courier Forschungsinstitut Senckenberg, V171, P319; RIGHTMIRE GP, 1993, EVOLUTION HOMO ERECT; RINK WJ, 1994, J ARCHAEOL SCI, V21, P839, DOI 10.1006/jasc.1994.1081; ROBERTS RG, 1990, NATURE, V345, P153, DOI 10.1038/345153a0; SANTALUCA AP, 1980, YALE U PUBL ANTHR, V78; SCHWARCZ HP, 1992, PHILOS T ROY SOC B, V337, P145, DOI 10.1098/rstb.1992.0091; SCHWARCZ HP, 1991, URANIUM SERIES DISEQ, P513; SHUTLER R, IN PRESS FELICITATIO; SIXUN Y, 1991, ACTA ANTHR SIN, V10, P189; SIXUN Y, 1986, ACTA ANTHR SIN, V5, P179; STORM P, 1996, SCRI GEOL, V110, P1; STRINGER CB, 1991, NATURE, V351, P701, DOI 10.1038/351701a0; STRINGER CB, 1992, SEARCH NEANDERTHALS; STRINGER CB, 1992, CONTINUITY REPLACEME, P9; SUZUKI M, 1985, SPEC PUBL GEOLOGICAL, V4, P309; SWISHER C, COMMUNICATION; SWISHER CC, UNPUB; TAMARAT E, 1994, PALAEOGEOGR PALAEOCL, V114, P273; TATTERSALL I, IN PRESS P NAT ACADS; TERHAAG C, 1934, ING NED INDLE MIJNIN, V4, P51; THORNE AG, 1981, AM J PHYS ANTHROPOL, V55, P337, DOI 10.1002/ajpa.1330550308; TIEMEI C, 1988, ARCHAEOMETRY, V30, P59; VALLADAS H, 1988, NATURE, V331, P614, DOI 10.1038/331614a0; VANDERPLICHT J, 1989, APPL GEOCHEM, V4, P339; von Koenigswald G. H. R., 1934, INGENIEUR NEDERLANDS, V1, P185; Von Koenigswald G.H.R., 1956, M PREH MAN; VONKOENIGSWALD GHR, UNPUB; Webb S, 1995, PALAEOPATHOLOGY ABOR; WEIDENREICH F, UNPUB; Weidenreich F., 1951, ANTHROPOLOGICAL PAPE, V43, P205; WOLPOFF MH, 1992, NATURE, V356, P200, DOI 10.1038/356200b0; Wolpoff Milford H., 1994, Courier Forschungsinstitut Senckenberg, V171, P341; [No title captured]	82	214	220	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1870	1874		10.1126/science.274.5294.1870	http://dx.doi.org/10.1126/science.274.5294.1870			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VY200	8943192				2022-12-28	WOS:A1996VY20000032
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			A 35-year-old pregnant woman considering maternal serum screening and amniocentesis, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		MENNUTI M, 1996, JAMA-J AM MED ASSOC, V275, P1410	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1840	1840		10.1001/jama.276.22.1840	http://dx.doi.org/10.1001/jama.276.22.1840			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946906				2022-12-28	WOS:A1996VV99700035
J	Goodman, DC; Fisher, ES; Bubolz, TA; Mohr, JE; Poage, JF; Wennberg, JE				Goodman, DC; Fisher, ES; Bubolz, TA; Mohr, JE; Poage, JF; Wennberg, JE			Benchmarking the US physician workforce - An alternative to needs-based or demand-based planning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRADUATE MEDICAL-EDUCATION; HEALTH-CARE; REFORM	Objective.-To propose population-based benchmarking as an alternative to needs- or demand-based planning for estimating a reasonably sized, clinically active physician workforce for the United States and its regional health care markets. Design.-Cross-sectional analysis of 1993 American Medical Association and American Osteopathic Association physician masterfiles. Population.-The resident population of the 306 hospital referral regions in the United States. Main Outcome Measures.-Per capita number of clinically active physicians by specialty adjusted for age and sex population differences and out-of-region health care utilization, The measured physician workforce was compared with 4 benchmarks: the staffing within a large (2.4 million members) health maintenance organization (HMO), a hospital referral region dominated by managed care (Minneapolis, Minn), a hospital referral region dominated by fee-for-service (Wichita, Kan), and the proposed ''balanced'' physician supply (50% generalists). Results.-The proportion of the US population residing in hospital referral regions with a higher per capita generalist workforce than the benchmark was 96% for the HMO benchmark, 60% for Wichita, and 27% for Minneapolis. The specialist workforce exceeded all 3 benchmarks for 74% of the population, The per capita workforce of generalists was not related to the proportion of generalists among regions (Pearson correlation coefficient=0.06; P=.26). Conclusions.-Population-based benchmarking offers practical advantages to needs- or demand-based planning for estimating a reasonably sized per capita workforce of clinically active physicians. The physician workforce within the benchmarks of an HMO and health care markets indicates the varying opportunities for regional physician employment and services. The ratio of generalists to specialists does not measure the adequacy of the supply of the generalist workforce either nationally or for specific regions. Research measuring the relationship between physician workforces of different sizes and population outcomes will guide the selection of future regional benchmarks.	DARTMOUTH COLL, SCH MED, DEPT PEDIAT, HANOVER, NH 03755 USA; DARTMOUTH COLL, SCH MED, DEPT MED, HANOVER, NH 03755 USA; DEPT VET AFFAIRS MED CTR, WHITE RIVER JCT, VT USA	Dartmouth College; Dartmouth College	Goodman, DC (corresponding author), DARTMOUTH COLL, SCH MED, CTR EVALUAT CLIN SCI, DEPT COMMUNITY & FAMILY MED, 211 STRASENBURGH HALL, HANOVER, NH 03755 USA.		Goodman, David/AAG-7497-2020		NHLBI NIH HHS [R29-HL52076-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052076] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM MED ASS, 1995, SOC CHAR MED PRACT; *AM MED ASS, 1971, DISTR PHYS US; American Medical Association, 1994, PHYS CHAR DISTR US; *BUR HLTH PROF, 1982, HLTH PERS US 8 REP C; COHEN JJ, 1995, ACAD MED, V70, pS7, DOI 10.1097/00001888-199501000-00018; COHEN JJ, 1994, JAMA-J AM MED ASSOC, V272, P712, DOI 10.1001/jama.272.9.712; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; DIAL TH, 1995, HEALTH AFFAIR, V14, P168, DOI 10.1377/hlthaff.14.2.168; FISHER ES, 1992, JAMA-J AM MED ASSOC, V267, P1925, DOI 10.1001/jama.267.14.1925; Goodman D C, 1992, J Rural Health, V8, P106, DOI 10.1111/j.1748-0361.1992.tb00335.x; Graduate Medical Education National Advisory Committee, 1980, REP GRAD MED ED NAT, V1; *INT, 1995, INT COMP EDG 5 2; JACOBSEN SJ, 1987, HEALTH AFFAIR, V6, P48, DOI 10.1377/hlthaff.6.2.48; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V271, P1505, DOI 10.1001/jama.271.19.1505; Krakauer H, 1996, HEALTH SERV RES, V31, P191; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LEWIS CE, 1969, NEW ENGL J MED, V281, P880, DOI 10.1056/NEJM196910162811606; MARDER WD, 1988, PHYSICIAN SUPPL UTIL; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; *NAT CTR HLTH STAT, 1989, NAT AMB MED CAR SURV; PAGANO M, 1993, PRINCIPLES BIOSTATIS; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; ROOS NP, 1986, AM J PUBLIC HEALTH, V76, P45, DOI 10.2105/AJPH.76.1.45; SCHROEDER SA, 1994, JAMA-J AM MED ASSOC, V272, P239, DOI 10.1001/jama.272.3.239; SCHWARTZ A, 1993, JAMA-J AM MED ASSOC, V270, P1079, DOI 10.1001/jama.270.9.1079; SCHWARTZ WB, 1988, JAMA-J AM MED ASSOC, V259, P233, DOI 10.1001/jama.259.2.233; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; TARLOV AR, 1995, JAMA-J AM MED ASSOC, V274, P1558, DOI 10.1001/jama.274.19.1558; *US DHEW, 1975, US DHEW PUBL HRA, V7560; Weinber JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; WENNBERG JE, 1973, SCIENCE, V246, P120; WENNBERG JE, 1996, DARTMOUTH ATLAS HLTH, V198, P223; WHITCOMB ME, 1995, JAMA-J AM MED ASSOC, V274, P692	37	107	107	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	1996	276	22					1811	1817		10.1001/jama.276.22.1811	http://dx.doi.org/10.1001/jama.276.22.1811			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV997	8946901				2022-12-28	WOS:A1996VV99700030
J	Eron, JJ; Ashby, MA; Giordano, MF; Chernow, M; Reiter, WM; Deeks, SG; Lavelle, JP; Conant, MA; Yangco, BG; Pate, PG; Torres, RA; Mitsuyasu, RT; Twaddell, T				Eron, JJ; Ashby, MA; Giordano, MF; Chernow, M; Reiter, WM; Deeks, SG; Lavelle, JP; Conant, MA; Yangco, BG; Pate, PG; Torres, RA; Mitsuyasu, RT; Twaddell, T			Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-LYMPHOCYTE ACTIVITY; TYPE-1 HIV-1; ANTIBODY; SEROCONVERSION; PROGRESSION; VIREMIA; DISEASE; CELLS; GP120	Background Most individuals infected with HIV-1 show disease progression despite both cellular and humoral immune responses. We investigated whether immunisation of patients who had symptomless HIV-1 infection with an envelope subcomponent Vaccine (MNrgp120) to augment immune response can slow progression of HIV-1 disease. Methods In a randomised, double-blind, placebo-controlled trial, carried out in university infectious disease clinics and community infectious disease practices, we enrolled 573 HIV-infected patients with CD4 counts above 600 cells/mu L (0.6x10(9)/L). Patients received 600 mu g vaccine or placebo by intramuscular injection monthly for 6 months then every alternate month throughout the study. The primary endpoint was the rate of decline in CD4 count; secondary endpoints were HIV-1 RNA concentrations in plasma and minor clinical events associated with HIV. Analysis was by intention to treat. Findings At baseline, the study participants had a mean CD4 count of 775 cells/mu L (SD 172) and 89% of participants had detectable HIV RNA (>200 copies/mL). These RNA-positive individuals had a median viral load of 9250 copies/mL (IQR 2670-26 960). Analysis after 15 months of follow-up of the 568 subjects who had at least one CD4 count done after randomisation showed no difference between the 287 vaccine recipients and 281 placebo recipients in rate of decline of CD4 count (yearly decrease 53.8 [SE 7.6] vs 42.3 [7.6] cells/mu L; ratio of mean gradients 1.27 [95% CI 0.63-2.55]) or in plasma HIV-1 RNA concentrations (p greater than or equal to 0.63). The study was designed with power to detect a vaccine-induced reduction in rate of decline in CD4 count of 60%; these results exclude with 95% confidence a reduction of 40% or more. More vaccine-treated patients than placebo recipients showed a 50% decrease in CD4 count (11 vs 5; relative risk 2.15 [95% CI 0.76-6.12], p=0.13). The frequencies of HIV-related minor clinical events were similar in the two groups. Pain at the injection site was the only adverse event that occurred more frequently in vaccine-treated group. Interpretation Postinfection immunisation of symptom-free HIV-infected patients with MNrgp120 vaccine did not alter HIV-1 disease progression as measured by immunological, virological, and clinical endpoints over a 15-month period.	GENENTECH INC,SAN FRANCISCO,CA 94080; CORNELL UNIV,MED CTR,NEW YORK HOSP,CORNELL CLIN TRIALS UNIT,NEW YORK,NY 10021; CTR SPECIAL IMMUNOL,FT LAUDERDALE,FL; UNIV CALIF SAN FRANCISCO,AIDS PROGRAM,SAN FRANCISCO,CA 94143; GEORGETOWN UNIV,MED CTR,WASHINGTON,DC 20007; CONANT MED GRP,SAN FRANCISCO,CA; INFECT DIS RES INST INC,TAMPA,FL; DALLAS ID ASSOCIATES,DALLAS,TX; ST VINCENTS HOSP & MED CTR,NEW YORK,NY 10011; UNIV CALIF LOS ANGELES,CTR CLIN AIDS RES & EDUC,LOS ANGELES,CA	Roche Holding; Genentech; Cornell University; NewYork-Presbyterian Hospital; University of California System; University of California San Francisco; Georgetown University; Saint Vincents Hospital Manhattan; University of California System; University of California Los Angeles	Eron, JJ (corresponding author), UNIV N CAROLINA,AIDS CLIN TRIAL UNIT,CHAPEL HILL,NC 27599, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865, M01RR000046] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00865, RR00046] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLAN JD, 1993, 9TH INT C AIDS BERL; BARKER E, 1995, P NATL ACAD SCI USA, V92, P11135, DOI 10.1073/pnas.92.24.11135; BELSHE RB, 1994, JAMA-J AM MED ASSOC, V272, P475, DOI 10.1001/jama.272.6.475; BERMAN PW, 1992, J VIROL, V66, P4464, DOI 10.1128/JVI.66.7.4464-4469.1992; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CAVACINI LA, 1993, J ACQ IMMUN DEF SYND, V6, P1093; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DAWSON JD, 1993, BIOMETRICS, V49, P1022, DOI 10.2307/2532244; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; HAMILTON B, 1993, 9 INT C AIDS BERL; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; MASCOLA JR, 1993, AIDS RES HUM RETROV, V9, P1175, DOI 10.1089/aid.1993.9.1175; Mascola JR, 1996, J INFECT DIS, V173, P340, DOI 10.1093/infdis/173.2.340; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; SCHLESSELMAN J, 1973, J CHRON DIS, V25, P561; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; TRAUGER RJ, 1994, J INFECT DIS, V169, P1256, DOI 10.1093/infdis/169.6.1256; USA Council of State and Territorial Epidemiologists, 1987, Morbidity and Mortality Weekly Report, V36, P1; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537	31	63	65	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1547	1551						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950881				2022-12-28	WOS:A1996VX02300009
J	Kimura, T; Tomioka, Y; Kuwahara, H; Asamitsu, A; Tamura, M; Tokura, Y				Kimura, T; Tomioka, Y; Kuwahara, H; Asamitsu, A; Tamura, M; Tokura, Y			Interplane tunneling magnetoresistance in a layered manganite crystal	SCIENCE			English	Article							GIANT MAGNETORESISTANCE; SPIN POLARIZATION; MULTILAYERS; FILMS; CO	The current-perpendicular-to-plane magnetoresistance (CPP-MR) has been investigated for the layered manganite, La2-2xSr1-2xMn2O7 (x = 0,3), which is composed of the ferromagnetic-metallic MnO2 bilayers separated by nonmagnetic insulating block layers, The CPP-MR is extremely large (10(4) percent at 50 kilo-oersted) al temperatures near above the three-dimensional ordering temperature (T-c approximate to 90 kelvin) because of the field-induced coherent motion between planes oi the spin-polarized electrons. Below T-c, the interplane magnetic domain boundary on the insulating block layer serves as the charge-transport barrier, but it can be removed by a low saturation field which gives rise to the low-field tunneling MR as large as 240 percent.	JRCAT, TSUKUBA, IBARAKI 305, JAPAN; UNIV TOKYO, DEPT APPL PHYS, TOKYO 113, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Kimura, T (corresponding author), JRCAT, TSUKUBA, IBARAKI 305, JAPAN.		Tokura, Yoshinori/C-7352-2009; Tomioka, Yasuhide/M-2808-2018; Kimura, Tsuyoshi/F-8090-2018	Tokura, Yoshinori/0000-0002-2732-4983; Tomioka, Yasuhide/0000-0001-9028-1691; 				ANDERSON PW, 1955, PHYS REV, V100, P675, DOI 10.1103/PhysRev.100.675; BAIBICH MN, 1988, PHYS REV LETT, V61, P2472, DOI 10.1103/PhysRevLett.61.2472; BERKOWITZ AE, 1992, PHYS REV LETT, V68, P3745, DOI 10.1103/PhysRevLett.68.3745; CHAHARA K, 1993, APPL PHYS LETT, V63, P1990, DOI 10.1063/1.110624; COOPER SL, 1994, PHYSICAL PROPERTIES, V4, pCH3; DEGENNES PG, 1960, PHYS REV, V118, P141, DOI 10.1103/PhysRev.118.141; DIENY B, 1991, PHYS REV B, V43, P1297, DOI 10.1103/PhysRevB.43.1297; GIJS MAM, 1993, PHYS REV LETT, V70, P3343, DOI 10.1103/PhysRevLett.70.3343; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7; KUBO K, 1972, J PHYS SOC JPN, V33, P21, DOI 10.1143/JPSJ.33.21; Kuwahara H, 1996, SCIENCE, V272, P80, DOI 10.1126/science.272.5258.80; MAEKAWA S, 1982, IEEE T MAGN, V18, P707, DOI 10.1109/TMAG.1982.1061834; MAENO Y, 1994, NATURE, V372, P532, DOI 10.1038/372532a0; MIYAZAKI T, 1995, J MAGN MAGN MATER, V139, pL231, DOI 10.1016/0304-8853(94)01648-8; Moritomo Y, 1996, NATURE, V380, P141, DOI 10.1038/380141a0; OKIMOTO Y, 1995, PHYS REV LETT, V75, P109, DOI 10.1103/PhysRevLett.75.109; OSBORN JA, 1945, PHYS REV, V67, P351, DOI 10.1103/PhysRev.67.351; PARKIN SSP, 1991, APPL PHYS LETT, V58, P2710, DOI 10.1063/1.104765; PERRING TG, PREPRINT; TEDROW PM, 1973, PHYS REV B, V7, P318, DOI 10.1103/PhysRevB.7.318; Tomioka Y, 1996, PHYS REV B, V53, pR1689, DOI 10.1103/PhysRevB.53.R1689; XIAO JQ, 1992, PHYS REV LETT, V68, P3749, DOI 10.1103/PhysRevLett.68.3749; ZENER C, 1951, PHYS REV, V82, P403, DOI 10.1103/PhysRev.82.403	24	441	459	1	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1698	1701		10.1126/science.274.5293.1698	http://dx.doi.org/10.1126/science.274.5293.1698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939857				2022-12-28	WOS:A1996VW71200056
J	Kronborg, O; Fenger, C; Olsen, J; Jorgensen, OD; Sondergaard, O				Kronborg, O; Fenger, C; Olsen, J; Jorgensen, OD; Sondergaard, O			Randomised study of screening for colorectal cancer with faecal-occult-blood test	LANCET			English	Article							MORTALITY; TRIAL	Background Case-control studies and a voluntary-based follow-up study have suggested that repeated screening with faecal-occult-blood (FOE) tests can lead to a reduction in mortality from colorectal cancer (CRC). The aim of this randomised study was to compare mortality rates after FOE tests every 2 years during a 10-year period with those of unscreened similar controls. Methods 140 000 people aged 45-75 years lived in Funen, Denmark, in August, 1985, and were considered for inclusion in our study. Before randomisation we excluded individuals who had CRC or precursor adenomas and those who had taken part in a previous pilot study. Randomisation of 137 485 people in blocks of 14 allocated three per 14 to the screening group (30 967), three per 14 to the control group (30 966), and eight not to be enrolled in the study (75 552). Controls were not told about the study and continued to use health-care facilities as normal. Hemoccult-II blood tests (with dietary restrictions but without rehydration) were sent to screening-group participants. Only those participants who completed the first screening round were invited for further screening-five rounds of screening during a 10-year period. Participants with positive tests were asked to attend a full examination and were offered colonoscopy whenever possible. The primary endpoint was death from CRC. Findings Of the 30 967 screening-group participants, 20 672 (67%) completed the first screening round and were invited for further screening; more than 90% accepted repeated screenings. During the 10-year study, 481 people in the screening group had a diagnosis of CRC, compared with 483 unscreened controls. There were 205 deaths attributable to CRC in the screening group, compared with 249 deaths in controls. CRC mortality, including deaths attributable to complications from CRC treatment, was significantly lower in the screening group than in controls (mortality ratio 0.82 [95% Cl 0.68-0.99]) p=0.03). Interpretation Our findings indicate that biennial screening by FOE tests can reduce CRC mortality. This study is being continued to improve its statistical power and to assess the effect of the removal of more precursor adenomas in the screening-group participants than in controls on CRC incidence.	ODENSE UNIV HOSP,DEPT PATHOL,DK-5000 ODENSE C,DENMARK; ODENSE UNIV HOSP,DEPT STAT,DK-5000 ODENSE C,DENMARK; AARHUS UNIV,DANISH EPIDEMIOL SCI CTR,DK-8000 AARHUS C,DENMARK	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Aarhus University	Kronborg, O (corresponding author), ODENSE UNIV HOSP,DEPT SURG A,DK-5000 ODENSE C,DENMARK.							ADAMSEN S, 1984, SCAND J GASTROENTERO, V19, P431; BECH K, 1991, WORLD J SURG, V15, P7, DOI 10.1007/BF01658953; Faivre J, 1991, Eur J Cancer Prev, V1, P49; HARDCASTLE JD, 1989, LANCET, V1, P1160; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KLAABORG K, 1986, SCAND J GASTROENTERO, V21, P1180, DOI 10.3109/00365528608996440; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; KRONBORG O, 1992, SCAND J GASTROENTERO, V27, P47, DOI 10.3109/00365529209011166; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; SELBY JV, 1993, ANN INTERN MED, V118, P1, DOI 10.7326/0003-4819-118-1-199301010-00001; TAYLOR WF, 1972, CANCER, V30, P1344, DOI 10.1002/1097-0142(197211)30:5<1344::AID-CNCR2820300530>3.0.CO;2-6; Wahrendorf J, 1993, Eur J Cancer Prev, V2, P221, DOI 10.1097/00008469-199305000-00005; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311	13	1943	1995	1	56	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1467	1471		10.1016/S0140-6736(96)03430-7	http://dx.doi.org/10.1016/S0140-6736(96)03430-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942774				2022-12-28	WOS:A1996VV46300007
J	Chanfreau, G; Noble, SM; Guthrie, C				Chanfreau, G; Noble, SM; Guthrie, C			Essential yeast protein with unexpected similarity to subunits of mammalian cleavage and polyadenylation specificity factor (CPSF)	SCIENCE			English	Article							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; SNRNP PROTEIN; MUTATION; 3'-END; GENE; SEPARATION; EXPRESSION; CLONING; END	The 3' ends of most eukaryotic messenger RNAs are generated by internal cleavage and polyadenylation. In mammals, there is a strict dependence of both reactions on the sequence AAUAAA, which occurs upstream of polyadenylation [poly(A)] sites and which is recognized by CPSF. In contrast, cis-acting signals for yeast 3'-end generation are highly divergent from those of mammals, suggesting that trans-acting factors other than poly(A) polymerase would not be conserved. The essential yeast protein Brr5/Ysh1 shows sequence similarity to subunits of mammalian CPSF and is required for 3'-end processing in vivo and in vitro. These results demonstrate a structural and functional conservation of the yeast and mammalian 3'-end processing machineries despite a lack of conservation of the cis sequences.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Noble, Suzanne/0000-0001-9855-8448	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BONNEAUD N, 1994, J CELL SCI, V107, P913; CHANFREAU G, UNPUB; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; GUO ZJ, 1995, P NATL ACAD SCI USA, V92, P4211, DOI 10.1073/pnas.92.10.4211; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; MANDART E, 1995, MOL CELL BIOL, V15, P6579; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; Noble SM, 1996, GENETICS, V143, P67; NOBLE SM, 1995, THESIS U CALIFORNIA; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647	32	60	62	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1511	1514		10.1126/science.274.5292.1511	http://dx.doi.org/10.1126/science.274.5292.1511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929408				2022-12-28	WOS:A1996VV77500043
J	Kaiser, RI; Ochsenfeld, C; HeadGordon, M; Lee, YT; Suits, AG				Kaiser, RI; Ochsenfeld, C; HeadGordon, M; Lee, YT; Suits, AG			A combined experimental and theoretical study on the formation of interstellar C3H isomers	SCIENCE			English	Article							NEUTRAL-NEUTRAL REACTIONS; GAUSSIAN-BASIS SETS; ATOMIC CARBON; MOLECULES; CLOUDS; CHEMISTRY; IRC+10216; ENVELOPE; RATES; BEAM	The reaction of ground-state carbon atoms with acetylene was studied under single-collision conditions in crossed beam experiments to investigate the chemical dynamics of forming cyclic and linear C3H isomers (c-C3H and l-C3H, respectively) in interstellar environments via an atom-neutral reaction. Combined state-of-the-art ab initio calculations and experimental identification of the carbon-hydrogen exchange channel to both isomers classify this reaction as an important alternative to ion-molecule encounters to synthesize C3H radicals in the interstellar medium. These findings strongly correlate with astronomical observations and explain a higher [c-C3H]/[l-C3H] ratio in the dark cloud TMC-1 than in the carbon star IRC+10216.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV CHEM SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kaiser, RI (corresponding author), UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA.		Ochsenfeld, Christian/E-8021-2015; Head-Gordon, Martin/AAR-4028-2020; Lee, Yuan-Tseh/F-7914-2012	Ochsenfeld, Christian/0000-0002-4189-6558; 				[Anonymous], 1991, MODERN MOL PHOTOCHEM; BETTENS RPA, 1995, ASTROPHYS J, V443, P664, DOI 10.1086/175558; CLARY DC, 1994, ASTROPHYS J, V422, P416, DOI 10.1086/173737; CLARY DC, 1993, J CHEM SOC FARADAY T, V89, P2185, DOI 10.1039/ft9938902185; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; ENTENNMANN EA, 1986, THESIS HARVARD U; HERBST E, 1994, MON NOT R ASTRON SOC, V268, P335, DOI 10.1093/mnras/268.2.335; HERBST E, 1990, ASTRON ASTROPHYS, V233, P177; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; HERBST E, 1984, ASTROPHYS J, V285, P618, DOI 10.1086/162538; HERBST E, 1976, CHEM PHYS LETT, V42, P54, DOI 10.1016/0009-2614(76)80550-7; KAISER RI, 1995, J CHEM PHYS, V103, P10395, DOI 10.1063/1.469877; Kaiser RI, 1996, J CHEM PHYS, V105, P8705, DOI 10.1063/1.472652; Kaiser RI, 1995, REV SCI INSTRUM, V66, P5405, DOI 10.1063/1.1146061; Kanada M, 1996, J CHEM PHYS, V104, P2192, DOI 10.1063/1.471811; KEENE J, 1993, ASTROPHYS J, V415, pL131, DOI 10.1086/187050; LEE YT, 1969, REV SCI INSTRUM, V40, P1402, DOI 10.1063/1.1683809; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LEVINE RD, 1987, MOL REACTION DYNAMIC; LIAO Q, 1995, ASTROPHYS J, V444, P694, DOI 10.1086/175642; MILLAR TJ, 1994, ASTRON ASTROPHYS, V288, P561; MILLER WB, 1967, DISCUSS FARADAY SOC, P108, DOI 10.1039/df9674400108; MILLER WB, 1967, DISCUSS FARADAY SOC, V44, P291; RAGHAVACHARI K, 1989, CHEM PHYS LETT, V157, P479, DOI 10.1016/S0009-2614(89)87395-6; ROBINSON MS, 1995, J AM CHEM SOC, V117, P6766, DOI 10.1021/ja00130a017; SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096; Seburg R. A., 1995, ANGEW CHEM, V107, P2198, DOI DOI 10.1002/ANGE.19951071826; SMITH D, 1992, CHEM REV, V92, P1580; STANTON JF, 1995, CHEM PHYS LETT, V237, P20, DOI 10.1016/0009-2614(95)00270-E; STANTON JF, 1992, INT J QUANTUM CHEM, P879; WATTS JD, 1992, CHEM PHYS LETT, V200, P1, DOI 10.1016/0009-2614(92)87036-O; WINNEWISSER G, 1987, TOP CURR CHEM, P121	32	153	153	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 29	1996	274	5292					1508	1511		10.1126/science.274.5292.1508	http://dx.doi.org/10.1126/science.274.5292.1508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929407				2022-12-28	WOS:A1996VV77500042
J	Moran, JV; Holmes, SE; Naas, TP; DeBerardinis, RJ; Boeke, JD; Kazazian, HH				Moran, JV; Holmes, SE; Naas, TP; DeBerardinis, RJ; Boeke, JD; Kazazian, HH			High frequency retrotransposition in cultured mammalian cells	CELL			English	Article							HUMAN TRANSPOSABLE ELEMENT; PRIMED REVERSE TRANSCRIPTION; RNA-POLYMERASE-III; OPEN-READING-FRAME; LINE-I ELEMENT; L1 ELEMENT; INDICATOR GENE; TARGET DNA; SACCHAROMYCES-CEREVISIAE; INSERTIONAL MUTAGENESIS	We previously isolated two human L1 elements (L1.2 and LRE2) as the progenitors of disease-producing insertions. Here, we show these elements can actively retrotranspose in cultured mammalian cells. When stably expressed from an episome in HeLa cells, both elements retrotransposed into a Variety of chromosomal locations at a high frequency. The retrotransposed products resembled endogenous L1 insertions, since they were variably 5' truncated, ended in poly(A) tracts, and were flanked by target-site duplications or short deletions. Point mutations in conserved domains of the L1.2-encoded proteins reduced retrotransposition by 100- to 1000-fold. Remarkably, L1.2 also retrotransposed in a mouse cell line, suggesting a potential role for L1-based vectors in random insertional mutagenesis.	UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; JOHNS HOPKINS UNIV, DEPT MOL BIOL & GENET, SCH MED, BALTIMORE, MD 21205 USA	University of Pennsylvania; Johns Hopkins University			Naas, Thierry/O-3999-2018	Naas, Thierry/0000-0001-9937-9572				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARKHIPOVA IR, 1995, NUCLEIC ACIDS RES, V23, P4480, DOI 10.1093/nar/23.21.4480; BELFORT M, 1993, SCIENCE, V262, P1009, DOI 10.1126/science.7694364; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; Boeke JD, 1991, CURR OPIN CELL BIOL, V3, P502, DOI 10.1016/0955-0674(91)90079-E; BUREAU TE, 1994, CELL, V77, P479, DOI 10.1016/0092-8674(94)90210-0; BURKE WD, 1987, MOL CELL BIOL, V7, P2221, DOI 10.1128/MCB.7.6.2221; BURTON FH, 1986, J MOL BIOL, V187, P291, DOI 10.1016/0022-2836(86)90235-4; CONWAY L, 1985, P NATL ACAD SCI USA, V82, P3949, DOI 10.1073/pnas.82.12.3949; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; CURCIO MJ, 1991, P NATL ACAD SCI USA, V88, P936, DOI 10.1073/pnas.88.3.936; DEMERS GW, 1986, MOL BIOL EVOL, V3, P179; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FANNING T, 1987, NUCLEIC ACIDS RES, V15, P2251, DOI 10.1093/nar/15.5.2251; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FREEMAN JD, 1994, BIOTECHNIQUES, V17, P47; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HEIDMANN T, 1988, P NATL ACAD SCI USA, V85, P2219, DOI 10.1073/pnas.85.7.2219; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; HOLMES SE, 1992, J BIOL CHEM, V267, P19765; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; HOLMES SE, 1994, THESIS J HOPKINS U B; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; JENSEN S, 1994, BIOCHEM BIOPH RES CO, V202, P111, DOI 10.1006/bbrc.1994.1900; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUROSE K, 1995, NUCLEIC ACIDS RES, V23, P3704, DOI 10.1093/nar/23.18.3704; LEIBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990, DOI 10.1073/pnas.87.18.6990; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MIKI Y, 1992, CANCER RES, V52, P643; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SINGER MF, 1993, GENE, V135, P183, DOI 10.1016/0378-1119(93)90064-A; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; Takahara T, 1996, HUM MOL GENET, V5, P989, DOI 10.1093/hmg/5.7.989; TANAKA I, 1995, FEBS LETT, V376, P146, DOI 10.1016/0014-5793(95)01262-2; TCHENIO T, 1993, EMBO J, V12, P1487, DOI 10.1002/j.1460-2075.1993.tb05792.x; USDIN K, 1989, J BIOL CHEM, V264, P15681; WOODSAMUELS P, 1989, GENOMICS, V4, P290, DOI 10.1016/0888-7543(89)90332-7; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6; [No title captured]	62	757	775	1	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					917	927		10.1016/S0092-8674(00)81998-4	http://dx.doi.org/10.1016/S0092-8674(00)81998-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945518	hybrid			2022-12-28	WOS:A1996VV77400017
J	Oshima, M; Dinchuk, JE; Kargman, SL; Oshima, H; Hancock, B; Kwong, E; Trzaskos, JM; Evans, JF; Taketo, MM				Oshima, M; Dinchuk, JE; Kargman, SL; Oshima, H; Hancock, B; Kwong, E; Trzaskos, JM; Evans, JF; Taketo, MM			Suppression of intestinal polyposis in Apc(Delta 716) knockout mice by inhibition of cyclooxygenase 2 (COX-2)	CELL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; PROSTAGLANDIN-G/H SYNTHASE; HUMAN COLON-CANCER; EPITHELIAL-CELLS; MAJOR MODIFIER; APC GENE; ASPIRIN; EXPRESSION; NEOPLASIA	Two cyclooxygenase isozymes catalyze conversion of arachidonic acid to prostaglandin H-2: constitutive COX-1 and inducible COX-2. To assess the role of COX-2 in colorectal tumorigenisis, we determined the effects of COX-2 gene (Ptgs2) knockouts and a novel COX-2 inhibitor on Apc(Delta 716) knockout mice, a model of human familial adenomatous polyposis. A Ptgs2 null mutation reduced the number and size of the intestinal polyps dramatically. Furthermore, treating Apc(Delta 716) mice with a novel COX-2 inhibitor reduced the polyp number more significantly than with sulindac, which inhibits both isoenzymes. These results provide direct genetic evidence that COX-2 plays a key role in tumorigenesis and indicate that COX-2-selective inhibitors can be a novel class of therapeutic agents for colorectal polyposis and cancer.	BANYU TSUKUBA RES INST MERCK, TSUKUBA, IBARAKI 30033, JAPAN; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; MERCK FROSST CTR THERAPEUT RES, POINTE CLAIRE, PQ H9R 4P8, CANADA; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT BIOMED GENET, BUNKYO KU, TOKYO 113, JAPAN	Merck & Company; DuPont; Merck & Company; University of Tokyo			Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Oshima, Hiroko/0000-0001-6855-4008; Hancock, Bruno/0000-0003-4387-2389				Boolbol SK, 1996, CANCER RES, V56, P2556; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HORII A, 1992, CANCER RES, V52, P3231; KARGMAN S, 1996, IN PRESS BIOCH PHARM; KARGMAN SL, 1995, CANCER RES, V55, P2556; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEE SH, 1992, J BIOL CHEM, V267, P25934; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARNETT LJ, 1992, CANCER RES, V52, P5575; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OSHIMA M, 1995, CARCINOGENESIS, V16, P2605, DOI 10.1093/carcin/16.11.2605; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Oshima M, 1996, MOL CARCINOGEN, V15, P11, DOI 10.1002/(SICI)1098-2744(199601)15:1<11::AID-MC3>3.0.CO;2-V; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAO CV, 1995, CANCER RES, V55, P1464; REDDY BS, 1993, CARCINOGENESIS, V14, P1493, DOI 10.1093/carcin/14.8.1493; RIGAS B, 1993, J LAB CLIN MED, V122, P518; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WILLIAMS CW, 1996, GASTROENTEROLOGY, V110, P1134; XIE WL, 1992, DRUG DEVELOP RES, V25, P249, DOI 10.1002/ddr.430250402	39	2138	2243	0	84	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					803	809		10.1016/S0092-8674(00)81988-1	http://dx.doi.org/10.1016/S0092-8674(00)81988-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945508	Bronze			2022-12-28	WOS:A1996VV77400007
J	Hennekens, CH; Albert, CM; Godfried, SL; Gaziano, JM; Buring, JE				Hennekens, CH; Albert, CM; Godfried, SL; Gaziano, JM; Buring, JE			Adjunctive drug therapy of acute myocardial infarction evidence from clinical trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR DYSFUNCTION; PROPHYLACTIC LIDOCAINE; MAGNESIUM-SULFATE; RANDOMIZED TRIALS; HEART-DISEASE; DOUBLE-BLIND; FOLLOW-UP; MORTALITY; PREVENTION; FIBRILLATION		BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02215 USA; MASSACHUSETTS GEN HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02114 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, DEPT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard Medical School	Hennekens, CH (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02215 USA.							ADAMS JH, 1979, THROMB HAEMOSTASIS, V42, P603; American Heart Association, 1992, HEART STROK FACTS; [Anonymous], 1986, LANCET, V2, P57; ANTMAN EM, 1995, CIRCULATION, V92, P2367, DOI 10.1161/01.CIR.92.9.2367; AVEZUM A, 1994, CARDIOLOGY, V84, P391; BALL SG, 1993, LANCET, V342, P821; BEHAR S, 1988, EUR HEART J, V9, P354; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1993, AM J CARDIOL, V72, pF87, DOI 10.1016/0002-9149(93)90969-J; CAMM AJ, 1993, AM J CARDIOL, V72, pF95, DOI 10.1016/0002-9149(93)90970-N; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHRISTENSEN CW, 1995, CIRCULATION, V92, P2617, DOI 10.1161/01.CIR.92.9.2617; COLLINS R, 1995, LANCET, V345, P669; CONTI CR, 1985, EUR HEART J, V6, P3, DOI 10.1093/eurheartj/6.suppl_A.3; DALY LE, 1987, BRIT HEART J, V58, P567; DESILVA RA, 1981, LANCET, V2, P855; DEVITA C, 1994, LANCET, V343, P1115; DUNN HM, 1985, AM HEART J, V110, P353, DOI 10.1016/0002-8703(85)90156-5; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GOLDBOURT U, 1993, ARCH INTERN MED, V153, P345, DOI 10.1001/archinte.153.3.345; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HANSEN JF, 1984, EUR HEART J, V5, P516; HENNEKENS CH, 1987, STAT MED, V6, P397, DOI 10.1002/sim.4780060337; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P243; HERZOG WR, 1995, CIRCULATION, V92, P2622, DOI 10.1161/01.CIR.92.9.2622; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HJALMARSON A, 1985, EUR HEART J, V6, P199; HJALMARSON A, 1984, AM J CARDIOL, V54, pE11, DOI 10.1016/S0002-9149(84)80305-7; JUGDUTT, 1989, CIRCULATION, V79, P1151; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; JUGDUTT BI, 1993, CAN J CARDIOL, V9, P103; JULIAN DG, 1982, LANCET, V1, P1142; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOSTER RW, 1985, NEW ENGL J MED, V313, P1105, DOI 10.1056/NEJM198510313131801; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEOR J, 1995, AM J CARDIOL, V75, P1292, DOI 10.1016/S0002-9149(99)80787-5; LIBERTHSON RR, 1974, CIRCULATION, V49, P790, DOI 10.1161/01.CIR.49.5.790; LIE KI, 1974, NEW ENGL J MED, V291, P1324, DOI 10.1056/NEJM197412192912504; LIE KI, 1975, CIRCULATION, V52, P755, DOI 10.1161/01.CIR.52.5.755; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MOSS AJ, 1990, NEW ENGL J MED, V322, P743, DOI 10.1056/NEJM199003153221107; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; *NAT HEART LUNG BL, 1982, NIH PUBL, P114; PEDERSEN TR, 1985, NEW ENGL J MED, V313, P1055; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PODRID PJ, 1995, ANN INTERN MED, V122, P689, DOI 10.7326/0003-4819-122-9-199505010-00008; Rengo F, 1996, AM J CARDIOL, V77, P365, DOI 10.1016/S0002-9149(97)89365-4; RIDKER PM, 1992, HEART DIS UPDATE, pA54; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; SCHAFFER WA, 1975, NEW ENGL J MED, V293, P259, DOI 10.1056/NEJM197508072930601; SEDERHOLM M, 1984, AM J CARDIOL, V54, pE14; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; TEO KK, 1993, DRUGS, V46, P347, DOI 10.2165/00003495-199346030-00002; TURLAPATY PDMV, 1980, SCIENCE, V208, P198, DOI 10.1126/science.7361117; VORMANN J, 1983, ARZNEIMITTEL-FORSCH, V33-1, P205; WALDO AL, 1995, AM J CARDIOL, V75, P1023, DOI 10.1016/S0002-9149(99)80717-6; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WATANABE Y, 1972, CARDIOVASC RES, V6, P67, DOI 10.1093/cvr/6.1.79; WEINBERG B, 1989, CLIN CARDIOL, V12, P86; WILCOX RG, 1986, BRIT MED J, V293, P1204, DOI 10.1136/bmj.293.6556.1204; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; Yusuf S, 1996, AM J CARDIOL, V77, P421, DOI 10.1016/S0002-9149(97)89376-9	72	197	201	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1660	1667		10.1056/NEJM199611283352207	http://dx.doi.org/10.1056/NEJM199611283352207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929364				2022-12-28	WOS:A1996VV93600007
J	Parada, CA; Roeder, RG				Parada, CA; Roeder, RG			Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain	NATURE			English	Article							TRANSCRIPTION FACTOR TFIIH; BASAL TRANSCRIPTION; ELONGATION; KINASE; INITIATION; BINDING; COMPLEX; VP16	THE protein Tat is encoded by the HIV-1 genome and is essential for viral replication because of its activation of viral transcription. Tat enhances the ability of RNA polymerase II (Pol II) to move long distances down the DNA through a poorly understood mechanism that involves its binding the to the 5' end of the nascent HIV-1 transcript(1-5), It has been suggested(6-10) that the stimulation of transcript elongation by conventional DNA-binding activators may involve phosphorylation of the carboxy-terminal domain (CTD) of Pol II by the transcription factor TFIIH11-13 through the associated CAK kinase(14-16). Here we show that Tat-enhanced HIV-1 transcription in vitro requires both TFIIH and the CTD of Pol II, In addition, Tat, through its activation domain, both interacts with a functional TFIIH-containing complex and stimulates phosphorylation of a CTD-containing substrate by the TFIIH kinase. Under conditions that jointly restrict transcriptional elongation(5,17) and TFIIH-mediated CTD phosphorylation, Tat stimulates both these activities. Furthermore, RNA synthesis is required for Tat to stimulate phosphorylation of the CTD when it is part of an initiation complex, as expected from Tat's interaction with viral transcripts(1). Thus, stimulation of Pol II elongation by Tat may involve direct effects on TFIIH-mediated CTD phosphorylation.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Blair WS, 1996, EMBO J, V15, P1658, DOI 10.1002/j.1460-2075.1996.tb00511.x; Blau J, 1996, MOL CELL BIOL, V16, P2044; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Herrmann CH, 1996, NUCLEIC ACIDS RES, V24, P501, DOI 10.1093/nar/24.3.501; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Wu-Baer Foon, 1996, Journal of Biological Chemistry, V271, P4201, DOI 10.1074/jbc.271.8.4201; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	30	237	240	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					375	378		10.1038/384375a0	http://dx.doi.org/10.1038/384375a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934526				2022-12-28	WOS:A1996VV27100054
J	van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL				van der Maas, PJ; vanderWal, G; Haverkate, I; deGraaff, CLM; Kester, JGC; OnwuteakaPhilipsen, BD; vanderHeide, A; Bosma, JM; Willems, DL			Euthanasia, physician-assisted suicide, and other medical practices involving the end of life in the Netherlands, 1990-1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATTITUDES	Background In 1991 a new procedure for reporting physician-assisted deaths was introduced in the Netherlands that led to a tripling in the number of reported cases. In 1995, as part of an evaluation of this procedure, a nationwide study of euthanasia and other medical practices concerning the end of life was begun that was identical to a study conducted in 1990. Methods We conducted two studies, the first involving interviews with 405 physicians (general practitioners, nursing home physicians, and clinical specialists) and the second involving questionnaires mailed to the physicians attending 6060 deaths that were identified from death certificates. The response rates were 89 percent and 77 percent, respectively. Results Among the deaths studied, 2.3 percent of those in the interview study and 2.4 percent of those in the death-certificate study were estimated to have resulted from euthanasia, and 0.4 percent and 0.2 percent, respectively, resulted from physician-assisted suicide. In 0.7 percent of cases, life was ended without the explicit, concurrent request of the patient. Pain and symptoms were alleviated with doses of opioids that may have shortened life in 14.7 to 19.1 percent of cases, and decisions to withhold or withdraw life-prolonging treatment were made in 20.2 percent. Euthanasia seems to have increased in incidence since 1990, and the ending of life without the patient's explicit request seems to have decreased slightly. For each type of medical decision except those in which life-prolonging treatment was withheld or withdrawn, cancer was the most frequently reported diagnosis. Conclusions Since the notification procedure was introduced, end-of-life decision making in the Netherlands has changed only slightly, in an anticipated direction. Close monitoring of such decisions is possible, and we found no signs of an unacceptable increase in the number of decisions or of less careful decision making. (C)1996, Massachusetts Medical Society.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BLACK AL, 1996, JAMA-J AM MED ASSOC, V275, P919; Bokhove J., 1996, BALANS REKENONDERWIJ; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Folker AP, 1996, BIOETHICS, V10, P233, DOI 10.1111/j.1467-8519.1996.tb00122.x; Heinisch O., 1963, PREIS S BIOM J, V1965, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; *ROYAL DUTCH MED A, 1995, POS PAP EUTH; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERMAAS PJ, 1992, HLTH POLICY, V22; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332	14	386	386	2	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1699	1705		10.1056/NEJM199611283352227	http://dx.doi.org/10.1056/NEJM199611283352227			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV936	8929370	Green Published, Bronze			2022-12-28	WOS:A1996VV93600034
J	Barondess, JA				Barondess, JA			Medicine against society - Lessons from the Third Reich	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	The engagement of German biomedicine in the design and execution of Nazi programs of ''racial cleansing'' was extensive and was organized by physicians and other professional leaders. In its active involvement and acquiescence, the German medical profession, one of the most sophisticated and respected medical enterprises in the world, dishonored itself and raised profound and persisting questions about the nature, strength, and relevance of the medical ethos and the relationship between medicine and the policies and programs of the state. Efforts to examine the history of German medicine under National Socialism are increasing in scale and number and involve German scholars to an important and expanding extent. Today, many bioethical issues, based on an increasingly sophisticated science and technology, confront medicine. A major lesson from the Nazi era is the fundamental ethical basis of medicine and the importance of an informed, concerned, and engaged profession.	US HOLOCAUST MEM MUSEUM, MED ADVISORY COMM, RES INST, WASHINGTON, DC USA; NEW YORK ACAD MED, NEW YORK, NY 10029 USA	New York Academy of Medicine								ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; Aly Glitz, 1994, CLEANSING FATHERLAND, P22; *AM MED ASS, 1939, P HOUS DEL AM MED AS; ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P15; BARONDESS JA, 1988, J AM GERIATR SOC, V36, P919, DOI 10.1111/j.1532-5415.1988.tb05786.x; Caplan A., 1992, WHEN MED WENT MAD BI; CRAWSHAW R, 1995, JAMA-J AM MED ASSOC, V273, P1553, DOI 10.1001/jama.273.19.1553; CYNKAR RJ, 1981, COLUMBIA LAW REV, V81, P1418, DOI 10.2307/1122204; GARVER KL, 1994, AM J HUM GENET, V54, P148; HANAUSKEABEL HM, 1986, LANCET, V2, P271; KUHL S, 1994, NAZI CONNECTION EUGE, P20; LEVINSKY NG, 1990, NEW ENGL J MED, V322, P1813, DOI 10.1056/NEJM199006213222512; LIFTON RJ, 1986, NAZI DOCTORS, V148, P163; MACKLIN R, 1992, WHEN MED WENT MAD BI, P173; MEHLER B, 1988, THESIS U MICHIGAN AN; Mitscherlich Alexander, 1947, DIKTAT MENSCHENVERAC; Muller-Hill B., 1988, MURDEROUS SCI; NETANYAHU B, 1995, ORIGINS INQUISITION; Proctor R., 1988, RACIAL HYGIENE MED; PROCTOR RN, 1992, WHEN MED WENT MAD BI, P27; Proctor Robert, 1992, NAZI DOCTORS NUREMBE, P17; Pross Christian, 1992, NAZI DOCTORS NUREMBE, P32; PRSS C, 1994, CLEANSING FATHERLAND; REILLY PR, 1987, Q REV BIOL, V62, P153, DOI 10.1086/415404; Rushton AR., 1994, GENETICS MED US 1800; SAUER PJJ, 1992, PEDIATRICS, V90, P729; SEIDELMAN WE, 1988, MILBANK Q, V66, P221, DOI 10.2307/3350031; Taylor T., 1992, NAZI DOCTORS NUREMBE, P67; TOELLNER R, 1996, HIPPOCRATES BETRAYED; Wikler Daniel, 1993, Kennedy Institute of Ethics Journal, V3, P39; Yellin P B, 1995, J Perinatol, V15, P232	31	47	49	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1657	1661		10.1001/jama.276.20.1657	http://dx.doi.org/10.1001/jama.276.20.1657			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922452				2022-12-28	WOS:A1996VU20900033
J	Sonis, J; Gorenflo, DW; Jha, P; Williams, C				Sonis, J; Gorenflo, DW; Jha, P; Williams, C			Teaching of human rights in US medical schools	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION	Objective.-To determine the extent to which human rights issues are included in required bioethics curricula in US medical schools and to identify medical school characteristics associated with the extent of human rights issues covered. Design.-Cross-sectional survey. Participants.-Bioethics course directors and bioethics section directors of 125 US medical schools. Main Outcome Measure.-The extent of human rights teaching at each school was measured as the percentage of 16 human rights issues. Results.-Course directors at 113 (90%) of the 125 US medical schools responded to the survey. Medical schools included about half (45%; 95% confidence interval, 41%-49%) of 16 human rights issues in their required bioethics curricula. Domestic human rights issues, such as discrimination in the provision of health care to minorities (82% of medical schools), were covered much more frequently than international human rights issues, such as physician participation in torture (17% of schools). Public medical schools included substantially fewer human rights issues than private medical schools (F-[1,F-112]=7.7; P<.01). Conclusions.-Required courses in medical education do not adequately address the medical aspects of human rights issues, especially international issues.	UNIV MICHIGAN, SCH MED, ANN ARBOR, MI USA	University of Michigan System; University of Michigan	Sonis, J (corresponding author), UNIV MICHIGAN, SCH MED, DEPT FAMILY PRACTICE, 1018 FULLER ST, ANN ARBOR, MI 48109 USA.				BHP HRSA HHS [1 D15 PE80035 03] Funding Source: Medline	BHP HRSA HHS		ADAY L, 1989, DESIGNING CONDUCTING; AUDET AM, 1995, ANN INTERN MED, V122, P607, DOI 10.7326/0003-4819-122-8-199504150-00009; BOYD KM, 1994, MED EDUC, V28, P488, DOI 10.1111/j.1365-2923.1994.tb02724.x; De Vellis R. F, 1991, SCALE DEV, V26; GANEM JL, 1995, JAMA-J AM MED ASSOC, V274, P723; GECK JE, 1995, FAM MED, V27, P636; Geiger H. Jack, 1993, JAMA (Journal of the American Medical Association), V270, P616, DOI 10.1001/jama.270.5.616; Glantz SA., 1987, PRIMER BIOSTATISTICS; GRABER DR, 1995, J OCCUP ENVIRON MED, V37, P807, DOI 10.1097/00043764-199507000-00009; JOLLY P, 1993, ACAD MED, V68, P92, DOI 10.1097/00001888-199301000-00018; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LUM CK, 1994, ACAD MED, V69, P239, DOI 10.1097/00001888-199403000-00021; ROSEN RC, 1993, SLEEP, V16, P249, DOI 10.1093/sleep/16.3.249; *SAS I, 1990, SAS 6 04 MS DOS VERS; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; VINCENT A, 1994, LANCET, V343, P1435, DOI 10.1016/S0140-6736(94)92561-5; ZIMMERMANN M, 1993, AM J CLIN NUTR, V58, P828, DOI 10.1093/ajcn/58.6.828; ZIV T, 1995, NEW ENGL J MED, V332, P1005	18	25	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1676	1678		10.1001/jama.276.20.1676	http://dx.doi.org/10.1001/jama.276.20.1676			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922456				2022-12-28	WOS:A1996VU20900037
J	Tyson, JE; Younes, N; Verter, J; Wright, LL				Tyson, JE; Younes, N; Verter, J; Wright, LL			Viability, morbidity, and resource use among newborns of 501- to 800-g birth weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSIS-RELATED GROUPS; NEONATAL INTENSIVE-CARE; EXTREMELY PREMATURE; GESTATIONAL-AGE; INFANTS BORN; MORTALITY; OUTCOMES; SEVERITY; CHILDREN; NETWORK	Objectives.-To assess risk factors affecting viability and analyze the effects of mechanical ventilation (MV) on neonatal outcome and resource use among extremely premature infants. Design.-Inception cohort study. Setting.-Neonatal intensive care units of the 12-center National Institute of Child Health and Human Development Neonatal Research Network. Participants.-A total of 1126 infants with a birth weight of 501 to 800 g born in network centers between January 1, 1994, and December 31, 1995. Main Outcome Measures.-Observed survival; maximum estimated survival (assuming the same survival among infants who died without MV as among infants in the same risk category who received MV); observed and maximum estimated survival without severe brain injury (either interventricular echodensity with ventricular dilation or parenchymal echodensity); hospital stay; resource investment. Results.-Overall mortality was 43%; mortality in infants without MV was 93%, A total of 15% of ail the infants died without MV. Females, small-for-gestational-age infants, and infants whose mothers received antenatal steroids had an advantage in survival with MV equivalent to an increase in birth weight of 90 g, 57 g, and 67 g, respectively, The corresponding advantage of these infants in survival without severe brain injury was 107 g, 97 g, and 64 g, respectively, Females in the lowest birth-weight group were more likely to die without MV than were larger males with a similar estimated likelihood of survival with MV. Mean hospital stay was 115 days for the survivors, values much greater than the 17.9-day standard for 501- to 800-g survivors under the diagnosis related group system. Resource investment was considerable (127 hospital days per survivor and 148 days per survivor without severe brain injury), but, like outcome, varied markedly between risk categories. Had MV been used for all infants who died, we estimate a substantial increase in resource use and a maximum of 8 additional survivors (no more than 6 without severe brain injury per 100 infants with a birth weight of 501 to 800 g. Conclusions.-Although recommendations to initiate or forgo MV for extremely premature infants have often focused on 1 factor(birth weight or gestational age), multiple factors should be considered. Other factors being equal, our analyses support use of MV for females at a minimum birth weight approximately 100 g lower than that for males. The current diagnosis related group reimbursement system can be expected to compromise resources for 501- to 800-g infants who would benefit from MV. Such care entails considerable resource use, although the cost per life-year gained is likely to be considerably less than that for many adults given intensive care. Our findings can be used to facilitate more appropriate treatment decisions, determine adequate resources, and better inform the debate about the benefits and burdens of intensive care for extremely premature newborns.	GEORGE WASHINGTON UNIV, CTR BIOSTAT, WASHINGTON, DC USA; NICHHD, BETHESDA, MD 20892 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV CINCINNATI, CINCINNATI, OH USA; EMORY UNIV, ATLANTA, GA 30322 USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA; UNIV NEW MEXICO, ALBUQUERQUE, NM 87131 USA; STANFORD UNIV, STANFORD, CA 94305 USA; WAYNE STATE UNIV, DETROIT, MI USA; BROWN UNIV, WOMEN & INFANTS HOSP, PROVIDENCE, RI USA; YALE UNIV, NEW HAVEN, CT USA	George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University; University System of Ohio; University of Cincinnati; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; University of New Mexico; Stanford University; Wayne State University; Brown University; Women & Infants Hospital Rhode Island; Yale University	Tyson, JE (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PEDIAT, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NICHD NIH HHS [2U01 HD 19897, 1U10 HD 21373] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021373] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD019897] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN AC, 1994, CAN MED ASSOC J, V151, P547; ALLEN MC, 1993, NEW ENGL J MED, V329, P1597, DOI 10.1056/NEJM199311253292201; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ARBUCKLE TE, 1989, CAN MED ASSOC J, V140, P157; ARRAS JD, 1987, CONT ISSUES FETAL NE, V3, P151; AVERY GB, 1987, CLIN PERINATOL, V14, P361, DOI 10.1016/S0095-5108(18)30770-X; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6; BAQUET D, 1995, NY TIMES        0305, P1; BERKI SE, 1987, PEDIATRICS, V79, P874; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BREGMAN J, 1992, CLIN PERINATOL, V19, P673, DOI 10.1016/S0095-5108(18)30451-2; BUCHANAN N, 1987, MED J AUSTRALIA, V147, P184, DOI 10.5694/j.1326-5377.1987.tb133354.x; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; *COMM FET NEWB AM, 1995, PEDIATRICS, V5, P974; *COMM FET NEWB AM, 1971, STAND REC HOSP CAR N; CONSTANTINE NA, 1987, J PEDIATR-US, V110, P921, DOI 10.1016/S0022-3476(87)80416-X; Donovan EF, 1996, PEDIATR RES, V39, P1220; DOYLE LW, 1989, AM J DIS CHILD, V143, P223, DOI 10.1001/archpedi.1989.02150140117032; FANAROFF AA, 1995, AM J OBSTET GYNECOL, V173, P1423, DOI 10.1016/0002-9378(95)90628-2; Frader JE, 1996, PEDIATRICS, V98, P149; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HACK M, 1993, NEW ENGL J MED, V329, P1649, DOI 10.1056/NEJM199311253292210; HANLEY JA, 1982, DIAGN RADIOL, V149, P29; HARRISON H, 1993, PEDIATRICS, V92, P643; HORBAR JD, 1995, FUTURE CHILD, V5, P139, DOI 10.2307/1602512; HORBAR JD, 1993, CRIT CARE MED, V21, P12, DOI 10.1097/00003246-199301000-00008; IMERSHEIN AW, 1992, PEDIATRICS, V89, P56; JONES R, 1995, PEDIATRICS, V96, P897; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KRAYBILL EN, 1988, J PEDIATR-US, V113, P327, DOI 10.1016/S0022-3476(88)80273-7; LICHTIG LK, 1989, PEDIATRICS, V84, P49; MILNER RDG, 1974, J OBSTET GYN BR COMM, V81, P956; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PHIBBS CS, 1986, PEDIATRICS, V78, P829; POLAND RL, 1985, PEDIATRICS, V76, P104; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P117; SAIGAL S, 1994, J PEDIATR-US, V125, P418, DOI 10.1016/S0022-3476(05)83289-5; Saigal S, 1996, JAMA-J AM MED ASSOC, V276, P453, DOI 10.1001/jama.276.6.453; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHWARTZ LS, 1991, GEN HOSP PSYCHIAT, V13, P19, DOI 10.1016/0163-8343(91)90005-H; SIMON NP, 1994, CLIN PERINATOL, V21, P411, DOI 10.1016/S0095-5108(18)30353-1; SINCLAIR JC, 1995, PAEDIATR PERINAT EP, V9, P373, DOI 10.1111/j.1365-3016.1995.tb00157.x; STRONG C, 1987, CONT ISSUES FETAL NE, V3, P187; TARNOWMORDI W, 1990, BRIT MED J, V300, P1611, DOI 10.1136/bmj.300.6740.1611; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; TYSON J, 1995, FUTURE CHILD, V5, P197, DOI 10.2307/1602515; TYSON J, 1992, Pediatric Research, V31, p26A; VOLPE J, 1995, NEUROLOGY NEWBORN, P427; WATTS JK, 1995, PAEDIATR PERINAT EP, V9, P375; YOUNG EWD, 1990, AM J DIS CHILD, V144, P549, DOI 10.1001/archpedi.1990.02150290043023; 1991, FED REG         0830, V56, P43292; [No title captured]; 1995, PAEDIATR PERINAT EP, V9, P370	58	116	117	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1645	1651		10.1001/jama.276.20.1645	http://dx.doi.org/10.1001/jama.276.20.1645			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922450				2022-12-28	WOS:A1996VU20900031
J	AckermannLiebrich, U; Voegeli, T; GunterWitt, K; Kunz, I; Zullig, M; Schindler, C; Maurer, M; Ashkenazi, E; Ashkenazi, J; Bachmann, U; Baumann, D; Egli, N; Frey, P; Gehrig, U; Glenck, U; Hofmann, P; Huber, M; Jordi, C; Landerer, C; Lattmann, P; Maggi, B; Niehus, R; Oertli, B; Rahle, D; Reichel, J; Walser, T; Winizki, D; America, C; Barlocher, I; Burki, H; Daemen, L; Geier, E; Gloor, S; Hagler, O; Herzog, R; Landheer, B; Meister, MJ; Schibli, E; Zingg, E				AckermannLiebrich, U; Voegeli, T; GunterWitt, K; Kunz, I; Zullig, M; Schindler, C; Maurer, M; Ashkenazi, E; Ashkenazi, J; Bachmann, U; Baumann, D; Egli, N; Frey, P; Gehrig, U; Glenck, U; Hofmann, P; Huber, M; Jordi, C; Landerer, C; Lattmann, P; Maggi, B; Niehus, R; Oertli, B; Rahle, D; Reichel, J; Walser, T; Winizki, D; America, C; Barlocher, I; Burki, H; Daemen, L; Geier, E; Gloor, S; Hagler, O; Herzog, R; Landheer, B; Meister, MJ; Schibli, E; Zingg, E			Home versus hospital deliveries: Follow up study of matched pairs for procedures and outcome	BRITISH MEDICAL JOURNAL			English	Article							UMBILICAL-CORD BLOOD; PERINATAL-MORTALITY; BIRTHS	Objective-To assess procedures and outcomes in deliveries planned at home versus those planned in hospital among women choosing the place of delivery. Design-Follow up study of matched pairs. Setting-Antenatal clinics and reference hospitals in Zurich between 1989 and 1992. Subjects-489 women opting for home delivery and 385 opting for hospital delivery; the women comprised all those attending members of the study team for antenatal care and those attending the reference hospital for antenatal care who could be matched with the women planning home confinement. Main outcome measures-Need for medication and incidence of interventions during delivery (caesarean section, forceps, vacuum extraction, episiotomy), duration of labour, occurrence of severe perineal lesions, maternal blood loss, and perinatal morbidity and death. Results-All women were followed up ti bm their first antenatal visit till three months after delivery. Referrals during pregnancy (n = 37) and labour (70), changes of mind (15 home to hospital, eight hospital to home), and 17 miscarriages resulted in 369 births occurring at home and 486 in hospital. During delivery the home birth group needed significantly less medication and fewer interventions whereas no differences were found in durations of labour, occurrence of severe perineal lesions, and maternal blood loss. Perinatal death was recorded in one planned hospital delivery and one planned home delivery (overall perinatal mortality 2.3/1000). There was no difference between home and hospital delivered babies in birth weight, gestational age, or clinical condition. Apgar scores were slightly higher and umbilical cord pH lower in home births, but these differences may have been due to differences in clamping and the time of transportation. Conclusion-Healthy low risk women who wish to deliver at home have no increased risk either to themselves or to their babies.	ZURICH CANTON,ZURICH,SWITZERLAND; ZURICH STUDY TEAM,ZURICH,SWITZERLAND		AckermannLiebrich, U (corresponding author), UNIV BASEL,INST SOCIAL & PREVENT MED,CH-4051 BASEL,SWITZERLAND.		Schindler, Christian/D-3472-2015					BEER V, 1986, SOZ PRAVENTIV MED, V31, P274, DOI 10.1007/BF02077499; Breslow N, 1980, STATISTICAL METHODS, V32; *BUND STAT, 1994, STAT JB SCHW; *BUND STAT, 1991, STAT JB SCHW 1992; CAMPBELL R, 1984, BRIT MED J, V289, P721, DOI 10.1136/bmj.289.6447.721; CAMPBELL R, 1994, TO BE BORN DEBATE EV; EGLI M, 1992, SCHWEIZERISCHE ARBEI, V2, P19; GUNTERWITT K, 1994, THESIS U BASEL; KUNZ I, 1993, THESIS U BASEL; LIEVAART M, 1984, OBSTET GYNECOL, V63, P44; MEHL LE, 1977, J REPROD MED, V19, P281; PAERREGAARD A, 1987, J PERINAT MED, V15, P559; PEL M, 1983, J PERINAT MED, V11, P169, DOI 10.1515/jpme.1983.11.3.169; Sato I, 1975, J Perinat Med, V3, P211; SCHW NEON, 1987, SCHW ARZT, V68, P1346; SHEARER JML, 1985, BRIT MED J, V291, P1477; SYKES GS, 1984, BRIT J OBSTET GYNAEC, V91, P989, DOI 10.1111/j.1471-0528.1984.tb03676.x; TEW M, 1984, PREGNANCY CARE 1980S, P105; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; ZULLIG M, 1993, THESIS U BASEL	20	71	73	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1313	1318						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942694				2022-12-28	WOS:A1996VV15300028
J	Srinivasan, U; Leonard, N; Jones, E; Kasarda, DD; Weir, DG; OFarrelly, C; Feighery, C				Srinivasan, U; Leonard, N; Jones, E; Kasarda, DD; Weir, DG; OFarrelly, C; Feighery, C			Absence of oats toxicity in adult coeliac disease	BRITISH MEDICAL JOURNAL			English	Article							CELIAC-DISEASE		ST JAMES HOSP,DEPT IMMUNOL,DUBLIN 8,IRELAND; ST JAMES HOSP,DEPT HISTOPATHOL,DUBLIN 8,IRELAND; USDA,ALBANY,CA 94710; ST JAMES HOSP,DEPT GASTROENTEROL,DUBLIN 8,IRELAND; TRINITY COLL DUBLIN,DUBLIN,IRELAND; ST VINCENTS HOSP,EDUC & RES CTR,DUBLIN 4,IRELAND	Trinity College Dublin; Trinity College Dublin; United States Department of Agriculture (USDA); Trinity College Dublin; Trinity College Dublin; University College Dublin				O'Farrelly, Cliona/0000-0002-0616-2874				FEIGHERY C, 1991, EUR J GASTROEN HEPAT, V3, P119; JANATUINEN EK, 1995, NEW ENGL J MED, V333, P1033, DOI 10.1056/NEJM199510193331602; LEIGH RJ, 1985, SCAND J GASTROENTERO, V20, P715, DOI 10.3109/00365528509089201; LOCKHART HB, 1978, OATS CHEM TECHNOLOGY, P153; MEEUWISSE GW, 1970, ACTA PAEDIATR SCAND, V59, P461	5	109	111	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1300	1301						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942690	Green Published			2022-12-28	WOS:A1996VV15300024
J	Boering, KA; Wofsy, SC; Daube, BC; Schneider, HR; Loewenstein, M; Podolske, JR				Boering, KA; Wofsy, SC; Daube, BC; Schneider, HR; Loewenstein, M; Podolske, JR			Stratospheric mean ages and transport rates from observations of carbon dioxide and nitrous oxide	SCIENCE			English	Article							TROPOSPHERE; EXCHANGE; AIR; N2O; MIDLATITUDES; SPECTROMETER; CONSTITUENTS; SIMULATIONS; AEROSOL; CO2	Measurements of stratospheric carbon dioxide (CO2) and nitrous oxide (N2O) concentrations were analyzed to investigate stratospheric transport rates. Temporal variations in tropospheric CO2 were observed to propagate into the stratosphere, showing that tropospheric air enters the lower tropical stratosphere continuously, ascends, and is transported rapidly (in less than 1 month) to both hemispheres. The mean age A of stratospheric air determined from CO2 data is approximately 5 years in the mid-stratosphere. The mean age is mathematically equivalent to a conserved tracer analogous to exhaust from stratospheric aircraft. Comparison of values for A from models and observations indicates that current model simulations likely underestimate pollutant concentrations from proposed stratospheric aircraft by 25 to 100 percent.	HARVARD UNIV,DIV ENGN & APPL SCI,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT EARTH & PLANETARY SCI,CAMBRIDGE,MA 02138; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; NOAA,CLIMATE MONITORING & DIAGNOST LAB,BOULDER,CO 80303	Harvard University; Harvard University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Oceanic Atmospheric Admin (NOAA) - USA				Boering, Kristie/0000-0003-0920-0503				[Anonymous], COMMUNICATION; Avallone LM, 1996, J GEOPHYS RES-ATMOS, V101, P1457, DOI 10.1029/95JD03010; BISCHOF W, 1985, NATURE, V316, P708, DOI 10.1038/316708a0; BOERING KA, 1994, GEOPHYS RES LETT, V21, P2567, DOI 10.1029/94GL01985; BOERING KA, 1995, GEOPHYS RES LETT, V22, P2737, DOI 10.1029/95GL02337; BREWER AW, 1949, Q J ROY METEOR SOC, V75, P351, DOI 10.1002/qj.49707532603; BUI TN, COMMUNICATION; Carter A., 1989, GEOPHYS MONOGR SER, V55, P165, DOI DOI 10.1029/GM055P0165; CONWAY TJ, 1994, J GEOPHYS RES-ATMOS, V99, P22831, DOI 10.1029/94JD01951; DLUGOKENCKY EJ, 1994, J GEOPHYS RES-ATMOS, V99, P17021, DOI 10.1029/94JD01245; DOBSON GMB, 1956, PROC R SOC LON SER-A, V236, P187, DOI 10.1098/rspa.1956.0127; EHHALT DH, 1983, J ATMOS CHEM, V1, P27, DOI 10.1007/BF00113978; Elkins JW, 1996, GEOPHYS RES LETT, V23, P347, DOI 10.1029/96GL00244; Eluszkiewicz J, 1996, J ATMOS SCI, V53, P217, DOI 10.1175/1520-0469(1996)053<0217:RCITSA>2.0.CO;2; FOLLOWS MJ, 1992, J ATMOS SCI, V49, P879, DOI 10.1175/1520-0469(1992)049<0879:OTCTEO>2.0.CO;2; GARY BL, 1989, J GEOPHYS RES, V94, P223; GELLER LS, UNPUB; Grant WB, 1996, J GEOPHYS RES-ATMOS, V101, P3973, DOI 10.1029/95JD03164; HALL TA, UNPUB; HALL TM, 1993, J GEOPHYS RES-ATMOS, V98, P10573, DOI 10.1029/93JD00325; HALL TM, 1994, J GEOPHYS RES-ATMOS, V99, P1059, DOI 10.1029/93JD03192; Harnisch J, 1996, GEOPHYS RES LETT, V23, P1099, DOI 10.1029/96GL01198; HOLTON JR, 1986, J GEOPHYS RES-ATMOS, V91, P2681, DOI 10.1029/JD091iD02p02681; HOLTON JR, 1990, J ATMOS SCI, V47, P392, DOI 10.1175/1520-0469(1990)047<0392:OTGEOM>2.0.CO;2; HOLTON JR, 1995, REV GEOPHYS, V33, P403, DOI 10.1029/95RG02097; Ko Maw Ko, COMMUNICATION; MAHLMAN JD, 1986, J GEOPHYS RES-ATMOS, V91, P2687, DOI 10.1029/JD091iD02p02687; Matsueda H, 1996, ATMOS ENVIRON, V30, P1647, DOI 10.1016/1352-2310(95)00374-6; Minschwaner K, 1996, J GEOPHYS RES-ATMOS, V101, P9433, DOI 10.1029/96JD00335; Mote PW, 1996, J GEOPHYS RES-ATMOS, V101, P3989, DOI 10.1029/95JD03422; NAKAZAWA T, 1991, TELLUS B, V43, P106, DOI 10.1034/j.1600-0889.1991.t01-1-00005.x; Plumb RA, 1996, J GEOPHYS RES-ATMOS, V101, P3957, DOI 10.1029/95JD03002; PLUMB RA, 1992, J GEOPHYS RES-ATMOS, V97, P10145, DOI 10.1029/92JD00450; PODOLSKE J, 1993, APPL OPTICS, V32, P5324, DOI 10.1364/AO.32.005324; POLLOCK WH, 1992, J GEOPHYS RES-ATMOS, V97, P12993, DOI 10.1029/92JD01029; ROSENLOF KH, 1993, J GEOPHYS RES-ATMOS, V98, P10465, DOI 10.1029/93JD00392; ROSENLOF KH, 1995, J GEOPHYS RES-ATMOS, V100, P5173, DOI 10.1029/94JD03122; SCHMIDT U, 1991, GEOPHYS RES LETT, V18, P763, DOI 10.1029/91GL00022; STOLARSKI RS, 1995, NASA REF PUBL, V1381; STOLARSKI RS, 1993, NASA REF PUBL, V1313; TELEGADAS K, 1969, J GEOPHYS RES, V74, P1339, DOI 10.1029/JB074i006p01339; TELEGADAS K, 1971, 243 US AT EN COMM; TREPTE CR, 1993, J GEOPHYS RES-ATMOS, V98, P18563, DOI 10.1029/93JD01362; TREPTE CR, 1992, NATURE, V355, P626, DOI 10.1038/355626a0; Volk CM, 1996, SCIENCE, V272, P1763, DOI 10.1126/science.272.5269.1763; WEBSTER CR, 1994, APPL OPTICS, V33, P454, DOI 10.1364/AO.33.000454; WOFSY SC, UNPUB; *WORLD MET ORG, 1995, 37 WORLD MET ORG GLO	48	170	171	3	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1340	1343		10.1126/science.274.5291.1340	http://dx.doi.org/10.1126/science.274.5291.1340			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910266				2022-12-28	WOS:A1996VU95400042
J	Lieu, R; Mittaz, JPD; Bowyer, S; Breen, JO; Lockman, FJ; Murphy, EM; Hwang, CY				Lieu, R; Mittaz, JPD; Bowyer, S; Breen, JO; Lockman, FJ; Murphy, EM; Hwang, CY			Diffuse extreme-ultraviolet emission from the Coma cluster: Evidence for rapidly cooling gases at submegakelvin temperatures	SCIENCE			English	Article							ABSORPTION CROSS-SECTIONS; ROSAT	The central region of the Coma cluster of galaxies was observed in the energy band from 0.065 to 0.245 kiloelectron volts by the Deep Survey telescope aboard the Extreme Ultraviolet Explorer. A diffuse emission halo of angular diameter similar to 30 are minutes was detected. The extreme-ultraviolet (EUV) emission level exceeds that expected from the x-ray temperature gas in Coma. This halo suggests the presence of two more phases in the emitting gas, one at a temperature of similar to 2 x 10(6) kelvin and the other at similar to 8 x 10(5) kelvin. The latter phase cools rapidly and, in steady state, would have produced cold matter with a mass of similar to 10(14) solar masses within the EUV halo. Although a similar EUV enhancement was discovered in the Virgo cluster, this detection in Coma applies to a noncooling flow system.	UCL, MULLARD SPACE SCI LAB, DORKING RH5 6NT, SURREY, ENGLAND; UNIV CALIF BERKELEY, CTR EXTREME ULTRAVIOLET ASTROPHYS, BERKELEY, CA 94720 USA; UNIV VIRGINIA, DEPT ASTRON, CHARLOTTESVILLE, VA 22903 USA; NATL RADIO ASTRON OBSERV, GREEN BANK, WV 24944 USA	University of London; University College London; University of California System; University of California Berkeley; University of Virginia; National Radio Astronomy Observatory (NRAO)	Lieu, R (corresponding author), UNIV ALABAMA, DEPT PHYS, HUNTSVILLE, AL 35899 USA.		Murphy, Edward/AAB-7206-2022	Murphy, Edward/0000-0003-2925-738X				BALUCINSKACHURCH M, 1992, ASTROPHYS J, V400, P699, DOI 10.1086/172032; Bauer F, 1996, ASTROPHYS J, V457, P382, DOI 10.1086/176737; Bowyer S, 1996, SCIENCE, V274, P1338, DOI 10.1126/science.274.5291.1338; BRIEL UG, 1992, ASTRON ASTROPHYS, V259, pL31; DANLY L, 1992, ASTROPHYS J SUPPL S, V81, P125, DOI 10.1086/191689; Fabian AC, 1996, SCIENCE, V271, P1244, DOI 10.1126/science.271.5253.1244; FREYBERG M, COMMUNICATION; Heiles C, 1996, ASTROPHYS J, V462, P326, DOI 10.1086/177154; HUGHES JP, 1993, ASTROPHYS J, V404, P611, DOI 10.1086/172314; LAMPTON M, 1976, ASTROPHYS J, V208, P177, DOI 10.1086/154592; LAOR A, 1994, ASTROPHYS J, V435, P611, DOI 10.1086/174841; Lieu R, 1996, ASTROPHYS J, V458, pL5, DOI 10.1086/309908; LOCKMAN FJ, 1986, ASTROPHYS J, V302, P432, DOI 10.1086/164002; MEWE R, 1986, ASTRON ASTROPHYS SUP, V65, P511; Mewe R., 1985, Astronomy & Astrophysics Supplement Series, V62, P197; MORRISON R, 1983, ASTROPHYS J, V270, P119, DOI 10.1086/161102; SNOWDEN SL, 1994, ASTROPHYS J, V424, P714, DOI 10.1086/173925; STARK AA, 1992, ASTROPHYS J SUPPL S, V79, P77, DOI 10.1086/191645; Wheelock S., 1994, JPL PUBLICATION, V94-11; WILLACY K, 1993, MON NOT R ASTRON SOC, V261, P165, DOI 10.1093/mnras/261.1.165	21	137	137	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1335	1338		10.1126/science.274.5291.1335	http://dx.doi.org/10.1126/science.274.5291.1335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910264				2022-12-28	WOS:A1996VU95400040
J	Marshall, CR; Ward, PD				Marshall, CR; Ward, PD			Sudden and gradual molluscan extinctions in the latest Cretaceous of western European Tethys	SCIENCE			English	Article							TERTIARY BOUNDARY; CONFIDENCE-INTERVALS; STRATIGRAPHIC RANGES; FOSSIL RECORD; BISCAY REGION; SPAIN; FRANCE; FORAMINIFERA; DINOSAURS; EVOLUTION	Incompleteness of the fossil record has confounded attempts to establish the role of the end-Cretaceous bolide impact in the Late Cretaceous mass extinctions. Statistical analysis of latest Cretaceous outer-shelf macrofossils from western European Tethys reveals (i) a major extinction at or near the Cretaceous-Tertiary (K-T) boundary, probably caused by the impact, (ii) either a faunal abundance change or an extinction of up to nine ammonite species associated with a regression event shortly before the boundary, (iii) gradual extinction of most inoceramid bivalves well before the K-T boundary, and (iv) background extinction of approximately six ammonites throughout the latest Cretaceous.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095; UNIV WASHINGTON,DEPT GEOL SCI,SEATTLE,WA 98195	University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle	Marshall, CR (corresponding author), UNIV CALIF LOS ANGELES,INST MOL BIOL,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90095, USA.							ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Birkelund T, 1993, B GEOL SOC DENMARK, V40, P33; CANUDO JI, 1991, MAR MICROPALEONTOL, V17, P319, DOI 10.1016/0377-8398(91)90019-3; DHONDT AV, 1983, ZITTELIANA, V10; HURLBERT SH, 1995, GEOLOGY, V23, P881, DOI 10.1130/0091-7613(1995)023<0881:NSSFSO>2.3.CO;2; JABLONSKI D, 1995, SCIENCE, V268, P389, DOI 10.1126/science.11536722; JABLONSKI D, 1991, SCIENCE, V253, P754, DOI 10.1126/science.253.5021.754; KELLER G, 1989, GEOL SOC AM BULL, V101, P1408, DOI 10.1130/0016-7606(1989)101<1408:EPOEAT>2.3.CO;2; KELLER G, 1988, MAR MICROPALEONTOL, V13, P239, DOI 10.1016/0377-8398(88)90005-9; MACLEOD KG, 1994, GEOLOGY, V22, P139, DOI 10.1130/0091-7613(1994)022<0139:BIEAMM>2.3.CO;2; MACLEOD KG, 1994, J PALEONTOL, V68, P1048, DOI 10.1017/S0022336000026652; MACLEOD KG, 1993, PALEOBIOLOGY, V19, P235, DOI 10.1017/S009483730001589X; MACLEOD KG, 1990, GEOLOGICAL SOC AM SP, V247, P509; MARSHALL CR, 1994, PALEOBIOLOGY, V20, P459, DOI 10.1017/S0094837300012938; MARSHALL CR, 1995, GEOLOGY, V23, P731, DOI 10.1130/0091-7613(1995)023<0731:DBSAGE>2.3.CO;2; MARSHALL CR, 1990, PALEOBIOLOGY, V16, P1, DOI 10.1017/S0094837300009672; MATHEY B, 1988, PALAEONTOLOGY EVOLUT, P142; MOUNT JF, 1986, J SEDIMENT PETROL, V56, P228, DOI 10.1306/212F88C8-2B24-11D7-8648000102C1865D; RAUP D M, 1975, Paleobiology, V1, P333; RAUP DM, 1989, PHILOS T ROY SOC B, V325, P421, DOI 10.1098/rstb.1989.0097; RUSSELL DA, 1979, ANNU REV EARTH PL SC, V7, P163, DOI 10.1146/annurev.ea.07.050179.001115; Schultz, 1982, GEOLOGICAL SOC AM SP, V190, P291, DOI DOI 10.1130/SPE190-P291; SHARPTON VL, 1992, NATURE, V359, P819, DOI 10.1038/359819a0; SMIT J, 1985, EARTH PLANET SC LETT, V74, P155, DOI 10.1016/0012-821X(85)90019-6; Smith A. G., COMMUNICATION; SPRINGER MS, 1990, PALEOBIOLOGY, V16, P512, DOI 10.1017/S0094837300010228; STRAUSS D, 1989, MATH GEOL, V21, P411, DOI 10.1007/BF00897326; Ward P.D., 1993, J PALEONTOL, V34, P1; WARD PD, 1991, GEOLOGY, V19, P1181, DOI 10.1130/0091-7613(1991)019<1181:AAIBEP>2.3.CO;2	29	103	106	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1360	1363		10.1126/science.274.5291.1360	http://dx.doi.org/10.1126/science.274.5291.1360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910273				2022-12-28	WOS:A1996VU95400049
J	Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP				Katz, DA; Griffith, JL; Beshansky, JR; Selker, HP			The use of empiric clinical data in the evaluation of practice guidelines for unstable angina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ACUTE CARDIAC ISCHEMIA; CORONARY-CARE-UNIT; MEDICAL-PRACTICE GUIDELINES; PREDICTIVE INSTRUMENT; CHEST PAIN; PROSPECTIVE MULTICENTER; HEART-DISEASE; EMERGENCY; PECTORIS	Objective.-To determine the applicability to emergency department (ED) clinical practice of a nationally disseminated practice guideline on the disposition of patients with a diagnosis of unstable angina, and to determine the potential impact of the guideline on hospital admissions and demand for intensive care beds. Design.-Application of guideline criteria for ED disposition decisions to a validation sample derived from a prospective clinical trial. Setting.-Five hospitals, including 2 urban general teaching hospitals, 2 urban tertiary care university hospitals, and 1 suburban university-affiliated community hospital. Patients.-A consecutive sample of 457 patients who presented with symptoms suggestive of acute cardiac ischemia and who had ''unstable angina'' or ''rule out unstable angina'' diagnosed by ED physicians. Greater than 90% of eligible patients were enrolled in the clinical trial, follow-up data sufficient for assignment of a definitive diagnosis were obtained for 99% of subjects. Main outcome Measures.-Acute myocardial infarction and unstable angina, based on blind review of initial and follow-up clinical data, including cardiac enzyme levels and electrocardiograms. After completion of the trial, without knowledge of final diagnosis or outcome, the investigators classified patients into risk groups specified by the unstable angina guideline. Results.-Of subjects with an ED diagnosis of unstable angina, only 6% (n=28) met the guideline's criteria corresponding to low risk for adverse events and were therefore suitable for discharge directly to home. Fifty-four percent (n=247) mel the intermediate-risk criteria; 40% (n=182) met the high-risk criteria and were identified as requiring admission to an intensive care unit. Actual ED disposition differed from guideline recommendations in 2 major areas: only 4% (1/28) of low-risk patients were discharged to home with outpatient follow-up, and only 40% (72/182) of high-risk patients were admitted to an intensive care unit. Conclusions.-Although the guideline was intended to reduce hospitalization by identifying a low-risk group, the small size of this group among ED patients suggests that little reduction in hospitalization can be expected. Indeed, the guideline may increase demand for the limited number of intensive care beds to accommodate patients with unstable angina considered high-risk but currently placed elsewhere. These results emphasize the need to use empiric data from target clinical settings to assess the likely actual impact of guidelines on clinical care prior to national dissemination.	TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV CLIN CARE RES, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University				Katz, David/0000-0001-5348-6532	AHRQ HHS [R01-HS07360] Funding Source: Medline; NLM NIH HHS [LM7092] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007360] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ATKINS J, 1995, AM J EMERG MED, V13, P188; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BERTINI G, 1991, Journal of Emergency Medicine, V9, P57, DOI 10.1016/0736-4679(91)90589-8; BRAUNWALD E, 1994, CLIN PRACTICE GUIDEL, V10; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CANNON CP, 1995, AM J CARDIOL, V75, P977, DOI 10.1016/S0002-9149(99)80707-3; CANTRILL S, 1992, EMERG MED CLIN N AM, V8, P507; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Field MJ., 1992, GUIDELINES CLIN PRAC; FUCHS R, 1981, JAMA-J AM MED ASSOC, V246, P2037, DOI 10.1001/jama.246.18.2037; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRAVES E, 1993, NATL CTR HLTH STAT S, V13; GRIJSEELS EWM, 1995, EUR HEART J, V16, P325; JAYES RL, 1992, J GEN INTERN MED, V7, P387, DOI 10.1007/BF02599153; KARCZ A, 1990, ANN EMERG MED, V19, P865, DOI 10.1016/S0196-0644(05)81559-8; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCDONALD C, 1994, CLIN PRACTICE GUIDEL, P71; MCNUTT RA, 1988, MED DECIS MAKING, V8, P90, DOI 10.1177/0272989X8800800204; NATTEL S, 1980, CAN MED ASSOC J, V122, P180; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; RIZIK DG, 1995, AM J CARDIOL, V75, P993, DOI 10.1016/S0002-9149(99)80710-3; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; SAS, 2021, SAS PROC KAPP COEFF; Selker H. P., 1995, Journal of Investigative Medicine, V43, p497A; SELKER HP, 1987, JAMA-J AM MED ASSOC, V257, P1181, DOI 10.1001/jama.257.9.1181; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; VANDERDOES E, 1976, HEART B, V7, P91; WHITE LD, 1990, J AM COLL CARDIOL, V16, P304, DOI 10.1016/0735-1097(90)90577-C	35	60	62	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1568	1574						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918854				2022-12-28	WOS:A1996VT02500029
J	Bromilow, I; Duguid, JKM; Walkinshaw, S				Bromilow, I; Duguid, JKM; Walkinshaw, S			Lesson of the week - Importance of accurate assessment of fetomaternal haemorrhage after late abortions	BRITISH MEDICAL JOURNAL			English	Article									MERSEY & N WALES CTR,NATL BLOOD SERV,LIVERPOOL L7 8TW,MERSEYSIDE,ENGLAND; LIVERPOOL WOMENS HOSP,LIVERPOOL L8 7SS,MERSEYSIDE,ENGLAND	University of Liverpool								[Anonymous], 1991, PRESCRIBERS J, V1, P137; DUGUID JKM, 1994, BRIT MED J, V309, P240, DOI 10.1136/bmj.309.6949.240	2	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1200	1201		10.1136/bmj.313.7066.1200a	http://dx.doi.org/10.1136/bmj.313.7066.1200a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916760	Green Published			2022-12-28	WOS:A1996VR90700033
J	Schneerson, R; Robbins, JB; Taranger, J; Lagergard, T; Trollfors, B				Schneerson, R; Robbins, JB; Taranger, J; Lagergard, T; Trollfors, B			A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned	LANCET			English	Editorial Material							WHOOPING-COUGH; FILAMENTOUS HEMAGGLUTININ; EFFICACY; TOXIN; ANTIBODIES; INFECTION; CHILDREN; TRIAL		GOTHENBURG UNIV, DEPT PAEDIAT, GOTHENBURG, SWEDEN; GOTHENBURG UNIV, DEPT MED MICROBIOL & IMMUNOL, GOTHENBURG, SWEDEN	University of Gothenburg; University of Gothenburg	Schneerson, R (corresponding author), NICHHD, DEV & MOL IMMUN LAB, NIH, ROOM 424, BLDG 6, BETHESDA, MD 20892 USA.							*AD HOC GROUP, 1984, LANCET, V1, P955; [Anonymous], 1951, Br Med J, V1, P1463; BLACKWELDER WC, 1991, AM J DIS CHILD, V145, P1285, DOI 10.1001/archpedi.1991.02160110077024; BRUSS JB, 1993, 33 ICAAC; *CDC, 1995, MMWR-MORBID MORTAL W, V4, P236; Davis Susan F., 1992, Morbidity and Mortality Weekly Report, V41, P11; FINE PEM, 1987, REV INFECT DIS, V9, P866; GIBBONS R. J., 1945, Canadian Journal of Public Health, V36, P341; GRANSTROM M, 1991, LANCET, V338, P1230, DOI 10.1016/0140-6736(91)92101-7; GRANSTROM M, 1985, J INFECT DIS, V151, P646, DOI 10.1093/infdis/151.4.646; GRANSTROM M, 1993, VACCINE, V11, P445, DOI 10.1016/0264-410X(93)90286-7; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; GROB PR, 1981, BRIT MED J, V282, P1925, DOI 10.1136/bmj.282.6280.1925; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; IPSEN J, 1946, J IMMUNOL, V54, P325; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; KENDRICK PL, 1975, J INFECT DIS, V132, P707, DOI 10.1093/infdis/132.6.707; MAPLE PA, 1995, LANCET, V345, P963, DOI 10.1016/S0140-6736(95)90705-X; MEADE BD, 1984, INFECT IMMUN, V45, P718, DOI 10.1128/IAI.45.3.718-725.1984; MORSE SI, 1968, ANN INTERN MED, V68, P953, DOI 10.7326/0003-4819-68-4-953; NELSON JD, 1978, AM J DIS CHILD, V132, P371, DOI 10.1001/archpedi.1978.02120290043006; ONORATO IM, 1992, JAMA-J AM MED ASSOC, V267, P2745, DOI 10.1001/jama.267.20.2745; Pappenheimer AM., 1984, BACTERIAL VACCINES, P1; PITTMAN M, 1979, REV INFECT DIS, V1, P401; Poland GA, 1996, LANCET, V347, P209, DOI 10.1016/S0140-6736(96)90398-0; ROBBINS JB, 1993, PEDIATR INFECT DIS J, V12, P795, DOI 10.1097/00006454-199310000-00001; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; ROBINS JB, 1984, ASM, P176; SATO H, 1984, INFECT IMMUN, V46, P415, DOI 10.1128/IAI.46.2.415-421.1984; SATO HH, 1996, IVI NEWSLETTER, V2, P7; Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37; SMITH JWG, 1969, BRIT MED BULL, V25, P177, DOI 10.1093/oxfordjournals.bmb.a070689; STEINHOFF MC, 1995, PEDIATRICS, V96, P567; STEINHOFF MC, 1995, INT S PERT VACC TRIA; STORSAETER J, 1990, VACCINE, V8, P457, DOI 10.1016/0264-410X(90)90246-I; TARANGER J, 1994, LANCET, V344, P1703, DOI 10.1016/S0140-6736(94)90485-5; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604; Warin JF, 1940, BRIT MED J, V1940, P655, DOI 10.1136/bmj.1.4137.655; WILSON GS, 1906, PRINCIPES BACTERIOLO, P1668; ZACKRISSON G, 1990, J PEDIATR-US, V116, P190, DOI 10.1016/S0022-3476(05)82873-2	40	44	45	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	1996	348	9037					1289	1292		10.1016/S0140-6736(96)05243-9	http://dx.doi.org/10.1016/S0140-6736(96)05243-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909384				2022-12-28	WOS:A1996VR55500014
J	Shohat, T; Green, MS; Merom, D; Gill, ON; Reisfeld, A; Matas, A; Blau, D; Gal, N; Slater, PE				Shohat, T; Green, MS; Merom, D; Gill, ON; Reisfeld, A; Matas, A; Blau, D; Gal, N; Slater, PE			International epidemiological and microbiological study of outbreak of Salmonella agona infection from a ready to eat savoury snack .2. Israel	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explain an increase in the incidence of salmonellosis caused by Salmonella agona in Israel between October 1994 and January 1995 in the light of an outbreak of S agona phage type 15 infection in England and Wales caused by consumption of a ready to eat savoury snack produced in Israel. Design-Epidemiology of S agona in 1994-5 was analysed and two consecutive, case-control studies of 32 and 26 case-control pairs were performed. Phage typing and molecular methods were used to characterise strains of S agona isolated from cases and samples of the snack in Israel and England and Wales. Results-The increase in the incidence of S agona between October 1994 and January 1995 was countrywide. Cases of infection with group B salmonella increased from 60% to 80% in children under 5 years old. In both case-control studies, cases consumed more of the snack than did controls (4.25 v 2.94 packets per week in the first study (P=0.086) and 4.04 v 2.37 packets per week in the second study (P=0.034)). When the two studies were combined there was a significant dose-response relation for the number of packets consumed weekly. Compared with consumption of less than two packets, the odds ratio was 1.43 for between two and six packets and 3.37 for seven or more packets (chi(2) for trend=5.27, P=0.02) S agona phage type 15 was isolated from a packet of the snack sold in Israel, and the strain was identical with those isolated from packets and cases in Israel and England and Wales. Conclusions-This outbreak of S agona was caused by the contamination of a snack produced in Israel. Even under modern operating conditions, large, widespread international outbreaks of foodborne disease can occur. The success of this investigation resulted from excellent international collaboration between public health authorities.	PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND	Public Health England	Shohat, T (corresponding author), SCHNEIDER CHILDRENS MED CTR ISRAEL, ISRAEL CTR DIS CONTROL, ISRAEL MINIST HLTH, POB 559, IL-49202 PETAH TIQWA, ISRAEL.		Merom, Dafna/AAW-5357-2021	Merom, Dafna/0000-0001-6459-8628; Green, Manfred S./0000-0002-9753-5612				CHALKER RB, 1988, REV INFECT DIS, V10, P111; CLARK GM, 1973, LANCET, V2, P490; Killalea D, 1996, BMJ-BRIT MED J, V313, P1105, DOI 10.1136/bmj.313.7065.1105; *NAT SALM CTR, 1968, SALM FIND ISR ANN RE; Threlfall EJ, 1996, EMERG INFECT DIS, V2, P130, DOI 10.3201/eid0202.960209; 1972, BRIT MED J, V4, P559; 1995, COMMUN DIS REP CDR W, V5, P29	7	58	59	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1107	1109		10.1136/bmj.313.7065.1107	http://dx.doi.org/10.1136/bmj.313.7065.1107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916694	Green Published			2022-12-28	WOS:A1996VR21700019
J	Waern, M; Beskow, J; Runeson, B; Skoog, I				Waern, M; Beskow, J; Runeson, B; Skoog, I			High rate of antidepressant treatment in elderly people who commit suicide	BRITISH MEDICAL JOURNAL			English	Article									UNIV STOCKHOLM,KAROLINSKA INST,CTR SUICIDE RES & PREVENT,STOCKHOLM,SWEDEN	Karolinska Institutet; Stockholm University	Waern, M (corresponding author), SAHLGRENS UNIV HOSP,INST CLIN NEUROSCI,SECT PSYCHIAT,S-41345 GOTHENBURG,SWEDEN.			Runeson, Bo/0000-0003-4122-4636				CATTELL H, 1995, BRIT J PSYCHIAT, V166, P451, DOI 10.1192/bjp.166.4.451; CLARK DC, 1993, SUICIDAL BEHAV STATE; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Conwell Y, 1995, Int Psychogeriatr, V7, P149, DOI 10.1017/S1041610295001943; ISACSSON G, 1994, BRIT MED J, V308, P71	5	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1118	1118		10.1136/bmj.313.7065.1118	http://dx.doi.org/10.1136/bmj.313.7065.1118			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916699	Green Published			2022-12-28	WOS:A1996VR21700024
J	Henderson, A				Henderson, A			Coronary heart disease: Overview	LANCET			English	Article							MYOCARDIUM; RESISTANCE; ANGINA											BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; DAVIES MJ, 1985, BRIT HEART J, V53, P363; EGASHIRA K, 1993, NEW ENGL J MED, V328, P1659, DOI 10.1056/NEJM199306103282302; GOODFELLOW J, 1996, DIABETES RES CLIN S, V31, P163; GRIFFITH TM, 1987, NATURE, V329, P442, DOI 10.1038/329442a0; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; RAHIMTOOLA SH, 1989, AM HEART J, V117, P211, DOI 10.1016/0002-8703(89)90685-6; RAMSEY MW, 1995, CIRCULATION, V92, P3212, DOI 10.1161/01.CIR.92.11.3212; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; TUNSTALLPEDOE H, 1996, OXFORD TXB PUBLIC HL; 1987, LANCET, V2, P1247	12	23	23	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV	1996	348			1			S1	S4		10.1016/S0140-6736(96)98001-0	http://dx.doi.org/10.1016/S0140-6736(96)98001-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU008	8918518				2022-12-28	WOS:A1996VU00800002
J	Tanaka, E; Alter, HJ; Nakatsuji, Y; Shih, JWK; Kim, JP; Matsumoto, A; Kobayashi, M; Kiyosawa, K				Tanaka, E; Alter, HJ; Nakatsuji, Y; Shih, JWK; Kim, JP; Matsumoto, A; Kobayashi, M; Kiyosawa, K			Effect of hepatitis G virus infection on chronic hepatitis C	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; ANTIBODY; THERAPY; RNA; GENOTYPES	Objective: To clarify the effect of hepatitis G virus (HGV) infection on chronic hepatitis C. Design: Retrospective study. Setting: University hospital in Matsumoto, Japan. Patients: 189 randomly selected patients with histologically proven chronic hepatitis C, including 101 patients receiving interferon-alpha. Measurements: Serum levels of HGV RNA were measured by reverse-transcription polymerase chain reaction. Clinical features, including liver histologic findings, hepatitis C virus (HCV) markers, and response of HCV to interferon-alpha were compared between HGV RNA-positive and HGV RNA-negative patients. Results: 21 of 189 (11%) patients with chronic hepatitis C were positive for HCV RNA. On average, patients with HGV RNA were younger than those without HCV RNA (mean age +/- SD, 46.6 +/- 13.0 years and 51.7 +/- 10.7 years, respectively); other demographic and clinical features were similar. The HCV genotype and HCV RNA level were distributed similarly between patients with and those without HCV infection. Ten of 101 patients with chronic hepatitis C who received interferon-alpha were positive for HCV RNA. The rate of sustained HCV response to intepferon-alpha: in patients with HGV infection (30%) was similar to that in patients without HGV infection (36%). The HGV RNA level decreased during therapy in all 9 patients in whom this value was measured. However, only 2 of these patients had a sustained HGV response after discontinuation of therapy. Conclusions: Patients who only had HCV infection did not differ from patients with HCV and HGV co-infection in clinical presentation, HCV RNA level, or response of HCV to interferon-alpha therapy. Thus, HCV infection had no apparent influence on the clinical or virologic course of HCV, infection. Hepatitis G virus was uniformly sensitive to interferon-alpha therapy, but only a few patients had a sustained virologic response.	NIH, DEPT TRANSFUS MED, BETHESDA, MD 20852 USA; SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, MATSUMOTO, NAGANO 390, JAPAN; GENELABS TECHNOL INC, REDWOOD CITY, CA 94063 USA	National Institutes of Health (NIH) - USA; Shinshu University								ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1995, J VIRAL HEPATITIS, V2, P121, DOI 10.1111/j.1365-2893.1995.tb00017.x; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; FONG TL, 1991, HEPATOLOGY, V14, P64, DOI 10.1002/hep.1840140111; Jeffers L. J., 1995, Hepatology, V22, p182A, DOI 10.1016/0270-9139(95)94452-4; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MATSUMOTO A, 1994, DIGEST DIS SCI, V39, P1273, DOI 10.1007/BF02093793; NAKATSUJI Y, IN PRESS J VIRAL HEP; OINNEN J, 1996, SCIENCE, V271, P505; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; Tanaka E, 1996, HEPATOLOGY, V23, P1330, DOI 10.1002/hep.510230606; TANAKA E, 1991, J MED VIROL, V33, P117, DOI 10.1002/jmv.1890330210; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	18	175	176	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					740	743		10.7326/0003-4819-125-9-199611010-00007	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929008				2022-12-28	WOS:A1996VQ07200006
J	Nakamura, A; Amikura, R; Mukai, M; Kobayashi, S; Lasko, PF				Nakamura, A; Amikura, R; Mukai, M; Kobayashi, S; Lasko, PF			Requirement for a noncoding RNA in Drosophila polar granules for germ cell establishment	SCIENCE			English	Article							LARGE RIBOSOMAL-RNA; XENOPUS-OOCYTES; MESSENGER-RNA; POSTERIOR DETERMINANT; VEGETAL CORTEX; MATERNAL GENE; EMBRYOS; PLASM; LOCALIZATION; PROTEIN	In Drosophila embryos, germ cell formation is induced by specialized cytoplasm at the posterior of the egg, the pole plasm. Pole plasm contains polar granules, organelles in which maternally produced molecules required for germ cell formation are assembled. An untranslatable RNA, called Polar granule component (Pgc), was identified and found to be localized in polar granules. Most pole cells in embryos produced by transgenic females expressing antisense Pge RNA failed to complete migration and to populate the embryonic gonads, and females that developed from these embryos often had agametic ovaries. These results support an essential role for Pge RNA in germline development.	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; UNIV TSUKUBA, INST BIOL SCI, GENE EXPT CTR, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	McGill University; University of Tsukuba; University of Tsukuba			Nakamura, Akira/V-6869-2019; Lasko, Paul/C-6761-2014	Nakamura, Akira/0000-0001-6506-9146; Lasko, Paul/0000-0002-4037-3501				Amikura R, 1996, DEV GROWTH DIFFER, V38, P489, DOI 10.1046/j.1440-169X.1996.t01-4-00005.x; AMIKURA R, 1993, DEV GROWTH DIFFER, V35, P617; AMIKURA R, UNPUB; ASHBURNER M, 1990, DROSOPHILA CODON TAB; BARDSLEY A, 1993, DEVELOPMENT, V119, P207; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; Breitwieser W, 1996, GENE DEV, V10, P2179, DOI 10.1101/gad.10.17.2179; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1993, ATLAS DROSOPHILA GEN, P359; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVRIES GE, 1992, J BACTERIOL, V174, P5346, DOI 10.1128/JB.174.16.5346-5353.1992; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; Grunert S, 1996, CURR OPIN GENET DEV, V6, P395, DOI 10.1016/S0959-437X(96)80059-1; HAY B, 1988, DEVELOPMENT, V103, P625; IKENISHI K, 1986, DEV GROWTH DIFFER, V28, P563; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; KOBAYASHI S, 1994, INT J DEV BIOL, V38, P193; KOBAYASHI S, 1993, SCIENCE, V260, P1521, DOI 10.1126/science.7684857; LANTZ V, 1992, DEVELOPMENT, V115, P75; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1962, J EXP ZOOL, V151, P201, DOI 10.1002/jez.1401510302; MAHOWALD AP, 1971, DEV BIOL, V24, P37, DOI 10.1016/0012-1606(71)90045-5; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NAKAMURA A, UNPUB; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; St Johnston Daniel, 1993, P325; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; SUGIYAMA S, 1990, ROUX ARCH DEV BIOL, V198, P402, DOI 10.1007/BF00376159; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel CS, 1992, DROS INF SERV, V71, P150; TIAN SS, 1994, J BIOL CHEM, V269, P28478; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WILLIAMS MA, 1971, DEV BIOL, V25, P568, DOI 10.1016/0012-1606(71)90006-6	48	158	160	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 20	1996	274	5295					2075	2079		10.1126/science.274.5295.2075	http://dx.doi.org/10.1126/science.274.5295.2075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953037				2022-12-28	WOS:A1996VY97400047
J	Scott, WG; Murray, JB; Arnold, JRP; Stoddard, BL; Klug, A				Scott, WG; Murray, JB; Arnold, JRP; Stoddard, BL; Klug, A			Capturing the structure of a catalytic RNA intermediate: The hammerhead ribozyme	SCIENCE			English	Article							CLEAVAGE REACTION; ENZYME; OLIGORIBONUCLEOTIDES; MECHANISM	The crystal structure of an unmodified hammerhead RNA in the absence of divalent metal ions has been solved, and it was shown that this ribozyme can cleave itself in the crystal when divalent metal ions are added. This biologically active RNA fold is the same as that found previously for two modified hammerhead ribozymes. Addition of divalent cations at low pH makes it possible to capture the uncleaved RNA in metal-bound form. A conformational intermediate, having an additional Mg(II) bound to the cleavage-site phosphate, was captured by freeze-trapping the RNA at an active pH prior to cleavage. The most significant conformational changes were limited to the active site of the ribozyme, and the changed conformation requires only small additional movements to reach a proposed transition-state.	UNIV LEEDS,DEPT BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of Leeds; Fred Hutchinson Cancer Center	Scott, WG (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Scott, William/0000-0002-9273-3564	NIGMS NIH HHS [GM-49857] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amiri KMA, 1996, J MOL BIOL, V261, P125, DOI 10.1006/jmbi.1996.0446; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BRUNGER AT, 1993, XPLOR 3 1 SYSTEM CRY; DAHM S, 1993, BIOCHEMISTRY-US, V32, P13010; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERTEL KJ, 1995, BIOCHEMISTRY-US, V34, P1744, DOI 10.1021/bi00005a031; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P145; McKay DB, 1996, RNA, V2, P395; MOFFAT K, 1995, CURR OPIN STRUC BIOL, V5, P656, DOI 10.1016/0959-440X(95)80059-X; MURRAY JB, 1994, ANAL BIOCHEM, V218, P177, DOI 10.1006/abio.1994.1157; MURRAY JB, 1995, BIOCHEM J, V311, P487, DOI 10.1042/bj3110487; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SCOTT WG, 1995, J MOL BIOL, V250, P327, DOI 10.1006/jmbi.1995.0380; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SIGURDSSON ST, 1995, RNA, V1, P575; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; TUSHL T, 1994, SCIENCE, V266, P785; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	27	410	418	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2065	2069		10.1126/science.274.5295.2065	http://dx.doi.org/10.1126/science.274.5295.2065			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953035	Green Submitted			2022-12-28	WOS:A1996VY97400045
J	Tang, XY; Frederick, RD; Zhou, JM; Halterman, DA; Jia, YL; Martin, GB				Tang, XY; Frederick, RD; Zhou, JM; Halterman, DA; Jia, YL; Martin, GB			Initiation of plant disease resistance by physical interaction of AvrPto and Pto kinase	SCIENCE			English	Article							PROTEIN-KINASE; GENE RPS2; TOMATO; PATHOGENICITY; SPECIFICITY; SENSITIVITY; THALIANA	Resistance to bacterial speck disease in tomato occurs when the Pto kinase in the plant responds to expression of the avirulence gene avrPto in the Pseudomonas pathogen. Transient expression of an avrPto transgene in plant cells containing Pto elicited a defense response. In the yeast two-hybrid system, the Pto kinase physically interacted with AvrPto. Alterations of AvrPto or Pto that disrupted the interaction in yeast also abolished disease resistance in plants. The physical interaction of AvrPto and Pto provides an explanation of gene-for-gene specificity in bacterial speck disease resistance.			Tang, XY (corresponding author), PURDUE UNIV,DEPT AGRON,W LAFAYETTE,IN 47907, USA.		Zhou, Jian-Min/A-3140-2013; Martin, Gregory B/F-6262-2011; Frederick, Reid/AAC-7488-2021; jia, yu/HHR-9047-2022; Jia, Yulin/T-8235-2019	Zhou, Jian-Min/0000-0002-9943-2975; Martin, Gregory B/0000-0003-0044-6830; Jia, Yulin/0000-0002-2132-0498				BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BLISKA JB, 1993, TRENDS GENET, V9, P85, DOI 10.1016/0168-9525(93)90229-B; BROWN I, 1993, MOL PLANT MICROBE IN, V6, P376, DOI 10.1094/MPMI-6-376; Dangl J L, 1994, Curr Top Microbiol Immunol, V192, P99; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; ELLINGBOE A, 1980, ACTIVE DEFENSE MECH, P179; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FREDERICK RD, UNPUB; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; HOOD EE, 1993, TRANSGENIC RES, V2, P208, DOI 10.1007/BF01977351; Jia Y., UNPUB; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; Menard R, 1996, TRENDS MICROBIOL, V4, P220, DOI 10.1016/0966-842X(96)10039-1; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SALMERON JM, 1993, MOL GEN GENET, V239, P6, DOI 10.1007/BF00281595; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; TANG X, UNPUB; THILMONY RL, 1995, PLANT CELL, V7, P1529, DOI 10.1105/tpc.7.10.1529; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8; WHITHAM S, 1994, CELL, V78, P1011; YOUNG SA, 1994, MOL PLANT MICROBE IN, V7, P799, DOI 10.1094/MPMI-7-0799; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	34	510	550	10	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2060	2063		10.1126/science.274.5295.2060	http://dx.doi.org/10.1126/science.274.5295.2060			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953033				2022-12-28	WOS:A1996VY97400043
J	Telling, GC; Parchi, P; DeArmond, SJ; Cortelli, P; Montagna, P; Gabizon, R; Mastrianni, J; Lugaresi, E; Gambetti, P; Prusiner, SB				Telling, GC; Parchi, P; DeArmond, SJ; Cortelli, P; Montagna, P; Gabizon, R; Mastrianni, J; Lugaresi, E; Gambetti, P; Prusiner, SB			Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity	SCIENCE			English	Article							FATAL FAMILIAL INSOMNIA; CREUTZFELDT-JAKOB-DISEASE; TRANSMISSIBLE MINK ENCEPHALOPATHY; GERSTMANN-STRAUSSLER SYNDROME; DNA POLYMORPHISM; TRANSGENIC MICE; AGENT-STRAIN; SCRAPIE; MOUSE; GENE	The fundamental event in prion diseases seems to be a conformational change in cellular prion protein (PrPC) whereby it is converted into the pathologic isoform PrPSc. In fatal familial insomnia (FFI), the protease-resistant fragment of PrPSc after deglycosylation has a size of 19 kilodaltons, whereas that from other inherited and sporadic prion diseases is 21 kilodaltons. Extracts from the brains of FFI patients transmitted disease to transgenic mice expressing a chimeric human-mouse PrP gene about 200 days after inoculation and induced formation of the 19-kilodalton PrPSc fragment, whereas extracts from the brains of familiar and sporadic Creutzfeldt-Jakob disease patients produced the 21-kilodalton PrPSc fragment in these mice. The results presented indicate that the conformation of PrPSc functions as a template in directing the formation of nascent PrPSc and suggest a mechanism to explain strains of prions where diversity is encrypted in the conformation of PrPSc.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; HEBREW UNIV JERUSALEM,HADASSAH MED CTR,DEPT NEUROL,IL-91120 JERUSALEM,ISRAEL; UNIV BOLOGNA,DEPT NEUROL,I-40123 BOLOGNA,ITALY; CASE WESTERN RESERVE UNIV,DEPT PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Bologna; Case Western Reserve University; University of California System; University of California San Francisco			Parchi, Piero/L-9833-2015; Telling, Glenn C/G-1217-2019; Cortelli, Pietro/K-6063-2016	Parchi, Piero/0000-0002-9444-9524; Telling, Glenn C/0000-0002-6294-1805; Cortelli, Pietro/0000-0002-3633-8818	NINDS NIH HHS [NS07219] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BRUCE ME, 1976, NEUROPATH APPL NEURO, V2, P471, DOI 10.1111/j.1365-2990.1976.tb00521.x; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; CARP RI, 1991, J GEN VIROL, V72, P293, DOI 10.1099/0022-1317-72-2-293; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DEARMOND S, UNPUB; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GABIZON R, 1993, AM J HUM GENET, V33, P828; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; GELLING GC, 1995, CELL, V83, P79; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; Meggendorfer F, 1930, Z GESAMTE NEUROL PSY, V128, P337, DOI 10.1007/BF02864269; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARCHI P, 1995, ANN NEUROL, V38, P21, DOI 10.1002/ana.410380107; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Pergami P, 1996, ANAL BIOCHEM, V236, P63, DOI 10.1006/abio.1996.0132; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; PETERSEN RB, 1996, J BIOL CHEM, V271; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SCOTT M, UNPUB; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; TELLING G, UNPUB; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; TELLING GC, 1994, P NATL ACAD SCI USA, V91, P9936, DOI 10.1073/pnas.91.21.9936; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	53	704	723	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2079	2082		10.1126/science.274.5295.2079	http://dx.doi.org/10.1126/science.274.5295.2079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953038				2022-12-28	WOS:A1996VY97400048
J	Zhang, L; Rzigalinski, BA; Ellis, EF; Satin, LS				Zhang, L; Rzigalinski, BA; Ellis, EF; Satin, LS			Reduction of voltage-dependent Mg2+ blockade of NMDA current in mechanically injured neurons	SCIENCE			English	Article							CONCUSSIVE BRAIN INJURY; EXCITATORY AMINO-ACIDS; D-ASPARTIC ACID; CHANNELS; ANTAGONISTS; RECEPTORS; RELEASE; CULTURE; CELLS	Activation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors is implicated in the pathophysiology of traumatic brain injury. Here, the effects of mechanical injury on the voltage-dependent magnesium (Mg2+) block of NMDA currents in cultured rat cortical neurons were examined. Stretch-induced injury was found to reduce the Mg2+ blockade, resulting in significantly larger ionic currents and increases in intracellular free calcium (Ca2+) concentration after NMDA stimulation of injured neurons. The Mg2+ blockade was partially restored by increased extracellular Mg2+ concentration or by pretreatment with the protein kinase C inhibitor calphostin C. These findings could account for the secondary pathological changes associated with traumatic brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07537-14] Funding Source: Medline; NINDS NIH HHS [NS 27214] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1994, INTRACRANIAL PRESSUR, P264; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HERRINGTON J, 1994, PULSE CONTROL V 4 3; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PERSSON K, 1995, AM J PHYSIOL-CELL PH, V269, pC1018, DOI 10.1152/ajpcell.1995.269.4.C1018; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1	26	187	197	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1921	1923		10.1126/science.274.5294.1921	http://dx.doi.org/10.1126/science.274.5294.1921			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943207				2022-12-28	WOS:A1996VY20000047
J	Joseph, AM; Norman, SM; Ferry, LH; Prochazka, AV; Westman, EC; Steele, BG; Sherman, SE; Cleveland, M; Antonnucio, DO; Hartman, N; McGovern, PG				Joseph, AM; Norman, SM; Ferry, LH; Prochazka, AV; Westman, EC; Steele, BG; Sherman, SE; Cleveland, M; Antonnucio, DO; Hartman, N; McGovern, PG			The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; CIGARETTE-SMOKING; ATRIAL-FIBRILLATION; HEMOSTATIC FUNCTION; FOLLOW-UP; PATCH; BLOOD; SMOKERS; THERAPY	Background Transdermal nicotine therapy is widely used to aid smoking cessation, but there is uncertainty about its safety in patients with cardiac disease. Methods In a randomized, double-blind, placebo-controlled trial at 10 Veterans Affairs medical centers, we randomly assigned 584 outpatients (of whom 576 were men) with at least one diagnosis of cardiovascular disease to a 10-week course of transdermal nicotine or placebo as an aid to smoking cessation. The subjects were monitored for a total of 14 weeks for the primary end points of the study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive heart failure); the secondary end points (admission to the hospital for other reasons and outpatient visits necessitated by increased severity of heart disease); any side effects of therapy; and abstinence from smoking. Results There were 48 primary and 78 secondary end points noted in a total of 95 subjects. At least one of the primary end points was reached by 5.4 percent of the subjects in the nicotine group and 7.9 percent of the subjects in the placebo group (difference, 2.5 percent; 95 percent confidence interval, -1.6 to 6.5 percent; P=0.23). In the nicotine group, 11.9 percent of the subjects had at least one of the secondary end points, as compared with 9.7 percent in the placebo group (difference, 2.2 percent; 95 percent confidence interval, -2.2 to 7.4 percent; P=0.37). After 14 weeks the rate of abstinence from smoking was 21 percent in the nicotine group, as compared with 9 percent in the placebo group (P=0.001), but after 24 weeks the abstinence rates were not significantly different (14 percent vs. 11 percent, P=0.67). Conclusions Transdermal nicotine does not cause a significant increase in cardiovascular events in high-risk outpatients with cardiac disease. However, the efficacy of transdermal nicotine as an aid to smoking cessation in such patients is limited and may not be sustained over time. (C) 1996, Massachusetts Medical Society.	UNIV MINNESOTA,MINNEAPOLIS,MN 55455; VET AFFAIRS MED CTR,DEPT PSYCHOL,KANSAS CITY,MO; VET AFFAIRS MED CTR,DEPT MED,LOMA LINDA,CA; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO; VET AFFAIRS MED CTR,DEPT MED,DURHAM,NC 27705; VET AFFAIRS MED CTR,NURSING SERV,SEATTLE,WA 98108; VET AFFAIRS MED CTR,PRIMARY AMBULATORY CARE & EDUC CTR,SEPULVEDA,CA; VET AFFAIRS MED CTR,DEPT MED,PORTLAND,OR; VET AFFAIRS MED CTR,PSYCHOL SERV,RENO,NV; VET AFFAIRS MED CTR,DEPT PSYCHIAT,LOS ANGELES,CA; UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Minnesota System; University of Minnesota Twin Cities	Joseph, AM (corresponding author), VET AFFAIRS MED CTR,SECT GEN INTERNAL MED 1110,DEPT MED,1 VET DR,MINNEAPOLIS,MN 55417, USA.			Joseph, Anne/0000-0002-3440-2679; Sherman, Scott/0000-0003-1752-7303				ALLEN SS, 1994, PREV MED, V23, P190, DOI 10.1006/pmed.1994.1026; ALLRED EN, 1989, NEW ENGL J MED, V321, P1426, DOI 10.1056/NEJM198911233212102; ALLRED EN, 1990, NEW ENGL J MED, V322, P1019; [Anonymous], 1991, JAMA, V266, P3133; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P497; ARNAOT MR, 1995, BRIT MED J, V310, P663, DOI 10.1136/bmj.310.6980.663c; BENOWITZ NL, 1993, J AM COLL CARDIOL, V22, P1159, DOI 10.1016/0735-1097(93)90431-Y; BENOWITZ NL, 1990, J PHARMACOL EXP THER, V254, P1000; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; DACOSTA A, 1993, EUR HEART J, V14, P1709, DOI 10.1093/eurheartj/14.12.1709; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; *DHHS, 1983, DHHS PUBL PHS; *DHHS, 1990, DHHS PUBL CDC; FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549; *FED TRAD COMM, 1991, TAR NIC CARB MON CON; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FIORE MC, 1996, AHCPR PUBL; FITZGERALD GA, 1988, AM HEART J, V115, P267, DOI 10.1016/0002-8703(88)90648-5; FREDRICKSON PA, 1995, PSYCHOPHARMACOLOGY, V122, P215, DOI 10.1007/BF02246542; FRID D, 1991, AM J PREV MED, V7, P131, DOI 10.1016/S0749-3797(18)30927-9; GILLUM RF, 1994, AM J EPIDEMIOL, V139, P894, DOI 10.1093/oxfordjournals.aje.a117095; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807; HWANG SL, 1992, WALL STREET J   0619, pB1; JACKSON M, 1993, LANCET, V342, P236, DOI 10.1016/0140-6736(93)92323-L; Joseph A. M., 1995, JGIM, V10, P101; KAIJSER L, 1985, CLIN PHYSIOL, V5, P541, DOI 10.1111/j.1475-097X.1985.tb00767.x; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; *NCI, 1993, NIH PUBL; OTTERVANGER JP, 1995, CHEST, V107, P1765, DOI 10.1378/chest.107.6.1765; PIERCE JR, 1994, ANN PHARMACOTHER, V28, P402, DOI 10.1177/106002809402800320; RIGOTTI NA, 1986, JAMA-J AM MED ASSOC, V255, P1018, DOI 10.1001/jama.255.8.1018; RIGOTTI NA, 1994, ANN INTERN MED, V120, P287, DOI 10.7326/0003-4819-120-4-199402150-00005; *SAS I, 1989, SAS STAT US GUID VER, V2; *SAS I, 1989, SAS STAT US GUID VER, V1; STEWART PM, 1985, BRIT HEART J, V54, P222; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; WARNER JG, 1994, ANN INTERN MED, V120, P695, DOI 10.7326/0003-4819-120-8-199404150-00023; *WORK GROUP STUD T, 1994, ARCH INTERN MED, V154, P989	40	344	352	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1792	1798		10.1056/NEJM199612123352402	http://dx.doi.org/10.1056/NEJM199612123352402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943160	Bronze			2022-12-28	WOS:A1996VW68300002
J	Stillman, B				Stillman, B			Cell Cycle Control of DNA replication	SCIENCE			English	Review							ORIGIN RECOGNITION COMPLEX; SISTER-CHROMATID SEPARATION; PROTEIN-KINASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; S-PHASE; FISSION YEAST; CDC7 PROTEIN; IN-VIVO; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOMAL REPLICATION	The initiation of DNA replication in eukaryotic cells is a highly regulated process that leads to the duplication of the genetic information for the next cell generation. This requires the ordered assembly of many proteins at the origins of DNA replication to form a competent, pre-replicative chromosomal stale. In addition to this competen: complex, at least two cell cycle regulated protein kinase pathways are required to affect a transition to a post-replicative chromosomal state. Protein kinases required to establish mitosis prevent re-replication of the DNA. As cells exit mitosis, the cell cycle is reset, allowing the establishment of a new, competent replication state.			Stillman, B (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091				ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1996, DNA REPLICATION EUKA, P971; Botchan M, 1996, P NATL ACAD SCI USA, V93, P9997, DOI 10.1073/pnas.93.19.9997; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GERBI SA, 1996, DNA REPLICATION EUKA, P947; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HAMLIN JL, 1994, BBA-REV CANCER, V1198, P85, DOI 10.1016/0304-419X(94)90008-6; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; HARDY CFJ, IN PRESS MOL CELL BI; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; Heintz N. H, 1996, DNA REPLICATION EUKA, P983; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HOLLINGSWORTH RE, 1990, P NATL ACAD SCI USA, V87, P6272, DOI 10.1073/pnas.87.16.6272; HOLLOWAY SL, 1995, CURR OPIN GENET DEV, V5, P243, DOI 10.1016/0959-437X(95)80015-8; Hori Y, 1996, MOL BIOL CELL, V7, P409, DOI 10.1091/mbc.7.3.409; Huang RY, 1996, NUCLEIC ACIDS RES, V24, P816, DOI 10.1093/nar/24.5.816; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KITADA K, 1992, GENETICS, V131, P21; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kornberg A., 1992, DNA REPLICATION; Kroll ES, 1996, GENETICS, V143, P95; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUHNE C, 1993, EMBO J, V12, P3437, DOI 10.1002/j.1460-2075.1993.tb06018.x; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lei M, 1996, MOL CELL BIOL, V16, P5081; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MOIR D, 1982, GENETICS, V100, P547; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NASMYTH K, 1996, DNA REPLICATION EUKA, P331; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PIERRON G, 1996, DNA REPLICATION EUKA, P933; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; ROMANOWSKI P, IN PRESS CURR BIOL; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Singer JD, 1996, MOL CELL BIOL, V16, P1356; Stern Bodo, 1996, Trends in Genetics, V12, P345, DOI 10.1016/0168-9525(96)10036-6; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WOHLGEMUTH JG, 1994, MOL BIOL CELL, V5, P839, DOI 10.1091/mbc.5.8.839; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574	110	434	446	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1659	1664		10.1126/science.274.5293.1659	http://dx.doi.org/10.1126/science.274.5293.1659			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939847				2022-12-28	WOS:A1996VW71200046
J	Brat, DJ; Hruban, RH				Brat, DJ; Hruban, RH			A metastasis caught in the act	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Brat, DJ (corresponding author), JOHNS HOPKINS UNIV HOSP,BALTIMORE,MD 21287, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1733	1733						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929265				2022-12-28	WOS:A1996VW79500004
J	Shuker, SB; Hajduk, PJ; Meadows, RP; Fesik, SW				Shuker, SB; Hajduk, PJ; Meadows, RP; Fesik, SW			Discovering high-affinity ligands for proteins: SAR by NMR	SCIENCE			English	Article							ATOMIC-STRUCTURE; DRUG DESIGN; BINDING; COMPLEX; SPECTROSCOPY; FKBP-FK506; INHIBITORS; PROGRAM; FK506	A nuclear magnetic resonance (NMR)-based method is described in which small organic molecules that bind to proximal subsites of a protein are identified, optimized, and linked together to produce high-affinity ligands. The approach is called ''SAR by NMR'' because structure-activity relationships (SAR) are obtained from NMR. With this technique, compounds with nanomolar affinities for the FK506 binding protein were rapidly discovered by tethering two ligands with micromolar affinities. The method reduces the amount of chemical synthesis and time required for the discovery of high-affinity ligands and appears particularly useful in target-directed drug research.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories								Allen KN, 1996, J PHYS CHEM-US, V100, P2605, DOI 10.1021/jp952516o; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; ECKER DJ, 1995, BIO-TECHNOL, V13, P351, DOI 10.1038/nbt0495-351; EISEN MB, 1994, PROTEINS, V19, P199, DOI 10.1002/prot.340190305; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; HAUSKE JR, 1992, J MED CHEM, V35, P4284, DOI 10.1021/jm00101a005; HOLT DA, 1993, J AM CHEM SOC, V115, P9925, DOI 10.1021/ja00075a008; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MEADOWS RP, 1993, BIOCHEMISTRY-US, V32, P754, DOI 10.1021/bi00054a004; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ROTSTEIN SH, 1993, J MED CHEM, V36, P1700, DOI 10.1021/jm00064a003; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VERLINDE CLMJ, 1992, J COMPUT AID MOL DES, V6, P131, DOI 10.1007/BF00129424; WANG GT, 1994, BIOORG MED CHEM LETT, V4, P1161, DOI 10.1016/S0960-894X(01)80248-1; WERNER S, Patent No. 17356	22	1638	1813	12	328	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 29	1996	274	5292					1531	1534		10.1126/science.274.5292.1531	http://dx.doi.org/10.1126/science.274.5292.1531			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV775	8929414				2022-12-28	WOS:A1996VV77500049
J	Schieber, RA; BrancheDorsey, CM; Ryan, GW; Rutherford, GW; Stevens, JA; ONeil, J				Schieber, RA; BrancheDorsey, CM; Ryan, GW; Rutherford, GW; Stevens, JA; ONeil, J			Risk factors for injuries from in-line skating and the effectiveness of safety gear	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Of the estimated 22.5 million people participating in in-line skating in the United States in 1995, about 100,000 were sufficiently injured to require emergency department care. We investigated the effectiveness of wrist guards, elbow pads, knee pads, and helmets in preventing skating injuries. Methods We used data from the 91 hospital emergency departments participating in the National Electronic Injury Surveillance System, a national probability sample of randomly selected hospitals with 24-hour emergency departments. Injured in-line skaters who sought medical attention between December 1992 and July 1993 were interviewed by telephone. We conducted a case-control study of skaters who injured their wrists, elbows, knees, or heads as compared with skaters with injuries to other parts of their bodies. Results Of 206 eligible injured subjects, 161 (78 percent) were interviewed. Wrist injuries were the most common (32 percent); 25 percent of all injuries were wrist fractures. Seven percent of injured skaters wore all the types of safety gear; 46 percent wore none. Forty-five percent wore knee pads, 33 percent wrist guards, 28 percent elbow pads, and 20 percent helmets. The odds ratio for wrist injury, adjusted for age and sex, for those who did not wear wrist guards, as compared with those who did, was 10.4 (95 percent confidence interval, 2.9 to 36.9). The odds ratio for elbow injury, adjusted for the number of lessons skaters had had and whether or not they performed trick skating, was 9.5 (95 percent confidence interval, 2.6 to 34.4) for those who did not wear elbow pads. Nonuse of knee pads was associated with a nonsignificant increase in the risk of knee injury (crude odds ratio, 2.2; 95 percent confidence interval, 0.7 to 7.2). The effectiveness of helmets could not be assessed. Conclusions Wrist guards and elbow pads are effective in protecting in-line skaters against injuries. (C)1996, Massachusetts Medical Society.	CONSUMER PROD SAFETY COMMISS,DIRECTORATE EPIDEMIOL & HLTH SCI,WASHINGTON,DC		Schieber, RA (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,MAILSTOP K-63,4770 BUFORD HWY,NE,ATLANTA,GA 30341, USA.							Agresti A., 1990, CATEGORICAL DATA ANA, pXV; *AM SPORTS DAT, 1996, AM SPORTS AN SUMM RE; CALLE SC, 1994, AM J PUBLIC HEALTH, V84, P675, DOI 10.2105/AJPH.84.4.675; *CONS PROD SAF COM, 1991, SAF COMM WARNS HAZ I; *CONS PROD SAF COM, 1992, NEISS SAMPL DES IMPL; FRANKEL LR, 1982, DEFINITION RESPONSE; HELLER D, 1993, HAZARD, V10, P11; *INT INL SKAT ASS, 1992, GUID EST INL SKAT TR; *NAT EL INJ SURV S, 1996, CONS PROD SAF COMM; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Shah BV, 1996, SUDAAN USERS MANUAL; *SHUG RES, 1992, INL SKAT FOC GROUP S; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; ULLIS K, 1979, NEW ENGL J MED, V301, P1350; 1995, MMWR-MORBID MORTAL W, V44, P1	17	117	118	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 28	1996	335	22					1630	1635		10.1056/NEJM199611283352202	http://dx.doi.org/10.1056/NEJM199611283352202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV936	8929359	Bronze			2022-12-28	WOS:A1996VV93600002
J	Appleby, J				Appleby, J			Promoting efficiency in the NHS: Problems with the labour productivity index	BRITISH MEDICAL JOURNAL			English	Article											Appleby, J (corresponding author), UNIV E ANGLIA,SCH HLTH POLICY & PRACTICE,NORWICH NR4 7TJ,NORFOLK,ENGLAND.							Appleby J, 1993, Health Serv J, V103, P20; Appleby J, 1993, Health Serv J, V103, P22; CLARKE A, 1993, BRIT MED J, V307, P1436, DOI 10.1136/bmj.307.6917.1436; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; *NHSE, 1995, LAB PROD IND TABL	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1319	1321						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV153	8942695				2022-12-28	WOS:A1996VV15300029
J	deAndrade, ALSS; Zicker, F; deOliveira, RM; Silva, SAE; Luquetti, A; Travassos, LR; Almeida, IC; deAndrade, SS; deAndrade, JG; Martelli, CMT				deAndrade, ALSS; Zicker, F; deOliveira, RM; Silva, SAE; Luquetti, A; Travassos, LR; Almeida, IC; deAndrade, SS; deAndrade, JG; Martelli, CMT			Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection	LANCET			English	Article							ALPHA-GALACTOSYL ANTIBODIES; CHAGAS-DISEASE; CHEMOTHERAPY; DIAGNOSIS; SEROLOGY; ANTIGENS; BRAZIL	Background Benznidazole, a nitroimidazole derivative, has been recommended for the treatment of acute and congenital Trypanosoma cruzi infection (Chagas' disease). We have examined the safety and efficacy of this drug in the treatment of the early chronic phase of T cruzi infection. Methods Between 1991 and 1995, we carried out a randomised, double-blind, placebo-controlled trial in a rural area of Brazil with endemic Chagas' disease. 82% of 2434 schoolchildren (aged 7-12 years) identified in a census were screened for antibodies to T cruzi by indirect immunofluorescence, indirect haemagglutination, and ELISA. 130 were positive in all tests and were randomly assigned benznidazole (7.5 mg/kg daily for 60 days by mouth) or placebo. The primary endpoint for efficacy was the disappearance of specific antibodies (negative seroconversion) by the end of 3-year follow-up. The secondary endpoint was the reduction of antibody titres on repeated serological tests. One child moved away from the area just after randomisation and was excluded from the analyses. Insecticidal measures were taken throughout the trial to reduce the risk of reinfection. Findings Minor side-effects requiring no specific medication were recorded in a small proportion of individuals. On a chemiluminescent ELISA with purified trypomastigote glycoconjugate, serum from all participants was positive at the beginning of the trial. At the end of follow-up, 37 (58%) of the 64 benznidazole-treated participants and 3 (5%) of those who received placebo were negative for T cruzi antibodies. The efficacy of benznidazole treatment estimated by intention to treat was 55.8% (95% CI 40.8-67.0). At the end of follow-up, children who received benznidazole had five-fold lower geometric mean titres by indirect immunofluorescence than placebo-treated children (196 [147-256] vs 1068 [809-1408], p<0.00001). Interpretation The trial showed that a 60-day course of benznidazole treatment of early chronic T cruzi infection was safe and 55.8% effective in producing negative seroconversion of specific antibodies. The results are very encouraging and justify the recommendation of treatment for seropositive children as public health policy.	UNIV FED GOIAS,INST PATOL TROP & SAUDE PUBL,DEPT COMMUNITY HLTH,GOIANIA,GO,BRAZIL; UNIV FED GOIAS,INST PATOL TROP & SAUDE PUBL,DEPT PARASITOL,GOIANIA,GO,BRAZIL; UNIV FED GOIAS,INST PATOL TROP & SAUDE PUBL,DEPT TROP MED,GOIANIA,GO,BRAZIL; WHO,PAN AMER HLTH ORG,COMMUNICABLE DIS PROGRAM,WASHINGTON,DC; UNIV FED SAO PAULO,DEPT MICROBIOL IMMUNOL & PARASITOL,SAO PAULO,BRAZIL	Universidade Federal de Goias; Universidade Federal de Goias; Universidade Federal de Goias; Pan American Health Organization; World Health Organization; Universidade Federal de Sao Paulo (UNIFESP)			Zicker, Fabio/I-4138-2012; Travassos, Luiz/V-2467-2019; Travassos, Luiz R/J-3631-2012; Almeida, Igor C./AAF-9409-2019; Ostermayer, Alejandro Luquetti/AAC-6385-2021	Zicker, Fabio/0000-0002-9751-7430; Almeida, Igor C./0000-0002-2443-8213; Ostermayer, Alejandro Luquetti/0000-0003-0335-0877; Turchi Martelli, Celina Maria/0000-0002-2491-0688				ALMEIDA IC, 1991, J IMMUNOL, V146, P2394; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; ALMEIDA IC, 1994, J CLIN LAB ANAL, V8, P424, DOI 10.1002/jcla.1860080614; ALMEIDA IC, 1995, MEM I O CRUZ, V90, P72; ANDRADE ALS, 1995, AM J TROP MED HYG, V92, P183; ANDRADE ALS, 1992, B WORLD HEALTH ORGAN, V70, P625; Andrade Ana Lucia S. Sgambatti De, 1995, American Journal of Tropical Medicine and Hygiene, V53, P443; ANDRADE SG, 1991, B WORLD HEALTH ORGAN, V69, P191; [Anonymous], [No title captured]; BRITTO C, 1995, PARASITOLOGY, V110, P241, DOI 10.1017/S0031182000080823; CAMARGO ME, 1984, REV I MED TROP, V26, P192, DOI 10.1590/S0036-46651984000400003; CERISOLA J A, 1970, Revista do Instituto de Medicina Tropical de Sao Paulo, V12, P403; Chiari E., 1992, CHAGAS DIS AM TRYPAN, P153; DIAS JCP, 1991, ANN SOC BELG MED TR, V71, P75; Ferreira H. O., 1990, Revista da Sociedade Brasileira de Medicina Tropical, V23, P209, DOI 10.1590/S0037-86821990000400005; Fragata Filho AA, 1994, REV SOC CARDIOL ESTA, V4, P192; GALVAO LMC, 1993, T ROY SOC TROP MED H, V87, P220, DOI 10.1016/0035-9203(93)90501-G; GAZINELLI RT, 1993, AM J TROP MED HYG, V49, P625; Krettli A. U., 1984, Memorias do Instituto Oswaldo Cruz, V79, P157, DOI 10.1590/S0074-02761984000500027; KRETTLI AU, 1982, T ROY SOC TROP MED H, V76, P334, DOI 10.1016/0035-9203(82)90184-5; LUQUETTI AO, 1990, MEM I OSWALDO CRUZ, V85, P497, DOI 10.1590/S0074-02761990000400021; Rassi A, 1992, CHAGAS DIS AM TYP IT, P237; REED GF, 1995, PEDIATRICS, V96, P600; SMITH PG, 1987, INT J EPIDEMIOL, V16, P159, DOI 10.1093/ije/16.2.159; Smith PG, 1992, METHODS FIELD TRIALS; *UNDP WORLD BANK W, 1995, 12 UNDP WHO WORLD BA, P125; VOLLER A, 1975, LANCET, V1, P426; *WHO, 1991, WHO TECHN REP SERS, V811; Zaidenberg Mario, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P35, DOI 10.1590/S0036-46651993000100006; ZICKER F, 1990, AM J TROP MED HYG, V43, P498, DOI 10.4269/ajtmh.1990.43.498	30	333	348	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1407	1413						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937280				2022-12-28	WOS:A1996VU98600011
J	Fafard, S; Hinzer, K; Raymond, S; Dion, M; McCaffrey, J; Feng, Y; Charbonneau, S				Fafard, S; Hinzer, K; Raymond, S; Dion, M; McCaffrey, J; Feng, Y; Charbonneau, S			Red-emitting semiconductor quantum dot lasers	SCIENCE			English	Article							SELF-ORGANIZED GROWTH; RADIATIVE RECOMBINATION; VISIBLE LUMINESCENCE; OPTICAL-PROPERTIES; GAAS; PHOTOLUMINESCENCE; RELAXATION; INGAAS; ENSEMBLES; EPITAXY	Visible-stimulated emission in a semiconductor quantum dot (QD) laser structure has been demonstrated. Red-emitting, self-assembled QDs of highly strained InAlAs have been grown by molecular beam epitaxy on a GaAs substrate. Carriers injected electrically from the doped regions of a separate confinement heterostructure thermalized efficiently into the zero-dimensional QD states, and stimulated emission at similar to 707 nanometers was observed at 77 kelvin with a threshold current of 175 milliamperes for a 60-micrometer by 400-micrometer broad area laser. An external efficiency of similar to 8.5 percent at low temperature and a peak power greater than 200 milliwatts demonstrate the good size distribution and high gain in these high-quality QDs.			Fafard, S (corresponding author), NATL RES COUNCIL CANADA,INST MICROSTRUCT SCI,OTTAWA,ON K1A 0R6,CANADA.							Alferov ZI, 1996, SEMICONDUCTORS+, V30, P194; BOCKELMANN U, 1993, PHYS REV B, V48, P17637, DOI 10.1103/PhysRevB.48.17637; BOCKELMANN U, 1992, PHYS REV B, V46, P15574, DOI 10.1103/PhysRevB.46.15574; BOCKELMANN U, 1990, PHYS REV B, V42, P8947, DOI 10.1103/PhysRevB.42.8947; DREXLER H, 1994, PHYS REV LETT, V73, P2252, DOI 10.1103/PhysRevLett.73.2252; FAFARD S, 1994, PHYS REV B, V50, P8086, DOI 10.1103/PhysRevB.50.8086; Fafard S, 1996, SURF SCI, V361, P778, DOI 10.1016/0039-6028(96)00532-8; FAFARD S, 1994, APPL PHYS LETT, V65, P1388, DOI 10.1063/1.112060; Fafard S, 1996, APPL PHYS LETT, V68, P991, DOI 10.1063/1.116122; FAFARD S, 1994, SUPERLATTICE MICROST, V16, P303, DOI 10.1016/S0749-6036(09)80020-7; FAFARD S, 1995, PHYS REV B, V52, P5752; GRUNDMANN M, 1995, PHYS REV LETT, V74, P4043, DOI 10.1103/PhysRevLett.74.4043; GRUNDMANN M, 1995, PHYS STATUS SOLIDI B, V188, P249, DOI 10.1002/pssb.2221880122; Grundmann M, 1996, APPL PHYS LETT, V68, P979, DOI 10.1063/1.116118; HECHT J, 1993, LASER FOCUS WORLD, V29, P83; Heitz R, 1996, APPL PHYS LETT, V68, P361, DOI 10.1063/1.116716; IMAMURA K, 1995, JPN J APPL PHYS A, V11, pL1445; Kamath K, 1996, ELECTRON LETT, V32, P1374, DOI 10.1049/el:19960921; KIRSTAEDTER N, 1994, ELECTRON LETT, V30, P1416, DOI 10.1049/el:19940939; LEON R, 1995, SCIENCE, V267, P1966, DOI 10.1126/science.267.5206.1966; LEON R, 1995, APPL PHYS LETT, V67, P521, DOI 10.1063/1.115175; LEONARD D, 1994, PHYS REV B, V50, P11687, DOI 10.1103/PhysRevB.50.11687; LEONARD D, 1994, J VAC SCI TECHNOL B, V12, P1063, DOI 10.1116/1.587088; LEONARD D, 1994, J VAC SCI TECHNOL B, V12, P2516, DOI 10.1116/1.587794; MARZIN JY, 1994, PHYS REV LETT, V73, P716, DOI 10.1103/PhysRevLett.73.716; MEHUYS D, 1995, LASER FOCUS WORLD, V31, P117; MOISON JM, 1994, APPL PHYS LETT, V64, P196, DOI 10.1063/1.111502; NOTZEL R, 1995, APPL PHYS LETT, V66, P2525, DOI 10.1063/1.113155; Raymond S, 1995, PHYS REV B, V52, P17238, DOI 10.1103/PhysRevB.52.17238; Raymond S, 1996, PHYS REV B, V54, P11548, DOI 10.1103/PhysRevB.54.11548; Schmidt OG, 1996, ELECTRON LETT, V32, P1302, DOI 10.1049/el:19960851; Shoji H, 1995, IEEE PHOTONIC TECH L, V7, P1385, DOI 10.1109/68.477257; Shoji H, 1996, JPN J APPL PHYS 2, V35, pL903, DOI 10.1143/JJAP.35.L903; STRASS A, 1994, LASER FOCUS WORLD, V30, P79; Tersoff J, 1996, PHYS REV LETT, V76, P1675, DOI 10.1103/PhysRevLett.76.1675; Xie Q, 1996, IEEE PHOTONIC TECH L, V8, P965, DOI 10.1109/68.508705	36	260	263	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1350	1353		10.1126/science.274.5291.1350	http://dx.doi.org/10.1126/science.274.5291.1350			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910269				2022-12-28	WOS:A1996VU95400045
J	Blondel, M; Mann, C				Blondel, M; Mann, C			G2 cyclins are required for the degradation of G1 cyclins in yeast	NATURE			English	Article							UBIQUITIN-CONJUGATING ENZYME; B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; BUDDING YEAST; S-PHASE; PROTEOLYSIS; INHIBITOR; TURNOVER	PROGRESSION Of the eukaryotic cell cycle is controlled by cyclin-dependent kinases (CDKs)(1). Cdc28, the budding yeast homologue of Cdc2 (Cdk1), is required for both the G1/S and G2/M transitions of the cell cycle(2), The functional specificity of the Cdc28 kinase is determined by its association with G1 or G2 cyclins. Alternation of cell cycle phases is thus mainly due to mechanisms that ensure that one cyclin family succeeds another, Here we show that the G2 cyclins Clb1, Clb2, Clb3 and Clb4 are required for the proteolysis of the G1 cyclins Cln1 and Cln2, providing a mechanism for coupling synthesis of G2 cyclins with the disappearance of G1 cyclins. Our data indicate that this pathway involves the Ubc9 ubiquitin-conjugating enzyme(3). The Cdc34 ubiquitin-conjugating activity(4) may function redundantly with Ubc9, or it may only be involved in Cln1,2 turnover through its role in promoting the degradation of Sic1, a specific inhibitor of Cdc28-Clb complexes(5).	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay			Blondel, Marc/AAJ-9049-2020	Blondel, Marc/0000-0003-4897-2995; Mann, Carl/0000-0001-7212-1512				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Koch C, 1996, GENE DEV, V10, P129, DOI 10.1101/gad.10.2.129; KUHNE C, 1993, EMBO J, V12, P3437, DOI 10.1002/j.1460-2075.1993.tb06018.x; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	29	35	37	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 21	1996	384	6606					279	282		10.1038/384279a0	http://dx.doi.org/10.1038/384279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU381	8918881				2022-12-28	WOS:A1996VU38100056
J	Modan, B				Modan, B			Carrying a genetic passport for ovarian	LANCET			English	Editorial Material							RISK				Modan, B (corresponding author), TEL AVIV UNIV,STANLEY STEYER INST,CHAIM SHEBA MED CTR,IL-52621 TEL HASHOMER,ISRAEL.							COLLINS F, 1996, J CLIN ONCOL, V14, P1730; JOHNSON BB, 1995, RISK ANAL, V15, P485, DOI 10.1111/j.1539-6924.1995.tb00341.x; MODAN B, 1984, PUBLIC HEALTH REP, V99, P228; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; SLOVIC P, 1986, RISK ANAL, V6, P403, DOI 10.1111/j.1539-6924.1986.tb00953.x; 1996, J CLIN ONCOL, V14, P1730	7	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 16	1996	348	9038					1328	1328		10.1016/S0140-6736(05)65406-2	http://dx.doi.org/10.1016/S0140-6736(05)65406-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VT332	8918274				2022-12-28	WOS:A1996VT33200007
J	Sepkowitz, KA				Sepkowitz, KA			Occupationally acquired infections in health care workers .1.	ANNALS OF INTERNAL MEDICINE			English	Review							RESPIRATORY SYNCYTIAL VIRUS; VARICELLA-ZOSTER VIRUS; HUMAN PARVOVIRUS-B19 INFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS; NOSOCOMIAL VIRAL-INFECTIONS; MEDICAL TECHNOLOGY STUDENTS; HOSPITAL STAFF MEMBERS; NEW-YORK-CITY; UNITED-STATES; ERYTHEMA-INFECTIOSUM	Background: Health care workers are at occupational risk for a vast array of infections that cause substantial illness and occasional deaths. Despite this, few studies have examined the incidence, prevalence, or exposure-associated rates of infection or have considered infection-specific interventions recommended to maintain worker safety. Objectives: To review all recent reports of occupationally acquired infection in health care workers in order to characterize the type and frequency of infections, the recommended interventions, and the costs of protecting workers. Part I of this two-part review focuses on the historical a-nd ethical aspects of the problem and reviews data on infections caused by specific airborne organisms. Data Sources: A MEDLINE search and examination of infectious disease and infection control journals. Data Selection: All English-language articles and meeting abstracts published between January 1983 and February 1996 related to occupationally acquired infections among health care workers were reviewed. Outbreak- and non-outbreak-associated incidence and prevalence rates were derived, as were costs to prevent, control, and treat infections in health care workers. Data Synthesis: More than 15 airborne infections have been transmitted to health care workers, including tuberculosis, varicella, measles, influenza, and respiratory syncytial virus infection. Outbreak-associated attack rates range from 15% to 40%. Most occupational transmission is associated with violation of one or more of three basic principles of infection control: handwashing, vaccination of health care workers, and prompt placement of infectious patients into appropriate isolation. Conclusions: The risk for occupationally acquired infection is an unavoidable part of daily patient care. Infections that result from airborne transmission of organisms cause substantial illness and occasional deaths among health care workers. Further studies are needed to identify new infection control strategies to 1) improve protection of health care workers and 2) enhance compliance with established approaches. As health care is being reformed, the risk for and cost of occupationally acquired infection must be considered.	CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital	Sepkowitz, KA (corresponding author), MEM SLOAN KETTERING CANC CTR, INFECT DIS SERV, 1275 YORK AVE, BOX 288, NEW YORK, NY 10021 USA.							ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; ADLER SP, 1993, J INFECT DIS, V168, P361, DOI 10.1093/infdis/168.2.361; *ADV COMM IMMM PRA, 1996, MMWR-MORBID MORTAL W, V45, P13; ALTER SJ, 1986, INFECT CONT HOSP EP, V7, P448, DOI 10.1017/S0195941700064936; AMMARI LK, 1993, INFECT CONT HOSP EP, V14, P81, DOI 10.2307/30147165; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; AOUN H, 1989, NEW ENGL J MED, V321, P693, DOI 10.1056/NEJM198909073211020; AOUN H, 1992, ANN INTERN MED, V116, P335, DOI 10.7326/0003-4819-116-4-335; ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; ATKINSON WL, 1994, INFECT CONT HOSP EP, V15, P5; BAILEY TC, 1995, ANN INTERN MED, V122, P580, DOI 10.7326/0003-4819-122-8-199504150-00004; BALKOVIC ES, 1980, AM J MED TECHNOL, V46, P318; BARNARD DL, 1973, BRIT MED J, V2, P165, DOI 10.1136/bmj.2.5859.165; Barry SC, 1916, AM J NURS, V16, P687, DOI 10.2307/3405249; BASS JW, 1987, PEDIATR INFECT DIS J, V6, P141, DOI 10.1097/00006454-198702000-00001; BASSETT DCJ, 1993, J HOSP INFECT, V23, P161, DOI 10.1016/0195-6701(93)90020-Z; BEAN B, 1983, DIAGN MICR INFEC DIS, V1, P177, DOI 10.1016/0732-8893(83)90016-0; BELL LM, 1989, NEW ENGL J MED, V321, P485, DOI 10.1056/NEJM198908243210801; BERLINBERG CD, 1989, INFECT CONT HOSP EP, V10, P70; BERMAN J, 1981, AM J PUBLIC HEALTH, V71, P1217, DOI 10.2105/AJPH.71.11.1217; Black P M, 1989, Clin Neurosurg, V35, P487; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; BLUMENFELD HL, 1959, J CLIN INVEST, V38, P199, DOI 10.1172/JCI103789; BOGER WP, 1962, AM J PUBLIC HEALTH N, V52, P834, DOI 10.2105/AJPH.52.5.834; BOWDEN KM, 1994, J OCCUP ENVIRON MED, V36, P320, DOI 10.1097/00043764-199403000-00009; BREESE C, 1975, NEW ENGL J MED, V293, P1343, DOI 10.1056/NEJM197512252932604; BREUER J, 1990, J HOSP INFECT, V16, P191, DOI 10.1016/0195-6701(90)90109-2; BREWER TF, 1995, CLIN INFECT DIS, V20, P136, DOI 10.1093/clinids/20.1.136; BRISS PA, 1994, J INFECT DIS, V169, P77, DOI 10.1093/infdis/169.1.77; BROWN MP, 1979, AM J PUBLIC HEALTH, V69, P1040, DOI 10.2105/AJPH.69.10.1040; BRUMMITT CF, 1988, J INFECT DIS, V158, P423, DOI 10.1093/infdis/158.2.423; BRUNELL PA, 1968, NEW ENGL J MED, V279, P1357, DOI 10.1056/NEJM196812192792502; BUFFINGTON J, 1993, J AM GERIATR SOC, V41, P1177, DOI 10.1111/j.1532-5415.1993.tb07299.x; CARTTER ML, 1991, J INFECT DIS, V163, P282, DOI 10.1093/infdis/163.2.282; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; CHORBA T, 1986, J INFECT DIS, V154, P383, DOI 10.1093/infdis/154.3.383; CHRISTIE CDC, 1994, NEW ENGL J MED, V331, P16, DOI 10.1056/NEJM199407073310104; CLEVER LH, 1995, ANNU REV PUBL HEALTH, V16, P141; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Collins C. H., 1988, LAB ACQUIRED INFECT; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295; DIEKEMA DJ, 1995, INFECT CONT HOSP EP, V16, P292; DiPersio JR, 1996, CLIN INFECT DIS, V22, P490, DOI 10.1093/clinids/22.3.490; DOWELL SF, 1995, J INFECT DIS, V172, P1076, DOI 10.1093/infdis/172.4.1076; EICKHOFF TC, 1994, ANN INTERN MED, V120, P310; EMANUEL EJ, 1988, NEW ENGL J MED, V318, P1686, DOI 10.1056/NEJM198806233182511; FAOAGALI JL, 1995, AM J INFECT CONTROL, V23, P247, DOI 10.1016/0196-6553(95)90069-1; FARIZO KM, 1991, PEDIATRICS, V87, P74; Federal Bureau of Investigation, 1995, UN CRIM REP US 1994; Fischer PR, 1996, AM J INFECT CONTROL, V24, P13, DOI 10.1016/S0196-6553(96)90048-6; FOSTER DR, 1994, BRIT J RADIOL, V67, P599, DOI 10.1259/0007-1285-67-798-599; FOULON G, 1986, JAMA-J AM MED ASSOC, V256, P1135, DOI 10.1001/jama.256.9.1135; FREEBECK PC, 1992, CHEST, V102, P625, DOI 10.1378/chest.102.2.625; FRIEDLANDER WJ, 1990, REV INFECT DIS, V12, P191; GALA CL, 1986, JAMA-J AM MED ASSOC, V256, P2706; Garner JS, 1996, AM J INFECT CONTROL, V24, P24; GERBERDING JL, 1987, J INFECT DIS, V156, P1, DOI 10.1093/infdis/156.1.1; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; GERTH HJ, 1987, EPIDEMIOL INFECT, V98, P47, DOI 10.1017/S0950268800061707; GERTH HJ, 1987, EPIDEMIOL INFECT, V98, P33, DOI 10.1017/S0950268800061690; GESTAL JJ, 1987, BRIT J IND MED, V44, P435; GILLESPIE SM, 1990, JAMA-J AM MED ASSOC, V263, P2061, DOI 10.1001/jama.263.15.2061; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; GOODALL JWD, 1952, LANCET, V262, P807; GOODMAN RA, 1991, JAMA-J AM MED ASSOC, V265, P2377, DOI 10.1001/jama.265.18.2377; GORDON JE, 1962, AM J MED SCI, V244, P362, DOI 10.1097/00000441-196209000-00013; GREAVES WL, 1982, JAMA-J AM MED ASSOC, V248, P861, DOI 10.1001/jama.248.7.861; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; GRIFFITH DE, 1995, AM J RESP CRIT CARE, V152, P808, DOI 10.1164/ajrccm.152.2.7633747; GROEN J, 1995, EPIDEMIOL INFECT, V114, P373, DOI 10.1017/S0950268800058003; GUREVICH I, 1990, INFECT CONT HOSP EP, V11, P510; GUSTAFSON TL, 1982, PEDIATRICS, V70, P550; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463, DOI 10.7326/0003-4819-88-4-463; Ha K G, 1991, Tex Med, V87, P76; HAIDUVEN DJ, 1994, INFECT CONT HOSP EP, V15, P329; HALEVY A, 1994, AM J MED, V96, P282, DOI 10.1016/0002-9343(94)90154-6; HALL CB, 1978, PEDIATRICS, V62, P728; HALL CB, 1981, AM J DIS CHILD, V135, P512, DOI 10.1001/archpedi.1981.02130300012006; HAMMOND GW, 1984, CAN MED ASSOC J, V131, P449; HARNISCH JP, 1989, ANN INTERN MED, V111, P71, DOI 10.7326/0003-4819-111-1-71; HARRIS RW, 1969, AM J EPIDEMIOL, V89, P264, DOI 10.1093/oxfordjournals.aje.a120939; HARRISON J, 1995, OCCUP MED-OXFORD, V45, P93, DOI 10.1093/occmed/45.2.93; HASTIE IR, 1980, LANCET, V2, P154; HEIMBERGER T, 1995, INFECT CONT HOSP EP, V16, P412; HENDLEY JO, 1973, NEW ENGL J MED, V288, P1361, DOI 10.1056/NEJM197306282882601; Hoffmann K K, 1991, AAOHN J, V39, P167; Holzman RS, 1995, CLIN INFECT DIS, V21, P733; HOPESIMPSON RE, 1952, LANCET, V2, P549, DOI DOI 10.1016/S0140-6736(52)91357-3; HUANG KG, 1994, INFECT CONT HOSP EP, V15, P4; HYAMS PJ, 1984, AM J INFECT CONTROL, V12, P2, DOI 10.1016/0196-6553(84)90064-6; Imperato P J, 1989, J Community Health, V14, P191, DOI 10.1007/BF01338870; ISAACS D, 1991, ARCH DIS CHILD, V66, P227, DOI 10.1136/adc.66.2.227; ISTRE GR, 1987, PEDIATRICS, V79, P356; JEFFRIES DJ, 1995, J HOSP INFECT, V30, P140, DOI 10.1016/0195-6701(95)90014-4; JEREB JA, 1995, ARCH INTERN MED, V155, P854, DOI 10.1001/archinte.155.8.854; JOHNSTON JM, 1986, INFECT CONT HOSP EP, V7, P172, DOI 10.1017/S019594170006402X; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KIM JH, 1988, AM J MED, V84, P135, DOI 10.1016/0002-9343(88)90021-6; KIM M, 1992, INFECT CONT HOSP EP, V13, P399, DOI 10.1086/646557; KLEEMOLA M, 1992, J HOSP INFECT, V21, P213, DOI 10.1016/0195-6701(92)90078-Z; KLEIN WA, 1991, B NEW YORK ACAD MED, V67, P439; KOENIG S, 1995, AM J INFECT CONTROL, V23, P40, DOI 10.1016/0196-6553(95)90007-1; KOZIOL DE, 1992, INFECT CONT HOSP EP, V13, P343, DOI 10.1086/646542; KRASINSKI K, 1986, INFECT CONT HOSP EP, V7, P312, DOI 10.1017/S019594170006433X; KUHLS TL, 1987, AM J PUBLIC HEALTH, V77, P1306, DOI 10.2105/AJPH.77.10.1306; LECLAIR JM, 1980, NEW ENGL J MED, V302, P450, DOI 10.1056/NEJM198002213020807; LECLAIR JM, 1987, NEW ENGL J MED, V317, P329, DOI 10.1056/NEJM198708063170601; LEVANDOWSKI RA, 1981, J INFECT DIS, V143, P28, DOI 10.1093/infdis/143.1.28; Lohiya GS, 1995, AM J INFECT CONTROL, V23, P373, DOI 10.1016/0196-6553(95)90269-4; LOUTHER J, 1995, 35 INT C ANT AG CHEM, P276; MADGE P, 1992, LANCET, V340, P1079, DOI 10.1016/0140-6736(92)93088-5; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MARKOWITZ SB, 1994, OCCUP MED, V9, P589; MARRIE TJ, 1986, AM J INFECT CONTROL, V14, P209, DOI 10.1016/0196-6553(86)90119-7; MAST EE, 1993, HEPATITIS B VACCINES, P295; MATSON DO, 1993, PEDIATR INFECT DIS J, V12, P292, DOI 10.1097/00006454-199304000-00007; Mattson EF, 1941, AM J NURS, V41, pA27; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; MILLER PJ, 1985, PEDIATRICS, V75, P989; MOORE RM, 1990, AM J INFECT CONTROL, V18, P316, DOI 10.1016/0196-6553(90)90231-G; MUCHMORE H G, 1960, J Okla State Med Assoc, V53, P142; MURPHY D, 1981, J PEDIATR-US, V99, P746, DOI 10.1016/S0022-3476(81)80401-5; *NAT FIR PROT ASS, LESS 100 US FIR FAT; Neidle E A, 1994, J Am Coll Dent, V61, P12; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; NICHOL KL, 1993, ARCH INTERN MED, V153, P1913, DOI 10.1001/archinte.153.16.1913; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; OMENN GS, 1984, AM J IND MED, V6, P129, DOI 10.1002/ajim.4700060207; PACHUCKI CT, 1989, ARCH INTERN MED, V149, P77, DOI 10.1001/archinte.149.1.77; PATTERSON WB, 1985, ANN INTERN MED, V102, P658, DOI 10.7326/0003-4819-102-5-658; PELLEGRINO ED, 1989, J LEGAL MED, V10, P29, DOI 10.1080/01947648909513559; PICKERING LK, 1990, JAMA-J AM MED ASSOC, V263, P2096, DOI 10.1001/jama.263.15.2096; PILLAY D, 1992, LANCET, V339, P107, DOI 10.1016/0140-6736(92)91009-W; POLAND GA, 1990, ARCH INTERN MED, V150, P44, DOI 10.1001/archinte.150.1.44; POLK BF, 1980, NEW ENGL J MED, V303, P541, DOI 10.1056/NEJM198009043031001; PORTER JD, 1981, J HOSP INFECT, V18, P201; PREBLUD SR, 1988, AM J PUBLIC HEALTH, V78, P13, DOI 10.2105/AJPH.78.1.13; PUGLIESE G, 1995, INFECT CONT HOSP EP, V16, P555, DOI 10.1017/S0195941700008109; RAAD II, 1989, INFECT CONT HOSP EP, V10, P161, DOI 10.2307/30144322; Reed Elizabeth, 1993, Journal of Emergency Medicine, V11, P9, DOI 10.1016/0736-4679(93)90003-P; REGAN WA, 1978, RN, V41, P27; RESNIC FS, 1995, ARCH INTERN MED, V155, P75, DOI 10.1001/archinte.155.1.75; Richardson DL, 1915, AM J NURS, V15, P1082, DOI 10.2307/3405284; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; ROSENBLUM LS, 1994, ANN INTERN MED, V121, P786, DOI 10.7326/0003-4819-121-10-199411150-00009; RUNNELLS R, 1994, CDS REV, P31; RUUSKANEN O, 1995, J HOSP INFECT, V30, P494, DOI 10.1016/0195-6701(95)90053-5; SCHWARCZ S, 1992, ARCH INTERN MED, V152, P1481, DOI 10.1001/archinte.152.7.1481; SCHWARTZMAN K, 1994, AM J RESP CRIT CARE, V149, pA853; SENG C, 1994, EPIDEMIOL INFECT, V113, P345, DOI 10.1017/S0950268800051773; SEPKOWITZ KA, 1995, INFECT CONT HOSP EP, V16, P344; SEPKOWITZ KA, 1995, CLIN INFECT DIS, V20, P232, DOI 10.1093/clinids/20.2.232; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SHANKS NJ, 1995, J HOSP INFECT, V29, P221, DOI 10.1016/0195-6701(95)90332-1; SHAPIRO CN, 1995, SURG CLIN N AM, V75, P1047; SHEFER A, 1995, J INFECT DIS, V171, P1053, DOI 10.1093/infdis/171.4.1053; SHERETZ RJ, 1993, PREVENTION CONTROL N, P295; SHISHIBA T, 1993, J AM ACAD DERMATOL, V29, P265, DOI 10.1016/S0190-9622(08)81846-4; SIENKO DG, 1987, AM J PUBLIC HEALTH, V77, P1222, DOI 10.2105/AJPH.77.9.1222; SINGHNAZ N, 1993, PEDIATR INFECT DIS J, V12, P922, DOI 10.1097/00006454-199311000-00006; SINGHNAZ N, 1990, PEDIATR INFECT DIS J, V9, P31, DOI 10.1097/00006454-199001000-00007; SNIDER DE, 1984, AM J INFECT CONTROL, V12, P305, DOI 10.1016/0196-6553(84)90001-4; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; STORCH GA, 1985, INFECT CONT HOSP EP, V6, P150, DOI 10.1017/S0195941700062950; STOVER BH, 1994, INFECT CONT HOSP EP, V15, P18; STRASSBURG MA, 1981, OBSTET GYNECOL, V57, P283; STRASSBURG MA, 1984, INFECT CONT HOSP EP, V5, P123, DOI 10.1017/S019594170005997X; TAN CC, 1991, SCAND J WORK ENV HEA, V17, P221, DOI 10.5271/sjweh.1709; TEMPLETON GL, 1995, ANN INTERN MED, V122, P922, DOI 10.7326/0003-4819-122-12-199506150-00005; Thomson FH, 1916, LANCET, V1, P341; Thomson FH, 1914, LANCET, V1, P1669; VALENTI WM, 1980, INFECT CONT HOSP EP, V1, P33, DOI 10.1017/S0195941700052371; VALENTI WM, 1995, AM J INFECT CONTROL, V23, P78, DOI 10.1016/0196-6553(95)90098-5; VALENTI WM, 1981, INFECT CONT HOSP EP, V2, P38, DOI 10.1017/S0195941700053728; VALENTI WM, 1980, INFECT CONT HOSP EP, V1, P165, DOI 10.1017/S0195941700052899; VALENTI WM, 1992, HOSP INFECT, P789; VANVORIS LP, 1982, ANN INTERN MED, V96, P153, DOI 10.7326/0003-4819-96-2-153; VENKITARAMAN AR, 1982, LANCET, V2, P165; Vitek CR, 1996, CLIN INFECT DIS, V22, P824, DOI 10.1093/clinids/22.5.824; WARREN D, 1989, J INFECT DIS, V160, P938, DOI 10.1093/infdis/160.6.938; WATKINS NM, 1987, AM J INFECT CONTROL, V15, P201, DOI 10.1016/0196-6553(87)90096-4; Weaver GH, 1918, AM J NURS, V18, P769, DOI 10.2307/3405652; WEBER DJ, 1988, AM J PUBLIC HEALTH, V78, P19, DOI 10.2105/AJPH.78.1.19; WEBER DJ, 1994, INFECT CONT HOSP EP, V15, P411; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; Wells WF, 1942, AM J HYG, V35, P97, DOI 10.1093/oxfordjournals.aje.a118789; WENZEL RP, 1977, PEDIATRICS, V60, P367; WHARTON M, 1990, ARCH INTERN MED, V150, P47, DOI 10.1001/archinte.150.1.47; WHITE CB, 1994, PEDIATR INFECT DIS J, V13, P743, DOI 10.1097/00006454-199408000-00014; WILLIAMS WW, 1984, AM J INFECT CONTROL, V12, P34, DOI 10.1016/0196-6553(84)90071-3; WILLY ME, 1994, INFECT CONT HOSP EP, V15, P12; WOERNLE CH, 1987, J INFECT DIS, V156, P17, DOI 10.1093/infdis/156.1.17; Wright HD, 1941, J PATHOL BACTERIOL, V52, P111; WRIGHT LJ, 1994, INFECT CONT HOSP EP, V15, P8; YANNELLI B, 1990, AM J INFECT CONTROL, V18, P93, DOI 10.1016/0196-6553(90)90088-A; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1990, MMWR-MORBID MORTAL W, V39, P598; 1951, BRIT MED J, V1, P288; 1995, HIV AIDS SURVEILLANC, V7, P21; 1996, MMWR-MORBID MORTAL W, V45, P365; 1995, MMWR-MORBID MORTAL W, V43, P1; 1981, MMWR-MORBID MORTAL W, V29, P629	202	96	98	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					826	834		10.7326/0003-4819-125-10-199611150-00007	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU524	8928990				2022-12-28	WOS:A1996VU52400010
J	Wang, HG; Rapp, UR; Reed, JC				Wang, HG; Rapp, UR; Reed, JC			Bcl-2 targets the protein kinase Raf-1 to mitochondria	CELL			English	Article							CONSERVED DOMAINS; PLASMA-MEMBRANE; CELL-DEATH; APOPTOSIS; RAS; ONCOPROTEIN; INHIBITION; GROWTH; IDENTIFICATION; REQUIREMENT	A green fluorescent protein (GFP)-Raf-1 fusion protein was used to show that Bcl-2 can target this kinase to mitochondria. Active Raf-1 fused with targeting sequences from an outer mitochondrial membrane protein protected cells from apoptosis and resulted in phosphorylation of BAD, a proapoptotic Bcl-2 homolog. Plasma membrane-targeted Raf-1 did not protect from apoptosis and resulted in phosphorylation of ERK-1 and ERK-5. Untargeted active Raf-1 improved Bcl-2-mediated resistance to apoptosis, whereas a kinase-inactive Raf-1 mutant abrogated apoptosis suppression by Bcl-2. Bcl-2 can therefore target Raf-1 to mitochondrial membranes, allowing this kinase to phosphorylate BAD or possibly other protein substrates involved in apoptosis regulation.	UNIV WURZBURG,INST MED RADIAT & CELL RES,D-097078 WURZBURG,GERMANY	University of Wurzburg	Wang, HG (corresponding author), BURNHAM INST,PROGRAM APOPTOSIS & CELL DEATH RES,LA JOLLA,CA 92037, USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA-67329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOULAKIA CA, 1996, ONCOGENE, V12, P29; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIETENPOL JA, 1994, CANCER RES, V54, P3714; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	696	718	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					629	638		10.1016/S0092-8674(00)81383-5	http://dx.doi.org/10.1016/S0092-8674(00)81383-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929532	Bronze			2022-12-28	WOS:A1996VU03500006
J	Horrobin, DF				Horrobin, DF			Peer review of grant applications: A harbinger for mediocrity in clinical research?	LANCET			English	Article							HYPERACTIVITY				Horrobin, DF (corresponding author), SCOTIA PHARMACEUT,WOODBRIDGE MEADOWS,GUILDFORD GU1 1BA,SURREY,ENGLAND.							ANGIER N, 1988, NATURAL OBSESSIONS S, P24; COLQUHOUN I, 1981, MED HYPOTHESES, V7, P673, DOI 10.1016/0306-9877(81)90014-1; HORROBIN DF, 1989, NATURE, V339, P654, DOI 10.1038/339654b0; HORROBIN DF, 1990, JAMA-J AM MED ASSOC, V263, P1438, DOI 10.1001/jama.263.10.1438; HORROBIN DF, 1974, BRIT MED J, V2, P216, DOI 10.1136/bmj.2.5912.216; HORROBIN DF, 1974, BRIT MED J, V4, P463; HORROBIN DF, 1987, SCI MED SUCCESS FAIL; KENDREW J, 1983, PRIORITIES RES, P171; LLOYD V, 1995, LANCET, V346, P1039, DOI 10.1016/S0140-6736(95)91721-7; MADDOX J, 1995, NATURE, V376, P721, DOI 10.1038/376721a0; MARSHALL E, 1994, SCIENCE, V265, P20, DOI 10.1126/science.8016650; MORROBIN DF, 1982, NEW SCI, V94, P842; NAYLOR CD, 1994, CAN MED ASSOC J, V150, P1207; REES M, 1995, FINANCIAL TIMES 0912, P23; STEVENS LJ, 1995, AM J CLIN NUTR, V62, P761, DOI 10.1093/ajcn/62.4.761; SURTMAN RJ, 1995, NAT MED, V1, P1122; *US GEN ACC OFF, 1994, PEER NEED ENS FAIRN	17	61	61	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1293	1295		10.1016/S0140-6736(96)08029-4	http://dx.doi.org/10.1016/S0140-6736(96)08029-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909385				2022-12-28	WOS:A1996VR55500016
J	Martyn, CN; Barker, DJP; Osmond, C				Martyn, CN; Barker, DJP; Osmond, C			Mothers' pelvic size, fetal growth, and death from stroke and coronary heart disease in men in the UK	LANCET			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; FACTOR-VII; FIBRINOGEN; NUTRITION; MORTALITY; THINNESS; ENGLAND; BIRTH; WALES	Background People who have a low birthweight show increased death rates from coronary heart disease and a higher prevalence for its risk factors. These findings have led to the hypothesis that the disease is programmed in fetal life. The aim of this study was to explore whether risk of stroke in adult life was linked to impaired fetal growth. Methods We ascertained deaths from stroke and coronary heart disease in 13249 men in two cohorts from Hertfordshire and Sheffield, UK. We related death rates from these diseases to body size at birth, weight at 1 year, and to measurements of the mothers' pelvises. Findings Death rates from both stroke and coronary heart disease tended to be highest in men whose birthweight had been low. Standardised mortality ratios (SMRs) far stroke felt by 12% (95% CI 1-22) and for coronary heart disease by 10% (6-14) between each of five groupings of increasing birthweight (less than or equal to 5 5 lb, 5.6-6.5 lb, 6.6-7.5 lb, 7.6-8.5 lb, and > 8.5 lb). Mortality from stroke was most strongly associated with low birthweight in relation to head size. and low placental weight in relation to head size. These patterns of growth occurred in offspring of mothers with flat bony pelvises. The SMR in sans of these women was 184 (67-396) compared with 104 (78-138) in the remainder of the cohort. In contrast, mortality from coronary heart disease was associated with small head circumference, thinness or shortness al birth and an altered ratio of placental weight to birthweight. Interpretation Stroke may originate in poor nutrition during the mother's childhood, which deforms the bony pelvis and subsequently impairs her ability to sustain the growth of the placenta and fetus in late pregnancy. Coronary heart disease, on the other hand, seems to originate in adaptations made by the fetus to inadequate delivery of nutrients when it occurs for reasons other than failure of placental growth.			Martyn, CN (corresponding author), UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1986, LANCET, V1, P1077; BERKELEY C, 1941, PICTORICAL MIDWIERY; BERNARD R M, 1952, Edinb Med J, V59, P1; CAMPBELL JM, 1924, 25 PUBL HLTH MED SUB; CAMPBELL JM, 1932, 68 PUBL HLTH MED SUB; *ENC BRITT INC, 1984, ENC BRITT; Greulich WW, 1939, J AMER MED ASSOC, V112, P485, DOI 10.1001/jama.1939.02800060001001; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; MARTYN CN, 1995, BRIT HEART J, V73, P116; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Mellanby E, 1933, LANCET, V2, P1131; NICHOLSON C, 1945, J ANAT, V79, P131; NICHOLSON C, 1946, LANCET, V251, P192; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; RICHEDWARDS J, 1995, AM J EPIDEMIOL, V141, pS78; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804	25	285	291	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 9	1996	348	9037					1264	1268		10.1016/S0140-6736(96)04257-2	http://dx.doi.org/10.1016/S0140-6736(96)04257-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909378				2022-12-28	WOS:A1996VR55500008
J	Killalea, D; Ward, LR; Roberts, D; deLouvois, J; Sufi, F; Stuart, JM; Wall, PG; Susman, M; Schwieger, M; Sanderson, PJ; Fisher, IST; Mead, PS; Gill, ON; Bartlett, CLR; Rowe, B				Killalea, D; Ward, LR; Roberts, D; deLouvois, J; Sufi, F; Stuart, JM; Wall, PG; Susman, M; Schwieger, M; Sanderson, PJ; Fisher, IST; Mead, PS; Gill, ON; Bartlett, CLR; Rowe, B			International epidemiological and microbiological study of outbreak of Salmonella agona infection from a ready to eat savoury snack .1. England and Wales and the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To identify the source of an international outbreak of food poisoning due to Salmonella agona phage type 15 and to measure how long the underlying cause persisted. Design-Case-control study of 16 primary household cases and 32 controls of similar age and dietary habit. Packets of the implicated foodstuff manufactured on a range of days were examined for salmonella. All isolates of the epidemic phage type were further characterised by pulsed field gel electrophoresis. Results-27 cases were identified, of which 26 were in children. The case-control study showed a strong association between infection with S agona phage type 15 and consumption of a peanut flavoured ready to eat kosher savoury snack imported from Israel. S agona phage type 15 was isolated from samples of this snack. The combined food sampling results from the United Kingdom, Canada, the United States, and Israel showed that contaminated snacks were manufactured on at least seven separate dates during a four month period between October 1994 and February 1995. Voluntary recalls of the product successfully interrupted transmission. Conclusions-Rapid international exchanges of information led to the identification of the source of a major outbreak of S agona in Israel and of associated cases in North America. The outbreak showed the value of the Salm-Net surveillance system and its links outside Europe, both for increasing case ascertainment and for improving the information on the duration of the fault at the manufacturing plant.	PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND; PUBL HLTH LAB SERV, CENT PUBL HLTH LAB, LONDON NW9 5HT, ENGLAND; PUBL HLTH LAB SERV, LAB ENTER PATHOGENS, SALMONELLA REFERENCE LAB, LONDON NW9 5EQ, ENGLAND; PUBL HLTH LAB SERV, FOOD HYG LAB, LONDON NW9 5EQ, ENGLAND; PUBL HLTH LAB SERV, STAT UNIT, LONDON NW9 5EQ, ENGLAND; COLINDALE HOSP, BARNET DIST HLTH AUTHOR, LONDON NW9 5HG, ENGLAND	Public Health England; Public Health England; Public Health England; Public Health England; Public Health England								AITKEN M, 1990, STAT MODELLING GLIM; *BRIT STAND I, 1993, 5763 BSI; Fisher I. S. T., 1994, PHLS Microbiology Digest, V11, P181; FROST JA, 1995, EMERG INFECT DIS, V1, P26, DOI 10.3201/eid0101.950105; Joseph C A, 1991, CDR (Lond Engl Rev), V1, pR16; Shohat T, 1996, BMJ-BRIT MED J, V313, P1107, DOI 10.1136/bmj.313.7065.1107; Threlfall EJ, 1996, EMERG INFECT DIS, V2, P130, DOI 10.3201/eid0202.960209	7	116	119	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	1996	313	7065					1105	1107		10.1136/bmj.313.7065.1105	http://dx.doi.org/10.1136/bmj.313.7065.1105			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916693	Green Published			2022-12-28	WOS:A1996VR21700018
J	Ely, EW; Baker, AM; Dunagan, DP; Burke, HL; Smith, AC; Kelly, PT; Johnson, MM; Browder, RW; Bowton, DL; Haponik, EF				Ely, EW; Baker, AM; Dunagan, DP; Burke, HL; Smith, AC; Kelly, PT; Johnson, MM; Browder, RW; Bowton, DL; Haponik, EF			Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEANING PATIENTS; INSPIRATORY PRESSURE; OCCLUSION PRESSURE; PREDICTORS; EXTUBATION; SUPPORT; RATIO; PARAMETERS; FAILURE; TRIALS	Background Prompt recognition of the reversal of respiratory failure may permit earlier discontinuation of mechanical ventilation, without harm to the patient. Methods We conducted a randomized, controlled trial in 300 adult patients receiving mechanical ventilation in medical and coronary intensive care units. In the intervention group, patients underwent daily screening of respiratory function by physicians, respiratory therapists, and nurses to identify those possibly capable of breathing spontaneously; successful tests were followed by two-hour trials of spontaneous breathing in those who met the criteria. Physicians were notified when their patients successfully completed the trials of spontaneous breathing. The control subjects had daily screening but no other interventions. In both groups, all clinical decisions, including the decision to discontinue mechanical ventilation, were made by the attending physicians. Results Although the 149 patients randomly assigned to the intervention group had more severe disease, they received mechanical ventilation for a median of 4.5 days, as compared with 6 days in the 151 patients in the control group (P=0.003). The median interval between the time a patient met the screening criteria and the discontinuation of mechanical ventilation was one day in the intervention group and three days in the control group (P<0.001). Complications - removal of the breathing tube by the patient, reintubation, tracheostomy, and mechanical ventilation for more than 21 days - occurred in 20 percent of the intervention group and 41 percent of the control group (P=0.001). The number of days of intensive care and hospital care was similar in the two groups. Total costs for the intensive care unit were lower in the intervention group (median, $15,740, vs. $20,890 in the controls; P=0.03); hospital costs were lower, though not significantly so (median, $26,229 and $29,048, respectively; P=0.3). Conclusions Daily screening of the respiratory function of adults receiving mechanical ventilation, followed by trials of spontaneous breathing in appropriate patients and notification of their physicians when the trials were successful, can reduce the duration of mechanical ventilation and the cost of intensive care and is associated with fewer complications than usual care.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,PULM & CRIT CARE MED SECT,WINSTON SALEM,NC 27103; LYNCHBURG PULM ASSOCIATES,LYNCHBURG,VA; MAYO CLIN,JACKSONVILLE,FL 32224	Wake Forest University; Wake Forest Baptist Medical Center; Mayo Clinic			Bowton, David/AAZ-2916-2020; Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172				Bland M, 1987, INTRO MED STAT; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; CAPDEVILA XJ, 1995, CHEST, V108, P482, DOI 10.1378/chest.108.2.482; COHEN IL, 1991, CRIT CARE MED, V19, P1278, DOI 10.1097/00003246-199110000-00010; COHEN IL, 1994, INTENS CARE MED, V20, P317, DOI 10.1007/BF01720902; COX DR, 1972, J R STAT SOC B, V34, P187; Dojat M, 1996, AM J RESP CRIT CARE, V153, P997, DOI 10.1164/ajrccm.153.3.8630586; EPSTEIN SK, 1995, AM J RESP CRIT CARE, V152, P545, DOI 10.1164/ajrccm.152.2.7633705; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; GANDIA F, 1992, INTENS CARE MED, V18, P327, DOI 10.1007/BF01694360; GLUCK EH, 1995, CRIT CARE MED, V23, P504, DOI 10.1097/00003246-199503000-00015; HALL JB, 1987, JAMA-J AM MED ASSOC, V257, P1621, DOI 10.1001/jama.257.12.1621; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LISTELLO D, 1994, CHEST, V105, P1496, DOI 10.1378/chest.105.5.1496; MADOR MJ, 1992, CHEST, V102, P1642, DOI 10.1378/chest.102.6.1642; MOHSENIFAR Z, 1993, ANN INTERN MED, V119, P794, DOI 10.7326/0003-4819-119-8-199310150-00004; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; SAHN SA, 1973, CHEST, V63, P1002, DOI 10.1378/chest.63.6.1002; SASSOON CSH, 1993, AM REV RESPIR DIS, V148, P860, DOI 10.1164/ajrccm/148.4_Pt_1.860; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SHIKORA SA, 1994, ARCH SURG-CHICAGO, V129, P269; STRICKLAND JH, 1993, CHEST, V103, P1220, DOI 10.1378/chest.103.4.1220; STROETZ RW, 1995, AM J RESP CRIT CARE, V152, P1034, DOI 10.1164/ajrccm.152.3.7663780; TINDOL GA, 1994, CHEST, V105, P1804, DOI 10.1378/chest.105.6.1804; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; WEINBERGER SE, 1995, NEW ENGL J MED, V332, P388, DOI 10.1056/NEJM199502093320609; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101; YANG KL, 1993, INTENS CARE MED, V19, P204, DOI 10.1007/BF01694771; YANG KL, 1992, CHEST, V102, P1829, DOI 10.1378/chest.102.6.1829	31	897	937	0	23	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 19	1996	335	25					1864	1869		10.1056/NEJM199612193352502	http://dx.doi.org/10.1056/NEJM199612193352502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX874	8948561				2022-12-28	WOS:A1996VX87400002
J	Atchison, RE; Gosling, J; Monteclaro, FS; Franci, C; Digilio, L; Charo, IF; Goldsmith, MA				Atchison, RE; Gosling, J; Monteclaro, FS; Franci, C; Digilio, L; Charo, IF; Goldsmith, MA			Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines	SCIENCE			English	Article							EXPRESSION; INFECTION; RECEPTOR; CLONING	The human beta-chemokine receptor CCR5 is an important cofactor for entry of human immunodeficiency virus-type 1 (HIV-1), The murine form of CCR5, despite its 82 percent identity to the human form, was not functional as an HIV-1 coreceptor. HIV-1 entry function could be reconstituted by fusion of various individual elements derived from the extracellular region of human CCR5 onto murine CCR5. Analysis of chimeras containing elements from human CCR5 and human CCR2B suggested that a complex structure rather than single contact sites is responsible for facilitation of viral entry, Further, certain chimeras lacking the domains necessary to signal in response to their natural chemokine ligands retained vigorous HIV-1 coreceptor activity.	UNIV CALIF SAN FRANCISCO,SCH MED,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,SCH MED,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes					NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; ATCHSION R, UNPUB; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DENG H, 1996, SCIENCE, V272, P1955; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P6511; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; GOSLING J, UNPUB; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LORES P, 1992, AIDS RES HUM RETROV, V8, P2063, DOI 10.1089/aid.1992.8.2063; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MONTECLARO FS, UNPUB; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g	22	274	284	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1924	1926		10.1126/science.274.5294.1924	http://dx.doi.org/10.1126/science.274.5294.1924			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943208				2022-12-28	WOS:A1996VY20000048
J	Bulaj, ZJ; Griffen, LM; Jorde, LB; Edwards, CQ; Kushner, JP				Bulaj, ZJ; Griffen, LM; Jorde, LB; Edwards, CQ; Kushner, JP			Clinical and biochemical abnormalities in people heterozygous for hemochromatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HLA-LINKED HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; IDIOPATHIC HEMOCHROMATOSIS; ANCESTRAL HAPLOTYPE; IRON OVERLOAD; UNITED-STATES; ASSOCIATION; EXPRESSION; POPULATION; PREVALENCE	Background Ten percent of whites are heterozygous for the HLA-linked hemochromatosis mutation. We performed a cross-sectional analysis of 1058 genotyped heterozygotes to define the effects of age and sex on the phenotype. Methods The heterozygous genotype was assigned to 505 male and 553 female members of 202 pedigrees, each with an HLA-typed homozygous proband. We measured serum iron, transferrin saturation, and ferritin in all heterozygotes and in 321 genetically normal subjects (unaffected family members or spouses of family members). Liver biopsies were performed in a subgroup of heterozygotes. Results The mean serum iron concentrations and transferrin-saturation values were higher in heterozygotes than in normal subjects and did not increase with age. Initial transferrin-saturation levels exceeding the threshold associated with the homozygous genotype were found in 4 percent of male and 8 percent of female heterozygotes. The geometric mean serum ferritin concentration was higher in heterozygotes than in normal subjects and increased with age. Higher-than-normal values were found in 20 percent of male and 8 percent of female heterozygotes. The clinical and biochemical expression of hemochromatosis was more marked in heterozygotes with paternally transmitted mutations than in those with maternally transmitted mutations. Liver-biopsy abnormalities were generally associated with alcohol abuse, hepatitis, or porphyria cutanea tarda. Conclusions The phenotype of persons heterozygous for hemochromatosis differs from that of normal subjects, but complications due to iron overload alone in these heterozygotes are extremely rare. (C) 1996, Massachusetts Medical Society.	UNIV UTAH,SCH MED,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132; LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143; UNIV UTAH,SCH MED,DIV HEMATOL ONCOL,DEPT INTERNAL MED,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NCRR NIH HHS [RR 00064] Funding Source: Medline; NIDDK NIH HHS [DK 20630] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020630] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1994, AM J HEMATOL, V45, P146, DOI 10.1002/ajh.2830450210; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BASSETT ML, 1981, HEPATOLOGY, V1, P120, DOI 10.1002/hep.1840010206; BUITING K, 1995, NAT GENET, V10, P249, DOI 10.1038/ng0695-249c; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CARTWRIGHT GE, 1980, J CLIN INVEST, V65, P989, DOI 10.1172/JCI109785; CARTWRIGHT GE, 1979, NEW ENGL J MED, V301, P175, DOI 10.1056/NEJM197907263010402; COOK JD, 1986, BLOOD, V68, P726; COOK JD, 1982, SEMIN HEMATOL, V19, P6; CRAWFORD DHG, 1995, AM J HUM GENET, V57, P362; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; EDWARDS CQ, 1989, GASTROENTEROLOGY, V97, P972, DOI 10.1016/0016-5085(89)91506-0; EDWARDS CQ, 1977, NEW ENGL J MED, V297, P7, DOI 10.1056/NEJM197707072970102; EDWARDS CQ, 1982, CLIN HAEMATOL, V11, P411; EDWARDS CQ, 1981, PROG HEMATOL, V12, P43; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1981, BLOOD, V58, P844; EDWARDS CQ, 1990, AM J MED SCI, V300, P245, DOI 10.1097/00000441-199010000-00009; EDWARDS CQ, 1993, WINTROBES CLIN HEMAT, V1, P872; FARGION S, 1986, AM J CLIN PATHOL, V86, P645, DOI 10.1093/ajcp/86.5.645; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; JAZWINSKA EC, 1995, AM J HUM GENET, V56, P428; MARGARITTEJEANNIN P, 1995, AM J HUM GENET, V56, P1080; MCLAREN CE, 1995, BLOOD, V86, P2021, DOI 10.1182/blood.V86.5.2021.bloodjournal8652021; MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277; RAHACHOWDHURY R, 1995, J MED GENET, V32, P446, DOI 10.1136/jmg.32.6.446; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAY JG, 1976, DHEW PUBL NIH; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SIMON M, 1977, NEW ENGL J MED, V297, P1017, DOI 10.1056/NEJM197711102971901; SIMON M, 1987, AM J HUM GENET, V41, P89; VALBERG LS, 1980, GASTROENTEROLOGY, V79, P884; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2	35	259	262	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1799	1805		10.1056/NEJM199612123352403	http://dx.doi.org/10.1056/NEJM199612123352403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943161				2022-12-28	WOS:A1996VW68300003
J	Corsini, A; Pazzucconi, F; Pfister, P; Paoletti, R; Sirtori, CR				Corsini, A; Pazzucconi, F; Pfister, P; Paoletti, R; Sirtori, CR			Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin	LANCET			English	Letter							ATHEROSCLEROSIS		UNIV MILAN,CTR ENRICA GROSSI,I-20133 MILAN,ITALY; SANDOZ PHARMA LTD,CH-4002 BASEL,SWITZERLAND	University of Milan; Novartis; Sandoz			Sirtori, Cesare/F-4658-2012					CORSINI A, 1995, AM J CARDIOL, V76, pA21; HERD JA, 1994, AM J CARDIOL, V73, pD42, DOI 10.1016/0002-9149(94)90632-7; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; TSE FLS, 1992, J CLIN PHARMACOL, V32, P630, DOI 10.1002/j.1552-4604.1992.tb05773.x	5	60	65	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1584	1584		10.1016/S0140-6736(05)66196-X	http://dx.doi.org/10.1016/S0140-6736(05)66196-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950895				2022-12-28	WOS:A1996VX02300040
J	Freeman, BC; Toft, DO; Morimoto, RI				Freeman, BC; Toft, DO; Morimoto, RI			Molecular chaperone machines: Chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; SIGNAL-TRANSDUCTION; HSP90; BINDING; HSP70; DNAK; IDENTIFICATION; HETEROCOMPLEX	Molecular chaperones are essential proteins that participate in the regulation of steroid receptors in eukaryotes. The steroid aporeceptor complex contains the molecular chaperones Hsp90 and Hsp70, p48, the cyclophilin Cyp-40, and the associated proteins p23 and p60. In vitro folding assays showed that Cyp-40 and p23 functioned as molecular chaperones in a manner similar to that of Hsp90 or Hsp70. Although neither Cyp-40 nor p23 could completely refold an unfolded substrate, both proteins interacted with the substrate to maintain a nonnative folding-competent intermediate. Thus, the steroid aporeceptor complexes have multiple chaperone components that maintain substrates in an intermediate folded state.	NORTHWESTERN UNIV, RICE INST BIOMED RES, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA	Northwestern University; Mayo Clinic					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038109, R01GM038109] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38109] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BOHEN SP, 1995, J BIOL CHEM, V270, P29433, DOI 10.1074/jbc.270.49.29433; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FREEMAN BC, UNPUB; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEITMAN J, 1992, NEW BIOL, V4, P448; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1995, CELL, V83, P589; HUTCHISON KA, 1992, J BIOL CHEM, V267, P3190; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SMITH DF, 1995, SCI MED, V2, P38; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; [No title captured]	34	286	290	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1718	1720		10.1126/science.274.5293.1718	http://dx.doi.org/10.1126/science.274.5293.1718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939864				2022-12-28	WOS:A1996VW71200063
J	Annas, GJ				Annas, GJ			Cowboys, camels, and the first amendment - The FDA's restrictions on tobacco advertising	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				BROWNLEE LL, 1996, WALL STREET J   0710, pB1; *COMM PREV NIC ADD, 1994, GROW TOB FREE PREV N, P131; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE, P195; *FDA, 1996, FED REGISTER, V61, P44396; GLANTZ L, IN PRESS AM J PUBLIC; Kessler DA, 1996, NEW ENGL J MED, V335, P988, DOI 10.1056/NEJM199609263351321; PARKERPOPE T, 1996, WALL STREET J   1009, pB1; 1996, NY TIMES        0829, pB12; 1995, MMWR-MORBID MORTAL W, V44, P521	9	10	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1779	1783		10.1056/NEJM199612053352322	http://dx.doi.org/10.1056/NEJM199612053352322			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929272	Green Published			2022-12-28	WOS:A1996VW79500030
J	Lord, SM; Barnsley, L; Wallis, BJ; McDonald, GJ; Bogduk, N				Lord, SM; Barnsley, L; Wallis, BJ; McDonald, GJ; Bogduk, N			Percutaneous radio-frequency neurotomy for chronic cervical zygapophyseal-joint pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOCAL-ANESTHETIC BLOCKS; RADIOFREQUENCY NEUROTOMY; DIAGNOSIS; WHIPLASH	Background Chronic pain in the cervical zygapophyseal joints is a common problem after whiplash injury, but treatment is difficult. Percutaneous radiofrequency neurotomy can relieve the pain by denaturing the nerves innervating the painful joint, but the efficacy of this treatment has not been established. Methods In a randomized, double-blind trial, we compared percutaneous radio-frequency neurotomy in which multiple lesions were made and the temperature of the electrode making the lesions was raised to 80 degrees C with a control treatment using an identical procedure except that the radio-frequency current was not turned on. We studied 24 patients (9 men and 15 women; mean age, 43 years) who had pain in one or more cervical zygapophyseal joints after an automobile accident (median duration of pain, 34 months). The source of their pain had been identified with the use of double-blind, placebo-controlled local anesthesia. Twelve patients received each treatment. The patients were followed by telephone interviews and clinic visits until they reported that their pain had returned to 50 percent of the preoperative level. Results The median time that elapsed before the pain returned to at least 50 percent of the preoperative level was 263 days in the active-treatment group and 8 days in the control group (P = 0.04). At 27 weeks, seven patients in the active-treatment group and one patient in the control group were free of pain. Five patients in the active-treatment group had numbness in the territory of the treated nerves, but none considered it troubling. Conclusions In patients with chronic cervical zygapophyseal-joint pain confirmed with double-blind, placebo-controlled local anesthesia, percutaneous radio-frequency neurotomy with multiple lesions of target nerves can provide lasting relief. (C) 1996, Massachusetts Medical Society.	MATER MISERICORDIAE HOSP,WARATAH,NEW SOUTH WALES,AUSTRALIA		Lord, SM (corresponding author), UNIV NEWCASTLE,FAC MED,CERVICAL SPINE RES UNIT,CALLAGHAN,NSW 2308,AUSTRALIA.		Lord, Susan M/AAG-4342-2021	Lord, Susan M/0000-0002-8990-836X				BARNSLEY L, 1994, NEW ENGL J MED, V330, P1047, DOI 10.1056/NEJM199404143301504; BARNSLEY L, 1993, REGION ANESTH, V18, P343; BARNSLEY L, 1995, SPINE, V20, P20, DOI 10.1097/00007632-199501000-00004; BARNSLEY L, 1994, PAIN, V58, P283, DOI 10.1016/0304-3959(94)90123-6; BARNSLEY L, 1993, PAIN, V55, P99, DOI 10.1016/0304-3959(93)90189-V; BOAS RA, 1988, NEURAL BLOCKADE CLIN, P885; BOGDUK N, 1987, NEUROSURGERY, V20, P529, DOI 10.1227/00006123-198704000-00004; Collett D, 1994, MODELLING SURVIVAL D; DEROGATIS LR, 1983, SCL 90 R ADM SCORING, V11; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Evans F. J., 1985, PLACEBO THEORY RES M, P215; Hildebrandt J, 1986, MANUAL MED, V2, P48; Huskisson E., 1983, PAIN MEASUREMENT ASS, P33; LIBERMAN R, 1964, J PSYCHIAT RES, V2, P233, DOI 10.1016/0022-3956(64)90010-X; Lord SM, 1996, SPINE, V21, P1737, DOI 10.1097/00007632-199608010-00005; LORD SM, 1995, NEUROSURGERY, V36, P732, DOI 10.1227/00006123-199504000-00014; LORD SM, 1995, CLIN J PAIN, V11, P208, DOI 10.1097/00002508-199509000-00008; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MELZACK R, 1983, PAIN MEASUREMENT ASS, P41; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; SCHAERER JP, 1978, INT SURG, V63, P53; Schaerer JP, 1980, J NEUROL ORTHOP SURG, V1, P127; Schaerer JP, 1988, J NEUROL ORTH MED S, V9, P74; SLUIJTER ME, 1980, ANAESTHESIA, V35, P302, DOI 10.1111/j.1365-2044.1980.tb05102.x; SLUIJTER ME, 1981, PERSISTENT PAIN, V3, P141; SPITZER WO, 1995, SPINE, V20, pS1; VERVEST A C M, 1991, Pain Clinic, V4, P103; WALL PD, 1992, PAIN, V51, P1, DOI 10.1016/0304-3959(92)90002-S	28	464	483	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 5	1996	335	23					1721	1726		10.1056/NEJM199612053352302	http://dx.doi.org/10.1056/NEJM199612053352302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW795	8929263	Bronze			2022-12-28	WOS:A1996VW79500002
J	Brojatsch, J; Naughton, J; Rolls, MM; Zingler, K; Young, JAT				Brojatsch, J; Naughton, J; Rolls, MM; Zingler, K; Young, JAT			CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis sarcoma viruses and mediates apoptosis	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; UNINTEGRATED VIRAL-DNA; DENSITY-LIPOPROTEIN RECEPTOR; DEATH DOMAIN; ENVELOPE GLYCOPROTEIN; MOLECULAR-CLONING; FAS ANTIGEN; T-CELLS; INFECTION	Viral envelope (Env)-receptor interactions have been implicated in the cell death associated with infection by subgroups B and D avian leukosis-sarcoma viruses (ALVs). A chicken protein, CAR1, was identified that permitted infection of mammalian cells by these viral subgroups. CAR1 bound to a viral Env fusion protein, comprising an ALV-B surface Env protein and the Fc region of an immunoglobulin, indicating that it is a specific Viral receptor. CAR1 contains two extracellular cysteine-rich domains characteristic of the TNFR family and a cytoplasmic region strikingly similar to the death domain of TNFR1 and Pas, implicating this receptor in cell killing. Chicken embryo fibroblasts susceptible to ALV-B infection and transfected quail QT6 cells expressing CAR1 underwent apoptosis in response to the Env-lg fusion protein, demonstrating that this cytopathic ALV receptor can mediate cell death.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Brojatsch, J (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA.		Rolls, Melissa/G-6402-2014	Rolls, Melissa/0000-0002-5021-4360; brojatsch, jurgen/0000-0002-7424-365X; Young, John/0000-0003-1824-2561	NCI NIH HHS [CA70810, CA62000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062000, R29CA062000, R01CA070810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1992, SHORIT PROTOCOLS MOL; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BELANGER C, 1995, J VIROL, V69, P1019; BERGERON L, 1992, J VIROL, V66, P5777, DOI 10.1128/JVI.66.10.5777-5787.1992; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOVA CA, 1988, J VIROL, V62, P75, DOI 10.1128/JVI.62.1.75-83.1988; Cao J, 1996, J VIROL, V70, P1340, DOI 10.1128/JVI.70.3.1340-1354.1996; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAPMAN BS, 1995, FEBS LETT, V374, P216, DOI 10.1016/0014-5793(95)01113-S; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CONNOLLY L, 1994, J VIROL, V68, P2760, DOI 10.1128/JVI.68.4.2760-2764.1994; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; DONAHUE PR, 1991, J VIROL, V65, P4461, DOI 10.1128/JVI.65.8.4461-4469.1991; DORNER AJ, 1986, CELL, V45, P365, DOI 10.1016/0092-8674(86)90322-3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HAAKFRENDSCHO M, 1993, IMMUNOLOGY, V79, P594; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KESHET E, 1979, J VIROL, V31, P376, DOI 10.1128/JVI.31.2.376-388.1979; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASTER SM, 1988, J IMMUNOL, V141, P2629; LAURENTCRAWFORD AG, 1993, J GEN VIROL, V74, P2619, DOI 10.1099/0022-1317-74-12-2619; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LU YY, 1994, J VIROL, V68, P390, DOI 10.1128/JVI.68.1.390-399.1994; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; PAQUETTE Y, 1989, P NATL ACAD SCI USA, V86, P3896, DOI 10.1073/pnas.86.10.3896; PAUZA CD, 1990, J EXP MED, V172, P1035, DOI 10.1084/jem.172.4.1035; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PITTI RM, 1994, MOL IMMUNOL, V31, P1345, DOI 10.1016/0161-5890(94)90053-1; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RESNICKROGUEL N, 1989, J VIROL, V63, P4325, DOI 10.1128/JVI.63.10.4325-4330.1989; RIEDEL N, 1988, P NATL ACAD SCI USA, V85, P2758, DOI 10.1073/pnas.85.8.2758; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHREIBER M, 1994, VIROLOGY, V204, P692, DOI 10.1006/viro.1994.1585; Siliciano RF, 1996, CURR TOP MICROBIOL, V205, P159; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOMASUNDARAN M, 1987, J VIROL, V61, P3114, DOI 10.1128/JVI.61.10.3114-3119.1987; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STUMPH WE, 1981, NUCLEIC ACIDS RES, V9, P5383, DOI 10.1093/nar/9.20.5383; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; WEISS RA, 1993, RETROVIRIDAE, V2, P1; WELLER SK, 1981, J VIROL, V39, P713, DOI 10.1128/JVI.39.3.713-721.1981; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993; Zingler K, 1996, J VIROL, V70, P7510, DOI 10.1128/JVI.70.11.7510-7516.1996; ZINGLER K, 1995, J VIROL, V69, P4261, DOI 10.1128/JVI.69.7.4261-4266.1995	67	215	241	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					845	855		10.1016/S0092-8674(00)81992-3	http://dx.doi.org/10.1016/S0092-8674(00)81992-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945512	Bronze			2022-12-28	WOS:A1996VV77400011
J	Zecca, M; Basler, K; Struhl, G				Zecca, M; Basler, K; Struhl, G			Direct and long-range action of a wingless morphogen gradient	CELL			English	Article							POLARITY GENE ARMADILLO; PROTEIN-KINASE-A; DROSOPHILA EMBRYO; SIGNALING PATHWAY; PATTERN-FORMATION; SHAGGY ZESTE-WHITE-3; LIMB DEVELOPMENT; DISC DEVELOPMENT; DORSAL PROTEIN; IMAGINAL DISC	Wingless (Wg), a founding member of the Wingless/Int-1 (Wnt) family of secreted proteins, acts as a short-range inducer and as a long-range organizer during Drosophila development. Here, we determine the consequences of ectopically expressing (i) a wild-type form of Wg, (ii) a membrane-tethered form of Wg, and (iii) a constitutively active form of the cytosolic protein Armadillo (Arm), which normally acts to transduce Wg, and we compare them with the effects of removing endogenous Wg or Arm activity. Our results indicate that wild-type Wg acts at long range, up-regulating the transcription of particular target genes as a function of concentration and distance from secreting cells. In contrast, tethered Wg and Arm have only short-range or autonomous effects, respectively, on the transcription of these genes. We interpret these findings as evidence that Wg can act directly and at long range as a gradient morphogen during normal development.	COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Zecca, M (corresponding author), UNIV ZURICH, INST ZOOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1992, DEV BIOL, V152, P263, DOI 10.1016/0012-1606(92)90134-3; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; CASANOVA J, 1995, GENE DEV, V9, P2539, DOI 10.1101/gad.9.20.2539; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COUSO JP, 1994, DEVELOPMENT, V120, P621; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAWRENCE PA, 1996, IN PRESS DEVELOPMENT; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; Morgan T.H., 1897, ROUX ARCH DEV BIOL, V5, P570; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SLACK JMW, 1987, TRENDS BIOCHEM SCI, V12, P200, DOI 10.1016/0968-0004(87)90094-6; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; VINCENT JP, 1994, TRENDS GENET, V10, P383, DOI 10.1016/0168-9525(94)90040-X; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; Wilson EB, 1925, CELL DEV INHERITANCE; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XU T, 1993, DEVELOPMENT, V117, P1223; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZECCA M, 1995, DEVELOPMENT, V121, P2265	69	625	631	1	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					833	844		10.1016/S0092-8674(00)81991-1	http://dx.doi.org/10.1016/S0092-8674(00)81991-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945511	Green Accepted, hybrid			2022-12-28	WOS:A1996VV77400010
J	Barron, SL; Blain, P; Bullough, CHW; Carney, T; Gomersall, R; Herve, J; Hey, EN; Irani, A; Johnson, FS; Lamb, W; Lowry, MF; Lawson, JB; Layton, R; Morris, D; Morrell, P; Parsons, L; Reid, W; Ryall, A; Thomson, R; Platt, MW; Welch, RG; Wright, C; West, S; Wyllie, J; Young, G				Barron, SL; Blain, P; Bullough, CHW; Carney, T; Gomersall, R; Herve, J; Hey, EN; Irani, A; Johnson, FS; Lamb, W; Lowry, MF; Lawson, JB; Layton, R; Morris, D; Morrell, P; Parsons, L; Reid, W; Ryall, A; Thomson, R; Platt, MW; Welch, RG; Wright, C; West, S; Wyllie, J; Young, G			Collaborative survey of perinatal loss in planned and unplanned home births	BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL BIRTHS; DELIVERIES; SAFETY; PLACE	Objective-To document the outcome of planned and unplanned births outside hospital. Design-Confidential review of every pregnancy ending in stillbirth or neonatal death in which plans had been made for home delivery, irrespective of where delivery eventually occurred, The review was part of a sustained collaborative survey of all perinatal deaths. Setting-Northern Regional Health Authority area. Subjects-All 558 691 registered births to women normally resident in the former Northern Regional Health Authority area during 1981-94. Main outcome measure-Perinatal death. Results-The estimated perinatal mortality during 1981-94 among women booked for a home birth was 14 deaths in 2888 births. This was less than half that among all women in the region. Only three of the 14 women delivered outside hospital. Independent review suggested that two of the 14 deaths might have been averted by different management. Both births occurred in hospital, and in only one was management before admission of the mother judged inappropriate. Perinatal loss to the 64 women who booked for hospital delivery but delivered outside and to the 67 women who delivered outside hospital without ever making arrangements to receive professional care during labour accounted for the high perinatal mortality (134 deaths in 3466 deliveries) among all births outside hospital. Conclusions-The perinatal hazard associated with planned home birth in the few women who exercised this option (<1%) was low and mostly unavoidable. Health authorities purchasing maternity care need to address the much greater hazard associated with unplanned delivery outside hospital.	MATERN SURVEY OFF,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND									Anderson RE, 1995, J NURSE-MIDWIFERY, V40, P483, DOI 10.1016/0091-2182(95)00051-8; ATAULLAH I, 1990, COLLABORATIVE SURVEY; BARRON SL, 1977, BRIT J OBSTET GYNAEC, V84, P401, DOI 10.1111/j.1471-0528.1977.tb12614.x; CAMPBELL R, 1984, BRIT MED J, V289, P721, DOI 10.1136/bmj.289.6447.721; CAMPBELL R, 1994, TO BE BORN DEBATE EV; CAPLAN M, 1985, PUBLIC HEALTH, V99, P307, DOI 10.1016/S0033-3506(85)80066-4; COLE SK, 1995, J PUBLIC HEALTH MED, V17, P17; Davies J, 1996, BRIT MED J, V313, P1302; Department of Health, 1993, CHANGING CHILDBIRTH; DURAND AM, 1992, AM J PUBLIC HEALTH, V82, P450, DOI 10.2105/AJPH.82.3.450; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; GLASIER A, 1992, BRIT MED J, V305, P476, DOI 10.1136/bmj.305.6851.476-c; HAFNEREATON C, 1994, J HEALTH POLIT POLIC, V19, P813, DOI 10.1215/03616878-19-4-813; HOFF GA, 1985, HASTINGS CENT REP, V15, P19, DOI 10.2307/3563065; HOLDSWORTH JE, 1989, BRIT MED J, V298, P1177, DOI 10.1136/bmj.298.6681.1177-b; *HOUS COMM HLTH CO, 1992, MAT SERV 2 REP SESS; JOHNSON M, 1992, BRIT MED J, V305, P255, DOI 10.1136/bmj.305.6847.255; LILFORD RJ, 1987, BRIT MED J, V295, P1298, DOI 10.1136/bmj.295.6609.1298; *MARK OP RES I, 1993, RES STUD COND DEP HL; MORGAN BM, 1984, BRIT J OBSTET GYNAEC, V91, P624, DOI 10.1111/j.1471-0528.1984.tb04820.x; MURPHY JF, 1984, BRIT MED J, V288, P1429, DOI 10.1136/bmj.288.6428.1429; *NHS MAN EX, 1994, EL949 NHS MAN EX; *NO REG HLTH AUTH, 1984, BRIT MED J, V288, P717; O'Brien M, 1978, J R Coll Gen Pract, V28, P460; Settatree RS, 1996, BRIT MED J, V312, P756; Shepperdson B, 1983, Health Visit, V56, P405; TAYLOR A, 1986, J ROY COLL GEN PRACT, V36, P157; TEW M, 1990, CHANGING CHILDBIRTH; TYSON H, 1991, BIRTH-ISS PERINAT C, V18, P14, DOI 10.1111/j.1523-536X.1991.tb00047.x; Woodcock H C, 1994, Midwifery, V10, P125, DOI 10.1016/0266-6138(94)90042-6	30	34	35	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 23	1996	313	7068					1306	1309						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VV153	8942692				2022-12-28	WOS:A1996VV15300026
J	Baxter, GF; Sumeray, MS; Walker, JM				Baxter, GF; Sumeray, MS; Walker, JM			Infarct size and magnesium: Insights into LIMIT-2 and ISIS-4 from experimental studies	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; INTERVENTION-TRIAL LIMIT-2; INTRAVENOUS-MAGNESIUM; SULFATE; ARRHYTHMIAS; MODEL; REPERFUSION; THERAPY; HEART		UNIV LONDON SCH MED, LONDON WC1E 6DB, ENGLAND	University of London	Baxter, GF (corresponding author), UCL HOSP, DEPT ACAD & CLIN CARDIOL, HATTER INST, LONDON WC1E 6DB, ENGLAND.			Baxter, Gary/0000-0002-7887-6841; Walker, John Malcolm/0000-0002-8559-7218				ABRAHAM AS, 1987, ARCH INTERN MED, V147, P753, DOI 10.1001/archinte.147.4.753; BARROS LFM, 1995, INT J CARDIOL, V48, P3, DOI 10.1016/0167-5273(94)02208-Z; CEREMUZYNSKI L, 1989, AM HEART J, V118, P1333, DOI 10.1016/0002-8703(89)90027-6; CHANG C, 1985, J AM COLL CARDIOL, V5, P2622; CHRISTENSEN CW, 1995, CIRCULATION, V92, P2617, DOI 10.1161/01.CIR.92.9.2617; COLLINS R, 1995, LANCET, V345, P669; FELDSTEDT M, 1991, EUR HEART J, V12, P1215, DOI 10.1093/eurheartj/12.11.1215; FELDSTEDT M, 1988, European Heart Journal, V9, P226; HAIGNEY MCP, 1995, CIRCULATION, V92, P2190, DOI 10.1161/01.CIR.92.8.2190; HERZOG WR, 1995, CIRCULATION, V92, P2622, DOI 10.1161/01.CIR.92.9.2622; LEOR J, 1995, AM J CARDIOL, V75, P1292, DOI 10.1016/S0002-9149(99)80787-5; Morton B C, 1984, Magnesium, V3, P346; MORTON BC, 1981, MAGNESIUM-B, V1, P192; MORTON BC, 1984, MAGNESIUM-B, V4, P133; RASMUSSEN HS, 1986, LANCET, V1, P234; RASMUSSEN HS, 1988, CLIN CARDIOL, V11, P377, DOI 10.1002/clc.4960110604; SHATTOCK MJ, 1987, J AM COLL NUTR, V6, P27; SHECHTER M, 1990, AM J CARDIOL, V66, P271, DOI 10.1016/0002-9149(90)90834-N; SHECHTER M, 1995, AM J CARDIOL, V75, P391; SMITH LF, 1986, INT J CARDIOL, V12, P175, DOI 10.1016/0167-5273(86)90239-1; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; WOODS KL, 1994, LANCET, V343, P816, DOI 10.1016/S0140-6736(94)92024-9; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; WOODS KL, 1991, BRIT J CLIN PHARMACO, V32, P3, DOI 10.1111/j.1365-2125.1991.tb05605.x	24	32	32	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 23	1996	348	9039					1424	1426		10.1016/S0140-6736(96)07281-9	http://dx.doi.org/10.1016/S0140-6736(96)07281-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937284				2022-12-28	WOS:A1996VU98600016
J	Fourmy, D; Recht, MI; Blanchard, SC; Puglisi, JD				Fourmy, D; Recht, MI; Blanchard, SC; Puglisi, JD			Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic	SCIENCE			English	Article							NMR-SPECTROSCOPY; NOE CONTACTS; A-SITE; RESONANCE; H-1; RESISTANCE; ASSIGNMENT; RIBOZYME; BINDING; PROTONS	Aminoglycoside antibiotics that bind to 30S ribosomal A-site RNA cause misreading of the genetic code and inhibit translocation. The aminoglycoside antibiotic paromomycin binds specifically to an RNA oligonucleotide that contains the 30S subunit A site, and the solution structure of the RNA-paromomycin complex was determined by nuclear magnetic resonance spectroscopy. The antibiotic binds in the major groove of the model A-site RNA within a pocket created by an A-A base pair and a single bulged adenine. Specific interactions occur between aminoglycoside chemical groups important for antibiotic activity and conserved nucleotides in the RNA. The structure explains binding of diverse aminoglycosides to the ribosome, their specific activity against prokaryotic organisms, and various resistance mechanisms, and provides insight into ribosome function.	UNIV CALIF SANTA CRUZ,CTR MOL BIOL RNA,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064; UNIV CALIF SANTA CRUZ,CTR MOL BIOL RNA,DEPT BIOL,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz			Blanchard, Scott C./A-5804-2009; fourmy, dominique/J-4766-2014	Blanchard, Scott C./0000-0003-2717-9365; fourmy, dominique/0000-0002-2170-3536	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51266-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BEAUCLERK AAD, 1987, J MOL BIOL, V193, P661, DOI 10.1016/0022-2836(87)90349-4; BENVENISTE R, 1973, ANTIMICROB AGENTS CH, V4, P402, DOI 10.1128/AAC.4.4.402; Blanchard S., UNPUB; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; DAVIES J, 1968, J BIOL CHEM, V243, P3312; DESTASIO EA, 1989, EMBO J, V8, P1213, DOI 10.1002/j.1460-2075.1989.tb03494.x; DESTASIO EA, 1990, J MOL BIOL, V212, P127, DOI 10.1016/0022-2836(90)90309-A; Dirheimer G., 1995, P93; EDELMANN P, 1977, CELL, V10, P131, DOI 10.1016/0092-8674(77)90147-7; FOURMY D, UNPUB; Gale E.F., 1981, MOL BASIS ANTIBIOTIC, Vsecond; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; KARIMI R, 1994, EUR J BIOCHEM, V226, P355, DOI 10.1111/j.1432-1033.1994.tb20059.x; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; MARINO JP, 1994, J AM CHEM SOC, V116, P6472, DOI 10.1021/ja00093a073; MARINO JP, 1994, J AM CHEM SOC, V116, P2205, DOI 10.1021/ja00084a095; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MUELLER L, 1995, J AM CHEM SOC, V117, P11043, DOI 10.1021/ja00150a001; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PATAPOV AP, 1995, J BIOL CHEM, V270, P17680; Puglisi JD, 1995, METHOD ENZYMOL, V261, P323; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Recht MI, 1996, J MOL BIOL, V262, P421, DOI 10.1006/jmbi.1996.0526; REID DG, 1987, J BIOL CHEM, V262, P7967; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Simorre JP, 1996, J AM CHEM SOC, V118, P5316, DOI 10.1021/ja954208+; SMALLCOMBE SH, 1993, J AM CHEM SOC, V115, P4776, DOI 10.1021/ja00064a043; WILHELM JM, 1978, BIOCHEMISTRY-US, V17, P1143, DOI 10.1021/bi00600a001; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; YOSHIZAWA S, UNPUB; ZIMMERMANN RA, 1990, RIBOSOME, P331	41	692	725	3	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1367	1371		10.1126/science.274.5291.1367	http://dx.doi.org/10.1126/science.274.5291.1367			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910275				2022-12-28	WOS:A1996VU95400051
J	Smith, JR; Freije, D; Carpten, JD; Gronberg, H; Xu, JF; Isaacs, SD; Brownstein, MJ; Bova, GS; Guo, H; Bujnovszky, P; Nusskern, DR; Damber, JE; Bergh, A; Emanuelsson, M; Kallioniemi, OP; WalkerDaniels, J; BaileyWilson, JE; Beaty, TH; Meyers, DA; Walsh, PC; Collins, FS; Trent, JM; Isaacs, WB				Smith, JR; Freije, D; Carpten, JD; Gronberg, H; Xu, JF; Isaacs, SD; Brownstein, MJ; Bova, GS; Guo, H; Bujnovszky, P; Nusskern, DR; Damber, JE; Bergh, A; Emanuelsson, M; Kallioniemi, OP; WalkerDaniels, J; BaileyWilson, JE; Beaty, TH; Meyers, DA; Walsh, PC; Collins, FS; Trent, JM; Isaacs, WB			Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search	SCIENCE			English	Article							INHERITANCE	Despite its high prevalence, very little is known regarding genetic predisposition to prostate cancer. A genome-wide scan performed in 66 high-risk prostate cancer families has provided evidence of linkage to the long arm of chromosome 1 (1q24-25). Analysis of an additional set of 25 North American and Swedish families with markers in this region resulted in significant evidence of linkage in the combined set of 91 families. The data provide strong evidence of a major prostate cancer susceptibility locus on chromosome 1.	NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NIMH,NIH,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT UROL,UMEA,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Johns Hopkins University; University of Michigan System; University of Michigan; Umea University; Umea University			Smith, Jeff/C-3484-2012; Kallioniemi, Olli P/H-5111-2011; Brownstein, Michael/B-8609-2009	Kallioniemi, Olli P/0000-0002-3231-0332; Smith, Jeffrey/0000-0001-8424-910X; Bova, George/0000-0003-1639-3104; Bailey-Wilson, Joan/0000-0002-9153-2920	NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAWLEY OW, 1996, COMPREHENSIVE TXB GE, P565; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; Cannon L., 1982, CANCER SURV, V1, P47; Cannon-Albright L. A., 1994, American Journal of Human Genetics, V55, pA147; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; Cher ML, 1996, CANCER RES, V56, P3091; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Freije Diha, 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P670; ISAACS WB, 1995, GENETICS CANC 2 LOOK, P357; KOSARY CL, 1995, NIH PUB; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OTT J, 1985, ANAL HUMAN GENETIC L, P200; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; VANDENBERG C, 1995, CLIN CANCER RES, V1, P11; VISAKORPI T, 1995, CANCER RES, V55, P342	19	596	611	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 22	1996	274	5291					1371	1374		10.1126/science.274.5291.1371	http://dx.doi.org/10.1126/science.274.5291.1371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VU954	8910276	Green Submitted			2022-12-28	WOS:A1996VU95400052
J	Wagner, JM; McKinney, WP; Carpenter, JL				Wagner, JM; McKinney, WP; Carpenter, JL			Does this patient have appendicitis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE ABDOMINAL-PAIN; RIGHT LOWER QUADRANT; PHYSICAL-EXAMINATION; ACUTE ABDOMEN; DECISION-MAKING; SCORING SYSTEM; DIAGNOSTIC-ACCURACY; PRACTICAL SCORE; HISTORY-TAKING; APPENDECTOMY	Appendicitis is a common cause of abdominal pain for which prompt diagnosis is rewarded by a marked decrease in morbidity and mortality. The history and physical examination are at least as accurate as any laboratory modality in diagnosing or excluding appendicitis. Those signs and symptoms most helpful in diagnosing or excluding appendicitis are reviewed. The presence of a positive psoas sign, fever, or migratory pain to the right lower quadrant suggests an increased likelihood of appendicitis. Conversely, the presence of vomiting before pain makes appendicitis unlikely. The lack of the classic migration of pain, right lower quadrant pain, guarding, or fever makes appendicitis less likely, This article reviews the literature evaluating the operating characteristics of the most useful elements of the history and physical examination for the diagnosis of appendicitis.			Wagner, JM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.			Wagner, James/0000-0001-9903-6588				ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; ALVARADO A, 1986, ANN EMERG MED, V15, P557, DOI 10.1016/S0196-0644(86)80993-3; ANTEBY SO, 1975, ANN SURG, V181, P484, DOI 10.1097/00000658-197504000-00022; AVORN J, 1991, ARCH INTERN MED, V151, P694, DOI 10.1001/archinte.151.4.694; BALSANO N, 1990, Emergency Medicine Clinics of North America, V8, P399; BARR D, 1991, WORLD J SURG, V15, P526, DOI 10.1007/BF01675654; BERRY J, 1984, ANN SURG, V200, P567, DOI 10.1097/00000658-198411000-00002; BJERKE K, 1986, GUT, V27, P667, DOI 10.1136/gut.27.6.667; BOND GR, 1990, ANN EMERG MED, V19, P1014; BONGARD F, 1985, AM J SURG, V150, P90, DOI 10.1016/0002-9610(85)90015-7; BRAZAITIS MP, 1993, MED CLIN N AM, V77, P939; BREWER RJ, 1976, AM J SURG, V131, P219, DOI 10.1016/0002-9610(76)90101-X; Britt H, 1994, Aust Fam Physician, V23, P375; BUGLIOSI TF, 1990, ANN EMERG MED, V19, P1383, DOI 10.1016/S0196-0644(05)82602-2; BUSCHARD K, 1973, ACTA CHIR SCAND, V139, P293; CHANG FC, 1973, AM J SURG, V126, P752, DOI 10.1016/S0002-9610(73)80063-7; CHRISTIAN F, 1992, ANN ROY COLL SURG, V74, P281; DAVIES AH, 1991, BRIT J SURG, V78, P1178, DOI 10.1002/bjs.1800781010; DEDOMBAL FT, 1993, POSTGRAD MED J, V69, pS94; DEDOMBAL FT, 1991, DIAGNOSIS ACUTE ABDO, V2, P1; DIXON JM, 1991, BRIT MED J, V302, P386, DOI 10.1136/bmj.302.6773.386; DOMBAL FTD, 1974, BRIT MED J, V1, P376, DOI 10.1136/bmj.1.5904.376; ESKELINEN M, 1995, SCAND J GASTROENTERO, V30, P349, DOI 10.3109/00365529509093289; ESKELINEN M, 1994, INT J BIOMED COMPUT, V36, P239, DOI 10.1016/0020-7101(94)90059-0; FENYO G, 1982, AM J SURG, V143, P751, DOI 10.1016/0002-9610(82)90052-6; FENYO G, 1974, ACTA CHIR SCAND, V140, P396; FENYO G, 1987, ACTA CHIR SCAND, V153, P545; FRANZ MG, 1995, AM SURGEON, V61, P40; GAMAL R, 1990, AM J SURG, V159, P589, DOI 10.1016/S0002-9610(06)80073-5; HAMPTON JR, 1975, BRIT MED J, V2, P486, DOI 10.1136/bmj.2.5969.486; HENNINGTON MH, 1991, ANN SURG, V214, P61; HOUGHTON A, 1988, GASTROINTEST ENDOSC, V34, P489, DOI 10.1016/S0016-5107(88)71451-0; HOWIE JGR, 1966, LANCET, V2, P1334; IRVIN TT, 1989, BRIT J SURG, V76, P1121, DOI 10.1002/bjs.1800761105; IZBICKI JR, 1992, EUR J SURG, V158, P227; Jerman R P, 1969, Br J Clin Pract, V23, P466; JESS P, 1981, AM J SURG, V141, P232, DOI 10.1016/0002-9610(81)90164-1; JOHN H, 1993, WORLD J SURG, V17, P243, DOI 10.1007/BF01658936; JOHNSON JE, 1986, ARCH INTERN MED, V146, P937, DOI 10.1001/archinte.146.5.937; JONES PF, 1990, BRIT J SURG, V77, P365, DOI 10.1002/bjs.1800770404; KANG WM, 1989, SURGERY, V167, P187; KOLLIAS J, 1994, AUST NZ J SURG, V64, P830, DOI 10.1111/j.1445-2197.1994.tb04558.x; LAVELLE SM, 1990, INT J BIOMED COMPUT, V26, P203, DOI 10.1016/0020-7101(90)90043-T; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; LIDDINGTON MI, 1991, BRIT J SURG, V78, P795, DOI 10.1002/bjs.1800780710; LIM HK, 1992, AM J ROENTGENOL, V159, P539, DOI 10.2214/ajr.159.3.1503019; LIN J, 1990, AM J MED, V89, P377, DOI 10.1016/0002-9343(90)90353-F; LOPEZNAVIDAD A, 1990, REV INFECT DIS, V12, P297; MAXWELL JM, 1991, AM SURGEON, V57, P282; MITTELPUNKT A, 1966, SURGERY, V60, P971; MORGAN DL, 1995, ANN EMERG MED, V25, P140; NADLER S, 1990, DIGEST DIS SCI, V35, P603, DOI 10.1007/BF01540408; NARDONE DA, 1988, SOUTH MED J, V81, P770, DOI 10.1097/00007611-198806000-00019; NAUTA RJ, 1986, AM J SURG, V151, P746, DOI 10.1016/0002-9610(86)90057-7; NEUTRA RR, 1978, MED CARE, V16, P956, DOI 10.1097/00005650-197811000-00006; OHMANN C, 1995, EUR J SURG, V161, P273; ORIENT JM, 1985, MED DECIS MAKING, V5, P77, DOI 10.1177/0272989X8500500116; OWENS BJ, 1978, ANN SURG, V187, P392, DOI 10.1097/00000658-197804000-00008; PELTOKALLIO P, 1970, ARCH SURG-CHICAGO, V100, P140; PETERSON MC, 1992, WESTERN J MED, V156, P163; POOLE GV, 1990, SOUTH MED J, V83, P771, DOI 10.1097/00007611-199007000-00013; PUTNAM TC, 1990, SURG GYNECOL OBSTET, V170, P527; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; RAMIREZ JM, 1994, BRIT J SURG, V81, P680, DOI 10.1002/bjs.1800810516; SACKETT KL, 1991, CLIN EPIDEMIOLOGY BA, V2, P173; SARFATI MR, 1993, AM J SURG, V166, P660, DOI 10.1016/S0002-9610(05)80675-0; SCHROCK TR, 1996, GASTROINTESTINAL DIS, P1339; SCHRODER DM, 1993, AM SURGEON, V59, P541; SCHWARTZ SI, 1987, NEW ENGL J MED, V317, P703, DOI 10.1056/NEJM198709103171109; SHEN GK, 1991, ARCH SURG-CHICAGO, V126, P569; SILEN W, 1987, COPES EARLY DIAGNOSI, V17, P1; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; STANILAND JR, 1972, BMJ-BRIT MED J, V3, P393, DOI 10.1136/bmj.3.5823.393; TAOUREL P, 1992, GASTROINTEST RADIOL, V17, P287, DOI 10.1007/BF01888571; TEICHER I, 1983, ANN SURG, V198, P753, DOI 10.1097/00000658-198312000-00014; TODD BS, 1993, MED INFORM, V18, P255, DOI 10.3109/14639239309025314; WADE DS, 1993, ARCH SURG-CHICAGO, V128, P1039; Wasson J H, 1981, Med Decis Making, V1, P215, DOI 10.1177/0272989X8100100302; WHITE JJ, 1975, AM SURGEON, V41, P793; WHITWORTH CM, 1988, SURG GYNECOL OBSTET, V167, P187; WIENER S, 1976, JAMA-J AM MED ASSOC, V236, P852, DOI 10.1001/jama.236.7.852; WILSON DH, 1977, BRIT J SURG, V64, P250, DOI 10.1002/bjs.1800640407	83	188	192	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 20	1996	276	19					1589	1594		10.1001/jama.276.19.1589	http://dx.doi.org/10.1001/jama.276.19.1589			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VT025	8918857				2022-12-28	WOS:A1996VT02500032
J	Vinetz, JM; Glass, GE; Flexner, CE; Mueller, P; Kaslow, DC				Vinetz, JM; Glass, GE; Flexner, CE; Mueller, P; Kaslow, DC			Sporadic urban leptospirosis	ANNALS OF INTERNAL MEDICINE			English	Article						Leptospira interrogans; leptospirosis; urban population; rats; polymerase chain reaction	RISK-FACTORS; ROCHALIMAEA	Background: Surprisingly, many inner-city residents have antibodies to Leptospira interrogans. The manner in which these persons acquire this organism in the absence of recognized occupational, recreational, or epidemic risk factors is not known. Objective: To study the epidemiology of patients with leptospirosis who acquired L. interrogans in inner-city Baltimore, Maryland. Design: Epidemiologic investigation. Setting: Inner-city university hospital. Patients: Three inner-city residents who developed leptospirosis. Measurements: Trapping rats in alleys where the patients may have acquired L. interrogans; polymerase chain reaction (PCR) analysis of patient serum and cerebrospinal fluid specimens and rat tissues to determine the presence of leptospiral DNA; and serologic testing of serum from patients and rats by microagglutination assay to confirm L. interrogans infection. Results: Three patients developed leptospirosis after probable percutaneous exposure to rat (Rattus norvegicus) urine in Baltimore alleys. A PCR assay detected L. interrogans DNA in samples of body fluid obtained from the first two patients at presentation (one in cerebrospinal fluid, the other in serum). Results of PCR done on serum drawn from the third patient after antibiotic therapy began were negative. A microagglutination test showed that all patients had high levels of antibodies to the L. interrogans serogroup Icterohaemorrhagiae. In 19 of 21 rats that were trapped in the alleys where the patients had sustained lacerations before illness developed, kidney or brain tissues were positive by PCR for the presence of L. interrogans. Conclusions: A population was discovered to be at risk for acquiring L. interrogans: urban residents who are sporadically exposed to rat urine in the inner city. Inner-city rats often carry L. interrogans. Polymerase chain reaction can quickly establish the diagnosis of leptospirosis and is useful for epidemiologic study. An endemic substrate for the transmission of the organism is present in inner-city Baltimore. Leptospirosis may become increasingly recognized in deteriorating inner cities in which rat populations are expanding.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT MOL MICROBIOL & IMMUNOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21287 USA; NIH, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA	Vinetz, JM (corresponding author), NIAID, PARASIT DIS LAB, 9000 ROCKVILLE PIKE, BLDG 4, ROOM 126, BETHESDA, MD 20892 USA.			Vinetz, Joseph/0000-0001-8344-2004				BABUDIERI B, 1958, ANN NY ACAD SCI, V70, P393, DOI 10.1111/j.1749-6632.1958.tb35398.x; CACCIAPUOTI B, 1994, EUR J EPIDEMIOL, V10, P173, DOI 10.1007/BF01730367; CHILDS JE, 1992, AM J PUBLIC HEALTH, V82, P597, DOI 10.2105/AJPH.82.4.597; COLE JR, 1973, APPL MICROBIOL, V25, P976, DOI 10.1128/AEM.25.6.976-980.1973; DEMERS RY, 1983, J FAM PRACTICE, V17, P1007; DRANCOURT M, 1995, NEW ENGL J MED, V332, P419, DOI 10.1056/NEJM199502163320702; EDWARDS GA, 1964, MEDICINE, V39, P117; FARR RW, 1995, CLIN INFECT DIS, V21, P1, DOI 10.1093/clinids/21.1.1; FEIGIN RD, 1973, ANN INTERN MED, V79, P777, DOI 10.7326/0003-4819-79-6-777; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691, DOI 10.1099/00221287-139-8-1691; HEATH CW, 1965, NEW ENGL J MED, V273, P857, DOI 10.1056/NEJM196510142731606; MERIEN F, 1995, J INFECT DIS, V172, P281, DOI 10.1093/infdis/172.1.281; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; RELMAN DA, 1995, NEW ENGL J MED, V332, P463, DOI 10.1056/NEJM199502163320710; SASAKI DM, 1993, AM J TROP MED HYG, V48, P35, DOI 10.4269/ajtmh.1993.48.35; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STARR L, 1992, BIOTECHNIQUES, V13, P612; TORTEN M, 1994, HDB ZOONOSES A, P245; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8; 1972, MMWR-MORBID MORTAL W, V21, P401; 1994, MMWR-MORBID MORTAL W, V42, P36; 1995, MMWR-MORBID MORTAL W, V44, P841	22	170	175	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					794	+		10.7326/0003-4819-125-10-199611150-00002	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928985				2022-12-28	WOS:A1996VU52400005
J	Basser, RL; Rasko, JEJ; Clarke, K; Cebon, J; Green, MD; Hussein, S; Alt, C; Menchaca, D; Tomita, D; Marty, J; Fox, RM; Begley, CG				Basser, RL; Rasko, JEJ; Clarke, K; Cebon, J; Green, MD; Hussein, S; Alt, C; Menchaca, D; Tomita, D; Marty, J; Fox, RM; Begley, CG			Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer	LANCET			English	Article							CARBOPLATIN-INDUCED THROMBOCYTOPENIA; C-MPL LIGAND; PLATELET PRODUCTION; OVARIAN-CANCER; INTERLEUKIN-1-ALPHA; PURIFICATION; CHEMOTHERAPY; STIMULATION; EXPRESSION; REGULATOR	Background Pegytated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) is a potent stimulator of megakaryocyte colony formation and platelet production. It is likely to be useful in the management of severe thrombocytopenia, To determine its clinical activity and safety, we gave it to patients with advanced cancer before chemotherapy. Methods Patients were randomly assigned to receive either PEG-rHuMGDF or placebo in a three to one ratio. PEG-rHuMGDF was given at a dose of 0.03, 0.1, 0.3, or I.0 mu g/kg body weight. The study drug or placebo were administered daily by subcutaneous injection for up to 10 days or until a target platelet count was reached. Findings 17 patients, median age 59 years, received either PEG-rHuMGDF (13 patients) or placebo (four patients), PEG-rHuMGDF produced a dose-dependent increase in platelet counts. Patients given placebo, 0.03, and 0.1 mu g/kg of PEG-rHuMGDF had median increases in platelet counts of 16%, 12%, and 39%. Those receiving 0.3 and 1.0 mu g/kg of PEG-rHuMGDF had an increase in blood platelets of between 51% and 584%. Platelets rose from day 6 of PEG-rHuMGDF administration and continued to rise after stopping the drug. The platelet count peaked between days 12 and 18 and remained above 450x10(9)/L for up to 21 days. There were no alterations in white-blood-cell count or haematocrit, and low toxicity. Platelets taken from patients during PEG-rHuMGDF administration and at the time of peak platelet count were morphologically and functionally normal. Interpretation The potency with which PEG-rHuMGDF stimulates platelet production and its low toxicity indicate that this is likely to be a useful agent for the management of thrombocytopenia.	AUSTIN REPATRIAT MED CTR,LUDWIG INST,ONCOL UNIT,PARKVILLE,VIC,AUSTRALIA; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,ROTARY BONE MARROW RES LABS,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT HAEMATOL,MELBOURNE,VIC,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT MED ONCOL,MELBOURNE,VIC,AUSTRALIA; WESTERN HOSP,MELBOURNE,VIC,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; AMGEN AUSTRALIA,KEW,VIC,AUSTRALIA; AMGEN INC,THOUSAND OAKS,CA 91320	Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Royal Melbourne Hospital; Royal Melbourne Hospital; Western Hospital; Walter & Eliza Hall Institute; Amgen	Basser, RL (corresponding author), ROYAL MELBOURNE HOSP,CTR DEV CANC THERAPEUT,PARKVILLE,VIC 3050,AUSTRALIA.		Rasko, John EJ/F-5754-2013; Cebon, Jonathan S/H-1643-2013	rasko, John/0000-0003-2975-807X; Cebon, Jonathan/0000-0002-3898-950X				BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BEGLEY G, 1996, P ASCO, V15, P271; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; CHOI ES, 1995, STEM CELLS, V13, P317, DOI 10.1002/stem.5530130313; COLUMBYOVA L, 1995, CANCER RES, V55, P3509; DELGADO C, 1992, CRIT REV THER DRUG, V9, P249; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DHONDT V, 1995, BLOOD, V85, P2347, DOI 10.1182/blood.V85.9.2347.bloodjournal8592347; DU XX, 1994, BLOOD, V83, P2023; FARESE AM, 1995, BLOOD, V86, P54, DOI 10.1182/blood.V86.1.54.bloodjournal86154; Gordon MS, 1996, BLOOD, V87, P3615, DOI 10.1182/blood.V87.9.3615.bloodjournal8793615; Harker LA, 1996, BLOOD, V87, P1833, DOI 10.1182/blood.V87.5.1833.bloodjournal8751833; HOKOM MM, 1995, BLOOD, V86, P4486, DOI 10.1182/blood.V86.12.4486.bloodjournal86124486; KATO T, 1995, J BIOCHEM-TOKYO, V118, P229, DOI 10.1093/oxfordjournals.jbchem.a124883; KUTER DJ, 1994, P NATL ACAD SCI USA, V91, P11104, DOI 10.1073/pnas.91.23.11104; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; NICOLA NA, 1994, STEM CELLS, V12, P3; OMALLEY CJ, 1996, IN PRESS BLOOD; SMITH JW, 1993, NEW ENGL J MED, V328, P756, DOI 10.1056/NEJM199303183281103; ULICH TR, 1995, BLOOD, V86, P971; VADHANRAJ S, 1994, J CLIN ONCOL, V12, P707, DOI 10.1200/JCO.1994.12.4.707; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	23	177	185	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1279	1281		10.1016/S0140-6736(96)04471-6	http://dx.doi.org/10.1016/S0140-6736(96)04471-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909381				2022-12-28	WOS:A1996VR55500011
J	Cetron, MS; Chitsulo, L; Sullivan, JJ; Pilcher, J; Wilson, M; Noh, J; Tsang, VC; Hightower, AW; Addiss, DG				Cetron, MS; Chitsulo, L; Sullivan, JJ; Pilcher, J; Wilson, M; Noh, J; Tsang, VC; Hightower, AW; Addiss, DG			Schistosomiasis in Lake Malawi	LANCET			English	Article							ADULT MICROSOMAL ANTIGENS; SEROLOGIC REAGENT; FAST-ELISA; MANSONI; HAEMATOBIUM; COMPONENTS; MAMA	Background In 1992 two US Peace Corps volunteers (PCVs) developed central nervous system schistosomiasis due to infection with Schistosoma haematobium following recreational water exposure at Cape Maclear on Lake Malawi, an African lake considered by many to be free of schistosomiasis, To determine the transmission potential and risk for aquiring schistosomiasis in Lake Malawi, a cross-sectional survey of resident expatriates and visitors to Malawi was done during March and April, 1993. Methods A volunteer cohort of expatriates and visitors representing a cross-section of Malawi's foriegn population answered detailed questions about freshwater contact and provided blood specimens to determine the seroprevalence of S haematobium and S mansoni by ELISA and immunoblot analyses, A survey for Vector snails was conducted along Lake Malawi's southwestern shore. Findings The study population of 955 included 305 US citizens and 650 non-US foreign nationals. 303 of the study population had seroiogical evidence of current or past schistosome infection. Seroprevalence was 32% (141/440) among expatriates whose freshwater exposure was limited to Lake Malawi; S haematobium antibodies were found in 135 of 141 (96%) seropositive specimens. Risk of seropositivity increased with the number of freshwater exposures at Lake Malawi resorts. Although many resort areas in the southwestern lake region posed a significant risk, Cape Maclear was the location most strongly associated with seropositivity (OR 2.9, 95% CI 1.6-5.1). Methods Schistosome-infected Bulinus globosus, the snail vector of Objectives S haematobium in Malawi. were found at Cape Maclear and other locations along the lakeshore. Interpretation S haematobium infection is highly prevalent among expatriates and tourists in Malawi, Recreational water contact at popular resorts on Lake Malawi is the most likely source of infection. Transmission of schistosomiasis is occurring in Lake Malawi, a previously under-recognised site of transmission.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA	Centers for Disease Control & Prevention - USA								BLANCHARD TJ, 1993, LANCET, V341, P959, DOI 10.1016/0140-6736(93)91249-L; BLUNT SB, 1993, LANCET, V341, P557, DOI 10.1016/0140-6736(93)90317-A; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P565; CROWTHER G, 1992, AFRICA SHOESTRING, P581; EULDERINK F, 1994, AM J DERMATOPATH, V16, P434, DOI 10.1097/00000372-199408000-00015; EVANS AC, 1975, MALAWI INVESTIGATION, P2; GOLDSMITH PC, 1993, BMJ-BRIT MED J, V307, P556, DOI 10.1136/bmj.307.6903.556; HANCOCK K, 1986, J IMMUNOL METHODS, V92, P167, DOI 10.1016/0022-1759(86)90162-6; HARRIES AD, 1986, LANCET, V1, P86; MCKAYE KR, 1986, EXP BIOL, V45, P279; POLLNER JH, 1994, CLIN INFECT DIS, V18, P354, DOI 10.1093/clinids/18.3.354; PUGH RNH, 1993, BRIT MED J, V307, P1354, DOI 10.1136/bmj.307.6915.1354-b; RUSSELL JM, 1993, BRIT MED J, V307, P937, DOI 10.1136/bmj.307.6909.937; SCRIMGEOUR EM, 1985, BRAIN, V108, P1023, DOI 10.1093/brain/108.4.1023; STAUFFER JR, IN PRESS BIOSCIENCE; TEESDALE CH, 1985, TROPENMED PARASITOL, V36, P1; TSANG VCW, 1984, J IMMUNOL, V132, P2607; TSANG VCW, 1983, J IMMUNOL, V130, P1366; TSANG VCW, 1983, J IMMUNOL, V130, P1359; TSANG VCW, 1991, CLIN LAB MED, V11, P1029, DOI 10.1016/S0272-2712(18)30533-X; WHITWORTH JAG, 1993, BRIT MED J, V307, P936, DOI 10.1136/bmj.307.6909.936-c	21	83	84	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1274	1278		10.1016/S0140-6736(96)01511-5	http://dx.doi.org/10.1016/S0140-6736(96)01511-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909380				2022-12-28	WOS:A1996VR55500010
J	Benhamou, Y; Katlama, C; Lunel, F; Coutellier, A; Dohin, E; Hamm, N; Tubiana, R; Herson, S; Poynard, T; Opolon, P				Benhamou, Y; Katlama, C; Lunel, F; Coutellier, A; Dohin, E; Hamm, N; Tubiana, R; Herson, S; Poynard, T; Opolon, P			Effects of lamivudine on replication of hepatitis B virus in HIV-infected men	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis B; human immunodeficiency; virus infections; lamivudine; virus replication; comorbidity	HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC ACTIVE HEPATITIS; ALPHA-INTERFERON; SURVIVAL; CARRIERS; EFFICACY; INVITRO; THERAPY; TRIAL	Background: Therapy for hepatitis B virus (HBV) infection is still unsatisfactory, particularly in patients who are co-infected with the human immunodeficiency virus (HIV). Lamivudine, a retroviral inhibitor, has been shown to have activity against HBV replication in vitro, in animal models, and in studies of immunocompetent persons. Objective: To assess the efficacy of lamivudine in inhibiting HBV replication during a 12-month period in patients with both HBV and HIV infection. Design: Prospective, open study. Setting: University hospital. Patients: 40 consecutive patients (39 men and 1 woman) infected with both HIV and HBV. All had progressive HIV disease; were refractory to or unable to tolerate therapies other than lamivudine; and received lamivudine, 600 mg/d or 600 mg/d followed by 300 mg/d, as therapy for HIV disease. Measurements: Serum concentrations of HBV DNA were assessed every 2 months by using molecular hybridization. Polymerase chain reaction (PCR) for HBV DNA was done at baseline and was done at months 2, 6, and 12 only if the HBV DNA concentration was less than 5 pg/mL. Results: Two groups were retrospectively identified at baseline: patients with high HBV replication (serum HBV DNA concentrations >5 pg/mL) (n = 30) and patients with low HBV replication (serum HBV DNA concentrations <5 pg/mL) (n = 10). After 12 months of treatment, 26 of 27 patients (96.3% [95% Cl, 81% to 99.9%]) who had had high HBV replication at baseline had serum HBV DNA concentrations less than 5 pg/mL. However, PCR could still detect HBV DNA in serum in 11.5% (Cl, 2% to 30%) of these patients. Among patients who had had low HBV replication at baseline, the results of PCR for serum HBV DNA became negative in the 6 patients who had had a positive result on PCR at baseline. No serious adverse events occurred during treatment. Conclusion: Although this study was not a randomized, blinded trial, it suggests that lamivudine is active against HBV replication in men infected with both HBV and HIV.	GRP HOSP PITIE SALPETRIERE, SERV MALAD INFECT, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, VIROL LAB, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, SERV MED INTERNE, F-75651 PARIS 13, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Benhamou, Y (corresponding author), GRP HOSP PITIE SALPETRIERE, SERV HEPATOGASTROENTEROL, 47 BLVD HOP, F-75651 PARIS 13, FRANCE.		françoise, lunel/B-7273-2015; Poynard, Thierry/C-1355-2010	françoise, lunel/0000-0002-1856-0300; Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; ANTINORI S, 1993, J HEPATOL, V18, P255, DOI 10.1016/S0168-8278(05)80254-5; ASHMAN C, 1994, 6 INT S VIR HEP MADR, P65; BROOK MG, 1989, HEPATOLOGY, V10, P761, DOI 10.1002/hep.1840100502; BROOK MG, 1988, VIRAL HEPATITIS LIVE, P906; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHOSSEGROS P, 1993, GASTROENTEROLOGY, V104, pA888; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DIANZANI F, 1993, GUT, V34, pS74, DOI 10.1136/gut.34.2_Suppl.S74; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; FRIED MW, 1992, HEPATOLOGY, V20, pA209; GARCIA F, 1995, J CLIN MICROBIOL, V33, P413, DOI 10.1128/JCM.33.2.413-415.1995; KANE MA, 1993, GUT, V34, pS10, DOI 10.1136/gut.34.2_Suppl.S10; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KROGSGAARD K, 1987, HEPATOLOGY, V7, P37, DOI 10.1002/hep.1840070109; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MARCELLIN P, 1989, HEPATOLOGY, V10, P328, DOI 10.1002/hep.1840100313; MARCELLIN P, 1989, NEW ENGL J MED, V321, P1758; MCDONALD JA, 1987, HEPATOLOGY, V7, P719, DOI 10.1002/hep.1840070417; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MONNO L, 1988, VIRAL HEPATITIS LIVE, P205; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; RUSTGI VK, 1984, ANN INTERN MED, V101, P795, DOI 10.7326/0003-4819-101-6-795; Taylor PE, 1988, VIRAL HEPATITIS LIVE, P198; TYRRELL DL, 1993, CLIN INVEST MED S4, V16, P877; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG DKH, 1995, GASTROENTEROLOGY, V108, P165, DOI 10.1016/0016-5085(95)90021-7	31	135	137	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					705	+		10.7326/0003-4819-125-9-199611010-00001	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929003				2022-12-28	WOS:A1996VQ07200001
J	Holmes, TC; Fadool, DA; Ren, RB; Levitan, IB				Holmes, TC; Fadool, DA; Ren, RB; Levitan, IB			Association of Src tyrosine kinase with a human potassium channel mediated by SH3 domain	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR; HIPPOCAMPAL-NEURONS; PROTEIN; BINDING; MEMBRANE; FAMILY; KV1.5; IDENTIFICATION; LOCALIZATION; MODULATION	The human Kv1.5 potassium channel (hKv1.5) contains proline-rich sequences identical to those that bind to src homology 3 (SH3) domains. Direct association of the Src tyrosine kinase with cloned hKv1.5 and native hKv1.5 in human myocardium was observed. This interaction was mediated by the proline-rich motif of hKv1.5 and the SH3 domain of Src. Furthermore, hKv1.5 was tyrosine phosphorylated, and the channel current was suppressed, in cells coexpressing v-Src. These results provide direct biochemical evidence for a signaling complex composed of a potassium channel and a protein tyrosine kinase.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,VOLEN CTR COMPLEX SYST,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University; Brandeis University; Brandeis University; Brandeis University				Holmes, Todd/0000-0001-8152-8832	NINDS NIH HHS [F32 NS009952] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009952] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BIELEFELDT K, 1994, BIOPHYS J, V66, P1904, DOI 10.1016/S0006-3495(94)80984-1; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FUHRER C, IN PRESS J BIOL CHEM; Holmes TC, 1996, J NEUROSCI, V16, P1581; HOLMES TJ, UNPUB; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KOMAU HC, 1995, SCIENCE, V269, P1737; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; MAYS DJ, 1995, J CLIN INVEST, V96, P282, DOI 10.1172/JCI118032; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; OVERTURF KE, 1994, AM J PHYSIOL-CELL PH, V267, pC1231, DOI 10.1152/ajpcell.1994.267.5.C1231; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; REINHART PH, 1995, J NEUROSCI, V15, P4572; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SASAKI Y, 1995, FEBS LETT, V372, P20, DOI 10.1016/0014-5793(95)00954-8; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; SWOPE SL, 1994, J BIOL CHEM, V269, P29817; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	31	240	244	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 20	1996	274	5295					2089	2091		10.1126/science.274.5295.2089	http://dx.doi.org/10.1126/science.274.5295.2089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY974	8953041				2022-12-28	WOS:A1996VY97400051
J	Adamson, DC; Wildemann, B; Sasaki, M; Glass, JD; McArthur, JC; Christov, VI; Dawson, TM; Dawson, VL				Adamson, DC; Wildemann, B; Sasaki, M; Glass, JD; McArthur, JC; Christov, VI; Dawson, TM; Dawson, VL			Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER; NERVOUS-SYSTEM; COAT PROTEIN; CYTOKINE EXPRESSION; CORTICAL CULTURES; ENVELOPE PROTEIN; NEURONAL INJURY	Indirect mechanisms are implicated in the pathogenesis of the dementia associated with human immunodeficiency virus-typo 1 (HIV-1) infection. Proinflammatory molecules such as tumor necrosis factor alpha and eicosanoids are elevated in the central nervous system of patients with HIV-1-related dementia. Nitric oxide (NO) is a potential mediator of neuronal injury, because cytokines may activate the immunologic (type II) isoform of No synthase (iNOS). The levels of iNOS in severe HIV-1-associated dementia coincided with increased expression of the HIV-1 coat protein gp41. Furthermore, gp41 induced iNOS in primary cultures of mixed rat neuronal and glial cells and killed neurons through a NO-dependent mechanism. Thus, gp41-induced NO formation may contribute to the severe cognitive dysfunction associated with HIV-1 infection.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035042] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35042] Funding Source: Medline; NINDS NIH HHS [NS22643, NS07392] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson DC, 1996, MOL MED, V2, P417, DOI 10.1007/BF03401901; ADAMSON DR, UNPUB; ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BONOFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Dickson D W, 1996, J NeuroAIDS, V1, P57; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GELBARD HA, 1995, NEUROPATH APPL NEURO, V21, P208, DOI 10.1111/j.1365-2990.1995.tb01052.x; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; GLASS JD, 1995, ANN NEUROL, V38, P755, DOI 10.1002/ana.410380510; GRIFFIN DE, 1994, ANN NEUROL, V35, P592, DOI 10.1002/ana.410350513; HARRISON MJG, 1995, AIDS NEUROLOGY, P32; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; HILL JM, 1993, BRAIN RES, V603, P222, DOI 10.1016/0006-8993(93)91241-J; JANSSEN RS, 1991, NEUROLOGY, V41, P778; Johnson RT, 1996, ANN NEUROL, V39, P392, DOI 10.1002/ana.410390319; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOKA P, 1995, J NEUROIMMUNOL, V57, P179, DOI 10.1016/0165-5728(94)00184-P; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; Lane TE, 1996, MOL MED, V2, P27, DOI 10.1007/BF03402200; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; MACKENZIEGRAHAM AJ, 1994, DEV NEUROSCI-BASEL, V16, P162, DOI 10.1159/000112103; MASLIAH E, 1992, LAB INVEST, V66, P285; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V194, P439, DOI 10.1006/bbrc.1993.1839; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; PETITO CK, 1995, AM J PATHOL, V146, P1121; PIETRAFORTE D, 1994, J LEUKOCYTE BIOL, V55, P175, DOI 10.1002/jlb.55.2.175; POWER C, 1994, J VIROL, V68, P4643, DOI 10.1128/JVI.68.7.4643-4649.1994; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; SAVIO T, 1993, J NEUROSCI RES, V34, P265, DOI 10.1002/jnr.490340303; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TOMATORE C, 1994, NEUROLOGY, V44, P481; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; VAZEUX R, 1992, AM J PATHOL, V140, P137; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WILDEMANN B, UNPUB; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WILEY CA, 1994, ANN NEUROL, V36, P673, DOI 10.1002/ana.410360422; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581	69	372	379	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1917	1921		10.1126/science.274.5294.1917	http://dx.doi.org/10.1126/science.274.5294.1917			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943206				2022-12-28	WOS:A1996VY20000046
J	Yamaguchi, H; Hendrickson, WA				Yamaguchi, H; Hendrickson, WA			Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; DOMAINS; P56LCK; CD4; ICK	REGULATION through phosphorylation is a characteristic of signalling pathways(1,2), and the lymphocyte kinase Lck (p56(lck)) both performs phosphorylation and is affected by it. Lck is a Src-family tyrosine kinase expressed in T lymphocytes, where it participates in the cellular immune response(3). Like all Src homologues, it comprises SH3, SH2 and kinase domains. Lck associates through its distinctive amino-terminal segment with the cytoplasmic tails of either T cell co-receptor, CD4 or CD8-alpha(4,5) Activated Lck phosphorylates T-cell receptor zeta-chains, which then recruit the ZAP70 kinase to promote T cell activation(6). Lck is activated by autophosphorylation at Tyr 394 in the activation loop(7) and it is inactive when Tyr 505 near the carboxy terminus is phosphorylated and interacts with its own SH2 domain(8). Here we report the crystal structure of the Lck tyrosine kinase domain (LCKK) in its activated state at 1.7 Angstrom resolution. The structure reveals how a phosphoryl group at Tyr 394 generates a competent active site. Comparisons with other kinase structures indicate that tyrosine phophophorylation and ligand binding may in general elicit two distinct hinge-like movements between the kinase subdomains. From modelling studies, we suggest a basis for inhibition by phosphorylation at Tyr 505.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute; Columbia University								Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FISCHER EH, 1955, J BIOL CHEM, V216, P121; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; *SERC, 1979, 4 SERC DAR LAB; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1990, ONCOGENE, V5, P1455; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	28	421	430	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					484	489		10.1038/384484a0	http://dx.doi.org/10.1038/384484a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945479				2022-12-28	WOS:A1996VW68700069
J	Quinn, TC; Gaydos, C; Shepherd, M; Bobo, L; Hook, EW; Viscidi, R; Rompalo, A				Quinn, TC; Gaydos, C; Shepherd, M; Bobo, L; Hook, EW; Viscidi, R; Rompalo, A			Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; PELVIC INFLAMMATORY DISEASE; FIRST-VOID URINE; REACTION ASSAY; MONOCLONAL-ANTIBODIES; NEISSERIA-GONORRHOEAE; ENZYME-IMMUNOASSAY; ASYMPTOMATIC MEN; DIAGNOSIS; WOMEN	Objectives.-To determine the frequency of Chlamydia trachomatis genital infection within sexual partnerships using highly sensitive polymerase chain reaction (PCR) amplification and to identify the variables that might modify transmission. Design.-Cross-sectional study of sexual partnerships comparing in vitro culture and PCR amplification for C trachomatis. Setting.-Two outpatient sexually transmitted disease clinics. Participants.-Four hundred ninety-four people in sexual partnerships attending sexually transmitted disease clinics. Main Outcome Measure.-Genital infection with C trachomatis. Methods.-DNA sequencing was performed to examine specific genotypes within and between partnerships. Cross-sectional analysis was performed to determine characteristics associated with concordance or discordance of infection with partnerships. Results.-Cultures were positive for C trachomatis in 8.5% of males and 12.9% of females (P=.03), Using PCR, more infections were identified both in males (14.2%) and in females (15.8%), and the difference in infection rates analyzed by sex was no longer significant. In 20.4% of 494 couples, at least 1 partner had PCR results positive for C trachomatis, with a concordant infection rate of 10.7%, significantly higher than the 5.5% concordant infection rate demonstrable by culture (P<.01). Male-female and female-male transmission frequencies were equal (68%). The nucleotide sequences of the major outer membrane protein gene products were identical and unique for each of 15 culture-negative, PCR-positive concordant partnerships. In concordant infections, factors associated with infection in female partners were age less than 20 years, more than 1 partner in the past 6 months, and cervical ectopy greater than 25%. Conclusions.-Using PCR, the frequency of chlamydia transmission by infected males and females was nearly identical. The high rate of concordant infection, high frequency of infection among asymptomatic individuals, and high frequency of transmission regardless of sex underscore the importance of routine screening for chlamydia in both males and females, along with provision of treatment to all sexual partners of chlamydia-infected individuals.	NIAID, NIH, BETHESDA, MD 20892 USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Quinn, TC (corresponding author), JOHNS HOPKINS UNIV, DIV INFECT DIS, DEPT MED, ROSS 1159, 720 RUTLAND AVE, BALTIMORE, MD 21205 USA.		Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Viscidi, Raphael/0000-0002-7906-8002	NIAID NIH HHS [5R01 AI27727-03, 5R01 AI29508-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027727, R01AI029508] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; BARNES RC, 1985, J CLIN MICROBIOL, V22, P609, DOI 10.1128/JCM.22.4.609-613.1985; BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L; BRUNHAM RC, 1994, SEX TRANSM DIS, V21, P353, DOI 10.1097/00007435-199411000-00010; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; CHERNESKY MA, 1994, J INFECT DIS, V170, P1308, DOI 10.1093/infdis/170.5.1308; DUNLOP EMC, 1985, SEX TRANSM DIS, V12, P68, DOI 10.1097/00007435-198504000-00003; *GLOB PROGR AIDS W, 1995, OV SEL CUR SEX TRANS; HARRISON HR, 1985, AM J OBSTET GYNECOL, V153, P244, DOI 10.1016/S0002-9378(85)80105-8; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; HOOK EW, 1992, AM J EPIDEMIOL, V136, P662, DOI 10.1093/oxfordjournals.aje.a116546; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; JONES RB, 1986, J CLIN MICROBIOL, V24, P1029, DOI 10.1128/JCM.24.6.1029-1033.1986; Katz BP, 1990, CHLAMYDIA INFECT, P567; KUNIMOTO D, 1985, REV INFECT DIS, V7, P665; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; LYCKE E, 1980, SEX TRANSM DIS, V7, P6, DOI 10.1097/00007435-198001000-00002; MAHONY JB, 1992, J CLIN MICROBIOL, V30, P2241, DOI 10.1128/JCM.30.9.2241-2245.1992; PAAVONEN J, 1978, SEX TRANSM DIS, V5, P93, DOI 10.1097/00007435-197807000-00003; PAAVONEN J, 1979, SEX TRANSM DIS, V6, P69, DOI 10.1097/00007435-197904000-00005; QUINN TC, 1994, SEX TRANSM DIS, V21, pS19; QUINN TC, 1992, ADV HOST DEFENSE MEC, V8, P1; RAMSTEDT K, 1991, SEX TRANSM DIS, V18, P205, DOI 10.1097/00007435-199110000-00002; ROLFS RT, 1992, AM J OBSTET GYNECOL, V166, P983, DOI 10.1016/0002-9378(92)91377-M; RYS PN, 1990, J CLIN MICROBIOL, V28, P1968; SCHACHTER J, 1989, NEW ENGL J MED, V320, P802, DOI 10.1056/NEJM198903233201210; SCHACHTER J, 1990, WESTERN J MED, V153, P523; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SHAFER MA, 1987, J INFECT DIS, V156, P223, DOI 10.1093/infdis/156.1.223; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; VISCIDI RP, 1993, J INFECT DIS, V168, P488, DOI 10.1093/infdis/168.2.488; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WOLCOTT MJ, 1992, CLIN MICROBIOL REV, V5, P370, DOI 10.1128/CMR.5.4.370-386.1992; WORM AM, 1987, GENITOURIN MED, V63, P19; YUAN Y, 1989, INFECT IMMUN, V57, P1040, DOI 10.1128/IAI.57.4.1040-1049.1989	41	167	168	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1737	1742		10.1001/jama.276.21.1737	http://dx.doi.org/10.1001/jama.276.21.1737			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940322				2022-12-28	WOS:A1996VV56600031
J	Tinker, A; Jan, YN; Jan, LY				Tinker, A; Jan, YN; Jan, LY			Regions responsible for the assembly of inwardly rectifying potassium channels	CELL			English	Article							RECTIFIER K+ CHANNEL; FUNCTIONAL EXPRESSION; ACETYLCHOLINE-RECEPTOR; MOLECULAR-CLONING; PROTEINS; MG2+; RECTIFICATION; MUTATIONS; AGONISTS; NEURONS	Inwardly rectifying potassium channels have an important role in determining the resting potential of the cell. They are tetrameric proteins with two transmembrane segments (M1 and M2), a pore-forming loop (H5), a cytoplasmic N-terminal, and longer C-terminal domain. We have used biochemical and electrophysiological methods to identify regions required for homotypic interactions and those responsible for the incompatibility between IRK1 and two other members of the same subfamily (IRK2 and IRK3) and two members from other subfamilies (ROMK1 and 6.1\uK(ATP)). The data indicate that, in contrast to the voltage-gated class of potassium channel, the proximal C-terminus and the transmembrane segment M2 determine homo- and heteromultimerization and that heteromultimerization between members of the same or different subfamilies is case specific.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048200] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48200] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; Collins A, 1996, J NEUROSCI, V16, P1; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; Fink M, 1996, FEBS LETT, V378, P64, DOI 10.1016/0014-5793(95)01388-1; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Isomoto S, 1996, BIOCHEM BIOPH RES CO, V218, P286, DOI 10.1006/bbrc.1996.0050; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KIM KM, 1995, NEUROSCIENCE, V69, P1145, DOI 10.1016/0306-4522(95)00326-E; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIAO YJ, 1996, IN PRESS J NEUROSCI; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, J GEN PHYSIOL, V104, P477, DOI 10.1085/jgp.104.3.477; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MCNICHOLAS CM, 1996, IN PRESS AM J PHYSL; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; PREMKUMAR LS, 1994, J NEUROPHYSIOL, V71, P2570, DOI 10.1152/jn.1994.71.6.2570; Reuveny E, 1996, BIOPHYS J, V70, P754, DOI 10.1016/S0006-3495(96)79615-7; SHEN NV, 1993, NEURON, V11, P67; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAKAHASHI N, 1994, J BIOL CHEM, V269, P23274; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	52	134	138	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	1996	87	5					857	868		10.1016/S0092-8674(00)81993-5	http://dx.doi.org/10.1016/S0092-8674(00)81993-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945513	Bronze			2022-12-28	WOS:A1996VV77400012
J	Sidel, VW				Sidel, VW			The social responsibilities of health professionals - Lessons from their role in Nazi Germany	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONFLICTS		ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Sidel, VW (corresponding author), MONTEFIORE MED CTR, DEPT EPIDEMIOL & SOCIAL MED, 111 E 210TH ST, BRONX, NY 10467 USA.							ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; *AMN INT, 1996, PRESCR CHANG HLTH PR; Annas George J., 1992, NAZI DOCTORS NUREMBE; AYRES BD, 1996, NY TIMES        0827, pA10; AYRES BD, 1996, NY TIMES        0827, pA1; Barondess JA, 1996, JAMA-J AM MED ASSOC, V276, P1657, DOI 10.1001/jama.276.20.1657; Brink P J, 1991, West J Nurs Res, V13, P162, DOI 10.1177/019394599101300201; British Medical Association, 1992, MED BETR PART DOCT H; Geiger H. Jack, 1993, JAMA (Journal of the American Medical Association), V270, P616, DOI 10.1001/jama.270.5.616; Goffman E., 1963, BEHAV PUBLIC PLACES, P3; Goldhagen DJ., 1996, HITLERS WILLING EXEC; HAHN S, 1994, MED ETHICS 3 REICH H, P143; HANAUSKEABEL HM, 1986, LANCET, V2, P271; Iacopino V, 1996, JAMA-J AM MED ASSOC, V276, P396, DOI 10.1001/jama.276.5.396; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LENRER BH, 1995, ANN INTERN MED, V122, P793; Lifton R. J., 1986, NAZI DOCTORS MED KIL; Mitscherlich A, 1949, DOCTORS INFAMY STORY; MOSS R, 1957, MED WAR, V3, P43; Pagels Elaine, 1995, ORIGIN SATAN; Proctor Robert, 1992, NAZI DOCTORS NUREMBE, P17; Proctor Robert N., 1988, RACIAL HYGIENE MED N; RODWIN MA, 1995, NEW ENGL J MED, V332, P604, DOI 10.1056/NEJM199503023320913; SIDEL V, 1986, NEW PHYSICIAN, V35, P7; SIDEL V, 1986, NEW PHYSICIAN, V35, P32; SIDEL VW, 1989, JAMA-J AM MED ASSOC, V262, P680, DOI 10.1001/jama.262.5.680; Sidel VW, 1995, BRIT MED J, V311, P1677, DOI 10.1136/bmj.311.7021.1677; Sonis J, 1996, JAMA-J AM MED ASSOC, V276, P1676, DOI 10.1001/jama.276.20.1676; Steppe H, 1992, West J Nurs Res, V14, P744, DOI 10.1177/019394599201400607; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P331, DOI 10.1001/jama.272.5.331; *UN, 1949, UNIV DECL HUM RIGHTS; Westermeyer J, 1996, JAMA-J AM MED ASSOC, V276, P416, DOI 10.1001/jama.276.5.416; *WHO, 1985, WHO BAS DOC; *WORLD MED ASS, 1985, WORLD MED ASS HDB DE, P3; ZWI AB, 1987, SOC SCI MED, V25, P649, DOI 10.1016/0277-9536(87)90092-X; 1993, JAMA-J AM MED ASSOC, V270, P365; 1996, ECONOMICST      0427, P91	37	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1679	1681		10.1001/jama.276.20.1679	http://dx.doi.org/10.1001/jama.276.20.1679			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922457				2022-12-28	WOS:A1996VU20900038
J	Oliver, S; Rajan, L; Turner, H; Oakley, A; Entwistle, V; Watt, I; Sheldon, TA; Rosser, J				Oliver, S; Rajan, L; Turner, H; Oakley, A; Entwistle, V; Watt, I; Sheldon, TA; Rosser, J			Informed choice for users of health services: Views on ultrasonography leaflets of women in early pregnancy, midwives, and ultrasonographers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE	With the aim of promoting the informed choice of pregnant women, staff and pregnant women at two urban hospitals were offered leaflets summarising the best available evidence about the effectiveness of routine ultrasonography in early pregnancy. Ultrasonographers doubted the credibility of the evidence and were concerned that the leaflets would raise women's anxiety, reduce uptake of scans, disrupt hospital organisation, and reinforce media messages about the poor safety record of ultrasonography. Midwives thought that the leaflets would inform women, help them to talk about their care with health professionals, and help them to get better care. Women were shocked at some of the contents but thought that it was appropriate to include both advantages and disadvantages of routine scanning in the leaflet. This case study highlights the resistance of some health professionals to evidence based health care; underlying conflicts with the principle of professional autonomy; concern that informed choice may create anxiety; and professional and organisational barriers to allowing informed choice.	UNIV YORK, NHS CTR REVIEWS & DISSEMINAT, YORK YO1 5DD, N YORKSHIRE, ENGLAND; MIDWIVES INFORMAT & RESOURCE SERV, BRISTOL BS8 1SL, AVON, ENGLAND	University of York - UK	Oliver, S (corresponding author), UNIV LONDON, INST EDUC, SOCIAL SCI RES UNIT, LONDON WC1H 0NS, ENGLAND.		Entwistle, Vikki Ann/I-9266-2019; Sheldon, Trevor/AAK-7088-2021	Entwistle, Vikki Ann/0000-0002-0856-4025; Sheldon, Trevor/0000-0002-7479-5913; Oliver, Sandy/0000-0001-9571-269X				ALDERSON P, 1992, SSRU CONSENT C SERIE, V1; BEECH BL, 1993, ASS IMPROVEMENTS MAT, V5, P9; BERWICK DM, 1985, MED CARE, V23, P881, DOI 10.1097/00005650-198507000-00005; *BMJ PUBL GROUP, 1995, COCHR PREGN CHILDB D; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; College of Radiographers, 1994, COD PROF COND; Department of Health, 1993, CHANG CHILDB; Department of Health, 1991, PAT CHART; ENKIN M, 1995, GUIDE EFFECTIVE CARE, P40; HUGHES TE, 1991, MED CARE, V29, P297, DOI 10.1097/00005650-199103000-00011; HYATT J, 1994, IT TOGETHER PROMOTIN; MCKINLAY JB, 1981, MILBANK FUND Q, V59, P374, DOI 10.2307/3349685; MEREDITH P, 1993, SOCIOL HEALTH ILL, V15, P315, DOI 10.1111/1467-9566.ep10490539; NEILSON JP, 1995, PREGNANCY CHILDBIRTH; OLIVER S, 1996, 7 CRD; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; *ROYAL COLL OBST G, 1994, INF PAMPHL SER; SHACKLEY P, 1994, J SOC POLICY, V23, P517, DOI 10.1017/S0047279400023333	18	27	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	1996	313	7067					1251	1253		10.1136/bmj.313.7067.1251a	http://dx.doi.org/10.1136/bmj.313.7067.1251a			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU208	8939120	Green Published			2022-12-28	WOS:A1996VU20800031
J	Strauchen, JA; Hauser, AD; Burstein, D; Jimenez, R; Moore, PS; Chang, Y				Strauchen, JA; Hauser, AD; Burstein, D; Jimenez, R; Moore, PS; Chang, Y			Body cavity-based malignant lymphoma containing Kaposi sarcoma-associated herpesvirus in an HIV-negative man with previous Kaposi sarcoma	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; DNA-SEQUENCES; DISEASE; VIRUS; AIDS	Background: The role of Kaposi sarcoma-associated herpesvirus in the development of malignant lymphomas in patients negative for the human immunodeficiency virus (HIV) has not been established. Objective: To examine the possible role of Kaposi sarcoma-associated herpesvirus in a case of body cavity-based malignant lymphoma that occurred in an HIV-negative patient who had previously had Kaposi sarcoma. Design: Case study. Setting: Academic medical center. Patient: A 94-year-old man with lymphomatous ascites. Measurements: Polymerase chain reaction (PCR) and Southern blot DNA analysis. Results: The body cavity-based lymphoma cells were positive for Kaposi sarcoma-associated herpesvirus by PCR and were negative for other herpesviruses, including Epstein-Barr virus, cytomegalovirus, and human herpesviruses 6 and 7. Southern blot analysis of lymphoma DNA showed high levels of Kaposi sarcoma-associated herpesvirus (>40 to 80 genomes/cell). Clonal rearrangement of the immunoglobulin JH and JK genes was present, confirming the presence of a clonal B-cell proliferation. Conclusions: Kaposi sarcoma-associated herpesvirus may be involved in the development of malignant lymphoma after Kaposi sarcoma in HIV-negative patients. This type of lymphoma, in contrast to body cavity-based lymphoma related to the acquired immunodeficiency syndrome, may have an indolent clinical course.	CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT EPIDEMIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Strauchen, JA (corresponding author), CUNY MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY 10029 USA.		Moore, Patrick/GVR-8294-2022; Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041				BALLERINI P, 1993, BLOOD, V81, P166; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BOSHOFF C, 1995, LANCET, V345, P1043; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; COLLANDRE H, 1995, LANCET, V345, P1043, DOI 10.1016/S0140-6736(95)90779-3; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; FRENKEL N, 1992, FRONTIERS VIROLOGY, V1, P243; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; LIN JC, 1993, BLOOD, V81, P3372; MITCHELL SM, 1994, J MED VIROL, V43, P336, DOI 10.1002/jmv.1890430404; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; ROWLEY AH, 1994, PEDIATR RES, V36, P567, DOI 10.1203/00006450-199411000-00003; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; SAMBROOK J, 1989, BIOMOLECULAR CLONING; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276	20	72	75	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					822	825		10.7326/0003-4819-125-10-199611150-00006	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928989				2022-12-28	WOS:A1996VU52400009
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Statistics notes - Detecting skewness from summary information	BRITISH MEDICAL JOURNAL			English	Article									ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	Altman, DG (corresponding author), INST HLTH SCI,IMPERIAL CANC RES FUND,MED STAT GRP,CTR STAT MED,OXFORD OX3 7LF,ENGLAND.							ALTMAN DG, 1994, BRIT MED J, V309, P996, DOI 10.1136/bmj.309.6960.996; ALTMAN DG, 1995, BRIT MED J, V310, P298, DOI 10.1136/bmj.310.6975.298; Bland JM, 1996, BRIT MED J, V312, P770; MATSUKURA S, 1984, NEW ENGL J MED, V311, P828, DOI 10.1056/NEJM198409273111305	4	560	561	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1200	1200		10.1136/bmj.313.7066.1200	http://dx.doi.org/10.1136/bmj.313.7066.1200			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916759	Bronze, Green Published			2022-12-28	WOS:A1996VR90700032
J	Sacchini, V				Sacchini, V			Multicentricity end recurrence of breast cancer	LANCET			English	Editorial Material							SURGERY				Sacchini, V (corresponding author), EUROPEAN INST ONCOL,BREAST DEPT,I-20141 MILAN,ITALY.							FOWBLE B, 1990, INT J RADIAT ONCOL, V19, P833, DOI 10.1016/0360-3016(90)90002-2; FUKUTOMI T, 1993, SURG TODAY, V23, P402, DOI 10.1007/BF00309497; HOLLAND R, 1990, J CLIN ONCOL, V8, P113, DOI 10.1200/JCO.1990.8.1.113; HOLLAND R, 1985, CANCER, V56, P979, DOI 10.1002/1097-0142(19850901)56:5<979::AID-CNCR2820560502>3.0.CO;2-N; VAIDYA JS, 1996, BRIT J CANCER, V73, P820; VERONESI U, 1995, J NATL CANCER I, V87, P19, DOI 10.1093/jnci/87.1.19; VERONESI U, 1996, BREAST J, V2, P100	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1256	1257		10.1016/S0140-6736(05)65752-2	http://dx.doi.org/10.1016/S0140-6736(05)65752-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909374				2022-12-28	WOS:A1996VR55500004
J	Uhari, M; Kontiokari, T; Koskela, M; Niemela, M				Uhari, M; Kontiokari, T; Koskela, M; Niemela, M			Xylitol chewing gum in prevention of acute otitis media: Double blind randomised trial	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; INFANTS; GROWTH; CARIES; BACTERIA	Objective-To examine whether xylitol, which reduces the growth of Streptococcus pneumoniae, might have clinical importance in the prevention of acute otitis media. Design-A double blind randomised trial with xylitol administered in chewing gum. Setting-Eleven day care nurseries in the city of Oulu. Most of the children had had problems with recurrent acute otitis media. Subjects-306 day care children: 149 children in the sucrose group (76 boys; mean (SD) age 4.9 (1.5) years) and 157 in the xylitol group (80 boys; 5.0 (1.4) years). Intervention-Either xylitol (8.4 g a day) or sucrose (control) chewing gum for two months. Main outcome measures-The occurrence of acute otitis media and antimicrobial treatment received during the intervention and nasopharyngeal carriage of S pneumoniae. Results-During the two month monitoring period at least one event of acute otitis media was experienced by 31/149 (20.8%) children who received sucrose compared with 19/157 (12.1%) of those receiving chewing gum containing xylitol (difference 8.7%; 95% confidence interval 0.4% to 17.0%; P = 0.04). Significantly fewer antimicrobials were prescribed among those receiving xylitol: 29/157 (18.5%) children had at least one period of treatment versus 43/149 (28.9%) (difference 10.4%; 0.9% to 19.9%; P = 0.032). The carriage rate of S pneumoniae varied from 17.4% to 28.2% with no difference between the groups. Two children in the xylitol group experienced diarrhoea, but no other adverse effects were noted among the xylitol users. Conclusion-Xylitol seems to have a preventive effect against acute otitis media.	UNIV HOSP OULU,DIV MICROBIOL,FIN-90220 OULU,FINLAND		Uhari, M (corresponding author), UNIV OULU,DEPT PAEDIAT,FIN-90220 OULU,FINLAND.		Renko, Marjo/F-7811-2014	Renko, Marjo/0000-0003-0507-4773				Akerblom H K, 1982, Int J Vitam Nutr Res Suppl, V22, P53; ALHO OP, 1991, INT J PEDIATR OTORHI, V21, P7, DOI 10.1016/0165-5876(91)90054-F; HARRISON CJ, 1993, PEDIATR INFECT DIS J, V12, P62, DOI 10.1097/00006454-199301000-00013; ISOKANGAS P, 1988, J AM DENT ASSOC, V117, P315, DOI 10.1016/S0002-8177(88)72017-6; KANDELMAN D, 1988, CARIES RES, V22, P55, DOI 10.1159/000261084; KARMA P, 1987, ANN OTO RHINOL LARYN, V96, P1; KARMA PH, 1989, INT J PEDIATR OTORHI, V17, P37, DOI 10.1016/0165-5876(89)90292-9; KNUUTTILA MLE, 1975, CARIES RES, V9, P177, DOI 10.1159/000260156; KONTIOKARI T, 1995, ANTIMICROB AGENTS CH, V39, P1820, DOI 10.1128/AAC.39.8.1820; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; MAKINEN KK, 1980, J FOOD SCI, V45, P367, DOI 10.1111/j.1365-2621.1980.tb02616.x; Makinen KK, 1995, J DENT RES, V74, P1904, DOI 10.1177/00220345950740121501; RUUSKANEN O, 1991, PEDIATR INFECT DIS J, V10, P425, DOI 10.1097/00006454-199106000-00001; SCHEININ A, 1985, INT DENT J, V35, P50; Scheinin A., 1975, ACTA ODONTOL SCAND, V33, P1; SIPILA M, 1987, ACTA OTO-LARYNGOL, V104, P138, DOI 10.3109/00016488709109059; VADEBONCOEUR C, 1983, J DENT RES, V62, P882, DOI 10.1177/00220345830620080601	17	136	145	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 9	1996	313	7066					1180	1183		10.1136/bmj.313.7066.1180	http://dx.doi.org/10.1136/bmj.313.7066.1180			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR907	8916749	Green Published			2022-12-28	WOS:A1996VR90700022
J	ODonnell, PJ; Calvert, C; Atzorn, R; Wasternack, C; Leyser, HMO; Bowles, DJ				ODonnell, PJ; Calvert, C; Atzorn, R; Wasternack, C; Leyser, HMO; Bowles, DJ			Ethylene as a signal mediating the wound response of tomato plants	SCIENCE			English	Article							INHIBITOR-INDUCING FACTOR; PROTEINASE-INHIBITOR; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; JASMONIC ACID; LEAVES; EXPRESSION; GENE; INDUCTION; BIOSYNTHESIS; ACCUMULATION	Plants respond to physical injury, such as that caused by foraging insects, by synthesizing proteins that function in general defense and tissue repair. In tomato plants, one class of wound-responsive genes encodes proteinase inhibitor (pin) proteins shown to block insect feeding. Application of many different factors will induce or inhibit pin gene expression. Ethylene is required in the transduction pathway leading from injury, and ethylene and jasmonates act together to regulate pin gene expression during the wound response.	UNIV YORK,DEPT BIOL,PLANT LAB,YORK YO1 5YW,N YORKSHIRE,ENGLAND; INST BIOCHEM PFLANZEN,D-06120 HALLE,GERMANY	University of York - UK; Leibniz Institut fur Pflanzenbiochemie			Leyser, Ottoline/AAC-5577-2019					Barry CS, 1996, PLANT J, V9, P525, DOI 10.1046/j.1365-313X.1996.09040525.x; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; BISHOP PD, 1981, P NATL ACAD SCI-BIOL, V78, P3536, DOI 10.1073/pnas.78.6.3536; CORTES HP, 1993, PLANTA, V191, P123; CORTES HP, 1996, PLANTA, V198, P447; DOARES SH, 1995, P NATL ACAD SCI USA, V92, P4095, DOI 10.1073/pnas.92.10.4095; DOARES SH, 1995, PLANT PHYSIOL, V108, P1741, DOI 10.1104/pp.108.4.1741; DOHERTY HM, 1988, PHYSIOL MOL PLANT P, V33, P377, DOI 10.1016/0885-5765(88)90004-5; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FARMER EE, 1994, PLANT PHYSIOL, V106, P337, DOI 10.1104/pp.106.1.337; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FELIX G, 1995, PLANT J, V7, P381, DOI 10.1046/j.1365-313X.1995.7030381.x; GHOSH S, 1995, SCIENCE, V270, P2018; GLASS ADM, 1974, PLANT PHYSIOL, V54, P855, DOI 10.1104/pp.54.6.855; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; Greulich F, 1995, J PLANT PHYSIOL, V147, P359, DOI 10.1016/S0176-1617(11)82168-1; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KERNAN A, 1989, PLANT PHYSIOL, V91, P73, DOI 10.1104/pp.91.1.73; LEHMANN, 1995, PLANTA, V187, P156; LINCOLN JE, 1993, J BIOL CHEM, V268, P19422; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; NAKAGAWA N, 1991, PLANT CELL PHYSIOL, V32, P1153; OLSON DC, 1991, P NATL ACAD SCI USA, V88, P5340, DOI 10.1073/pnas.88.12.5340; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PECK SC, 1995, PLANT MOL BIOL, V28, P293, DOI 10.1007/BF00020248; ROTTMANN WH, 1991, J MOL BIOL, V222, P937, DOI 10.1016/0022-2836(91)90587-V; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; RYAN CA, 1992, PLANT MOL BIOL, V19, P123, DOI 10.1007/BF00015610; RYAN CA, 1974, PLANT PHYSIOL, V54, P328, DOI 10.1104/pp.54.3.328; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALLER A, 1995, PLANT CELL, V7, P1893, DOI 10.1105/tpc.7.11.1893; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; SISLER EC, 1990, PLANT GROWTH REGUL, V9, P157, DOI 10.1007/BF00027443; Veen H., 1987, Acta Horticulturae, P213; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YEN HC, 1995, PLANT PHYSIOL, V107, P1343, DOI 10.1104/pp.107.4.1343; YIP WK, 1992, P NATL ACAD SCI USA, V89, P2475, DOI 10.1073/pnas.89.6.2475	39	541	583	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1914	1917		10.1126/science.274.5294.1914	http://dx.doi.org/10.1126/science.274.5294.1914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943205				2022-12-28	WOS:A1996VY20000045
J	Wortsman, J				Wortsman, J			Hemochromatosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Wortsman, J (corresponding author), SO ILLINOIS UNIV,SPRINGFIELD,IL 62794, USA.								0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1815	1815		10.1056/NEJM199612123352406	http://dx.doi.org/10.1056/NEJM199612123352406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943164				2022-12-28	WOS:A1996VW68300006
J	Chardin, P; Paris, S; Antonny, B; Robineau, S; BeraudDufour, S; Jackson, CL; Chabre, M				Chardin, P; Paris, S; Antonny, B; Robineau, S; BeraudDufour, S; Jackson, CL; Chabre, M			A human exchange factor for ARF contains Sec7- and pleckstrin-homology domains	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GUANINE-NUCLEOTIDE; BREFELDIN-A; BINDING-SITE; PROTEIN; APPARATUS; ENCODES; CELL	THE small G protein ARF1 is involved in the coating of vesicles that bud from the Golgi compartments(1,2). Its activation is controlled by as-yet unidentified guanine-nucleotide exchange factors(3,4). Gea1, the first ARF exchange factor to be discovered in yeast(5), is a large protein containing a domain of homology with Sec7, another yeast protein that is also involved in secretion(6) Here we characterized a smaller human protein (relative molecular mass 47K) named ARNO, which contains a central Sec7 domain that promotes guanine-nucleotide exchange on ARF1. ARNO also contains an amino-terminal coiled-coil motif and a carboxy-terminal pleckstrin-homology (PH) domain. The PH domain mediates an enhancement of ARNO exchange activity by negatively charged phospholipid vesicles supplemented with phosphatidylinositol bisphosphate. The exchange activity of ARNO is not inhibited by brefeldin A, an agent known to block vesicular transport and inhibit the exchange activity on ARF1 in cell extracts(7,8). This suggests that a regulatory component which is sensitive to brefeldin A associates with ARNO in vivo, possibly through the amino-terminal coiled-coil. We propose that other proteins with a Sec7 domain regulate different members of the ARF family.	CEA SACLAY,SERV BIOCHIM & GENET MOL,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay	Chardin, P (corresponding author), CNRS,INST PHARMACOL MOL & CELLULAIRE,660 ROUTE LUCIOLES,F-06560 VALBONNE,FRANCE.		Jackson, Catherine/T-5688-2019; Antonny, Bruno/ABH-7434-2020; Jackson, Catherine/A-3421-2013; BERAUD-DUFOUR, Sophie/M-4641-2016	Antonny, Bruno/0000-0002-9166-8668; Jackson, Catherine/0000-0002-0843-145X; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; PORFIRI E, 1994, J BIOL CHEM, V269, P2262; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x	19	406	418	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					481	484		10.1038/384481a0	http://dx.doi.org/10.1038/384481a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945478				2022-12-28	WOS:A1996VW68700068
J	Kotzbauer, PT; Lampe, PA; Heuckeroth, RO; Golden, JP; Creedon, DJ; Johnson, EM; Milbrandt, J				Kotzbauer, PT; Lampe, PA; Heuckeroth, RO; Golden, JP; Creedon, DJ; Johnson, EM; Milbrandt, J			Neurturin, a relative of glial-cell-line-derived neurotrophic factor	NATURE			English	Article							MIDBRAIN DOPAMINERGIC-NEURONS; NERVE GROWTH-FACTOR; IN-VIVO; SYMPATHETIC NEURONS; SURVIVAL FACTOR; MOTOR-NEURONS; GDNF; DEATH; SYSTEM	THE normal development of the vertebrate nervous system entails the death of 30-70% of the neurons originally generated in most neuronal populations(1), This naturally occurring cell death is regulated by specific neurotrophic factors that promote neuronal survival and which are produced in limiting quantities by target cells, glial cells and neurons. These factors are also of potential utility as therapeutic agents for neurodegenerative diseases(2). Here we describe the purification and cloning of a new neurotrophic factor, identified on the basis of its ability to support the survival of sympathetic neurons in culture, This factor, neurturin, is structurally related to glial-cell-line-derived neurotrophic factor (GDNF)(3). These factors can each activate the MAP kinase signalling pathway in cultured sympathetic neurons and support the survival of sympathetic neurons, as well as of sensory neurons of the nodose and dorsal root ganglia, Thus, neurturin and GDNF together now define a new family of neurotrophic factors.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Lampe, Patricia/AAH-9545-2020	Milbrandt, Jeffrey/0000-0002-5477-7689; Heuckeroth, Robert/0000-0002-3282-1765; Golden, Judith/0000-0002-5168-8525				BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BORNSTEIN MB, 1958, LAB INVEST, V7, P134; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAY ML, 1990, J BIOL CHEM, V265, P15253; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOTZBAUER PT, 1994, NEURON, V12, P763, DOI 10.1016/0896-6273(94)90329-8; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; OPPENHEIM RW, 1992, J NEUROBIOL, V23, P1111, DOI 10.1002/neu.480230903; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; ZUM AD, 1994, NEUROREPORT, V6, P113	30	619	681	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					467	470		10.1038/384467a0	http://dx.doi.org/10.1038/384467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945474				2022-12-28	WOS:A1996VW68700064
J	Yamagata, K; Oda, N; Kaisaki, PJ; Menzel, S; Furuta, H; Vaxillaire, M; Southam, L; Cox, RD; Lathrop, GM; Boriraj, VV; Chen, XN; Cox, NJ; Oda, Y; Yano, H; LeBeau, MM; Yamada, S; Nishigori, H; Takeda, J; Fajans, SS; Hattersley, AT; Iwasaki, N; Hansen, T; Pedersen, O; Polonsky, KS; Turner, RC; Velho, G; Chevre, JC; Froguel, P; Bell, GI				Yamagata, K; Oda, N; Kaisaki, PJ; Menzel, S; Furuta, H; Vaxillaire, M; Southam, L; Cox, RD; Lathrop, GM; Boriraj, VV; Chen, XN; Cox, NJ; Oda, Y; Yano, H; LeBeau, MM; Yamada, S; Nishigori, H; Takeda, J; Fajans, SS; Hattersley, AT; Iwasaki, N; Hansen, T; Pedersen, O; Polonsky, KS; Turner, RC; Velho, G; Chevre, JC; Froguel, P; Bell, GI			Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity-onset diabetes of the young (MODY3)	NATURE			English	Article							CHROMOSOME 12Q; HNF1; LOCALIZATION; HNF-1-ALPHA; MELLITUS; SUBTYPE; CELL	THE disease non-insulin-dependent (type 2) diabetes mellitus (NIDDM) is characterized by abnormally high blood glucose resulting from a relative deficiency of insulin(1). It affects about 2% of the world's population and treatment of diabetes and its complications are an increasing health-care burden(2). Genetic factors are important in the aetiology of NIDDM, and linkage studies are starting to Localize some of the genes that influence the development of this disorder(3). Maturity-onset diabetes of the young (MODY), a single-gene disorder responsible for 2-5% of NIDDM, is characterized by autosomal dominant inheritance and an age of onset of 25 years or younger(4-6). MODY genes have been localized to chromosomes 7, 12 and 20 (refs 5, 7, 8) and clinical studies indicate that mutations in these genes are associated with abnormal patterns of glucose-stimulated insulin secretion(1,9). The gene on chromosome 7 (MODY2) encodes the glycolytic enzyme glucokinase(5) which plays a key role in generating the metabolic signal for insulin secretion and in integrating hepatic glucose uptake. Here we show that subjects with the MODY3-form of NIDDM have mutations in the gene encoding hepatocyte nuclear factor-1 alpha (HNF-1 alpha, which is encoded by the gene TCF1). HNF-1 alpha is a transcription factor that helps in the tissue-specific regulation of the expression of several liver genes(10,11) and also functions as a weak transactivator of the rat insulin-I gene(12).	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; INST PASTEUR,CNRS,EP10,F-59019 LILLE,FRANCE; GUNMA UNIV,INST MOL & CELLULAR REGULAT,MAEBASHI,GUMMA 371,JAPAN; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV EXETER,POSTGRAD MED SCH,DEPT VASC MED & DIABET RES,EXETER EX2 5AX,DEVON,ENGLAND; TOKYO WOMENS MED COLL,CTR DIABET,TOKYO 162,JAPAN; STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK; RADCLIFFE INFIRM,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND; HOP ST LOUIS,INSERM,U358,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Oxford; Wellcome Centre for Human Genetics; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Gunma University; University of Michigan System; University of Michigan; University of Exeter; Tokyo Women's Medical University; Steno Diabetes Center; Radcliffe Infirmary; University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Menzel, Stephan/U-6906-2019; FROGUEL, Philippe/O-6799-2017; Velho, Gilberto/Q-6724-2017; Pedersen, Oluf/AAG-8015-2020; Chevre, Jean-Claude/C-3943-2015	FROGUEL, Philippe/0000-0003-2972-0784; Velho, Gilberto/0000-0001-8811-363X; Hattersley, Andrew/0000-0001-5620-473X; Menzel, Stephan/0000-0002-1590-9108; Chevre, Jean-Claude/0000-0002-5329-5231	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACH I, 1992, NUCLEIC ACIDS RES, V20, P4199, DOI 10.1093/nar/20.16.4199; BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BYME MM, 1996, AM J PHYSIOL, V270, pE572; Byrne MM, 1996, DIABETES, V45, P1503, DOI 10.2337/diabetes.45.11.1503; CHUMAKOV IM, 1995, NATURE, V377, P175; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HORLEIN A, 1993, BIOL CHEM H-S, V374, P419, DOI 10.1515/bchm3.1993.374.7-12.419; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Kenny S.J., 1995, NIH PUBLICATION, P47; KOM B, 1992, HUM MOL GENET, V1, P235; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LEDERMANN HM, 1995, LANCET, V345, P648, DOI 10.1016/S0140-6736(95)90548-0; LESAGE S, 1995, DIABETES, V44, P1243, DOI 10.2337/diabetes.44.10.1243; Mahtani MM, 1996, NAT GENET, V14, P90, DOI 10.1038/ng0996-90; McCarty D, 1994, DIABETES 1994 2010 G; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MENZEL S, 1995, DIABETES, V44, P1408, DOI 10.2337/diabetes.44.12.1408; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; VAXILLAIRE M, 1995, NAT GENET, V9, P418, DOI 10.1038/ng0495-418; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	30	951	982	0	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 5	1996	384	6608					455	458		10.1038/384455a0	http://dx.doi.org/10.1038/384455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW687	8945470	Green Submitted			2022-12-28	WOS:A1996VW68700060
J	Ginsburg, ES; Mello, NK; Mendelson, JH; Barbieri, RL; Teoh, SK; Rothman, M; Gao, XY; Sholar, JW				Ginsburg, ES; Mello, NK; Mendelson, JH; Barbieri, RL; Teoh, SK; Rothman, M; Gao, XY; Sholar, JW			Effects of alcohol ingestion on estrogens in postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE-REPLACEMENT THERAPY; PITUITARY-GONADAL-HORMONES; BREAST-CANCER; CARDIOVASCULAR-DISEASE; TRANSDERMAL ESTRADIOL; MENOPAUSAL ESTROGENS; LUTEINIZING-HORMONE; RISK; CONSUMPTION; ETHANOL	Objective.-To determine if moderate alcohol drinking increases circulating estradiol levels in postmenopausal women who are taking estrogen replacement. Design.-Randomized, double-blind, placebo-controlled crossover study of the effects of alcohol ingestion on plasma estradiol and estrone. Setting.-Inpatient Clinical Research Center. Participants.-Twelve healthy postmenopausal women receiving oral estrogen (estradiol, 1 mg/day) and progestin (medroxyprogesterone acetate) replacement therapy were compared with 12 postmenopausal women who were not using estrogen replacement therapy (ERT). Intervention.-Each group drank alcohol (0.7 g/kg) and an isoenergetic (isocaloric) placebo (randomized sequence) on consecutive days. Women who were taking ERT were studied during the estrogen-only portion of their replacement cycle, and estrogen was administered each evening at 2100 hours. Main Outcome Measure.-The impact of alcohol ingestion on plasma estradiol and estrone levels. Results.-Alcohol ingestion lead to a 3-fold increase in circulating estradiol in women on ERT; however, alcohol did not change estradiol significantly in control women who were not on ERT. In women using ERT, estradiol levels increased from 297 to 973 pmol/L (81 to 265 pg/ml) within 50 minutes (P<.001) during the ascending limb of the blood alcohol curve and remained significantly above baseline for 5 hours (P<.001). No significant increase in circulating estrone was detected in either group, However, estrone levels decreased after alcohol and placebo in women on ERT (P<.05). Blood alcohol levels did not differ significantly in women who used ERT and those who did not. Peak blood alcohol levels of 21 mmol/L were attained in each of the 2 groups within 50 to 60 minutes after drinking began. Changes in estradiol were significantly correlated with changes in blood alcohol levels on both the ascending (P<.001) and descending (P<.001) limb of the blood alcohol curve. Conclusions.-Acute alcohol ingestion may lead to significant and sustained elevations in circulating estradiol to levels 300% higher than those targeted in clinical use of ERT, Potential health risks and benefits of the interactions between acute alcohol ingestion and ERT should be further evaluated.	MCLEAN HOSP, DRUG & ALCOHOL ABUSE RES CTR, BELMONT, MA 02178 USA	Harvard University; McLean Hospital	Ginsburg, ES (corresponding author), BRIGHAM & WOMENS HOSP, DEPT OBSTET & GYNECOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000064] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA 10040] Funding Source: Medline; NIDA NIH HHS [K05 DA001011, K05 DA0064] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1974, NEW ENGL J MED, V290, P15; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; *BUR CENS, 1995, CURR POP REP P25, V1104; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; CRONHOLM T, 1982, BIOCHIM BIOPHYS ACTA, V711, P159, DOI 10.1016/0005-2760(82)90022-4; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; FISHMAN J, 1965, J CLIN ENDOCR METAB, V25, P365, DOI 10.1210/jcem-25-3-365; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; GAVALER JS, 1993, ALCOHOL CLIN EXP RES, V17, P786, DOI 10.1111/j.1530-0277.1993.tb00842.x; GAVALER JS, 1987, J STUD ALCOHOL, V48, P295, DOI 10.15288/jsa.1987.48.295; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; GINSBURG ES, 1995, J SOC GYNECOL INVEST, V2, P26, DOI 10.1016/1071-5576(94)00048-6; GINSBURG ES, 1995, FERTIL STERIL, V63, P1227, DOI 10.1016/S0015-0282(16)57602-X; GOLDSTEIN DB, 1992, MED DIAGNOSIS TREATM, P25; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; LONGNECKER MP, 1995, JNCI-J NATL CANCER I, V87, P923, DOI 10.1093/jnci/87.12.923; LONGNECKER MP, 1993, JNCI-J NATL CANCER I, V85, P692, DOI 10.1093/jnci/85.9.692; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MARTINS OO, 1982, J STEROID BIOCHEM, V16, P265, DOI 10.1016/0022-4731(82)90174-1; MCNAMEE B, 1979, BRIT J ADDICT, V74, P316; MENDELSON J H, 1984, Alcohol, V1, P417, DOI 10.1016/0741-8329(84)90014-4; MENDELSON JH, 1989, J PHARMACOL EXP THER, V250, P902; MENDELSON JH, 1987, J STUD ALCOHOL, V48, P287, DOI 10.15288/jsa.1987.48.287; MENDELSON JH, 1988, PSYCHOPHARMACOLOGY, V94, P464, DOI 10.1007/BF00212838; MENDELSON JH, 1981, J PHARMACOL EXP THER, V218, P23; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; REICHMAN ME, 1993, J NATL CANCER I, V85, P722, DOI 10.1093/jnci/85.9.722; SELBY PL, 1989, CLIN ENDOCRINOL, V30, P241, DOI 10.1111/j.1365-2265.1989.tb02232.x; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; TEOH SK, 1990, J PHARMACOL EXP THER, V254, P407; Van Thiel D H, 1988, Adv Alcohol Subst Abuse, V7, P131; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; YEN SSC, 1975, J CLIN ENDOCR METAB, V40, P518, DOI 10.1210/jcem-40-3-518; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613	47	169	171	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	1996	276	21					1747	1751		10.1001/jama.276.21.1747	http://dx.doi.org/10.1001/jama.276.21.1747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV566	8940324				2022-12-28	WOS:A1996VV56600033
J	Feng, QH; Moran, JV; Kazazian, HH; Boeke, JD				Feng, QH; Moran, JV; Kazazian, HH; Boeke, JD			Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition	CELL			English	Article							GROUP-II INTRON; YEAST MITOCHONDRIAL-DNA; PRIMED REVERSE TRANSCRIPTION; HUMAN TRANSPOSABLE ELEMENT; ESCHERICHIA-COLI-CELLS; REPAIR ENZYME HAP1; MAURICEVILLE PLASMID; KINETOPLAST DNA; EXONUCLEASE-III; RIBONUCLEASE-H	Human L1 elements are highly abundant poly(A) (non-LTR) retrotransposons whose second open reading frame (ORF2) encodes a reverse transcriptase (RT). We have identified an endonuclease (EN) domain at the L1 ORF2 N-terminus that is highly conserved among poly(A) retrotransposons and resembles the apurinic/apyrimidinic (AP) endonucleases. Purified L1 EN protein (L1 ENp) makes 5'-PO4, 3'-OH nicks in supercoiled plasmids, shows no preference for AP sites, and preferentially cleaves sequences resembling L1 in vivo target sequences. Mutations in conserved amino acid residues of L1 EN abolish its nicking activity and eliminate L1 retrotransposition. We propose that L1 EN cleaves the target site for L1 insertion and primes reverse transcription.	JOHNS HOPKINS UNIV,DEPT MOL BIOL & GENET,SCH MED,BALTIMORE,MD 21205; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	Johns Hopkins University; University of Pennsylvania					NCI NIH HHS [CA-16519] Funding Source: Medline; NIGMS NIH HHS [GM-45398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAD P, 1989, P NATL ACAD SCI USA, V86, P8887, DOI 10.1073/pnas.86.22.8887; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; BOEKE JD, 1996, IN PRESS RETROVIRUSE; BRANCIFORTE D, 1994, MOL CELL BIOL, V14, P2584, DOI 10.1128/MCB.14.4.2584; BUCHETON A, 1984, CELL, V38, P153, DOI 10.1016/0092-8674(84)90536-1; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; DROLET M, 1994, J BIOL CHEM, V269, P2068; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; HOHJOH H, 1990, NUCLEIC ACIDS RES, V18, P4099, DOI 10.1093/nar/18.14.4099; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KINSEY JA, 1990, GENETICS, V126, P317; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LEHMAN IR, 1974, SCIENCE, V186, P790; LILLY DMJ, 1981, NUCLEIC ACIDS RES, V9, P1271, DOI 10.1093/nar/9.6.1271; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUAN DD, 1995, MOL CELL BIOL, V15, P3882; Maniatis T., 1982, MOL CLONING; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MIKI Y, 1992, CANCER RES, V52, P643; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; PRICE PA, 1975, J BIOL CHEM, V250, P1981; ROBERTS RJ, 1994, BIOSCIENCE REP, V14, P103, DOI 10.1007/BF01240243; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHIMAMOTO T, 1995, J BACTERIOL, V177, P264, DOI 10.1128/jb.177.1.264-267.1995; SINDEN RR, 1980, CELL, V21, P773, DOI 10.1016/0092-8674(80)90440-7; SINDEN RR, 1981, P NATL ACAD SCI-BIOL, V78, P224, DOI 10.1073/pnas.78.1.224; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; STELLWAGEN NC, 1983, BIOCHEMISTRY-US, V22, P6186, DOI 10.1021/bi00295a023; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WANG H, 1993, J BIOL CHEM, V268, P18951; WEISS B, 1976, J BIOL CHEM, V251, P1896; WOODSAMUELS P, 1989, GENOMICS, V4, P290, DOI 10.1016/0888-7543(89)90332-7; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	58	831	853	2	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					905	916		10.1016/S0092-8674(00)81997-2	http://dx.doi.org/10.1016/S0092-8674(00)81997-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945517	hybrid			2022-12-28	WOS:A1996VV77400016
J	Proudfoot, N				Proudfoot, N			Ending the message is not so simple	CELL			English	Review							MESSENGER-RNA; SITE; POLYADENYLATION; SPLICE; SEQUENCES; PROTEIN; YEAST; SNRNP				Proudfoot, N (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,CHEM PATHOL UNIT,S PARKS RD,OXFORD OX1 3RE,ENGLAND.			Proudfoot, Nicholas/0000-0001-8646-3222				ASHE MP, 1995, GENE DEV, V9, P3008, DOI 10.1101/gad.9.23.3008; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; EDWALDSGILBERT G, 1995, MOL CELL BIOL, V15, P6420; FURTH PA, 1994, MOL CELL BIOL, V14, P5278, DOI 10.1128/MCB.14.8.5278; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; PETERSON ML, 1994, MOL CELL BIOL, V14, P7891, DOI 10.1128/MCB.14.12.7891; PETERSON ML, 1989, MOL CELL BIOL, V9, P726, DOI 10.1128/MCB.9.2.726; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; YAN DH, 1995, MOL CELL BIOL, V15, P1901	14	66	67	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					779	781		10.1016/S0092-8674(00)81982-0	http://dx.doi.org/10.1016/S0092-8674(00)81982-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945502	Bronze			2022-12-28	WOS:A1996VV77400001
J	Neumann, S; Doubell, TP; Leslie, T; Woolf, CJ				Neumann, S; Doubell, TP; Leslie, T; Woolf, CJ			Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons	NATURE			English	Article							NERVE GROWTH-FACTOR; RAT SPINAL-CORD; SUBSTANCE-P; DORSAL HORN; RECEPTOR ACTIVATION; FACTOR CONTRIBUTES; MESSENGER-RNAS; INJURY; REFLEX; SENSITIZATION	PAIN is normally evoked only by stimuli that are sufficiently intense to activate high-threshold A delta and C sensory fibres, which relay the signal tp the spinal cord, Peripheral inflammation leads to profoundly increased pain sensitivity: noxious stimuli generate a greater response and stimuli that are normally innocuous Elicit pain. Inflammation increases the sensitivity of the peripheral terminals of A delta and C fibres at the site of inflammation(1). It also increases the excitability of spinal cord neurons(2,3), which now amplify all sensory inputs including the normally innocuous tactile stimuli that are conveyed by low-threshold A beta fibres. This central sensitization has been attributed to the enhanced activity of C fibers(4), which increase the excitability of their postsynaptic targets by releasing glutamate and the neuropeptide substance P5-7. Here we show that inflammation results in A beta fibres also acquiring the capacity to increase the excitability of spinal cord neurons. This is due fa a phenotypic switch in a subpopulation of these fibres so that they, like C-fibres, now express substance P. A beta fibres thus appear to contribute to inflammatory hypersensitivity by switching their phenotype to one resembling pain fibres, thereby enhancing synaptic transmission in the spinal cord and exaggerating the central response to innocuous stimuli.			Neumann, S (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Woolf, Clifford/A-9784-2010	doubell, timothy/0000-0003-1054-5592				AVERILL S, 1995, EUR J NEUROSCI, V7, P1484, DOI 10.1111/j.1460-9568.1995.tb01143.x; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; FITZGERALD M, 1985, BRAIN RES, V332, P131, DOI 10.1016/0006-8993(85)90396-8; HEATH MJS, 1994, J NEUROPHYSIOL, V72, P1192, DOI 10.1152/jn.1994.72.3.1192; LESLIE TA, 1995, NEUROSCIENCE, V67, P753, DOI 10.1016/0306-4522(95)00101-N; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; Ma QP, 1996, PAIN, V67, P97, DOI 10.1016/0304-3959(96)03105-3; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; NOGUCHI K, 1995, J NEUROSCI, V15, P7633; Reeh PW, 1994, CELLULAR MECH SENSOR, V79, P119; ROBERTSON B, 1991, J NEUROCYTOL, V20, P387, DOI 10.1007/BF01355535; THOMPSON SWN, 1990, EUR J NEUROSCI, V2, P638, DOI 10.1111/j.1460-9568.1990.tb00453.x; THOMPSON SWN, 1994, J NEUROSCI, V14, P3672; TOREBJORK HE, 1992, J PHYSIOL-LONDON, V448, P765, DOI 10.1113/jphysiol.1992.sp019069; URBAN L, 1984, BRAIN RES, V290, P336, DOI 10.1016/0006-8993(84)90952-1; VERGE VMK, 1995, J NEUROSCI, V15, P2081, DOI 10.1523/JNEUROSCI.15-03-02081.1995; WARDEN MK, 1988, J COMP NEUROL, V272, P90, DOI 10.1002/cne.902720107; WOOLF CJ, 1986, J NEUROSCI, V6, P1433; WOOLF CJ, 1990, J NEUROSCI, V10, P2717; WOOLF CJ, 1994, PAIN, V58, P141, DOI 10.1016/0304-3959(94)90195-3; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, 1987, J COMP NEUROL, V261, P105, DOI 10.1002/cne.902610109; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7	28	426	438	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					360	364		10.1038/384360a0	http://dx.doi.org/10.1038/384360a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934522				2022-12-28	WOS:A1996VV27100050
J	Harkness, JM				Harkness, JM			Nuremberg and the issue of wartime experiments on US prisoners - The Green Committee	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Defense attorneys at the Nuremberg Medical Trial argued that no ethical difference existed between experiments in Nazi concentration camps and research in US prisons. Investigations that had taken place in an Illinois prison became an early focus of this argument. Andrew C. Ivy, MD, whom the American Medical Association had selected as a consultant to the Nuremberg prosecutors, responded to courtroom criticism of research in his home state by encouraging the Illinois governor to establish a committee to evaluate prison research. The governor named a committee and accepted Ivy's offer to chair the panel. Late in the trial, Ivy testified-drawing on the authority of this committee-that research on US prisoners was ethically ideal. However, the governor's committee had never met. After the trial's conclusion, the committee report was published in JAMA, where it became a source of support for experimentation on prisoners.			Harkness, JM (corresponding author), CORNELL UNIV,DEPT SCI & TECHNOL STUDIES,726 UNIV AVE,ITHACA,NY 14850, USA.							*ADV COMM HUM RAD, 1995, FIN REP ADV COMM HUM, P137; ANANS GJ, 1992, NAZI DOCTORS NUREMBE, P204; BILL DB, 1979, PHYSIOLOGIST     OCT, P21; DRAGSTEDT CA, 1944, Q B NW U MED SCH SUM, P139; GREEN DH, 1947, COMMUNICATION   0313; GROSSMAN MI, 1978, PHYSIOLOGIST     APR, P11; HARKNESS JM, 1996, THESIS U WISCONSIN M, P137; Ivy AC, 1946, REPORT WAR CRIMES ME; IVY AC, 1947, COMMUNICATION   0421; IVY AC, 1947, COMMUNICATION   0624; TAYLOR T, 1949, FINAL REPORT SECRETA, P89; 1948, JAMA-J AM MED ASSOC, V136, P457; 1945, LIFE            0604, P43; 1947, TIME            0113, P47; 1945, LIFE            0604, P46	15	50	50	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1672	1675		10.1001/jama.276.20.1672	http://dx.doi.org/10.1001/jama.276.20.1672			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VU209	8922455				2022-12-28	WOS:A1996VU20900036
J	Symmons, DPM				Symmons, DPM			Safety profile of low-dose aspirin	LANCET			English	Editorial Material							RISK				Symmons, DPM (corresponding author), UNIV MANCHESTER, ARC, EPIDEMIOL RES UNIT, MANCHESTER M13 9PT, LANCS, ENGLAND.			Symmons, Deborah/0000-0002-8625-1200				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827	5	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1996	348	9039					1394	1395		10.1016/S0140-6736(05)67495-8	http://dx.doi.org/10.1016/S0140-6736(05)67495-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937273				2022-12-28	WOS:A1996VU98600003
J	Elder, AG; ODonnell, B; McCruden, EAB; Symington, IS; Carman, WF				Elder, AG; ODonnell, B; McCruden, EAB; Symington, IS; Carman, WF			Incidence and recall of influenza in a cohort of Glasgow healthcare workers during the 1993-4 epidemic: Results of serum testing and questionnaire	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,INST VIROL,GLASGOW G11 5JR,LANARK,SCOTLAND; STOBHILL NHS TRUST,GLASGOW OCCUPAT HLTH,GLASGOW G1 1JA,LANARK,SCOTLAND; W GLASGOW HOSP UNIV NHS TRUST,DEPT CLIN MICROBIOL,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow								*ADV COMM IMM PRAC, 1994, MMWR            0421, P44; FLEMING DM, 1995, BRIT MED J, V311, P290, DOI 10.1136/bmj.311.7000.290; *JOINT COMM VACC I, 1992, IMM INF DIS; POTTER J, IN PRESS J INF DIS; WOOD JM, 1994, VACCINE, V12, P167, DOI 10.1016/0264-410X(94)90056-6	5	171	189	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 16	1996	313	7067					1241	1242		10.1136/bmj.313.7067.1241	http://dx.doi.org/10.1136/bmj.313.7067.1241			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU208	8939114	Green Published			2022-12-28	WOS:A1996VU20800023
J	Baumann, P; Benson, FE; West, SC				Baumann, P; Benson, FE; West, SC			Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro	CELL			English	Article							ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; HETERODUPLEX FORMATION; GENETIC-RECOMBINATION; COMPLEX-FORMATION; XENOPUS-LAEVIS; DNA; EXCHANGE; SEQUENCE; POLARITY	The human testis Rad51 protein, a structural homolog of E. coli RecA, binds single- and double-stranded DNA and exhibits DNA-dependent ATPase activity. Using circular ssDNA and linear dsDNA (3.0 kb in length), we demonstrate that hRad51 promotes homologous pairing and strand exchange reactions in vitro. Joint molecule formation was dependent upon ATP hydrolysis and DNA homology and was stimulated by the single-strand DNA-binding protein RP-A. In these reactions, the 5' terminus of the complementary strand of the linear duplex was efficiently transferred to the ssDNA. However, under standard conditions, extensive strand exchange was not observed. These results establish hRad51 as a functional homolog of RecA, but indicate that the human protein and its bacterial counterpart differ in their ability to promote extensive strand transfer. It is proposed that hRad51 mediates homology recognition and initiates strand exchange, but that extensive heteroduplex formation in higher organisms requires the actions of additional proteins.			Baumann, P (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418; Baumann, Peter/0000-0003-4892-1485; Benson, Fiona Elizabeth/0000-0002-3918-7015				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BAYNE ML, 1984, J MOL BIOL, V172, P87, DOI 10.1016/0022-2836(84)90416-9; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; Eggleston AK, 1996, TRENDS GENET, V12, P20, DOI 10.1016/0168-9525(96)81384-9; Game J., 1983, YEAST GENETICS FUNDA, P109; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; RUSCHE JR, 1985, J BIOL CHEM, V260, P949; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VOLOSHIN ON, 1996, SCIENCE, V272, P8685; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	47	571	592	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					757	766		10.1016/S0092-8674(00)81394-X	http://dx.doi.org/10.1016/S0092-8674(00)81394-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929543	Bronze			2022-12-28	WOS:A1996VU03500017
J	Fletcher, CF; Lutz, CM; OSullivan, TN; Shaughnessy, JD; Hawkes, R; Frankel, WN; Copeland, NG; Jenkins, NA				Fletcher, CF; Lutz, CM; OSullivan, TN; Shaughnessy, JD; Hawkes, R; Frankel, WN; Copeland, NG; Jenkins, NA			Absence epilepsy in tottering mutant mice is associated with calcium channel defects	CELL			English	Article							TYROSINE-HYDROXYLASE GENE; PROGRAMMED CELL-DEATH; CA2+ CHANNELS; INTRACELLULAR CALCIUM; SELECTIVE INCREASE; CENTRAL NEURONS; PURKINJE-CELLS; SPIKE-WAVE; MOUSE; EXPRESSION	Mutations at the mouse tottering (tg) locus cause a delayed-onset, recessive neurological disorder resulting in ataxia, motor seizures, and behavioral absence seizures resembling petit mal epilepsy in humans. A more severe allele, leaner (tg(la)), also shows a slow, selective degeneration of cerebellar neurons. By positional cloning, we have identified an alpha(1A) voltage-sensitive calcium channel gene that is mutated in tg and tg(la) mice. The alpha(1A) gene is widely expressed in the central nervous system with prominent, uniform expression in the cerebellum. alpha(1A) expression does not mirror the localized pattern of cerebellar degeneration observed in tg(la) mice, providing evidence for regional differences in biological function of alpha(1A) channels. These studies define the first mutations in a mammalian central nervous system-specific voltage-sensitive calcium channel and identify the first gene involved in absence epilepsy.	JACKSON LAB,BAR HARBOR,ME 04609; UNIV CALGARY,FAC MED,DEPT ANAT,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,FAC MED,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	Jackson Laboratory; University of Calgary; University of Calgary	Fletcher, CF (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.		Hawkes, Richard/F-7971-2011					ADACHI K, 1975, IRCS (International Research Communications System) Medical Science Library Compendium, V3, P329; ANDERSON VE, 1991, GENETIC STRATEGIES E, P89; ANNEGERS JF, 1991, GENETIC STRATEGIES E, P139; AUSTIN MC, 1992, MOL BRAIN RES, V15, P227, DOI 10.1016/0169-328X(92)90113-P; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; de Curtis M, 1994, Funct Neurol, V9, P307; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; GALLI C, 1995, J NEUROSCI, V15, P1172; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREEN MC, 1962, J HERED, V53, P79; Green MC., 1989, GENETIC VARIANTS STR, P12; HAUSER JF, 1991, GENETIC STRATEGIES E, P45; HAWKES R, 1991, PROG NEUROBIOL, V36, P309, DOI 10.1016/0301-0082(91)90004-K; HECKROTH JA, 1994, BRAIN RES, V658, P93, DOI 10.1016/S0006-8993(09)90014-2; HELLAR AH, 1983, EPILEPSIA, V2, P25; HERRUP K, 1982, NEUROSCIENCE, V7, P2185, DOI 10.1016/0306-4522(82)90129-4; HESS EJ, 1991, NEURON, V6, P123, DOI 10.1016/0896-6273(91)90127-L; HILLE B, 1992, IONIC CHANNELS EXCIT, P83; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KATER SB, 1991, J NEUROSCI, V11, P891; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KOELLER DM, 1995, GENOMICS, V28, P508, DOI 10.1006/geno.1995.1182; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KRAWCZAK M, 1992, HUM GENET, V90, P41; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; LEVITT P, 1981, P NATL ACAD SCI-BIOL, V78, P4630, DOI 10.1073/pnas.78.7.4630; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS RR, 1989, ANN NY ACAD SCI, V560, P103, DOI 10.1111/j.1749-6632.1989.tb24084.x; MARESCAUX C, 1992, J NEURAL TRANSM-SUPP, V35, P37; MEIER H, 1971, J HERED, V62, P297, DOI 10.1093/oxfordjournals.jhered.a108176; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Nishimura Y, 1975, ADV NEUROL SCI, V19, P670; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; NOEBELS JL, 1984, NATURE, V310, P409, DOI 10.1038/310409a0; NOEBELS JL, 1984, ANN NEUROL, V16, pS18, DOI 10.1002/ana.410160705; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, V43, P1; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PTACEK LJ, 1994, CELL, V77, P863; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; QIAO XX, 1991, BRAIN RES, V555, P43, DOI 10.1016/0006-8993(91)90857-R; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; ROSS ME, 1990, P NATL ACAD SCI USA, V87, P4189, DOI 10.1073/pnas.87.11.4189; RYAN SG, 1995, NAT GENET, V10, P4, DOI 10.1038/ng0595-4; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; Spitzer Nicholas C., 1994, Current Opinion in Neurobiology, V4, P70, DOI 10.1016/0959-4388(94)90034-5; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TESSAROLLO L, 1995, METHOD ENZYMOL, V254, P419; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; Volsen SG, 1995, MOL BRAIN RES, V34, P271, DOI 10.1016/0169-328X(95)00234-J; Wheeler DB, 1995, PROG BRAIN RES, V105, P65; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P3075; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	68	600	614	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 15	1996	87	4					607	617		10.1016/S0092-8674(00)81381-1	http://dx.doi.org/10.1016/S0092-8674(00)81381-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VU035	8929530	Bronze			2022-12-28	WOS:A1996VU03500004
J	Wannamethee, SG; Whincup, PH; Shaper, G; Walker, M				Wannamethee, SG; Whincup, PH; Shaper, G; Walker, M			Influence of fathers' social class on cardiovascular disease in middle-aged men	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; BIRTH-WEIGHT; ADULT LIFE; SOCIOECONOMIC-STATUS; LIVING-CONDITIONS; BRITISH MEN; CHILDHOOD; RISK; MORTALITY; GROWTH	Background The independent effect of early life circumstances on adult cardiovascular risk is still unresolved. We assessed the associations of father's social class with cardiovascular risk factors and with risk of ischaemic heart disease and stroke in adult life. Methods We did a longitudinal study of cardiovasular disease in 5934 men aged 40-59 years at enrolment. A cross-sectional measurement survey was done between 1978 and 1980 and a follow-up questionnaire was completed in 1992. The main endpoints were non-fatal myocardial infarction and stroke based on general practitioners' reports obtained between screening and 1992 and on recall of physician-diagnosed ischaemic heart disease in the 1992 questionnaire. Findings Father's social class was strongly associated with social class in adulthood (fathers' occupation was manual for 41.3% of professionals [I] vs 89.1% for unskilled manual workers [VI]) and was significantly related to height (nonmanual vs manual 175.4 cm [SE 0.2] vs 172.9 cm [0.1], p < 0.0001) and obesity (213 [14.1%] vs 804 [20.1%], p < 0.0001) irrespective of adult social class; no association was found with blood glucose (log, 1.69 [0005] vs 1.70 [0.003], p = 0.22) or cholesterol (6.4 [0.03] vs 6.29 mmol/L [0.02], p = 0.16. Men whose fathers' social class was manual had significantly higher rates of non-fatal myocardial infarction (342/4006 vs 92/1510) and self-reported physician-diagnosed ischaemic heart disease (686/4006 vs 192/1510) than men whose fathers' social class was nonmanual, even after adjustment for adult social class and other established risk factors (relative odds 1.3 [95% CI 1.0-1.7], p < 0.05 and 1.3 [1.1-1.6], p < 0.01, respectively). The influence of father's social class on non-fatal myocardial infarction and ischaemic heart disease was only seen in men whose adult social class was non-manual. No association was seen between father's social class and non-fatal stroke. Interpretation Father's social class is strongly associated with adult social class. The higher risk of non-fatal myocardial infarction and self-reported physician-diagnosed ischaemic heart disease seen in men whose father's social class was manual suggests that socioeconomic status early in life has some persisting influence on ischaemic heart disease risk in adult life.			Wannamethee, SG (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107				ARNESEN E, 1985, J EPIDEMIOL COMMUN H, V39, P210, DOI 10.1136/jech.39.3.210; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BRUCE NG, 1988, J HYPERTENS, V6, P375; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PECK MN, 1994, SOC SCI MED, V39, P553; PETERS TJ, 1983, BRIT J OBSTET GYNAEC, V90, P1040, DOI 10.1111/j.1471-0528.1983.tb06442.x; POCOCK SJ, 1987, LANCET, V2, P197; RODRIGUEZ C, 1995, J EPIDEMIOL COMMUN H, V49, P38, DOI 10.1136/jech.49.1.38; RONA RJ, 1981, BRIT MED BULL, V37, P265, DOI 10.1093/oxfordjournals.bmb.a071713; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; STRACHAN DP, 1995, BRIT MED J, V310, P423, DOI 10.1136/bmj.310.6977.423; STRONG JP, 1969, J ATHEROSCLER RES, V9, P251, DOI 10.1016/S0368-1319(69)80020-7; WALKER M, 1984, J ROY COLL GEN PRACT, V34, P365; WANNAMETHEE G, 1995, BRIT HEART J, V74, P324; WILCOX MA, 1995, ACTA OBSTET GYN SCAN, V74, P15, DOI 10.3109/00016349509009936	31	183	184	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1259	1263		10.1016/S0140-6736(96)02465-8	http://dx.doi.org/10.1016/S0140-6736(96)02465-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR555	8909377				2022-12-28	WOS:A1996VR55500007
J	Condemi, JJ				Condemi, JJ			Update in allergy and immunology	ANNALS OF INTERNAL MEDICINE			English	Article											Condemi, JJ (corresponding author), ALLERGY ASTHMA IMMUNOL ROCHESTER, 919 WESTFALL RD, BLDG B, ROCHESTER, NY 14618 USA.							LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; WONG S, 1990, ARCH INTERN MED, V150, P1323, DOI 10.1001/archinte.150.6.1323	2	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					744	750		10.7326/0003-4819-125-9-199611010-00008	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929009				2022-12-28	WOS:A1996VQ07200007
J	Lee, DC; Halliday, AN				Lee, DC; Halliday, AN			Hf-W isotopic evidence for rapid accretion and differentiation in the early solar system	SCIENCE			English	Article							U-PB SYSTEMATICS; IRON-METEORITES; AGE	The time scales over which inner solar system objects accreted and differentiated are unclear because the isotopic systems of many meteorites are disturbed. Hf-182 decays to W-182 with a half-life of 9 million years and is a particularly useful chronometer because both elements are highly refractory and immobile. Tungsten isotopic data for IIA, IIIA, IVA, and anomalous iron meteorites and H, L, and LL chondrites indicate that their parent bodies accreted rapidly and segregated metal within just a few million years.			Lee, DC (corresponding author), UNIV MICHIGAN,DEPT GEOL SCI,1006 CC LITTLE BLDG,ANN ARBOR,MI 48109, USA.		Lee, Der-Chuen/N-9225-2013	Lee, Der-Chuen/0000-0001-8855-9594				AHRENS LH, 1970, EARTH PLANET SC LETT, V9, P345, DOI 10.1016/0012-821X(70)90133-0; ALLEGRE CJ, 1995, GEOCHIM COSMOCHIM AC, V59, P1445, DOI 10.1016/0016-7037(95)00054-4; BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; Chen J. H., 1996, EARTH PROCESSES READ, P1; CHOI BG, 1995, GEOCHIM COSMOCHIM AC, V59, P593, DOI 10.1016/0016-7037(94)00384-X; DODD RT, 1981, METEORITES PETROLOGI; Galer S.J.G., 1996, EARTH PROCESSES READ, P75; GOPEL C, 1994, EARTH PLANET SC LETT, V121, P153, DOI 10.1016/0012-821X(94)90038-8; GOPEL C, 1985, GEOCHIM COSMOCHIM AC, V49, P1681, DOI 10.1016/0016-7037(85)90139-5; GOPEL C, 54 MET SOC M; Halliday A, 1996, EARTH PLANET SC LETT, V142, P75, DOI 10.1016/0012-821X(96)00096-9; Harper C.L., 1991, LUNAR PLANET SCI, V22, P515; Harper CL, 1996, GEOCHIM COSMOCHIM AC, V60, P1131, DOI 10.1016/0016-7037(96)00027-0; IRELAND TR, 1992, EARTH PLANET SC LETT, V109, P1, DOI 10.1016/0012-821X(92)90069-8; IRELAND TR, 1991, LUNAR PLANET SCI, V22, P609; KELLY WR, 1978, GEOPHYS RES LETT, V5, P1079, DOI 10.1029/GL005i012p01079; LEE DC, 1995, NATURE, V378, P771, DOI 10.1038/378771a0; LEE T, 1977, ASTROPHYS J, V211, pL107, DOI 10.1086/182351; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; LUGMAIR GW, 1994, LPS, V25, P813; PERRON C, 1988, METEORITICS, V27, P275; REYNOLDS JH, 1960, PHYS REV LETT, V4, P8, DOI 10.1103/PhysRevLett.4.8; SETSER JL, 1964, GEOCHIM COSMOCHIM AC, V28, P769, DOI 10.1016/0016-7037(64)90031-6; Shen JJ, 1996, GEOCHIM COSMOCHIM AC, V60, P2887, DOI 10.1016/0016-7037(96)00120-2; Smoliar MI, 1996, SCIENCE, V271, P1099, DOI 10.1126/science.271.5252.1099; STEWART BW, 1994, GEOCHIM COSMOCHIM AC, V58, P3487, DOI 10.1016/0016-7037(94)90100-7; SWINDLE TD, 1988, METEORITES EARLY SOL, P1127; Taylor SR, 1992, SOLAR SYSTEM EVOLUTI; [No title captured]	30	135	136	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1876	1879		10.1126/science.274.5294.1876	http://dx.doi.org/10.1126/science.274.5294.1876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VY200	8943194				2022-12-28	WOS:A1996VY20000034
J	Gabbiani, F; Metzner, W; Wessel, R; Koch, C				Gabbiani, F; Metzner, W; Wessel, R; Koch, C			From stimulus encoding to feature extraction in weakly electric fish	NATURE			English	Article							LATERAL-LINE LOBE; JAMMING AVOIDANCE-RESPONSE; GYMNOTIFORM FISH; EIGENMANNIA; NEURONS; ELECTRORECEPTORS; COMMUNICATION; CORTEX; MONKEY	ANIMALS acquire information about sensory stimuli around them and encode it using an analogue or a pulse-based code. Behaviourally relevant features need to be extracted from this representation for further processing. In the electrosensory system of weakly electric fish, single P-type electroreceptor afferents accurately encode the time course of random modulations in electric-field amplitude(1). We applied a stimulus estimation method(2) and a signal-detection method to both P-receptor afferents and their targets, the pyramidal cells in the electrosensory lateral-line lobe. We found that although pyramidal cells do not accurately convey detailed information about the time course of the stimulus, they reliably encode up- and downstrokes of random modulations in electric-field amplitude. The presence of such temporal features is best signalled by short bursts of spikes, probably caused by dendritic processing, rather than by isolated spikes. Furthermore, pyramidal cells outperform P-receptor afferents in signalling the presence of temporal features in the stimulus waveform. We conclude that the sensory neurons are specialized to acquire information accurately with little processing, whereas the following stage extracts behaviourally relevant features, thus performing a nonlinear pattern-recognition task.	UNIV CALIF RIVERSIDE, DEPT BIOL, RIVERSIDE, CA 92521 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California Riverside; University of California System; University of California San Diego	Gabbiani, F (corresponding author), CALTECH, COMPUTAT & NEURAL SYST PROGRAM, DIV BIOL 13974, PASADENA, CA 91125 USA.			Koch, Christof/0000-0001-6482-8067				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Anderson TW, 1984, INTRO MULTIVARIATE S; BAIR W, 1994, J NEUROSCI, V14, P2870; BASTIAN J, 1980, J COMP PHYSIOL, V136, P135, DOI 10.1007/BF00656908; Bastian J., 1986, P577; BASTIAN J, 1991, J COMP PHYSIOL A, V168, P393, DOI 10.1007/BF00199600; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; CARR CE, 1982, J COMP NEUROL, V211, P139, DOI 10.1002/cne.902110204; Gabbiani F, 1996, NEURAL COMPUT, V8, P44, DOI 10.1162/neco.1996.8.1.44; Gabbiani F, 1996, NETWORK-COMP NEURAL, V7, P61, DOI 10.1080/0954898X.1996.11978655; Heiligenberg W., 1991, NEURAL NETS ELECT FI; HOPKINS CD, 1988, ANNU REV NEUROSCI, V11, P497, DOI 10.1146/annurev.ne.11.030188.002433; HOPKINS CD, 1976, J COMP PHYSIOL, V111, P171, DOI 10.1007/BF00605531; Jolliffe IT., 2002, PRINCIPAL COMPONENT, DOI DOI 10.1007/B98835; KAWASAKI M, 1988, NATURE, V336, P173, DOI 10.1038/336173a0; KRUEGER J, 1991, Trends in Neurosciences, V14, P282; LEHKY SR, 1992, J NEUROSCI, V12, P3568; MALER L, 1994, J COMP NEUROL, V345, P224, DOI 10.1002/cne.903450206; MALER L, 1981, J COMP NEUROL, V195, P87, DOI 10.1002/cne.901950107; MALER L, 1991, J CHEM NEUROANAT, V4, P1, DOI 10.1016/0891-0618(91)90030-G; METZNER W, 1991, J COMP PHYSIOL A, V169, P135, DOI 10.1007/BF00215861; METZNER W, 1993, J NEUROSCI, V13, P1862; Poor H.V., 2013, INTRO DETECTION ESTI; RAUDYS SJ, 1991, IEEE T PATTERN ANAL, V13, P252, DOI 10.1109/34.75512; SHUMWAY CA, 1989, J NEUROSCI, V9, P4388; TURNER RW, 1994, J NEUROSCI, V14, P6453; Turner RW, 1996, J NEUROPHYSIOL, V76, P2364, DOI 10.1152/jn.1996.76.4.2364; Wessel R, 1996, J NEUROPHYSIOL, V75, P2280, DOI 10.1152/jn.1996.75.6.2280; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4; Zakon H.H., 1986, P103	30	183	186	0	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 12	1996	384	6609					564	567		10.1038/384564a0	http://dx.doi.org/10.1038/384564a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VX769	8955269				2022-12-28	WOS:A1996VX76900059
J	Stiehm, ER; Roberts, RL; HanleyLopez, J; Wakim, ME; Pallavicini, MG; Cowan, MJ; Ettenger, RB; Feig, SA				Stiehm, ER; Roberts, RL; HanleyLopez, J; Wakim, ME; Pallavicini, MG; Cowan, MJ; Ettenger, RB; Feig, SA			Bone marrow transplantation in severe combined immunodeficiency from a sibling who had received a paternal bone marrow transplant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-CELLS; TOLERANCE; DONOR; RECONSTITUTION; DEFICIENCY; DISEASE; HOST		UNIV CALIF LOS ANGELES,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF SAN FRANCISCO,CTR CANC,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	University of California System; University of California Los Angeles; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCRR NIH HHS [RR00865] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000865] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; BENKERROU M, 1994, J CLIN IMMUNOL, V14, P98, DOI 10.1007/BF01541342; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; BUCKLEY RH, 1996, IMMUNOLOGIC DISORDER, P1014; CONLEY ME, 1996, IMMUNOLOGIC DISORDER, P201; DEVILLARTAY JP, 1986, EUR J IMMUNOL, V16, P117, DOI 10.1002/eji.1830160202; DROR Y, 1993, BLOOD, V81, P2021; FISCHER A, 1994, BLOOD, V83, P1149; Friedrich W., 1995, Blood, V86, p393A; GEHA RS, 1977, CLIN IMMUNOL IMMUNOP, V8, P105, DOI 10.1016/0090-1229(77)90097-6; KEEVER CA, 1989, HUM IMMUNOL, V26, P27, DOI 10.1016/0198-8859(89)90030-X; Kline RM, 1996, BONE MARROW TRANSPL, V17, P543; MEHROTRA B, 1995, BLOOD, V86, P1139; MERINO A, 1993, BONE MARROW TRANSPL, V12, P483; OREILLY RJ, 1984, SEMIN HEMATOL, V21, P188; PARKMAN R, 1986, CLIN IMMUNOL IMMUNOP, V40, P142, DOI 10.1016/0090-1229(86)90078-4; RAO AS, 1994, TRANSPLANT P, V26, P3377; REISNER Y, 1983, BLOOD, V61, P341; ROSENKRANTZ K, 1990, J IMMUNOL, V144, P1721; SCHIFF SE, 1987, J IMMUNOL, V138, P2088; STIEHM ER, 1972, NEW ENGL J MED, V286, P797, DOI 10.1056/NEJM197204132861501	21	15	15	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 12	1996	335	24					1811	1814		10.1056/NEJM199612123352405	http://dx.doi.org/10.1056/NEJM199612123352405			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VW683	8943163				2022-12-28	WOS:A1996VW68300005
J	Haynes, BF				Haynes, BF			New frontiers of immunotherapy for HIV	LANCET			English	Editorial Material											Haynes, BF (corresponding author), DUKE UNIV,MED CTR,DUKE CTR AIDS RES,DURHAM,NC 27710, USA.							Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Haynes BF, 1996, LANCET, V348, P933, DOI 10.1016/S0140-6736(96)09339-7; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Moss RB, 1996, J CLIN IMMUNOL, V16, P266, DOI 10.1007/BF01541391; PELLETIER E, 1996, J NIH RES, V8, P45; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1531	1532		10.1016/S0140-6736(05)66165-X	http://dx.doi.org/10.1016/S0140-6736(05)66165-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950876				2022-12-28	WOS:A1996VX02300004
J	Mistry, PK; Wraight, EP; Cox, TM				Mistry, PK; Wraight, EP; Cox, TM			Therapeutic delivery of proteins to macrophages: Implications for treatment of Gaucher's disease	LANCET			English	Article							MANNOSE-TERMINATED GLUCOCEREBROSIDASE; INHERITED ENZYME DEFICIENCY; REPLACEMENT THERAPY; ALGLUCERASE; EFFICACY; TYPE-1; CELLS; CLEARANCE; REGIMEN; LIVER	Background The primary defect in Gaucher's disease, a lysosomal disorder affecting macrophages, is in the activity of glucocerebrosidase. Treatment with exogenous enzyme (modified to increase its affinity for macrophage glycoprotein receptors) aims to restore this activity. However, the fate of the exogenous enzyme in vivo is unknown. We used radiolabelled enzyme to assess macrophage receptor activity for mannosylated ligands in vivo. Methods We examined the uptake and tissue distribution of radiolabelled enzyme molecules by gamma scintigraphy after bolus injection of iodine-123-labelled recombinant or placental enzyme (imiglucerase and alglucerase, respectively) in eight patients with type 1 Gaucher's disease, and in one healthy individual. The metabolism of the tracer enzyme was followed by scintigraphy and by analysis of blood, urine, and faeces. Results The tracer enzyme was rapidly cleared from blood (half-life 4.7 min [SD 1.0]). Concomitantly, there was avid uptake by the liver (about 30% of the injected dose), the spleen (about 15%), and the bone marrow. 40-55% of the tracer was cleared rapidly from the viscera (half-life 1-2 h) and 45-60% was cleared slowly (half-life 34-42 h). The half-life in the bone marrow was 14.1 h. Infusion of alglucerase at dose of 5 U/kg bodyweight normalised acid beta-glucosidase activity of splenic Gaucher's cells in vivo. When the enzyme was administered at a seven-fold higher dose (35 U/kg over 1 h), the receptor-mediated uptake in vivo was saturated, as shown by the increase in blood-clearance half-life of tracer enzyme from 4.5 min to 12 min. Interpretation Avid and saturable uptake of modified glucocerebrosidase was found, which indicates high-affinity targeting to the macrophage system in vivo. The rate of enzyme turnover suggests a rational basis for use of this therapy in treatment of Gaucher's disease.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP TRUST,DEPT NUCL MED,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital								ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; BARTON NW, 1993, NEW ENGL J MED, V328, P1564; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1995, MOL MED, V1, P320, DOI 10.1007/BF03401556; Beutler E., 1995, METABOLIC MOL BASES, P2641; Bijsterbosch MK, 1996, EUR J BIOCHEM, V237, P344, DOI 10.1111/j.1432-1033.1996.00344.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADY RO, 1994, BIOCHEM MED METAB B, V52, P1, DOI 10.1006/bmmb.1994.1026; BURNS GF, 1977, J CLIN PATHOL, V30, P981, DOI 10.1136/jcp.30.10.981; COHEN Y, 1994, AM J HEMATOL, V47, P235, DOI 10.1002/ajh.2830470317; DEDUVE C, 1964, FED PROC, V23, P1045; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; HOLLAK CEM, 1995, LANCET, V345, P1474, DOI 10.1016/S0140-6736(95)91037-9; LENNARTZ MR, 1987, J BIOL CHEM, V262, P9942; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MISTRY PK, 1992, LANCET, V339, P889, DOI 10.1016/0140-6736(92)90928-V; MISTRY PK, 1993, J MED GENET, V30, P889, DOI 10.1136/jmg.30.11.889; MISTRY PK, 1992, Q J MED, V84, P541; MURRAY GJ, 1995, J CELL BIOCHEM, V57, P208, DOI 10.1002/jcb.240570205; MYERS MJ, 1981, BRIT J RADIOL, V54, P1062, DOI 10.1259/0007-1285-54-648-1062; *NIH TECHN ASS PAN, 1996, JAMA-J AM MED ASSOC, V275, P548; PASTORES GM, 1993, BLOOD, V82, P408; PENTCHEV PG, 1975, J MOL MED, V1, P73; RAGHAVAN SS, 1980, AM J HUM GENET, V32, P158; SATO Y, 1993, J CLIN INVEST, V91, P1909, DOI 10.1172/JCI116409; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; VANFURTH R, 1992, MONONUCLEAR PHAGOCYTES, P3; WILLEMSEN R, 1995, HISTOCHEM J, V27, P639; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6	32	75	99	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1555	1559		10.1016/S0140-6736(96)04451-0	http://dx.doi.org/10.1016/S0140-6736(96)04451-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950883				2022-12-28	WOS:A1996VX02300011
J	OBrien, E				OBrien, E			Ave atque vale: The centenary of clinical sphygmomanometry	LANCET			English	Editorial Material							BLOOD-PRESSURE MEASUREMENT				OBrien, E (corresponding author), BEAUMONT HOSP,BLOOD PRESSURE UNIT,DUBLIN 9,IRELAND.							Grim C. E., 1994, American Journal of Hypertension, V7, p116A; LAHER M, 1982, BRIT MED J, V285, P1796, DOI 10.1136/bmj.285.6357.1796; O'Brien, 1996, Blood Press Monit, V1, P55; OBRIEN E, 1994, J HUM HYPERTENS, V8, P73; OBRIEN E, 1991, J HUM HYPERTENS, V5, P7; OBRIEN E, 1990, J HYPERTENS, V8, P621, DOI 10.1097/00004872-199007000-00005; OBrien E, 1995, J HUM HYPERTENS, V9, P933; OBRIEN ET, 1995, ABC HYPERTENSION; PICKERING T, IN PRESS BLOOD PRESS; Riva-Rocci S., 1896, GAZ MED TORINO, V47, P981; Riva-Rocci S., 1897, GAZZETTA MED TORINO, V48, P181; RIVAROCCI S, 1896, GAZZ MED TORINO, V47, P1001; RIVAROCCI S, 1897, GAZZETTA MED TORINO, V48, P161; WIDE C, 1986, BRIT MED J, V293, P1409; Zanchetti A, 1996, J HYPERTENS, V14, P1	15	25	25	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 7	1996	348	9041					1569	1570		10.1016/S0140-6736(96)10033-7	http://dx.doi.org/10.1016/S0140-6736(96)10033-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VX023	8950887				2022-12-28	WOS:A1996VX02300015
J	Mayford, M; Bach, ME; Huang, YY; Wang, L; Hawkins, RD; Kandel, ER				Mayford, M; Bach, ME; Huang, YY; Wang, L; Hawkins, RD; Kandel, ER			Control of memory formation through regulated expression of a CaMKII transgene	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; II MUTANT MICE; GENE-EXPRESSION; FEAR; RAT; AMYGDALA; LTP; AUTOPHOSPHORYLATION; THREONINE-286	One of the major limitations in the use of genetically modified mice for studying cognitive,, functions is the lack of regional and temporal control of gene function, To overcome these limitations, a forebrain-specific promoter was combined with the tetracycline transactivator system to achieve both regional and temporal control of transgene expression, Expression of an activated calcium-independent form of calcium-calmodulin-dependent dent kinase II (CaMKII) resulted in a loss of hippocampal long-term potentiation in response to 10-hertz stimulation and a deficit in spatial memory, a form of explicit memory, Suppression of transgene expression reversed both the physiological and the memory deficit, When the transgene was expressed at high levels in the lateral amygdala and the striatum but not other forebrain Structures, there was a deficit in fear conditioning, an implicit memory task, that also was reversible Thus, the CaMKII signaling pathway is critical for both explicit and implicit memory storage,in a manner that is independent of its potential role in development.	COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute				Mayford, Mark/0000-0002-9001-5024				BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CANTERAS NS, 1995, J COMP NEUROL, V360, P213, DOI 10.1002/cne.903600203; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DAVIS M, 1992, P255; FONG YL, 1989, J BIOL CHEM, V264, P16759; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KITA H, 1990, J COMP NEUROL, V298, P40, DOI 10.1002/cne.902980104; LEDOUX J E, 1992, P339; LEDOUX JE, 1990, J NEUROSCI, V10, P1062; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Neveu D, 1996, NEURON, V16, P619, DOI 10.1016/S0896-6273(00)80081-1; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; SCHACTER DL, 1994, MEMORY SYSTEMS BRAIN; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUNYER T, 1990, P NATL ACAD SCI USA, V87, P278, DOI 10.1073/pnas.87.1.278; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	38	1066	1125	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 6	1996	274	5293					1678	1683		10.1126/science.274.5293.1678	http://dx.doi.org/10.1126/science.274.5293.1678			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VW712	8939850				2022-12-28	WOS:A1996VW71200049
J	Logan, RPH; Berg, DE				Logan, RPH; Berg, DE			Genetic diversity of Helicobacter pylori	LANCET			English	Editorial Material									WASHINGTON UNIV,SCH MED,DEPT MOL GENET,ST LOUIS,MO 63119	Washington University (WUSTL)	Logan, RPH (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND.							Akopyants Natalia S., 1996, Gut, V39, pA67; Atherton J. C., 1996, Gut, V39, pA73; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; Censini S., 1996, Gut, V39, pA72; COVER TL, 1995, J CLIN MICROBIOL, V33, P1496, DOI 10.1128/JCM.33.6.1496-1500.1995; Dubois A., 1996, Gut, V39, pA74; Go MF, 1996, J BACTERIOL, V178, P3934, DOI 10.1128/jb.178.13.3934-3938.1996; Hazell S. L., 1996, Gut, V39, pA74; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; Kuipers E. J., 1996, Gut, V39, pA10; Tomb J.-F., 1996, Gut, V39, pA3; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x	13	57	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 30	1996	348	9040					1462	1463		10.1016/S0140-6736(05)65885-0	http://dx.doi.org/10.1016/S0140-6736(05)65885-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VV463	8942769				2022-12-28	WOS:A1996VV46300002
J	Manna, AC; Pai, KS; Bussiere, DE; Davies, C; White, SW; Bastia, D				Manna, AC; Pai, KS; Bussiere, DE; Davies, C; White, SW; Bastia, D			Helicase-contrahelicase interaction and the mechanism of termination of DNA replication	CELL			English	Article							BACILLUS-SUBTILIS CHROMOSOME; RIBOSOMAL-RNA GENES; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; POLAR CONTRAHELICASE; TOPOISOMERASE-IV; ANTIGEN HELICASE; PROTEIN IMPEDES; TERMINUS REGION; FORK MOVEMENT	Termination of DNA replication at a sequence-specific replication terminus is potentiated by the binding of the replication terminator protein (RTP) to the terminus sequence, causing polar arrest of the replicative helicase (contrahelicase activity). Two alternative models have been proposed to explain the mechanism of replication fork arrest. In the first model, the RTP-terminus DNA interaction simply imposes a polar barrier to helicase movement without involving any specific interaction between the helicase and the terminator proteins. The second model proposes that there is a specific interaction between the two proteins, and that the DNA-protein interaction both restricts the fork arrest to the replication terminus and determines the polarity of the process. The evidence presented in this paper strongly supports the second model.	DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	Duke University			White, Stephen W/N-8164-2018		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019881] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI19881] Funding Source: Medline; NIGMS NIH HHS [GM-49264] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; AMIN AA, 1992, J BIOL CHEM, V267, P18612; Bastia D., 1996, DNA REPLICATION EUKA, P177; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BLAKELY G, 1991, NEW BIOL, V3, P789; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUSSIERE DE, 1995, CELL, V80, P651; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; HERNANDEZ P, 1988, EMBO J, V7, P303, DOI 10.1002/j.1460-2075.1988.tb02813.x; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1992, J BIOL CHEM, V267, P5361; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KRALICEK AV, 1991, BIOCHEM J, V275, P823, DOI 10.1042/bj2750823; KUEMPEL PL, 1991, NEW BIOL, V3, P799; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LEWIS PJ, 1991, RES MICROBIOL, V142, P893, DOI 10.1016/0923-2508(91)90070-Q; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; MARCZALEK J, 1994, J BIOL CHEM, V269, P4883; MARTIN MCS, 1995, J STRUCT BIOL, V114, P167; Meijer WJJ, 1996, MOL MICROBIOL, V19, P1295, DOI 10.1111/j.1365-2958.1996.tb02474.x; MOHANTY BK, 1996, EMBO J, V15, P2520; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NAKAYAMA N, 1984, J BIOL CHEM, V259, P97; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pai KS, 1996, EMBO J, V15, P3164, DOI 10.1002/j.1460-2075.1996.tb00679.x; Pai KS, 1996, P NATL ACAD SCI USA, V93, P10647, DOI 10.1073/pnas.93.20.10647; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; SMITH MT, 1994, J MOL BIOL, V241, P335, DOI 10.1006/jmbi.1994.1510; Smith MT, 1996, J MOL BIOL, V260, P54, DOI 10.1006/jmbi.1996.0381; SMITH MT, 1992, J MOL BIOL, V227, P648, DOI 10.1016/0022-2836(92)90214-5; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; YOSHIKAWA H, 1963, P NATL ACAD SCI USA, V49, P559, DOI 10.1073/pnas.49.4.559; YOSHIKAWA H, 1963, P NATL ACAD SCI USA, V49, P806, DOI 10.1073/pnas.49.6.806; YOUNG PA, 1994, J MOL BIOL, V240, P275, DOI 10.1006/jmbi.1994.1444; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	56	37	38	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					881	891		10.1016/S0092-8674(00)81995-9	http://dx.doi.org/10.1016/S0092-8674(00)81995-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945515	Bronze			2022-12-28	WOS:A1996VV77400014
J	Prescott, SM; White, RL				Prescott, SM; White, RL			Self-promotion? Intimate connections between APC and prostaglandin H synthase-2	CELL			English	Review							CYCLOOXYGENASE-2; EXPRESSION; ADENOMAS; GENE				Prescott, SM (corresponding author), UNIV UTAH,HUNTSMAN CANC INST,SALT LAKE CITY,UT 84112, USA.							Boolbol SK, 1996, CANCER RES, V56, P2556; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; Dove WF, 1995, CANCER SURV, V25, P335; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Jacoby RF, 1996, CANCER RES, V56, P710; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; MARNETT LJ, 1994, CANCER METAST REV, V13, P303, DOI 10.1007/BF00666100; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; SANO H, 1995, CANCER RES, V55, P3785; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5	14	189	207	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 29	1996	87	5					783	786		10.1016/S0092-8674(00)81983-2	http://dx.doi.org/10.1016/S0092-8674(00)81983-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VV774	8945503	Bronze			2022-12-28	WOS:A1996VV77400002
J	Kitson, J; Raven, T; Jiang, YP; Goeddel, DV; Giles, KM; Pun, KT; Grinham, CJ; Brown, R; Farrow, SN				Kitson, J; Raven, T; Jiang, YP; Goeddel, DV; Giles, KM; Pun, KT; Grinham, CJ; Brown, R; Farrow, SN			A death-domain-containing receptor that mediates apoptosis	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; CELL-DEATH; PROTEIN; INTERACTS; FAS; SYSTEM; YEAST	THE cell-killing effects of the cytokines TNF-alpha and Fast are mediated by the distinct cell-surface receptors TNFR1, TNFR2 and Fas (also known as CD95/APO-1), which are all members of a receptor superfamily that is important for regulating cell survival(1-4). The cytoplasmic regions of TNFR1 and Fas contain a conserved 'death' domain which is an essential component of the signal pathway that triggers apoptosis and activation of the transcription factor NF-kappa B (refs 5, 6). Here we report the isolation of a 54K receptor that is a new member of the TNFR superfamily, using the death domain of TNFR1 in a yeast two-hybrid system(7,8). This protein, WSL-1, is most similar to TNFR1 itself, particularly in the death-domain region, The gene wsl-1 is capable of inducing apoptosis when transfected into 3T3 and 293 cells, and can also activate NF-kappa B in 293 cells, Like TNFR1, WSL-1 will homodimerize in yeast. WSL-1 also interacts specifically with the TNFR1-associated molecule TRADD(9). The tissue distribution is very restricted and significantly different from that of Fas and TNFR1.	GLAXO WELLCOME MED RES CTR,CELL BIOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; TULARIK INC,S SAN FRANCISCO,CA 94080	GlaxoSmithKline				Pun, Tao/0000-0001-5241-2187				Baker SJ, 1996, ONCOGENE, V12, P1; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	22	285	329	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					372	375		10.1038/384372a0	http://dx.doi.org/10.1038/384372a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934525				2022-12-28	WOS:A1996VV27100053
J	Tinsley, JM; Potter, AC; Phelps, SR; Fisher, R; Trickett, JI; Davies, KE				Tinsley, JM; Potter, AC; Phelps, SR; Fisher, R; Trickett, JI; Davies, KE			Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; ORAL SODIUM PHENYLBUTYRATE; MUSCLE-SPECIFIC EXPRESSION; SKELETAL ACTIN GENE; EXTRACELLULAR-MATRIX; FULL-LENGTH; THERAPY; PROTEIN; COMPLEX; MOUSE	DUCHENNE muscular dystrophy (DMD) is a severe, progressive muscle-wasting disease that causes cardiac or respiratory failure(1,2) and results in death at about 20 years of age, Replacement of the missing protein, dystrophin, using myoblast transfer in humans or viral/liposomal delivery in the mouse DMD model is inefficient and short-lived(3,4). One alternative approach to treatment would be to upregulate the closely related protein, utrophin(5,6), which might be able to compensate for the dystrophin deficiency in all relevant muscles(7,8). As a first step to this approach, we have expressed a utrophin transgene at high levels in the dystrophin-deficient mdx mouse. Our results indicate that high expression of the utrophin transgene in skeletal and diaphragm muscle can markedly reduce the dystrophic pathology. These data suggest that systemic upregulation of utrophin in DMD patients may lead to the development of an effective treatment for this devastating disorder.	UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND	University of Oxford								Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BRENNAN KJ, 1993, J BIOL CHEM, V268, P719; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DOVER GJ, 1994, BLOOD, V84, P339; EMERY AEH, 1993, OXFORD MONOGR MED GE, V24; Hoffman EP, 1996, BRAIN PATHOL, V6, P49, DOI 10.1111/j.1750-3639.1996.tb00782.x; HOFFMAN EP, 1994, NAT GENET, V8, P311, DOI 10.1038/ng1294-311; HOGAN B, 1986, MANIPULATING MOUSE E; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MORGAN JE, 1994, HUM GENE THER, V5, P165, DOI 10.1089/hum.1994.5.2-165; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NHUYEN TM, 1991, J CELL BIOL, V155, P1695; PARTRIDGE TA, 1995, BRIT MED BULL, V51, P123, DOI 10.1093/oxfordjournals.bmb.a072942; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; SHERRATT TG, 1992, BIOCHEM J, V287, P755, DOI 10.1042/bj2870755; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TINSLEY JM, 1993, NEUROMUSCULAR DISORD, V3, P537, DOI 10.1016/0960-8966(93)90111-V; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; WELLS DJ, 1995, HUM MOL GENET, V4, P1245, DOI 10.1093/hmg/4.8.1245	27	394	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	NOV 28	1996	384	6607					349	353		10.1038/384349a0	http://dx.doi.org/10.1038/384349a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VV271	8934518				2022-12-28	WOS:A1996VV27100046
J	Katz, J				Katz, J			The Nuremberg Code and the Nuremberg Trial - A reappraisal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The Nuremberg Code includes 10 principles to guide physician-investigators in experiments involving human subjects. These principles, particularly the first principle on ''voluntary consent,'' primarily were based on legal concepts because medical codes of ethics existent at the time of the Nazi atrocities did not address consent and other safeguards for human subjects. The US judges who presided over the proceedings did not intend the Code to apply only to the case before them, to be a response to the atrocities committed by the Nazi physicians, or to be inapplicable to research as it is customarily carried on in medical institutions. Instead, a careful reading of the judgment suggests that they wrote the Code for the practice of human experimentation whenever it is being conducted.			Katz, J (corresponding author), YALE UNIV, SCH MED, 127 WALL ST, NEW HAVEN, CT 06511 USA.							Advisory Committee on Human Radiation Experiments, 1995, FIN REP; Bernard C., 1927, INTRO STUDY EXPT MED, P101; GRODIN MA, 1992, NAZI DOCTORS NUREMBE, P127; HARRIS SH, 1994, FACTORIES DEATH; IVY AC, 1972, EXPT HUMAN BEINGS, P300; JONAS H, 1974, PHILOS ESSAYS; JONES WHS, 1962, HIPPOCRATES, P301; KATZ J, 1992, NAZI DOCTORS NUREMBE, P236; LEAKE CD, 1975, PERCIVALS MED ETHICS, P76; Lederer S., 1995, SUBJECTED SCI; LEVINE RJ, 1996, ETHICS RES HUMAN SUB; REICH WT, 1995, ENCY BIOETHICS, V5, P2637; RICKHAM PP, 1964, BRIT MED J, V2, P173; TAYLOR T, 1949, FINAL REPORT SECRETA, P115; 1946, JAMA-J AM MED ASSOC, V132, P714; 1947, JAMA-J AM MED ASSOC, V133, P35; 1946, TRIALS WAR CRIMINALS, V1; 1946, JAMA-J AM MED ASSOC, V132, P1090	18	94	98	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	1996	276	20					1662	1666		10.1001/jama.276.20.1662	http://dx.doi.org/10.1001/jama.276.20.1662			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU209	8922453				2022-12-28	WOS:A1996VU20900034
J	Templeton, A; Morris, JK; Parslow, W				Templeton, A; Morris, JK; Parslow, W			Factors that affect outcome of in-vitro fertilisation treatment	LANCET			English	Article							FERTILIZATION-EMBRYO TRANSFER; UNEXPLAINED INFERTILITY; ASSISTED CONCEPTION; PREGNANCY RATES; OOCYTE DONATION; COUPLES; AGE; REPRODUCTION; INSEMINATION; CYCLES	Background The effectiveness of in-vitro fertilisation (IVF) treatment depends both on the overall success rate in the treating clinic and on the characteristics of the couple seeking treatment. Since 1991, the Human Fertilisation and Embryology Authority (HFEA) has been collecting information on all IVF cycles carried out in the UK. This database has been analysed to identify the factors that affect the outcome of treatment. Methods All IVF treatment cycles and outcomes registered between August, 1991, and April, 1994, were identified (52 507). Cycles that involved gamete or embryo donation, frozen embryo transfer, or micromanipulation and unstimulated cycles were excluded. Thus, 36 961 cycles (70% of those registered) were included in the analysis. The main outcome measure was livebirth rate per cycle started, The relation between age and outcome was investigated by fitting of different fractional polynomials of age with logistic regression models. All other factors were analysed by logistic regression with age included in the model. Findings The overall livebirth rate per cycle of treatment was 13.9%. The highest livebirth rates were in the age-group 25-30 years; younger women had lower rates and there was a sharp decline in older women. At all ages over 30, use of donor eggs was associated with a significantly higher livebirth rate than use of the woman's own eggs, hut there was also a downward trend in success rate with age (p=0.04. After adjustment for age, there was a significant decrease in livebirth rate with increasing duration of infertility from 1 to 12 years (p<0.001). The medical indication for treatment had no significant effect on the outcome. Previous pregnancy and livebirth significantly increased treatment success. The possibility of success decreased with each IVF treatment cycle. Interpretation We were able to identify by logistic regression the factors that significantly affect the outcome of IVF treatment, and to measure the magnitude of that effect. These factors should be taken into account in assessment of IVF results. After allowance for background clinic success rates, these factors can be used to predict outcome in individual cases.	ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT, HUMAN FERTILISAT & EMBRYOL AUTHOR, LONDON, ENGLAND; ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT, WOLFSTON INST PREVENT MED, LONDON, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London			Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				ABDALLA HI, 1993, HUM REPROD, V8, P1512, DOI 10.1093/oxfordjournals.humrep.a138289; AZEM F, 1994, FERTIL STERIL, V61, P1088; BAIRD DT, 1992, BRIT MED J, V305, P204, DOI 10.1136/bmj.305.6847.204; BUITENDIJK SE, 1995, LANCET, V346, P901, DOI 10.1016/S0140-6736(95)92740-9; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; CHAPKO KM, 1995, FERTIL STERIL, V64, P757, DOI 10.1016/S0015-0282(16)57851-0; CHECK JH, 1994, FERTIL STERIL, V61, P257; COLLINS JA, 1995, FERTIL STERIL, V64, P538, DOI 10.1016/S0015-0282(16)57789-9; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; COLLINS JA, 1991, INT J FERTIL, V36, P140; EDWARDS RG, 1992, HUM REPROD, V7, P733, DOI 10.1093/oxfordjournals.humrep.a137728; HEALY DL, 1994, LANCET, V343, P1539, DOI 10.1016/S0140-6736(94)92941-6; HULL MGR, 1992, BRIT MED J, V304, P1465, DOI 10.1136/bmj.304.6840.1465; *HUM FERT EMBR AUT, 1996, 5 HUM FERT EMBR AUTH; JANSEN RPS, 1995, FERTIL STERIL, V64, P252, DOI 10.1016/S0015-0282(16)57718-8; KENNY DT, 1995, BRIT J OBSTET GYNAEC, V102, P317, DOI 10.1111/j.1471-0528.1995.tb09139.x; KOVACS GT, 1993, MED J AUSTRALIA, V158, P805, DOI 10.5694/j.1326-5377.1993.tb137665.x; LOGEROTLEBRUN H, 1995, FERTIL STERIL, V64, P746; MACKENNA AI, 1992, HUM REPROD, V7, P223, DOI 10.1093/oxfordjournals.humrep.a137621; NEUMANN PJ, 1994, NEW ENGL J MED, V331, P239, DOI 10.1056/NEJM199407283310406; Roseboom TJ, 1995, HUM REPROD, V10, P3035, DOI 10.1093/oxfordjournals.humrep.a135842; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; SIMON C, 1994, HUM REPROD, V9, P725, DOI 10.1093/oxfordjournals.humrep.a138578; STRANDELL A, 1994, HUM REPROD, V9, P861, DOI 10.1093/oxfordjournals.humrep.a138606; TAN SL, 1992, LANCET, V339, P1390, DOI 10.1016/0140-6736(92)91205-M; TAN SL, 1994, AM J OBSTET GYNECOL, V170, P34; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055, DOI 10.1093/oxfordjournals.humrep.a138191; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; YARON Y, 1993, FERTIL STERIL, V60, P314; 1992, EFFECTIVE HLTH CARE, V3, P1; 1995, FERTIL STERIL, V64, P13	31	516	530	1	53	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 23	1996	348	9039					1402	1406		10.1016/S0140-6736(96)05291-9	http://dx.doi.org/10.1016/S0140-6736(96)05291-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU986	8937279				2022-12-28	WOS:A1996VU98600010
J	Berwick, DM				Berwick, DM			Quality comes home	ANNALS OF INTERNAL MEDICINE			English	Article								Without a clear focus on the needs and experiences of individual patients, much of the financial and structural reorganization now rampant in health care will be unlikely to yield improvements that matter to the patients we serve. As we change the system of care, five principles can help guide our investment of energy: 1) Focus on integrating experiences, not just structures; 2) learn to use measurement for improvement, not measurement for judgment; 3) develop better ways to learn from each other, not just to discover ''best practices''; 4) reduce total costs, not just local costs; acid 5) compete against disease, not against each other.			Berwick, DM (corresponding author), INST HEALTHCARE IMPROVEMENT, 135 FRANCIS ST, BOSTON, MA 02215 USA.							BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; Deming EW., 1986, OUT CRISIS; HORN S, 1994, CLIN PRACTICE IMPROV, P253; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; PESTOTNIK SL, 1993, P 33 INT C ANT AG CH; SANDMIRE HF, 1994, AM J OBSTET GYNECOL, V170, P1790	6	39	40	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1996	125	10					839	843		10.7326/0003-4819-125-10-199611150-00009	http://dx.doi.org/10.7326/0003-4819-125-10-199611150-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VU524	8928992				2022-12-28	WOS:A1996VU52400012
J	Hall, W; Sannibale, C				Hall, W; Sannibale, C			Are there two types of alcoholism?	LANCET			English	Editorial Material							MEN		CENT SYDNEY AREA HLTH SERV,DRUG & ALCOHOL SERV,SYDNEY,NSW,AUSTRALIA		Hall, W (corresponding author), UNIV NEW S WALES,NATL DRUG & ALCOHOL RES CTR,SYDNEY,NSW 2052,AUSTRALIA.		Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; FILLMORE KM, 1988, DRUGS SOC, V2, P69; LITTRELL J, 1988, J STUD ALCOHOL, V49, P491, DOI 10.15288/jsa.1988.49.491; PENICK EC, 1990, ALCOHOL CLIN EXP RES, V14, P623, DOI 10.1111/j.1530-0277.1990.tb01213.x; SEARLES JS, 1988, J ABNORM PSYCHOL, V97, P153, DOI 10.1037/0021-843X.97.2.153; Sigvardsson S, 1996, ARCH GEN PSYCHIAT, V53, P681	6	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 9	1996	348	9037					1258	1258		10.1016/S0140-6736(05)65754-6	http://dx.doi.org/10.1016/S0140-6736(05)65754-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VR555	8909376				2022-12-28	WOS:A1996VR55500006
J	Hoa, HT; Toan, NV; Johansson, A; Hoa, VT; Hojer, B; Persson, LA				Hoa, HT; Toan, NV; Johansson, A; Hoa, VT; Hojer, B; Persson, LA			Child spacing and two child policy in practice in rural Vietnam: Cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							FERTILITY	Objective-To explore the reproductive pattern of women in rural Vietnam in relation to the existing family planning policies and laws. Design-Cross sectional survey with questionnaires on reproductive history. Setting-Tien Hai, a district in Red River Delta area, where the population density is one of the highest in Vietnam. Subjects-1132 women who had at least one child under 5 years of age in April 1992. Main outcome measures-Birth spacing and probability of having a third child. Results-The mean age at first birth was 22.2 years. The average spacing between the first and the second child was 2.6 years. Mothers with a lower educational level, farmers, and women belonging to the Catholic religion had shorter spacing between the first and second child and also a higher probability of having a third child. In addition, women who had no sons or who had lost a previous child were more likely to have a third child. Conclusion-Most families do not adhere to the official family planning policy, which was introduced in 1988, stipulating that each couple should have a maximum of two children with 3-5 years' spacing in between. More consideration should be given to family planning needs and perceptions of the population, supporting the woman to be in control of her fertility. This may imply improved contraceptive services and better consideration of sex issues and cultural differences as well as improved social support for elderly people.	KAROLINSKA INST,DIV INT HLTH CARE RES,DEPT PUBL HLTH SCI,S-17177 STOCKHOLM,SWEDEN; THAI BINH MED COLL,DEPT BIOL,THAI BINH,VIETNAM; UMEA UNIV,DEPT EPIDEMIOL & PUBL HLTH,S-90185 UMEA,SWEDEN	Karolinska Institutet; Umea University	Hoa, HT (corresponding author), HANOI SCH MED,DEPT ENVIRONM HYG & EPIDEMIOL,HANOI,VIETNAM.							ALLMAN J, 1991, STUD FAMILY PLANN, V22, P308, DOI 10.2307/1966685; BANISTER J, 1993, INDOCHINA RES MONOGR, V6, P2; BONGAARTS J, 1985, POPUL DEV REV, V4, P586; *CTR POP SOC WORK, 1994, VIETN POP FAM PLANN; DEAN AG, 1994, EPI INFO VERSION 6; *EP RES INC, 1988, EGRET EP GRAPH EST T; *GEN STAT OFF, 1991, VIETN POP CENS 1989; GODKIND D, 1994, STUD FAM PLAN, V26, P342; Johansson A, 1996, J PSYCHOSOM OBST GYN, V17, P59; Johansson A, 1996, INT FAM PLAN PERSPEC, V22, P103, DOI 10.2307/2950750; LAI T, 1991, SOCIAL SCI; LUC N, 1993, J BIOSOC SCI, V25, P303, DOI 10.1017/S0021932000020642; MARTIN EC, 1979, J TROP PED ENV CH H, V25, P46, DOI 10.1093/tropej/25.2.46; *NAT COMM POP FAM, 1990, VIETN DEM HLTH SURV; NHAN VQ, 1994, VIETNAM SOC SCI REV, V1, P3; Pebley A.R., 1986, INT FAM PLAN, V1, P71, DOI [10.2307/2947752, DOI 10.2307/2947752]; TERESA CM, 1995, INT FAM PLANN PERSPE, V21, P52; *THAI BINH PROV CO, 1984, FAM PLANN POL; THANG NM, 1992, CONTRACEPTION, V45, P409; Toan NV, 1996, J EPIDEMIOL COMMUN H, V50, P451, DOI 10.1136/jech.50.4.451; TUYET LN, 1994, VIETNAM SOCIAL SCI J, V1, P21; *UN, 1994, CHILDR WOM VIETN SIT	22	14	15	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1113	1116		10.1136/bmj.313.7065.1113	http://dx.doi.org/10.1136/bmj.313.7065.1113			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VR217	8916696	Green Published			2022-12-28	WOS:A1996VR21700021
J	Vandenbroucke, JP; vanderMeer, FJM; Helmerhorst, FM; Rosendaal, FR				Vandenbroucke, JP; vanderMeer, FJM; Helmerhorst, FM; Rosendaal, FR			Factor V Leiden: Should we screen oral contraceptive users and pregnant women?	BRITISH MEDICAL JOURNAL			English	Article							ACTIVATED PROTEIN-C; DEEP-VEIN THROMBOSIS; COAGULATION-FACTOR-V; VENOUS THROMBOEMBOLISM; MUTATION; RESISTANCE; RISK; GENE; ANTICOAGULATION; PROGESTAGEN	The factor V Leiden mutation is the most common genetic risk factor for deep vein thrombosis: it is present in about 5% of the white population. The risk of deep vein thrombosis among women who use oral contraceptives is greatly increased by the presence of the mutation. The same seems to be true of the risk of postpartum thrombosis. Several authors have called for all women to be screened before prescription of oral contraceptives and during pregnancy Such a policy might deny effective contraception to a substantial number of women while preventing only a small number of deaths due to pulmonary emboli. Moreover, in pregnancy the ensuing use of oral anticoagulation prophylaxis might carry a penalty of fatal bleeding that is equal to or exceeds the risk of death due to postpartum thrombosis. It might pay, however, to take a personal and family history of deep vein thrombosis when prescribing oral contraceptives or at a first antenatal visit to detect women hom families with a tendency to multiple thrombosis.	UNIV LEIDEN HOSP,THROMBOSIS CTR,NL-2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT OBSTET & GYNAECOL,NL-2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,HAEMOSTASIS & THROMBOSIS RES CTR,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Vandenbroucke, JP (corresponding author), UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL & HAEMOSTASIS,POB 9600,NL-2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BADARACC.MA, 1974, BRIT MED J, V1, P215, DOI 10.1136/bmj.1.5901.215; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; BONNAR J, 1992, HAEMOSTASIS THROMBOS, P257; BRIDEY F, 1995, THROMB HAEMOSTASIS, V74, P1582; BRIET E, 1994, BRIT J HAEMATOL, V87, P348, DOI 10.1111/j.1365-2141.1994.tb04920.x; CARTER CJ, 1994, PROG CARDIOVASC DIS, V36, P423, DOI 10.1016/S0033-0620(94)80051-0; *CENTR BUR STAT, 1996, STAT JB CENTR BUR ST, P502; Dahlback B, 1996, LANCET, V347, P1346, DOI 10.1016/S0140-6736(96)91004-1; DAHLBACK B, 1995, J INTERN MED, V237, P221, DOI 10.1111/j.1365-2796.1995.tb01170.x; DAHLBACK B, 1995, THROMB HAEMOSTASIS, V73, P739; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; FIHN SD, 1995, NEW ENGL J MED, V333, P54, DOI 10.1056/NEJM199507063330112; HELLGREN M, 1995, AM J OBSTET GYNECOL, V173, P210, DOI 10.1016/0002-9378(95)90192-2; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; KOSTER T, 1995, J INTERN MED, V238, P31, DOI 10.1111/j.1365-2796.1995.tb00896.x; MACHIN SJ, 1995, BRIT J FAM PLAN, V21, P13; MAJERUS PW, 1994, NATURE, V369, P14, DOI 10.1038/369014a0; PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P441; PASI KJ, 1995, LANCET, V345, P1437, DOI 10.1016/S0140-6736(95)92625-9; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Rosendaal FR, 1996, THROMB HAEMOSTASIS, V75, P524; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; TENGBORN L, 1989, AM J OBSTET GYNECOL, V160, P90, DOI 10.1016/0002-9378(89)90095-1; Toglia MR, 1996, NEW ENGL J MED, V335, P108, DOI 10.1056/NEJM199607113350207; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; VANDENBROUCKE JP, 1994, LANCET, V344, P1454; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; 1995, LANCET, V346, P1582	34	179	181	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 2	1996	313	7065					1127	1130		10.1136/bmj.313.7065.1127	http://dx.doi.org/10.1136/bmj.313.7065.1127			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VR217	8916702	Green Published, Green Submitted			2022-12-28	WOS:A1996VR21700028
J	Roth, A; Elkayam, U				Roth, A; Elkayam, U			Acute myocardial infarction associated with pregnancy	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY-ARTERY DISSECTION; TISSUE PLASMINOGEN-ACTIVATOR; MASSIVE PULMONARY-EMBOLISM; CESAREAN-SECTION; ANESTHETIC MANAGEMENT; CARDIOPULMONARY RESUSCITATION; SUPRAVENTRICULAR TACHYCARDIA; ELECTROCARDIOGRAPHIC CHANGES; VENTRICULAR-FIBRILLATION; RECEIVING BROMOCRIPTINE	Purpose: To review available information on the epidemiology, cause, diagnosis, prognosis, and treatment of acute myocardial infarction during pregnancy or in the early postpartum period and to develop guidelines for the management of this condition. Data Sources: MEDLINE and Index Medicus searches and a manual search of bibliographies from reviewed articles. Study Selection: Published reports of well-documented acute myocardial infarction during pregnancy or the early postpartum period or potentially relevant information. Data Extraction: 125 well-documented cases of myocardial infarction were identified. Data Synthesis: The highest incidence seems to occur in the third trimester and in multigravidas older than 33 years of age. Acute myocardial infarction during pregnancy is most commonly located in the anterior wall. The maternal death rate was 21%; death occurred most often at the time of acute myocardial infarction or within 2 weeks of the infarction and was usually related to labor and delivery. Most fetal deaths were associated with maternal deaths. Coronary artery morphology was studied in 54% of described patients. Coronary atherosclerosis with or without intracoronary thrombus was found in 43% of patients, coronary thrombus without atherosclerotic disease in 21%, coronary dissection in 16%, and normal coronary arteries in 29%. Conclusions: Acute myocardial infarction during pregnancy or the early postpartum period is rare but may be associated with high risk. Although atherosclerosis can be documented in many cases, coronary dissection and arteries that are normal on angiography are common, especially in acute myocardial infarction occurring in the peripartum or postpartum period. Early diagnosis is often hindered by the normal changes of pregnancy and low level of suspicion. Management should follow the usual principles of care for acute myocardial infarction. However, selection of diagnostic and therapeutic approaches may be greatly influenced by fetal safety.	UNIV SO CALIF, SCH MED, DIV CARDIOL, LOS ANGELES, CA 90033 USA; SACKLER SCH MED, TEL AVIV, ISRAEL; TEL AVIV UNIV, IL-69978 TEL AVIV, ISRAEL	University of Southern California; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University								ADLER J J, 1968, Illinois Medical Journal, V134, P143; AGLIO LS, 1990, BRIT J ANAESTH, V65, P258, DOI 10.1093/bja/65.2.258; AHRONHEIM JH, 1977, AM J CARDIOL, V40, P287, DOI 10.1016/0002-9149(77)90022-4; ALLEN JN, 1990, CRIT CARE MED, V18, P888, DOI 10.1097/00003246-199008000-00020; AMLAS AG, 1977, BRIT MED J, V1, P1414; ANDERSON DR, 1991, THROMB HAEMOSTASIS, V65, P248; ANTONIUS NA, 1955, AM HEART J, V49, P83, DOI 10.1016/0002-8703(55)90056-9; ASUNCION CM, 1972, OBSTET GYNECOL, V40, P202; BARCLAY GR, 1990, POSTGRAD MED J, V66, P398, DOI 10.1136/pgmj.66.775.398; BAUDO F, 1990, AM J OBSTET GYNECOL, V163, P1274, DOI 10.1016/0002-9378(90)90706-D; BEARY JF, 1979, AM J CARDIOL, V43, P158, DOI 10.1016/0002-9149(79)90058-4; BECHTEL J T, 1963, J Fla Med Assoc, V49, P658; BEDFORD JRD, 1964, OBSTET GYNECOL, V71, P459; BEMBRIDGE M, 1988, ANAESTHESIA, V43, P202; BEROYZ G, 1994, LANCET, V343, P619; Bielak J, 1973, Wiad Lek, V26, P951; BONNET J, 1986, EUR HEART J, V7, P904, DOI 10.1093/oxfordjournals.eurheartj.a061979; BORNSTEIN A, 1984, ANGIOLOGY, V35, P591, DOI 10.1177/000331978403500908; BRADY JP, 1967, PEDIATRICS, V40, P100; BRENT RL, 1989, SEMIN ONCOL, V16, P347; BRIGGS GG, 1994, DRUGS PREGNANCY LACT, P287; BRIGGS GG, 1994, DRUGS PREGNANCY LACT, P513; BROCK HJ, 1953, JAMA-J AM MED ASSOC, V152, P1030, DOI 10.1001/jama.1953.63690110003011a; BROWN A, 1960, NEW ENGL J MED, V262, P1163, DOI 10.1056/NEJM196006092622303; BRUSCHKE AV, 1971, BRIT HEART J, V33, P585; Canning B S, 1969, J Obstet Gynaecol Br Commonw, V76, P1018; CARPENTER MW, 1988, JAMA-J AM MED ASSOC, V259, P3006, DOI 10.1001/jama.259.20.3006; CHANT GN, 1980, AM J CARDIOL, V45, P912, DOI 10.1016/0002-9149(80)90153-8; CHESTNUT DH, 1986, AM J OBSTET GYNECOL, V155, P372, DOI 10.1016/0002-9378(86)90830-6; CHILDRESS CH, 1994, OBSTET GYNECOL, V83, P616, DOI 10.1097/00006250-199404000-00024; CLARK RB, 1980, ANESTHESIOLOGY, V53, P514, DOI 10.1097/00000542-198012000-00016; CLARK SL, 1987, OBSTET GYNECOL, V18, P237; COHEN WR, 1983, JAMA-J AM MED ASSOC, V250, P2179, DOI 10.1001/jama.250.16.2179; COMP PC, 1986, BLOOD, V68, P881; CORTIS BS, 1981, ILLINOIS MED J, V160, P170; CORTIS BS, 1981, IMJ ILL MED J, V160, P174; COTTON DB, 1986, AM J OBSTET GYNECOL, V154, P1053, DOI 10.1016/0002-9378(86)90749-0; COWAN NC, 1988, BRIT HEART J, V59, P588; CURRY JJ, 1970, CHEST, V58, P82, DOI 10.1378/chest.58.1.82; DAVIS RB, 1987, THROMB RES, V46, P175, DOI 10.1016/0049-3848(87)90279-9; DAWSON PJ, 1988, ANAESTHESIA, V43, P659, DOI 10.1111/j.1365-2044.1988.tb04152.x; DELCLOS GL, 1986, AM J OBSTET GYNECOL, V155, P375, DOI 10.1016/0002-9378(86)90832-X; DEMENT'EVA M P, 1975, Klinicheskaya Meditsina (Moscow), V53, P141; DEPACE NL, 1982, JAMA-J AM MED ASSOC, V248, P971, DOI 10.1001/jama.248.8.971; DILLON WP, 1982, JAMA-J AM MED ASSOC, V248, P1089, DOI 10.1001/jama.248.9.1089; DIMAIO VJM, 1971, NEW YORK STATE J MED, V71, P767; DUKE M, 1982, CONN MED, V46, P626; EFSTRATIOU A, 1994, CATHETER CARDIO DIAG, V31, P29, DOI 10.1002/ccd.1810310107; ELKAYAM U, 1995, AM J CARDIOL, V75, P521, DOI 10.1016/S0002-9149(99)80597-9; ELKAYAM U, 1990, CARDIAC PROBLEMS PRE, P5; ELKAYAM U, 1992, HEART DIS TXB CARDIO, P1790; Elkayam U, 1990, CARDIAC PROBLEMS PRE, P215; ELKAYAM U, 1990, CARDIAC PROBLEMS PRE, P31; EMORI T, 1993, CHEST, V104, P289, DOI 10.1378/chest.104.1.289; ETIENNE Y, 1994, AM HEART J, V127, P443, DOI 10.1016/0002-8703(94)90138-4; Fagher B, 1990, ACTA OBSTET GYN SCAN, V69, P659, DOI 10.3109/00016349009028716; FISHBURNE JI, 1988, AM J OBSTET GYNECOL, V158, P829, DOI 10.1016/0002-9378(88)90079-8; FLETCHER AP, 1979, AM J OBSTET GYNECOL, V134, P743, DOI 10.1016/0002-9378(79)90940-2; FLETCHER E, 1967, BRIT MED J, V3, P586, DOI 10.1136/bmj.3.5565.586; FLOSSDORF T, 1990, INTENS CARE MED, V16, P454, DOI 10.1007/BF01711225; FORSSELL J, 1957, ACTA MED SCAND, V157, P387; FREEDMAN JR, 1956, AM J OBSTET GYNECOL, V71, P1106, DOI 10.1016/0002-9378(56)90735-9; FRENKEL Y, 1991, CARDIOLOGY, V78, P363, DOI 10.1159/000174818; FRENKEL Y, 1991, OBSTET GYNECOL, V77, P822; FRISHMAN W, 1990, CARDIAC PROBLEMS PRE, P351; GANT NF, 1973, J CLIN INVEST, V52, P2682, DOI 10.1172/JCI107462; GAZZANIGA AB, 1990, CARDIAC PROBLEMS PRE, P264; GINSBERG JS, 1995, CHEST, V108, pS305, DOI 10.1378/chest.108.4_Supplement.305S; GINZ B, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P610; GIUDICI MC, 1989, AM HEART J, V118, P614, DOI 10.1016/0002-8703(89)90280-9; GLANCY DL, 1971, CIRCULATION, V44, P495, DOI 10.1161/01.CIR.44.4.495; GOLDBERGER E, 1950, NEW YORK STATE J MED, V50, P95; GOODWIN APL, 1992, ANAESTHESIA, V47, P433, DOI 10.1111/j.1365-2044.1992.tb02228.x; GORE M, 1987, AM J OBSTET GYNECOL, V156, P674, DOI 10.1016/0002-9378(87)90076-7; Gregg A R, 1988, J Perinatol, V8, P33; HALL RJC, 1972, BMJ-BRIT MED J, V4, P647, DOI 10.1136/bmj.4.5841.647; Hands M E, 1990, J Clin Anesth, V2, P258, DOI 10.1016/0952-8180(90)90106-D; HANKINS GDV, 1985, OBSTET GYNECOL, V65, P139; HEINONEN OP, 1977, BIRTH DEFECTS DRUGS, P434; HENION WA, 1982, NEW YORK STATE J MED, V82, P57; HILL LM, 1985, MAYO CLIN PROC, V60, P469, DOI 10.1016/S0025-6196(12)60871-4; HUGHES TBJ, 1975, BRIT J OBSTET GYNAEC, V82, P505, DOI 10.1111/j.1471-0528.1975.tb00677.x; HUSAINI MH, 1971, POSTGRAD MED J, V47, P660, DOI 10.1136/pgmj.47.552.660; HUTCHISON SJ, 1985, SCOT MED J, V30, P116, DOI 10.1177/003693308503000212; IFFY L, 1986, AM J OBSTET GYNECOL, V155, P371, DOI 10.1016/0002-9378(86)90829-X; JACOBS M, 1961, J Newark Beth Isr Hosp, V12, P216; Jaffe R, 1987, Obstet Gynecol Surv, V42, P137; JENSEN SE, 1994, J INTERN MED, V235, P487, DOI 10.1111/j.1365-2796.1994.tb01107.x; JESSURUN CR, 1993, TEX HEART I J, V20, P120; JEWETT JF, 1957, NEW ENGL J MED, V256, P574, DOI 10.1056/NEJM195703212561215; KARLSSON K, 1974, J PERINAT MED, V2, P176, DOI 10.1515/jpme.1974.2.3.176; KATZ H, 1922, ARCH GYNAKOL, V115, P283; KATZ VL, 1986, OBSTET GYNECOL, V68, P571; KAUFFMAN RE, 1994, PEDIATRICS, V93, P137; KIRSHON B, 1988, AM J OBSTET GYNECOL, V159, P604, DOI 10.1016/S0002-9378(88)80017-6; KOH CLS, 1992, INT J GYNECOL OBSTET, V38, P9, DOI 10.1016/0020-7292(92)90723-V; Krawczuk A, 1965, Ginekol Pol, V36, P1183; LAMB MA, 1987, HEART LUNG, V16, P658; LEE RV, 1986, AM J MED, V81, P311, DOI 10.1016/0002-9343(86)90268-8; LEES C, 1994, LANCET, V343, P1325, DOI 10.1016/S0140-6736(94)92468-6; LEVINE EL, 1956, MO MED, V53, P967; LEWIS JF, 1973, SOUTHERN MED J, V66, P379, DOI 10.1097/00007611-197303000-00024; LIAO JK, 1991, AM J CARDIOL, V68, P823, DOI 10.1016/0002-9149(91)90669-C; LISTO M, 1966, ACTA OBSTET GYN SCAN, V45, P268, DOI 10.3109/00016346609158452; LIU SS, 1992, CAN J ANAESTH, V39, P858, DOI 10.1007/BF03008297; LUDWIG H, 1981, THROMB HAEMOSTASIS, V46, P438; MABIE WC, 1988, OBSTET GYNECOL, V71, P503; MACKINNON S, 1987, BRIT J HAEMATOL, V65, P339, DOI 10.1111/j.1365-2141.1987.tb06864.x; MAGNER D, 1961, J OBSTET GYN BR COMM, V68, P128; MAJDAN JF, 1983, AM J CARDIOL, V52, P1145, DOI 10.1016/0002-9149(83)90552-0; MANALOESTRELLA P, 1967, ARCH PATHOL, V83, P336; MARX GF, 1982, ANESTHESIOLOGY, V56, P156, DOI 10.1097/00000542-198202000-00018; MARZANI PC, 1969, MINERVA MED, V60, P1407; MCGEHEE W, 1990, CARDIAC PROBLEMS PRE, P397; McHugh M J, 1990, J Cardiovasc Nurs, V4, P57; McKeon V A, 1989, Dimens Crit Care Nurs, V8, P92, DOI 10.1097/00003465-198903000-00005; MCLINTIC AJ, 1992, ANESTH ANALG, V74, P51; MCTAGGART DR, 1977, MED J AUSTRALIA, V1, P18, DOI 10.5694/j.1326-5377.1977.tb130465.x; MENDELSON CL, 1952, AM J OBSTET GYNECOL, V63, P381, DOI 10.1016/S0002-9378(15)32833-7; MENEGAKIS NE, 1991, AM J OBSTET GYNECOL, V165, P1383; MOVSESIAN MA, 1989, BRIT HEART J, V62, P154; MYERS R F, 1957, Can Med Assoc J, V76, P754; NADEN RS, 1961, JAMA-J AM MED ASSOC, V178, P659, DOI 10.1001/jama.1961.73040450016019; NISELL H, 1985, CLIN PHYSIOL, V5, P479, DOI 10.1111/j.1475-097X.1985.tb00779.x; NOLAN TE, 1990, SOUTHERN MED J, V83, P1360, DOI 10.1097/00007611-199011000-00038; NOLAN TE, 1989, CLIN OBSTET GYNECOL, V32, P68, DOI 10.1097/00003081-198903000-00010; ODONNELL M, 1987, POSTGRAD MED J, V63, P1095, DOI 10.1136/pgmj.63.746.1095; OTTMAN EH, 1993, OBSTET GYNECOL, V81, P804; PAGE RL, 1995, AM HEART J, V130, P871, DOI 10.1016/0002-8703(95)90090-X; PALMER CM, 1990, ANESTH ANALG, V70, P36; PALOMINO SJ, 1969, AM J CLIN PATHOL, V51, P119; Pantev I, 1968, Akush Ginekol (Sofiia), V7, P158; PARDO J, 1990, REV MED CHILE, V118, P300; PARRY G, 1992, CLIN CARDIOL, V15, P305, DOI 10.1002/clc.4960150416; PERRY JC, 1991, J PEDIATR-US, V118, P303, DOI 10.1016/S0022-3476(05)80509-8; Perucca E, 1991, Rev Chil Obstet Ginecol, V56, P210; PFAFFENSCHLAGER F., 1964, WIENER KLIN WOCHENSCHR, V76, P297; PFEIFER GW, 1970, AUSTRALAS ANN MED, V19, P28; PHILLIPS E, 1962, JAMA-J AM MED ASSOC, V181, P63, DOI 10.1001/jama.1962.03050270065018; RALLINGS P, 1989, AUST NZ J MED, V19, P347, DOI 10.1111/j.1445-5994.1989.tb00276.x; RAMAMURTHY S, 1994, AM HEART J, V127, P446, DOI 10.1016/0002-8703(94)90140-6; REECE EA, 1992, PRINCIPLES PRACTICE, P817; Reis RA, 1935, AM J OBSTET GYNECOL, V29, P44, DOI 10.1016/S0002-9378(35)90585-3; Rekosz J, 1992, Kardiol Pol, V36, P224; ROBERTS ADG, 1983, BRIT J OBSTET GYNAEC, V90, P969, DOI 10.1111/j.1471-0528.1983.tb06773.x; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; RUCH A, 1989, OBSTET GYNECOL, V74, P448; Sala D J, 1992, NAACOGS Clin Issu Perinat Womens Health Nurs, V3, P443; SAMRA D, 1989, CARDIOLOGY, V76, P455, DOI 10.1159/000174533; SANCHEZRAMOS L, 1994, AM J OBSTET GYNECOL, V171, P1392, DOI 10.1016/0002-9378(94)90172-4; SASSE L, 1975, AM J CARDIOL, V35, P448, DOI 10.1016/0002-9149(75)90040-5; SAXENA R, 1992, OBSTET GYNECOL, V79, P810; SBAROUNI E, 1994, BRIT HEART J, V71, P196; SHALEV Y, 1993, CLIN CARDIOL, V16, P754, DOI 10.1002/clc.4960161013; SHAPIRA E, 1961, JAMA-J AM MED ASSOC, V179, P966; SHAVER PJ, 1978, BRIT HEART J, V40, P83; SHECHTER M, 1995, AM J CARDIOL, V75, P321, DOI 10.1016/S0002-9149(99)80546-3; SHEIKH AU, 1993, AM J OBSTET GYNECOL, V169, P279, DOI 10.1016/0002-9378(93)90076-U; Shepard TH, 1989, CATALOG TERATOGENIC, P655; SHOTAN A, 1994, AM J MED, V96, P451, DOI 10.1016/0002-9343(94)90172-4; SIEGLER AM, 1956, OBSTET GYNECOL, V7, P306; SMITH JC, 1975, ARCH PATHOL, V99, P117; SONEL A, 1988, CARDIOLOGY, V75, P218, DOI 10.1159/000174374; SPERRY KL, 1987, J FORENSIC SCI, V32, P1464; STOKES IM, 1984, BRIT J OBSTET GYNAEC, V91, P197, DOI 10.1111/j.1471-0528.1984.tb05907.x; STRONG TH, 1989, AM J EMERG MED, V7, P489, DOI 10.1016/0735-6757(89)90251-9; STUART MJ, 1982, NEW ENGL J MED, V307, P909, DOI 10.1056/NEJM198210073071502; SULLIVAN JM, 1985, NEW ENGL J MED, V313, P304, DOI 10.1056/NEJM198508013130506; TAYLOR GJ, 1985, OBSTET GYNECOL, V66, P821; TAYLOR GW, 1993, AM HEART J, V126, P1462, DOI 10.1016/0002-8703(93)90546-L; TISSOT H, 1991, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V20, P1093; Troiano N H, 1989, J Perinat Neonatal Nurs, V3, P1; TROUTON TG, 1988, INT J CARDIOL, V18, P35, DOI 10.1016/0167-5273(88)90028-9; Turrentine M A, 1995, Obstet Gynecol Surv, V50, P534, DOI 10.1097/00006254-199507000-00020; URDAN BE, 1959, OBSTET GYNECOL, V14, P378; VANENK A, 1992, BRIT J OBSTET GYNAEC, V99, P162; VASICKA AI, 1959, AM J OBSTET GYNECOL, V77, P899, DOI 10.1016/S0002-9378(16)36802-8; VERKAAIK APK, 1993, BRIT J ANAESTH, V71, P301, DOI 10.1093/bja/71.2.301; VIINIKKA L, 1993, BRIT J OBSTET GYNAEC, V100, P809, DOI 10.1111/j.1471-0528.1993.tb14304.x; WAGNER X, 1990, AM HEART J, V119, P700, DOI 10.1016/S0002-8703(05)80306-0; WARING PH, 1990, ANESTH ANALG, V71, P96; WATSON H, 1960, LANCET, V2, P523; WELLS AL, 1960, J PATHOL BACTERIOL, V79, P404, DOI 10.1002/path.1700790222; White PD, 1937, J AMER MED ASSOC, V109, P863, DOI 10.1001/jama.1937.92780370001012; WIDERHORN J, 1991, AM HEART J, V122, P1162, DOI 10.1016/0002-8703(91)90489-5; WIDERHORN J, 1995, CURRENT OBSTET MED, V3, P95; WIDERHORN J, 1992, PRINCIPLES PRACTICE, P767; WITCHITZ S, 1980, BRIT HEART J, V44, P545; WITTRY MD, 1989, AM HEART J, V117, P191, DOI 10.1016/0002-8703(89)90677-7; YLAOUTINEN A, 1989, UPSALA J MED SCI, V94, P287; YOSHIMURA T, 1992, EUR J OBSTET GYN R B, V44, P195, DOI 10.1016/0028-2243(92)90098-J; ZIERLER S, 1985, NEW ENGL J MED, V313, P347, DOI 10.1056/NEJM198508083130603; ZOLL PM, 1985, CIRCULATION, V71, P937, DOI 10.1161/01.CIR.71.5.937; 1958, OHIO STATE MED J, V54, P187	194	170	179	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1996	125	9					751	762		10.7326/0003-4819-125-9-199611010-00009	http://dx.doi.org/10.7326/0003-4819-125-9-199611010-00009			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VQ072	8929010				2022-12-28	WOS:A1996VQ07200008
